Clustering O 0 2.761837276921142e-05
of O 0 4.109784185857279e-06
missense O 0 1.163510387414135e-05
mutations O 0 2.617429117890424e-07
in O 0 1.393256923165609e-07
the O 0 3.045235644094646e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 3.465778263489483e-06
in O 0 1.2740683530410024e-07
a O 0 1.0206612444108032e-07
sporadic B-Disease 0 8.980848360806704e-05
T I-Disease 1 0.9999998807907104
- I-Disease 1 0.9892895817756653
cell I-Disease 1 0.9697614312171936
leukaemia I-Disease 1 0.99998939037323
. O 0 3.575469463612535e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.01969504915177822
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 6.092566451343373e-08
is O 0 3.0955393803822062e-09
a O 0 4.4468682069975785e-09
recessive B-Disease 0 5.132271212460182e-07
multi I-Disease 0 0.09312352538108826
- I-Disease 1 0.9974902868270874
system I-Disease 1 0.9972878694534302
disorder I-Disease 1 1.0
caused O 0 5.2895775297656655e-06
by O 0 1.2225338075211312e-08
mutations O 0 7.832069215396587e-09
in O 0 7.0912351546326136e-09
the O 0 1.5935025743374354e-08
ATM O 0 2.2836184143670835e-05
gene O 0 1.2708321150967095e-07
at O 0 7.172179721237626e-07
11q22 O 0 1.6556667105760425e-05
- O 0 4.940483904647408e-06
q23 O 0 3.177472171955742e-05
( O 0 1.4763070055323624e-07
ref O 0 2.012213008129038e-05
. O 0 6.117274864436695e-08
3 O 0 5.615155487248558e-07
) O 0 5.664519875381302e-08
. O 0 3.1234131370183604e-07

The O 0 2.535668272685143e-06
risk O 0 9.697340601633186e-07
of O 0 6.36885442872881e-06
cancer B-Disease 1 0.9881019592285156
, O 0 2.5896545352566136e-08
especially O 0 5.97343756680857e-08
lymphoid B-Disease 1 0.5028250217437744
neoplasias I-Disease 1 0.898475170135498
, O 0 3.120146629953524e-08
is O 0 4.017525423449797e-09
substantially O 0 6.102649763306545e-08
elevated O 0 4.698552402260248e-06
in O 0 1.0525945981498808e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 6.317034717540082e-07
and O 0 1.2472098021021338e-08
has O 0 2.937760035237602e-09
long O 0 6.064772684055697e-09
been O 0 2.9163440551371878e-09
associated O 0 3.8657120171592396e-08
with O 0 1.2605383403752057e-07
chromosomal O 1 1.0
instability O 1 0.9999580383300781
. O 0 7.671678758924827e-06

By O 0 1.8059267858916428e-06
analysing O 0 0.00016907363897189498
tumour B-Disease 1 1.0
DNA O 0 2.528773075027857e-05
from O 0 2.508254510757979e-07
patients O 0 9.302571868374798e-08
with O 0 8.70715943790401e-09
sporadic B-Disease 0 2.4207560272770934e-05
T I-Disease 1 0.9999971389770508
- I-Disease 0 0.00016105486429296434
cell I-Disease 0 9.427723125554621e-05
prolymphocytic I-Disease 0 0.3597818911075592
leukaemia I-Disease 1 0.999990701675415
( O 0 1.4386044995262637e-06
T B-Disease 1 0.9999961853027344
- I-Disease 0 0.0004265683819539845
PLL I-Disease 1 0.9997838139533997
) O 0 6.25439184887e-08
, O 0 1.1132231136912196e-08
a O 0 7.216657937902937e-09
rare O 0 3.097649710070982e-07
clonal B-Disease 0 0.00022341783915180713
malignancy I-Disease 0 0.43457794189453125
with O 0 1.1257526466579293e-08
similarities O 0 2.1768055802340314e-08
to O 0 5.198558472585546e-09
a O 0 1.0349719303803795e-07
mature B-Disease 0 2.8532965643535135e-06
T I-Disease 1 0.9999433755874634
- I-Disease 0 0.00010280622518621385
cell I-Disease 0 2.662850783963222e-05
leukaemia I-Disease 0 0.16577860713005066
seen O 0 1.1299403723796786e-07
in O 0 3.860436237346221e-08
A B-Disease 1 0.9999892711639404
- I-Disease 1 0.9999847412109375
T I-Disease 1 1.0
, O 0 3.041649065949059e-08
we O 0 6.926911266802449e-10
demonstrate O 0 4.068823500347207e-09
a O 0 1.8127274126200632e-09
high O 0 5.741726649688417e-09
frequency O 0 7.740675656009444e-09
of O 0 1.1319944981380559e-08
ATM O 0 7.462407666025683e-06
mutations O 0 1.1138754985040578e-07
in O 0 9.774843192644767e-07
T B-Disease 1 0.9999827146530151
- I-Disease 0 0.0038222859147936106
PLL I-Disease 1 0.9828084111213684
. O 0 5.618054728984134e-06

In O 0 2.1026510239607887e-06
marked O 0 9.013660360324138e-07
contrast O 0 8.722854971665583e-08
to O 0 4.036428080667065e-09
the O 0 1.9634091685816202e-08
ATM O 0 2.3473665351048112e-05
mutation O 0 6.902281057818982e-08
pattern O 0 8.861471201271343e-08
in O 0 3.0434129882905836e-08
A B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999991655349731
T I-Disease 1 1.0
, O 0 1.8224458386839615e-08
the O 0 2.948706834260406e-09
most O 0 1.7953089015421142e-10
frequent O 0 7.93288601474984e-10
nucleotide O 0 6.763472004678306e-09
changes O 0 1.05058395316604e-09
in O 0 6.680775044287657e-09
this O 0 6.507693495194644e-09
leukaemia B-Disease 0 0.0007267221808433533
were O 0 3.2567035646025033e-07
missense O 0 1.2198270269436762e-05
mutations O 0 3.053331738556153e-06
. O 0 3.941072918678401e-06

These O 0 7.214189849946706e-07
clustered O 0 6.659773589490214e-06
in O 0 1.5822881493932073e-07
the O 0 6.195702439981687e-08
region O 0 1.4450621144135312e-08
corresponding O 0 4.186898383551352e-09
to O 0 3.1174267611788764e-09
the O 0 1.6780449030306954e-08
kinase O 0 5.1565024250521674e-08
domain O 0 1.2871391952273825e-08
, O 0 1.108474423361372e-09
which O 0 5.259774282784235e-10
is O 0 3.228805001143087e-10
highly O 0 2.004632015939478e-09
conserved O 0 1.0506926884090717e-08
in O 0 5.282972725950685e-09
ATM O 0 9.288170986110345e-06
- O 0 4.1610513790146797e-07
related O 0 7.519829381408272e-08
proteins O 0 9.99437244075807e-09
in O 0 4.150215104914423e-08
mouse O 0 3.907470045305672e-07
, O 0 1.199704424692527e-08
yeast O 0 2.664749558789481e-07
and O 0 5.131796498858421e-08
Drosophila O 0 1.1255291610723361e-05
. O 0 1.489075430072262e-06

The O 0 6.830109214206459e-06
resulting O 0 2.1319472125469474e-06
amino O 0 1.2659635331147001e-06
- O 0 1.4656737903351313e-06
acid O 0 1.467364256768633e-07
substitutions O 0 2.3067293852818693e-07
are O 0 3.3146374533998824e-09
predicted O 0 4.2525510224322716e-08
to O 0 6.4085363682409024e-09
interfere O 0 1.0233044633878308e-07
with O 0 9.956664825949701e-08
ATP O 1 0.9999997615814209
binding O 0 7.707852205385279e-07
or O 0 2.0238812226125447e-07
substrate O 0 1.2548426866487716e-06
recognition O 0 8.084016940301808e-07
. O 0 8.492937695336877e-07

Two O 0 1.0004271189245628e-06
of O 0 2.9401437586784596e-06
seventeen O 0 1.652521314099431e-05
mutated O 0 2.2233563868212514e-05
T B-Disease 1 0.9825173020362854
- I-Disease 0 2.9715616619796492e-05
PLL I-Disease 0 0.003882469842210412
samples O 0 4.5701204953729757e-07
had O 0 2.021781675409784e-08
a O 0 6.854013800960956e-09
previously O 0 8.797744044386491e-08
reported O 0 6.280051252360863e-07
A B-Disease 1 0.9999991655349731
- I-Disease 1 0.9999980926513672
T I-Disease 1 1.0
allele O 0 5.445543592941249e-06
. O 0 1.3469866644300055e-06

In O 0 1.1143106348754372e-06
contrast O 0 2.3078604272086523e-07
, O 0 1.6698043836527177e-08
no O 0 7.188619033371424e-09
mutations O 0 4.235638506600026e-09
were O 0 3.75394249019223e-09
detected O 0 3.237336798633805e-08
in O 0 1.0814776851830743e-09
the O 0 3.3398697141251432e-09
p53 O 0 1.4392829150722264e-08
gene O 0 1.1169407621025584e-08
, O 0 3.2981462005921003e-09
suggesting O 0 1.1714618608493765e-08
that O 0 6.376174033206894e-10
this O 0 9.938332823367091e-09
tumour B-Disease 1 1.0
suppressor O 0 1.0604679118841887e-05
is O 0 1.213174982694909e-08
not O 0 8.36512858981564e-10
frequently O 0 7.591304473919536e-09
altered O 0 7.688061742783248e-08
in O 0 3.8334199814471503e-08
this O 0 8.767256787223232e-08
leukaemia B-Disease 1 0.9591972827911377
. O 0 1.5940717048579245e-06

Occasional O 0 2.1631201889249496e-05
missense O 0 1.2841488569392823e-05
mutations O 0 1.3678382515536214e-07
in O 0 4.79359876237595e-08
ATM O 0 4.075057586305775e-05
were O 0 8.241057258828732e-08
also O 0 8.408868268361402e-09
found O 0 6.7576175766248525e-09
in O 0 2.700195089744284e-08
tumour B-Disease 1 1.0
DNA O 0 6.993739134486532e-06
from O 0 1.438449146462517e-07
patients O 0 2.5234053069311813e-08
with O 0 1.7030956200869696e-08
B B-Disease 0 0.030156614258885384
- I-Disease 0 8.228825208789203e-06
cell I-Disease 0 3.0997530302556697e-06
non I-Disease 0 0.0001357059518340975
- I-Disease 1 0.9946858882904053
Hodgkins I-Disease 1 1.0
lymphomas I-Disease 1 0.999927282333374
( O 0 3.9921374650475627e-07
B B-Disease 0 0.0001940809888765216
- I-Disease 0 2.1067194211354945e-06
NHL I-Disease 0 3.7756009987788275e-05
) O 0 7.777881450010682e-09
and O 0 2.6093218696843223e-09
a O 0 5.391078516936432e-08
B B-Disease 0 0.000151374566485174
- I-Disease 0 7.1588597165828105e-06
NHL I-Disease 0 0.01694394275546074
cell O 0 1.4490771718556061e-05
line O 0 6.1080404520907905e-06
. O 0 6.762518864888989e-07

The O 0 1.1556338677110034e-06
evidence O 0 9.29444638586574e-07
of O 0 1.875923061334106e-07
a O 0 8.105043747264062e-09
significant O 0 1.4792735925084344e-09
proportion O 0 4.16919165857621e-09
of O 0 3.6558311933276855e-08
loss O 0 2.595029855001485e-06
- O 0 1.0780892125694663e-06
of O 0 5.276993988445611e-07
- O 0 5.183695179766801e-07
function O 0 2.2497879115235264e-09
mutations O 0 2.146189670426679e-09
and O 0 1.41681411047756e-09
a O 0 2.715647262618859e-09
complete O 0 6.420626874614754e-08
absence O 0 1.221820866703638e-07
of O 0 7.387559719518322e-08
the O 0 1.753759093503504e-08
normal O 0 9.388681831978829e-09
copy O 0 3.405776993758991e-08
of O 0 1.555669015829153e-08
ATM O 0 4.871548753726529e-06
in O 0 1.442699293363603e-08
the O 0 9.610118922864785e-09
majority O 0 1.524392168050781e-09
of O 0 6.829847620792862e-08
mutated O 0 6.051416676200461e-06
tumours B-Disease 1 0.9999991655349731
establishes O 0 1.609853029549413e-06
somatic O 0 7.35902813175926e-06
inactivation O 0 2.2077021640143357e-05
of O 0 1.9446035537384887e-07
this O 0 1.411155858832558e-09
gene O 0 3.89400867106815e-09
in O 0 2.539521037903114e-09
the O 0 1.115816505858902e-08
pathogenesis O 0 3.970657871832373e-06
of O 0 3.187791435266263e-07
sporadic B-Disease 0 1.5069405890244525e-05
T I-Disease 1 0.9999716281890869
- I-Disease 0 3.8677550037391484e-05
PLL I-Disease 0 0.44782474637031555
and O 0 2.1400632377321926e-08
suggests O 0 7.484096897769632e-09
that O 0 6.135439933885323e-10
ATM O 0 5.201549356570467e-06
acts O 0 2.5116202095887274e-07
as O 0 2.0835271641317377e-07
a O 0 1.0992697525580297e-06
tumour B-Disease 1 1.0
suppressor O 0 0.0006520790047943592
. O 0 7.806993380654603e-06

As O 0 9.4150618679123e-07
constitutional O 0 7.694140435887675e-07
DNA O 0 5.110983693157323e-06
was O 0 1.5635139050118596e-07
not O 0 5.293550597862406e-10
available O 0 1.726710441296575e-09
, O 0 2.477817950818917e-09
a O 0 1.288008544264585e-08
putative O 0 7.016158633632585e-06
hereditary O 1 0.9999861717224121
predisposition O 0 0.01649138703942299
to O 0 1.7845955881057307e-05
T B-Disease 1 1.0
- I-Disease 1 0.9683547019958496
PLL I-Disease 1 0.9996979236602783
will O 0 1.768684398939513e-08
require O 0 7.395620560401994e-09
further O 0 1.6068094410570666e-08
investigation O 0 1.4249987145831255e-07
. O 0 7.977411797810419e-08
. O 0 4.988791602045239e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 3.9732443838147447e-05
kinase O 0 9.966247489501256e-06
is O 0 8.321151767631818e-08
involved O 0 1.5959390253783567e-08
in O 0 1.030276131075425e-08
the O 0 4.725232205515795e-09
modulation O 0 2.1890464552143385e-08
of O 0 2.3348013300505954e-08
the O 0 1.706535890377836e-08
Ca2 O 0 6.615525194320071e-08
+ O 0 3.465139570835163e-07
homeostasis O 0 5.34726541445707e-06
in O 0 5.898864401387982e-07
skeletal O 1 0.9980970025062561
muscle O 0 0.0021168275270611048
cells O 0 1.3460541595122777e-05
. O 0 1.3771199292023084e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.999929666519165
DM B-Disease 1 1.0
) O 0 5.337391939974623e-06
, O 0 2.6679886744318537e-08
the O 0 6.433545252093609e-09
most O 0 4.554068233630915e-09
prevalent O 0 0.00035346404183655977
muscular B-Disease 1 0.9999998807907104
disorder I-Disease 1 0.9999994039535522
in O 0 2.714142055992852e-06
adults O 0 9.019045421609917e-08
, O 0 2.2903936525153767e-08
is O 0 4.309797851931307e-09
caused O 0 8.380355609460821e-08
by O 0 3.675582860296345e-08
( O 0 1.1481635198151707e-07
CTG O 0 0.002553206402808428
) O 0 1.0503881320289565e-08
n O 0 2.0868752059755025e-08
- O 0 7.767032883521097e-08
repeat O 0 1.719067732608437e-08
expansion O 0 1.6333897789877483e-08
in O 0 1.9819577090629537e-09
a O 0 2.58794474738977e-09
gene O 0 3.6613072573743466e-09
encoding O 0 7.947671853969496e-09
a O 0 2.6092834559676703e-08
protein O 0 1.1578519121258068e-07
kinase O 0 1.141158918471774e-06
( O 0 3.915661750397703e-07
DM B-Disease 1 1.0
protein O 0 2.467159561092558e-07
kinase O 0 2.1187430832014797e-07
; O 0 2.110005326017017e-08
DMPK O 1 0.9945843815803528
) O 0 7.376095734201726e-09
and O 0 1.593696286050772e-09
involves O 0 4.737288339384804e-09
changes O 0 2.4683464161512347e-09
in O 0 2.4735411940923768e-08
cytoarchitecture O 0 1.69949016708415e-05
and O 0 1.9395528738641588e-07
ion O 0 2.5646242647781037e-05
homeostasis O 0 0.0010307453339919448
. O 0 9.143003808276262e-06

To O 0 4.55381012898215e-07
obtain O 0 2.332582909048142e-07
clues O 0 4.1233496972381545e-07
to O 0 7.952523972676317e-09
the O 0 8.841107401735826e-09
normal O 0 1.3068003568150743e-08
biological O 0 4.2351800288997765e-08
role O 0 2.1097799063340972e-08
of O 0 1.4988719954089902e-07
DMPK O 1 0.7115896344184875
in O 0 1.024505493774086e-07
cellular O 0 6.559567964359303e-07
ion O 0 6.262180818339402e-07
homeostasis O 0 2.345251959923189e-05
, O 0 6.595165302769601e-08
we O 0 1.7715396927187044e-09
have O 0 2.2865456750231772e-10
compared O 0 5.2430499941635844e-09
the O 0 1.142366645723314e-08
resting O 0 2.0856098217336694e-06
[ O 0 9.713578918990606e-08
Ca2 O 0 2.5128246150529776e-08
+ O 0 1.2592010989465052e-07
] O 0 1.713758450705427e-07
i O 0 3.6701187866583496e-08
, O 0 8.899913028770357e-10
the O 0 9.082825047634913e-10
amplitude O 0 3.7902392335809054e-09
and O 0 1.1896640339514875e-09
shape O 0 3.106483248416225e-08
of O 0 6.171830335688355e-08
depolarization O 0 2.0856305127381347e-07
- O 0 1.0159526482311776e-06
induced O 0 1.1907167163371923e-06
Ca2 O 0 3.719760854892229e-08
+ O 0 8.11508584774856e-08
transients O 0 2.3286401074074092e-07
, O 0 6.210702618858477e-09
and O 0 1.2750870359568012e-09
the O 0 3.856842845095798e-09
content O 0 2.4124184871965326e-09
of O 0 2.4768270989738994e-08
ATP O 0 0.33598601818084717
- O 0 4.3142986783095694e-07
driven O 0 9.096078201764612e-08
ion O 0 6.492718540584974e-08
pumps O 0 1.7577282562797336e-07
in O 0 2.967802181785828e-08
cultured O 0 8.783858334027173e-07
skeletal O 0 5.088822581456043e-05
muscle O 0 6.218896260179463e-07
cells O 0 5.0409255436534295e-08
of O 0 2.545145605381549e-07
wild O 0 5.758465135841107e-07
- O 0 6.266602099458396e-07
type O 0 3.056036064208456e-07
and O 0 1.2015540562515525e-07
DMPK O 1 0.9999703168869019
[ O 0 3.1927522741170833e-06
- O 0 1.2489087566791568e-05
/ O 0 1.4962574823584873e-05
- O 0 1.777168654371053e-05
] O 0 5.325123311195057e-06
knockout O 1 0.998528242111206
mice O 0 1.0345578630222008e-05
. O 0 5.979285901958065e-07

In O 0 1.810282469705271e-06
vitro O 0 5.725746632379014e-06
- O 0 7.477517101506237e-06
differentiated O 0 8.667859219713137e-06
DMPK O 1 0.9829918742179871
[ O 0 2.166646254408988e-06
- O 0 1.1147719305881765e-05
/ O 0 1.1001330676663201e-05
- O 0 3.923813892470207e-06
] O 0 2.9940218837509747e-07
myotubes O 0 1.75230502463819e-06
exhibit O 0 1.6091810550733499e-07
a O 0 2.2516006836781344e-08
higher O 0 1.4125573954970605e-07
resting O 0 3.0369649266503984e-06
[ O 0 8.756060054793124e-08
Ca2 O 0 3.127505010525056e-08
+ O 0 1.246707199697994e-07
] O 0 8.131014084256094e-08
i O 0 9.837209269392133e-09
than O 0 7.924644274126535e-10
do O 0 1.4264809333752737e-09
wild O 0 7.470138285725625e-08
- O 0 2.1555035800702171e-07
type O 0 3.2861862564459443e-07
myotubes O 0 3.7760228224215098e-06
because O 0 6.0821720992976225e-09
of O 0 1.2731095289097993e-08
an O 0 1.1676822841977241e-09
altered O 0 1.3029874068593017e-08
open O 0 1.7491590398321932e-08
probability O 0 1.668635118967643e-09
of O 0 8.679370111508433e-09
voltage O 0 1.2894396661522478e-07
- O 0 1.0890484958281377e-07
dependent O 0 1.515510206218096e-08
l O 0 4.844104140033778e-08
- O 0 1.5555940535705304e-07
type O 0 4.405940146057219e-08
Ca2 O 0 3.0656977401122276e-08
+ O 0 4.67871608123005e-08
and O 0 4.5107256596566e-08
Na O 0 6.868451237096451e-06
+ O 0 2.2029423973890516e-07
channels O 0 1.910894837919841e-07
. O 0 2.299343151435096e-07

The O 0 7.970832484716084e-06
mutant O 0 1.3102719094604254e-05
myotubes O 0 4.499290662351996e-05
exhibit O 0 9.84250277724641e-07
smaller O 0 7.495814458025052e-08
and O 0 3.097596135148706e-08
slower O 0 1.7477358937867393e-07
Ca2 O 0 3.096904777066811e-08
+ O 0 2.7602295560313905e-08
responses O 0 2.000663190671048e-09
upon O 0 1.1353244566691956e-08
triggering O 0 1.54887331405007e-07
by O 0 1.1272588196220568e-08
acetylcholine O 0 6.712870117553393e-07
or O 0 6.669014140925356e-08
high O 0 5.017568014409335e-07
external O 0 5.090064405521844e-07
K O 0 7.363864824583288e-06
+ O 0 1.8552223082224373e-06
. O 0 4.5959032490827667e-07

In O 0 7.683376566092193e-07
addition O 0 2.1657672277797246e-07
, O 0 3.0983763110725704e-08
we O 0 1.9334698286854746e-09
observed O 0 4.152176824590015e-09
that O 0 5.671213845759304e-11
these O 0 2.3310256502817595e-10
Ca2 O 0 1.708463948091321e-08
+ O 0 7.711707183943872e-08
transients O 0 2.1450127007938136e-07
partially O 0 9.147682078491925e-08
result O 0 3.1512275011635893e-09
from O 0 2.052945591302091e-09
an O 0 7.143970137679645e-11
influx O 0 4.897219296751132e-10
of O 0 5.1952575574887305e-09
extracellular O 0 5.7415734389110185e-09
Ca2 O 0 7.216369279916535e-09
+ O 0 1.745676136977181e-08
through O 0 4.31432134462284e-09
the O 0 8.946824614497473e-09
l O 0 5.820724524596699e-08
- O 0 2.2284190492882772e-07
type O 0 1.9163586273407418e-07
Ca2 O 0 1.834226281971496e-07
+ O 0 4.841457439397345e-07
channel O 0 4.158333979376039e-07
. O 0 2.989459630953206e-07

Neither O 0 7.645567166036926e-06
the O 0 2.050340981440968e-07
content O 0 4.106443185492026e-08
nor O 0 4.7781810508240596e-08
the O 0 5.90411319834061e-09
activity O 0 1.074715072491017e-08
of O 0 5.120220691878785e-08
Na O 0 3.363834821357159e-06
+ O 0 1.434449075077282e-07
/ O 0 4.630500711755303e-07
K O 0 6.034158559486968e-07
+ O 0 1.253140453627566e-07
ATPase O 0 5.071115083410405e-07
and O 0 6.905678162638651e-08
sarcoplasmic O 0 3.2048753837443655e-06
reticulum O 0 1.4124176459517912e-06
Ca2 O 0 4.111471696433e-07
+ O 0 6.537641752402124e-07
- O 0 3.9703590459794214e-07
ATPase O 0 2.2303814262158994e-07
are O 0 2.563743217720571e-09
affected O 0 4.4541454968793914e-08
by O 0 1.9531641726189264e-07
DMPK O 1 0.9996832609176636
absence O 0 8.680811879457906e-05
. O 0 5.1576225814642385e-06

In O 0 8.503627100253652e-07
conclusion O 0 3.591524091461906e-07
, O 0 2.5105155287974412e-08
our O 0 5.581538786714191e-09
data O 0 1.540415617284907e-08
suggest O 0 4.977824819007992e-09
that O 0 1.1904494057191073e-09
DMPK O 0 0.30315887928009033
is O 0 6.634299776209218e-09
involved O 0 4.5871080267545494e-09
in O 0 7.024560044754935e-09
modulating O 0 1.99702384406919e-07
the O 0 1.3458572034608096e-08
initial O 0 5.47989165156082e-09
events O 0 4.105963569145388e-09
of O 0 2.478410188189173e-08
excitation O 0 6.288339591264958e-07
- O 0 3.0415121727855876e-06
contraction O 0 1.0536265335758799e-06
coupling O 0 3.726329680375784e-07
in O 0 4.623603615527827e-07
skeletal O 1 0.8345244526863098
muscle O 0 5.277326999930665e-05
. O 0 4.6748627369197493e-07
. O 0 7.07973697444686e-07

Constitutional O 0 0.00018192807328887284
RB1 O 1 0.9999960660934448
- O 0 0.00026708346558734775
gene O 0 6.687495783808117e-07
mutations O 0 1.7433809773592657e-07
in O 0 9.780748655430216e-08
patients O 0 1.2648240499402164e-07
with O 0 4.1890494628660235e-08
isolated O 0 2.280836815771181e-05
unilateral B-Disease 0 5.3670322813559324e-05
retinoblastoma I-Disease 1 0.9986114501953125
. O 0 2.995866998389829e-05

In O 0 1.7786661601348897e-06
most O 0 7.179399830192779e-08
patients O 0 7.633239818005677e-08
with O 0 5.467071240161658e-09
isolated O 0 4.4967666212869517e-07
unilateral B-Disease 0 1.221309958054917e-06
retinoblastoma I-Disease 1 0.813564658164978
, O 0 9.005635206449369e-07
tumor B-Disease 0 0.023092158138751984
development O 0 1.7428207854663924e-07
is O 0 3.411496640737255e-09
initiated O 0 1.976835228845175e-08
by O 0 3.244481128206189e-09
somatic O 0 8.766794508119347e-07
inactivation O 0 3.1522024528385373e-06
of O 0 5.6629424705079145e-08
both O 0 2.1347175138686225e-09
alleles O 0 3.6975755790535914e-09
of O 0 1.0079239132210205e-07
the O 0 9.577858008924522e-07
RB1 O 1 0.9998358488082886
gene O 0 8.264467396656983e-06
. O 0 2.8542301606648834e-06

However O 0 2.265583589178277e-06
, O 0 7.175361815825454e-08
some O 0 2.4890063343718793e-09
of O 0 2.5454339080965838e-08
these O 0 5.3827533541550565e-09
patients O 0 5.394576163553211e-08
can O 0 4.860557289987355e-09
transmit O 0 1.3668470273842104e-05
retinoblastoma B-Disease 0 0.006831291597336531
predisposition O 0 1.4953476238588337e-05
to O 0 1.1833488144930016e-07
their O 0 2.3683398353568919e-07
offspring O 0 2.621281055326108e-06
. O 0 9.120606137003051e-07

To O 0 2.1167939223687426e-07
determine O 0 7.535953727710876e-08
the O 0 2.2380534758781323e-08
frequency O 0 3.551140537183528e-08
and O 0 3.4620026845288976e-09
nature O 0 2.071211824272723e-08
of O 0 3.242626789301539e-08
constitutional O 0 4.076516404438735e-07
RB1 O 1 0.9989417195320129
- O 0 1.6122605757118436e-06
gene O 0 4.164838074416366e-08
mutations O 0 1.0140903228261777e-08
in O 0 1.0482466450412176e-08
patients O 0 2.886627292753019e-08
with O 0 6.378853889543734e-09
isolated O 0 4.712418046892708e-07
unilateral B-Disease 0 1.120232695939194e-06
retinoblastoma I-Disease 0 0.007924352772533894
, O 0 5.939310554481381e-08
we O 0 2.6807549513563345e-09
analyzed O 0 2.7356376719467335e-08
DNA O 0 2.51536192763524e-07
from O 0 7.065209928214244e-08
peripheral O 0 2.0611978470697068e-05
blood O 0 2.4403036604780937e-06
and O 0 8.754257407872501e-08
from O 0 4.792913841811242e-06
tumor B-Disease 1 0.9988918900489807
tissue O 0 0.0025183800607919693
. O 0 1.911778326757485e-06

The O 0 8.767639201323618e-07
analysis O 0 1.6221900978052872e-07
of O 0 2.585780748631805e-06
tumors B-Disease 1 0.999998927116394
from O 0 2.6998557700608217e-07
54 O 0 3.5347642324268236e-07
( O 0 4.684455490178152e-09
71 O 0 1.6374909250771452e-07
% O 0 2.6036295341924642e-09
) O 0 1.2008118943640511e-09
of O 0 1.6661964252762118e-08
76 O 0 4.872910039921408e-07
informative O 0 1.3799751741316868e-07
patients O 0 9.671982326153739e-08
showed O 0 1.9942719120535912e-07
loss O 0 1.990717692024191e-06
of O 0 5.590869136540277e-07
constitutional O 0 1.0709478601711453e-06
heterozygosity O 0 0.22434484958648682
( O 0 3.84106488127145e-06
LOH O 1 0.9999998807907104
) O 0 2.991961025600176e-07
at O 0 2.9118102702341275e-06
intragenic O 0 0.00016704777954146266
loci O 0 1.3056266652711201e-05
. O 0 4.138787971896818e-06

Three O 0 3.206229848728981e-06
of O 0 7.318959433177952e-06
13 O 0 1.533942668174859e-05
uninformative O 0 0.367881178855896
patients O 0 2.866541080948082e-06
had O 0 1.2222614031998091e-07
constitutional O 0 1.0738153832789976e-06
deletions O 0 1.8594577340991236e-05
. O 0 3.82778353014146e-06

For O 0 1.8023497432295699e-06
39 O 0 9.361145885122824e-07
randomly O 0 8.148293062504308e-08
selected O 0 1.1497197647258872e-06
tumors B-Disease 1 0.9999995231628418
, O 0 4.220483731387503e-07
SSCP O 1 0.9999979734420776
, O 0 3.843850038265373e-07
hetero O 0 1.893999069579877e-05
- O 0 4.460488014501607e-07
duplex O 0 1.7938496910119284e-07
analysis O 0 2.416010058681195e-09
, O 0 8.771162685050626e-10
sequencing O 0 1.8055303030450887e-08
, O 0 3.2732661026102505e-09
and O 0 1.7009846864368683e-09
Southern O 0 6.468825120009569e-08
blot O 0 1.1210695447516628e-06
analysis O 0 3.3267602006503694e-09
were O 0 6.089856618984868e-09
used O 0 7.836551851880813e-09
to O 0 1.2450706243782861e-08
identify O 0 3.594570614495751e-07
mutations O 0 1.4227488236429053e-06
. O 0 2.122345904354006e-06

Mutations O 0 1.746234374877531e-06
were O 0 3.344969172758283e-07
detected O 0 4.2399128119541274e-07
in O 0 2.436177481968116e-08
21 O 0 1.1173909086892309e-07
( O 0 3.65164121163275e-09
91 O 0 1.0101295089270934e-07
% O 0 1.8707406734819187e-09
) O 0 1.1505464359018447e-09
of O 0 7.69078951634583e-08
23 O 0 9.00679879123345e-05
tumors B-Disease 1 1.0
with O 0 2.6475996492081322e-05
LOH O 1 1.0
. O 0 3.5857367038261145e-05

In O 0 3.939674570574425e-06
6 O 0 2.8326421670499258e-06
( O 0 2.7438156635639643e-08
38 O 0 8.735242573720825e-08
% O 0 1.5089792748668174e-09
) O 0 6.648128714203949e-10
of O 0 5.1241968890280987e-08
16 O 0 1.1476382496766746e-05
tumors B-Disease 1 1.0
without O 0 2.0507961835392052e-06
LOH O 1 1.0
, O 0 2.5678016157826278e-08
one O 0 2.5766606626120847e-09
mutation O 0 5.177214656981732e-09
was O 0 5.0741572721335615e-08
detected O 0 9.491025565466771e-08
, O 0 3.753999333611091e-09
and O 0 2.107651164706681e-09
in O 0 8.580477661723762e-09
9 O 0 1.165920764378825e-07
( O 0 2.4326842762434353e-09
56 O 0 3.6763680100193596e-08
% O 0 1.0616468815172198e-09
) O 0 1.151439943392063e-09
of O 0 4.550128807068177e-08
the O 0 1.27596808852104e-06
tumors B-Disease 1 1.0
without O 0 3.5747059428103967e-06
LOH O 1 1.0
, O 0 3.850229646218395e-08
both O 0 3.431263051467681e-09
mutations O 0 2.0562620051123304e-08
were O 0 4.934409858492472e-08
found O 0 3.5100538298138417e-07
. O 0 5.361807211556879e-07

Thus O 0 2.5854501473077107e-06
, O 0 3.6891666610472384e-08
a O 0 4.544679299556265e-09
total O 0 3.5119096519764526e-09
of O 0 1.1042629033397589e-08
45 O 0 1.1384730491670325e-08
mutations O 0 3.276332982693475e-09
were O 0 3.2293179241804637e-09
identified O 0 1.4342213638940393e-08
in O 0 1.279818775401509e-07
tumors B-Disease 1 0.9999998807907104
of O 0 1.7522885173093528e-05
36 O 0 1.6496651369379833e-05
patients O 0 3.29097019857727e-06
. O 0 1.952238335434231e-06

Thirty O 0 0.00012703891843557358
- O 0 9.05153683561366e-06
nine O 0 3.893899247486843e-07
of O 0 9.09682427163716e-08
the O 0 2.160368239856325e-08
mutations O 0 9.074621942772865e-09
- O 0 1.9463716682821541e-07
including O 0 2.1517241322044356e-08
34 O 0 6.92595278906083e-08
small O 0 4.576751866380846e-09
mutations O 0 8.608968649070903e-09
, O 0 1.0153948792890333e-08
2 O 0 7.136856794431878e-08
large O 0 2.6106276251880445e-08
structural O 0 1.255703409697162e-06
alterations O 0 7.209710929600988e-06
, O 0 3.0790058502816464e-08
and O 0 1.688868778160213e-08
hypermethylation O 0 5.231065006228164e-05
in O 0 2.159034124815662e-07
3 O 0 3.7856930248381104e-06
tumors O 1 0.9999997615814209
- O 0 3.9444577737413056e-07
were O 0 9.026424940827837e-09
not O 0 3.169708107098046e-10
detected O 0 3.106364587779353e-08
in O 0 2.800269571778813e-09
the O 0 1.2271570426491962e-08
corresponding O 0 9.624761077020594e-08
peripheral O 0 0.00018620463379193097
blood O 0 4.504734170041047e-05
DNA O 0 4.534166509984061e-05
. O 0 1.579675199536723e-06

In O 0 3.6759131489816355e-06
6 O 0 2.6739855911728228e-06
( O 0 3.531215853058711e-08
17 O 0 7.016608805088254e-08
% O 0 1.921796499715356e-09
) O 0 2.686630085069197e-10
of O 0 3.1030114033825384e-09
the O 0 9.542846512999859e-09
36 O 0 9.930889177667268e-08
patients O 0 2.4328944192575364e-08
, O 0 2.3681416827514568e-09
a O 0 1.107502711761299e-08
mutation O 0 1.4001215298264924e-08
was O 0 1.739086741281426e-07
detected O 0 5.8955414772299264e-08
in O 0 2.7573445748885206e-09
constitutional O 0 2.026878398453391e-08
DNA O 0 4.728389910724218e-07
, O 0 3.367593315317663e-09
and O 0 1.5357680682726027e-09
1 O 0 1.3532809539640311e-08
of O 0 2.9480655694413826e-09
these O 0 1.8681295399503028e-10
mutations O 0 3.21068416297976e-09
is O 0 8.073348656267854e-10
known O 0 4.094693917267023e-09
to O 0 1.769405399976165e-09
be O 0 2.812323707246378e-09
associated O 0 6.171218558392866e-08
with O 0 6.130906626822252e-08
reduced O 0 4.679654466599459e-06
expressivity O 0 0.00030779000371694565
. O 0 4.134534719923977e-06

The O 0 1.4695239087814116e-06
presence O 0 1.7177738698137546e-07
of O 0 1.3635143147894269e-07
a O 0 2.1988888931900874e-08
constitutional O 0 4.993556146359879e-08
mutation O 0 2.9442123405942766e-08
was O 0 9.590493021960356e-08
not O 0 3.8410499780816565e-10
associated O 0 3.1043136949904238e-09
with O 0 4.926016816675372e-10
an O 0 5.759877019784199e-10
early O 0 1.1714824665887136e-07
age O 0 6.466739677080113e-08
at O 0 8.411581120526535e-07
treatment O 0 2.3474483441532357e-06
. O 0 9.538716767565347e-07

In O 0 2.594284978840733e-06
1 O 0 2.345282155147288e-06
patient O 0 1.5872544736339478e-06
, O 0 2.8332472368219896e-08
somatic O 0 1.3523706911655609e-05
mosaicism O 0 0.327805757522583
was O 0 1.4742430494152359e-06
demonstrated O 0 1.9129144490648287e-08
by O 0 7.397437107314886e-10
molecular O 0 3.104564072486937e-08
analysis O 0 2.056135484096444e-09
of O 0 1.3321273861777172e-08
DNA O 0 4.4811750399276207e-07
and O 0 1.6622159648704837e-08
RNA O 0 1.5272587461367948e-06
from O 0 6.65658433263161e-07
peripheral O 0 0.0006802446441724896
blood O 0 7.099231879692525e-05
. O 0 3.126263891317649e-06

In O 0 5.24844335814123e-06
2 O 0 5.486317604663782e-06
patients O 0 1.6233988731073623e-07
without O 0 1.1107182729119813e-08
a O 0 1.4796750491541388e-08
detectable O 0 3.172214064761647e-06
mutation O 0 2.3052596276329496e-08
in O 0 3.546064419879258e-08
peripheral O 0 4.688263652496971e-05
blood O 0 1.2752838301821612e-05
, O 0 7.140628355273293e-08
mosaicism O 0 0.008283689618110657
was O 0 2.655393984696275e-07
suggested O 0 6.916867079098665e-09
because O 0 1.7520397355141881e-09
1 O 0 2.0282746149291597e-08
of O 0 7.955406111648244e-09
the O 0 7.3128898492313965e-09
patients O 0 9.789129506998506e-08
showed O 0 2.2812150746176485e-06
multifocal O 1 1.0
tumors B-Disease 1 1.0
and O 0 1.9010175833500398e-07
the O 0 1.7846355149231385e-07
other O 0 1.1797606447316866e-08
later O 0 3.4984807939508755e-07
developed O 0 5.205909019423416e-07
bilateral B-Disease 0 9.002234037325252e-06
retinoblastoma I-Disease 0 0.048495516180992126
. O 0 6.9217330747051165e-06

In O 0 8.311664601023949e-07
conclusion O 0 3.0971210662755766e-07
, O 0 1.7804495655582286e-08
our O 0 1.5450885015866334e-08
results O 0 6.5673586568948394e-09
emphasize O 0 1.8391826728247906e-08
that O 0 6.564487842197764e-10
the O 0 2.7080901965348403e-09
manifestation O 0 5.223110406404885e-07
and O 0 2.027613099642167e-08
transmissibility O 0 3.5936352560383966e-06
of O 0 3.088051983013429e-07
retinoblastoma B-Disease 0 1.2128623438911745e-06
depend O 0 2.9832263326312614e-09
on O 0 1.4428341188477134e-08
the O 0 4.257141750230176e-09
nature O 0 1.1455086657008451e-08
of O 0 1.0512580139732108e-08
the O 0 3.164719819537254e-09
first O 0 1.1358790352744563e-08
mutation O 0 2.287955824797905e-09
, O 0 6.205229108324772e-10
its O 0 6.429015098063928e-10
time O 0 6.574060185116082e-10
in O 0 2.15878959153315e-09
development O 0 6.272273367358139e-09
, O 0 2.303496060562793e-09
and O 0 1.4373645607079766e-09
the O 0 1.620767520194022e-09
number O 0 4.2444675552033573e-10
and O 0 3.7045766454468776e-10
types O 0 7.69780150733368e-09
of O 0 4.922903329429573e-08
cells O 0 3.586365693308835e-08
that O 0 7.808140800591445e-10
are O 0 6.848757116983961e-10
affected O 0 4.191759117588845e-08
. O 0 1.1312720005207666e-07
. O 0 5.082570169179235e-07

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9960373044013977
the I-Disease 0 0.00015094346599653363
fifth I-Disease 0 0.2129783034324646
component I-Disease 0 2.75654747383669e-06
of I-Disease 0 3.0793589189670456e-07
complement I-Disease 0 5.579710204983712e-07
in O 0 4.6229644112827373e-07
man O 0 1.396341212966945e-05
. O 0 1.5556593098153826e-06

I O 0 0.0842137336730957
. O 0 8.735176379559562e-05

Clinical O 0 0.01079641655087471
, O 0 1.4577307183571975e-06
immunochemical O 0 0.0013195271603763103
, O 0 1.198135066715622e-07
and O 0 4.3383110437389405e-08
family O 0 1.0240874814826384e-07
studies O 0 3.4917943025902787e-07
. O 0 5.982457196296309e-07

The O 0 2.5928036393452203e-06
first O 0 6.229735163287842e-07
recognized O 0 1.449991060553657e-07
human O 0 1.3661616549143218e-07
kindred O 0 0.00012430331844370812
with O 0 1.176971181848785e-06
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9999415874481201
the I-Disease 0 0.0001688759366516024
fifth I-Disease 0 0.04303586855530739
component I-Disease 0 1.1901842071893043e-06
of I-Disease 0 4.988173145648034e-07
complement I-Disease 0 1.5106782029761234e-06
( O 0 1.661587589296687e-06
C5 O 1 0.9999977350234985
) O 0 1.7777796301743365e-07
is O 0 4.5213461419280065e-08
described O 0 5.940357823419617e-07
. O 0 1.0137953267985722e-06

The O 0 1.4061992260394618e-05
proband O 0 0.0005968530313111842
, O 0 4.460445097720367e-07
a O 0 1.0890526169760051e-07
20 O 0 1.5991300017503818e-07
- O 0 2.913372156854166e-07
year O 0 1.0900210867248461e-07
- O 0 2.221621343778679e-06
old O 0 6.082399977458408e-06
black O 0 7.134814836717851e-07
female O 0 6.922809347997827e-08
with O 0 4.0073800278150884e-07
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 0 0.2216043323278427
age O 0 7.531206847488647e-06
11 O 0 5.522836090676719e-07
, O 0 1.8159154180352743e-08
lacked O 0 2.488348854967626e-06
serum O 0 9.839358244789764e-05
hemolytic O 1 0.9999992847442627
complement O 0 4.508890469878679e-06
activity O 0 1.6925891941355076e-06
, O 0 5.3803130839469304e-08
even O 0 3.955814875666874e-08
during O 0 6.166665684759209e-07
remission O 0 2.902110463764984e-05
. O 0 1.0747939995781053e-06

C5 O 1 0.9999797344207764
was O 0 7.570444722659886e-05
undetectable O 0 4.907524271402508e-05
in O 0 3.405276771673016e-08
her O 0 7.714086258658881e-09
serum O 0 2.2186054593476e-07
by O 0 5.895470778227718e-09
both O 0 2.63820361112721e-08
immunodiffusion O 0 0.0008529891492798924
and O 0 3.5198625027987873e-06
hemolytic O 1 1.0
assays O 0 0.0002311731514055282
. O 0 1.7923150153364986e-05

Other O 0 4.005393350325903e-07
complement O 0 8.56811539051705e-07
components O 0 3.3270778203586815e-06
were O 0 8.89042013341168e-08
normal O 0 4.7411056414148334e-08
during O 0 6.387816853248296e-08
remission O 0 9.291574656344892e-07
of O 0 3.514385014113941e-07
lupus O 1 0.999953031539917
, O 0 9.266428691034889e-08
but O 0 2.6278129894308222e-08
C1 O 0 0.0004901550710201263
, O 0 1.9320115995924425e-07
C4 O 1 0.9999978542327881
, O 0 8.979067160908016e-07
C2 O 0 0.0037927867379039526
, O 0 2.1806231131904497e-07
and O 0 3.574027118702361e-07
C3 O 1 0.999998927116394
levels O 0 1.5422348951688036e-05
fell O 0 0.00019979331409558654
during O 0 3.857282536046114e-06
exacerbations O 0 0.0006750512984581292
. O 0 2.018843360929168e-06

A O 0 0.00013211806071922183
younger O 0 4.353091753728222e-06
half O 0 6.0086790654168e-07
- O 0 3.440506816332345e-06
sister O 0 9.254626434085367e-07
, O 0 2.0030622494005e-08
who O 0 1.4601285514004303e-08
had O 0 3.4355149836073906e-08
no O 0 4.198232161911619e-08
underlying O 0 0.08873555809259415
disease O 1 0.9996631145477295
, O 0 3.049153818324157e-08
was O 0 4.1401753492209536e-07
also O 0 1.863205589813788e-09
found O 0 2.285683420311102e-09
to O 0 6.7535332881618615e-09
lack O 0 1.4687477687402861e-06
immunochemically O 1 0.9940041899681091
detectable O 1 0.9918938279151917
C5 O 1 0.9998996257781982
. O 0 4.6057057261350565e-06

By O 0 1.558134135848377e-05
hemolytic O 1 0.9999934434890747
assay O 0 3.638542693806812e-05
, O 0 8.062828555921442e-07
she O 0 4.224441951805602e-08
exhibited O 0 2.1036245811956178e-07
1 O 0 1.620688721004626e-07
- O 0 1.7182767919621256e-07
2 O 0 2.8382231676005176e-08
% O 0 6.639536698216375e-10
of O 0 1.2348717604027115e-09
the O 0 3.5304190681983982e-09
normal O 0 7.320707595681597e-08
serum O 0 5.545807198359398e-06
C5 O 0 0.492747962474823
level O 0 8.82773179000651e-08
and O 0 1.1950584966058386e-09
normal O 0 2.059950876542871e-09
concentrations O 0 7.959489067843606e-09
of O 0 6.727396417716136e-09
other O 0 2.966493273248716e-09
complement O 0 3.002053290401818e-07
components O 0 1.3047007996647153e-05
. O 0 1.994889316847548e-06

C5 O 1 0.9975441098213196
levels O 0 3.2643417853250867e-06
of O 0 3.644956052539783e-07
other O 0 1.0473872436023157e-08
family O 0 6.6777428031628006e-09
members O 0 2.376508101420427e-09
were O 0 3.4715905705695604e-09
either O 0 1.8147962022041497e-09
normal O 0 4.855368107570257e-09
or O 0 8.377167848294675e-10
approximately O 0 2.3881769894984473e-09
half O 0 7.701267179527349e-09
- O 0 6.214603587295642e-08
normal O 0 2.301420032324586e-08
, O 0 2.3340076538147514e-09
consistent O 0 1.6615885556348076e-08
with O 0 4.101658568345101e-09
autosomal O 0 2.2411670670408057e-06
codominant O 0 5.445165152195841e-05
inheritance O 0 3.9636435644752055e-07
of O 0 2.437795671994536e-07
the O 0 2.515560879601253e-07
gene O 0 1.9273754787718644e-06
determining O 0 0.0003381564747542143
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 5.793404488940723e-05

Normal O 0 0.0008384873508475721
hemolytic O 1 1.0
titers O 0 0.00904112122952938
were O 0 2.0650648480113887e-07
restored O 0 6.298026278273028e-07
to O 0 8.1375111093962e-09
both O 0 1.392679838119193e-08
homozygous O 0 1.7725951693137176e-05
C5 B-Disease 1 1.0
- I-Disease 1 0.9999978542327881
deficient I-Disease 1 1.0
( O 0 6.257302175072255e-06
C5D B-Disease 1 1.0
) O 0 1.490410852511559e-07
sera O 0 2.734501094892039e-06
by O 0 4.320184210371281e-09
addition O 0 1.8476352892093928e-08
of O 0 1.0346640522129746e-07
highly O 0 1.4336463891595486e-06
purified O 0 3.5122287954436615e-05
human O 0 1.6698873878340237e-05
C5 O 1 0.9999330043792725
. O 0 5.8673449530033395e-06

In O 0 2.485659251760808e-06
specific O 0 1.4570816802006448e-06
C5 O 1 0.995648205280304
titrations O 0 0.00013427114754449576
, O 0 1.9440528831182746e-07
however O 0 1.5981230561123994e-08
, O 0 3.525399305814858e-09
it O 0 1.6875832953289205e-09
was O 0 1.5480146942081774e-08
noted O 0 1.66212021923684e-09
that O 0 1.752212680505849e-10
when O 0 9.16545339624264e-10
limited O 0 5.569880112687997e-10
amounts O 0 2.6854427570555117e-09
of O 0 2.7030548466200344e-08
C5 O 0 0.00021568867668975145
were O 0 9.946164780672007e-09
assayed O 0 1.3570513601735001e-07
in O 0 1.829814855192069e-09
the O 0 2.682396971209755e-09
presence O 0 4.3466661381330596e-09
of O 0 4.6703707567985475e-08
low O 0 1.9469045753339742e-07
dilutions O 0 3.11016424348054e-06
of O 0 1.4224026756437524e-07
either O 0 3.7772113614664704e-07
C5D B-Disease 1 1.0
serum O 0 4.416164301801473e-05
, O 0 3.7763861371331586e-08
curving O 0 2.0310062609496526e-07
rather O 0 2.8294764309322318e-09
than O 0 4.3724743270523447e-10
linear O 0 2.8206932345398172e-09
dose O 0 8.761139014268338e-08
- O 0 8.368584047957484e-08
response O 0 1.980982711202728e-09
plots O 0 1.143921313229157e-08
were O 0 5.3931019650121925e-09
consistently O 0 1.1735864724471412e-08
obtained O 0 8.276891172442902e-09
, O 0 2.951858091293502e-09
suggesting O 0 1.067100274809718e-08
some O 0 2.9874056561851603e-09
inhibitory O 0 3.084661273078382e-07
effect O 0 1.124572122535028e-06
. O 0 6.851388434370165e-07

Further O 0 5.286296982376371e-07
studies O 0 1.0818582296678869e-07
suggested O 0 3.3581404323967945e-08
that O 0 1.4629545352917717e-09
low O 0 2.547911606143316e-07
dilutions O 0 2.204475094913505e-05
of O 0 1.1798339983215556e-05
C5D B-Disease 1 1.0
serum O 0 1.4177254342939705e-05
contain O 0 8.971246501232599e-08
a O 0 1.625204504307476e-08
factor O 0 1.4832184369595325e-08
( O 0 3.1397202615579545e-09
or O 0 3.332844666914525e-09
factors O 0 4.534514097542797e-09
) O 0 3.254068570157642e-09
interfering O 0 2.6137465525266634e-08
at O 0 3.1521306453896614e-08
some O 0 3.6313857476599765e-10
step O 0 6.013881836963719e-09
in O 0 5.5597464410084285e-09
the O 0 5.973038952333809e-08
hemolytic O 1 0.9995166063308716
assay O 0 1.9664751107484335e-06
of O 0 2.606053567433264e-05
C5 O 1 0.9999994039535522
, O 0 8.35854976344308e-08
rather O 0 8.030657916435757e-09
than O 0 2.6149817866638614e-09
a O 0 4.0656061628396856e-08
true O 0 1.172344582300866e-06
C5 O 1 0.9503651261329651
inhibitor O 0 4.547614025796065e-06
or O 0 6.408819785974629e-07
inactivator O 0 0.0002123784797731787
. O 0 2.0284776383050485e-06

Of O 0 1.2460309335438069e-05
clinical O 0 3.0454970328719355e-05
interest O 0 8.749849911282581e-08
are O 0 1.88085147456718e-09
( O 0 4.8869575053345216e-09
a O 0 8.283682184639929e-09
) O 0 9.692177060927065e-10
the O 0 9.735328099225171e-10
documentation O 0 2.106023373471544e-07
of O 0 9.985674296331126e-07
membranous O 1 0.9999850988388062
glomerulonephritis B-Disease 1 1.0
, O 0 0.00014891229511704296
vasculitis B-Disease 1 1.0
, O 0 1.3816523278364912e-05
and O 0 0.0009427754557691514
arthritis B-Disease 1 1.0
in O 0 1.3894741641706787e-06
an O 0 1.2831852913564035e-08
individual O 0 4.470520664767719e-08
lacking O 0 8.544014417566359e-05
C5 O 1 0.9999998807907104
( O 0 6.609672453805615e-08
and O 0 4.810440046298936e-09
its O 0 3.4806206805626516e-09
biologic O 0 4.14155721273346e-07
functions O 0 3.503292544948522e-09
) O 0 1.2573796448478447e-09
, O 0 9.797768152353115e-10
and O 0 2.229956441723857e-09
( O 0 1.251897696619153e-08
b O 0 1.543074716892079e-07
) O 0 1.8539602075762218e-09
a O 0 3.5196079384292034e-09
remarkable O 0 1.5060127367405585e-08
propensity O 0 3.1958518320607254e-07
to O 0 1.0784814463704606e-07
bacterial B-Disease 1 1.0
infections I-Disease 1 0.9999996423721313
in O 0 4.012289878119191e-08
the O 0 7.456330308741599e-08
proband O 0 9.740560926729813e-05
, O 0 1.1069642091854348e-08
even O 0 7.513198951869526e-10
during O 0 3.4066849341485295e-09
periods O 0 8.173006271761096e-09
of O 0 1.8466170814690486e-08
low O 0 4.5133245407669165e-07
- O 0 2.6850148060475476e-07
dose O 0 1.2554288275623549e-07
or O 0 8.217728719728257e-09
alternate O 0 1.3939640552962373e-07
- O 0 2.2387553144653793e-06
day O 0 1.9349042759131407e-06
corticosteroid O 0 0.003040091833099723
therapy O 0 0.00019082189828623086
. O 0 1.7345430478599155e-06

Other O 0 2.3618463274033275e-07
observations O 0 7.760915536891844e-07
indicate O 0 5.8357539245434964e-08
that O 0 1.7861562229271044e-09
the O 0 7.126995171802264e-08
C5D B-Disease 1 1.0
state O 0 5.1723414884463637e-08
is O 0 3.00828761901073e-09
compatible O 0 6.038089850335382e-08
with O 0 2.0811106171692018e-09
normal O 0 4.35196092496426e-08
coagulation O 0 1.1238173556193942e-06
function O 0 7.1672476842365995e-09
and O 0 3.2703519892152144e-09
the O 0 3.967752348899012e-09
capacity O 0 1.6248137058028078e-08
to O 0 6.01613026063319e-09
mount O 0 2.5484259822405875e-05
a O 0 5.240778477855201e-07
neutrophilic O 1 0.9793382287025452
leukocytosis O 0 0.10497733950614929
during O 0 0.00014236831339076161
pyogenic B-Disease 1 0.99993896484375
infection I-Disease 0 0.00037820969009771943
. O 0 2.791076099128986e-07
. O 0 9.481650522502605e-07

Susceptibility O 0 0.0023279329761862755
to O 0 0.00026753894053399563
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.00014732930867467076
twins O 0 4.6482018660753965e-05
: O 0 9.603339456987214e-09
the O 0 6.939119501225832e-09
role O 0 5.327211116679109e-09
of O 0 3.72627972922146e-08
genes O 0 6.010636433018135e-09
, O 0 1.2853335285001322e-08
HLA O 0 0.008981497026979923
, O 0 4.3996003284973995e-08
and O 0 1.9546877894072168e-08
the O 0 1.1558704215985927e-07
environment O 0 8.543163971808099e-07
. O 0 7.932346193229023e-07

OBJECTIVE O 0 4.332829485065304e-05
To O 0 7.567122395357728e-08
determine O 0 4.0086561625685135e-08
the O 0 1.7216041925394165e-08
relative O 0 1.6788677115187056e-08
effects O 0 1.983475783617905e-07
of O 0 9.934072409123473e-08
genetic O 0 1.4416819738016784e-07
and O 0 6.8649512741103536e-09
environmental O 0 4.941492903753897e-08
factors O 0 1.1561191115561087e-08
in O 0 2.2122367937527088e-08
susceptibility O 0 1.424045194653445e-06
to O 0 4.148160769545939e-06
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.00039965746691450477
AS B-Disease 1 1.0
) O 0 4.7314708240264736e-07
. O 0 3.007979785252246e-07

METHODS O 0 0.00010140311496797949
Twins O 0 3.236169504816644e-05
with O 0 4.825909272199169e-08
AS B-Disease 1 0.9488754272460938
were O 0 2.2588013237623272e-08
identified O 0 7.2307524412451585e-09
from O 0 6.642022931657721e-09
the O 0 1.4536095882533573e-08
Royal O 0 6.048240538802929e-05
National O 0 7.861236372264102e-05
Hospital O 1 0.9999992847442627
for O 0 0.00025890959659591317
Rheumatic B-Disease 1 1.0
Diseases I-Disease 1 1.0
database O 0 6.805727753089741e-05
. O 0 3.644998059826321e-06

Clinical O 0 0.0006791428313590586
and O 0 6.328684207801416e-07
radiographic O 0 9.564237552694976e-05
examinations O 0 7.908781299192924e-06
were O 0 1.472208595032498e-07
performed O 0 3.1312720238929614e-07
to O 0 3.1931077781877093e-09
establish O 0 9.672628209500544e-08
diagnoses O 0 0.0002202097821282223
, O 0 1.3544783428187657e-07
and O 0 3.5005741665372625e-06
disease O 1 0.9999953508377075
severity O 0 0.000288523908238858
was O 0 9.924959840645897e-07
assessed O 0 5.599188312999104e-08
using O 0 5.519395607223032e-09
a O 0 6.4860325998949975e-09
combination O 0 4.470674141998643e-08
of O 0 5.677348013932715e-08
validated O 0 9.051674396687304e-07
scoring O 0 9.900343229674036e-07
systems O 0 2.2913014618097804e-05
. O 0 1.7358205468553933e-06

HLA O 0 0.0013063106453046203
typing O 0 7.3608039201644715e-06
for O 0 4.3950254280389345e-07
HLA O 0 0.00027306744595989585
- O 0 1.172487191070104e-05
B27 O 0 2.2440746761276387e-05
, O 0 1.089717613922403e-07
HLA O 0 3.486399873509072e-05
- O 0 2.341677372896811e-06
B60 O 0 8.836228516884148e-06
, O 0 2.3644600943839578e-08
and O 0 5.510625200599861e-08
HLA O 0 0.04660435765981674
- O 0 0.00011798398190876469
DR1 O 1 0.9999347925186157
was O 0 1.022336277856084e-06
performed O 0 2.0946242784702918e-07
by O 0 1.7561249121555988e-09
polymerase O 0 1.459900857980756e-07
chain O 0 9.47588603139593e-08
reaction O 0 6.018356923931378e-09
with O 0 1.0293563779129045e-09
sequence O 0 6.160984167280503e-09
- O 0 1.795492110545638e-08
specific O 0 7.752727904097867e-10
primers O 0 1.4383421387265116e-07
, O 0 9.111285059759666e-09
and O 0 1.685071993051679e-08
zygosity O 0 3.1359566492028534e-05
was O 0 2.302074761928452e-07
assessed O 0 1.377793523715809e-07
using O 0 5.161757243854481e-08
microsatellite O 0 1.4279237802838907e-05
markers O 0 1.9799161236733198e-05
. O 0 2.726088041526964e-06

Genetic O 0 2.989545464515686e-05
and O 0 1.8670276347165782e-07
environmental O 0 1.4200172415712586e-07
variance O 0 1.4700375139398147e-08
components O 0 1.5463508873381215e-07
were O 0 8.930184591804391e-09
assessed O 0 1.9158026276500095e-08
with O 0 5.20877896370564e-10
the O 0 7.216258701703282e-09
program O 0 2.1427302598908682e-08
Mx O 0 2.354816160732298e-06
, O 0 5.77103920207378e-10
using O 0 1.9444304499849352e-10
data O 0 8.235769288766903e-10
from O 0 9.573012382801949e-10
this O 0 1.165181007234395e-10
and O 0 3.510347568180805e-10
previous O 0 3.358772815431621e-09
studies O 0 1.7526649020993545e-09
of O 0 1.0546118645038405e-08
twins O 0 6.284304845394217e-07
with O 0 3.051736996440013e-08
AS B-Disease 1 0.9999936819076538
. O 0 3.4777870041580172e-06

RESULTS O 0 3.800088234129362e-05
Six O 0 9.430680165678496e-07
of O 0 6.865562340863107e-07
8 O 0 2.4399546418862883e-06
monozygotic O 0 4.0117749449564144e-05
( O 0 8.37667869291181e-07
MZ O 1 0.9999998807907104
) O 0 1.5338373771101033e-07
twin O 0 2.270755430799909e-06
pairs O 0 8.196036560548237e-08
were O 0 6.296158403529262e-07
disease O 0 0.00018000378622673452
concordant O 0 5.769393737864448e-06
, O 0 1.9857878896800685e-08
compared O 0 2.4810683285636514e-08
with O 0 3.4912990276581013e-09
4 O 0 9.850938909039542e-08
of O 0 9.099687758862274e-08
15 O 0 9.268620715374709e-08
B27 O 0 1.838893695094157e-06
- O 0 6.221352464308438e-07
positive O 0 2.6933129504413955e-08
dizygotic O 0 2.5225010176654905e-05
( O 0 4.257513808170188e-07
DZ O 1 0.999975323677063
) O 0 1.3082348004900268e-07
twin O 0 9.760805141922901e-07
pairs O 0 2.0128165800770148e-08
( O 0 7.520930545013016e-09
27 O 0 1.996079532773365e-07
% O 0 1.20716836526924e-09
) O 0 6.778450023503524e-10
and O 0 1.0592297039480059e-09
4 O 0 3.231186340713066e-08
of O 0 7.937357793252886e-08
32 O 0 7.965109602992015e-07
DZ O 1 0.9999717473983765
twin O 0 6.3251404753827956e-06
pairs O 0 3.114831059747303e-08
overall O 0 2.651790396157594e-07
( O 0 2.465232817883134e-08
12 O 0 1.681404881992421e-07
. O 0 7.452715777844787e-09
5 O 0 8.469653067777472e-08
% O 0 8.606243717679263e-09
) O 0 2.568114965129098e-08
. O 0 2.85401029032073e-07

Nonsignificant O 0 0.002901487983763218
increases O 0 1.2779653388861334e-06
in O 0 8.862974709700211e-08
similarity O 0 3.369952850107438e-08
with O 0 1.2360265033706241e-09
regard O 0 9.004483381147566e-09
to O 0 2.588759207000635e-09
age O 0 1.4949804949537793e-07
at O 0 4.379973324830644e-05
disease O 1 0.7685771584510803
onset O 0 0.000205982054467313
and O 0 9.098851450062284e-09
all O 0 3.2441282993289633e-09
of O 0 6.032851729287358e-08
the O 0 5.855672498000786e-07
disease O 1 0.7836734056472778
severity O 0 6.358072823786642e-07
scores O 0 5.4926289294598973e-08
assessed O 0 3.826611560953097e-08
were O 0 5.756980225868347e-09
noted O 0 7.876667318384989e-09
in O 0 9.061169237156719e-08
disease O 0 0.15587729215621948
- O 0 3.973971979576163e-05
concordant O 0 0.00029786929371766746
MZ O 1 0.9999964237213135
twins O 0 1.2514949048636481e-05
compared O 0 2.908178373672854e-07
with O 0 1.1832720758775395e-07
concordant O 0 0.0005857511423528194
DZ O 1 0.9999998807907104
twins O 0 0.002640464808791876
. O 0 8.437229553237557e-06

HLA O 0 0.1533779799938202
- O 0 8.693544077686965e-05
B27 O 0 5.610294101643376e-05
and O 0 8.847571564274403e-08
B60 O 0 5.233264801063342e-06
were O 0 2.041610613900957e-08
associated O 0 2.0830180247344288e-08
with O 0 3.168597162428455e-09
the O 0 2.2142087630072638e-07
disease O 0 0.001790750538930297
in O 0 3.0776966752910084e-08
probands O 0 0.0016627199947834015
, O 0 5.2671560446526655e-09
and O 0 2.255416298169166e-09
the O 0 3.5251841445926857e-09
rate O 0 9.738099215894636e-09
of O 0 7.519427214219832e-08
disease O 0 1.461450938222697e-05
concordance O 0 7.639137038495392e-07
was O 0 1.1505947128398475e-07
significantly O 0 4.329629099686372e-09
increased O 0 1.5896464145015443e-09
among O 0 1.2584646214008899e-08
DZ O 1 0.9854688048362732
twin O 0 7.748964208076359e-07
pairs O 0 9.194418559843598e-09
in O 0 6.5526442050156675e-09
which O 0 3.805102455345377e-09
the O 0 5.3365194929710924e-08
co O 0 1.0286354381605634e-06
- O 0 2.6317411538911983e-06
twin O 0 4.715659997600596e-06
was O 0 1.8464221795966296e-07
positive O 0 1.339622968110632e-09
for O 0 2.3359449929927223e-09
both O 0 3.2001150174210125e-08
B27 O 0 5.179342770134099e-05
and O 0 3.794526946876431e-06
DR1 O 1 0.9994392991065979
. O 0 9.28608096728567e-06

Additive O 0 5.44037311556167e-06
genetic O 0 2.0720119664474623e-06
effects O 0 1.8330036937186378e-06
were O 0 6.506044769594155e-08
estimated O 0 4.9890314102185584e-09
to O 0 1.2458253317859658e-09
contribute O 0 3.829778716379906e-09
97 O 0 1.7738625501806382e-07
% O 0 1.1557085288771418e-09
of O 0 4.0549554825020095e-09
the O 0 3.0220554947391065e-09
population O 0 3.3075622796197024e-10
variance O 0 2.009786115308998e-08
. O 0 2.3054141706779774e-07

CONCLUSION O 0 6.943524203961715e-05
Susceptibility O 0 1.889225677587092e-05
to O 0 2.572908215370262e-07
AS B-Disease 1 0.989846408367157
is O 0 5.573708161676905e-09
largely O 0 7.80451170356855e-09
genetically O 0 1.9012889040936898e-08
determined O 0 8.001912910060582e-09
, O 0 5.5778670571271505e-09
and O 0 1.592152854001938e-09
the O 0 8.410985685713968e-09
environmental O 0 1.820309734057446e-07
trigger O 0 8.882996382908459e-08
for O 0 6.7918346502438e-09
the O 0 7.068598506521084e-07
disease O 1 0.6650965809822083
is O 0 2.1044385789537046e-08
probably O 0 2.5823874238994904e-07
ubiquitous O 0 7.854818250052631e-06
. O 0 7.787650702084647e-07

HLA O 1 0.9796156883239746
- O 0 9.912985115079209e-05
B27 O 0 8.548236110073049e-06
accounts O 0 2.1318703247175108e-08
for O 0 1.0047870979690288e-08
a O 0 6.924233186822448e-09
minority O 0 1.1542149458421136e-09
of O 0 1.2155281226000625e-08
the O 0 1.68057212590611e-08
overall O 0 2.9302580628609576e-07
genetic O 0 3.3018051226463285e-07
susceptibility O 0 8.380865210710908e-07
to O 0 2.550401063672325e-07
AS B-Disease 1 0.9999955892562866
. O 0 5.039371899329126e-06

Cell O 0 0.00012361280096229166
cycle O 0 6.314713118626969e-06
- O 0 2.479375780239934e-06
dependent O 0 1.5436560829584778e-07
colocalization O 0 9.923597644956317e-06
of O 0 1.4788505495744175e-06
BARD1 O 1 0.9999305009841919
and O 0 8.037496002089028e-08
BRCA1 O 0 3.400448633783526e-07
proteins O 0 9.14373643468025e-09
in O 0 1.8017461300701143e-08
discrete O 0 2.853577427686105e-07
nuclear O 0 1.702377267065458e-05
domains O 0 1.8009786799666472e-06
. O 0 1.1784043181251036e-06

Germ O 1 0.9999978542327881
- O 0 0.0003672009625006467
line O 0 2.473945642122999e-06
mutations O 0 5.220072907263784e-08
of O 0 1.758415777430855e-07
the O 0 1.8612534802286973e-07
BRCA1 O 0 1.7197213310282677e-05
gene O 0 2.2479518690943223e-07
predispose O 0 1.322788847346601e-07
women O 0 3.7324805468585964e-09
to O 0 4.217137750117672e-09
early O 0 3.659424919533194e-06
- O 0 0.0002592180680949241
onset O 1 0.9999970197677612
breast B-Disease 1 0.9999954700469971
and I-Disease 1 0.953672468662262
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 3.725583397340415e-08
compromising O 0 1.6547244285902707e-06
the O 0 6.74711131409822e-08
genes O 0 2.0159133029551413e-08
presumptive O 0 1.989706106542144e-06
function O 0 1.4516977842049528e-08
as O 0 3.245547119945513e-08
a O 0 2.972740560380771e-07
tumor B-Disease 0 0.001305410172790289
suppressor O 0 0.00017317204037681222
. O 0 7.92731862020446e-06

Although O 0 1.3091975006318535e-06
the O 0 2.595539854155504e-07
biochemical O 0 1.7195700365846278e-06
properties O 0 5.340240818441089e-07
of O 0 7.389503480226267e-07
BRCA1 O 0 2.030779114647885e-06
polypeptides O 0 8.405088181007159e-08
are O 0 6.662727036754745e-10
not O 0 7.902742349408243e-10
understood O 0 1.6925644885645852e-08
, O 0 3.112934798821243e-09
their O 0 1.5289114418948202e-09
expression O 0 1.002574112618504e-08
pattern O 0 3.282664806647517e-08
and O 0 5.566356708897047e-09
subcellular O 0 4.101884201190842e-07
localization O 0 4.67281239480144e-07
suggest O 0 1.0244288972671711e-08
a O 0 5.5339106630469814e-09
role O 0 1.4442823825788764e-08
in O 0 3.5519125418659314e-08
cell O 0 4.806682682101382e-06
- O 0 6.292422767728567e-06
cycle O 0 1.384512643198832e-06
regulation O 0 2.979895043608849e-06
. O 0 6.737928970323992e-07

When O 0 6.569630386366043e-06
resting O 0 0.00014163902960717678
cells O 0 4.21862068833434e-07
are O 0 2.551264977057599e-09
induced O 0 5.105422360429657e-07
to O 0 1.422940787421112e-08
proliferate O 0 9.364056836602686e-07
, O 0 1.3442870816504637e-08
the O 0 1.1901549079595952e-08
steady O 0 1.0458006016733634e-07
- O 0 4.646283713327648e-08
state O 0 2.5830033667517682e-09
levels O 0 7.962450254694886e-09
of O 0 2.085514516636522e-08
BRCA1 O 0 3.687379646066802e-08
increase O 0 1.6014298775957059e-09
in O 0 7.448480499050447e-09
late O 0 1.1444949450378772e-06
G1 O 0 4.236566383042373e-05
and O 0 5.6904521095191285e-09
reach O 0 3.201804599228808e-09
a O 0 1.4932634018194335e-09
maximum O 0 5.992984331015805e-09
during O 0 2.5378477630511043e-07
S O 0 2.5642646505730227e-05
phase O 0 8.404801519645844e-06
. O 0 4.833513571611547e-07

Moreover O 0 4.7999715206969995e-06
, O 0 2.1138890815564082e-07
in O 0 9.885138041454411e-08
S O 0 6.7261294134368654e-06
phase O 0 1.5674569340262678e-06
cells O 0 9.293545133459702e-08
, O 0 1.745120137286449e-08
BRCA1 O 0 2.895638999689254e-07
polypeptides O 0 9.38440649633776e-08
are O 0 3.782836266452705e-09
hyperphosphorylated O 0 7.644962352060247e-06
and O 0 4.3161506368960545e-08
accumulate O 0 8.434491292064195e-07
into O 0 1.0425522845025625e-07
discrete O 0 2.81619605857486e-07
subnuclear O 0 1.3974122339277528e-05
foci O 0 2.0638848582166247e-05
termed O 0 1.2994258213439025e-05
" O 0 4.991631612938363e-06
BRCA1 O 0 5.056181544205174e-05
nuclear O 0 0.0006635566242039204
dots O 0 0.00013371599197853357
. O 0 3.0769740533287404e-06

" O 0 0.00013800474698655307
BRCA1 O 0 0.00012614000297617167
associates O 0 2.4683375158929266e-05
in O 0 5.061075398771209e-07
vivo O 0 1.4718998500029556e-06
with O 0 1.6645383738023156e-08
a O 0 3.9229199444434926e-08
structurally O 0 4.91662558488315e-06
related O 0 1.8287014427187387e-06
protein O 0 1.783194193194504e-06
termed O 0 0.00012942087778355926
BARD1 O 1 0.999996542930603
. O 0 1.1374429050192703e-05

Here O 0 3.43340707331663e-06
we O 0 4.3014068751290324e-08
show O 0 3.92769656798464e-08
that O 0 6.61685650715782e-10
the O 0 7.398696322269416e-09
steady O 0 6.943280084215075e-08
- O 0 3.6975073669509584e-08
state O 0 1.7401203811218124e-09
levels O 0 1.2822312100979616e-08
of O 0 4.508781614731561e-08
BARD1 O 1 0.9992765784263611
, O 0 6.972725952181236e-09
unlike O 0 3.2090863300027195e-09
those O 0 7.787021583105513e-10
of O 0 5.374692690907068e-08
BRCA1 O 0 2.247431893920293e-06
, O 0 2.5638668077476723e-08
remain O 0 2.604480364709616e-08
relatively O 0 3.6652341162124458e-09
constant O 0 8.24694978973639e-09
during O 0 1.31778762124668e-07
cell O 0 3.442236220507766e-06
cycle O 0 1.911811068566749e-06
progression O 0 4.254191935615381e-06
. O 0 1.9907430726107123e-07

However O 0 6.394024694600375e-06
, O 0 6.809133310525795e-07
immunostaining O 0 0.00026913153124041855
revealed O 0 4.11834116675891e-06
that O 0 6.616004810666709e-08
BARD1 O 1 0.9995488524436951
resides O 0 5.398458597483113e-06
within O 0 2.824162379511108e-07
BRCA1 O 0 1.4014248108651373e-06
nuclear O 0 1.5607411114615388e-05
dots O 0 8.622092195764708e-07
during O 0 3.675071695852239e-07
S O 0 3.0327737476909533e-06
phase O 0 2.8379238870002155e-07
of O 0 4.879406745317283e-08
the O 0 2.0789572729995598e-08
cell O 0 3.011691092069668e-07
cycle O 0 7.068498319995342e-08
, O 0 2.3587651831746825e-09
but O 0 2.3674584515021024e-10
not O 0 4.6502154904537463e-10
during O 0 3.5296064737622146e-08
the O 0 4.094852101843571e-08
G1 O 0 0.00019789474026765674
phase O 0 6.691217095067259e-06
. O 0 6.921567887729907e-07

Nevertheless O 0 5.7669025409268215e-05
, O 0 1.2894165593024809e-06
BARD1 O 0 0.05681770667433739
polypeptides O 0 8.589722710894421e-07
are O 0 3.0496871694651873e-09
found O 0 3.766651435199719e-09
exclusively O 0 6.844294464514178e-09
in O 0 3.190928188345765e-09
the O 0 3.8785756828474405e-09
nuclear O 0 1.9866789102707116e-07
fractions O 0 3.694849581847848e-08
of O 0 1.461669452140768e-08
both O 0 4.208403847627551e-09
G1 O 0 3.49248293787241e-05
- O 0 4.277431457921921e-07
and O 0 4.781545470677884e-08
S O 0 1.4282206393545493e-05
- O 0 1.2994057669857284e-06
phase O 0 6.649226179433754e-06
cells O 0 7.05502145592618e-07
. O 0 3.1358561614069913e-07

Therefore O 0 6.605238922929857e-06
, O 0 4.022665507363854e-07
progression O 0 8.011359682313923e-07
to O 0 2.2445087566325128e-08
S O 0 8.585467185184825e-06
phase O 0 9.420703008800047e-07
is O 0 1.6306963557255472e-09
accompanied O 0 8.823687558390247e-09
by O 0 7.065567020347885e-10
the O 0 2.2818460454487877e-09
aggregation O 0 2.121186781778306e-08
of O 0 5.691638449434322e-08
nuclear O 0 1.3557963939092588e-05
BARD1 O 1 0.7911052107810974
polypeptides O 0 1.2460218385967892e-06
into O 0 5.37078733486851e-07
BRCA1 O 0 1.7936676158569753e-05
nuclear O 0 0.0002662779879756272
dots O 0 6.782300624763593e-05
. O 0 3.449101086516748e-06

This O 0 6.901213964738417e-07
cell O 0 2.6771572265715804e-06
cycle O 0 5.408277274909778e-07
- O 0 4.199754073397344e-07
dependent O 0 5.684467296873663e-08
colocalization O 0 6.2056178649072535e-06
of O 0 8.626525414001662e-07
BARD1 O 1 0.9999858140945435
and O 0 3.0222042823879747e-07
BRCA1 O 0 3.205765096936375e-06
indicates O 0 5.0871623358261786e-08
a O 0 1.792135861933275e-08
role O 0 3.272737103543477e-08
for O 0 3.696428407806707e-08
BARD1 O 1 0.9999483823776245
in O 0 1.3071801276964834e-06
BRCA1 O 0 9.800216503208503e-05
- O 0 8.654626435600221e-05
mediated O 0 0.0002152471715817228
tumor B-Disease 1 0.9979696869850159
suppression O 0 0.026150165125727654
. O 0 3.4475356187613215e-06

Ethnic O 0 6.691138310088718e-07
differences O 0 4.270449380783248e-07
in O 0 1.719978541814271e-07
the O 0 3.229532410387037e-07
HFE O 0 0.3016740381717682
codon O 0 1.3739042515226174e-05
282 O 0 2.4481321815983392e-05
( O 0 3.6119965898251394e-06
Cys O 1 0.9999963045120239
/ O 0 0.002873223042115569
Tyr O 0 0.1633300483226776
) O 0 2.3166421669884585e-06
polymorphism O 0 1.3217767445894424e-05
. O 0 2.424562126179808e-06

Recent O 0 1.9944213818234857e-06
studies O 0 2.1463753796524543e-07
have O 0 2.5692894478623884e-09
shown O 0 1.7836105925539414e-08
that O 0 1.1146831724317963e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 0.00030029864865355194
HH B-Disease 1 1.0
) O 0 2.2085124840032222e-07
is O 0 2.974703372515819e-09
likely O 0 2.0921351318037296e-09
to O 0 2.0085471064135163e-09
be O 0 2.931602738343031e-09
caused O 0 1.3822617006553628e-07
by O 0 1.523497772382143e-08
homozygosity O 0 4.194921075395541e-06
for O 0 1.1930867849230253e-08
a O 0 6.307210753675463e-08
Cys282Tyr O 0 3.801810089498758e-05
mutation O 0 3.9389050243698875e-08
in O 0 1.4041972917766543e-08
the O 0 6.147475772877442e-08
HFE O 0 0.11661887168884277
gene O 0 6.556784342137689e-07
located O 0 1.6895813814699068e-06
4 O 0 1.7759610955181415e-06
. O 0 5.447956255011377e-07

5 O 0 8.250345854321495e-05
Mb O 0 0.00039879808900877833
telomeric O 0 0.000104016340628732
to O 0 1.3751146070717368e-06
HLA O 1 0.8174606561660767
- O 0 0.00040699398959986866
A O 0 8.806401456240565e-05
. O 0 3.1759464036440477e-06

Population O 0 4.6166725553575816e-08
studies O 0 6.788767592524891e-08
of O 0 2.1690221174708313e-08
this O 0 6.874355529262743e-10
polymorphism O 0 5.845620876243629e-09
are O 0 1.3348475103036606e-10
facilitated O 0 1.1303440849985691e-08
by O 0 2.859467773674851e-09
the O 0 7.543773605789283e-09
fact O 0 4.232561412464975e-09
that O 0 3.3989530634492837e-10
the O 0 1.1959166101860319e-08
Cys282Tyr O 0 0.0002305175003129989
mutation O 0 5.2085859181261185e-08
creates O 0 8.461224609845885e-08
a O 0 3.832484196664154e-08
Rsal O 0 2.6126455850317143e-05
restriction O 0 4.96956488404976e-07
site O 0 3.3415683446946787e-06
. O 0 8.059176366259635e-07

We O 0 9.077755862563208e-07
have O 0 1.2253233983017253e-08
studied O 0 3.819928622306179e-07
the O 0 9.234261355572926e-09
codon O 0 4.980396397513687e-07
282 O 0 2.6281195459887385e-06
( O 0 3.6838304140474065e-07
Cys O 1 0.9999934434890747
/ O 0 0.00013435479195322841
Tyr O 0 0.0018492479575797915
) O 0 3.212443999700554e-08
polymorphism O 0 5.546573333958804e-08
in O 0 3.696842609812734e-09
different O 0 6.802903240732405e-10
ethnic O 0 2.791502584642558e-09
groups O 0 7.975643256941112e-09
. O 0 5.623552397082676e-07

In O 0 1.682715151218872e-06
agreement O 0 3.8841378113829705e-07
with O 0 8.099851456222495e-09
previous O 0 4.718191704000674e-08
observations O 0 1.0284603746413268e-07
the O 0 5.5587523917211e-08
Tyr O 0 0.00028643812402151525
allele O 0 3.520428748515769e-08
appeared O 0 1.3895171235844828e-08
to O 0 7.513198951869526e-10
be O 0 7.171168103781156e-10
rare O 0 2.302921586760931e-08
or O 0 1.7568057231187595e-08
absent O 0 1.1819412293334608e-07
in O 0 2.6485594162295456e-08
Asiatic O 0 5.663083811668912e-06
( O 0 1.3888096894731916e-08
Indian O 0 6.753200665343684e-08
, O 0 4.777030770952706e-09
Chinese O 0 2.0266115896561132e-08
) O 0 5.868052710411575e-09
populations O 0 1.0447256393320004e-08
. O 0 8.379780069844855e-08

The O 0 4.802137482329272e-06
highest O 0 3.591692802729085e-06
allele O 0 2.711911406549916e-08
frequency O 0 2.8842388033467614e-08
( O 0 8.62195115303166e-09
7 O 0 3.581772034522146e-08
. O 0 4.6307518930532865e-10
5 O 0 4.403762243754272e-09
% O 0 3.8855635375867337e-10
) O 0 3.5644442952786903e-10
was O 0 1.3702726953113142e-08
found O 0 3.502631296115055e-09
in O 0 6.8183649837294524e-09
Swedes O 0 3.3630778943916084e-06
. O 0 1.140097197094292e-06

Saamis O 0 0.0018726696725934744
( O 0 1.1421660701671499e-06
2 O 0 8.692625215189764e-07
% O 0 1.0083696544427312e-08
) O 0 2.182108715942377e-09
and O 0 5.147155146545401e-09
Mordvinians O 0 2.5202049073413946e-05
( O 0 2.3758067513313108e-08
1 O 0 2.1485252688080436e-08
. O 0 9.542096002235212e-10
8 O 0 9.163938052836329e-09
% O 0 6.587766998578104e-10
) O 0 5.429191540784473e-10
had O 0 1.0001136585557902e-09
significantly O 0 4.022862487573775e-09
lower O 0 1.9340978596460445e-08
frequencies O 0 2.5611004872416743e-08
of O 0 3.1643715203699685e-08
the O 0 1.592075307144114e-07
Tyr O 0 0.000732418498955667
allele O 0 1.936645048772334e-06
. O 0 7.63368973366596e-07

Comparisons O 0 3.1873310035734903e-06
with O 0 7.297120419025305e-08
allele O 0 4.1034759590274916e-08
frequencies O 0 3.158016070869962e-08
based O 0 1.8817349456412558e-08
on O 0 2.6174282297120044e-08
prevalence O 0 7.094336496038522e-08
estimates O 0 8.091760150819027e-09
of O 0 6.009664588191299e-08
HH B-Disease 1 0.9999978542327881
showed O 0 3.8963770521149854e-07
some O 0 5.290313520589507e-09
disagreements O 0 6.040968969500682e-08
with O 0 2.1219546120221366e-09
the O 0 2.0593745375663275e-08
RFLP O 0 1.7528082025819458e-05
data O 0 3.2799988503029454e-08
, O 0 8.313660870840067e-09
particularly O 0 9.11441411233227e-09
in O 0 5.051840545888808e-08
Finns O 0 8.579876521253027e-06
. O 0 8.263531867669371e-07

The O 0 8.969482223619707e-06
newly O 0 2.9795923182973638e-05
described O 0 1.1837640158773866e-05
HFE O 1 0.9998551607131958
marker O 0 2.2144560716697015e-05
provides O 0 4.6905736184044144e-08
a O 0 1.1392463861170654e-08
new O 0 4.661496078028904e-09
approach O 0 8.388683525595297e-09
to O 0 1.2689295170176251e-09
the O 0 1.916050207384501e-09
screening O 0 2.5382874468959926e-08
of O 0 3.4544321181328996e-08
HH B-Disease 1 0.9999316930770874
as O 0 1.442085739711274e-08
well O 0 1.4613592558276878e-09
as O 0 7.044924088539517e-10
studies O 0 1.2122236547895682e-09
of O 0 4.113457130472398e-09
the O 0 6.887483472439726e-09
relationship O 0 1.9546795293479136e-09
between O 0 6.019895693043509e-09
the O 0 7.222829623287907e-08
HFE O 1 0.9998880624771118
Tyr O 0 0.0021582895424216986
allele O 0 1.346113123190662e-07
and O 0 2.6303050404408168e-08
different O 0 4.86098628016407e-08
disorders O 1 0.9999995231628418
including O 0 0.49493882060050964
cancer B-Disease 1 1.0

Autosomal B-Disease 1 0.9999921321868896
dominant I-Disease 1 0.9999958276748657
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999998807907104
associated O 0 6.891908014949877e-06
with O 0 7.540597835031804e-08
a O 0 1.453137628004697e-07
missense O 0 2.1811231363244588e-06
mutation O 0 6.217817372089485e-08
encoding O 0 1.4869537778849917e-07
Gly23 O 0 0.0003735749050974846
- O 0 7.216648373287171e-05
- O 0 2.8152931918157265e-05
> O 0 2.131583187292563e-06
Val O 0 6.01129031565506e-05
in O 0 4.71000987545267e-07
neurophysin O 0 0.3314203917980194
II O 1 1.0
. O 0 1.2676654478127602e-05

Autosomal B-Disease 1 0.9999794960021973
dominant I-Disease 1 0.9999749660491943
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 0.00014730318798683584
ADNDI B-Disease 1 1.0
) O 0 3.4559087680463563e-07
is O 0 1.3254567221565594e-08
an O 0 8.931551320756626e-08
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 0.01363039668649435
by O 0 3.3779653563215106e-07
progressive O 1 0.9724021553993225
degeneration O 1 1.0
of O 0 9.946306090569124e-05
the O 0 2.201549023084226e-06
magnocellular O 0 0.07501058280467987
neurons O 0 6.767687068531814e-07
of O 0 6.515601285173034e-07
the O 0 1.2932355275552254e-06
hypothalamus O 0 1.2486336345318705e-05
leading O 0 2.017573251578142e-06
to O 0 1.8132192636244326e-08
decreased O 0 9.349157181759438e-08
ability O 0 2.1372759118065687e-09
to O 0 2.634646945054442e-09
produce O 0 6.446445155461333e-08
the O 0 1.6361219934424298e-07
hormone O 0 1.5990094652806874e-06
arginine O 0 4.236729637341341e-06
vasopressin O 0 9.349242645839695e-06
( O 0 1.1374777386663482e-06
AVP O 1 0.9893051385879517
) O 0 7.019572763056203e-07
. O 0 6.766925366719079e-07

Affected O 0 3.399019760763622e-06
individuals O 0 2.274369137467147e-08
are O 0 3.1888778284638875e-09
not O 0 3.800112668983502e-09
symptomatic O 0 3.505184167806874e-06
at O 0 2.8812314667447936e-06
birth O 0 1.9712401808646973e-06
, O 0 1.1661427379294764e-08
but O 0 1.949095107534049e-09
usually O 0 2.8210928704197613e-08
develop O 0 1.2641980902117211e-05
diabetes B-Disease 1 0.9999985694885254
insipidus I-Disease 1 0.909644603729248
at O 0 2.5657764126663096e-05
1 O 0 2.398381866441923e-06
- O 0 3.0998949114291463e-06
6 O 0 1.6033399106163415e-06
yr O 0 6.213393498910591e-05
of O 0 8.18537216673576e-07
age O 0 1.4316407259684638e-06
. O 0 6.568350841007486e-07

The O 0 2.3207574031403055e-06
genetic O 0 1.59435285240761e-06
locus O 0 6.307319040388393e-07
of O 0 4.6761735461586795e-07
the O 0 1.0241611789751914e-06
disease O 0 0.07113423943519592
is O 0 1.0368783165404238e-08
the O 0 1.0760425084299641e-07
AVP O 1 0.9999697208404541
- O 0 9.582221537129954e-06
neurophysin O 0 0.06480339169502258
II O 1 1.0
( O 0 5.203879140935896e-07
NPII O 1 0.999958872795105
) O 0 1.4955245930536876e-08
gene O 0 1.4099297729330829e-08
, O 0 1.6646393152797145e-09
and O 0 1.6816485981507867e-09
mutations O 0 1.1883084738428806e-08
that O 0 3.412518267964515e-09
cause O 0 1.3903371609558235e-06
ADNDI B-Disease 1 0.9999979734420776
have O 0 1.9376489301947686e-09
been O 0 3.185558705709468e-09
found O 0 1.0659015892144907e-09
in O 0 1.3216112648706257e-09
both O 0 7.411121161204903e-10
the O 0 1.0624657598157228e-08
signal O 0 6.185253198509599e-08
peptide O 0 3.076921828437662e-08
of O 0 3.490401923045283e-08
the O 0 5.2194355504298073e-08
prepro O 0 0.00011629865184659138
- O 0 8.692566188983619e-05
AVP O 1 0.9999948740005493
- O 0 6.769868195988238e-05
NPII O 1 0.9999109506607056
precursor O 0 3.67028042091988e-05
and O 0 2.6760520199786697e-07
within O 0 2.4554049105063314e-06
NPII O 1 0.9991798996925354
itself O 0 1.1347354302415624e-05
. O 0 2.2306014670903096e-06

An O 0 4.895571237284457e-07
affected O 0 8.308510928145552e-07
girl O 0 1.583621042300365e-06
who O 0 1.372527425047565e-08
presented O 0 1.2833351092922385e-07
at O 0 7.689247922826326e-07
9 O 0 2.4951302179943013e-07
months O 0 1.4777120860287596e-08
of O 0 1.4730211717051134e-08
age O 0 2.9343787844027247e-08
and O 0 4.053625435318509e-09
her O 0 5.6542082127464255e-09
similarly O 0 1.3707014190345035e-08
affected O 0 1.4770019873822093e-08
younger O 0 1.4725722508046601e-07
brother O 0 1.2247928680153564e-06
and O 0 2.109759833501812e-08
father O 0 3.20073212378702e-07
were O 0 1.0847649889456079e-08
all O 0 3.469855958115886e-09
found O 0 3.1672195976995e-09
to O 0 1.0013238016526316e-09
have O 0 5.42286826554772e-10
a O 0 7.942822399797933e-09
novel O 0 7.117920119981136e-08
missense O 0 8.668137638778717e-07
mutation O 0 5.488125864872018e-08
( O 0 2.4700147704947994e-08
G1758 O 0 1.1386638107069302e-05
- O 0 9.200400199915748e-06
- O 0 7.275589723576559e-06
> O 0 1.606039518264879e-06
T O 0 8.524255099473521e-05
) O 0 3.3233735763360528e-09
encoding O 0 1.786019776517378e-09
the O 0 3.1091844654440592e-09
amino O 0 9.88854687022922e-09
acid O 0 5.249016510333604e-08
substitution O 0 2.816983055708988e-07
Gly23 O 0 0.00015272028394974768
- O 0 2.2775113393436186e-05
- O 0 2.5342094886582345e-05
> O 0 1.0515404028410558e-05
Val O 0 0.00018053612438961864
within O 0 5.725637493014801e-06
NPII O 1 0.9998294115066528
. O 0 5.518078978639096e-06

The O 0 6.623771241720533e-06
mutation O 0 8.160889137798222e-07
was O 0 9.84808934845205e-07
confirmed O 0 5.627346411074541e-08
by O 0 5.3346949080435024e-09
restriction O 0 3.111968638336293e-08
endonuclease O 0 1.6157115396708832e-06
analysis O 0 3.532388461735536e-07
. O 0 8.626163321423519e-07

A O 0 0.0008877760847099125
T1 O 1 0.8846191167831421
- O 0 5.113914085086435e-06
weighted O 0 2.1315801745913632e-07
magnetic O 0 4.4425132728065364e-07
resonance O 0 4.5162093442741025e-07
imaging O 0 3.5187413232051767e-06
of O 0 4.432044136137847e-07
the O 0 5.511271297109488e-07
fathers O 0 0.00010497371840756387
pituitary O 1 0.9969273209571838
gland O 0 0.12031415849924088
demonstrates O 0 1.6713231616449775e-06
an O 0 2.0825976321248163e-07
attenuated O 0 0.0007716321269981563
posterior O 0 8.089994662441313e-05
pituitary O 1 0.9929375052452087
bright O 0 0.002659575315192342
spot O 0 0.00037851810338906944
. O 0 9.584250619809609e-06

This O 0 6.391351234924514e-07
mutation O 0 3.922808389233978e-07
may O 0 2.1538756556083172e-08
be O 0 4.016575072540718e-09
valuable O 0 5.018381443733233e-08
for O 0 2.6860780266702022e-09
developing O 0 1.2694966855519851e-08
models O 0 4.279263166040437e-08
of O 0 2.617608743094024e-07
dominantly B-Disease 1 0.882092297077179
inherited I-Disease 1 0.9999871253967285
neurodegeneration I-Disease 1 1.0
, O 0 2.8784307914975216e-07
as O 0 1.3552078570455706e-08
the O 0 3.493976885593497e-09
early O 0 2.5330933794975863e-08
age O 0 1.1650577391719708e-08
of O 0 2.557020017945888e-08
onset O 0 0.0004171634209342301
of O 0 1.9468507161946036e-05
symptoms O 1 0.9051496386528015
suggests O 0 2.12980584279876e-08
that O 0 4.2953191004002633e-10
this O 0 3.191267528013242e-10
mutation O 0 4.553260435358197e-09
may O 0 1.8317598549089098e-09
be O 0 9.043601423286418e-10
particularly O 0 1.359806311995726e-08
deleterious O 0 1.2207051724999474e-07
to O 0 1.7824813625111346e-08
the O 0 1.82613462129666e-07
magnocellular O 0 0.000368225242709741
neuron O 0 6.49155163046089e-06
. O 0 2.163552181855266e-07
. O 0 5.856493885403324e-07

Frequent O 0 1.6442352716694586e-05
inactivation O 0 0.0006838567787781358
of O 0 0.00023236246488522738
PTEN O 1 0.9999997615814209
/ O 0 0.24201323091983795
MMAC1 O 1 0.9999803304672241
in O 0 3.5410569125815528e-06
primary O 1 0.9985865354537964
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.3805130947730504e-05

Sporadic B-Disease 1 0.9999994039535522
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 1.480097921557899e-06
the O 0 4.449772461612156e-07
most O 0 2.1265908145551293e-08
common O 0 8.000466777957627e-08
male B-Disease 0 2.1638616942709632e-07
cancer I-Disease 0 6.315381597232772e-06
in O 0 1.0376320247473814e-08
the O 0 3.335809850568694e-08
Western O 0 2.617586289943574e-07
world O 0 2.7769965527113527e-07
, O 0 6.1055347444494146e-09
yet O 0 2.0642616505028855e-09
many O 0 2.2538326760468408e-10
of O 0 4.6324948321796455e-09
the O 0 7.968588455753434e-09
major O 0 1.0616761869641778e-07
genetic O 0 3.367395606801438e-08
events O 0 6.063824109503457e-09
involved O 0 5.578463024846769e-09
in O 0 3.98078991992179e-09
the O 0 1.82050712282944e-08
progression O 0 4.0091038044920424e-07
of O 0 1.5234482120263237e-08
this O 0 2.473851345996536e-09
often O 0 4.5091081091186425e-08
fatal O 1 0.9999953508377075
cancer B-Disease 1 0.9872845411300659
remain O 0 1.6587299001002975e-07
to O 0 2.6422574350704053e-08
be O 0 3.9821060227041016e-08
elucidated O 0 7.889352855272591e-05
. O 0 2.6437908218213124e-06

Numerous O 0 1.592167063790839e-05
cytogenetic O 0 0.0013283885782584548
and O 0 1.0224025572824758e-06
allelotype O 0 0.0007010296685621142
studies O 0 2.0718960058729863e-07
have O 0 1.1060962146203224e-09
reported O 0 2.983466629302711e-08
frequent O 0 3.477397569895402e-08
loss O 0 3.11937242258864e-06
of O 0 1.6909838223000406e-06
heterozygosity O 0 0.01665893755853176
on O 0 1.0608137927192729e-05
chromosomal O 0 0.0007521731895394623
arm O 0 0.005296727176755667
10q O 0 0.00024016840325202793
in O 0 3.2709485822124407e-06
sporadic B-Disease 1 0.999991774559021
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.4445514756953344e-05

Deletion O 0 3.666708289529197e-05
mapping O 0 5.185734607948689e-06
studies O 0 2.4018876843001635e-07
have O 0 6.768504867693537e-09
unambiguously O 0 6.954730906727491e-07
identified O 0 4.8523340012707195e-08
a O 0 1.3958817213222119e-08
region O 0 4.6313839874301266e-08
of O 0 4.726681481770356e-07
chromosome O 0 3.139926150197425e-07
10q23 O 0 1.1851868748635752e-06
to O 0 4.77740380588898e-09
be O 0 2.0092638663982143e-09
the O 0 2.2135580479698547e-08
minimal O 0 1.520888162076517e-07
area O 0 1.4182104735027679e-07
of O 0 4.976204195372702e-07
loss O 0 6.915941776242107e-05
. O 0 2.9566292596427957e-06

A O 0 2.383069477218669e-05
new O 0 1.3434383845378761e-06
tumor B-Disease 0 3.525322608766146e-05
suppressor O 0 7.533814823545981e-06
gene O 0 7.244076414281153e-07
, O 0 1.6384531420499115e-07
PTEN O 1 0.9999576807022095
/ O 0 0.0005944787990301847
MMAC1 O 1 0.9999996423721313
, O 0 9.38358368784975e-08
was O 0 3.472129321835382e-07
isolated O 0 1.4846229134946043e-07
recently O 0 2.5085146404535408e-08
at O 0 4.7358454935420013e-08
this O 0 4.2977282843637e-10
region O 0 5.00747887599573e-09
of O 0 4.756757476798157e-08
chromosome O 0 8.326311728978908e-08
10q23 O 0 1.0375458714406705e-06
and O 0 6.588549261721255e-09
found O 0 3.380618895931775e-09
to O 0 7.909151666929404e-10
be O 0 1.3094394457624503e-09
inactivated O 0 9.238789289156557e-07
by O 0 1.8364827436556652e-09
mutation O 0 2.0660775312819624e-09
in O 0 5.240020861663197e-09
three O 0 8.701524620846612e-07
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 0.0750504732131958
lines O 0 5.105483523948351e-06
. O 0 1.1558323649296653e-06

We O 0 2.2079007067077328e-06
screened O 0 2.524587580410298e-05
80 O 0 0.00010230121552012861
prostate B-Disease 1 1.0
tumors I-Disease 1 0.9999998807907104
by O 0 6.128217933110136e-08
microsatellite O 0 1.3045524838162237e-06
analysis O 0 2.9952122559961936e-08
and O 0 1.6154384496758212e-08
found O 0 1.9317935695539745e-08
chromosome O 0 6.989479572894197e-08
10q23 O 0 8.58381781654316e-07
to O 0 6.566819976683291e-09
be O 0 2.3396236059625153e-09
deleted O 0 4.2471928196619047e-08
in O 0 2.6399350261385734e-08
23 O 0 3.6210013831805554e-07
cases O 0 4.5074315835336165e-08
. O 0 3.4787649383360986e-07

We O 0 4.7639306899327494e-07
then O 0 9.550479518338761e-08
proceeded O 0 1.56653172211918e-07
with O 0 1.479104283497179e-09
sequence O 0 1.0232292790846031e-09
analysis O 0 1.1180207870609138e-09
of O 0 8.402326834300311e-09
the O 0 2.3746016708514617e-08
entire O 0 2.3869499727879884e-06
PTEN O 1 0.9999948740005493
/ O 0 0.004747452680021524
MMAC1 O 1 0.9999815225601196
coding O 0 1.976765361177968e-06
region O 0 6.884281589236707e-08
and O 0 5.649432477383698e-09
tested O 0 2.944066324062078e-08
for O 0 2.9917737176532455e-09
homozygous O 0 3.473135379294945e-08
deletion O 0 1.2877334754080039e-08
with O 0 1.8067283225065012e-09
new O 0 3.7859418711150283e-08
intragenic O 0 3.877693598042242e-05
markers O 0 5.70174790937017e-07
in O 0 9.064640593692275e-09
these O 0 3.0400928441309816e-09
23 O 0 1.2510425051459606e-07
cases O 0 5.823608706378991e-09
with O 0 8.411980445544032e-09
10q23 O 0 3.269952139817178e-05
loss O 0 8.56199039844796e-05
of O 0 2.78639308817219e-05
heterozygosity O 1 0.9317790269851685
. O 0 1.46206293720752e-05

The O 0 3.677539837099175e-07
identification O 0 3.2823399465087277e-07
of O 0 3.018891732153861e-07
the O 0 7.889180864140144e-08
second O 0 4.536566962087818e-07
mutational O 0 3.3427127164031845e-06
event O 0 3.370242609435081e-07
in O 0 2.0985025273034807e-08
10 O 0 3.444576179845171e-08
( O 0 7.324476136716385e-09
43 O 0 1.042103079385015e-07
% O 0 1.5132398445416584e-08
) O 0 2.925430351297109e-07
tumors B-Disease 1 0.9999998807907104
establishes O 0 0.0001335495908278972
PTEN O 1 1.0
/ O 0 0.1298818439245224
MMAC1 O 1 0.999982476234436
as O 0 8.736042644841291e-08
a O 0 1.7001097418756217e-08
main O 0 1.3407488097527676e-07
inactivation O 0 1.318398972216528e-06
target O 0 4.105981332713782e-08
of O 0 8.515461757951925e-08
10q O 0 1.591217005625367e-05
loss O 0 5.1727743084484246e-06
in O 0 6.672671588603407e-07
sporadic B-Disease 1 0.9999758005142212
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.0851045974268345e-06
. O 0 1.7780131429390167e-06

Risk O 0 9.252304153051227e-06
reversals O 0 6.468593255704036e-06
in O 0 6.38525889939956e-08
predictive O 0 2.778615169063414e-07
testing O 0 3.162750317642349e-06
for O 0 3.5135039979650173e-06
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 2.8583881430677138e-05

The O 0 1.1533064707691665e-06
first O 0 1.806440224072503e-07
predictive O 0 1.0239722314508981e-07
testing O 0 3.2218019896390615e-07
for O 0 2.1415867479390727e-07
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 2.050468168590669e-07
HD B-Disease 1 0.5449381470680237
) O 0 4.393711172667736e-09
was O 0 9.8877164234068e-09
based O 0 2.9119084921092053e-09
on O 0 2.16240358952291e-09
analysis O 0 1.1204374095186154e-09
of O 0 2.769732887486498e-08
linked O 0 2.3328321674398467e-07
polymorphic O 0 3.7143058762012515e-07
DNA O 0 1.0343893563913298e-06
markers O 0 1.5442157064171624e-07
to O 0 1.8051919958850249e-09
estimate O 0 9.334045536490976e-09
the O 0 2.6339836978195308e-09
likelihood O 0 6.373210847954169e-09
of O 0 3.75544786379578e-08
inheriting O 0 2.762189410532301e-07
the O 0 3.461680719851756e-08
mutation O 0 9.872979767067136e-09
for O 0 3.7738153935151786e-08
HD B-Disease 0 0.002155798487365246
. O 0 6.851585112599423e-07

Limits O 0 2.3254297047969885e-06
to O 0 5.455500939888225e-08
accuracy O 0 1.4547738658166054e-07
included O 0 5.438556271997186e-08
recombination O 0 5.279258630253025e-08
between O 0 5.115922352416646e-09
the O 0 8.28829715970869e-09
DNA O 0 2.025306287123385e-07
markers O 0 1.2063614462931582e-07
and O 0 3.7207807945804916e-09
the O 0 9.404364398335474e-09
mutation O 0 9.301433401276427e-09
, O 0 3.921743374490916e-09
pedigree O 0 1.026533951176134e-07
structure O 0 1.3161951528672944e-07
, O 0 4.6896229122239674e-09
and O 0 1.2595253728875377e-09
whether O 0 9.350897833826366e-10
DNA O 0 3.4939585447091304e-08
samples O 0 7.670482027322123e-09
were O 0 1.0545709860920738e-09
available O 0 1.1280884004705172e-09
from O 0 1.1830889157238289e-08
family O 0 3.9202273427463297e-08
members O 0 4.652393315041081e-08
. O 0 4.216931301925797e-07

With O 0 1.9455401911727677e-07
direct O 0 6.571007560296493e-08
tests O 0 1.0335161704233542e-07
for O 0 3.598636055812676e-09
the O 0 3.004057447242303e-08
HD B-Disease 0 0.012043256312608719
mutation O 0 1.6387978973853023e-08
, O 0 1.2352487921418742e-09
we O 0 3.396231351704415e-10
have O 0 9.76517131046073e-11
assessed O 0 9.799998146320377e-09
the O 0 3.4599627607434513e-09
accuracy O 0 3.4168056828320914e-08
of O 0 2.6139858277929306e-08
results O 0 2.2139368116569358e-09
obtained O 0 1.7005954422444347e-09
by O 0 8.129099060560918e-10
linkage O 0 2.411067079322038e-08
approaches O 0 2.3503682555769956e-08
when O 0 2.205204685523654e-09
requested O 0 2.873277837878163e-09
to O 0 1.4964083305812892e-09
do O 0 1.6813791470227102e-09
so O 0 2.651726060953763e-10
by O 0 6.677141062283454e-10
the O 0 8.732373046882458e-09
test O 0 1.1853909853698497e-07
individuals O 0 7.112651800866843e-09
. O 0 3.2851460218807915e-07

For O 0 4.497813108628179e-07
six O 0 6.917265693573427e-08
such O 0 5.510243816786442e-09
individuals O 0 1.179091824177192e-09
, O 0 8.381711325000651e-09
there O 0 4.375988904570249e-09
was O 0 6.940539520883249e-08
significant O 0 1.1711155600835355e-08
disparity O 0 8.26191026703782e-08
between O 0 1.3882032412482204e-08
the O 0 4.4854846947828264e-08
tests O 0 6.157380312288296e-07
. O 0 3.547228573097527e-07

Three O 0 2.4277737793454435e-06
went O 0 3.3131079817394493e-06
from O 0 1.3245511354398332e-07
a O 0 4.379740303761537e-08
decreased O 0 2.394934313088015e-07
risk O 0 8.86212614403803e-09
to O 0 1.035466712373534e-09
an O 0 3.4386515856965616e-10
increased O 0 1.7392013385020277e-09
risk O 0 1.0547928752657754e-08
, O 0 1.7068930713293184e-09
while O 0 1.215828993039736e-09
in O 0 7.774911270352902e-10
another O 0 1.1729771598467664e-09
three O 0 7.553171976759643e-10
the O 0 2.308181201726711e-08
risk O 0 3.3688351663840876e-07
was O 0 2.864354883058695e-06
decreased O 0 4.668252131523332e-06
. O 0 4.674488423006551e-07

Knowledge O 0 1.521081412647618e-05
of O 0 2.293083298354759e-06
the O 0 1.3487924377386662e-07
potential O 0 2.786562092182976e-08
reasons O 0 8.167443610318514e-09
for O 0 6.135393304518288e-10
these O 0 2.991326908396985e-10
changes O 0 1.1265918198333225e-09
in O 0 2.804235510467379e-09
results O 0 3.965747286116539e-09
and O 0 2.1995252286188816e-09
impact O 0 1.7485787040527612e-08
of O 0 1.0232844793733875e-08
these O 0 8.346672797365784e-10
risk O 0 1.289264517367883e-08
reversals O 0 1.5602711300743977e-07
on O 0 6.104512095816972e-08
both O 0 4.702162215153294e-09
patients O 0 1.029885154935073e-08
and O 0 2.878423055463486e-09
the O 0 1.790447967664477e-08
counseling O 0 1.2382787417664076e-07
team O 0 3.442467644276803e-08
can O 0 3.8227707110927156e-10
assist O 0 4.941980158434944e-09
in O 0 1.4365860723231094e-09
the O 0 2.339538784923434e-09
development O 0 3.804326631495769e-09
of O 0 1.2930373216590851e-08
strategies O 0 3.587260266613157e-09
for O 0 1.1736486227320597e-09
the O 0 1.3636866746935539e-08
prevention O 0 2.5360238851135364e-06
and O 0 2.6151913967709106e-09
, O 0 9.833546199544685e-10
where O 0 1.9280195218129847e-09
necessary O 0 3.901702960718012e-09
, O 0 3.4996596731673435e-09
management O 0 4.974135592306084e-08
of O 0 8.051213029602877e-08
a O 0 4.318867752317601e-08
risk O 0 3.1616082196705975e-08
reversal O 0 5.0427235720462704e-08
in O 0 4.785684737385054e-09
any O 0 1.5847422263348676e-09
predictive O 0 4.012917287354867e-08
testing O 0 1.4174410978284868e-07
program O 0 1.436824419442928e-07
. O 0 3.7629838800512516e-08
. O 0 3.0228790137698525e-07

A O 0 6.080121602280997e-05
novel O 0 3.052047759410925e-06
common O 0 5.737136916650343e-07
missense O 0 8.283413080789614e-06
mutation O 0 5.250238359622017e-07
G301C O 0 8.053275450947694e-06
in O 0 7.585547479038723e-08
the O 0 7.011190206185347e-08
N O 0 2.9650750548171345e-06
- O 0 2.6712152703112224e-06
acetylgalactosamine O 0 1.5076851013873238e-05
- O 0 2.262670705022174e-06
6 O 0 2.3078171125234803e-06
- O 0 1.0881790331040975e-06
sulfate O 0 1.1976100040556048e-06
sulfatase O 0 7.287893822649494e-05
gene O 0 2.7614467512648844e-07
in O 0 2.510441845515743e-07
mucopolysaccharidosis B-Disease 1 0.9855769276618958
IVA I-Disease 1 1.0
. O 0 1.0351815035392065e-05

Mucopolysaccharidosis B-Disease 1 0.9999350309371948
IVA I-Disease 1 1.0
( O 0 0.0005170361255295575
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 2.1319838197086938e-06
is O 0 2.058114034753089e-08
an O 0 1.718051478860616e-08
autosomal B-Disease 1 0.9630758166313171
recessive I-Disease 1 0.9999969005584717
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.9996578693389893
by O 0 7.080817567839404e-07
a O 0 2.836951807694277e-06
genetic B-Disease 1 0.9999978542327881
defect I-Disease 1 0.9999772310256958
in O 0 6.534474437103199e-07
N O 0 1.4313418432720937e-05
- O 0 5.48227444596705e-06
acetylgalactosamine O 0 0.00011404166434658691
- O 0 9.169671102426946e-06
6 O 0 1.024089942802675e-05
- O 0 1.4980309060774744e-05
sulfate O 0 2.2836573407403193e-05
sulfatase O 0 0.00893731601536274
( O 0 6.860791017970769e-06
GALNS O 1 0.999998927116394
) O 0 1.3105516245559556e-06
. O 0 2.1344189917726908e-06

In O 0 9.628172392694978e-07
previous O 0 3.002373603067099e-07
studies O 0 6.153141640652393e-08
, O 0 5.177254180921409e-09
we O 0 5.216036491617615e-10
have O 0 6.093057308698135e-11
found O 0 7.158213466418317e-10
two O 0 3.5029035228006933e-10
common O 0 1.6657192292157674e-09
mutations O 0 5.622687204720478e-09
in O 0 1.1077224471023328e-08
Caucasians O 0 2.5669183401078044e-07
and O 0 4.633124461861371e-08
Japanese O 0 1.1417823770898394e-05
, O 0 2.1267982219796977e-07
respectively O 0 7.368884666902886e-07
. O 0 5.586471729657205e-07

To O 0 1.9551114291971317e-06
characterize O 0 9.298814802605193e-06
the O 0 8.539547593500174e-07
mutational O 0 1.4799461496295407e-05
spectrum O 0 4.911663040729763e-07
in O 0 5.013853332513918e-09
various O 0 1.168774188542443e-09
ethnic O 0 3.7963074350777504e-10
groups O 0 2.9724672723219214e-10
, O 0 1.0244400883152593e-09
mutations O 0 2.5417792315352017e-09
in O 0 6.734868218671863e-09
the O 0 4.664672914600487e-08
GALNS O 1 0.8538539409637451
gene O 0 7.923760136918645e-08
in O 0 4.178675183652558e-08
Colombian O 0 5.567411790252663e-06
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 1.1683946468110662e-06
were O 0 2.9228496956079653e-08
investigated O 0 3.845683522740728e-07
, O 0 1.264103666187566e-08
and O 0 4.1404963901925385e-09
genetic O 0 2.7198680641049577e-08
backgrounds O 0 4.905429396018235e-09
were O 0 3.2606730648865323e-09
extensively O 0 2.8574246968560146e-08
analyzed O 0 4.691268706835672e-09
to O 0 6.334112678807458e-10
identify O 0 3.801830850136412e-09
racial O 0 3.393914926874686e-09
origin O 0 9.50953649159203e-10
, O 0 6.481552516923728e-10
based O 0 4.649419516056241e-09
on O 0 1.985999986686693e-08
mitochondrial O 0 9.695477132254382e-08
DNA O 0 7.556290029242518e-07
( O 0 2.6353317750249516e-08
mtDNA O 0 3.128030527932424e-07
) O 0 4.0505664600232194e-08
lineages O 0 5.991312832520634e-07
. O 0 5.952039714429702e-07

Three O 0 2.294824525961303e-06
novel O 0 1.9505448562995298e-06
missense O 0 1.1710546459653415e-05
mutations O 0 4.741611974168336e-07
never O 0 2.7780984623859695e-07
identified O 0 2.5818424731482992e-08
previously O 0 2.377574759293566e-08
in O 0 2.1756212387202822e-09
other O 0 5.306318162645596e-10
populations O 0 4.626311278510542e-10
and O 0 1.142431482747952e-09
found O 0 2.832013956677315e-09
in O 0 6.764671933723321e-09
16 O 0 4.176746770667705e-08
out O 0 1.0624900959044226e-08
of O 0 6.620953030278542e-08
19 O 0 6.634946885242243e-07
Colombian O 0 1.2558826711028814e-05
MPS B-Disease 1 0.999998927116394
IVA I-Disease 1 1.0
unrelated O 0 1.4718054444529116e-05
alleles O 0 7.279452063357894e-08
account O 0 3.318073993341386e-08
for O 0 1.745493847238322e-07
84 O 0 2.755061177595053e-05
. O 0 3.4773393053910695e-06

2 O 0 4.98503823109786e-06
% O 0 2.4419833266620117e-08
of O 0 1.1912222319665489e-08
the O 0 4.3425227858051585e-09
alleles O 0 1.0840157660396699e-09
in O 0 2.8582953781608467e-09
this O 0 1.752497702511846e-09
study O 0 6.670540386721768e-08
. O 0 3.702878359490569e-07

The O 0 1.2852478903369047e-05
G301C O 0 0.00013519656204152852
and O 0 9.75546413428674e-07
S162F O 0 2.478801616234705e-05
mutations O 0 1.132742326603875e-07
account O 0 4.087875637992511e-08
for O 0 1.4481061327842326e-07
68 O 0 2.1789734091726132e-05
. O 0 1.7321890481980518e-06

4 O 0 3.490535164019093e-05
% O 0 2.779778753847495e-07
and O 0 1.0175394749012412e-07
10 O 0 8.337681265402352e-07
. O 0 1.0106457466463326e-06

5 O 0 2.777952431642916e-06
% O 0 1.7743168712058832e-08
of O 0 3.9811265395428563e-08
mutations O 0 2.0445686033099264e-08
, O 0 6.7020891059144105e-09
respectively O 0 3.8386438916404586e-08
, O 0 3.1643212494714135e-09
whereas O 0 5.821787052440186e-09
the O 0 8.797656825265676e-09
remaining O 0 1.8217319563973433e-07
F69V O 1 0.9997023940086365
is O 0 1.0727571719826301e-08
limited O 0 5.8421099069505544e-09
to O 0 4.063495762096636e-09
a O 0 4.4193647852353024e-08
single O 0 1.6924491319514345e-07
allele O 0 2.9124109346412297e-07
. O 0 4.018171750885813e-07

The O 0 1.906252919070539e-06
skewed O 0 1.1613614105954184e-06
prevalence O 0 7.596673299303802e-07
of O 0 5.5906085094648006e-08
G301C O 0 2.370792572037317e-06
in O 0 1.3266353349195015e-08
only O 0 2.39475905772224e-09
Colombian O 0 1.5450007140316302e-07
patients O 0 2.0499259179018736e-08
and O 0 5.6297051465037384e-09
haplotype O 0 1.021750080099082e-07
analysis O 0 6.199719404520465e-09
by O 0 2.656617814622564e-09
restriction O 0 1.932040483154651e-08
fragment O 0 1.102945574871228e-07
length O 0 9.863286187794529e-09
polymorphisms O 0 4.128858321905682e-08
in O 0 1.0848353326764482e-08
the O 0 5.61933433118611e-08
GALNS O 1 0.9999220371246338
gene O 0 6.400745178325451e-08
suggest O 0 3.333105125236102e-09
that O 0 2.192605652595603e-09
G301C O 0 1.8106052266375627e-06
originated O 0 4.9035051574719546e-08
from O 0 2.2576987390721115e-08
a O 0 2.0297026281923536e-08
common O 0 8.03141233518545e-08
ancestor O 0 4.086237822775729e-06
. O 0 2.282928107888438e-06

Investigation O 0 4.9434579523222055e-06
of O 0 1.7863004586615716e-06
the O 0 1.475092403779854e-07
genetic O 0 1.7528235218833288e-07
background O 0 1.0840618180907313e-08
by O 0 9.004341161578111e-10
means O 0 1.8667130063931836e-09
of O 0 6.570753718904143e-09
mtDNA O 0 1.4013558313763497e-08
lineages O 0 9.052252281094297e-09
indicate O 0 1.7759174131271038e-09
that O 0 2.68829070115828e-10
all O 0 1.3794028141944636e-09
our O 0 1.049575004685721e-08
patients O 0 1.1970233693148202e-08
are O 0 3.060781073038754e-10
probably O 0 2.0311549775442472e-08
of O 0 4.5158731865058144e-08
native O 0 2.1757870172223193e-07
American O 0 2.085790811179322e-06
descent O 0 1.1788734809670132e-05

Low O 0 1.4041502254258376e-05
frequency O 0 9.165021879198321e-07
of O 0 1.2012956176477019e-06
BRCA1 O 0 6.6141524257545825e-06
germline O 0 3.891793312504888e-06
mutations O 0 4.441437084778954e-08
in O 0 2.5949203674713317e-08
45 O 0 8.329264460371633e-07
German O 1 0.9999996423721313
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 6.525307867377705e-07
. O 0 2.6995464850188e-06

In O 0 8.506661401952442e-07
this O 0 8.614126301154101e-09
study O 0 8.684569507977358e-09
we O 0 1.0396185023964222e-09
investigated O 0 3.8936541102430056e-08
45 O 0 1.1962762869188737e-07
German O 1 0.9999735355377197
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.062541692993136e-09
for O 0 3.41435435480264e-09
germline O 0 1.2902924027002882e-06
mutations O 0 1.0747929657384248e-08
in O 0 2.4529628106506607e-08
the O 0 3.04523695149328e-07
BRCA1 O 0 4.1027116822078824e-05
gene O 0 2.973264145111898e-06
. O 0 1.9761962448683335e-06

We O 0 8.933747039918671e-07
identified O 0 3.8495511489600176e-07
four O 0 9.102603826249833e-08
germline O 0 5.628405233437661e-06
mutations O 0 1.0969035457719656e-07
in O 0 3.380607438430161e-08
three O 0 4.2000462485702883e-07
breast B-Disease 1 0.9999983310699463
cancer I-Disease 1 0.9941796064376831
families O 0 2.1010766459994556e-09
and O 0 5.545448988897306e-09
in O 0 2.371478657892112e-08
one O 0 5.212660312281514e-07
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 6.207922069734195e-07
. O 0 8.508914461913264e-09
among O 0 1.6739043484648164e-09
these O 0 5.466057051428663e-10
were O 0 8.196486156464289e-09
one O 0 6.802024721253019e-09
frameshift O 0 1.0664266483217943e-06
mutation O 0 5.8813899528331604e-08
, O 0 2.2872852056821102e-08
one O 0 1.8400809764784753e-08
nonsense O 0 1.3581586699729087e-06
mutation O 0 4.716878265753621e-08
, O 0 8.070150769867723e-09
one O 0 4.631805161636748e-09
novel O 0 2.4240707219291835e-08
splice O 0 2.710520902837743e-06
site O 0 2.672501864253718e-07
mutation O 0 2.3902515522422618e-08
, O 0 6.989490763942285e-09
and O 0 2.1571977981693635e-08
one O 0 6.927947993062844e-08
missense O 0 1.3597769793705083e-05
mutation O 0 1.4736751836608164e-06
. O 0 1.745503368510981e-06

The O 0 3.825973180937581e-06
missense O 0 2.1258087144815363e-05
mutation O 0 5.757158305641497e-07
was O 0 7.126790251277271e-07
also O 0 1.530908022573385e-08
found O 0 3.344831256413272e-08
in O 0 3.884915145135892e-08
2 O 0 2.6078016617248068e-06
. O 0 6.367065452650422e-07

8 O 0 4.856625764659839e-06
% O 0 2.1421378448849282e-08
of O 0 4.960605792803108e-08
the O 0 3.4479399335651806e-09
general O 0 7.756370656863965e-09
population O 0 3.3214200834130736e-10
, O 0 6.372599670179113e-10
suggesting O 0 1.9326698019739297e-09
that O 0 6.155927156914487e-11
it O 0 3.526392788888444e-10
is O 0 7.426474990523957e-10
not O 0 9.354077512568892e-09
disease O 0 0.0001807781372917816
associated O 0 7.39665324545058e-07
. O 0 1.3531320064430474e-06

The O 0 1.0037241509053274e-06
average O 0 1.662919117961792e-07
age O 0 1.1412031142299384e-07
of O 0 1.2579938584167394e-06
disease O 1 0.9997864365577698
onset O 1 0.5983268022537231
in O 0 1.6414693604360764e-08
those O 0 1.3519361186098422e-09
families O 0 1.7337529190086798e-09
harbouring O 0 3.775993718591053e-06
causative O 0 1.919967644425924e-06
mutations O 0 1.9998770994789083e-07
was O 0 1.243262090611097e-06
between O 0 1.967801779301226e-07
32 O 0 1.7032974710673443e-06
. O 0 6.656096047663596e-07

3 O 0 8.421642996836454e-05
and O 0 4.231068942317506e-06
37 O 0 1.9823874026769772e-05
. O 0 2.6945003810396884e-06

4 O 0 2.3924672859720886e-05
years O 0 8.382096439163433e-07
, O 0 2.2419158085540403e-08
whereas O 0 1.7517832517910392e-08
the O 0 1.9857576916137987e-08
family O 0 5.2938897709964294e-08
harbouring O 0 1.1100743904535193e-05
the O 0 6.545888453501902e-08
missense O 0 1.0454111816216027e-06
mutation O 0 4.501520578514828e-08
had O 0 1.1649199826990753e-08
an O 0 9.57847356986008e-10
average O 0 9.094201836035154e-09
age O 0 1.6567339500284106e-08
of O 0 9.216017815560917e-08
onset O 0 4.758035720442422e-05
of O 0 4.934428488923004e-06
51 O 0 1.0134976037079468e-05
. O 0 1.4127273288977449e-06

2 O 0 0.00012527394574135542
years O 0 8.553332918381784e-06
. O 0 3.959902642236557e-06

These O 0 2.729805999024393e-07
findings O 0 2.7336616881257214e-07
show O 0 6.367842786403344e-08
that O 0 4.5615444754787404e-09
BRCA1 O 0 9.942363021764322e-07
is O 0 6.5081899869312565e-09
implicated O 0 3.753353894353495e-07
in O 0 1.6680662184853645e-08
a O 0 5.968515459642276e-09
small O 0 2.401061571788432e-09
fraction O 0 1.2426554008015955e-08
of O 0 1.4119070783635834e-06
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.0440005304701572e-08
suggesting O 0 3.616204224954345e-08
the O 0 1.8953834057811036e-08
involvement O 0 5.619752485586105e-08
of O 0 2.0770180242379865e-07
another O 0 1.394652713315736e-07
susceptibility O 0 4.605626600096002e-06
gene O 0 9.137269216807908e-07
( O 0 7.40515133657027e-07
s O 0 3.2378698961110786e-05
) O 0 5.761218744737562e-06

Paternal O 0 0.0005514104850590229
transmission O 0 0.2628951966762543
of O 1 0.9999960660934448
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.9998656511306763

We O 0 2.3759032501402544e-06
report O 0 3.182497039233567e-07
a O 0 5.507273570515281e-08
rare O 0 2.1841361785845947e-07
case O 0 4.869709258059629e-08
of O 0 3.8285097616608255e-06
paternally O 1 0.9999911785125732
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999983310699463
DM B-Disease 1 1.0
) O 0 3.965960786445066e-05
. O 0 3.424205488045118e-06

The O 0 1.5123319826670922e-05
proband O 0 0.0006892724195495248
is O 0 5.113720646932052e-08
a O 0 2.883996863545235e-08
23 O 0 3.134208839128405e-07
year O 0 6.967079002606624e-08
old O 0 1.4636101695941761e-05
, O 0 9.360833246319089e-07
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 1.7968004613067023e-05
who O 0 9.970068276743405e-06
suffers O 1 1.0
severe O 1 1.0
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 0 0.481047123670578

He O 0 7.191054010036169e-06
presented O 0 5.641263669531327e-06
with O 0 3.835771622107131e-06
respiratory O 1 1.0
and O 0 7.884314072725829e-06
feeding O 0 6.455162656493485e-05
difficulties O 0 2.5408620786038227e-05
at O 0 3.7424459151225165e-05
birth O 0 6.114933785283938e-05
. O 0 2.277786961712991e-06

His O 0 6.984758510952815e-05
two O 0 3.878632469422882e-06
sibs O 1 0.9985036849975586
suffer O 0 0.0001085599506041035
from O 0 2.9183958758949302e-05
childhood O 1 0.9999818801879883
onset O 1 1.0
DM B-Disease 1 1.0
. O 0 0.00017510561156086624

Their O 0 8.035822247620672e-07
late O 0 3.817524884652812e-06
father O 0 8.347316224899259e-07
had O 0 1.2236698765377696e-08
the O 0 5.134417779828482e-09
adult O 0 6.6329839398804324e-09
type O 0 5.4322423892472216e-08
of O 0 3.673722858366091e-06
DM B-Disease 1 1.0
, O 0 2.280490178918626e-07
with O 0 1.9248091120971367e-08
onset O 0 0.00021407809981610626
around O 0 2.2252463338645612e-07
30 O 0 2.906620011344785e-07
years O 0 1.8523289213590033e-07
. O 0 1.553036952373077e-07

Only O 0 4.908848723061965e-07
six O 0 6.581456091225846e-08
other O 0 1.3022015687980115e-09
cases O 0 2.212712679749984e-09
of O 0 6.325873158630202e-08
paternal O 0 6.954385867175006e-07
transmission O 0 0.00022464542416855693
of O 1 0.9989475607872009
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 6.016821885168611e-07
been O 0 2.5824783733696677e-07
reported O 0 3.3725319781297003e-07
recently O 0 1.0280734841217054e-06
. O 0 5.671665235240653e-07

We O 0 3.2782293146738084e-07
review O 0 1.1437516178602891e-07
the O 0 2.2522836928828838e-08
sex O 0 1.4173500595404676e-08
related O 0 4.263783281999167e-08
effects O 0 8.198723548957787e-07
on O 0 2.785893116197258e-07
transmission O 0 1.2778965356119443e-05
of O 0 0.0002881274849642068
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.0004201898700557649

Decreased O 0 2.2704505681758747e-05
fertility O 0 1.1167638149345294e-05
of O 0 2.51347728408291e-07
males O 0 2.2378390251986957e-09
with O 0 1.2138641203307543e-09
adult O 0 1.0404743733261057e-07
onset O 1 0.9985100626945496
DM B-Disease 1 1.0
and O 0 1.710215201455867e-06
contraction O 0 2.4221214971476e-06
of O 0 1.1770278973699533e-07
the O 0 1.3989843061779084e-08
repeat O 0 2.5857305629983784e-08
upon O 0 2.1213445222656446e-08
male O 0 1.986337139214811e-08
transmission O 0 4.6012093690706024e-08
contribute O 0 2.2895449980353533e-09
to O 0 3.2806977134924864e-09
the O 0 1.0345392986721436e-08
almost O 0 8.265910622640149e-09
absent O 0 2.988301872619559e-08
occurrence O 0 1.9369441162098155e-08
of O 0 2.830535628106645e-08
paternal O 0 6.124233777882182e-07
transmission O 0 2.023588058364112e-05
of O 0 0.10330885648727417
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.0023961106780916452

Also O 0 1.0907568821494351e-06
the O 0 2.079497534168695e-07
fathers O 0 3.0794262784183957e-07
of O 0 1.5543824360975123e-07
the O 0 1.4625918254296266e-07
reported O 0 2.426509126962628e-07
congenitally O 0 2.1604402718367055e-05
affected O 0 1.7317930200988485e-07
children O 0 4.0820555824439e-08
showed O 0 6.151264386744515e-08
, O 0 3.9516052652288636e-09
on O 0 1.5568119238196232e-08
average O 0 2.8038037669375626e-08
, O 0 1.8887901021003017e-08
shorter O 0 1.7350905636703828e-06
CTG O 0 0.10080322623252869
repeat O 0 1.2457081766115152e-06
lengths O 0 1.0673464885258e-06
and O 0 1.8562964498869405e-08
hence O 0 2.8669182583485053e-08
less O 0 4.303080913814483e-08
severe O 0 0.010593104176223278
clinical O 1 0.9990922212600708
symptoms O 0 0.004400074947625399
than O 0 5.44082556785952e-09
the O 0 2.6879602543772307e-08
mothers O 0 1.1630528540251817e-08
of O 0 1.0975481501418471e-07
children O 0 4.2119634713344567e-07
with O 0 1.8721335436566733e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.07652906328439713

We O 0 4.990224056200532e-07
conclude O 0 9.196875225825352e-07
that O 0 9.41728828252053e-09
paternal O 0 6.613827849832887e-07
transmission O 0 1.4909291166986804e-05
of O 1 0.9425649046897888
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 7.649564395251218e-06
rare O 0 8.286922934530594e-07
and O 0 1.9086431990444908e-08
preferentially O 0 4.997109925852783e-08
occurs O 0 8.723150202172292e-09
with O 0 2.5251758462019325e-09
onset O 0 4.1649214836070314e-05
of O 0 9.388922080688644e-06
DM B-Disease 1 1.0
past O 0 4.6098401185190596e-07
30 O 0 2.3185767972222493e-08
years O 0 2.9190931893907646e-09
in O 0 2.5581794460549645e-09
the O 0 1.0251247850590062e-08
father O 0 4.299983800137852e-07
. O 0 6.909459671078366e-08
. O 0 3.5289102129354433e-07

The O 0 3.295328133390285e-05
RB1 O 1 0.9989068508148193
gene O 0 1.4110927395449835e-06
mutation O 0 4.413569243411075e-08
in O 0 2.657105824255268e-08
a O 0 7.49691579926548e-08
child O 0 2.4303542431880487e-06
with O 0 1.1406528983570752e-06
ectopic B-Disease 1 0.9999821186065674
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 0.999990701675415
. O 0 7.09655141690746e-05

The O 0 4.9415008106734604e-05
RB1 O 1 0.9707415699958801
gene O 0 2.761880978141562e-06
mutation O 0 3.7819873455191555e-07
was O 0 4.2248251475029974e-07
investigated O 0 6.51979689791915e-07
in O 0 6.912887329235673e-08
a O 0 7.739320295740981e-08
child O 0 9.365512596559711e-07
with O 0 1.7731166224166373e-07
ectopic B-Disease 0 0.2229894995689392
intracranial I-Disease 1 0.9998106360435486
retinoblastoma I-Disease 0 0.00030029090703465044
using O 0 1.0823143981042449e-07
DNA O 0 9.392605306857149e-07
obtained O 0 2.4879536653088508e-08
from O 0 2.833501255850024e-08
both O 0 4.801475217419693e-09
the O 0 6.285497988756106e-08
pineal B-Disease 1 0.9894178509712219
and I-Disease 0 1.9769499886024278e-06
retinal I-Disease 1 0.9999992847442627
tumours I-Disease 1 1.0
of O 0 5.29494063812308e-05
the O 0 1.4654230653832201e-05
patient O 0 0.00021433156507555395
. O 0 5.326489826984471e-06

A O 0 9.586809756001458e-05
nonsense O 0 3.0741397495148703e-05
mutation O 0 2.443416633468587e-07
in O 0 1.536605935825719e-07
exon O 0 5.585322924162028e-06
17 O 0 9.170425414595229e-07
( O 0 2.2819950373786924e-08
codon O 0 3.276653899320081e-07
556 O 0 7.202235678960278e-07
) O 0 6.927997731054347e-09
of O 0 2.731820814005914e-08
the O 0 3.662985292862686e-08
RB1 O 1 0.9933383464813232
gene O 0 4.0170142767692596e-08
was O 0 5.960282578598708e-08
found O 0 2.0381314413953078e-09
to O 0 2.785331687515935e-10
be O 0 5.099271005448713e-10
present O 0 7.120741774002681e-09
homozygously O 0 7.13436429577996e-06
in O 0 1.4034208462021525e-08
both O 0 4.8400008445526055e-09
the O 0 1.240756404286003e-07
retinal B-Disease 0 0.0002333711599931121
and I-Disease 0 4.869695544584829e-07
the I-Disease 0 1.591729960637167e-05
pineal I-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 1.5764660929562524e-05

The O 0 1.9322837943036575e-06
same O 0 7.293642312333759e-08
mutation O 0 7.192763007424219e-08
was O 0 1.4206362664026528e-07
present O 0 1.1656134724091771e-08
heterozygously O 0 2.9752834507235093e-06
in O 0 1.543810057569317e-08
the O 0 3.138762361132308e-09
DNA O 0 1.0466846589451961e-07
from O 0 2.6922022389186395e-09
the O 0 2.496346906966096e-09
constitutional O 0 7.688806036298956e-09
cells O 0 7.409810987013543e-09
of O 0 2.3682511951506058e-08
the O 0 1.227658064095749e-08
patient O 0 3.368533327829937e-07
, O 0 1.0931811900150024e-08
proving O 0 3.948688345190021e-07
it O 0 9.643090770339313e-10
to O 0 7.575448046637234e-10
be O 0 8.007634000328778e-10
of O 0 3.427399164479539e-08
germline O 0 2.5536678549542557e-06
origin O 0 1.5288982524452877e-07
. O 0 6.546132453877362e-07

The O 0 1.202937255584402e-06
initial O 0 3.3852538194878434e-07
mutation O 0 1.4615558541208884e-07
was O 0 3.5617301819002023e-07
shown O 0 9.249226273766453e-09
to O 0 2.093979434292237e-09
have O 0 8.53094594965853e-10
occurred O 0 5.900704991290695e-08
in O 0 9.409872880894454e-09
the O 0 3.669516601689793e-08
paternally O 0 3.6509509300231002e-06
derived O 0 3.1331828722613864e-06
RB1 O 0 0.03884890675544739
allele O 0 4.34340563515434e-06
. O 0 1.0448361535964068e-06

The O 0 3.4558670449769124e-06
mutation O 0 2.647365988650563e-07
is O 0 9.744844042813838e-09
in O 0 5.986517948031178e-09
an O 0 5.262554281237897e-10
area O 0 1.4536040815471551e-08
of O 0 1.3387321473601332e-08
the O 0 1.150623862855582e-08
gene O 0 5.675266478988306e-09
that O 0 6.661710627575701e-10
encodes O 0 3.3392075771132568e-09
the O 0 1.4643119605750599e-08
protein O 0 3.032548434589444e-08
- O 0 3.031369146810903e-07
binding O 0 3.307843243760544e-08
region O 0 3.684609595211441e-08
known O 0 3.6643552192572315e-08
as O 0 4.211342385929129e-09
the O 0 3.205986232046598e-08
pocket O 0 1.0466020285093691e-05
region O 0 2.198872017800113e-08
and O 0 7.06544911466267e-09
has O 0 1.6178488548845849e-09
been O 0 1.8023880166140316e-09
detected O 0 2.3193109655039734e-08
in O 0 8.828564546092821e-10
other O 0 8.149124708367594e-10
cases O 0 6.035243860225137e-09
of O 0 3.7041007772131707e-07
retinoblastoma B-Disease 0 0.00022908783284947276
. O 0 7.464482791874616e-07
. O 0 1.6973577885437408e-06

Low O 0 1.3680141819349956e-05
levels O 0 2.026430649948452e-07
of O 0 1.2371987168080523e-07
beta O 0 3.394357293018402e-07
hexosaminidase O 0 6.178348030516645e-06
A O 0 1.770024908864798e-07
in O 0 1.9222264668883327e-08
healthy O 0 3.0690326724425177e-08
individuals O 0 9.579516069280203e-10
with O 0 3.327923181473125e-08
apparent O 0 0.12308913469314575
deficiency O 1 0.9999959468841553
of O 0 0.0014405675465241075
this O 0 2.7219317644266994e-07
enzyme O 0 2.208865225838963e-06
. O 0 2.6571240141493035e-06

Appreciable O 0 0.00014691239630337805
beta O 0 1.7978100004256703e-05
hexosaminidase O 0 0.00033754855394363403
A O 0 3.267764259362593e-05
( O 0 3.206503436103958e-07
hex O 0 1.7868911527330056e-05
A O 0 4.838032964471495e-06
) O 0 5.756552123870051e-09
activity O 0 8.954182284526269e-09
has O 0 7.729782924847939e-10
been O 0 6.364534455016724e-10
detected O 0 2.8365402471308698e-08
in O 0 1.0171782527379492e-08
cultured O 0 2.6191744382231263e-06
skin O 0 0.0003270880552008748
fibroblasts O 0 5.207232788961846e-06
and O 0 1.858420432654384e-06
melanoma B-Disease 1 1.0
tissue O 0 0.08204731345176697
from O 0 1.4265951904235408e-06
healthy O 0 2.935824454652902e-07
individuals O 0 2.6793187668516794e-09
previously O 0 1.750860576521518e-07
reported O 0 5.02657186984834e-08
as O 0 4.8102311467346226e-08
having O 0 1.1041396419386729e-06
deficiency B-Disease 1 0.6908538937568665
of I-Disease 0 4.996753705199808e-05
hex I-Disease 0 0.00016211364709306508
A I-Disease 0 1.1780244904002757e-06
activity O 0 1.5868815594899388e-08
indistinguishable O 0 8.991216660092505e-09
from O 0 1.1507571562319185e-09
that O 0 1.1587959064529585e-10
of O 0 6.3917395820567435e-09
patients O 0 4.9763276166459036e-08
with O 0 7.471491016985965e-07
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 4.181711847195402e-05
TSD B-Disease 1 1.0
) O 0 1.2594296094903257e-06
. O 0 1.4512058896798408e-06

Identification O 0 1.7354848750983365e-05
and O 0 1.6457192941743415e-06
quantitation O 0 0.0004437949100974947
of O 0 2.8939848562004045e-05
hex O 0 0.00020145007874816656
A O 0 6.135529838502407e-05
, O 0 7.69780470477599e-08
amounting O 0 1.635630582086378e-07
to O 0 7.701476079091663e-08
3 O 0 1.9328126654727384e-06
. O 0 3.7613878589581873e-07

5 O 0 3.313405977678485e-05
% O 0 8.473658112961857e-07
- O 0 1.2796258488378953e-05
6 O 0 1.2059917935403064e-05
. O 0 2.0219918042130303e-06

9 O 0 1.595648063812405e-05
% O 0 6.791914586301573e-08
of O 0 4.839892753238928e-08
total O 0 1.512625047439542e-08
beta O 0 1.8192233142144687e-07
hexosaminidase O 0 2.011739979934646e-06
activity O 0 2.560431511255956e-08
, O 0 1.9272621276655855e-09
has O 0 5.003533143366212e-10
been O 0 3.703178041991606e-10
obtained O 0 2.1480488499037165e-09
by O 0 1.0321131505008907e-08
cellulose O 0 0.0001518874050816521
acetate O 0 8.233833796111867e-06
gel O 0 1.899192398013838e-06
electrophoresis O 0 9.499779594079882e-07
, O 0 1.0137542716393e-07
DEAE O 0 0.031231414526700974
- O 0 1.5741967445137561e-06
cellulose O 0 1.4819234820606653e-05
ion O 0 7.518752909163595e-07
- O 0 5.232727744441945e-07
exchange O 0 7.590352169017933e-08
chromatography O 0 3.8279808904917445e-06
, O 0 5.345116704802422e-08
radial O 0 1.973124653886771e-06
immunodiffusion O 0 2.8869888410554267e-05
, O 0 1.1433404978333783e-07
and O 0 2.010348367775805e-07
radioimmunoassay O 0 0.0005837417556904256
. O 0 2.2033868845028337e-06

Previous O 0 1.5274514225893654e-05
family O 0 1.882270339592651e-07
studies O 0 5.00749059995087e-08
suggested O 0 8.59058157942627e-09
that O 0 1.1916710673798292e-10
these O 0 1.8180727756611503e-10
individuals O 0 9.528722949569968e-11
may O 0 3.2855571596712707e-09
be O 0 9.689514746114014e-10
compound O 0 9.343488471813544e-08
heterozygotes O 0 1.0661058524874534e-07
for O 0 2.6279418641195207e-09
the O 0 7.976221461092337e-09
common O 0 4.927882457650412e-08
mutant O 0 9.988913234337815e-07
TSD B-Disease 1 0.9288111329078674
gene O 0 8.99574885693255e-08
and O 0 8.06444244716431e-09
a O 0 1.9285097963006592e-08
rare O 0 2.461587200741633e-07
( O 0 6.9192978457977e-08
allelic O 0 6.7604187279357575e-06
) O 0 1.428050211416121e-07
mutant O 0 3.5932000628235983e-06
gene O 0 1.0077986871692701e-06
. O 0 7.579225780318666e-07

Thus O 0 2.5157653453788953e-06
, O 0 8.958267727621205e-08
the O 0 1.5463326619169493e-08
postulated O 0 1.2495877399487654e-07
rate O 0 1.2423710060716076e-08
mutant O 0 1.0011164874867973e-07
gene O 0 1.4082178090291109e-08
appears O 0 3.7034906252841893e-09
to O 0 2.538657617456863e-10
code O 0 7.696197013018491e-10
for O 0 4.323759683622086e-10
the O 0 2.2868129612163557e-09
expression O 0 2.390058817525187e-09
of O 0 9.73538849535771e-09
low O 0 3.4022061612404286e-08
amounts O 0 8.498063586159788e-09
of O 0 1.580674364731749e-07
hex O 0 2.639018748595845e-05
A O 0 1.896941648737993e-05
. O 0 8.252891348092817e-07

Heterozygotes O 0 7.193300552899018e-05
for O 0 3.020259384811652e-07
the O 0 3.394765144548728e-07
rare O 0 1.5958833046170184e-06
mutant O 0 1.0970495623041643e-06
may O 0 1.582426278901039e-08
be O 0 1.7646802907833603e-09
indistinguishable O 0 6.55143423955451e-08
from O 0 9.796335298517533e-09
heterozygotes O 0 9.741874151814045e-08
for O 0 6.132261365365821e-09
the O 0 6.817743525289188e-08
common O 0 7.846948619771865e-07
TSD B-Disease 1 0.9999599456787109
mutant O 0 2.9295273634488694e-05
. O 0 1.6409394447691739e-06

However O 0 1.5045274039948708e-06
, O 0 2.6632502425627536e-08
direct O 0 1.4454756502857435e-08
visualization O 0 1.17116678666207e-06
and O 0 7.259360756961541e-08
quantitation O 0 0.00014957816165406257
of O 0 8.979411177278962e-06
hex O 0 4.031391654280014e-05
A O 0 9.010738040160504e-07
by O 0 3.3964016044052414e-09
the O 0 4.105509265883711e-09
methods O 0 2.092471262926665e-08
described O 0 1.6837024929827749e-07
may O 0 1.5451002255417734e-08
prevent O 0 2.636468110495116e-08
false O 0 1.3782259600247926e-07
- O 0 2.1650794224115089e-07
positive O 0 4.092343797168496e-09
prenatal O 0 7.236756687234447e-07
diagnosis O 0 1.258853217223077e-06
of O 0 1.3492572179529816e-06
TSD B-Disease 1 0.9999980926513672
in O 0 2.8573847998814017e-07
fetuses O 0 1.4781470554225962e-06
having O 0 3.3443974700730905e-08
the O 0 5.134038261189744e-08
incomplete O 0 5.860304554516915e-06
hex B-Disease 0 0.0031991591677069664
A I-Disease 1 0.9948491454124451
deficiency I-Disease 1 0.9992983341217041
of O 0 2.3243712348630652e-05
the O 0 7.186660582192417e-07
type O 0 2.6943230295728426e-06
described O 0 1.447838258172851e-07
in O 0 2.001454291189475e-08
the O 0 5.2591680343994085e-08
four O 0 1.4788616908845142e-07
healthy O 0 9.029938041749119e-07
individuals O 0 3.102474863680982e-07

The O 0 2.6992174753104337e-05
tumor B-Disease 0 0.0010450711706653237
suppressor O 0 0.00012232217704877257
gene O 0 6.852396381873405e-06
Smad4 O 1 0.7677454352378845
/ O 0 0.0002547138719819486
Dpc4 O 0 0.0013850934337824583
is O 0 1.9233267423146572e-08
required O 0 8.74675887274634e-09
for O 0 6.267287133709942e-09
gastrulation O 0 2.838970067386981e-05
and O 0 1.462430798682135e-08
later O 0 1.2014623962386395e-07
for O 0 1.2581910624476222e-08
anterior O 0 1.6636948885206948e-07
development O 0 5.2797116012470724e-08
of O 0 4.6120038632579963e-07
the O 0 4.837327196582919e-07
mouse O 0 3.5036300687352195e-06
embryo O 0 2.552864089011564e-06
. O 0 8.902313197722833e-07

Mutations O 0 4.8148995119845495e-06
in O 0 6.044952556294447e-07
the O 0 1.5084610822668765e-06
SMAD4 O 1 1.0
/ O 0 0.11916166543960571
DPC4 O 1 0.9999982118606567
tumor B-Disease 0 0.00020883549586869776
suppressor O 0 4.15813383369823e-06
gene O 0 5.9169902755229487e-08
, O 0 8.025451414539475e-09
a O 0 9.96496307692496e-09
key O 0 1.8579176241928508e-07
signal O 0 3.7764729654554685e-07
transducer O 0 1.1366015542080277e-06
in O 0 3.7152368292936444e-08
most O 0 1.944640182216517e-08
TGFbeta O 0 0.00012583784700836986
- O 0 2.3514501208410366e-06
related O 0 4.429812747730466e-07
pathways O 0 4.321298945342278e-07
, O 0 5.713159723086392e-09
are O 0 1.9358305236583107e-10
involved O 0 1.551759387652396e-09
in O 0 2.222389827721827e-09
50 O 0 3.4749046307069875e-08
% O 0 9.155132651983422e-09
of O 0 1.7039295698850765e-06
pancreatic B-Disease 1 1.0
cancers I-Disease 1 0.9999997615814209
. O 0 1.0626799848978408e-05

Homozygous O 0 0.0006988993845880032
Smad4 O 0 0.017270894721150398
mutant O 0 0.0002600889711175114
mice O 0 3.570116314222105e-05
die O 0 1.6519919881829992e-05
before O 0 1.2423661246430129e-06
day O 0 8.343018293999194e-07
7 O 0 3.826546162599698e-06
. O 0 5.500401698554924e-07

5 O 0 3.904245750163682e-05
of O 0 1.645736483624205e-05
embryogenesis O 0 0.00033578326110728085
. O 0 7.242395440698601e-06

Mutant O 0 1.6071433492470533e-05
embryos O 0 1.0809480954776518e-06
have O 0 5.7144133869257985e-09
reduced O 0 3.072007714877145e-08
size O 0 3.864016662191716e-08
, O 0 1.4317806495967034e-08
fail O 0 4.462614811018284e-08
to O 0 1.1227483831532936e-08
gastrulate O 0 2.081613456539344e-05
or O 0 3.35587380106972e-08
express O 0 2.9798099987488058e-08
a O 0 1.745516264861635e-08
mesodermal O 0 4.5724973460892215e-06
marker O 0 3.6391697904036846e-06
, O 0 1.3789405173270097e-08
and O 0 1.3204277671263753e-08
show O 0 2.3313131691793387e-07
abnormal O 0 2.8221638785908e-06
visceral O 0 1.395151048200205e-05
endoderm O 0 0.21526864171028137
development O 0 1.1677000657073222e-05
. O 0 3.915462912118528e-06

Growth B-Disease 1 0.9999943971633911
retardation I-Disease 1 0.9999998807907104
of O 0 2.3482643882744014e-05
the O 0 5.62631157663418e-06
Smad4 O 1 0.9996871948242188
- O 0 8.415261254413053e-05
deficient O 0 2.161433258152101e-06
embryos O 0 7.604640472891333e-08
results O 0 3.0652298477207296e-08
from O 0 4.17232008942392e-08
reduced O 0 2.3147948979840294e-07
cell O 0 1.3380654309003148e-06
proliferation O 0 2.317795633643982e-06
rather O 0 4.034480749481872e-09
than O 0 1.0291227869885233e-09
increased O 0 2.0123177790765112e-08
apoptosis O 0 1.2625957424461376e-05
. O 0 1.0336458444726304e-06

Aggregation O 0 5.1695542424567975e-06
of O 0 2.0912677882733988e-06
mutant O 0 6.88604086462874e-06
Smad4 O 0 0.0011426209239289165
ES O 0 0.0006560938782058656
cells O 0 3.124932845821604e-07
with O 0 1.0376439263382053e-08
wild O 0 2.0273676000215346e-06
- O 0 1.4587640180252492e-06
type O 0 1.1502307870614459e-06
tetraploid O 0 1.0778665455291048e-05
morulae O 0 0.0003172107390128076
rescues O 0 3.904335244442336e-05
the O 0 1.4696431662741816e-06
gastrulation B-Disease 1 0.9980079531669617
defect I-Disease 0 0.004366244655102491
. O 0 4.305668880988378e-06

These O 0 2.546024404637137e-07
results O 0 1.1054329007720298e-07
indicate O 0 3.6154524707399105e-08
that O 0 2.426298939539606e-09
Smad4 O 0 1.9744404198718257e-05
is O 0 4.3470307353743465e-09
initially O 0 3.227495382063239e-09
required O 0 6.448431233430085e-10
for O 0 5.497465260795309e-10
the O 0 1.9441792620256138e-09
differentiation O 0 1.49616941058639e-08
of O 0 2.1427018381814378e-08
the O 0 2.0640225528723022e-08
visceral O 0 1.1465008356026374e-06
endoderm O 0 0.00024128222139552236
and O 0 1.9429569064755015e-08
that O 0 9.489823371566786e-10
the O 0 1.499654977976661e-08
gastrulation B-Disease 0 0.0005076951929368079
defect I-Disease 0 1.0145159876628895e-06
in O 0 2.5814632209630872e-08
the O 0 8.337006818237569e-08
epiblast O 0 0.005657402332872152
is O 0 7.892202447123964e-09
secondary O 0 2.377668408826139e-07
and O 0 1.998433241112707e-08
non O 0 8.013980732357595e-06
- O 0 8.498095849063247e-05
cell O 0 1.2548818631330505e-05
autonomous O 0 4.398607870825799e-06
. O 0 1.0390083389211213e-06

Rescued O 0 0.00020462529209908098
embryos O 0 3.661254231701605e-05
show O 0 1.4987367649155203e-05
severe O 0 0.41850483417510986
anterior O 0 0.001071752281859517
truncations O 1 0.9999613761901855
, O 0 1.7686121509541408e-06
indicating O 0 2.8583515359059675e-06
a O 0 8.158806252822615e-08
second O 0 2.7124139023726457e-07
important O 0 2.852948277620726e-08
role O 0 4.928737951104267e-08
for O 0 3.7982740508368806e-08
Smad4 O 0 0.023231253027915955
in O 0 2.0465445231820922e-06
anterior O 0 1.7611457224120386e-05
patterning O 0 0.00014157811529003084
during O 0 2.158401366614271e-05
embryogenesis O 0 0.0005381989758461714
. O 0 7.683173862460535e-06

Prevalence O 0 5.894814967177808e-05
of O 0 4.383645318739582e-06
p16 O 0 1.0778717296489049e-05
and O 0 6.667658567494072e-07
CDK4 O 1 0.9999709129333496
germline O 0 1.822649937821552e-05
mutations O 0 2.324719332591485e-07
in O 0 1.6141854075613082e-07
48 O 0 2.6166650059167296e-05
melanoma B-Disease 1 1.0
- O 0 0.22957023978233337
prone O 0 0.00014427912537939847
families O 0 5.4707459895553257e-08
in O 0 2.7436465188657166e-07
France O 0 4.141134922974743e-05
. O 0 3.3631386031629518e-06

The O 0 7.884508704592008e-06
French O 0 0.00021786574507132173
Familial B-Disease 1 0.9999806880950928
Melanoma I-Disease 1 1.0
Study O 0 3.3055948733817786e-05
Group O 0 4.837022515857825e-06
. O 0 1.205630496770027e-06

Germline O 0 0.0002699469041544944
mutations O 0 1.2423471389411134e-06
in O 0 2.2586576164940197e-07
the O 0 1.8603411433559813e-07
p16 O 0 5.3077578741067555e-06
and O 0 1.770902855469103e-07
CDK4 O 1 0.9998012185096741
genes O 0 1.0800949468148247e-08
have O 0 9.290949676277194e-10
been O 0 2.7665054691539126e-09
reported O 0 2.7830391324812354e-09
in O 0 2.1314869869115682e-09
a O 0 2.6743864900424796e-09
subset O 0 3.988825980627553e-08
of O 0 5.87332920076733e-07
melanoma B-Disease 1 0.9999406337738037
pedigrees O 0 4.5552187657449394e-06
, O 0 4.615554516362863e-08
but O 0 2.296385082090069e-09
their O 0 1.0216464119139346e-08
prevalence O 0 1.9160206932156143e-07
is O 0 8.060239697904592e-10
not O 0 4.5269246684576103e-10
well O 0 8.868535239514586e-09
known O 0 5.049629976383585e-07
. O 0 8.189908839995041e-07

We O 0 2.1712868658596562e-07
searched O 0 4.3052565956713806e-07
for O 0 7.440273730452418e-09
such O 0 1.7424460097004157e-08
germline O 0 2.087145503537613e-06
mutations O 0 3.705753570670822e-08
in O 0 2.6192111590717104e-08
48 O 0 3.526639318351954e-07
French O 0 0.0011244146153330803
melanoma B-Disease 1 1.0
- O 0 0.42668312788009644
prone O 0 4.778470247401856e-05
families O 0 2.188953462933796e-09
selected O 0 3.5466729997324364e-08
according O 0 7.115582789651853e-09
to O 0 2.550423428004933e-09
two O 0 3.533861869797761e-09
major O 0 1.2718989239601797e-07
criteria O 0 3.5786513308266876e-08
families O 0 1.086512213532842e-09
with O 0 4.422617383426086e-09
at O 0 3.126840510958573e-07
least O 0 2.169558976916619e-09
three O 0 2.400182275152929e-09
affected O 0 1.1401485089379548e-08
members O 0 6.980150679680719e-09
( O 0 1.144608763326005e-08
n O 0 2.261577591866626e-08
= O 0 1.5863820479466995e-08
20 O 0 2.1648601133961165e-08
) O 0 5.997246033118131e-10
or O 0 7.63862084696143e-10
families O 0 6.348915143616907e-11
with O 0 1.8586010508414574e-10
two O 0 3.258147085460905e-10
affected O 0 4.229148142798067e-09
members O 0 1.2986273167925333e-09
, O 0 2.3836717044645184e-09
one O 0 1.2630304579985818e-09
of O 0 8.512762050827405e-09
them O 0 1.6437964323046117e-09
affected O 0 5.929030155726878e-09
before O 0 1.9651325899872063e-08
the O 0 4.7308956752090126e-09
age O 0 6.591012624568293e-09
of O 0 9.694141489546837e-09
50 O 0 1.7650783945555304e-08
( O 0 2.3958737216389636e-09
n O 0 7.048502670414791e-09
= O 0 8.168674625608219e-09
28 O 0 6.755171710892682e-08
) O 0 1.4149103000349328e-09
, O 0 9.675995560343154e-10
and O 0 1.427615914373348e-09
one O 0 2.1940196326397654e-09
additional O 0 1.3347751348646852e-08
minor O 0 1.1933201676583849e-05
criterion O 0 6.832383223809302e-05
. O 0 2.6462676032679155e-06

Sixteen O 0 4.3690597522072494e-05
different O 0 1.308217321138727e-07
p16 O 0 6.739201580785448e-06
germline O 0 5.666314336849609e-06
mutations O 0 8.210430735289265e-08
were O 0 3.11908152639262e-08
found O 0 7.816161051721338e-09
in O 0 3.2718805442755183e-09
21 O 0 3.738096765459886e-08
families O 0 3.5001249121258127e-10
, O 0 2.7850675099472255e-09
while O 0 6.131302132672545e-09
one O 0 5.19579312907581e-09
germline O 0 7.46189186884294e-07
mutation O 0 6.770780203169124e-08
, O 0 6.840694766196975e-08
Arg24His O 0 0.00013523858797270805
, O 0 6.686794762345016e-08
was O 0 4.5139444182495936e-07
detected O 0 2.916129631103104e-07
in O 0 2.6513141904160875e-08
the O 0 2.4384374341934745e-07
CDK4 O 1 0.9999463558197021
gene O 0 6.376511464623036e-06
. O 0 2.4365085664612707e-06

The O 0 9.121475841311621e-07
frequency O 0 1.0783662673929939e-07
of O 0 2.52787884846839e-07
p16 O 0 7.170353342189628e-07
gene O 0 4.4065959770023255e-08
mutation O 0 6.004414299098926e-09
in O 0 4.962988242596111e-09
our O 0 4.066294412297111e-09
sample O 0 3.1407505485248066e-09
( O 0 1.8431359771753364e-09
44 O 0 1.691125284253303e-08
% O 0 1.534069871134136e-09
) O 0 5.863451391086016e-10
is O 0 5.040920458831977e-10
among O 0 1.3086903782877357e-09
the O 0 3.736212672578176e-09
highest O 0 1.4025128791672614e-07
rates O 0 7.183356132145491e-09
yet O 0 2.7890332265911866e-09
reported O 0 9.374206300094556e-09
and O 0 2.1762813773307244e-09
the O 0 4.710063450374946e-08
CDK4 O 1 0.9997674822807312
mutation O 0 5.867238783707762e-08
is O 0 4.35155200761983e-09
the O 0 8.562984099569348e-09
second O 0 1.0093590674387087e-07
mutation O 0 1.0758676616262619e-08
detected O 0 4.26558095512064e-08
in O 0 7.233539101036968e-09
this O 0 2.0660617661150127e-09
gene O 0 1.7127061369137664e-07
worldwide O 0 3.926959379896289e-07
. O 0 1.34557183173456e-06

In O 0 2.3251900529430714e-06
summary O 0 3.637639792941627e-06
, O 0 7.624392139859992e-08
our O 0 2.4645560259273225e-08
results O 0 1.2229651957795795e-08
show O 0 7.953798508708587e-09
frequent O 0 4.682436660630174e-09
involvement O 0 9.549236956729601e-09
of O 0 1.0363780056366068e-08
the O 0 1.2005261673664336e-08
p16 O 0 4.232257140301954e-07
gene O 0 2.35539001636198e-08
in O 0 2.9112714017287544e-08
familial B-Disease 0 0.00029019018984399736
melanoma I-Disease 1 0.9999895095825195
and O 0 8.708824594805264e-08
confirm O 0 4.608016013207816e-08
the O 0 2.906826956916575e-08
role O 0 1.2887900524560791e-08
of O 0 8.305803333996664e-08
the O 0 2.4208966920014063e-07
CDK4 O 1 0.9999979734420776
gene O 0 1.693582447614972e-07
as O 0 2.2014026157535227e-08
a O 0 4.926336600874492e-07
melanoma B-Disease 1 0.999984622001648
- O 0 0.0001305503974435851
predisposing O 0 4.9330072215525433e-05
gene O 0 1.256532414117828e-06
. O 0 2.0394863042838551e-07
. O 0 1.0139588084712159e-06

Progression O 0 7.546155393356457e-05
of O 0 4.417857780936174e-06
somatic O 0 0.0004554786719381809
CTG O 1 0.9650139808654785
repeat O 0 2.427697154416819e-06
length O 0 4.508514805934283e-08
heterogeneity O 0 1.4167613926474587e-07
in O 0 7.227581200197619e-09
the O 0 1.968471430302543e-08
blood O 0 1.486790893068246e-06
cells O 0 5.235652906776522e-07
of O 0 0.00019049995171371847
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.999257504940033
. O 0 3.268331420258619e-05

The O 0 9.074752256310603e-07
genetic O 0 1.6653457635129598e-07
basis O 0 8.226624004237237e-08
of O 0 1.5539155356236733e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9283677935600281
DM B-Disease 1 1.0
) O 0 1.9761442615617852e-07
is O 0 1.0763926416856862e-09
the O 0 1.0883415280105169e-09
expansion O 0 1.7484586223304177e-08
of O 0 2.6606862491007632e-08
an O 0 1.1363535890041021e-08
unstable O 0 5.439237156679155e-06
CTG O 0 0.02787766046822071
repeat O 0 6.398035452548356e-07
in O 0 1.9784309301940084e-08
the O 0 4.3608682886997485e-08
34 O 0 1.7517707817660266e-07
UTR O 0 0.0001347065408481285
of O 0 1.0206744036622695e-06
the O 0 6.03154035161424e-07
DM B-Disease 1 1.0
protein O 0 6.508961973850091e-07
kinase O 0 1.1691023473758833e-06
gene O 0 1.3222755512742879e-07
on O 0 5.08416064803896e-07
chromosome O 0 6.665154046459065e-07
19 O 0 1.9897668153134873e-06
. O 0 5.672163183589873e-07

One O 0 1.7423251392756356e-06
of O 0 9.794122206585598e-07
the O 0 1.373768157009181e-07
principal O 0 1.7694712539650936e-07
features O 0 1.661296877841778e-08
of O 0 8.029497422512577e-08
the O 0 5.865828143214458e-07
DM B-Disease 1 1.0
mutation O 0 1.543707668361094e-07
is O 0 2.037342516914009e-09
an O 0 9.233111497586322e-10
extraordinarily O 0 5.628269406088293e-08
high O 0 5.263533466859371e-07
level O 0 7.836884208245465e-08
of O 0 4.12070733091241e-08
somatic O 0 1.0046616807812825e-05
mosaicism O 0 0.030825894325971603
, O 0 3.7798308483161236e-08
due O 0 5.481650333649668e-08
to O 0 3.4195422049521085e-09
an O 0 1.7192143264566084e-09
extremely O 0 1.8043460059402605e-08
high O 0 1.3251171537831397e-07
degree O 0 5.1122672317660545e-08
of O 0 1.931590887238599e-08
somatic O 0 2.435539727230207e-06
instability O 0 8.255688044300769e-08
both O 0 3.493630496009814e-09
within O 0 1.724555431792396e-08
and O 0 5.550168324930382e-09
between O 0 9.32728205782496e-09
different O 0 2.237319485232092e-08
tissues O 0 1.5756515495013446e-05
. O 0 2.1140494936844334e-06

This O 0 1.1881043064931873e-06
instability O 0 2.798968580464134e-06
appears O 0 5.4461338550026994e-08
to O 0 2.1143673478718483e-09
be O 0 4.438383827132242e-10
biased O 0 9.199224493272595e-09
towards O 0 3.6032379302497475e-09
further O 0 9.211229556882472e-10
expansion O 0 1.766634305511161e-08
and O 0 7.925657352636506e-10
continuous O 0 4.915423179596701e-09
throughout O 0 2.1676564987416214e-09
the O 0 1.5578061063337145e-09
life O 0 1.998782916956543e-09
of O 0 5.737271102645991e-09
an O 0 1.8185929151481872e-10
individual O 0 9.17516063125845e-10
, O 0 2.2176813718743915e-09
features O 0 4.946365095293004e-09
that O 0 4.280189258576428e-10
could O 0 1.2802582327609002e-09
be O 0 7.604603613486915e-10
associated O 0 3.079650312542981e-09
with O 0 5.096849609032006e-10
the O 0 1.433570595565925e-08
progressive O 0 2.662435747424752e-07
nature O 0 1.2725833187232638e-07
of O 0 7.141540550037462e-07
the O 0 6.676040811726125e-06
disease O 1 0.9182665348052979
. O 0 1.1761958376155235e-06

Although O 0 5.039714210397506e-07
increasing O 0 5.110580758582728e-08
measured O 0 7.231597010104451e-08
allele O 0 1.931834070489913e-08
size O 0 1.3662744713371922e-08
between O 0 2.2869492966037797e-08
patients O 0 6.687024267648667e-08
clearly O 0 1.5193856839346154e-08
correlates O 0 6.846947542271664e-08
with O 0 1.5451820933876093e-09
an O 0 4.535238573577516e-10
increased O 0 2.7462698781732797e-09
severity O 0 6.85670329403365e-07
of O 0 1.8783894120133482e-06
symptoms O 0 2.68142503045965e-05
and O 0 6.977715294453901e-09
an O 0 5.059385688177542e-10
earlier O 0 1.081222489318634e-08
age O 0 1.0234348479798427e-08
of O 0 3.1001615496961676e-08
onset O 0 7.721985457465053e-05
, O 0 2.4084829686188414e-09
this O 0 9.495865205266796e-11
correlation O 0 7.402574664361339e-10
is O 0 1.2274953276047995e-10
not O 0 7.078282404648917e-11
precise O 0 5.177214656981732e-09
and O 0 3.1265730005003434e-09
measured O 0 4.7725155383204765e-08
allele O 0 9.189193406200502e-09
length O 0 2.5041297924133232e-09
cannot O 0 6.577647315708646e-10
be O 0 2.9617033825424244e-10
used O 0 2.9258491185402136e-09
as O 0 1.4948764448519114e-09
an O 0 2.890812034195278e-10
accurate O 0 2.4735836490208385e-08
predictor O 0 2.4073922304523876e-06
of O 0 2.355988328872627e-07
age O 0 3.5818135302179144e-07
of O 0 1.1647355222521583e-06
onset O 0 0.05823865160346031
. O 0 1.9895048808393767e-06

In O 0 9.514259318166296e-07
order O 0 1.8043155591840332e-07
to O 0 1.0166777641984481e-08
further O 0 1.2818521355484336e-08
characterize O 0 2.4854168145793665e-07
the O 0 7.321825279404948e-08
dynamics O 0 1.5153575532167451e-06
of O 0 1.8622191419126466e-05
DM B-Disease 1 1.0
CTG O 1 0.9998486042022705
repeat O 0 5.245041393209249e-06
somatic O 0 7.121082035155268e-06
instability O 0 3.8980235217422887e-07
, O 0 1.895412360397586e-08
we O 0 1.6818217929426282e-09
have O 0 3.974263695916136e-10
studied O 0 6.334916236028221e-08
repeat O 0 1.9387515592939053e-08
length O 0 1.1970067159694509e-09
changes O 0 7.57671925200043e-10
over O 0 1.764761115019553e-09
time O 0 2.994713810267058e-09
in O 0 1.2551541139771416e-08
111 O 0 0.01474433671683073
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 3.917650246876292e-05
with O 0 5.2304674369452187e-08
varying O 0 2.4601698100923386e-07
clinical O 0 7.894750160630792e-05
severity O 0 4.6582616050727665e-05
and O 0 9.795924142963486e-07
CTG O 0 0.15072046220302582
repeat O 0 2.646141581408301e-07
size O 0 1.3505423446247278e-08
over O 0 4.886528515157806e-09
time O 0 2.407467780685124e-09
intervals O 0 1.642524871670048e-08
of O 0 2.7676996694481204e-08
1 O 0 1.6885717002423917e-07
- O 0 7.221872238005744e-07
7 O 0 3.202976586180739e-07
years O 0 8.946486218519567e-08
. O 0 1.6349646614344238e-07

We O 0 2.008937798336774e-07
have O 0 2.3419988171013983e-09
found O 0 3.986481367235228e-09
a O 0 1.5790155849515486e-09
direct O 0 2.6116022677769024e-09
progression O 0 6.060427182319472e-08
of O 0 1.4585308960590737e-08
the O 0 5.5479878469100186e-09
size O 0 7.327857431960183e-09
heterogeneity O 0 5.8751108866772483e-08
over O 0 1.0613193879294158e-08
time O 0 4.530329889007589e-09
related O 0 1.528562165731273e-08
to O 0 4.862207525491158e-09
initial O 0 1.1941868649500975e-07
CTG O 0 0.0001738972932798788
repeat O 0 9.561452429807105e-08
size O 0 9.010496349048935e-09
and O 0 1.5789793916809458e-09
the O 0 2.7561719573299115e-09
time O 0 2.1801367378060377e-09
interval O 0 1.2543667438080774e-08
and O 0 1.0739767963841018e-09
always O 0 2.906670237834419e-09
biased O 0 1.408655680990023e-08
towards O 0 2.216726713299977e-08
further O 0 1.1320723025676216e-08
expansion O 0 7.050683166198723e-07
. O 0 5.705920216314553e-07

Attempts O 0 5.965342097624671e-06
to O 0 4.161725186691001e-08
mathematically O 0 3.1620578511137865e-07
model O 0 1.9506655846157628e-08
the O 0 1.920881231853855e-08
dynamics O 0 4.424598500918364e-07
have O 0 2.9327884565333306e-09
proved O 0 1.064208348111606e-07
only O 0 1.585915399004989e-09
partially O 0 6.538974872682957e-08
successful O 0 1.8570259996408822e-08
suggesting O 0 5.150189164027097e-09
that O 0 6.368732624606466e-11
individual O 0 3.5167455753049026e-11
specific O 0 4.625164140570348e-10
genetic O 0 1.0822648732755624e-07
and O 0 7.804366219943404e-08
/ O 0 1.30931503008469e-05
or O 0 1.728734666528453e-08
environmental O 0 1.3162880918571318e-07
factors O 0 5.696001004196205e-09
also O 0 2.6065809510811278e-09
play O 0 2.0044419457576623e-08
a O 0 4.679187259881701e-09
role O 0 1.4428644057318252e-08
in O 0 4.349007198811705e-08
somatic O 0 2.927164860011544e-05
mosaicism O 0 0.005414556711912155
. O 0 6.047887382010231e-07
. O 0 9.740551831782795e-07

Aspartylglucosaminuria B-Disease 1 0.9999992847442627
among O 0 7.275520601979224e-06
Palestinian O 0 2.6348065148340538e-05
Arabs O 0 1.1291305781924166e-05
. O 0 4.810704467672622e-06

Aspartylglucosaminuria B-Disease 1 1.0
( O 1 0.844025731086731
AGU B-Disease 1 1.0
) O 0 1.29861530240305e-06
is O 0 2.9629493525362705e-08
a O 0 5.702004202134958e-08
rare O 0 1.25614869830315e-05
disorder B-Disease 1 0.999998927116394
of I-Disease 1 0.9998974800109863
glycoprotein I-Disease 1 0.9999985694885254
metabolism I-Disease 1 0.9999902248382568
caused O 0 5.6104225222952664e-05
by O 0 1.1059664473123121e-07
the O 0 5.099892860016553e-06
deficiency B-Disease 1 0.9995810389518738
of I-Disease 0 4.9863578169606626e-05
the I-Disease 0 3.7162053558859043e-06
lysosomal I-Disease 1 0.6524178981781006
enzyme I-Disease 0 8.851114216668066e-06
aspartylglucosaminidase I-Disease 0 0.2940748333930969
( O 0 2.328114533156622e-06
AGA O 1 0.9999943971633911
) O 0 2.5194917725457344e-06
. O 0 1.3248990171632613e-06

AGU B-Disease 1 1.0
is O 0 1.387744032399496e-05
inherited O 0 0.006149036344140768
as O 0 2.1601543664928613e-07
an O 0 7.063174933819028e-08
autosomal O 0 0.010216997936367989
recessive O 0 0.004108284134417772
trait O 0 2.305553607584443e-06
and O 0 2.5709118744998705e-07
occurs O 0 2.733295900725352e-08
with O 0 3.258932013139315e-09
a O 0 8.958213726373287e-09
high O 0 1.9933897021928715e-07
frequency O 0 1.0054006516213576e-08
in O 0 2.5908239997818328e-09
Finland O 0 1.891177134893951e-07
because O 0 2.2208093142239704e-09
of O 0 3.598088937906141e-08
a O 0 8.391824479758725e-08
founder O 0 4.0985662053572014e-05
effect O 0 1.1274639746261528e-06
. O 0 6.302772703747905e-07

While O 0 3.0353751299116993e-06
very O 0 9.673975398527546e-08
few O 0 8.595715428327821e-08
patients O 0 1.3327505143934104e-07
with O 0 8.764315140297185e-08
AGU B-Disease 1 1.0
have O 0 1.5492847893483486e-08
been O 0 5.020130977584358e-09
reported O 0 6.378988004485109e-09
from O 0 6.7653687096935755e-09
non O 0 5.081174094812013e-07
- O 0 3.5910824180973577e-07
Finnish O 0 6.792790827603312e-06
origin O 0 1.5017331378430754e-08
, O 0 7.711967953127896e-09
we O 0 7.557411585423779e-09
diagnosed O 0 1.7697930161375552e-05
the O 0 7.673529012208746e-08
disorder O 0 0.25588518381118774
in O 0 9.434300096700099e-08
8 O 0 5.442570909508504e-07
patients O 0 9.779756560135411e-09
originating O 0 1.3404414467288461e-08
from O 0 7.970001547619177e-09
3 O 0 2.9123432554456485e-08
unrelated O 0 1.1711669856140361e-08
families O 0 2.8944199814695537e-10
, O 0 5.850191442391406e-10
all O 0 4.084730609310583e-10
Palestinian O 0 1.7502804539049066e-08
Arabs O 0 1.3049547220589375e-08
from O 0 1.7975104071865644e-08
the O 0 1.66885545382911e-08
region O 0 4.619799653937662e-08
of O 0 2.7232690058554e-07
Jerusalem O 0 8.945241279434413e-05
. O 0 4.708443157142028e-06

The O 0 3.1705476430943236e-06
clinical O 0 9.240738290827721e-05
diagnosis O 1 0.9925754070281982
of O 1 0.9999817609786987
AGU B-Disease 1 1.0
is O 0 1.7194226131778123e-07
often O 0 5.389606094752253e-09
difficult O 0 1.576638908318273e-08
, O 0 2.012285893471244e-09
in O 0 8.119119820904075e-10
particular O 0 2.5114851864849186e-10
early O 0 7.318540440337529e-09
in O 0 1.3856101821474454e-09
the O 0 2.1159809460158385e-09
course O 0 3.030715234331183e-08
of O 0 1.711340402721362e-08
the O 0 3.384695332897536e-07
disease O 0 0.30500170588493347
, O 0 2.79625056442967e-09
and O 0 1.3173102608732279e-09
most O 0 1.0770867531206818e-09
of O 0 8.289466890687436e-09
the O 0 2.6217753301693847e-08
patients O 0 2.096102313942083e-08
are O 0 2.7122928347722564e-09
diagnosed O 0 4.686558895627968e-06
after O 0 2.108770047470898e-08
the O 0 1.2973877971944603e-08
age O 0 3.558870531605862e-08
of O 0 8.695214859244516e-08
5 O 0 2.515577932626911e-07
years O 0 1.98855914845808e-07
. O 0 2.965774399399379e-07

However O 0 3.2215978080785135e-06
, O 0 1.1764893059762471e-07
since O 0 1.7430776821925065e-08
these O 0 2.7654452061653956e-09
patients O 0 2.708112134541807e-08
excrete O 0 3.120492522157292e-07
early O 0 3.186125141496632e-08
large O 0 3.837383300009378e-09
amounts O 0 6.773309024765695e-09
of O 0 1.3414266675226827e-07
aspartylglucosamine O 0 7.197825652838219e-06
in O 0 3.5991593705375635e-08
urine O 0 5.177460025151959e-07
, O 0 6.604830904421988e-09
biochemical O 0 3.6293783978180727e-07
screening O 0 4.1553292362550565e-07
is O 0 3.3536005084044973e-09
easy O 0 1.057113063751558e-08
by O 0 1.3671556331473766e-08
urine O 0 2.9649843327206327e-06
chromatography O 0 5.007606159779243e-05
. O 0 1.3690028026758227e-06
. O 0 2.1592823031824082e-06

Detection O 0 7.675967208342627e-05
of O 0 1.634732029742736e-06
heterozygous O 0 1.0026624863712641e-07
carriers O 0 2.5300270323214136e-08
of O 0 1.575087082983373e-07
the O 0 1.0125539802174899e-06
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 1.1645589665931766e-06
ATM O 1 0.7358716130256653
) O 0 6.308894739959214e-08
gene O 0 2.7124080759222124e-08
by O 0 1.6745694608744088e-08
G2 O 0 0.0021879193373024464
phase O 0 1.0082427252200432e-05
chromosomal O 0 9.010239409690257e-06
radiosensitivity O 0 0.00013212788326200098
of O 0 3.8028905692044646e-05
peripheral O 1 0.9997949004173279
blood O 1 0.802091658115387
lymphocytes O 0 0.0005187556962482631
. O 0 5.811505616293289e-06

In O 0 0.00010422704508528113
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 0.0013791898963972926
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.8070467433517479e-07
patients O 0 5.888955456612166e-08
, O 0 3.216261701410872e-09
mutations O 0 5.812156977924587e-09
in O 0 4.941018261206409e-09
a O 0 8.877284685127051e-09
single O 0 1.950196804045845e-08
gene O 0 1.9283222130184186e-08
, O 0 1.1515767006642363e-08
ATM O 0 0.0035134193021804094
, O 0 3.002218917913524e-08
result O 0 1.473822042186157e-08
in O 0 1.0451979726155969e-08
an O 0 1.0839340092161365e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 1.6156776609932422e-06
embraces O 0 2.5008457669173367e-06
a O 0 2.240983931756091e-08
variety O 0 6.706541455514525e-08
of O 0 4.758150282668794e-07
clinical O 0 3.064170596189797e-05
features O 0 3.014716867255629e-07
and O 0 6.287559983775282e-08
manifests O 0 2.2870292468724074e-06
extreme O 0 8.989855814434122e-06
radiosensitivity O 0 0.0002040694234892726
and O 0 6.600526347710911e-08
a O 0 7.984657202086964e-08
strong O 0 1.1964507962147763e-07
pre O 0 0.0006113693816587329
- O 0 2.5001587346196175e-05
disposition O 0 5.084001531940885e-05
to O 0 1.640022560422949e-06
malignancy B-Disease 1 0.9805740714073181
. O 0 3.738228997463011e-06

Heterozygotes O 0 5.378446803661063e-05
for O 0 3.4634780377018615e-07
the O 0 3.2846008934939164e-07
ATM O 0 0.00022461757180280983
gene O 0 1.7317880462996982e-07
have O 0 2.8709550292660424e-09
no O 0 5.753302723121578e-09
clinical O 0 1.6940121838615596e-07
expression O 0 1.1287949241989281e-08
of O 0 1.502557324783993e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 1.2405760863032356e-08
may O 0 1.6384008816316964e-08
be O 0 2.8765089865601112e-08
cancer B-Disease 0 0.06134301796555519
prone O 0 1.8159053070121445e-06
with O 0 2.6154107768405765e-09
a O 0 2.33728751908302e-08
moderate O 0 3.148261029650712e-08
increase O 0 4.091500915848201e-09
in O 0 1.2569964624731256e-08
in O 0 3.8334491136993165e-08
vitro O 0 4.129002718400443e-06
radiosensitivity O 0 0.0001877419272204861
. O 0 1.108741230382293e-06

We O 0 1.8032369553111494e-06
performed O 0 1.3746512195211835e-05
a O 0 2.42493825908241e-07
blind O 0 2.8075769478164148e-06
chromosomal O 0 9.067606470125611e-07
analysis O 0 4.573464806867378e-08
on O 0 4.4066928239772096e-07
G2 O 0 0.0024081659503281116
- O 0 2.0765360204677563e-06
phase O 0 9.00621898836107e-07
lymphocytes O 0 3.6783748669222405e-07
from O 0 3.9489247427582086e-08
7 O 0 2.2816365685685014e-07
unrelated O 0 1.6263816178252455e-06
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
patients O 0 9.54477627601591e-07
, O 0 1.0881926471029146e-08
13 O 0 6.559524479143874e-08
obligate O 0 2.5365531541865494e-07
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999990463256836
T I-Disease 1 1.0
heterozygotes O 0 4.297763553040568e-06
( O 0 1.2550560590796067e-08
parents O 0 1.2704406415764424e-09
of O 0 2.0940484901643686e-08
the O 0 2.002561672043157e-08
patients O 0 1.6530284696614217e-08
) O 0 2.0056110106025926e-09
, O 0 2.1051440590724724e-09
and O 0 4.7834949334912835e-09
14 O 0 6.847235312079647e-08
normal O 0 1.0199758371243206e-08
controls O 0 9.473335005338868e-09
following O 0 1.0607688949448857e-08
X O 0 8.782669169704604e-07
- O 0 9.623383334655955e-08
irradiation O 0 1.6575390304751636e-07
with O 0 3.893548150557535e-09
1 O 0 7.711898319939792e-08
Gy O 0 1.4369082236953545e-05
in O 0 4.512228812814101e-09
order O 0 4.032373102091924e-09
to O 0 9.738688744320712e-10
evaluate O 0 2.434467916145877e-08
this O 0 1.0821172846675609e-09
cytogenetic O 0 7.615176969011372e-07
method O 0 1.0617688062097841e-08
as O 0 3.156509054136336e-09
a O 0 1.8983092875402008e-09
tool O 0 1.5330060776364007e-08
for O 0 1.0533448557836778e-09
detection O 0 8.961735034063167e-07
of O 0 1.307537615957699e-07
ATM O 0 0.000684585771523416
carriers O 0 1.2196153420518385e-06
. O 0 8.85004965311964e-07

Both O 0 1.2150076145189814e-05
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999995231628418
T I-Disease 1 1.0
homozygotes O 0 0.00012379988038446754
and O 0 6.785388961816352e-08
heterozygotes O 0 2.8634374302782817e-06
showed O 0 9.457883720642712e-08
significantly O 0 6.403587438086333e-09
increased O 0 1.4625248789812417e-09
levels O 0 8.033000931106926e-09
of O 0 3.1918187204382775e-08
radiation O 1 0.9621128439903259
- O 0 2.685094477783423e-05
induced O 0 0.0005324507947079837
chromatid O 0 4.077389894519001e-05
damage O 0 1.3581935718320892e-06
relative O 0 2.648807218008642e-08
to O 0 1.6091763477277254e-09
that O 0 5.856085616429141e-10
of O 0 4.749169590922975e-08
normal O 0 3.875509264616994e-07
controls O 0 1.9234717001381796e-06
. O 0 1.1569153457458015e-06

These O 0 2.9113974164829415e-07
results O 0 4.2472419181649457e-07
show O 0 4.54854962583795e-08
that O 0 2.304775037487161e-09
the O 0 4.617808713192062e-08
G2 O 0 0.38721537590026855
- O 0 1.6763323174018296e-06
phase O 0 2.196199602622073e-06
chromosomal O 0 2.0128991309320554e-06
radiosensitivity O 0 5.0340740926912986e-06
assay O 0 1.0764592417444874e-07
can O 0 7.003792545923204e-10
be O 0 2.4093041450790054e-10
used O 0 2.0428290170571017e-09
for O 0 7.5175710101405e-10
the O 0 3.146338745096955e-09
detection O 0 1.2612842965609161e-06
of O 0 4.7438916794817487e-07
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999980926513672
T I-Disease 1 1.0
heterozygotes O 0 0.00012790631444659084
. O 0 1.6037008663261076e-06

In O 0 2.4210453375417273e-06
combination O 0 1.0972578365908703e-06
with O 0 2.722328318327527e-08
molecular O 0 4.8171546040975954e-06
genetic O 0 2.459742916016694e-07
analyses O 0 1.3872600845843408e-07
, O 0 2.98414826183091e-09
this O 0 3.570970186217437e-10
test O 0 2.7957987924764893e-08
may O 0 1.3223400152639897e-09
be O 0 1.447267305998423e-10
of O 0 1.307635000280527e-09
value O 0 6.39335751007053e-10
in O 0 1.19546883503574e-09
studies O 0 1.248437242473699e-09
of O 0 7.872747787018852e-09
familial B-Disease 0 1.527472903717353e-07
and I-Disease 0 2.909084351188085e-08
sporadic I-Disease 0 4.8660836000635754e-06
cancers I-Disease 0 8.314730075653642e-05
aimed O 0 1.1224855001046308e-07
at O 0 2.2700055524182972e-07
determination O 0 9.982788817808341e-09
of O 0 2.711482238737517e-08
the O 0 1.2283795314260715e-08
potential O 0 6.647269845672099e-09
involvement O 0 2.0495976471579525e-08
of O 0 5.911113376555477e-08
ATM O 0 0.00020209088688716292
mutations O 0 7.217487052457727e-08
in O 0 1.1041453973348325e-07
tumor B-Disease 1 0.5752949714660645
risk O 0 1.365976771694477e-07
or O 0 2.609791316388055e-08
development O 0 1.376817664322516e-07
. O 0 1.4516984947476885e-07
. O 0 4.081791473709018e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
telangiectasia I-Disease 1 1.0
: O 0 9.475069759901089e-07
identification O 0 6.452706884374493e-07
and O 0 2.0844645121087524e-08
detection O 0 2.0075926840945613e-06
of O 0 5.0221154879182e-07
founder O 0 0.0004002318310085684
- O 0 8.577394510211889e-07
effect O 0 1.9106973780935732e-08
mutations O 0 1.9806047912851454e-09
in O 0 1.2589825848507985e-09
the O 0 7.0839760724084044e-09
ATM O 0 1.850813532655593e-05
gene O 0 3.058292463720136e-08
in O 0 8.550319563482844e-09
ethnic O 0 4.09082190344634e-09
populations O 0 3.544651150377831e-08
. O 0 3.5728106695387396e-07

To O 0 1.6791759094303416e-07
facilitate O 0 9.942640843974004e-08
the O 0 3.2455286458343835e-08
evaluation O 0 8.76249259817996e-08
of O 0 1.704750616227102e-07
ATM O 0 0.00024374383792746812
heterozygotes O 0 1.1908472288268968e-06
for O 0 3.2183805842578295e-08
susceptibility O 0 3.5255226293884334e-07
to O 0 6.410345587681832e-09
other O 0 1.4195163089425478e-07
diseases O 1 0.999998927116394
, O 0 1.204680266653213e-08
such O 0 1.2304547603037008e-08
as O 0 8.415071306444588e-07
breast B-Disease 1 0.9999960660934448
cancer I-Disease 1 0.9971350431442261
, O 0 1.7329602641780184e-08
we O 0 5.52787371432828e-10
have O 0 8.753609642697668e-11
attempted O 0 1.7482586045503012e-08
to O 0 1.0488739876635123e-09
define O 0 7.89985321603126e-09
the O 0 7.026756954076063e-09
most O 0 2.020632106081166e-09
common O 0 5.391230573081884e-09
mutations O 0 1.426559759210022e-09
and O 0 5.699965499594839e-10
their O 0 1.1202194727388814e-09
frequencies O 0 2.157658585133504e-08
in O 0 7.017036551815181e-08
ataxia B-Disease 1 1.0
- I-Disease 1 0.999930739402771
telangiectasia I-Disease 1 1.0
( O 0 1.5370018445537426e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 7.591655304395317e-08
homozygotes O 0 6.151881279947702e-07
from O 0 1.5443989198615782e-08
10 O 0 5.812378578440303e-09
ethnic O 0 1.6633507904373346e-09
populations O 0 1.1305531621985665e-08
. O 0 1.93122133396173e-07

Both O 0 3.798056980031106e-07
genomic O 0 1.1946236782023334e-06
mutations O 0 9.506607057119254e-08
and O 0 1.4574712992043715e-08
their O 0 9.492706176672527e-09
effects O 0 2.590895462617482e-07
on O 0 6.181349476719333e-08
cDNA O 0 3.4317957897656015e-07
were O 0 4.8770619542892746e-08
characterized O 0 3.264956660586904e-07
. O 0 3.432542143855244e-07

Protein O 0 4.034043286083033e-06
- O 0 3.0554290333384415e-06
truncation O 0 3.0331093512359075e-06
testing O 0 4.0451976701660897e-07
of O 0 6.830655507883421e-08
the O 0 1.637113911101551e-08
entire O 0 1.2398587045936438e-07
ATM O 0 5.898667495785048e-06
cDNA O 0 3.743726608718134e-07
detected O 0 1.6551871340197977e-07
92 O 0 4.935643005410384e-07
( O 0 1.50742351934241e-08
66 O 0 9.106899483413144e-07
% O 0 6.374159422506409e-09
) O 0 2.63820720824981e-09
truncating O 0 2.9329808626243903e-07
mutations O 0 1.4599892850242213e-08
in O 0 1.726279919012086e-08
140 O 0 1.8739847007509525e-07
mutant O 0 7.880673820181983e-07
alleles O 0 7.311372485219181e-08
screened O 0 2.0821516955038533e-06
. O 0 1.3430975513983867e-06

The O 0 1.3296620636538137e-05
haplotyping O 0 0.0014354302547872066
of O 0 1.6033283827709965e-05
patients O 0 1.031112446980842e-06
with O 0 2.771059115502794e-08
identical O 0 8.819415029392985e-07
mutations O 0 1.3104525464768813e-07
indicates O 0 3.864186126634195e-08
that O 0 9.95219462396335e-10
almost O 0 1.9013606245010806e-09
all O 0 4.458041713562011e-10
of O 0 2.3712558583355303e-09
these O 0 2.1498101909767087e-10
represent O 0 7.605909790875387e-10
common O 0 5.1337520901029166e-09
ancestry O 0 4.773442086047908e-09
and O 0 1.8746768581934248e-09
that O 0 6.941340835453502e-10
very O 0 1.5378491813322626e-09
few O 0 1.473276789454303e-08
spontaneously O 0 4.3556235596042825e-07
recurring O 0 6.847385520813987e-06
ATM O 0 0.0011625462211668491
mutations O 0 1.0248334092466393e-06
exist O 0 1.1545213283170597e-06
. O 0 1.7460511116951238e-06

Assays O 0 1.8350347090745345e-05
requiring O 0 1.0617060297590797e-06
minimal O 0 6.685060043309932e-07
amounts O 0 8.081413227500889e-08
of O 0 9.13394444523874e-08
genomic O 0 7.9619368875683e-08
DNA O 0 1.9994268996015307e-07
were O 0 3.3879130612035624e-09
designed O 0 2.094351891912538e-08
to O 0 4.995170388433223e-10
allow O 0 4.506094664069593e-10
rapid O 0 1.8543360624789784e-08
screening O 0 1.28438033542011e-08
for O 0 9.284891189231814e-10
common O 0 1.0641126202415307e-08
ethnic O 0 4.457916702449438e-09
mutations O 0 3.2510061487300845e-07
. O 0 7.07637582308962e-07

These O 0 3.6651314871960494e-07
rapid O 0 2.621633484523045e-06
assays O 0 8.474442552142136e-07
detected O 0 6.708831392643333e-07
mutations O 0 2.3325089415493494e-08
in O 0 1.884349742908853e-08
76 O 0 2.3084878364443284e-07
% O 0 4.183889235065408e-09
of O 0 2.590538805691267e-08
Costa O 0 3.912649617632269e-07
Rican O 0 8.56875260524248e-07
patients O 0 7.395130552367846e-08
( O 0 6.709929945003523e-09
3 O 0 7.657095579816087e-08
) O 0 9.640001019661781e-10
, O 0 6.482615555469806e-10
50 O 0 2.1818840068021927e-09
% O 0 2.7632240939823305e-10
of O 0 2.873091542454631e-09
Norwegian O 0 7.257484071487852e-07
patients O 0 2.765130169279928e-08
( O 0 4.308975842803875e-09
1 O 0 8.644051519013374e-08
) O 0 1.5122033625303288e-09
, O 0 9.562902691939712e-10
25 O 0 5.669564817623041e-09
% O 0 4.6176365509076334e-10
of O 0 4.278347010000516e-09
Polish O 0 0.0003065711644012481
patients O 0 2.485201378021884e-07
( O 0 1.0308382591972531e-08
4 O 0 2.705293979943235e-07
) O 0 2.1823001183918223e-09
, O 0 1.010350136887439e-09
and O 0 1.2973722096631946e-09
14 O 0 1.8396248080421174e-08
% O 0 8.123363648415705e-10
of O 0 7.142587854502835e-09
Italian O 0 1.0363631872678525e-06
patients O 0 6.011877218270456e-08
( O 0 4.3406185312733214e-09
1 O 0 2.251822621701649e-07
) O 0 4.0299430459356245e-09
, O 0 1.1871252869610771e-09
as O 0 1.3109138219391525e-09
well O 0 8.62783566812908e-10
as O 0 1.3684542388148202e-09
in O 0 2.3087258771425923e-09
patients O 0 4.039054424254118e-09
of O 0 6.90374264422644e-08
Amish O 0 0.00020159283303655684
/ O 0 2.751038846326992e-05
Mennonite O 0 0.000130523883854039
and O 0 3.230283880384377e-07
Irish O 0 1.63512522703968e-05
English O 0 1.7845704860519618e-06
backgrounds O 0 5.512470124813262e-07
. O 0 7.643655521860637e-07

Additional O 0 8.734340326554957e-07
mutations O 0 4.032598610592686e-07
were O 0 5.73714302731787e-08
observed O 0 2.6130287267278618e-08
in O 0 9.376334375588158e-09
Japanese O 0 3.571951765479753e-07
, O 0 8.475386614748004e-09
Utah O 0 3.2844252473296365e-07
Mormon O 0 1.8768929521684186e-07
, O 0 5.507207578858697e-09
and O 0 6.579319311583731e-09
African O 0 6.73451054922225e-08
American O 0 9.486353746979148e-07
patients O 0 5.492817081176327e-07
. O 0 1.0534246257520863e-06

These O 0 1.567053402595775e-07
assays O 0 7.673791060369695e-07
should O 0 1.0032589869979347e-08
facilitate O 0 9.623784436030292e-09
screening O 0 9.544870493982671e-08
for O 0 1.9096116687933318e-08
A B-Disease 1 0.9999974966049194
- I-Disease 1 0.9999867677688599
T I-Disease 1 1.0
heterozygotes O 0 6.300597306108102e-07
in O 0 3.7014848963679015e-09
the O 0 4.636861561380101e-09
populations O 0 1.4431140726856029e-09
studied O 0 9.753103569209998e-08
. O 0 1.1495928653459941e-08
. O 0 1.6137529712523246e-07

The O 0 2.7273565137875266e-05
von B-Disease 1 0.996649444103241
Hippel I-Disease 1 0.9999468326568604
- I-Disease 1 0.9853879809379578
Lindau I-Disease 1 0.9999843835830688
tumor I-Disease 1 0.7081217169761658
suppressor O 0 2.8058291718480177e-05
gene O 0 1.4997657160620292e-07
is O 0 2.59802890312244e-09
required O 0 5.515007117651294e-09
for O 0 5.468113961626386e-09
cell O 0 1.6985447928163921e-06
cycle O 0 2.5741920239852334e-07
exit O 0 1.3593880510143208e-07
upon O 0 5.661214430574546e-08
serum O 0 2.1814933006680803e-06
withdrawal O 0 1.5640597439414705e-06
. O 0 2.076052624033764e-06

The O 0 3.957070930482587e-06
inactivation O 0 5.9305679315002635e-05
of O 0 1.4374331840372179e-06
the O 0 3.869677698276064e-07
von B-Disease 1 0.6566005349159241
Hippel I-Disease 1 0.999947190284729
- I-Disease 0 0.24344131350517273
Lindau I-Disease 1 0.9999853372573853
( I-Disease 0 6.043071607564343e-06
VHL I-Disease 1 1.0
) I-Disease 0 9.34777290240163e-07
tumor I-Disease 0 0.2644861042499542
suppressor O 0 0.0002670086396392435
gene O 0 1.4754781432202435e-06
predisposes O 0 4.475747573451372e-06
affected O 0 4.20045083160403e-08
individuals O 0 1.3478704818936649e-09
to O 0 1.0998361332781315e-08
the O 0 2.8658229211941944e-07
human O 0 0.3813266456127167
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 7.251832130350522e-07
is O 0 2.2434814894722876e-08
associated O 0 3.88488530234099e-08
with O 0 3.89762178087949e-08
sporadic B-Disease 0 0.12846717238426208
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 0.00022655227803625166
RCC B-Disease 1 1.0
) O 0 1.5350740795838647e-05
and O 0 4.2776588088599965e-05
brain B-Disease 1 0.9999945163726807
hemangioblastomas I-Disease 1 0.9981818199157715
. O 0 1.4261953765526414e-05

VHL O 1 0.9990276098251343
- O 0 7.169715536292642e-05
negative O 0 9.918251180351945e-07
786 O 0 1.7342623323202133e-05
- O 0 7.3136570790666156e-06
0 O 0 1.976041630769032e-06
RCC B-Disease 1 0.999996542930603
cells O 0 3.360822518061468e-07
are O 0 4.002663978042165e-09
tumorigenic O 0 5.30834495293675e-06
in O 0 6.920829065393264e-08
nude O 0 5.733407306252047e-06
mice O 0 1.8337452445393865e-07
which O 0 3.989501173862209e-09
is O 0 3.0893696489897593e-09
suppressed O 0 8.406819773654206e-08
by O 0 3.226879874418387e-09
the O 0 2.0293891012101994e-08
reintroduction O 0 3.288993639216642e-06
of O 0 1.705701720311481e-06
VHL B-Disease 1 0.999972939491272
. O 0 1.0640033906383906e-05

Remarkably O 0 0.00015529582742601633
, O 0 7.152937087084865e-07
this O 0 7.669487267492059e-09
occurs O 0 1.1625051143937526e-08
without O 0 2.275248656147255e-09
affecting O 0 1.1132294197579995e-08
the O 0 7.016471403886726e-09
growth O 0 1.441893271447725e-08
rate O 0 4.405912967797576e-09
and O 0 2.5598683173200243e-09
cell O 0 9.875281392623947e-08
cycle O 0 1.710697539181183e-08
profile O 0 2.8707360932855863e-09
of O 0 4.273779552477208e-09
these O 0 7.891656217395848e-10
cells O 0 8.542657248256091e-09
in O 0 5.211752807099401e-09
culture O 0 2.1279547013364208e-07
. O 0 2.2053072257222084e-07

The O 0 1.1964516488660593e-05
786 O 0 9.220914944307879e-05
- O 0 1.3445108379528392e-05
0 O 0 4.4111413899372565e-07
cell O 0 5.695525260307477e-07
line O 0 2.3985299435480556e-07
, O 0 5.012629422651571e-09
like O 0 5.246100887035254e-09
many O 0 7.494253217998903e-09
cancer B-Disease 0 0.00028463327907957137
cells O 0 1.053261371453118e-07
, O 0 8.680048679821084e-09
fails O 0 1.7887071379618646e-08
to O 0 2.4490067751514744e-09
exit O 0 1.4438738560329512e-07
the O 0 2.273258736806838e-08
cell O 0 4.893526579508034e-07
cycle O 0 7.413701297309672e-08
upon O 0 3.140488402664232e-08
serum O 0 1.4590590353691368e-06
withdrawal O 0 1.0481845720278216e-06
. O 0 1.3820945241604932e-06

Here O 0 3.848923370242119e-06
, O 0 1.3740420001795428e-07
it O 0 8.561579889487803e-09
is O 0 1.6401947577904252e-09
shown O 0 9.142266943484856e-10
that O 0 6.851758743708913e-11
reintroduction O 0 6.589557699498982e-08
of O 0 1.553472017690183e-08
the O 0 9.549128598962398e-09
wild O 0 1.2165623957116622e-06
- O 0 2.8939375624759123e-06
type O 0 8.007677934074309e-06
VHL B-Disease 1 0.9999994039535522
gene O 0 2.0612260698271712e-07
restores O 0 5.419956892183109e-07
the O 0 2.2925002340912215e-08
ability O 0 1.4428038319636016e-08
of O 0 4.228948853324255e-07
VHL O 1 0.9999995231628418
- O 0 5.799838254461065e-05
negative O 0 2.3372977011604235e-06
RCC B-Disease 1 1.0
cancer I-Disease 1 0.9943435192108154
cells O 0 5.0588507605198174e-08
to O 0 4.877422021820621e-09
exit O 0 1.1203636063328304e-07
the O 0 1.801216953367657e-08
cell O 0 2.552873468175676e-07
cycle O 0 7.385531120007727e-08
and O 0 5.249264134477016e-09
enter O 0 4.5452406993717887e-07
G0 O 1 0.9984533786773682
/ O 0 5.971689006400993e-06
quiescence O 0 8.877270374796353e-06
in O 0 2.804387406740716e-07
low O 0 5.229687303653918e-06
serum O 0 2.9938308216514997e-05
. O 0 1.9853730464092223e-06

Both O 0 2.8348982596071437e-05
VHL O 1 0.9998781681060791
- O 0 4.0016187995206565e-05
positive O 0 1.2014567118967534e-07
and O 0 1.3348773109100875e-07
VHL O 1 0.9999624490737915
- O 0 1.1525671652634628e-05
negative O 0 7.675335496060143e-07
RCC B-Disease 1 0.9999994039535522
cells O 0 6.069022333576868e-07
exit O 0 3.1794601795809285e-07
the O 0 8.97102339081357e-08
cell O 0 5.360927843867103e-07
cycle O 0 1.1880766237482021e-07
by O 0 5.42035838435595e-09
contact O 0 2.707999158246821e-07
inhibition O 0 1.4885458767821547e-06
. O 0 9.459170655645721e-07

The O 0 1.0776034287118819e-05
cyclin O 0 1.4760390513401944e-05
- O 0 2.738624516496202e-06
dependent O 0 9.679826007413794e-08
kinase O 0 4.1522312699271424e-07
inhibitor O 0 1.6768426291946525e-07
, O 0 2.8038840582667035e-08
p27 O 0 2.103284714394249e-06
, O 0 1.0875909062235678e-08
accumulates O 0 1.1186255477468876e-07
upon O 0 8.876928525580752e-09
serum O 0 9.805592071643332e-08
withdrawal O 0 2.3417051409069245e-08
, O 0 3.509693202730091e-09
only O 0 3.526043346191443e-10
in O 0 8.417015973094522e-10
the O 0 1.5679533227341835e-09
presence O 0 1.7952824782341281e-09
of O 0 9.494809916077429e-08
VHL B-Disease 1 0.9999996423721313
, O 0 1.0980586218067856e-08
as O 0 3.8911132094199274e-09
a O 0 2.1088817359071754e-09
result O 0 2.7240720790189243e-09
of O 0 1.2963217166372942e-08
the O 0 6.440408206742632e-09
stabilization O 0 2.5767513989194413e-07
of O 0 1.4512887958062493e-07
the O 0 2.506963312498556e-07
protein O 0 8.680505629854451e-07
. O 0 7.399355581583222e-07

We O 0 3.419296774609393e-07
propose O 0 2.0199593109282432e-07
that O 0 4.602023206956574e-09
the O 0 1.985359965317457e-08
loss O 0 5.30057832293096e-07
of O 0 3.528398622165696e-07
wild O 0 7.967959390953183e-06
- O 0 4.733497462439118e-06
type O 0 3.383844614290865e-06
VHL B-Disease 1 0.9999974966049194
gene O 0 4.966191369248918e-08
results O 0 1.7743269964398678e-08
in O 0 5.053678364674852e-09
a O 0 3.843338092224258e-09
specific O 0 2.8666775619967666e-08
cellular O 0 2.1041969375801273e-05
defect O 0 5.906756541662617e-06
in O 0 5.718406725918612e-08
serum O 0 2.9725836157012964e-06
- O 0 1.1420897862990387e-06
dependent O 0 4.711169054871789e-08
growth O 0 1.776162328326336e-08
control O 0 3.272874593562847e-08
, O 0 2.376122854030882e-09
which O 0 1.25542409801227e-09
may O 0 1.0077640055783377e-08
initiate O 0 1.0979214266626514e-06
tumor B-Disease 0 0.013948493637144566
formation O 0 0.0001180513936560601
. O 0 1.916173687277478e-06

This O 0 7.37163986741507e-07
is O 0 8.265882200930719e-08
corrected O 0 6.056284860278538e-07
by O 0 5.234426669886716e-09
the O 0 1.0451183030113498e-08
reintroduction O 0 2.0849503812314651e-07
of O 0 4.451537805039152e-08
wild O 0 1.230989823852724e-06
- O 0 3.965109954151558e-06
type O 0 2.7481228244141676e-05
VHL B-Disease 1 1.0
, O 0 1.1701263247232419e-06
implicating O 1 0.9993137121200562
VHL B-Disease 1 0.9999998807907104
as O 0 3.527685521476087e-07
the O 0 1.4963296735004405e-07
first O 0 2.364848512570461e-07
tumor B-Disease 0 5.780171704827808e-06
suppressor O 0 5.32076057879749e-07
involved O 0 1.5314805423827238e-08
in O 0 7.883746988568419e-09
the O 0 6.991650369769786e-09
regulation O 0 1.4974018824887025e-07
of O 0 2.3804432203178294e-07
cell O 0 1.139252617576858e-06
cycle O 0 1.5257141683377995e-07
exit O 0 1.7915466798967827e-07
, O 0 5.670354408238154e-09
which O 0 1.864264964623885e-09
is O 0 9.454520499829755e-10
consistent O 0 1.244662239940908e-08
with O 0 1.4028392891773933e-09
its O 0 1.2692787265677907e-08
gatekeeper O 0 5.985322104606894e-07
function O 0 4.117115093293933e-09
in O 0 1.1786562836846315e-08
the O 0 2.5448130713812134e-07
kidney O 1 0.759319543838501
. O 0 3.2017365469982906e-07
. O 0 6.566571641997143e-07

Piebaldism B-Disease 1 1.0
with O 0 0.006102361250668764
deafness B-Disease 1 1.0
: O 0 2.3867678464739583e-06
molecular O 0 4.441421879164409e-06
evidence O 0 7.604785423609428e-08
for O 0 6.0169793592024234e-09
an O 0 1.126218673874746e-08
expanded O 0 8.283091301564127e-05
syndrome O 1 0.9999961853027344
. O 0 8.605936272942927e-06

In O 0 8.25088477540703e-07
a O 0 1.7144434139026998e-07
South O 0 4.253553242961061e-07
African O 0 1.7204068569753872e-07
girl O 0 3.2495739787918865e-07
of O 0 5.424373057394405e-07
Xhosa O 0 0.006094608921557665
stock O 0 7.446253107445955e-07
with O 0 8.972460818768013e-08
severe O 1 0.9876863956451416
piebaldism B-Disease 1 0.999992847442627
and O 0 2.3214115572045557e-05
profound O 1 0.9999996423721313
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 5.8283731050323695e-06
identified O 0 2.7440287908575556e-07
a O 0 1.8076459440408144e-08
novel O 0 7.795885892392107e-08
missense O 0 2.872852462587616e-07
substitution O 0 3.523153395690315e-07
at O 0 6.727424306518515e-07
a O 0 1.9577887755417578e-08
highly O 0 8.488283498309102e-08
conserved O 0 2.2846805336484977e-07
residue O 0 8.182507826859364e-07
in O 0 9.189333738390815e-09
the O 0 6.607640656852709e-09
intracellular O 0 3.306796259039402e-08
kinase O 0 2.993156300590272e-08
domain O 0 1.1126138232953053e-08
of O 0 2.2365515661704194e-08
the O 0 1.2536449389699555e-07
KIT O 1 0.9907482266426086
proto O 0 0.0002246060175821185
- O 0 1.6140073057613336e-05
oncogene O 0 9.728335135150701e-05
, O 0 9.24107098398963e-07
R796G O 0 9.429323836229742e-05
. O 0 1.9108285869151587e-06

Though O 0 6.7597220549941994e-06
auditory B-Disease 0 7.055242895148695e-05
anomalies I-Disease 0 1.1517497114255093e-05
have O 0 3.954168548148118e-09
been O 0 3.543182414134094e-09
observed O 0 5.804579039647706e-09
in O 0 1.0958721929910098e-08
mice O 0 4.792145347209953e-08
with O 0 6.279084807658819e-09
dominant O 0 1.1841972309412085e-06
white O 0 2.432839210086968e-07
spotting O 0 1.0841592484212015e-05
( O 0 4.3076016709164833e-07
W O 1 0.8740513324737549
) O 0 3.192890218883804e-08
due O 0 1.3091147366139921e-07
to O 0 3.284800698111212e-08
KIT O 1 0.999998927116394
mutations O 0 2.9573877782240743e-06
, O 0 3.82626512873685e-06
deafness B-Disease 1 1.0
is O 0 2.2385146181136406e-08
not O 0 1.3104138885111638e-09
typical O 0 3.43946169323317e-08
in O 0 3.164497996976934e-08
human O 0 2.654902573340223e-07
piebaldism B-Disease 0 0.0005278959288261831
. O 0 2.164552142858156e-06

Thus O 0 2.5563285817042924e-06
, O 0 3.992632002791652e-08
the O 0 2.351184313909016e-08
occurrence O 0 4.70019642762054e-07
of O 0 4.3614003516267985e-05
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 1.603163400432095e-05
this O 0 8.389280026221968e-08
patient O 0 9.210620532940084e-07
extends O 0 4.296396838299188e-08
considerably O 0 1.604151478318272e-08
the O 0 2.0295312097573515e-09
phenotypic O 0 1.6709703842821e-08
range O 0 1.6979253558702112e-08
of O 0 4.767875694255963e-08
piebaldism B-Disease 0 8.355061254405882e-06
due O 0 1.434425769275549e-07
to O 0 2.7623151765965304e-08
KIT O 1 0.9987497329711914
gene O 0 4.1735617628546606e-08
mutation O 0 6.7652266011464235e-09
in O 0 4.060852987208818e-09
humans O 0 5.998462171419305e-09
and O 0 5.398247626686725e-09
tightens O 0 5.002216880711785e-07
the O 0 2.4731448888815066e-08
clinical O 0 3.6196720998304954e-07
similarity O 0 3.6236333045280844e-08
between O 0 1.3890401717731038e-08
piebaldism B-Disease 0 4.424594953889027e-05
and O 0 1.1032165403435101e-08
the O 0 4.226301530962928e-09
various O 0 4.6065551373430935e-09
forms O 0 1.4414098359338823e-07
of O 0 0.00011205465852981433
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 4.22875746153295e-06
. O 0 4.345526576798875e-06

Cycloheximide O 0 0.0017633000388741493
facilitates O 0 2.204297061325633e-06
the O 0 1.7056889589639468e-07
identification O 0 2.638287242007209e-07
of O 0 4.551968970645248e-07
aberrant O 0 2.8399779239407508e-06
transcripts O 0 2.209223339377786e-06
resulting O 0 1.4977374007685285e-07
from O 0 7.544597480091397e-08
a O 0 1.515426362175276e-08
novel O 0 2.8848219812971365e-08
splice O 0 4.187322701909579e-06
- O 0 5.619236844722764e-07
site O 0 1.7877495395168808e-07
mutation O 0 1.0000760219952554e-08
in O 0 2.1893512780479796e-08
COL17A1 O 1 0.999515175819397
in O 0 1.417223529642797e-07
a O 0 1.1259839283184192e-07
patient O 0 1.1318454653519439e-06
with O 0 3.834649078271468e-07
generalized O 1 0.8232781887054443
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999915361404419
. O 0 0.00017427676357328892

Patients O 0 6.884816684760153e-05
with O 0 7.185852268776216e-07
generalized O 1 0.8895493745803833
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999958276748657
often O 0 1.0801237522173324e-06
show O 0 3.1327743954534526e-07
decreased O 0 6.109846850677059e-08
expression O 0 9.479172113913137e-09
of O 0 9.5599382632372e-08
type O 0 1.2245871403138153e-05
XVII O 1 1.0
collagen O 1 0.9999984502792358
, O 0 1.36248775106651e-06
a O 0 2.0900806418922002e-07
transmembrane O 0 3.062845053136698e-06
hemidesmosomal O 0 5.2274692279752344e-05
protein O 0 3.649923598914029e-07
encoded O 0 2.2576561775622395e-07
by O 0 6.08414779890154e-07
COL17A1 O 1 0.9993250370025635
. O 0 1.4096714039624203e-05

This O 0 2.424524154776009e-07
report O 0 1.0786748561031345e-07
documents O 0 1.831897691317863e-07
a O 0 4.778755169354554e-08
novel O 0 7.272083024645326e-08
splice O 0 8.191571396309882e-06
- O 0 7.260564984790108e-07
site O 0 2.414666653294262e-07
mutation O 0 1.3788458375074697e-08
in O 0 1.0203026867827703e-08
COL17A1 O 1 0.9997937083244324
in O 0 8.720875399603756e-08
a O 0 6.316371781167618e-08
patient O 0 6.079426384530962e-07
with O 0 4.253597651882046e-08
generalized O 0 0.03500397503376007
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999990463256836
, O 0 4.4246576180739794e-07
and O 0 3.936403913940012e-08
applies O 0 1.3967554224336709e-08
a O 0 2.6870721203664516e-09
new O 0 3.113112656549788e-09
methodology O 0 2.77312111052197e-08
to O 0 2.327543713320779e-09
define O 0 1.7518802408744705e-08
and O 0 2.783173158604768e-08
characterize O 0 3.534315737852012e-07
the O 0 3.3963125645186665e-08
resulting O 0 1.394692787926033e-07
mRNA O 0 4.230852539421903e-07
splice O 0 1.2670006071857642e-05
variants O 0 2.220570650024456e-06
. O 0 1.1459322877271916e-06

Mutational O 0 0.00015651782450731844
analysis O 0 1.5969429796314216e-06
of O 0 9.072052307601552e-06
COL17A1 O 1 0.9998657703399658
identified O 0 5.409758045971103e-07
a O 0 1.3134477683252044e-07
maternally O 0 3.818977802438894e-06
inherited O 0 5.41784283996094e-05
G O 0 0.007672145497053862
- O 0 1.7034963093465194e-05
to O 0 4.43104653413684e-07
- O 0 5.5582509958185256e-05
T O 0 0.028755439445376396
transversion O 0 2.952615795948077e-05
at O 0 2.4851988200680353e-07
the O 0 1.5280491538760543e-08
- O 0 1.0764469493551587e-07
1 O 0 5.3002043642891294e-08
position O 0 6.676217623180492e-08
of O 0 1.768585491390695e-07
exon O 0 8.637007340439595e-06
32 O 0 3.614901970649953e-06
. O 0 1.3683722954738187e-06

This O 0 3.079576345044188e-07
acceptor O 0 1.1400983339626691e-06
splice O 0 8.97896388778463e-05
- O 0 5.761954525951296e-06
site O 0 7.13192378043459e-07
mutation O 0 2.4179522384315533e-08
led O 0 2.9535717871453926e-08
to O 0 2.800739640207439e-09
the O 0 1.4059392761112122e-08
formation O 0 4.918717877444578e-07
of O 0 2.259967573081667e-07
aberrant O 0 5.781560616924253e-07
transcripts O 0 4.373430044779525e-07
present O 0 6.344251346490637e-08
at O 0 9.449279900763941e-07
extremely O 0 2.2432702451169462e-07
low O 0 2.3846610019973014e-06
levels O 0 8.011091949811089e-07
. O 0 3.9590611322637415e-07

Based O 0 5.25788209415623e-06
on O 0 4.537059794529341e-07
our O 0 4.4903124774009484e-08
recent O 0 1.9110254712018104e-08
finding O 0 2.6411438369677853e-08
that O 0 3.2452360798629343e-09
cycloheximide O 0 1.0450400623085443e-05
stabilized O 0 6.199418749019969e-06
mutant O 0 4.797797828359762e-06
COL17A1 O 0 0.004098942037671804
transcripts O 0 1.825953290790494e-06
in O 0 3.633045153605963e-08
keratinocytes O 0 8.604447430116124e-07
homozygous O 0 2.2377041375420959e-07
for O 0 5.362279509313339e-09
a O 0 3.2705408159472427e-08
frameshift O 0 1.7241020486835623e-06
mutation O 0 6.384345851984108e-08
, O 0 9.711204285167696e-09
the O 0 1.647388003789274e-08
effects O 0 2.0342648099358485e-07
of O 0 1.5227081462398928e-07
the O 0 6.988093304016729e-08
splice O 0 6.61527474221657e-06
- O 0 4.256243357758649e-07
site O 0 1.1286533663223963e-07
mutation O 0 2.821123556984162e-09
on O 0 7.989620520731933e-09
splicing O 0 2.4321479941136204e-07
of O 0 5.770812663286051e-07
COL17A1 O 1 0.9580900073051453
transcripts O 0 8.657266334921587e-07
were O 0 1.1956565515447437e-08
determined O 0 4.104726780695955e-09
using O 0 4.588026847329729e-09
reverse O 0 5.604776731615857e-08
transcriptase O 0 6.190127521676914e-08
polymerase O 0 2.3068086818511802e-07
chain O 0 7.529473577960744e-08
reaction O 0 3.2899092339278013e-09
of O 0 3.701910600284464e-08
total O 0 4.801896213990631e-09
RNA O 0 7.052930328654838e-08
from O 0 1.9004840368097575e-08
keratinocytes O 0 3.199633624717535e-07
incubated O 0 6.713273847935852e-08
for O 0 1.713345731957361e-08
2 O 0 1.3080842791168834e-06
. O 0 6.345636620608275e-07

5 O 0 1.0035194463853259e-05
h O 0 1.6704658492017188e-06
in O 0 3.60934748755426e-08
the O 0 1.6343028264032e-08
presence O 0 1.3060628134553554e-08
or O 0 8.684834185146428e-09
absence O 0 1.0868717481571366e-07
of O 0 2.0423591706730804e-07
10 O 0 3.7228451787996164e-07
microg O 0 6.0685884818667546e-05
cycloheximide O 0 3.4708351449808106e-05
per O 0 3.4720565622592403e-07
ml O 0 1.8130094758816995e-05
. O 0 1.6892994381123572e-06

Using O 0 8.222622227549437e-07
this O 0 1.921544523497687e-08
approach O 0 7.718858796579298e-08
, O 0 1.3516144647951478e-08
an O 0 2.9960562919484346e-09
abnormally O 0 1.2540089073809213e-06
spliced O 0 1.8414699525237666e-06
transcript O 0 1.4140726989353425e-06
was O 0 2.363189111065367e-07
identified O 0 1.3290262224074922e-08
that O 0 5.171981176665952e-10
contains O 0 3.00864333446782e-09
an O 0 4.880117976391318e-10
extra O 0 7.02161262466916e-09
264 O 0 5.033460226400166e-08
bases O 0 2.4992592884132137e-08
upstream O 0 2.985140312716794e-08
from O 0 1.4608417586714495e-08
exon O 0 5.042637098995328e-07
32 O 0 1.6351017961824255e-07
, O 0 7.408864188818143e-09
resulting O 0 2.9686853864063778e-08
in O 0 2.2424119450192848e-08
a O 0 5.482476339579989e-08
premature O 0 1.1715868595274515e-06
termination O 0 2.223390993094654e-06
codon O 0 3.072341087317909e-06
27 O 0 1.8535475874159602e-06
bp O 0 1.1817784297818434e-06
downstream O 0 4.379924405384372e-07
from O 0 7.918788469396532e-08
the O 0 1.022013194074134e-07
cryptic O 0 4.4382795749697834e-06
splice O 0 8.123931911541149e-05
site O 0 1.806630280043464e-05
. O 0 2.647166184033267e-06

Three O 0 1.150056391452381e-06
other O 0 1.2067113175362465e-07
splice O 0 1.0103169188369066e-05
variants O 0 3.5411579801802873e-07
, O 0 1.6196466390283604e-08
including O 0 1.1425366430728445e-08
one O 0 2.3634219026291703e-09
derived O 0 6.989943290847123e-09
from O 0 6.693248622013925e-09
the O 0 7.209229213600565e-09
skipping O 0 2.0204063844175835e-07
of O 0 6.183601897191693e-08
exon O 0 5.064054562353704e-07
32 O 0 1.0344588474708871e-07
, O 0 6.462422152964109e-09
were O 0 2.1342586364880844e-08
also O 0 5.2598704058937074e-08
identified O 0 2.1897652402458334e-07
. O 0 6.231470024431474e-07

These O 0 2.7108907829642703e-07
results O 0 1.9652887317533896e-07
indicate O 0 2.524445186224966e-08
the O 0 6.6708687462835314e-09
usefulness O 0 6.886408954187573e-08
of O 0 5.1647806031951404e-08
cycloheximide O 0 1.9628419977379963e-05
treatment O 0 1.4367435596795985e-07
in O 0 7.027320503283363e-09
evaluating O 0 6.691668374969595e-08
the O 0 3.6860718921616353e-08
abnormal O 0 1.182794875376203e-07
processing O 0 1.572802545979357e-07
of O 0 4.5214235910862044e-08
mRNA O 0 3.388340985566174e-08
due O 0 2.4728430858544925e-08
to O 0 6.672522978590223e-09
splice O 0 6.9592424551956356e-06
- O 0 3.3880994010360155e-07
site O 0 1.767521524698168e-07
mutations O 0 2.0508645448558127e-08
, O 0 4.684920007491655e-09
because O 0 9.201207795683786e-09
( O 0 1.3468227422208656e-08
i O 0 1.249967880312397e-07
) O 0 1.0807213790542392e-08
aberrant O 0 2.1109799774876592e-07
splicing O 0 3.372641117493913e-07
often O 0 5.2103215075760545e-09
generates O 0 2.591477787916574e-08
a O 0 1.0329914701401322e-08
premature O 0 2.1436260055907042e-07
termination O 0 1.7202755486778187e-07
codon O 0 6.177148179631331e-07
, O 0 2.3890939004900247e-08
( O 0 1.0843906217417043e-08
ii O 1 0.995105504989624
) O 0 3.418161398371922e-08
transcripts O 0 7.374409847216157e-07
with O 0 9.413265722457709e-09
premature O 0 9.805729632716975e-07
termination O 0 7.656736897843075e-07
codons O 0 2.3409064908719301e-07
can O 0 1.753935552351038e-09
occur O 0 2.7035638172634435e-09
at O 0 1.1887384943065626e-07
low O 0 1.1953171963341447e-07
or O 0 1.1093738372380813e-08
undetectable O 0 4.433245976542821e-06
levels O 0 1.0727653432240913e-08
due O 0 1.4350423072073681e-08
to O 0 2.7453430639923226e-09
nonsense O 0 4.687577472850535e-07
- O 0 1.3481121641234495e-07
mediated O 0 7.684162284249396e-08
mRNA O 0 5.10816384746704e-08
decay O 0 3.8097311971796444e-07
, O 0 3.81451314979131e-09
and O 0 2.594522818810674e-09
( O 0 8.107796212186713e-09
iii O 0 0.05916202813386917
) O 0 1.0049213017282455e-08
the O 0 6.887325820770229e-09
levels O 0 8.288960628988207e-09
of O 0 3.529368797217103e-09
these O 0 4.57941295994857e-10
transcripts O 0 4.070595238658825e-08
can O 0 4.940922115892477e-10
be O 0 7.413991642835072e-10
increased O 0 3.1761244745354134e-09
by O 0 3.896231604016975e-08
cycloheximide O 0 0.0001315578556386754
. O 0 1.6594132148384233e-06

A O 0 3.000201286340598e-05
deletion O 0 2.5733695565577364e-06
mutation O 0 1.90026710811253e-07
in O 0 7.96521817392204e-08
COL17A1 O 1 0.9998853206634521
in O 0 1.1481689909942361e-07
five O 0 4.198384218057072e-08
Austrian O 0 1.6623909687041305e-05
families O 0 9.99988269967389e-09
with O 0 1.0054431953676612e-07
generalized O 0 0.039358168840408325
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9998785257339478
represents O 0 2.6770244403451215e-06
propagation O 0 4.886559054284589e-06
of O 0 4.964264235240989e-07
an O 0 6.41932871303652e-08
ancestral O 0 1.1005349733750336e-05
allele O 0 1.4872318843117682e-06
. O 0 1.1354120488249464e-06

Patients O 0 3.187816037097946e-05
with O 0 6.116885060691857e-07
generalized O 0 0.3633035123348236
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999995231628418
, O 0 5.415291752797202e-07
a O 0 4.90998139923704e-08
usually O 0 1.3796850772962443e-08
nonlethal O 0 5.745137059420813e-06
form O 0 4.926482120026776e-07
of O 0 1.7815109458751976e-05
junctional B-Disease 1 0.9999995231628418
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999802112579346
, O 0 8.35696198464575e-07
have O 0 1.8141049551445576e-08
generalized O 0 1.1467948297649855e-06
blistering B-Disease 0 0.004397813696414232
, O 0 4.088993591722101e-05
nail B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 0.08049429208040237
patchy B-Disease 1 1.0
alopecia I-Disease 1 1.0
, O 0 0.0006608827970921993
and O 0 0.10605993866920471
dental B-Disease 1 1.0
abnormalities I-Disease 1 1.0
. O 0 0.000217517459532246

Skin B-Disease 1 1.0
fragility I-Disease 0 0.21255874633789062
in O 0 5.163756213732995e-07
most O 0 2.5834680172920343e-08
cases O 0 1.5712830148117973e-08
is O 0 2.071471660869406e-09
due O 0 1.692035134226444e-08
to O 0 2.4113235852496473e-09
mutations O 0 8.223811853724783e-09
in O 0 4.907750650318121e-09
the O 0 1.0773872460845269e-08
gene O 0 1.8734123585772977e-08
encoding O 0 7.660717926682992e-08
type O 0 1.2373464414849877e-05
XVII O 1 1.0
collagen O 1 0.9999996423721313
( O 0 3.5322820622241125e-05
COL17A1 O 1 0.9999997615814209
) O 0 7.475596248696093e-07
. O 0 9.674211014498724e-07

Recently O 0 3.311918044346385e-05
, O 0 2.475115934430505e-07
we O 0 2.3713971231131836e-08
reported O 0 3.779160451244934e-08
five O 0 2.0344234741287437e-08
Austrian O 0 6.567475793417543e-06
families O 0 1.561882889689059e-08
with O 0 7.355811248999089e-08
generalized O 0 0.06575854867696762
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999971389770508
who O 0 1.94336303138698e-06
share O 0 1.689639645974239e-07
the O 0 1.1802482902112388e-07
same O 0 3.160553490033635e-07
COL17A1 O 1 0.9999823570251465
mutation O 0 5.207600224821363e-06
. O 0 1.809704258448619e-06

Affected O 0 2.9775515031360555e-06
individuals O 0 3.400901960048941e-08
in O 0 3.631777190093999e-08
three O 0 5.229477295642937e-09
families O 0 3.4087305200714013e-10
are O 0 1.0547555884254933e-10
homozygous O 0 6.021480203344254e-09
for O 0 1.6862865548361583e-09
4003delTC O 0 3.3980149964918382e-06
, O 0 1.0664532368309665e-08
whereas O 0 6.7713075146969e-09
those O 0 1.2104884872243815e-09
in O 0 2.6889945825558925e-09
two O 0 8.762166547882089e-10
others O 0 4.078862581025078e-09
are O 0 1.6578205475070718e-09
compound O 0 2.4353423668799223e-06
heterozygotes O 0 1.304474426433444e-05
. O 0 1.917159124786849e-06

To O 0 1.520177761449304e-07
determine O 0 9.419554913847605e-08
if O 0 3.9583643030027815e-09
the O 0 3.4032689999463628e-09
occurrence O 0 4.114197338367376e-08
of O 0 5.515557077728772e-08
4003delTC O 0 1.1125713399451342e-06
in O 0 2.1907160530076908e-09
these O 0 3.9079947611320165e-10
unrelated O 0 1.503274837943991e-08
families O 0 3.111282897982903e-10
signifies O 0 1.596776222356766e-08
propagation O 0 2.433108647892368e-07
of O 0 2.8602546109368632e-08
an O 0 1.7259267348634921e-09
ancestral O 0 2.9752732189081144e-07
allele O 0 2.0901618213997608e-08
or O 0 1.5851210122264092e-08
a O 0 5.7295427069448124e-08
mutational O 0 4.0143393562175333e-05
hot O 0 4.756520138471387e-05
spot O 0 4.7663388613727875e-06
, O 0 3.207160403917442e-08
haplotypes O 0 7.007218982835184e-08
were O 0 7.199541407487686e-09
determined O 0 5.9009610531290946e-09
for O 0 2.742768012709007e-09
polymorphisms O 0 6.686488518425904e-08
both O 0 5.700739880154515e-09
within O 0 1.4231611089599028e-07
and O 0 2.3002380089565122e-07
flanking O 0 0.0017038536025211215
COL17A1 O 1 0.9999974966049194
. O 0 2.3861077352194116e-05

Five O 0 1.4284603821579367e-05
intragenic O 0 0.00025675297365523875
polymorphisms O 0 1.5431027122758678e-06
were O 0 5.142319992046396e-08
chosen O 0 1.0007461526129191e-07
based O 0 1.3459937520110543e-07
on O 0 2.1428698460113083e-07
their O 0 2.5239017986677936e-07
informativeness O 0 0.0004532301682047546
. O 0 2.73711521003861e-06

One O 0 1.236585831065895e-06
of O 0 3.850913401493017e-07
these O 0 1.0881759493486243e-08
, O 0 6.276917208225541e-09
not O 0 4.217160232133921e-10
previously O 0 1.4299384787364033e-08
reported O 0 1.8020692493792012e-08
, O 0 3.6247582713144766e-09
was O 0 1.1114328657413353e-07
2988 O 0 5.598842562903883e-06
A O 0 5.683160111402685e-07
or O 0 4.899195360508202e-08
C O 0 4.5538808990386315e-06
that O 0 1.168734109491254e-09
introduces O 0 1.9835242781596207e-08
a O 0 2.0712345172313462e-09
new O 0 1.2889614930955418e-09
restriction O 0 2.7583964001820505e-09
site O 0 7.287690095836297e-08
for O 0 1.286717044024499e-08
Eco0109 O 0 8.631696255179122e-05
I O 0 0.00010501026554265991
. O 0 8.142876595229609e-07

All O 0 1.6885794593690662e-06
the O 0 4.985500368093199e-07
4003delTC O 0 8.487233571941033e-06
alleles O 0 4.702245348653378e-08
showed O 0 5.1828887848159866e-08
the O 0 7.162163750962236e-09
same O 0 6.11973538511279e-09
haplotype O 0 8.19261387619008e-08
for O 0 2.649968022794269e-09
these O 0 4.939039843776527e-09
five O 0 3.119974323340102e-08
polymorphic O 0 4.60010051028803e-06
markers O 0 2.139188291039318e-05
. O 0 2.964034365504631e-06

Fourteen O 0 2.8433592888177373e-05
microsatellite O 0 1.0369610208726954e-05
polymorphisms O 0 7.866429427849653e-07
were O 0 3.238955059714499e-08
selected O 0 4.69972611938374e-08
based O 0 3.338845999678597e-08
on O 0 1.3463911763267333e-08
their O 0 7.674286983672118e-09
high O 0 3.8705857718923653e-07
heterozygosity O 0 5.766758931713412e-06
and O 0 6.819145248471159e-09
their O 0 2.2312414138525583e-09
location O 0 3.680283100493398e-08
within O 0 5.858471752162586e-08
10q23 O 0 1.0251373169012368e-05
- O 0 6.625698006246239e-06
q25 O 0 5.986663018120453e-05
near O 0 7.5177988037467e-05
COL17A1 O 1 0.9991984963417053
. O 0 4.917736987408716e-06

Three O 0 3.705856670421781e-07
families O 0 7.637780186087184e-09
shared O 0 5.6535746750796534e-08
microsatellite O 0 4.207718120596837e-06
polymorphisms O 0 6.48798391011951e-07
covering O 0 1.1963124052272178e-05
at O 0 2.5002088932524202e-06
most O 0 1.7729806955912863e-08
19 O 0 3.49094847251763e-07
cM O 0 1.6719020834443654e-07
, O 0 4.204937731344671e-09
whereas O 0 5.98968163956215e-09
the O 0 3.5894094363442264e-09
others O 0 1.691408235693359e-09
shared O 0 2.1904154046126223e-09
smaller O 0 4.562692890175413e-09
regions O 0 8.114897198652216e-09
consistent O 0 3.2990723042303216e-08
with O 0 3.35365157866363e-09
cross O 0 1.4355013888689427e-07
- O 0 2.391739144513849e-07
over O 0 7.631270726449202e-09
events O 0 4.195676250873248e-09
during O 0 6.954516518220544e-09
passage O 0 1.5363803562706835e-09
of O 0 1.2797261028651974e-09
this O 0 3.418418881295793e-10
mutation O 0 1.4763338329615294e-09
through O 0 1.769003832308158e-09
several O 0 5.646933143310662e-09
generations O 0 2.1176724374072364e-07
. O 0 3.7900679217273137e-07

These O 0 5.434438890006277e-07
results O 0 6.528208587042172e-07
indicate O 0 9.973333447987898e-08
that O 0 3.520977731596986e-09
4003delTC O 0 1.4608829133067047e-06
occurs O 0 1.4001481751790834e-08
on O 0 8.692225605955173e-09
a O 0 5.377448264454188e-09
single O 0 2.7932456347912193e-08
ancestral O 0 6.654794901805872e-07
allele O 0 8.34139726180183e-08
. O 0 6.825003850963185e-08
. O 0 4.05420024662817e-07

The O 0 1.7673846741672605e-05
haptoglobin O 0 0.000387423497159034
- O 0 2.2628566512139514e-05
gene O 0 2.911341709932458e-07
deletion O 0 4.526747829913802e-07
responsible O 0 5.230747319728835e-07
for O 0 4.2740754224723787e-07
anhaptoglobinemia B-Disease 1 0.7169533371925354
. O 0 7.1152780947159044e-06

We O 0 3.2424478035864013e-07
have O 0 4.810376097452718e-09
found O 0 7.460594808605947e-09
an O 0 1.2206969879358098e-09
allelic O 0 6.303945383479004e-07
deletion O 0 2.950717714611528e-07
of O 0 3.5431239098215883e-07
the O 0 3.269406079198234e-07
haptoglobin O 0 3.6889374314341694e-05
( O 0 1.0305281250566622e-07
Hp O 0 1.1965208841502317e-06
) O 0 1.6870014718506354e-08
gene O 0 1.340086175360966e-08
from O 0 7.3803456679399915e-09
an O 0 1.3399372722489034e-09
individual O 0 4.40824132752482e-09
with O 0 7.084140918323101e-08
anhaptoglobinemia B-Disease 0 0.47381630539894104
. O 0 6.393426247086609e-06

The O 0 1.6734455130062997e-05
Hp O 0 2.407644387858454e-05
gene O 0 1.3988824321131688e-06
cluster O 0 5.023959147365531e-06
consists O 0 2.6295435873180395e-07
of O 0 2.3104368551685184e-07
coding O 0 2.6939119379676413e-07
regions O 0 4.388127550214449e-08
of O 0 2.3530715509423317e-07
the O 0 1.0175531173217678e-07
alpha O 0 2.7371260102881934e-07
chain O 0 1.1857765969125467e-07
and O 0 7.532314327818312e-09
beta O 0 5.406731062862491e-08
chain O 0 7.16036367975903e-08
of O 0 1.7516162742481356e-08
the O 0 1.6991824836054548e-08
haptoglobin O 0 2.17179763239983e-06
gene O 0 3.752913002585956e-08
( O 0 5.643982614600418e-09
Hp O 0 4.693177970693796e-07
) O 0 6.768349880559299e-09
and O 0 3.5510712148578705e-09
of O 0 1.673502936228033e-08
the O 0 1.2087772560676058e-08
alpha O 0 1.071984456757491e-07
chain O 0 5.2714806741960274e-08
and O 0 2.8818838426758475e-09
beta O 0 2.3500051682390222e-08
chain O 0 2.6389182394837007e-08
of O 0 1.264817584001321e-08
the O 0 1.14004414797364e-08
haptoglobin O 0 1.771137135619938e-06
- O 0 2.636765543684305e-07
related O 0 8.681806917820722e-08
gene O 0 3.208090504358552e-08
( O 0 1.2909944224759329e-08
Hpr O 0 3.6471365092438646e-06
) O 0 1.490458600983402e-08
, O 0 2.887584171773483e-09
in O 0 7.367349841302939e-09
tandem O 0 8.02439672042965e-07
from O 0 1.0307364561867871e-07
the O 0 2.5363814870615897e-07
5 O 0 9.992867262553773e-07
side O 0 1.2526486443675822e-06
. O 0 4.017083767848817e-07

Southern O 0 4.404064384289086e-05
blot O 0 8.025421266211197e-05
and O 0 1.1367148999852361e-07
PCR O 0 4.822099981538486e-06
analyses O 0 2.6639975203579525e-07
have O 0 1.7826471410131717e-09
indicated O 0 4.6700834310797745e-09
that O 0 2.022678413649004e-10
the O 0 2.072064297919951e-09
individual O 0 3.0354446733937834e-10
with O 0 1.7702426191590348e-09
anhaptoglobinemia B-Disease 0 5.6785887863952667e-05
was O 0 2.999205719333986e-07
homozygous O 0 2.0929103783373648e-08
for O 0 1.3784295926910772e-09
the O 0 1.3916602092933772e-08
gene O 0 2.0469876460538217e-08
deletion O 0 2.7981194250514818e-08
and O 0 5.908461275794252e-09
that O 0 7.330873685873485e-10
the O 0 1.0375211800806028e-08
gene O 0 1.7833588827897984e-08
deletion O 0 3.945581994457825e-08
was O 0 6.782374128988522e-08
included O 0 1.561450879705717e-08
at O 0 6.610933667161589e-08
least O 0 8.651944716220328e-10
from O 0 3.521454683408365e-09
the O 0 6.7449081875281536e-09
promoter O 0 1.0181477591686416e-05
region O 0 7.90296041941474e-08
of O 0 2.565851389135787e-07
Hp O 0 9.4913309567346e-07
to O 0 3.666116654699181e-08
Hpr O 0 1.163706838269718e-05
alpha O 0 5.391201511883992e-07
but O 0 1.9808918949593135e-09
not O 0 5.663498559016489e-10
to O 0 6.428049648121714e-09
Hpr O 0 5.910768777539488e-06
beta O 0 2.2738890947948676e-06
( O 0 2.766051352409704e-07
Hpdel O 0 0.00043813828960992396
) O 0 3.6695382732432336e-07
. O 0 9.78233174464549e-07

In O 0 7.614966648361587e-07
addition O 0 1.3093868744817883e-07
, O 0 2.5267189229793985e-08
we O 0 1.8471973950440201e-09
found O 0 1.5744262560346556e-09
seven O 0 1.8342771745949449e-09
individuals O 0 1.655674070066837e-10
with O 0 3.6260443536662024e-09
hypohaptoglobinemia B-Disease 0 6.234909233171493e-05
in O 0 1.9301436893215396e-08
three O 0 2.003278876117065e-09
families O 0 3.8457118045620575e-10
, O 0 2.313420566224522e-09
and O 0 3.4299936224613248e-09
the O 0 8.456638056486554e-09
genotypes O 0 1.3215141336786473e-07
of O 0 4.504251549519722e-08
six O 0 1.3827726519366479e-08
of O 0 8.885809421599333e-08
the O 0 1.0965893970649176e-08
seven O 0 4.282404653110916e-09
individuals O 0 6.351821846273253e-11
were O 0 2.6281172793574115e-09
found O 0 4.7267105784953856e-09
to O 0 3.4912324142766238e-09
be O 0 6.830864407447734e-08
Hp2 O 1 0.997569739818573
/ O 0 0.005486330948770046
Hpdel O 0 0.19380314648151398
. O 0 8.698713827470783e-06

The O 0 5.4526781241293065e-06
phenotypes O 0 6.3523971221002284e-06
and O 0 8.776292048651158e-08
genotypes O 0 1.7952803545995266e-06
in O 0 5.544034564763933e-08
one O 0 4.329257397017727e-09
of O 0 2.861356840355711e-08
these O 0 7.054632433778352e-10
three O 0 2.8142659314056573e-09
families O 0 3.364624967527874e-10
showed O 0 1.3379076513331256e-08
the O 0 1.318814302209148e-08
father O 0 5.289044935352649e-08
to O 0 2.0613029061422594e-09
be O 0 5.5394551168319595e-09
hypohaptoglobinemic B-Disease 0 1.2543338925752323e-05
( O 0 6.340960112538596e-08
Hp2 O 0 5.817730925627984e-05
) O 0 2.0647233256454456e-08
and O 0 5.796572111194109e-08
Hp2 O 0 0.006845378782600164
/ O 0 1.8474189346306957e-05
Hpdel O 0 0.00035940445377491415
, O 0 1.9656498650988397e-08
the O 0 2.16753335280373e-08
mother O 0 1.8961065606504235e-08
to O 0 2.1950996575981208e-09
be O 0 4.416076393454205e-09
Hp2 O 0 1.6000214600353502e-05
- O 0 1.2119141956645763e-06
1 O 0 1.0754536106105661e-07
and O 0 9.031315251206706e-09
Hp1 O 0 0.00014568146434612572
/ O 0 3.420768507567118e-06
Hp2 O 0 4.4185104343341663e-05
, O 0 4.3632288893036275e-09
one O 0 1.1952773215639922e-09
of O 0 1.0506585823577552e-08
the O 0 3.412127691504452e-09
two O 0 1.1594641913248438e-09
children O 0 1.692579854051246e-09
to O 0 1.2250470637908961e-09
be O 0 4.708354595095443e-09
hypohaptoglobinemic B-Disease 0 1.529347719042562e-05
( O 0 5.248725898354678e-08
Hp2 O 0 0.00010985706467181444
) O 0 2.6040083866973873e-08
and O 0 2.5181501328574996e-08
Hp2 O 0 0.008063768967986107
/ O 0 1.267511925107101e-05
Hpdel O 0 0.001034448971040547
, O 0 1.524602311064882e-08
and O 0 2.1197903432579324e-09
the O 0 3.4606162380157457e-09
other O 0 1.6664564173041185e-09
child O 0 2.4292452494023564e-08
to O 0 2.0994903593418712e-09
be O 0 6.123728635287762e-09
Hp1 O 0 1.8445563910063356e-05
and O 0 1.3871292026124138e-07
Hp1 O 1 0.7069455981254578
/ O 0 9.760280954651535e-05
Hpdel O 0 0.000637795717921108
, O 0 4.813269427472733e-08
showing O 0 4.6141551024447836e-08
an O 0 1.1020697687769143e-09
anomalous O 0 3.254467912938708e-07
inheritance O 0 1.7165243093586469e-07
of O 0 3.148885298287496e-06
Hp O 0 5.873066129424842e-06
phenotypes O 0 8.939952067521517e-07
in O 0 7.807805246784483e-08
the O 0 1.4985631935360288e-07
child O 0 8.780692724030814e-07
with O 0 3.5753635074797785e-07
Hp1 O 1 0.9000935554504395
. O 0 5.42705583939096e-06

The O 0 1.4953803656680975e-05
Hp2 O 1 0.9994569420814514
/ O 0 0.0009207912371493876
Hpdel O 0 0.0002686323714442551
individuals O 0 4.251194063442654e-09
had O 0 1.3395162312690445e-08
an O 0 2.0076549311909275e-09
extremely O 0 4.2478895068143174e-08
low O 0 2.864109944766824e-07
level O 0 1.3974781154502125e-07
of O 0 6.817418807258946e-08
Hp O 0 6.853584295640758e-07
( O 0 1.6860203899682347e-08
mean O 0 1.5364397754069614e-08
+ O 0 4.937168185392693e-08
/ O 0 2.0587134486049763e-07
- O 0 3.743112415577343e-07
SD O 0 1.6626527212793007e-05
= O 0 5.699721228324961e-08
0 O 0 8.717029764682138e-09
. O 0 8.622818015169287e-10
049 O 0 4.73650970889139e-07
+ O 0 3.1561615543296284e-08
/ O 0 1.101955149351852e-07
- O 0 6.646612860095047e-08
0 O 0 8.427734954352673e-09
. O 0 2.124246556434173e-09
043 O 0 5.821723334520357e-07
mg O 0 3.7097324820933864e-06
/ O 0 5.052693268225994e-07
ml O 0 1.9019968533484644e-07
; O 0 2.1524699800323788e-09
n O 0 8.32991453592058e-09
= O 0 5.2183275478512314e-09
6 O 0 2.3200810161938534e-08
) O 0 5.758745702522106e-10
, O 0 2.6368676686594483e-10
compared O 0 5.166420624647117e-10
with O 0 1.0885278095562612e-10
the O 0 3.774281331914153e-09
level O 0 2.3265993576160326e-08
( O 0 1.3048668812132291e-09
1 O 0 7.206465646447668e-09
. O 0 7.314838734728824e-10
64 O 0 1.9113242544221976e-08
+ O 0 1.162773433094344e-08
/ O 0 9.304879000637811e-08
- O 0 8.382625793501575e-08
1 O 0 2.310568625318865e-08
. O 0 2.100836171692322e-09
07 O 0 5.698328777725692e-07
mg O 0 3.175507345076767e-06
/ O 0 4.1321519006487506e-07
ml O 0 1.3256973829811614e-07
) O 0 1.1112708531157978e-09
obtained O 0 2.1571391339847423e-09
from O 0 8.20454104655255e-09
52 O 0 4.844556755756457e-08
healthy O 0 2.339816695950958e-08
volunteers O 0 4.390597041492583e-08
having O 0 2.906217133613609e-08
phenotype O 0 1.5521781904226373e-07
Hp2 O 0 2.4859458790160716e-05
, O 0 2.2094326368460315e-08
whereas O 0 1.5459196589517887e-08
the O 0 2.0739472361697153e-08
serum O 0 6.961658414184058e-07
Hp O 0 4.657685508391296e-07
level O 0 1.0847488596255062e-07
of O 0 1.2762118473119699e-08
an O 0 3.624784083999799e-10
individual O 0 7.326023121478897e-10
with O 0 1.2145872752000741e-08
Hp1 O 1 0.9832144975662231
/ O 0 9.319754462921992e-05
Hpdel O 0 0.0013821389293298125
was O 0 2.9535292469518026e-06
0 O 0 5.318523221831128e-07
. O 0 2.576412043708842e-07

50 O 0 1.4839217328699306e-05
mg O 0 0.0001671708159847185
/ O 0 1.6738302292651497e-05
ml O 0 4.308564712118823e-06
, O 0 3.3421972744918094e-08
which O 0 2.981474178653798e-09
was O 0 3.083701827222285e-08
approximately O 0 2.2075528072207362e-09
half O 0 1.5329000291330885e-09
the O 0 1.351794232107295e-09
level O 0 1.1331567684180754e-08
of O 0 1.2514131064733647e-08
Hp O 0 1.68021387025874e-07
in O 0 1.2662707327137923e-08
control O 0 1.741355504236708e-07
sera O 0 4.273510967323091e-06
from O 0 3.5592780278648206e-08
the O 0 4.297699973676572e-08
Hp1 O 0 1.6623243936919607e-05
phenotype O 0 8.78895605183061e-08
( O 0 5.974415628884344e-09
1 O 0 2.9518030686404018e-08
. O 0 2.7041053840548557e-09
26 O 0 3.198009679294955e-08
+ O 0 2.9993799444127944e-08
/ O 0 8.848415689044486e-08
- O 0 5.737920005799424e-08
0 O 0 6.311708933282034e-09
. O 0 5.643894240847658e-10
33 O 0 3.72345922983186e-08
mg O 0 1.8925820768345147e-06
/ O 0 2.9324664296837e-07
ml O 0 1.8144203295378247e-07
; O 0 1.4706875717251933e-09
n O 0 1.0624393809166577e-08
= O 0 9.278946500046459e-09
9 O 0 6.449322853541162e-08
) O 0 1.398780868910876e-09
, O 0 1.011798533845365e-09
showing O 0 7.744544561205657e-09
a O 0 8.898491721254231e-09
gene O 0 8.314329846825785e-08
- O 0 2.174232349716476e-06
dosage O 0 1.403169062541565e-05
effect O 0 2.7895989660464693e-06
. O 0 7.474619678760064e-07

The O 0 1.0481605841050623e-06
other O 0 4.630695116247807e-08
allele O 0 1.5384520679617708e-07
( O 0 4.930947739012481e-08
Hp2 O 0 3.1005372875370085e-05
) O 0 7.391784517807309e-09
of O 0 1.41864004987724e-08
individuals O 0 2.27138419184314e-10
with O 0 4.801841146928609e-09
Hp2 O 1 0.9998051524162292
/ O 0 0.005707113537937403
Hpdel O 0 0.42498937249183655
was O 0 3.779460087116604e-07
found O 0 8.636792392380244e-10
to O 0 4.5322115505008753e-10
have O 0 2.127602954926644e-10
, O 0 7.085054209987618e-10
in O 0 8.328226441811637e-10
all O 0 2.059770132234462e-09
exons O 0 1.183671685112131e-07
, O 0 3.027513129083559e-09
no O 0 3.730985742578241e-09
mutation O 0 3.9099945503551226e-09
, O 0 1.3857898162328297e-09
by O 0 4.602058290004152e-09
DNA O 0 8.09446248695167e-07
sequencing O 0 1.507885826868005e-06
. O 0 3.0491366942442255e-07

On O 0 1.2183481885585934e-06
the O 0 3.2135471172978214e-08
basis O 0 1.636708013563748e-08
of O 0 2.7636273713937953e-08
the O 0 6.019229559228734e-09
present O 0 2.989640313089126e-09
study O 0 4.10435863074099e-09
, O 0 7.3614464524141e-10
the O 0 2.5269826231522075e-09
mechanism O 0 1.6789957868468264e-08
of O 0 1.3022636835557932e-07
anhaptoglobinemia B-Disease 0 4.400353645905852e-05
and O 0 1.0555778473531063e-08
the O 0 9.801493838779152e-09
mechanism O 0 1.4285808980218917e-08
of O 0 2.6933333785450486e-08
anomalous O 0 4.105159803202696e-07
inheritance O 0 1.9863151123900025e-07
of O 0 7.219193207674834e-07
Hp O 0 3.62060495717742e-06
phenotypes O 0 9.78003640739189e-07
were O 0 1.4271543591348745e-07
well O 0 2.122715301311473e-07
explained O 0 2.6440582132636337e-06
. O 0 1.4954239304643124e-06

However O 0 1.7846368791651912e-06
, O 0 8.566777864871256e-08
the O 0 5.5022756129119443e-08
mechanism O 0 2.464730357587541e-07
of O 0 1.6453677744721062e-06
hypohaptoglobinemia B-Disease 0 0.07130405306816101
remains O 0 2.0250261513865553e-05
unknown O 0 7.887524589023087e-06

ATM O 0 0.0017537960084155202
mutations O 0 2.0953243620169815e-06
and O 0 3.326210276100028e-07
phenotypes O 0 6.3246811805584e-06
in O 0 3.3849548799480544e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 7.256481637796242e-08
in O 0 6.292731313806144e-08
the O 0 5.48468328531726e-08
British O 0 9.298968279836117e-07
Isles O 0 1.2886212061857805e-06
: O 0 6.924550266518281e-09
expression O 0 7.78084974228932e-09
of O 0 6.84897258906858e-08
mutant O 0 2.896428838994325e-07
ATM O 0 1.0705623026296962e-05
and O 0 9.99993954309275e-09
the O 0 2.0439680170625252e-08
risk O 0 1.936327187479492e-08
of O 0 1.710880837890727e-06
leukemia B-Disease 1 1.0
, O 0 0.044780630618333817
lymphoma B-Disease 1 1.0
, O 0 3.213706077076495e-05
and O 0 0.00037900207098573446
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
. O 0 8.922533197619487e-06

We O 0 4.78104368539789e-07
report O 0 6.116936646094473e-08
the O 0 2.678762989205552e-08
spectrum O 0 1.357091434783797e-07
of O 0 1.3958769784494507e-07
59 O 0 3.030539517112629e-07
ATM O 0 9.657797818363179e-06
mutations O 0 4.8502521110549424e-08
observed O 0 9.03688430753391e-08
in O 0 2.3987493591448583e-07
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 7.754660327918828e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 6.416464515268672e-08
patients O 0 7.3955783719270585e-09
in O 0 2.9041986593369984e-09
the O 0 2.4877353510532885e-08
British O 0 4.168361556367017e-06
Isles O 0 2.9305698262760416e-05
. O 0 1.1205713690287666e-06

Of O 0 2.9324621209525503e-05
51 O 0 9.008572305901907e-06
ATM O 0 0.0003081135801039636
mutations O 0 2.512487355943449e-07
identified O 0 3.198644193957989e-08
in O 0 9.786399246536348e-09
families O 0 2.0938357714328504e-09
native O 0 1.215470213367098e-08
to O 0 3.382399027529459e-09
the O 0 2.3923588443608423e-08
British O 0 4.4933284470971557e-07
Isles O 0 1.0854582797037438e-06
, O 0 9.628870145661494e-09
11 O 0 4.7035193517785956e-08
were O 0 1.2796705917139661e-08
founder O 0 2.1170899344724603e-06
mutations O 0 3.594042041754619e-08
, O 0 7.118379219406279e-09
and O 0 7.021358161551916e-09
2 O 0 9.061929517883982e-08
of O 0 1.474378841237467e-08
these O 0 2.542734689470194e-09
11 O 0 5.851145701285532e-08
conferred O 0 1.3023729650285532e-07
a O 0 2.8593982293045883e-08
milder O 0 1.1895283478224883e-06
clinical O 0 7.831839866412338e-06
phenotype O 0 1.5560776489564887e-07
with O 0 2.4994579739257006e-09
respect O 0 5.681678683089331e-09
to O 0 2.6014022935783032e-08
both O 0 2.836519570337259e-07
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
and O 0 1.3105668585922103e-05
cellular O 0 0.0005109627381898463
features O 0 7.192199518613052e-06
. O 0 1.6542053344892338e-06

We O 0 1.038007098941307e-06
report O 0 1.6264547753053193e-07
, O 0 1.8733837592321834e-08
in O 0 6.59404308933631e-09
two O 0 5.983824102884228e-09
A B-Disease 1 0.9999446868896484
- I-Disease 1 0.9832340478897095
T I-Disease 1 1.0
families O 0 4.139967035854397e-09
, O 0 2.6451656420789504e-09
an O 0 1.3512220231604033e-09
ATM O 0 1.1733014616766013e-05
mutation O 0 3.604607456964004e-08
( O 0 1.5746524084647717e-08
7271T O 0 3.4532477002358064e-06
- O 0 2.57934266301163e-06
- O 0 1.9653803065011743e-06
> O 0 6.483511469923542e-07
G O 0 2.9846374673070386e-05
) O 0 5.532812874520232e-09
that O 0 3.6869679531648103e-10
may O 0 1.361689871970384e-09
be O 0 3.8840961003039354e-10
associated O 0 3.402379711303638e-09
with O 0 5.20805398807056e-10
an O 0 3.8971123550446407e-10
increased O 0 1.8146647517980341e-09
risk O 0 1.0990014231992973e-08
of O 0 6.996168053774454e-07
breast B-Disease 1 0.9999421834945679
cancer I-Disease 0 0.01455884799361229
in O 0 1.1301478863856573e-08
both O 0 3.874168985618098e-09
homozygotes O 0 7.922208737909386e-07
and O 0 7.575566840500869e-09
heterozygotes O 0 3.220278586013592e-07
( O 0 7.565242654550275e-09
relative O 0 3.374745105588772e-08
risk O 0 2.4578147517217985e-08
12 O 0 2.1373423919612833e-08
. O 0 1.3642219576226466e-09
7 O 0 3.031952644505509e-08
; O 0 9.671567990920948e-10
P O 0 6.127119149823557e-07
= O 0 1.7394576445894927e-08
. O 0 4.493343475076017e-09
0025 O 0 4.124425686313771e-06
) O 0 2.6050055446091847e-09
, O 0 9.805340983604083e-10
although O 0 8.026519449089164e-10
there O 0 4.4755585348887905e-10
is O 0 2.3562099493723565e-10
a O 0 1.1346917849763827e-09
less O 0 5.372086775423668e-09
severe O 0 0.14099828898906708
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 8.571648635324891e-08
in O 0 1.982551456336523e-09
terms O 0 2.7326376716985123e-09
of O 0 1.0092297664243688e-08
the O 0 5.368122835136546e-09
degree O 0 3.0870950240569073e-07
of O 0 4.117241587664466e-06
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
. O 0 2.0953219063812867e-05

This O 0 6.580664262401115e-07
mutation O 0 3.207515817393869e-07
( O 0 7.162302750884919e-08
7271T O 0 7.760835615044925e-06
- O 0 5.684559255314525e-06
- O 0 1.5907899069134146e-06
> O 0 3.533369010710885e-07
G O 0 9.218035302183125e-06
) O 0 4.717631618689211e-09
also O 0 4.019845845082415e-10
allows O 0 9.908058401508768e-11
expression O 0 9.55828860504937e-10
of O 0 9.662445954461418e-09
full O 0 8.608903812046265e-09
- O 0 4.999665037530576e-08
length O 0 4.425621646930722e-09
ATM O 0 1.3910545249018469e-06
protein O 0 1.3337494664256155e-08
at O 0 5.964830762650308e-08
a O 0 2.3936446158501212e-09
level O 0 1.3874143611758427e-08
comparable O 0 3.710024998326844e-08
with O 0 1.0980287790118837e-09
that O 0 7.18154369305779e-10
in O 0 1.9428123110287743e-08
unaffected O 0 7.064938927214826e-07
individuals O 0 8.272076357229707e-09
. O 0 5.129213604959659e-07

In O 0 7.759205686852511e-07
addition O 0 2.2107232666712662e-07
, O 0 2.033756096864181e-08
we O 0 1.2352534550785776e-09
have O 0 1.6251219814300555e-10
studied O 0 3.828721517606937e-08
18 O 0 1.8899059739396762e-07
A B-Disease 1 0.9999934434890747
- I-Disease 1 0.9999990463256836
T I-Disease 1 1.0
patients O 0 2.688627489533246e-07
, O 0 3.69109320885741e-09
in O 0 1.904652657813699e-09
15 O 0 5.045549755777756e-09
families O 0 2.72062289363717e-10
, O 0 1.9022057262674252e-09
who O 0 6.100087102112184e-09
developed O 0 9.35502157517476e-06
leukemia B-Disease 1 1.0
, O 0 0.42500919103622437
lymphoma B-Disease 1 1.0
, O 0 2.6180752684012987e-05
preleukemic O 1 0.9999995231628418
T O 1 1.0
- O 0 0.00060720753390342
cell O 0 1.7150305211544037e-05
proliferation O 0 6.410387868527323e-05
, O 0 4.911695583587061e-08
or O 0 1.4033938896318432e-05
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 8.559491107007489e-07
mostly O 0 3.99110895443755e-08
in O 0 9.450815241507371e-08
childhood O 0 4.818059460376389e-05
. O 0 8.174045547093556e-07

A O 0 3.813920557149686e-05
wide O 0 1.1964078794335364e-06
variety O 0 1.6589466156347044e-07
of O 0 5.197783252697263e-07
ATM O 0 0.0002540907298680395
mutation O 0 6.059571688865617e-08
types O 0 5.1511349852262356e-08
, O 0 6.317345313533451e-09
including O 0 6.4265055499390655e-09
missense O 0 4.151720531808678e-07
mutations O 0 9.511011533902547e-09
and O 0 1.104431390785976e-08
in O 0 8.141411456108472e-08
- O 0 1.5581774732709164e-06
frame O 0 2.0283680157717754e-07
deletions O 0 1.3890341676869866e-07
, O 0 8.553777242070737e-09
were O 0 1.026917395563487e-08
seen O 0 1.3769930085061333e-08
in O 0 4.6272403686487e-09
these O 0 1.1710463709846408e-08
patients O 0 3.0622939561908424e-07
. O 0 8.973853482530103e-07

We O 0 5.840881840413203e-07
also O 0 3.950461646695658e-08
show O 0 2.146788524726162e-08
that O 0 6.360432736052246e-10
25 O 0 9.26315557592261e-09
% O 0 5.47521861182787e-10
of O 0 6.034011956757013e-09
all O 0 9.439822257206743e-09
A B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 6.878926228637283e-08
carried O 0 1.6029035876385933e-08
in O 0 9.239776055380844e-09
- O 0 2.8009233687953383e-07
frame O 0 1.1694643120563342e-07
deletions O 0 4.319898039284453e-08
or O 0 9.938730727299117e-09
missense O 0 3.4250211911057704e-07
mutations O 0 8.605947954265503e-09
, O 0 3.823136918157388e-09
many O 0 3.2014851880646233e-10
of O 0 1.229790846934975e-08
which O 0 2.806729071380687e-09
were O 0 5.050016849139638e-09
also O 0 9.749617779775122e-10
associated O 0 1.8101775633994066e-09
with O 0 7.140418256668113e-10
expression O 0 1.0086081303484207e-08
of O 0 2.022717779937011e-07
mutant O 0 1.8085551118929288e-06
ATM O 0 0.00021142080368008465
protein O 0 5.847848569828784e-06
. O 0 2.178593149437802e-06

The O 0 1.996919854718726e-05
DMPK O 1 0.999935507774353
gene O 0 5.290773060551146e-06
of O 0 1.2758739103446715e-05
severely O 1 0.9993883371353149
affected O 1 0.9867716431617737
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9996743202209473
is O 0 1.26927227483975e-06
hypermethylated O 1 0.9436944127082825
proximal O 0 3.157867104164325e-05
to O 0 6.826122955772007e-08
the O 0 2.2203410310339677e-07
largely O 0 2.9020998226769734e-07
expanded O 0 5.364016715247999e-07
CTG O 0 0.002105692168697715
repeat O 0 7.28296208762913e-06
. O 0 8.571678904445434e-07

Using O 0 1.779484023245459e-06
methylation O 0 1.0224143807135988e-05
- O 0 3.7465770219569094e-06
sensitive O 0 4.0028882608567073e-07
restriction O 0 2.1312768438974672e-08
enzymes O 0 1.755335432562788e-08
, O 0 1.2601075738416512e-08
we O 0 3.419490024469951e-09
characterized O 0 2.1634939173509338e-08
the O 0 5.844350337014248e-09
methylation O 0 8.311602783805938e-08
pattern O 0 3.738474418923943e-08
on O 0 1.0017598306433229e-08
the O 0 1.0018610829831687e-08
5 O 0 3.0195675293498425e-08
side O 0 1.4448857221793787e-08
of O 0 3.507513213207858e-08
the O 0 8.217685376621375e-08
CTG O 0 0.0006490375380963087
repeat O 0 3.703662798670848e-07
in O 0 2.6003801778529123e-08
the O 0 3.246234570042361e-08
DMPK O 1 0.8813006281852722
gene O 0 3.888191457690482e-08
of O 0 2.5633241307332355e-08
normal O 0 1.389623260905637e-08
individuals O 0 1.8942793167386895e-10
and O 0 1.5846635115224217e-09
of O 0 8.552541430617566e-08
patients O 0 7.802832868719634e-08
affected O 0 9.490699426351057e-08
with O 0 1.9829508346447255e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 4.3012450987589546e-06
showing O 0 4.0086337094180635e-07
expansions O 0 4.888246962764242e-07
of O 0 3.9470052115575527e-07
the O 0 1.778651324002567e-07
repetitive O 0 4.099238503840752e-05
sequence O 0 5.939751872574561e-07
. O 0 5.090238914817746e-07

The O 0 7.4137260526185855e-06
gene O 0 1.4889135400153464e-06
segment O 0 5.60951889383432e-07
analyzed O 0 8.475082324821415e-08
corresponds O 0 3.073021659361075e-08
to O 0 4.250805041294825e-09
the O 0 1.3027041667612593e-08
genomic O 0 3.2676697969691304e-07
SacI O 0 6.572429265361279e-05
- O 0 2.227145159849897e-06
HindIII O 0 1.6603535186732188e-05
fragment O 0 8.023554869396321e-07
carrying O 0 3.027200250471651e-07
exons O 0 2.12294298762572e-06
11 O 0 6.749505132574996e-07
- O 0 3.183454737154534e-06
15 O 0 1.4708768958371365e-06
. O 0 5.593993819275056e-07

There O 0 1.6700294054317055e-06
is O 0 1.0293022967289289e-07
constitutive O 0 1.7977200741370325e-06
methylation O 0 8.296412374875217e-07
in O 0 1.0016722740147088e-07
intron O 0 4.133888069191016e-06
12 O 0 1.6516848688752361e-07
at O 0 3.444254303985872e-08
restriction O 0 1.895711587707183e-09
sites O 0 7.967645210271712e-09
of O 0 4.83957904862109e-08
SacII O 0 1.5054250070534181e-05
and O 0 5.357232168989867e-08
HhaI O 0 6.627758557442576e-05
, O 0 2.1476362022099238e-08
localized O 0 2.351631280816946e-07
1 O 0 1.0103607905875833e-07
, O 0 4.016429855369097e-09
159 O 0 4.843790080144572e-08
- O 0 1.7820725872752519e-07
1 O 0 7.470366369943804e-08
, O 0 6.142386599350402e-09
232 O 0 8.725634614847877e-08
bp O 0 2.3177042862698727e-07
upstream O 0 7.573489568812874e-08
of O 0 4.690806321150376e-08
the O 0 4.4224506723367085e-08
CTG O 0 0.0022465481888502836
repeat O 0 2.51777152016075e-07
, O 0 7.913334876263889e-09
whereas O 0 5.320235363370784e-09
most O 0 1.1229255303391028e-09
, O 0 8.560807618351873e-10
if O 0 8.54659329418972e-11
not O 0 6.262727836325865e-11
all O 0 1.884793432438414e-10
, O 0 3.0212124468853574e-10
of O 0 8.094657721890997e-10
the O 0 3.9598269108154227e-10
other O 0 8.205675722239292e-11
sites O 0 2.381199681877888e-09
of O 0 1.705741858870624e-08
SacII O 0 1.8671340512810275e-05
, O 0 1.9070855117320207e-08
HhaI O 0 3.109019962721504e-05
, O 0 1.0201119948760606e-08
and O 0 1.1905295416170247e-08
HpaII O 0 1.1173710845469031e-05
in O 0 1.278092476297843e-08
this O 0 5.316306839198148e-10
region O 0 4.428340805162634e-09
are O 0 7.213090125191002e-10
unmethylated O 0 1.5329234201999498e-06
, O 0 3.3824310019525683e-09
in O 0 1.5032625144684175e-09
normal O 0 4.695825506217943e-09
individuals O 0 9.170415121717568e-11
and O 0 2.216894667839142e-09
most O 0 2.9786322297553625e-09
of O 0 7.924515443846758e-08
the O 0 2.0031295377975766e-07
patients O 0 7.419968142130529e-07
. O 0 8.26599887204793e-07

In O 0 9.059507419806323e-07
a O 0 2.481110783492113e-08
number O 0 4.901613781527203e-09
of O 0 9.592651650791595e-08
young O 0 1.0016493945386173e-07
and O 0 9.255176536271392e-08
severely O 0 0.00018098665168508887
affected O 0 2.7695432436303236e-07
patients O 0 1.3473794524543337e-07
, O 0 7.744219487904047e-09
however O 0 5.143729886469828e-09
, O 0 2.0079689022622915e-09
complete O 0 1.6802964353246352e-08
methylation O 0 3.142310234238721e-08
of O 0 1.2803567095431845e-08
these O 0 2.4793392339184095e-10
restriction O 0 1.3405431209534413e-09
sites O 0 6.078738845616272e-09
was O 0 2.5359502942023937e-08
found O 0 1.4119850844096504e-09
in O 0 4.17893630810795e-09
the O 0 1.6392448287660955e-08
mutated O 0 6.713106586175854e-07
allele O 0 4.1579019693926966e-07
. O 0 4.967953941559244e-07

In O 0 7.205354677353171e-07
most O 0 1.6480322884149246e-08
of O 0 2.5709233852921898e-08
these O 0 3.987743912858832e-09
patients O 0 3.9195466428054715e-08
, O 0 3.50640783075562e-09
the O 0 1.0014866269614231e-08
onset O 0 3.081151589867659e-05
of O 0 7.834864845790435e-07
the O 0 1.6199041056097485e-05
disease O 1 1.0
was O 1 0.9997997879981995
congenital O 1 1.0
. O 0 2.6686289857025258e-05

Preliminary O 0 2.932434290414676e-05
in O 0 1.3631037063532858e-06
vivo O 0 2.0899935407214798e-05
footprinting O 0 0.00015671821893192828
data O 0 1.7705600896533724e-07
gave O 0 5.54473231773045e-08
evidence O 0 2.01556744627851e-08
for O 0 5.334542141355314e-09
protein O 0 3.8137294211537665e-08
- O 0 6.362816407090577e-07
DNA O 0 4.3232074631305295e-07
contact O 0 1.951242367681516e-08
in O 0 4.480916526716783e-09
normal O 0 1.6407588177003163e-08
genes O 0 2.2522610443331814e-09
at O 0 5.782161593970159e-08
an O 0 2.9149314073606547e-09
Sp1 O 0 2.989088443428045e-06
consensus O 0 3.361011025049265e-08
binding O 0 1.4810869863879361e-08
site O 0 7.644472788115309e-08
upstream O 0 5.5988039093790576e-08
of O 0 2.1108222725274572e-08
the O 0 3.301697404367587e-08
CTG O 0 0.005220561753958464
repeat O 0 2.211102696492162e-07
and O 0 3.959632621786113e-09
for O 0 1.7846033539825612e-09
a O 0 1.4903525080711688e-09
significant O 0 1.904540081199002e-09
reduction O 0 2.9674003698687557e-08
of O 0 1.194876908527931e-08
this O 0 2.466848392224108e-10
interaction O 0 1.0244400883152593e-09
in O 0 3.0260929317904584e-09
cells O 0 1.219610812341898e-08
with O 0 4.323629898550507e-09
a O 0 7.219510678169172e-08
hypermethylated O 0 0.0033616230357438326
DMPK O 1 0.999996542930603
gene O 0 1.6094616057671374e-06
. O 0 1.8598693429794366e-07
. O 0 4.435760843080061e-07

The O 0 7.820963946869597e-05
hemochromatosis B-Disease 1 1.0
gene O 0 6.683912943117321e-07
product O 0 2.188775738432014e-07
complexes O 0 2.8796497986149916e-07
with O 0 1.4631841516177246e-08
the O 0 9.276615031694746e-08
transferrin O 0 1.866534148575738e-06
receptor O 0 2.9898870934630395e-08
and O 0 1.084545697693784e-08
lowers O 0 4.552429402338021e-07
its O 0 8.150527364136906e-09
affinity O 0 1.5459670876794007e-08
for O 0 4.147443721791433e-09
ligand O 0 8.618400784143887e-07
binding O 0 1.980246679522679e-06
. O 0 1.8587254544399912e-06

We O 0 1.4571357951354003e-06
recently O 0 5.096583208796801e-07
reported O 0 5.9067517099720135e-08
the O 0 1.270770866312887e-08
positional O 0 1.5463466525034164e-06
cloning O 0 3.6135810432824655e-07
of O 0 6.43368238684161e-08
a O 0 1.766782631307251e-08
candidate O 0 9.360988428852579e-08
gene O 0 5.297142138260824e-07
for O 0 5.6234530347865075e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.9999953508377075
HFE O 1 1.0
. O 0 3.541831028996967e-05

The O 0 2.8424708489183104e-06
gene O 0 1.6519936707481975e-07
product O 0 1.728079439544672e-07
, O 0 8.462027523137294e-09
a O 0 7.531395951332343e-09
member O 0 1.2443583941035286e-08
of O 0 2.9469934048620416e-08
the O 0 7.137469992812839e-08
major O 0 9.632012734073214e-07
histocompatibility O 0 0.09561038762331009
complex O 0 3.7524878280237317e-06
class O 0 7.003905011515599e-07
I O 0 4.1530267480993643e-05
- O 0 4.350322058144229e-07
like O 0 1.7926144124658094e-08
family O 0 1.0402338546100509e-08
, O 0 6.831212928659625e-09
was O 0 2.132358467576978e-08
found O 0 1.40410016946646e-09
to O 0 3.3815455990904297e-10
have O 0 2.3597088172344627e-10
a O 0 7.075442010062716e-09
mutation O 0 1.525576820426977e-08
, O 0 2.4701090950429716e-08
Cys O 0 0.0005195541307330132
- O 0 4.274195816833526e-06
282 O 0 3.927823399862973e-06
- O 0 7.412672403006582e-06
- O 0 5.25854375155177e-06
> O 0 1.3777333833786543e-06
Tyr O 0 0.00020632486848626286
( O 0 6.675058727978467e-08
C282Y O 0 4.082985469722189e-06
) O 0 6.9854122486390224e-09
, O 0 1.039152541792987e-09
in O 0 1.440141672581774e-09
85 O 0 5.104657319066064e-08
% O 0 1.6758625598356502e-09
of O 0 5.09423081496152e-08
patient O 0 1.200301539938664e-06
chromosomes O 0 5.742391522289836e-07
. O 0 1.273041220883897e-06

This O 0 7.595347710775968e-07
mutation O 0 3.886312640588585e-07
eliminates O 0 8.449030701740412e-07
the O 0 3.3097116158842255e-08
ability O 0 1.6472718300519773e-08
of O 0 1.5736621605810797e-07
HFE O 0 0.11689440160989761
to O 0 2.1125543980815564e-08
associate O 0 1.341442015245775e-07
with O 0 1.7637219684729644e-08
beta2 O 0 0.000877421407494694
- O 0 4.432073546922766e-05
microglobulin O 0 0.0005159414722584188
( O 0 1.6260158020031668e-07
beta2m O 0 9.080533345695585e-05
) O 0 2.4032161149989406e-08
and O 0 1.4856222918524509e-08
prevents O 0 3.4427478112775134e-07
cell O 0 9.097307156480383e-06
- O 0 6.086763278290164e-06
surface O 0 2.4613132154627237e-06
expression O 0 8.242524813795171e-07
. O 0 5.879011837350845e-07

A O 0 3.567597741493955e-05
second O 0 3.014532239831169e-06
mutation O 0 4.466940950464959e-08
that O 0 1.1183663994884796e-09
has O 0 9.138518830553721e-10
no O 0 2.0777948250838563e-09
effect O 0 9.035709069848963e-09
on O 0 3.048496566293579e-08
beta2m O 0 1.4985509551479481e-05
association O 0 3.098234913068154e-07
, O 0 2.000027166104701e-08
H63D O 1 0.9999947547912598
, O 0 2.1362705382443892e-08
was O 0 6.253020501389983e-08
found O 0 1.9984016663698867e-09
in O 0 1.5618999427147173e-09
eight O 0 5.99539662360371e-09
out O 0 4.3623136214421265e-09
of O 0 2.5481053711473578e-08
nine O 0 1.5632812733201717e-07
patients O 0 2.0474095308031792e-08
heterozygous O 0 9.80158709751322e-09
for O 0 8.784024174701699e-09
the O 0 3.7977929423504975e-07
C282Y O 0 0.00012733082985505462
mutant O 0 1.6369367585866712e-05
. O 0 1.9681183403008617e-06

In O 0 5.801034603791777e-07
this O 0 6.0407834290288065e-09
report O 0 1.367119129014327e-08
, O 0 2.6543183206939602e-09
we O 0 3.244825796944184e-10
demonstrate O 0 2.2646065023224082e-09
in O 0 7.324448159096164e-09
cultured O 0 1.1862617554925237e-07
293 O 0 1.2866257748100907e-06
cells O 0 2.601105393296166e-07
overexpressing O 0 5.7876950450008735e-06
wild O 0 7.004907160990115e-07
- O 0 6.332228394967387e-07
type O 0 2.772114555682492e-07
or O 0 6.72006308377604e-08
mutant O 0 1.186747795145493e-06
HFE O 0 0.0001562041143188253
proteins O 0 2.3904236368110787e-09
that O 0 5.171626460409584e-10
both O 0 1.4965682026968352e-09
the O 0 9.407845169562279e-09
wild O 0 4.5688787508879614e-07
- O 0 5.534218985303596e-07
type O 0 6.162744625726191e-07
and O 0 3.8328209939209046e-07
H63D O 1 0.9999990463256836
HFE O 1 0.8845495581626892
proteins O 0 1.0367126179744446e-07
form O 0 7.648979760688235e-08
stable O 0 1.6610157160812378e-07
complexes O 0 2.87643842966645e-07
with O 0 1.8996287209915863e-08
the O 0 1.6240740308148816e-07
transferrin O 0 9.638383744459134e-06
receptor O 0 6.179988076837617e-07
( O 0 4.040332157728699e-07
TfR O 0 0.00018237929907627404
) O 0 5.131669809088635e-07
. O 0 8.503773756274313e-07

The O 0 9.722975846671034e-06
C282Y O 0 0.00014040886890143156
mutation O 0 6.243117240956053e-07
nearly O 0 9.467810713204017e-08
completely O 0 5.178353603696451e-07
prevents O 0 7.407143698401342e-08
the O 0 2.4459968273049526e-08
association O 0 7.546540103930965e-08
of O 0 1.0210389689291333e-07
the O 0 1.3235334961336775e-07
mutant O 0 3.0325916213769233e-06
HFE O 0 0.002650138922035694
protein O 0 2.5956757099265815e-07
with O 0 6.114405692869695e-08
the O 0 1.4620217143601622e-06
TfR O 0 0.0024138258304446936
. O 0 3.909892257070169e-06

Studies O 0 3.563079189916607e-06
on O 0 1.464255660721392e-06
cell O 0 5.787993359263055e-06
- O 0 1.5690376358179492e-06
associated O 0 9.3315200899724e-08
transferrin O 0 9.953282642527483e-07
at O 0 2.57994543062523e-07
37 O 0 5.075822429034815e-08
degrees O 0 1.3723317238145682e-07
C O 0 1.0074604688270483e-06
suggest O 0 2.900799600524806e-09
that O 0 3.393291758690964e-10
the O 0 1.6942763636507152e-08
overexpressed O 0 4.598218311002711e-06
wild O 0 7.267423143275664e-07
- O 0 1.4843286635368713e-06
type O 0 1.2591112863447051e-06
HFE O 0 0.01483374647796154
protein O 0 7.858019301920649e-08
decreases O 0 3.0996705646657574e-08
the O 0 5.942162761840564e-09
affinity O 0 1.234926649829049e-08
of O 0 3.4234073353900385e-08
the O 0 1.179423563257842e-07
TfR O 0 3.868363637593575e-05
for O 0 3.006878444011818e-07
transferrin O 0 7.299189019249752e-05
. O 0 3.291045686637517e-06

The O 0 2.5224358978448436e-05
overexpressed O 0 0.016518056392669678
H63D O 1 0.999843955039978
protein O 0 4.324044766690349e-07
does O 0 8.929878170249594e-09
not O 0 5.455016993671791e-10
have O 0 4.413528570390568e-11
this O 0 7.645147015455933e-11
effect O 0 1.7729052670389933e-09
, O 0 3.7160344246167654e-10
providing O 0 8.297878495433508e-10
the O 0 1.0268933481327736e-09
first O 0 9.402602030306184e-10
direct O 0 2.2683925571254093e-10
evidence O 0 1.885750888774851e-09
for O 0 5.990238305386697e-10
a O 0 3.209043475393969e-09
functional O 0 3.012067040231159e-08
consequence O 0 6.837420585270593e-08
of O 0 1.4226034750208782e-07
the O 0 4.5671708903682884e-07
H63D O 1 0.999983549118042
mutation O 0 1.5909658941382077e-06
. O 0 5.638175366584619e-07

Addition O 0 4.376235210656887e-06
of O 0 3.4684665024542483e-06
soluble O 0 4.257830369169824e-05
wild O 0 3.6939294659532607e-05
- O 0 3.547259620972909e-05
type O 0 4.813531268155202e-05
HFE O 1 1.0
/ O 0 0.013199374079704285
beta2m O 0 0.000721895310562104
heterodimers O 0 3.591791391954757e-05
to O 0 1.1426917723156294e-07
cultured O 0 6.381716275427607e-07
cells O 0 3.1622084861737676e-07
also O 0 1.3996462655541109e-08
decreased O 0 4.8574641198229074e-08
the O 0 5.655858448250228e-09
apparent O 0 2.6283341725275022e-08
affinity O 0 9.226145181173706e-09
of O 0 3.7800326424530795e-08
the O 0 2.379348451597707e-08
TfR O 0 3.2173666113521904e-06
for O 0 2.0311035076048256e-09
its O 0 3.1256905952403713e-09
ligand O 0 6.188073342627831e-08
under O 0 1.641224400827923e-07
steady O 0 5.775547720077157e-07
- O 0 1.208466358093574e-07
state O 0 7.733945928123376e-09
conditions O 0 4.499580441574835e-08
, O 0 2.2995145787518823e-09
both O 0 1.0044033382783368e-09
in O 0 5.193751650978129e-09
293 O 0 1.0693541696582542e-07
cells O 0 2.11112851644657e-08
and O 0 2.1155463159061583e-08
in O 0 2.3461518594558584e-07
HeLa O 0 0.0031234940979629755
cells O 0 5.135183073434746e-06
. O 0 1.410069103258138e-06

Furthermore O 0 6.0552902141353115e-06
, O 0 2.1653313808656094e-07
at O 0 2.918689290254406e-07
4 O 0 1.0250899151742487e-07
degrees O 0 3.0789800575803383e-07
C O 0 5.380474703997606e-06
, O 0 5.889671861325496e-09
the O 0 9.63261737041421e-09
added O 0 1.1245401054793547e-08
soluble O 0 1.9909919046767754e-07
complex O 0 2.580905231752695e-07
of O 0 1.5129099892874365e-06
HFE O 1 0.9999984502792358
/ O 0 5.8070552768185735e-05
beta2m O 0 1.522361344541423e-05
inhibited O 0 2.7150227310812625e-07
binding O 0 5.979422468271878e-08
of O 0 1.9088948022272234e-07
transferrin O 0 3.791868266489473e-06
to O 0 8.157483932791365e-08
HeLa O 0 0.0006925350753590465
cell O 0 4.531642844085582e-06
TfR O 0 1.2504927326517645e-05
in O 0 2.5036820616719524e-08
a O 0 2.5869541175893573e-08
concentration O 0 1.2952489669260103e-05
- O 0 3.348541667946847e-06
dependent O 0 1.4245843260596303e-07
manner O 0 7.007172371231718e-07
. O 0 9.812905545913964e-07

Scatchard O 0 4.538747816695832e-05
plots O 0 1.9462115687929327e-06
of O 0 5.039541406404169e-07
these O 0 3.6988454521491576e-09
data O 0 2.035059765148617e-08
indicate O 0 3.212472954317036e-09
that O 0 6.536987062766286e-10
the O 0 1.5723804480671788e-08
added O 0 7.533711965379553e-08
heterodimer O 0 1.8996960307049449e-06
substantially O 0 1.2018533368518547e-07
reduced O 0 2.3203464039056598e-08
the O 0 8.421324082519277e-09
affinity O 0 3.5312091029027215e-08
of O 0 1.5088309623934038e-07
TfR O 0 3.096553700743243e-05
for O 0 2.594915997633507e-07
transferrin O 0 0.00010358203144278377
. O 0 3.8929033507884014e-06

These O 0 3.271015316386183e-07
results O 0 1.0540572503714429e-07
establish O 0 7.29891596051857e-08
a O 0 3.8727375084590676e-08
molecular O 0 8.195573286684521e-07
link O 0 3.071633329909673e-07
between O 0 6.221446824383747e-08
HFE O 1 0.9882321953773499
and O 0 7.819012637355627e-08
a O 0 5.4029680285339055e-08
key O 0 2.3230924739436887e-07
protein O 0 3.81134412918982e-08
involved O 0 2.06260182267215e-08
in O 0 3.5218590710428543e-08
iron O 0 0.003984896000474691
transport O 0 1.9455308120086556e-06
, O 0 1.5553249355093612e-08
the O 0 1.9810629581229477e-08
TfR O 0 4.201338379061781e-05
, O 0 9.538425160826591e-09
and O 0 3.057445185916663e-09
raise O 0 7.221077513719365e-09
the O 0 3.391753322645741e-09
possibility O 0 5.947582870646784e-09
that O 0 3.122650193976284e-10
alterations O 0 1.2789622871878237e-07
in O 0 3.789624614114473e-09
this O 0 5.515803924716067e-10
regulatory O 0 1.9417120356024498e-08
mechanism O 0 4.367044681430343e-08
may O 0 1.4099244438625647e-08
play O 0 1.771604907219171e-08
a O 0 4.907450890101472e-09
role O 0 4.491423677421835e-09
in O 0 7.494453058143336e-09
the O 0 3.887420518822182e-08
pathogenesis O 0 0.0037556046154350042
of O 0 0.013044440187513828
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 2.9644117603311315e-05
. O 0 4.724144218926085e-06

Genomic O 0 1.2701024388661608e-05
organization O 0 3.608726046877564e-06
of O 0 1.960341023732326e-06
the O 0 4.548134256765479e-06
UBE3A O 1 0.9999854564666748
/ O 0 0.00023158481053542346
E6 O 1 0.9516018033027649
- O 0 7.232183270389214e-05
AP O 0 9.355988004244864e-05
gene O 0 2.0591512850387517e-07
and O 0 3.1434012726094807e-08
related O 0 8.754980740377505e-07
pseudogenes O 0 3.0040177080081776e-05
. O 0 3.5524219583749073e-06

The O 0 4.064725726493634e-05
UBE3A O 0 0.02255968376994133
gene O 0 1.3281210158311296e-06
encodes O 0 1.1797126830970228e-07
the O 0 8.41683061025833e-08
E6 O 0 0.0025398542638868093
- O 0 3.259964069002308e-05
AP O 0 2.1361953258747235e-05
ubiquitin O 0 2.013715175053221e-06
- O 0 9.831207989918767e-07
protein O 0 1.9729895939235575e-08
ligase O 0 3.1459896376873075e-07
and O 0 1.7516228467684414e-08
has O 0 5.827408333658468e-09
recently O 0 1.894852097450439e-08
been O 0 1.6439970496051615e-09
shown O 0 9.58594870148488e-10
to O 0 6.285240106151946e-10
be O 0 2.651383557150666e-09
mutated O 0 9.192446555061906e-07
in O 0 2.1236588509054855e-05
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 6.29705173196271e-05
who O 0 2.58597310676123e-07
lack O 0 1.874491886155738e-06
15q11 O 0 0.00048752748989500105
- O 0 4.297092164051719e-05
q13 O 0 2.9411554351099767e-05
deletions O 0 2.8170065888843965e-06
or O 0 7.858930644033535e-07
chromosome O 0 2.0301458789617755e-06
15 O 0 2.133407406290644e-06
paternal O 0 5.0405684305587783e-05
uniparental B-Disease 1 0.9987286925315857
disomy I-Disease 1 0.9495742321014404
. O 0 4.773410182679072e-05

Previous O 0 0.00013801975001115352
UBE3A O 0 0.006281910464167595
cDNA O 0 6.512801064673113e-06
analysis O 0 2.4080068783405295e-07
has O 0 1.166120444651142e-08
shown O 0 7.864072948393641e-09
a O 0 8.281217489525261e-09
coding O 0 7.389265022084146e-08
region O 0 2.98900886264164e-08
of O 0 7.908977295301156e-08
approximately O 0 1.976329002673083e-07
2 O 0 1.3975915180708398e-06
. O 0 4.612289785654866e-07

6 O 0 6.753019988536835e-05
kb O 0 5.6502562074456364e-05
and O 0 4.6740646553189436e-07
a O 0 2.5129571668003337e-07
3 O 0 1.5240809716488002e-06
- O 0 4.551214715320384e-06
untranslated O 0 0.0015782425180077553
region O 0 1.4924306412922306e-07
( O 0 3.218816502226218e-08
UTR O 0 0.003034131834283471
) O 0 1.7967460408385705e-08
of O 0 5.961305049595467e-08
< O 0 2.498092328551138e-07
50 O 0 4.1304410558495874e-08
bp O 0 1.9610668289260502e-07
, O 0 2.7864861529280915e-09
whereas O 0 6.4473035799039735e-09
Northern O 0 1.592505860514848e-08
analysis O 0 2.824020128855409e-09
has O 0 6.043845424130723e-10
indicated O 0 1.6943206837538582e-09
mRNA O 0 3.034126283552041e-09
sizes O 0 5.1569521986039035e-09
of O 0 6.960755882801095e-08
5 O 0 4.0203261164606374e-07
- O 0 1.907800651679281e-06
8 O 0 3.377737812115811e-06
kb O 0 3.181171268806793e-05
. O 0 1.5812863694009138e-06

We O 0 2.9106448096172244e-07
have O 0 3.3996292447824317e-09
analyzed O 0 1.7756745407382368e-08
additional O 0 6.255070239546967e-09
cDNA O 0 5.127218400957645e-07
clones O 0 8.123113843794272e-07
and O 0 6.221575254983236e-09
provide O 0 1.301347363202865e-09
evidence O 0 8.214485092139512e-09
for O 0 7.779925037532109e-10
an O 0 1.968293750209682e-09
additional O 0 3.594892206137956e-08
0 O 0 6.669146728199848e-07
. O 0 2.932161748958606e-07

5 O 0 1.8342332623433322e-05
kb O 0 2.3262828108272515e-05
of O 0 4.412846919876756e-06
5 O 0 3.3420685667806538e-06
- O 0 1.6265621525235474e-05
UTR O 0 0.0017480611568316817
and O 0 1.6598215779595193e-07
> O 0 3.9820460528972035e-07
2 O 0 2.6120824259123765e-07
kb O 0 2.8792564989998937e-06
of O 0 7.651867690583458e-07
3 O 0 5.667448931490071e-06
- O 0 5.994883395032957e-05
UTR O 1 0.9668634533882141
. O 0 2.5019357963174116e-06

We O 0 2.5352667876177293e-07
have O 0 4.10663725247673e-09
established O 0 1.8674475299462756e-08
the O 0 3.946423188239123e-09
genomic O 0 2.4254211083984956e-08
organization O 0 2.7501238619720425e-08
of O 0 1.4503464740300842e-07
UBE3A O 0 0.0601043738424778
and O 0 8.834700970794529e-09
the O 0 8.089136471767233e-09
sequence O 0 1.68517484411268e-08
of O 0 1.3295667145030166e-07
intron O 0 3.095169086009264e-05
- O 0 2.4214394215960056e-05
exon O 0 1.6168341971933842e-05
borders O 0 8.128561148623703e-07
. O 0 8.629290277895052e-07

We O 0 4.3835225937982614e-07
have O 0 1.395280246896391e-08
also O 0 5.597135199764125e-09
mapped O 0 1.1177105818660493e-07
two O 0 6.005101305106564e-09
highly O 0 3.703124917819878e-08
homologous O 0 6.7614855936426466e-09
processed O 0 9.280402224476347e-08
pseudogenes O 0 6.409858883671404e-07
, O 0 7.115382061329001e-08
UBE3AP1 O 0 0.08830784261226654
and O 0 1.7331296930933604e-07
UBE3AP2 O 1 0.9979996085166931
, O 0 3.1818014889495316e-08
to O 0 4.294355093747981e-09
chromosomes O 0 8.157993391932905e-09
2 O 0 2.9975613102806165e-08
and O 0 4.885783333463678e-09
21 O 0 6.082244397020986e-08
, O 0 2.3360207102030017e-09
respectively O 0 1.8044699956476506e-08
, O 0 1.3109188179427633e-09
and O 0 1.195899934636202e-09
determined O 0 5.016167925475656e-09
their O 0 2.7565503213367037e-09
genomic O 0 2.7647354272630764e-07
organization O 0 6.487630912488385e-07
. O 0 9.522728419142368e-07

These O 0 2.941746402029821e-07
results O 0 2.4198442361011985e-07
will O 0 7.81046782805106e-09
form O 0 7.125198209223527e-09
the O 0 3.223988187528448e-09
basis O 0 5.438353101183679e-10
for O 0 3.929558345383555e-10
studies O 0 4.0540353296592e-09
of O 0 9.043865212277069e-09
mutation O 0 1.5251316654030234e-08
and O 0 1.4246461788047782e-08
imprinting O 0 7.704950803599786e-06
of O 0 7.3363316914765164e-06
UBE3A O 1 0.9990103244781494
. O 0 1.0206188562733587e-05

Mutation O 0 9.6431376732653e-06
spectrum O 0 8.434623850916978e-06
and O 0 2.7457326723379083e-07
genotype O 0 7.148673830670305e-06
- O 0 6.622198270633817e-06
phenotype O 0 2.59946602909622e-07
analyses O 0 1.850900162025937e-07
in O 0 3.721663119904406e-07
Cowden B-Disease 1 0.9999998807907104
disease I-Disease 1 0.9993316531181335
and O 0 1.3899659734306624e-06
Bannayan B-Disease 1 1.0
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 7.86581381362339e-07
two O 0 1.2358501635389985e-06
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 0.9999990463256836
with O 0 5.019142190576531e-05
germline O 1 0.9999994039535522
PTEN O 1 0.9999998807907104
mutation O 0 3.6023498978465796e-05
. O 0 1.174990029539913e-05

The O 0 0.00012092548422515392
tumour B-Disease 1 1.0
suppressor O 0 0.0009278798825107515
gene O 0 1.965554110938683e-05
PTEN O 1 0.9428616166114807
, O 0 9.102743092626042e-08
which O 0 7.164814519455831e-09
maps O 0 1.0321293331116976e-07
to O 0 6.702756394361131e-08
10q23 O 0 7.842046761652455e-05
. O 0 1.6195776879612822e-06

3 O 0 1.813310336729046e-05
and O 0 1.670273377385456e-07
encodes O 0 7.225213494166383e-08
a O 0 2.977952107130477e-08
403 O 0 1.3590418745934585e-07
amino O 0 1.2219409484259813e-07
acid O 0 1.1550275047511604e-07
dual O 0 8.205515200643276e-08
specificity O 0 1.689214315092613e-07
phosphatase O 0 2.2908994651515968e-05
( O 0 1.7030573928877857e-07
protein O 0 1.545843701933336e-07
tyrosine O 0 1.3331082300283015e-06
phosphatase O 0 1.2398565559124108e-05
; O 0 2.979974844663502e-08
PTPase O 0 2.5951461793738417e-05
) O 0 1.681739192349596e-08
, O 0 3.6645417811342895e-09
was O 0 4.019144839162436e-08
shown O 0 2.6881794568112127e-09
recently O 0 1.0453355514528084e-08
to O 0 1.7748675862350183e-09
play O 0 2.03380654539842e-08
a O 0 1.9650576277285836e-08
broad O 0 6.614881442601472e-08
role O 0 3.492846190056298e-08
in O 0 1.2968094154075516e-07
human O 0 1.2628826198124443e-06
malignancy B-Disease 1 0.9861271381378174
. O 0 1.4914700159351924e-06

Somatic O 0 0.022829851135611534
PTEN O 1 0.998480498790741
deletions O 0 9.319474884250667e-06
and O 0 5.635025104311353e-07
mutations O 0 1.8363684262112656e-07
were O 0 3.668991865879434e-08
observed O 0 2.3027899587191314e-08
in O 0 6.416779996243349e-09
sporadic B-Disease 0 2.687550704649766e-06
breast I-Disease 0 0.08197741210460663
, I-Disease 0 4.5435984930009e-07
brain I-Disease 1 0.9998249411582947
, I-Disease 0 1.5116581835172838e-06
prostate I-Disease 1 1.0
and I-Disease 0 0.01848018169403076
kidney I-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.549135148525238
lines O 0 3.081368333823775e-07
and O 0 3.713116925041504e-09
in O 0 2.7899642596196372e-09
several O 0 4.627513927601967e-09
primary O 0 2.613921651573037e-06
tumours B-Disease 1 1.0
such O 0 7.288245740255661e-08
as O 0 3.339271415825351e-06
endometrial B-Disease 1 0.9999978542327881
carcinomas I-Disease 1 1.0
, O 1 0.9997264742851257
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 1.0
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 0.0017117341049015522

In O 0 1.3319059917193954e-06
addition O 0 2.512154537726019e-07
, O 0 2.3329144482886477e-07
PTEN O 1 0.9996565580368042
was O 0 1.938979039550759e-06
identified O 0 2.2687583367542175e-08
as O 0 4.1821897056593116e-09
the O 0 5.3843347558313326e-09
susceptibility O 0 1.4021344441061956e-07
gene O 0 8.466112255689495e-09
for O 0 4.155226829283265e-09
two O 0 1.4302773365670873e-07
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 1.0
Cowden B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.3726239558309317e-06
CD B-Disease 1 0.999991774559021
; O 0 1.2576037988765165e-07
MIM O 1 0.9916003942489624
158350 O 0 4.829233148484491e-05
) O 0 1.6030931249133573e-08
and O 0 2.542527255400273e-08
Bannayan B-Disease 0 0.0011541894637048244
- I-Disease 0 6.810468039475381e-05
Zonana I-Disease 1 0.9874300360679626
( I-Disease 0 3.94981810813988e-07
BZS I-Disease 1 0.9760828018188477
) I-Disease 0 7.037328941805754e-08
or I-Disease 0 4.4874273186223945e-08
Ruvalcaba I-Disease 0 5.619557487079874e-05
- I-Disease 0 1.4686898794025183e-05
Riley I-Disease 0 0.0006983025232329965
- I-Disease 0 0.18535831570625305
Smith I-Disease 1 0.9579800367355347
syndrome I-Disease 1 0.9999996423721313
( O 0 3.637900954345241e-05
MIM O 1 1.0
153480 O 1 0.9978916049003601
) O 0 1.296336108680407e-06
. O 0 1.1292460158074391e-06

Constitutive O 0 0.0001747786591295153
DNA O 0 2.8228125302121043e-05
from O 0 9.7878000815399e-07
37 O 0 1.869222160166828e-06
CD B-Disease 0 0.00011196761624887586
families O 0 5.892851540068023e-09
and O 0 2.6096618199744626e-08
seven O 0 1.2914654234918999e-07
BZS B-Disease 0 0.023209739476442337
families O 0 1.52271901754375e-08
was O 0 4.5079346477905347e-07
screened O 0 6.597838364541531e-07
for O 0 2.405989221188065e-07
germline O 0 0.0013631564797833562
PTEN O 1 0.9994230270385742
mutations O 0 3.5895820474252105e-05
. O 0 1.0597743312246166e-05

PTEN O 1 0.8339561223983765
mutations O 0 1.2983998658455675e-06
were O 0 1.7934321761003957e-07
identified O 0 3.5616682936279176e-08
in O 0 1.232453605837236e-08
30 O 0 2.681354693834237e-08
of O 0 8.067630119512614e-08
37 O 0 7.031666626744482e-08
( O 0 3.820527449960309e-09
81 O 0 3.1560114166495623e-07
% O 0 6.257551810051609e-09
) O 0 2.8079125691249374e-09
CD B-Disease 0 1.3543877685151529e-05
families O 0 7.49184825288296e-10
, O 0 1.2934189275171093e-09
including O 0 1.1370235419860819e-08
missense O 0 8.407563427681453e-07
and O 0 1.3623237293813872e-07
nonsense O 0 2.1866047973162495e-05
point O 0 3.5714990076485265e-07
mutations O 0 3.7990059098547135e-08
, O 0 1.1771151164907678e-08
deletions O 0 2.3008830396520352e-07
, O 0 3.905867274056618e-08
insertions O 0 1.3266235328046605e-06
, O 0 2.382304664649837e-08
a O 0 3.9503408544305785e-08
deletion O 0 6.879581633256748e-07
/ O 0 2.55984650721075e-06
insertion O 0 7.531440928687516e-07
and O 0 1.393698170204516e-07
splice O 0 0.00015470317157451063
site O 0 1.6916961612878367e-05
mutations O 0 3.047891368623823e-06
. O 0 2.1211642433627276e-06

These O 0 1.1936062094264344e-07
mutations O 0 1.0866913413565271e-07
were O 0 4.064311198703763e-08
scattered O 0 1.995611285110499e-07
over O 0 2.109735675048796e-08
the O 0 1.1571340330363e-08
entire O 0 3.3323818371400193e-08
length O 0 5.929030155726878e-09
of O 0 9.729859584695078e-08
PTEN O 1 0.8397697806358337
, O 0 8.934239126290322e-09
with O 0 9.122793076521418e-10
the O 0 3.0193243460985286e-09
exception O 0 6.7256387126235495e-09
of O 0 1.5115148244149168e-08
the O 0 8.45096259638467e-09
first O 0 5.117496471029881e-08
, O 0 1.0455149634935879e-08
fourth O 0 7.861209496695665e-07
and O 0 4.376108009296331e-08
last O 0 9.437104040443955e-07
exons O 0 1.7747028323356062e-05
. O 0 7.769357921461051e-07

A O 0 0.0001447382674086839
hot O 0 9.1964153398294e-05
spot O 0 5.565771516558016e-06
for O 0 1.2071740229657735e-07
PTEN O 0 0.0004933947348035872
mutation O 0 6.909143479560953e-08
in O 0 4.390446406432602e-08
CD B-Disease 0 0.0018854495137929916
was O 0 1.3709137647310854e-07
identified O 0 5.219741527895394e-09
in O 0 3.079386301507725e-09
exon O 0 1.813007202144945e-07
5 O 0 2.3602559906521492e-08
that O 0 2.5699745109797334e-10
contains O 0 7.45978390170876e-09
the O 0 3.063120246338258e-08
PTPase O 0 0.00010409315291326493
core O 0 9.265116204915103e-06
motif O 0 4.2174860936938785e-07
, O 0 2.1565342844809265e-09
with O 0 7.66537333607431e-10
13 O 0 2.6682380749321055e-08
of O 0 1.5148801324471606e-08
30 O 0 2.8725450462729896e-08
( O 0 1.794536186316975e-09
43 O 0 3.044214480496521e-08
% O 0 1.685116268745901e-09
) O 0 2.320858616400301e-09
CD B-Disease 0 7.28865124983713e-05
mutations O 0 2.0946554712963916e-08
identified O 0 1.6609199349204573e-08
in O 0 2.0236953446328698e-08
this O 0 2.4296250344946202e-08
exon O 0 1.7100219338317402e-05
. O 0 2.0711111119453562e-06

Seven O 0 8.280956535600126e-06
of O 0 1.5250086562446086e-06
30 O 0 2.8793999717890983e-07
( O 0 1.2150599637550386e-08
23 O 0 6.102091276716237e-08
% O 0 7.582270922235068e-10
) O 0 2.340479476892199e-10
were O 0 8.175123356046754e-10
within O 0 4.511738538326426e-09
the O 0 1.1440194569445339e-08
core O 0 1.8311080793864676e-06
motif O 0 1.5708792489022017e-07
, O 0 1.3841995327723566e-09
the O 0 1.6373191691343436e-09
majority O 0 3.330593023598283e-10
( O 0 2.999817338977806e-10
five O 0 1.528208781742535e-09
of O 0 1.2139990346327068e-08
seven O 0 9.837529013623225e-09
) O 0 6.511960970456698e-10
of O 0 5.217043685945555e-09
which O 0 4.3562420337650565e-10
were O 0 5.458402174696175e-09
missense O 0 2.573166000274796e-07
mutations O 0 1.609870992069773e-08
, O 0 1.174235819689784e-08
possibly O 0 8.868538969863948e-08
pointing O 0 4.8899998716933624e-08
to O 0 4.282200372074385e-09
the O 0 7.697448900501058e-09
functional O 0 4.624813865206079e-09
significance O 0 1.4025431482878048e-08
of O 0 4.912744699936411e-08
this O 0 7.342296104440038e-09
region O 0 1.7944741159681143e-07
. O 0 3.0199541356523696e-07

Germline O 0 0.25182604789733887
PTEN O 1 0.9624512791633606
mutations O 0 8.073061508184765e-07
were O 0 1.3468874726640934e-07
identified O 0 2.5004560200159176e-08
in O 0 8.90107187956346e-09
four O 0 1.0406942863028235e-08
of O 0 5.995147489556985e-08
seven O 0 8.062046674695011e-08
( O 0 3.284474914266866e-08
57 O 0 9.867586641121306e-07
% O 0 3.9470794632734396e-08
) O 0 3.814296789528271e-08
BZS B-Disease 0 0.0026016640476882458
families O 0 1.0229376101733578e-07
studied O 0 1.595882531546522e-05
. O 0 1.637968807699508e-06

Interestingly O 0 2.943119761766866e-05
, O 0 3.475661003449204e-07
none O 0 1.9462436284811702e-07
of O 0 3.1785500453906934e-08
these O 0 2.3183279740379703e-09
mutations O 0 1.9849018428885756e-08
was O 0 8.680698471152937e-08
observed O 0 1.3476963545144827e-08
in O 0 1.0263025096435285e-08
the O 0 7.538368862469724e-08
PTPase O 0 0.0018959236331284046
core O 0 0.00014153399388305843
motif O 0 2.7248710466665216e-05
. O 0 1.0475069984750007e-06

It O 0 8.160266702361696e-07
is O 0 3.183847141485785e-08
also O 0 2.4810717924594883e-09
worthy O 0 1.5461165503438679e-07
of O 0 1.1961530788084929e-07
note O 0 4.3008405725686316e-08
that O 0 7.567707571709548e-10
a O 0 8.00067656570036e-09
single O 0 2.5938216907661626e-08
nonsense O 0 6.3519274817736e-07
point O 0 2.9079860297542837e-08
mutation O 0 5.585287343734535e-09
, O 0 2.5077815379859203e-09
R233X O 0 1.123777792599867e-06
, O 0 2.1963360907761853e-08
was O 0 4.955839472131629e-08
observed O 0 5.865568475371674e-09
in O 0 1.990678955010594e-09
the O 0 5.013662374153682e-09
germline O 0 3.1952788503986085e-07
DNA O 0 1.8037719939911767e-07
from O 0 1.3622205585761549e-08
two O 0 3.0594167199637923e-09
unrelated O 0 2.6936552899314847e-07
CD B-Disease 0 0.00048092970973812044
families O 0 5.8072369135686586e-09
and O 0 3.260375791569459e-08
one O 0 1.5214975235267048e-07
BZS B-Disease 1 0.9980323910713196
family O 0 2.2749909476260655e-06
. O 0 3.2509269658476114e-06

Genotype O 0 8.062239794526249e-05
- O 0 1.6283918739645742e-05
phenotype O 0 3.4823199257516535e-07
studies O 0 1.0918392412406774e-08
were O 0 3.6446616835661416e-09
not O 0 4.459530245082277e-10
performed O 0 3.515523872010817e-08
on O 0 5.078550469050924e-09
this O 0 1.9688146946084117e-10
small O 0 2.3565438489470125e-09
group O 0 1.8587339667419656e-08
of O 0 2.5056533559109084e-07
BZS B-Disease 1 0.9933083057403564
families O 0 4.2149210344177845e-07
. O 0 2.677553084140527e-06

However O 0 4.643059583031572e-06
, O 0 4.975336196366698e-07
genotype O 0 1.9497081211738987e-06
- O 0 1.1168266382810543e-06
phenotype O 0 1.1132808452885001e-07
analysis O 0 1.6045461848079867e-08
inthe O 0 5.294659786159173e-06
group O 0 8.167649667711885e-08
of O 0 3.247259883210063e-07
CD B-Disease 1 0.9424737095832825
families O 0 4.4574743895964275e-09
revealed O 0 3.7757523330128606e-08
two O 0 4.712844559051632e-10
possible O 0 1.247806413751107e-09
associations O 0 2.9363818043748324e-09
worthy O 0 2.5872606101984275e-07
of O 0 3.8553889680770226e-07
follow O 0 9.947951440381075e-08
- O 0 1.416346776750288e-06
up O 0 1.103995828088955e-07
in O 0 2.4494564598853685e-08
independent O 0 3.2372444280781565e-08
analyses O 0 1.5596076536894543e-06
. O 0 1.1316749350953614e-06

The O 0 1.4166561186357285e-06
first O 0 9.657213695390965e-07
was O 0 7.839475983928423e-07
an O 0 6.9942114322429916e-09
association O 0 7.026370951734862e-08
noted O 0 1.2999588960838082e-08
in O 0 9.686156765553733e-09
the O 0 1.331837840012895e-08
group O 0 9.10499675654819e-09
of O 0 7.452263872664844e-08
CD B-Disease 1 0.7122157216072083
families O 0 7.449162620076777e-09
with O 0 4.620637241714576e-07
breast B-Disease 1 1.0
disease I-Disease 1 0.9999992847442627
. O 0 7.0474156927957665e-06

A O 0 1.4612600352847949e-05
correlation O 0 4.425121744588978e-07
was O 0 2.6532725883043895e-07
observed O 0 1.6199432906205402e-08
between O 0 1.4580627816229708e-09
the O 0 7.23628534871068e-09
presence O 0 3.1271113698494446e-08
/ O 0 5.067512915957195e-07
absence O 0 8.411888074988383e-08
of O 0 1.2744536093123315e-07
a O 0 1.0434992958607836e-07
PTEN O 1 0.9926405549049377
mutation O 0 2.9290220027178293e-08
and O 0 5.009570980263334e-09
the O 0 4.8885984149649175e-09
type O 0 1.219382141925962e-07
of O 0 1.2836990208597854e-06
breast O 0 0.0005796537734568119
involvement O 0 9.029197940435552e-07
( O 0 1.2860868991992902e-07
unaffected O 0 6.675403710687533e-06
versus O 0 1.1677268048515543e-05
benign O 0 0.0027761950623244047
versus O 0 0.00048066407907754183
malignant O 1 0.999849796295166
) O 0 6.770566756131302e-07
. O 0 5.359373744795448e-07

Specifically O 0 1.8001716171056614e-06
and O 0 5.891022425430492e-08
more O 0 8.21020418317886e-10
directly O 0 7.622469766488393e-09
, O 0 1.95014382420311e-09
an O 0 1.1520375764462187e-09
association O 0 1.3447235858166096e-07
was O 0 7.231651579786558e-07
also O 0 3.086554345443915e-09
observed O 0 3.8033687310701225e-09
between O 0 1.1721720261093083e-09
the O 0 1.5899557226362049e-09
presence O 0 3.315876684339969e-09
of O 0 2.323885262001113e-08
a O 0 8.271101847867612e-08
PTEN O 1 0.9999699592590332
mutation O 0 7.318229791053454e-07
and O 0 5.590795808529947e-06
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.2911200428789016e-05

Secondly O 0 5.146743205841631e-05
, O 0 6.4984180880856e-07
there O 0 2.5500161981995006e-08
appeared O 0 3.570994167034769e-08
to O 0 2.559741529850612e-09
be O 0 9.137246514967501e-10
an O 0 2.656374675780171e-09
interdependent O 0 9.72187081060838e-07
association O 0 3.766589031783951e-07
between O 0 3.159606976055329e-08
mutations O 0 5.03146360131268e-08
upstream O 0 1.2113210345887637e-07
and O 0 1.0427666730095098e-08
within O 0 2.799203002723516e-08
the O 0 7.428266712850018e-08
PTPase O 0 0.00020866112026851624
core O 0 1.2484669241530355e-05
motif O 0 8.654162115817599e-07
, O 0 6.016520615048648e-09
the O 0 1.7740291013979004e-08
core O 0 1.4457150427915622e-06
motif O 0 6.94680366564171e-08
containing O 0 1.1127708532399083e-08
the O 0 3.259939207467255e-09
majority O 0 5.743804876168213e-10
of O 0 1.0691315388555722e-08
missense O 0 2.8187997713757795e-07
mutations O 0 3.025540351586642e-08
, O 0 1.2980659214179013e-08
and O 0 3.78687881052997e-09
the O 0 6.021572129810693e-09
involvement O 0 1.6053144591410273e-08
of O 0 2.1512645886900827e-08
all O 0 4.087966853916214e-09
major O 0 5.62800607895042e-07
organ O 1 0.9920181632041931
systems O 1 0.8193591237068176
( O 0 2.915531638336688e-07
central O 0 8.165931831172202e-06
nervous O 0 8.648932634969242e-06
system O 0 1.6363106851713383e-06
, O 0 1.2175478332210332e-06
thyroid O 1 1.0
, O 0 3.585351578294649e-06
breast O 1 0.9999988079071045
, O 0 4.9584141379455104e-05
skin O 1 1.0
and O 0 0.4280446171760559
gastrointestinal O 1 1.0
tract O 1 0.9999998807907104
) O 0 1.2885185242339503e-05
. O 0 7.133983672247268e-06

However O 0 1.4771267160540447e-06
, O 0 4.6864329306117725e-08
these O 0 7.532224843842528e-10
observations O 0 1.2063219756441868e-08
would O 0 7.215099073754061e-10
need O 0 6.723069878589172e-10
to O 0 1.0030403174710045e-09
be O 0 1.4363285005813964e-09
confirmed O 0 3.054880126640569e-09
by O 0 3.18933240928132e-10
studying O 0 7.106996768868612e-09
a O 0 1.1807888000703315e-09
larger O 0 1.6155115023508415e-09
number O 0 2.320858616400301e-09
of O 0 6.27222789262305e-08
CD B-Disease 0 0.0008600717410445213
families O 0 3.4465479359369056e-08
. O 0 2.3696797768479883e-07

Molecular O 1 0.9999207258224487
defects O 1 0.9999988079071045
leading O 0 0.0001511593727627769
to O 0 2.1873151467843854e-07
human O 0 2.056352883528234e-07
complement B-Disease 0 1.0778686373669188e-05
component I-Disease 1 0.9999982118606567
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.2063844678777969e-07
an O 0 5.177313244786319e-09
African O 0 9.554378976872613e-08
- O 0 5.093599497740797e-07
American O 0 2.54444898928341e-07
family O 0 3.1300896807806566e-07
. O 0 5.48111131593032e-07

Complement B-Disease 0 0.0004696343676187098
component I-Disease 1 0.9999954700469971
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 6.363317424984416e-06
C6D B-Disease 1 1.0
) O 0 1.5199022129763762e-07
was O 0 5.711082394554978e-06
diagnosed O 0 9.736718311614823e-06
in O 0 1.0987877274715174e-08
a O 0 1.0790736304500115e-08
16 O 0 2.3652792435768788e-07
- O 0 3.8803170809842413e-07
year O 0 3.3054845971491886e-08
- O 0 4.98616145705455e-07
old O 0 2.298319941473892e-06
African O 0 2.315682507969541e-07
- O 0 9.296379062107007e-07
American O 0 1.969799541257089e-07
male O 0 1.6902521338124643e-07
with O 0 5.867573804607673e-07
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 1.0399132406746503e-05

The O 0 8.167583473550621e-06
patients O 0 2.3398267785523785e-06
father O 0 3.900131559930742e-06
and O 0 1.1502140040420272e-07
two O 0 3.161379069638315e-08
brothers O 0 6.560702331626089e-06
also O 0 9.149707125288842e-08
had O 0 4.0373817000727286e-07
C6D B-Disease 1 0.9999996423721313
, O 0 4.3027277740748104e-08
but O 0 1.8833210546631562e-09
gave O 0 7.457578554692645e-09
no O 0 1.5829658694954674e-09
history O 0 6.195454460566907e-08
of O 0 1.5100819155122736e-06
meningitis B-Disease 1 1.0
or O 0 3.499802119222295e-07
other O 0 6.109859214120661e-07
neisserial B-Disease 1 0.999993085861206
infection I-Disease 0 0.47122424840927124
. O 0 2.909267550421646e-06

By O 0 3.61998274911457e-07
using O 0 1.3843961710335861e-07
exon O 0 2.979156306537334e-06
- O 0 5.274246746012068e-07
specific O 0 1.2982095398683668e-08
polymerase O 0 3.309882288249355e-07
chain O 0 4.41514401927634e-07
reaction O 0 1.0986158649473055e-08
( O 0 1.0410416528827682e-08
PCR O 0 1.3449226798911695e-06
) O 0 2.513998964559505e-08
/ O 0 1.953011548039285e-07
single O 0 5.495773081065636e-08
- O 0 1.2665393001043412e-07
strand O 0 7.764189291492585e-08
conformation O 0 1.919346637180297e-08
polymorphism O 0 3.360793243700755e-08
as O 0 2.1822750273514657e-09
a O 0 6.281899445070849e-09
screening O 0 2.0423740920705313e-08
step O 0 7.479430408352528e-09
and O 0 1.1586218651160607e-09
nucleotide O 0 9.21425691302602e-09
sequencing O 0 2.4070605064707706e-08
of O 0 1.6462665897165607e-08
target O 0 3.645303436883296e-08
exons O 0 3.5573987133830087e-07
, O 0 6.941396790693943e-09
we O 0 8.56923698666634e-10
determined O 0 6.172416799898883e-09
that O 0 7.244554400820391e-10
the O 0 9.006509316122902e-09
proband O 0 1.2930868251714855e-05
was O 0 2.484284209458565e-07
a O 0 9.739882678161393e-09
compound O 0 2.0106665488128783e-07
heterozygote O 0 4.631366152807459e-07
for O 0 1.6053176565833382e-08
two O 0 9.055052885287296e-08
C6 O 1 0.9999905824661255
gene O 0 5.825794687552843e-06
mutations O 0 2.9908790111221606e-06
. O 0 2.924411091953516e-06

The O 0 3.896368980349507e-06
first O 0 3.920777658095176e-07
, O 0 1.7039923250194988e-08
1195delC O 0 9.388450052938424e-07
located O 0 1.8983399741046014e-07
in O 0 1.3771532358930472e-08
exon O 0 1.0114093811353086e-06
7 O 0 5.223066068538174e-07
, O 0 1.0144385775845421e-08
is O 0 1.1269637445465719e-09
a O 0 1.8138273105705593e-09
novel O 0 1.594469445365121e-08
mutation O 0 6.655795470322801e-09
, O 0 3.445743912422472e-09
while O 0 3.4998999254298724e-09
the O 0 8.90548701448779e-09
second O 0 7.653488864889368e-08
, O 0 6.537900443248645e-09
1936delG O 0 1.9729392874978657e-07
in O 0 8.951228203102346e-09
exon O 0 1.9216018642964627e-07
12 O 0 1.1914386277567246e-07
, O 0 4.1097791836364195e-09
has O 0 7.391668388478934e-10
been O 0 7.367557119941637e-10
described O 0 1.0694434671165709e-08
before O 0 2.9527434719511803e-08
to O 0 1.1477831129980132e-08
cause O 0 1.2688789183812332e-06
C6D B-Disease 1 0.9999709129333496
in O 0 4.440471457201056e-08
an O 0 2.6221138593740534e-09
unrelated O 0 1.8959805458962364e-07
African O 0 1.371767837099469e-07
- O 0 2.1270020624797326e-06
American O 0 3.8838416571707057e-07
individual O 0 6.571007560296493e-08
. O 0 8.457285503027379e-07

Both O 0 1.61108016527578e-06
mutations O 0 6.321192245195562e-07
result O 0 2.1486630430445075e-07
in O 0 2.6062204483423557e-07
premature O 0 4.928484031552216e-06
termination O 0 8.178800271707587e-06
codons O 0 7.0506557676708326e-06
and O 0 1.1265816510785953e-06
C6 O 1 0.9954984188079834
null O 0 1.843657810240984e-05
alleles O 0 8.572872047807323e-07
. O 0 1.4849388207949232e-06

Allele O 0 3.320807309137308e-06
- O 0 1.0128939038622775e-06
specific O 0 4.0443907778353605e-08
PCR O 0 3.327807462483179e-06
indicated O 0 7.002088864282996e-08
that O 0 1.308847696890325e-09
the O 0 1.2366497159632672e-08
probands O 0 8.74948273121845e-06
two O 0 2.1494802382449052e-08
brothers O 0 2.6513046123000095e-06
also O 0 2.666284437680133e-08
inherited O 0 6.943153948668623e-06
the O 0 1.3308314805726695e-07
1195delC O 0 2.3476186470361426e-06
mutation O 0 6.977582067690946e-09
from O 0 5.174223272064182e-09
their O 0 2.2252870657268886e-09
heterozygous O 0 2.165735679682257e-08
mother O 0 1.9006437312896196e-08
and O 0 1.1717880887829324e-08
the O 0 4.674719988884135e-08
1936delG O 0 1.9482617972244043e-06
mutation O 0 2.475518812161681e-08
from O 0 1.5277024090210034e-08
their O 0 1.6189918738973574e-08
homozygous O 0 1.387200995850435e-06
father O 0 1.5560984820695012e-06
. O 0 2.206243436830846e-07
. O 0 6.855885317236243e-07

PAX6 O 1 0.9991931319236755
mutations O 0 0.00014644609473180026
reviewed O 0 0.00012328990851528943
. O 0 2.304882582393475e-05

Mutations O 0 1.2259507457201835e-05
in O 0 1.6874574839675915e-06
PAX6 O 1 0.9821904897689819
are O 0 1.66193085959776e-08
responsible O 0 2.064779209831613e-07
for O 0 4.9070976615439577e-08
human O 0 6.25954783117777e-07
aniridia B-Disease 1 1.0
and O 0 4.3887801837172447e-08
have O 0 1.131635674056497e-09
also O 0 9.829645986059177e-10
been O 0 1.0907147407479556e-09
found O 0 1.606483723826102e-09
in O 0 1.7299078836074955e-09
patients O 0 1.3452514657785741e-08
with O 0 3.025655814781203e-08
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 2.557818561399472e-06
with O 0 0.029108352959156036
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 0 0.00021523036411963403
with O 0 3.906683105014963e-06
autosomal B-Disease 1 0.9997548460960388
dominant I-Disease 1 0.9996156692504883
keratitis I-Disease 1 0.9999998807907104
, O 0 1.0728286952144117e-06
and O 0 3.9393677297994145e-07
with O 0 1.0666046819096664e-06
isolated B-Disease 1 0.9999785423278809
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 0.0002281813940498978

No O 0 6.798733011237346e-06
locus O 0 1.178886464003881e-06
other O 0 1.7885023240182818e-08
than O 0 1.0803999472841497e-08
chromosome O 0 1.3685937005902815e-07
11p13 O 0 4.123407052247785e-06
has O 0 9.373615661445456e-09
been O 0 8.828670239324765e-09
implicated O 0 1.5459706048659427e-07
in O 0 1.717764064324001e-07
aniridia B-Disease 1 1.0
, O 0 1.666370366137926e-07
and O 0 1.2952372685504088e-07
PAX6 O 1 0.9999983310699463
is O 0 7.921523348386472e-08
clearly O 0 3.086455535594723e-08
the O 0 1.4968543737836626e-08
major O 0 3.793184930600546e-07
, O 0 8.147325480933887e-09
if O 0 5.678121861585339e-10
not O 0 1.7696240306452893e-10
only O 0 6.920717332548065e-10
, O 0 9.053529481661826e-09
gene O 0 1.328817518242431e-07
responsible O 0 1.7054512682079803e-06
. O 0 4.131854439037852e-06

Twenty O 0 5.117720866110176e-05
- O 0 4.498560429055942e-06
eight O 0 2.2551857625785487e-07
percent O 0 4.820637755642565e-08
of O 0 1.506817071117439e-08
identified O 0 7.798502821287912e-08
PAX6 O 0 0.03312838822603226
mutations O 0 5.600491448376488e-08
are O 0 5.818712178751184e-09
C O 0 0.00060728017706424
- O 0 8.286085358122364e-05
T O 0 0.00019727057951968163
changes O 0 1.3758929995333347e-08
at O 0 2.8566518039951916e-07
CpG O 0 1.9283056644781027e-06
dinucleotides O 0 1.865349076979328e-06
, O 0 3.7170497790839363e-09
20 O 0 9.987073390504975e-09
% O 0 3.483301980189424e-10
are O 0 5.1483574348143435e-11
splicing O 0 7.86014737741425e-08
errors O 0 1.1918311884073773e-06
, O 0 1.333200039255189e-08
and O 0 3.2443325803654943e-09
more O 0 1.9044192611783473e-10
than O 0 6.100537852660182e-10
30 O 0 9.248697807606732e-09
% O 0 8.236192838850798e-10
are O 0 1.2717346620227943e-10
deletion O 0 1.9096807690743844e-08
or O 0 1.134739946451191e-08
insertion O 0 6.79894583299756e-07
events O 0 1.0442084885653458e-06
. O 0 2.0480363218666753e-06

There O 0 2.5237527552235406e-06
is O 0 1.255540098554775e-07
a O 0 1.3077296046049014e-07
noticeably O 0 2.4280629986606073e-06
elevated O 0 7.151476893341169e-06
level O 0 9.451103011315354e-08
of O 0 2.565676915367021e-08
mutation O 0 3.1753917273391608e-09
in O 0 2.5923265756233604e-09
the O 0 1.4539673465208125e-08
paired O 0 2.9230168507865528e-08
domain O 0 5.1479305263057995e-09
compared O 0 2.987314617897141e-09
with O 0 5.805483871412775e-10
the O 0 8.611892532428556e-09
rest O 0 1.526408368590637e-07
of O 0 1.0304592734655671e-07
the O 0 1.2068562682543416e-07
gene O 0 5.95777009948506e-07
. O 0 5.69997553157009e-07

Increased O 0 1.1371240589141962e-06
mutation O 0 2.1888695300731342e-07
in O 0 3.210526600128105e-08
the O 0 3.0429777808649305e-08
homeodomain O 0 3.435152848396683e-06
is O 0 8.527712758166217e-09
accounted O 0 3.795500447267841e-08
for O 0 1.520457426629207e-09
by O 0 5.290484939024509e-09
the O 0 1.3054891212505026e-07
hypermutable O 0 0.00014247749641072005
CpG O 0 3.590678170439787e-05
dinucleotide O 0 2.5448949600104243e-05
in O 0 5.845490136380249e-07
codon O 0 5.052041615272174e-06
240 O 0 2.91051628664718e-06
. O 0 1.9998456082248595e-06

Very O 0 6.85344048179104e-07
nearly O 0 1.0313460307997957e-07
all O 0 1.060095389249227e-08
mutations O 0 5.1626926733661094e-08
appear O 0 2.4878778148718084e-08
to O 0 1.3790089070653266e-08
cause O 0 8.40574330140953e-07
loss O 0 6.1679038481088355e-06
of O 0 1.4342684551138518e-07
function O 0 2.971323631584255e-09
of O 0 1.6378789879922806e-08
the O 0 4.071354364754143e-09
mutant O 0 3.829934058785511e-08
allele O 0 2.5744550935513644e-09
, O 0 6.175145395026505e-10
and O 0 4.301156375507986e-10
more O 0 3.708024859383485e-11
than O 0 4.116123830666396e-10
80 O 0 9.41714439761654e-09
% O 0 9.48330969308131e-10
of O 0 1.722586340235921e-08
exonic O 0 2.378022827542736e-06
substitutions O 0 5.061765477876179e-07
result O 0 8.643046101042273e-08
in O 0 1.1494726948058087e-07
nonsense O 0 1.4056870895728935e-05
codons O 0 9.561847036820836e-06
. O 0 2.3207728645502357e-06

In O 0 2.8139188543718774e-06
a O 0 2.575820019501407e-07
gene O 0 4.7706226524724116e-08
with O 0 4.326236702212327e-09
such O 0 2.3571741891714737e-08
extraordinarily O 0 1.239348534909368e-06
high O 0 8.257276817857928e-07
sequence O 0 4.872642733744215e-09
conservation O 0 1.0113049953019981e-08
throughout O 0 9.16884512758287e-10
evolution O 0 4.821260279896933e-09
, O 0 4.4886472316818526e-10
there O 0 2.615055394450394e-10
are O 0 2.585313907399467e-10
presumed O 0 1.5497289496124722e-07
undiscovered O 0 1.2597871318575926e-05
missense O 0 5.537112315323611e-07
mutations O 0 2.3735331922125624e-08
, O 0 2.592633219222762e-09
these O 0 6.161709475982491e-10
are O 0 1.8555229575056842e-10
hypothesized O 0 5.532116542639187e-09
to O 0 8.565952391847986e-10
exist O 0 3.953957605773439e-09
in O 0 4.401562225808675e-09
as O 0 1.9750224566905672e-08
- O 0 3.770894636545563e-07
yet O 0 2.2407744992847256e-08
unidentified O 0 2.034788764149198e-07
phenotypes O 0 4.6866031766512606e-07
. O 0 5.018850401938835e-08
. O 0 3.4881662713814876e-07

Genetic O 0 3.7601937947329134e-05
heterogeneity O 0 2.039456921920646e-05
and O 0 3.780058364100114e-07
penetrance O 0 1.0196596122113988e-05
analysis O 0 9.507223808213894e-08
of O 0 2.0808704448427306e-07
the O 0 2.1435177188777743e-07
BRCA1 O 0 3.7193040043348446e-06
and O 0 1.6129375524087664e-07
BRCA2 O 0 4.249771791364765e-06
genes O 0 7.968257165202886e-08
in O 0 1.2799656587958452e-06
breast B-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9989921450614929
families O 0 6.574266819825425e-08
. O 0 9.6422775186511e-07

The O 0 0.22515176236629486
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 1 0.6228519678115845
Consortium O 0 6.356248923111707e-05
. O 0 3.6779399579245364e-06

The O 0 1.1602819540712517e-06
contribution O 0 6.896056561345176e-07
of O 0 7.872193350522139e-07
BRCA1 O 0 5.3271196520654485e-06
and O 0 1.7507470317923435e-07
BRCA2 O 0 2.3334103389061056e-05
to O 0 2.022034323090338e-06
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.00019137909112032503
assessed O 0 1.806715914653978e-07
by O 0 8.91673845870855e-09
linkage O 0 2.223400770162698e-07
and O 0 6.508636740676366e-09
mutation O 0 3.5275249388178054e-09
analysis O 0 1.148649730886575e-09
in O 0 1.2790160042186471e-09
237 O 0 1.9444176047045403e-08
families O 0 1.9786178251379738e-10
, O 0 1.5845064149644372e-09
each O 0 1.1513295872234153e-10
with O 0 1.4271095416518165e-09
at O 0 2.1583566933713882e-07
least O 0 1.1701594138102678e-09
four O 0 1.948671446427852e-09
cases O 0 4.187937108213191e-09
of O 0 2.301838549101376e-06
breast B-Disease 1 1.0
cancer I-Disease 1 0.999972939491272
, O 0 2.2127981225139592e-08
collected O 0 3.0273930917701364e-08
by O 0 1.1557443002629952e-08
the O 0 6.5413601078034844e-06
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.001408612122759223
Consortium O 0 4.1687279008328915e-05
. O 0 2.0217528344801394e-06

Families O 0 1.8338378993121296e-07
were O 0 4.940493880667418e-08
included O 0 3.519958724496064e-08
without O 0 1.0643602443849431e-08
regard O 0 8.497869075085873e-09
to O 0 2.6400295283224295e-09
the O 0 3.933850134529848e-09
occurrence O 0 1.984332840265779e-07
of O 0 3.845441369776381e-06
ovarian B-Disease 1 0.9999890327453613
or I-Disease 0 7.90021601915214e-07
other I-Disease 0 2.2054596229281742e-06
cancers I-Disease 1 0.9998164772987366
. O 0 3.38705081048829e-06

Overall O 0 0.00022236652148421854
, O 0 1.3980973562865984e-05
disease O 1 0.9972434043884277
was O 0 6.333385044854367e-06
linked O 0 9.340563451587514e-07
to O 0 1.3869910553410136e-08
BRCA1 O 0 1.6816053971524525e-07
in O 0 4.1786654136899415e-09
an O 0 5.829162708081981e-10
estimated O 0 2.011637301180258e-09
52 O 0 9.887114238438244e-09
% O 0 4.330329150814549e-10
of O 0 3.98259780709509e-09
families O 0 5.208014020041674e-10
, O 0 2.368638618577279e-09
to O 0 5.161970850764419e-09
BRCA2 O 0 1.663374433746867e-07
in O 0 8.904841308776668e-09
32 O 0 3.7491997062488736e-08
% O 0 9.149873081426563e-10
of O 0 2.4021975519872285e-09
families O 0 4.944769038672803e-10
, O 0 4.4809849164551e-09
and O 0 2.9910545151778933e-09
to O 0 2.4027839717888355e-09
neither O 0 1.4284936789010771e-08
gene O 0 6.574264244108008e-09
in O 0 6.668477325888489e-09
16 O 0 6.061328861051152e-08
% O 0 1.4739253151319076e-09
( O 0 1.2378525982015276e-09
95 O 0 4.4577912916565765e-08
% O 0 4.124880881306581e-09
confidence O 0 9.0773944805278e-08
interval O 0 8.140260092659446e-07
[ O 0 9.522810273665527e-07
CI O 0 0.007413981948047876
] O 0 8.598401564086089e-07
6 O 0 1.3161148615381535e-07
% O 0 2.639193530384887e-09
- O 0 3.6788090795880635e-08
28 O 0 4.690788202310614e-08
% O 0 1.6172997385766053e-09
) O 0 8.235722104288357e-10
, O 0 8.558244113388014e-10
suggesting O 0 1.3856478631169011e-08
other O 0 1.9272706097694936e-08
predisposition O 0 1.2205427083245013e-05
genes O 0 5.293697995512048e-07
. O 0 2.6566806354821892e-06

The O 0 4.053653810842661e-06
majority O 0 9.128736166985618e-08
( O 0 3.092778655400252e-08
81 O 0 4.99762450090202e-07
% O 0 4.592150659732397e-09
) O 0 6.914436800897761e-10
of O 0 1.2065243915060364e-08
the O 0 7.112884645721351e-07
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.518226764422707e-09
were O 0 1.2616635736151238e-08
due O 0 4.236618522668323e-08
to O 0 1.4431726036434611e-08
BRCA1 O 0 7.025512900327158e-07
, O 0 4.678883502862163e-09
with O 0 8.804920681448891e-10
most O 0 3.5357023975279844e-09
others O 0 1.1745404648877411e-08
( O 0 7.727560813464152e-09
14 O 0 1.8770433030113054e-07
% O 0 4.228470462663836e-09
) O 0 1.894395751378397e-09
due O 0 5.2572623587821e-08
to O 0 2.243467207563299e-07
BRCA2 O 0 0.00011468879529275
. O 0 3.6370845464261947e-06

Conversely O 0 1.6392299585277215e-05
, O 0 8.324215627908416e-08
the O 0 2.7455746121063385e-08
majority O 0 1.800597893009126e-09
of O 0 8.858441979953113e-09
families O 0 4.896864580494764e-10
with O 0 1.8965362613698744e-09
male B-Disease 0 2.4129901632363726e-08
and I-Disease 0 2.3302012763792845e-08
female I-Disease 0 1.7478738527643145e-06
breast I-Disease 1 0.9999901056289673
cancer I-Disease 1 0.9951134324073792
were O 0 8.216838409680349e-08
due O 0 1.9144188456721167e-07
to O 0 3.8416178682609825e-08
BRCA2 O 0 2.379553961873171e-06
( O 0 9.909810927410945e-08
76 O 0 3.3490496207377873e-06
% O 0 3.795340930423663e-08
) O 0 7.223615483553658e-08
. O 0 4.336069707733259e-07

The O 0 2.8672027383436216e-06
largest O 0 4.850020559388213e-06
proportion O 0 1.363477935001356e-07
( O 0 1.4317286911591509e-08
67 O 0 3.0303920084406855e-07
% O 0 3.1621916196655775e-09
) O 0 4.146049892295167e-10
of O 0 4.1794145921869585e-09
families O 0 1.6448932493862145e-10
due O 0 1.3695202305541443e-08
to O 0 1.3987702107698397e-09
other O 0 9.099957454239416e-10
genes O 0 2.2870223492788e-09
was O 0 3.534652393000215e-08
found O 0 1.669797189407518e-09
in O 0 7.795670220467343e-10
families O 0 6.479868031039615e-11
with O 0 8.154660280368375e-10
four O 0 8.448931332338816e-09
or O 0 9.492036490144073e-09
five O 0 6.707114419413074e-09
cases O 0 4.9874615548617385e-09
of O 0 5.058001875113405e-07
female O 0 1.6326679542544298e-05
breast B-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999276399612427
only O 0 5.117448154123849e-07
. O 0 1.6340899264832842e-06

These O 0 2.801756977532932e-07
estimates O 0 1.9477216994800983e-07
were O 0 1.7741916380487055e-08
not O 0 1.360007884088077e-09
substantially O 0 1.8254931788419526e-08
affected O 0 3.321598995853492e-09
either O 0 1.5317718204954645e-09
by O 0 1.0779952486217326e-09
changing O 0 5.530798041775142e-09
the O 0 4.539706388584364e-09
assumed O 0 2.9501597609282726e-08
penetrance O 0 1.9827569985864102e-07
model O 0 4.658686769687392e-09
for O 0 6.156308796079202e-09
BRCA1 O 0 4.5737482423646725e-07
or O 0 6.650668460395082e-09
by O 0 4.937589448417157e-09
including O 0 2.987247427199691e-08
or O 0 9.537027523265351e-08
excluding O 0 3.4749159567581955e-06
BRCA1 O 0 1.731809607008472e-05
mutation O 0 3.399586034902313e-07
data O 0 1.1841927971545374e-06
. O 0 1.3632624131787452e-06

Among O 0 1.1049096428905614e-06
those O 0 4.3245144354386866e-08
families O 0 6.642530081535369e-09
with O 0 1.2424047213244194e-07
disease O 1 0.9771375060081482
due O 0 7.501363370465697e-07
to O 0 3.3071998473133135e-08
BRCA1 O 0 3.009006945831061e-07
that O 0 7.07765179797093e-10
were O 0 4.3790864268089535e-09
tested O 0 1.1133100663585083e-08
by O 0 6.321765888550601e-10
one O 0 8.532589079734976e-10
of O 0 6.719496958851323e-09
the O 0 4.903867534267192e-09
standard O 0 1.368742008622803e-08
screening O 0 3.562984796090518e-09
methods O 0 3.3247431474592304e-09
, O 0 1.1870167071492688e-09
mutations O 0 1.9309343013418356e-09
were O 0 2.7964266458013753e-09
detected O 0 4.3303995056476197e-08
in O 0 4.012655097085371e-09
the O 0 3.1138434053445962e-09
coding O 0 3.3443146918443745e-08
sequence O 0 2.811674670866182e-09
or O 0 1.4128175296335144e-09
splice O 0 1.680337220477668e-07
sites O 0 7.581421712643532e-09
in O 0 2.8958464515227433e-09
an O 0 2.469220938827732e-10
estimated O 0 2.631432849398152e-09
63 O 0 6.197026891641144e-08
% O 0 1.715607877983416e-09
( O 0 1.4393287672831434e-09
95 O 0 1.0419280727091973e-07
% O 0 1.2313351227533076e-08
CI O 0 0.00012722634710371494
51 O 0 3.8376455790967157e-07
% O 0 8.669591267107535e-09
- O 0 3.053979185096978e-07
77 O 0 9.036554615704517e-07
% O 0 3.1859247684451475e-08
) O 0 4.6318962887426096e-08
. O 0 4.121097276765795e-07

The O 0 2.946709173556883e-06
estimated O 0 1.8523942912906932e-07
sensitivity O 0 2.4895851424844295e-07
was O 0 1.6603472374754347e-07
identical O 0 1.977872443603701e-08
for O 0 1.183589226627646e-09
direct O 0 1.6699945870612964e-09
sequencing O 0 5.696493232676403e-08
and O 0 1.008642769306789e-08
other O 0 5.344064302192919e-09
techniques O 0 2.190079612773843e-06
. O 0 1.1559690165086067e-06

The O 0 5.343131306290161e-06
penetrance O 0 0.00013813402620144188
of O 0 1.91916278708959e-05
BRCA2 O 0 2.0374332962092012e-05
was O 0 6.282207323238254e-07
estimated O 0 1.610033706356262e-08
by O 0 1.8708368187958513e-09
maximizing O 0 2.448975919833174e-07
the O 0 4.959867894172021e-08
LOD O 0 0.0017984373262152076
score O 0 2.6842772626878286e-07
in O 0 3.92064620768906e-08
BRCA2 O 0 5.195540325075854e-06
- O 0 1.447304157409235e-06
mutation O 0 1.8348938368717427e-08
families O 0 1.1991502235630946e-09
, O 0 5.653982171338612e-09
over O 0 6.611019287561248e-09
all O 0 2.3717170449799596e-09
possible O 0 4.047192092571095e-08
penetrance O 0 1.4107325114309788e-05
functions O 0 4.697283770838112e-07
. O 0 1.8743721739156172e-06

The O 0 1.5821703982510371e-06
estimated O 0 1.6448848327854648e-07
cumulative O 0 5.133001081958355e-07
risk O 0 1.5611151127359335e-07
of O 0 4.399614681460662e-06
breast B-Disease 1 0.9999656677246094
cancer I-Disease 0 0.047689083963632584
reached O 0 2.3206568755540502e-07
28 O 0 1.682063981434112e-07
% O 0 1.4794795388795023e-09
( O 0 4.977451784071718e-10
95 O 0 4.936179820447251e-08
% O 0 4.458477587121479e-09
CI O 0 4.2887193558271974e-05
9 O 0 3.304993185793137e-07
% O 0 3.854901287070334e-09
- O 0 4.271834086466697e-08
44 O 0 3.9480813285308614e-08
% O 0 2.258739861815684e-09
) O 0 3.6938943570596905e-10
by O 0 1.1615380879348436e-09
age O 0 1.3042207314128973e-08
50 O 0 5.673275182971338e-09
years O 0 2.0257451271987748e-09
and O 0 2.571461488187765e-09
84 O 0 8.039641841151024e-08
% O 0 1.0833481889349628e-09
( O 0 1.1823663159660214e-09
95 O 0 1.0944249595468136e-07
% O 0 1.3294217282577847e-08
CI O 0 5.589824650087394e-05
43 O 0 1.6050060480665707e-07
% O 0 2.385468267362967e-09
- O 0 3.0090237856938984e-08
95 O 0 2.2442431912850225e-08
% O 0 1.183476427968344e-09
) O 0 2.5877164300247557e-10
by O 0 9.356785346525953e-10
age O 0 3.374397294919618e-08
70 O 0 1.4899502787102392e-07
years O 0 1.2526733428330772e-07
. O 0 2.618240273477568e-07

The O 0 1.423152116331039e-05
corresponding O 0 0.24721720814704895
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 1.9243861970608123e-05
were O 0 8.308003884849313e-07
0 O 0 6.976040367590031e-07
. O 0 2.1899052171647782e-07

4 O 0 1.3534736353904009e-05
% O 0 7.97385197870426e-08
( O 0 1.599098631288598e-08
95 O 0 1.1580274872358132e-07
% O 0 4.218288385260394e-09
CI O 0 1.039665312418947e-05
0 O 0 1.6084038989561122e-08
% O 0 1.1496361640439545e-09
- O 0 1.2059009790732489e-08
1 O 0 1.2716244057742188e-08
% O 0 3.898837086513396e-10
) O 0 9.350839547117573e-11
by O 0 1.6524656643035485e-10
age O 0 1.9798871431220277e-09
50 O 0 1.960900775088703e-09
years O 0 1.940881677597872e-09
and O 0 5.978424422181661e-10
27 O 0 1.4008961990441549e-08
% O 0 4.597695835162341e-10
( O 0 5.259243041066952e-10
95 O 0 4.565759681440795e-08
% O 0 4.365942718465021e-09
CI O 0 1.4187818123900797e-05
0 O 0 3.823860694751602e-08
% O 0 1.429108942296864e-09
- O 0 1.5717986912022752e-08
47 O 0 1.0005014594582917e-08
% O 0 5.382237433515513e-10
) O 0 2.836358647950732e-10
by O 0 1.5906229666740046e-09
age O 0 2.965838596935555e-08
70 O 0 1.8427594739023334e-07
years O 0 1.8675636681564356e-07
. O 0 4.5138023097024416e-07

The O 0 2.9428226753225317e-06
lifetime O 0 6.146084615465952e-06
risk O 0 4.791756964550586e-07
of O 0 0.00016113673336803913
breast B-Disease 1 1.0
cancer I-Disease 1 1.0
appears O 0 6.62689103592129e-08
similar O 0 6.380958872398423e-09
to O 0 1.8488116593218251e-09
the O 0 1.2552666461829176e-08
risk O 0 1.1811137845540998e-08
in O 0 1.4520771252080067e-08
BRCA1 O 0 1.5352247828559484e-07
carriers O 0 7.334933105340724e-09
, O 0 3.5227445405183744e-09
but O 0 5.976714678723738e-10
there O 0 1.1959386814197615e-09
was O 0 1.210124356276765e-08
some O 0 1.9289454755710977e-10
suggestion O 0 1.1557178325460882e-08
of O 0 4.6328150204999474e-08
a O 0 2.2518369391377746e-08
lower O 0 8.575063361604407e-07
risk O 0 6.871792379570252e-08
in O 0 8.38323330754065e-08
BRCA2 O 0 1.3356202543945983e-06
carriers O 0 4.054384916685194e-08
< O 0 3.2246978776129254e-07
50 O 0 8.606772183838984e-08
years O 0 2.061905668426789e-08
of O 0 5.380272227739624e-08
age O 0 5.169451924302848e-07
. O 0 2.9866612294426886e-07

Eye B-Disease 1 0.9999942779541016
movement I-Disease 0 0.0034337753895670176
abnormalities I-Disease 1 0.9887986779212952
correlate O 0 1.8833598005585372e-06
with O 0 8.567987208607519e-08
genotype O 0 2.8528368147817673e-06
in O 0 3.8536686020052e-07
autosomal O 1 0.5456523299217224
dominant O 1 0.9903141856193542
cerebellar B-Disease 1 1.0
ataxia I-Disease 1 1.0
type I-Disease 1 1.0
I I-Disease 1 0.9999998807907104
. O 0 6.726918945787475e-05

We O 0 2.5708995963213965e-06
compared O 0 3.152051931465394e-06
horizontal O 0 8.721990525373258e-06
eye O 0 0.000113628753751982
movements O 0 1.5876919405855006e-06
( O 0 1.2933190873809508e-07
visually O 0 3.1147214940574486e-07
guided O 0 4.6902700887585524e-06
saccades O 0 4.010057818959467e-05
, O 0 1.1711082237297887e-07
antisaccades O 0 2.749417762970552e-05
, O 0 5.4454169173823175e-08
and O 0 1.1596394955404321e-08
smooth O 0 7.037288440869816e-08
pursuit O 0 2.902905009705137e-07
) O 0 2.4797566222645173e-09
in O 0 4.757880311956342e-09
control O 0 2.9095394538103392e-08
subjects O 0 9.38358368784975e-08
( O 0 4.939925801750178e-09
n O 0 2.1944435601994883e-08
= O 0 2.3658449421759542e-08
14 O 0 5.574168682187519e-08
) O 0 2.135405630099285e-09
and O 0 2.145559285793297e-09
patients O 0 8.86867024263438e-09
with O 0 7.985381800246216e-10
three O 0 3.5201048742550256e-09
forms O 0 3.155240690944083e-08
of O 0 1.4540083839165163e-06
autosomal O 0 0.033398065716028214
dominant O 0 0.0026274919509887695
cerebellar B-Disease 1 0.999889612197876
ataxias I-Disease 1 0.9985281229019165
type I-Disease 1 0.5247514843940735
I I-Disease 1 0.999782145023346
spinocerebellar B-Disease 1 0.9998362064361572
ataxias I-Disease 0 0.0006160825723782182
1 I-Disease 0 1.2814202818844933e-06
and I-Disease 0 4.5224066269611285e-08
2 I-Disease 0 3.1739102723804535e-07
( O 0 7.039960792099009e-08
SCA1 B-Disease 0 0.2752995789051056
, O 0 2.789843200901032e-08
n O 0 3.565943629268986e-08
= O 0 2.863759362981e-08
11 O 0 4.8333244961895616e-08
; O 0 5.194871199876161e-09
SCA2 B-Disease 0 0.0002477422822266817
, O 0 1.825148565615109e-08
n O 0 1.0615116785572809e-08
= O 0 8.197893031081094e-09
10 O 0 6.648182893087551e-09
) O 0 1.167308250060728e-09
and O 0 1.585749842547557e-08
SCA3 B-Disease 1 1.0
/ O 0 2.399552977294661e-05
Machado B-Disease 0 9.036477422341704e-06
- I-Disease 0 3.80716664949432e-06
Joseph I-Disease 0 0.26538994908332825
disease I-Disease 1 0.9746885299682617
( O 0 1.0559825796008226e-06
MJD B-Disease 1 1.0
) O 0 1.1936175781102065e-07
( O 0 2.3700678752902604e-08
n O 0 5.037763273207929e-08
= O 0 1.117806505135377e-07
16 O 0 3.915288573352882e-07
) O 0 4.929885122351152e-08
. O 0 2.678493160601647e-07

In O 0 2.996658622578252e-05
SCA1 B-Disease 1 0.9998488426208496
, O 0 3.0034220799279865e-07
saccade O 0 5.1049282774329185e-06
amplitude O 0 2.8694520892713626e-07
was O 0 1.2946235017352592e-07
significantly O 0 6.745641822902826e-09
increased O 0 2.9450306637812673e-09
, O 0 3.1720923665545797e-09
resulting O 0 2.63733301864022e-08
in O 0 6.608210156855421e-08
hypermetria B-Disease 0 0.00010763862519524992
. O 0 1.0440860478411196e-06

The O 0 8.761930985201616e-06
smooth O 0 2.592845476101502e-06
pursuit O 0 6.157090410852106e-06
gain O 0 2.2470931071438827e-06
was O 0 4.17751471104566e-06
decreased O 0 4.26122460339684e-06
. O 0 5.845267310178315e-07

In O 0 3.645871038315818e-05
SCA2 B-Disease 1 0.9994909763336182
, O 0 1.5946083067319705e-06
saccade O 0 4.6459415898425505e-05
velocity O 0 4.3157406253158115e-06
was O 0 4.364810592960566e-06
markedly O 0 4.3086429286631756e-06
decreased O 0 5.0239686970598996e-06
. O 0 7.516085815950646e-07

The O 0 2.8191730052640196e-06
percentage O 0 6.847939175713691e-07
of O 0 3.9624228520551696e-07
errors O 0 8.951638847065624e-06
in O 0 2.730144501583709e-07
antisaccades O 0 0.03894822672009468
was O 0 6.218006660674291e-07
greatly O 0 1.2328509768622098e-08
increased O 0 2.959965383908525e-09
and O 0 4.492109351161844e-09
was O 0 3.3219048845012367e-08
significantly O 0 3.241913848484046e-09
correlated O 0 7.674652913181035e-09
with O 0 1.1612856232190438e-09
age O 0 1.6241283162798936e-07
at O 0 1.2630051969608758e-05
disease O 1 0.6915956735610962
onset O 0 0.01904091238975525
. O 0 1.989036263694288e-06

In O 0 1.0730046824392048e-06
addition O 0 1.9805762008218153e-07
, O 0 1.850442643558381e-08
a O 0 5.239561229331002e-09
correlation O 0 4.244923079710361e-09
between O 0 3.733164000152556e-09
smooth O 0 3.7227415816687426e-08
pursuit O 0 1.3413499289072206e-07
gain O 0 1.1277404787790601e-08
and O 0 1.1075909078783752e-09
the O 0 2.0133454903259462e-09
number O 0 4.607299819436861e-10
of O 0 2.0251240684387994e-08
trinucleotide O 0 0.0001738328137435019
repeats O 0 1.1221285376450396e-06
was O 0 2.210736738561536e-06
found O 0 2.8191382739350956e-07
. O 0 6.135247190286464e-07

In O 0 7.995644409675151e-05
SCA3 B-Disease 1 1.0
, O 0 3.5815921819448704e-06
gaze B-Disease 0 5.9810816310346127e-05
- I-Disease 0 1.1502493180159945e-05
evoked I-Disease 0 1.2552912266983185e-05
nystagmus I-Disease 0 0.00023325391521211714
was O 0 1.8210230336990207e-06
often O 0 4.249329776939703e-09
present O 0 9.519903976240585e-09
as O 0 1.4319472718682391e-08
was O 0 3.97817814246082e-07
saccade O 0 5.193935521674575e-06
hypometria O 0 1.1767505384341348e-05
and O 0 8.263517514706109e-08
smooth O 0 2.0586996640759025e-07
pursuit O 0 7.486048048122029e-07
gain O 0 2.912586012371321e-07
was O 0 1.3628853139380226e-06
markedly O 0 1.3434704442261136e-06
decreased O 0 1.103328145291016e-06
. O 0 4.626991199074837e-07

Three O 0 4.35685069533065e-06
major O 0 4.213343800074654e-06
criteria O 0 1.9416104350966634e-06
, O 0 1.200096306774867e-07
saccade O 0 1.7827996998676099e-06
amplitude O 0 1.4016222849022597e-07
, O 0 6.541966968143242e-09
saccade O 0 1.8680036362184183e-07
velocity O 0 1.76851564503977e-08
, O 0 2.6049857826393463e-09
and O 0 1.8104883148239992e-09
presence O 0 3.606538401257353e-09
of O 0 2.573612079004306e-08
gaze B-Disease 0 3.450663598414394e-06
- I-Disease 0 1.6364947441616096e-06
evoked I-Disease 0 2.5373592507094145e-06
nystagmus I-Disease 0 1.3945737919129897e-05
, O 0 1.2252066028395348e-08
permitted O 0 8.307383225769627e-09
the O 0 8.165900844403495e-09
correct O 0 2.437841573055266e-08
assignment O 0 1.8768279375080965e-08
of O 0 2.1792315507696003e-08
90 O 0 1.295661711253615e-08
% O 0 6.266148155908979e-10
of O 0 3.18653081698983e-09
the O 0 1.3312180691116282e-08
SCA1 B-Disease 0 0.4630471169948578
, O 0 3.562848904792304e-09
90 O 0 6.035139943350032e-09
% O 0 4.140336129498934e-10
of O 0 4.805744691083191e-09
the O 0 2.0705678949184403e-08
SCA2 B-Disease 1 0.9973268508911133
, O 0 1.1055610649179926e-08
and O 0 7.370175136856005e-09
93 O 0 1.3956680788851372e-07
% O 0 1.5710905909571693e-09
of O 0 5.193384833290793e-09
the O 0 8.610019364141408e-09
patients O 0 3.3489232720285145e-08
with O 0 4.173234913196211e-08
SCA3 B-Disease 1 1.0
to O 0 2.146894928500842e-08
their O 0 8.548003194164266e-09
genetically O 0 2.2257343346154812e-07
confirmed O 0 6.835829680085226e-08
patient O 0 2.162784653592098e-07
group O 0 2.8990863043532045e-08
and O 0 8.533049822290195e-09
, O 0 3.126263026231868e-09
therefore O 0 4.752012561226593e-09
, O 0 2.543641741681313e-09
may O 0 3.4715839092314127e-09
help O 0 7.279823410755171e-09
orient O 0 8.677337064000312e-06
diagnoses O 0 2.586239361335174e-06
of O 0 2.4541454877180513e-06
SCA1 B-Disease 1 0.9999997615814209
, O 0 4.625813403436041e-07
SCA2 B-Disease 1 0.9999681711196899
, O 0 1.2282464467716636e-07
and O 0 1.2507658198046556e-07
SCA3 B-Disease 1 1.0
at O 0 1.3648611911776243e-06
early O 0 1.164684988452791e-07
clinical O 0 2.056694086149946e-07
stages O 0 7.254716365423519e-07
of O 0 3.6876193121315737e-07
the O 0 1.455803430872038e-05
diseases O 1 1.0
. O 0 6.008191917317163e-07
. O 0 1.059134319802979e-06

Genetic O 0 8.188345418602694e-06
basis O 0 6.928376592441055e-07
and O 0 1.1821069989537136e-07
molecular O 0 5.461416549223941e-06
mechanism O 0 5.456236522149993e-06
for O 0 1.0551666491664946e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 0 0.0005200979649089277

Ventricular B-Disease 1 1.0
fibrillation I-Disease 1 0.9999992847442627
causes O 0 1.3314715943124611e-05
more O 0 1.3939262188955581e-08
than O 0 1.030708496330135e-08
300 O 0 6.556209797281554e-08
, O 0 7.0311547695212084e-09
000 O 0 1.1579424352703427e-07
sudden O 0 1.3796592668313679e-07
deaths O 0 2.8845139610211845e-08
each O 0 3.139036253152483e-10
year O 0 5.638904010396573e-09
in O 0 5.697804894566616e-09
the O 0 1.5863071212152136e-07
USA O 0 0.0015981870237737894
alone O 0 1.2465674217310152e-06
. O 0 6.545976134475495e-07

In O 0 5.813279244648584e-07
approximately O 0 1.1393642296297912e-07
5 O 0 1.275652579124653e-07
- O 0 1.3614067029266153e-07
12 O 0 3.712913354547709e-08
% O 0 7.085310116394794e-10
of O 0 1.1388200382711489e-09
these O 0 1.099776242297068e-10
cases O 0 9.35223565257104e-10
, O 0 9.260484046258455e-10
there O 0 3.9638470283875904e-10
are O 0 1.6730800078690322e-10
no O 0 7.073930774481596e-09
demonstrable O 0 0.00029573566280305386
cardiac O 1 0.9999853372573853
or O 0 9.727128826853004e-07
non O 1 0.9972781538963318
- O 1 0.9999886751174927
cardiac O 1 1.0
causes O 0 3.5504302786648623e-07
to O 0 2.1110790893175135e-09
account O 0 1.909260971544313e-09
for O 0 1.4558729777292e-09
the O 0 2.2330858939767495e-08
episode O 0 2.0164024761015753e-07
, O 0 1.586968445543846e-09
which O 0 9.990136495829915e-10
is O 0 2.493680817394761e-10
therefore O 0 1.7189749623724992e-09
classified O 0 1.4142263182748138e-07
as O 0 5.864687295797921e-07
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 0 0.0008127111941576004
IVF B-Disease 1 1.0
) O 0 2.058873633359326e-06
. O 0 2.2899471332493704e-06

A O 0 3.328157254145481e-05
distinct O 0 2.2733027549293183e-07
group O 0 1.3684712030226365e-07
of O 0 2.254924538647174e-06
IVF B-Disease 1 1.0
patients O 0 1.243410338247486e-06
has O 0 2.5386397428661667e-09
been O 0 1.0230615243855823e-09
found O 0 8.70091332316747e-10
to O 0 4.471915060477727e-10
present O 0 3.1425542168506126e-09
with O 0 6.594408130666807e-09
a O 0 1.568433276588621e-07
characteristic O 0 2.328919799765572e-05
electrocardiographic O 1 0.637854814529419
pattern O 0 3.607650432968512e-05
. O 0 2.1005344024160877e-06

Because O 0 1.1575333473956562e-06
of O 0 4.0258854028252244e-07
the O 0 3.29782068320128e-08
small O 0 2.4792645714200034e-09
size O 0 2.7279507541777548e-09
of O 0 6.074161618130347e-09
most O 0 7.051685901870997e-10
pedigrees O 0 2.5796813574174848e-08
and O 0 4.699705069555193e-09
the O 0 1.5784291207410206e-08
high O 0 4.462095830604085e-07
incidence O 0 1.4873113229896262e-07
of O 0 2.7275360636735968e-08
sudden B-Disease 0 4.596030578341015e-07
death I-Disease 0 1.774738620952121e-06
, O 0 4.013183119155883e-09
however O 0 1.3763804540545266e-09
, O 0 5.435449867974285e-10
molecular O 0 2.0064998551561075e-08
genetic O 0 3.2397999838451597e-09
studies O 0 5.059214380764843e-09
of O 0 3.059832920371264e-08
IVF B-Disease 1 1.0
have O 0 2.118820230379015e-09
not O 0 7.871542306858714e-10
yet O 0 4.9488186881774254e-09
been O 0 1.9914507376483925e-08
done O 0 2.0173315817828552e-07
. O 0 4.3341182731637673e-07

Because O 0 4.7877474571578205e-05
IVF B-Disease 1 1.0
causes O 1 0.8802874088287354
cardiac O 1 1.0
rhythm O 1 1.0
disturbance O 1 0.999849796295166
, O 0 5.154398152740214e-08
we O 0 1.515440106736321e-09
investigated O 0 1.798954230025629e-08
whether O 0 8.102817972144294e-09
malfunction O 0 0.0003362807910889387
of O 0 1.476861797300444e-07
ion O 0 5.301756118569756e-07
channels O 0 4.900017813724844e-08
could O 0 1.4237770074032596e-08
cause O 0 1.1410605083028713e-07
the O 0 1.777549130110856e-07
disorder O 0 2.1019008272560313e-05
by O 0 3.3092046880511816e-09
studying O 0 6.508440719699138e-08
mutations O 0 8.881399615745522e-09
in O 0 9.441641246610288e-09
the O 0 7.037114357899554e-08
cardiac O 0 0.0004632303607650101
sodium O 0 1.7294076997131924e-06
channel O 0 1.473621864533925e-06
gene O 0 3.815588115685387e-06
SCN5A O 1 0.5505683422088623
. O 0 3.238824319851119e-06

We O 0 6.975874384806957e-07
have O 0 6.656582840491865e-09
now O 0 1.374911828833092e-08
identified O 0 7.75958142185118e-09
a O 0 6.046004585869014e-09
missense O 0 7.784131526022975e-07
mutation O 0 5.3360306395688895e-08
, O 0 1.6279532388807638e-08
a O 0 1.9906572390482324e-08
splice O 0 1.1424087460909504e-05
- O 0 2.046587496806751e-06
donor O 0 1.2743345223498181e-07
mutation O 0 9.077343321450826e-08
, O 0 1.8809528157248678e-08
and O 0 1.942949445776776e-08
a O 0 2.937722243245844e-08
frameshift O 0 7.20552634447813e-07
mutation O 0 1.5395345442925645e-08
in O 0 6.635919369557541e-09
the O 0 1.3271718835028423e-08
coding O 0 6.682638797883556e-08
region O 0 3.8510158617555135e-08
of O 0 2.0354738694550178e-07
SCN5A O 1 0.9999363422393799
in O 0 8.120521499677125e-08
three O 0 8.169301679572527e-08
IVF B-Disease 1 0.9999963045120239
families O 0 1.0913524306488398e-07
. O 0 1.9595502180891344e-06

We O 0 1.0112097470482695e-06
show O 0 2.0018252655518154e-07
that O 0 1.7285030073921348e-09
sodium O 0 9.175533222105514e-09
channels O 0 2.4831832146077204e-09
with O 0 5.859616680758961e-10
the O 0 9.571502701533063e-09
missense O 0 4.684448811076436e-07
mutation O 0 1.841618946230028e-08
recover O 0 2.5932536118489224e-07
from O 0 5.194437946443031e-08
inactivation O 0 2.0161382963124197e-06
more O 0 9.847961335296418e-10
rapidly O 0 1.0499233482619275e-08
than O 0 3.168438567069387e-10
normal O 0 3.1312041848252647e-09
and O 0 7.791804979007111e-10
that O 0 5.793437951595592e-10
the O 0 1.1130298460670929e-08
frameshift O 0 1.4726300605616416e-06
mutation O 0 2.6395827745773204e-08
causes O 0 2.1080019507735415e-08
the O 0 1.748425226821837e-08
sodium O 0 3.167076556565007e-08
channel O 0 1.5996356239611487e-08
to O 0 2.4383144392459144e-09
be O 0 5.0765267545216375e-09
non O 0 8.839405154503766e-07
- O 0 4.6945033318479545e-06
functional O 0 1.1607545502556604e-06
. O 0 4.595123073158902e-07

Our O 0 5.872472229384584e-06
results O 0 4.519212382092519e-07
indicate O 0 4.50918555827684e-08
that O 0 1.1085631301810395e-09
mutations O 0 5.428241856009208e-09
in O 0 2.3030448659255853e-08
cardiac O 0 7.759838626952842e-05
ion O 0 1.8867575590775232e-06
- O 0 4.059294496983057e-06
channel O 0 3.9444081778583495e-08
genes O 0 8.07901745503159e-10
contribute O 0 4.0223080421952773e-10
to O 0 6.601590940569224e-10
the O 0 5.050036389064871e-09
risk O 0 8.09231526233134e-09
of O 0 5.7186248625384906e-08
developing O 0 4.848836852033855e-07
IVF B-Disease 1 0.9999998807907104
. O 0 4.16111873846603e-07
. O 0 3.453876047387894e-07

Molecular O 0 9.636376489652321e-05
heterogeneity O 0 5.628691360470839e-05
in O 0 1.98342763724213e-06
mucopolysaccharidosis B-Disease 0 0.2957216799259186
IVA I-Disease 1 0.9999998807907104
in O 0 3.6505431921796117e-07
Australia O 0 1.7253260864436015e-07
and O 0 8.212887259162471e-09
Northern O 0 1.495083097324823e-07
Ireland O 0 2.758864354746038e-07
: O 0 8.627708325548156e-09
nine O 0 3.818591309823205e-08
novel O 0 1.7095787896437287e-08
mutations O 0 1.305649277583143e-08
including O 0 6.732738455639264e-08
T312S O 0 0.00011851846647914499
, O 0 6.615638170615057e-08
a O 0 1.9578820342758263e-08
common O 0 5.919654455510681e-08
allele O 0 3.265099124405424e-08
that O 0 2.5641295753331406e-09
confers O 0 4.306065761738864e-07
a O 0 8.553240036235366e-07
mild O 0 0.0007274428498931229
phenotype O 0 1.932107625179924e-05
. O 0 2.9607940632558893e-06

Mucopolysaccharidosis B-Disease 1 0.9999470710754395
IVA I-Disease 1 1.0
( O 0 0.000309061462758109
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 1.6713996728867642e-06
is O 0 2.4837577328185034e-08
an O 0 1.8273919266675875e-08
autosomal B-Disease 1 0.9877090454101562
recessive I-Disease 1 0.9999898672103882
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.9866242408752441
by O 0 2.489155406237842e-07
a O 0 1.1167808224854525e-06
genetic B-Disease 1 0.9999947547912598
defect I-Disease 1 0.9999768733978271
in O 0 5.042204520577798e-07
N O 0 1.1133525731565896e-05
- O 0 3.642666570158326e-06
acetylgalactosamine O 0 0.00012004749441985041
- O 0 7.515708603023086e-06
6 O 0 1.0189481145062018e-05
- O 0 8.30458702694159e-06
sulfate O 0 1.0696345270844176e-05
sulfatase O 0 0.0200845655053854
( O 0 3.456572130744462e-06
GALNS O 1 0.9999991655349731
) O 0 7.677553526264091e-07
. O 0 7.565967052869382e-07

Previous O 0 4.72828651254531e-06
studies O 0 4.203303660688107e-07
of O 0 4.789422405337973e-07
patients O 0 4.4992631842433184e-08
from O 0 3.218264055249165e-08
a O 0 1.7747433744830232e-08
British O 0 9.224456789524993e-07
- O 0 2.0384511572046904e-06
Irish O 0 2.523661066788918e-07
population O 0 2.635836826581084e-10
showed O 0 4.350880100645327e-09
that O 0 1.2875797650302445e-10
the O 0 9.890697150183314e-09
I113F O 0 6.336091701086843e-06
mutation O 0 4.460351021862152e-08
is O 0 1.3723855385450179e-09
the O 0 2.9099762599571477e-09
most O 0 1.2367433743776246e-09
common O 0 2.9924811517645367e-09
single O 0 1.2235904733870484e-08
mutation O 0 1.1640138630752972e-08
among O 0 1.0372367142963412e-07
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 0.0058019268326461315
and O 0 1.4623871038565994e-06
produces O 0 8.542539035261143e-06
a O 0 1.2457330740289763e-06
severe O 1 0.893064558506012
clinical O 1 0.9948593378067017
phenotype O 0 3.540989928296767e-05
. O 0 4.139841621508822e-06

We O 0 3.0656545391138934e-07
studied O 0 1.4858568420095253e-06
mutations O 0 4.7123013047212226e-08
in O 0 2.876986471278542e-08
the O 0 3.211377830325546e-08
GALNS O 1 0.9547941088676453
gene O 0 4.905207617866836e-08
from O 0 3.0677508533472064e-08
23 O 0 1.1400707222719575e-07
additional O 0 7.65845413752686e-08
MPS B-Disease 1 0.9999995231628418
IVA I-Disease 1 1.0
patients O 0 8.626560884295031e-06
( O 0 3.81479132727236e-08
15 O 0 6.370588323534321e-08
from O 0 2.0849139303891207e-08
Australia O 0 1.9384373217690154e-08
, O 0 1.8360972742215154e-09
8 O 0 8.923459304810422e-09
from O 0 1.9960892938541974e-09
Northern O 0 2.321785252945574e-08
Ireland O 0 1.1612291217488746e-07
) O 0 3.2342615252645146e-09
, O 0 1.1306217073681069e-09
with O 0 2.7601265717436263e-10
various O 0 1.1065779403907072e-08
clinical O 0 3.123192072962411e-05
phenotypes O 0 5.219129889155738e-06
( O 0 7.799602030900132e-07
severe O 1 0.7924964427947998
, O 0 2.1060733956801414e-07
16 O 0 1.8931872602934163e-07
cases O 0 3.3046505532041692e-09
; O 0 1.7546984976135604e-09
intermediate O 0 1.2549204484457732e-06
, O 0 9.753974516968356e-09
4 O 0 4.484321536324387e-08
cases O 0 2.6582094303506665e-09
; O 0 9.618224439122969e-09
mild O 0 2.584059984656051e-06
, O 0 5.1636281028777375e-08
3 O 0 4.3079344891339133e-07
cases O 0 2.9666079370826992e-08
) O 0 6.253271322975706e-08
. O 0 3.049485712836031e-07

We O 0 4.4536102450365433e-07
found O 0 4.019918975473047e-08
two O 0 3.6863792018948516e-09
common O 0 7.414009406403466e-09
mutations O 0 7.973498306057536e-09
that O 0 8.062822631771382e-10
together O 0 3.2279385830946694e-09
accounted O 0 3.295475181630536e-08
for O 0 3.0708402487533704e-09
32 O 0 4.4891397266155764e-08
% O 0 7.010047542443942e-10
of O 0 3.074051679874401e-09
the O 0 1.0683099738173496e-08
44 O 0 4.276521892165874e-08
unrelated O 0 4.5913644441952783e-08
alleles O 0 3.934758296963992e-09
in O 0 1.2806864013725772e-08
these O 0 4.5007649163153474e-08
patients O 0 1.5419523151649628e-06
. O 0 2.1298358205967816e-06

One O 0 3.180887233611429e-06
is O 0 8.310065169325753e-08
the O 0 1.103059190654676e-07
T312S O 0 2.4827670131344348e-05
mutation O 0 2.271304850864908e-07
, O 0 1.2208117183831746e-08
a O 0 1.103201885399585e-08
novel O 0 5.733390651130321e-08
mutation O 0 9.693789770892636e-09
found O 0 2.373504726094211e-09
exclusively O 0 1.6213279607768527e-08
in O 0 3.7726280766037235e-08
milder O 0 1.3538841812987812e-05
patients O 0 2.039716946455883e-06
. O 0 2.0758013761223992e-06

The O 0 1.5321459159167716e-06
other O 0 5.9573725508244024e-08
is O 0 1.4411289050997311e-08
the O 0 1.713594244279193e-08
previously O 0 1.0358409241462141e-07
described O 0 9.635744646629973e-08
I113F O 0 2.782470346573973e-06
that O 0 7.53883977466785e-09
produces O 0 2.222578245891782e-07
a O 0 2.224325470479016e-07
severe O 0 0.2660841643810272
phenotype O 0 1.6090127246570773e-05
. O 0 4.267670647095656e-06

The O 0 8.35458286019275e-06
I113F O 0 8.004250412341207e-05
and O 0 4.5342568455453147e-07
T312S O 0 6.661889528913889e-06
mutations O 0 3.182475083463032e-08
accounted O 0 5.967163474451809e-08
for O 0 1.1016962453425094e-08
8 O 0 2.7153799919688026e-07
( O 0 6.207339531272282e-09
18 O 0 5.580519513159743e-08
% O 0 1.1175645964200953e-09
) O 0 3.067092690933748e-10
and O 0 1.2498619916812004e-09
6 O 0 6.595794133090749e-08
( O 0 2.9925384392726073e-09
14 O 0 2.713215252470036e-08
% O 0 1.0252102500274418e-09
) O 0 4.715299262159078e-10
of O 0 1.03287325359247e-08
44 O 0 3.3474925942300615e-08
unrelated O 0 6.177954503527872e-08
alleles O 0 1.414816530598273e-08
, O 0 4.232781591895218e-08
respectively O 0 1.5613518371537793e-06
. O 0 1.7982223425860866e-06

The O 0 1.9956846699642483e-06
relatively O 0 4.6172584688974894e-07
high O 0 1.8546581941336626e-06
residual O 0 2.8076783564756624e-05
GALNS O 1 0.68936687707901
activity O 0 1.0112822934615906e-07
seen O 0 1.5295478661414563e-08
when O 0 2.4953474841993284e-09
the O 0 4.49730430673867e-09
T312S O 0 4.929904093842197e-07
mutant O 0 8.335353385291455e-08
cDNA O 0 9.70032232316953e-08
is O 0 2.485699424070731e-09
overexpressed O 0 2.609694718103128e-07
in O 0 6.648182893087551e-09
mutant O 0 1.652638133009532e-07
cells O 0 1.5324740587630004e-08
provides O 0 8.212068247637205e-10
an O 0 1.6145125514288594e-10
explanation O 0 2.26777063794259e-09
for O 0 1.5567012123796076e-09
the O 0 6.601269575412516e-08
mild O 0 2.8676988222287036e-05
phenotype O 0 1.8717680916324753e-07
in O 0 3.58092506758112e-08
patients O 0 2.0988109028508006e-08
with O 0 3.1852851467562004e-09
this O 0 1.7956462983192978e-08
mutation O 0 4.893088316748617e-07
. O 0 1.0075066256831633e-06

The O 0 5.780650553788291e-07
distribution O 0 6.300452781715649e-08
and O 0 6.930059637255681e-09
relative O 0 5.034763717048918e-09
frequencies O 0 1.3035218238144353e-08
of O 0 8.114107608037102e-09
the O 0 1.0512920312066854e-08
I113F O 0 1.0813790822794545e-06
and O 0 1.7214892622519073e-08
T312S O 0 1.121448008234438e-06
mutations O 0 1.5717388279767874e-08
in O 0 2.3995289311073975e-08
Australia O 0 3.138626425425173e-08
corresponded O 0 6.648449346613461e-09
to O 0 6.455606049726725e-10
those O 0 4.79610906545247e-10
observed O 0 5.378904877062496e-09
in O 0 3.23220183950923e-09
Northern O 0 4.673141873468012e-08
Ireland O 0 3.5969289768900126e-08
and O 0 1.729300924679933e-09
are O 0 1.406501026757212e-10
unique O 0 8.367538328890589e-10
to O 0 4.718295198991029e-10
these O 0 2.3007767913085786e-10
two O 0 2.0591799099189956e-10
populations O 0 3.710163010151035e-10
, O 0 8.514349225663409e-10
suggesting O 0 3.106173318556671e-09
that O 0 1.3805813436906789e-10
both O 0 1.7337917213033904e-10
mutations O 0 3.905887613342429e-09
were O 0 7.410843050337235e-09
probably O 0 1.7520539685733638e-08
introduced O 0 6.691282639081919e-09
to O 0 1.9487382818539345e-09
Australia O 0 1.6454409390576075e-08
by O 0 1.7059947898800942e-09
Irish O 0 6.346381553612446e-08
migrants O 0 1.0826519680762203e-09
during O 0 8.523062255960667e-09
the O 0 5.290232696353314e-09
19th O 0 1.6836444274304085e-06
century O 0 2.5363285658386303e-06
. O 0 3.318457117984508e-07

Haplotype O 0 3.8940837839618325e-05
analysis O 0 3.537654151841707e-07
using O 0 1.6370927369280253e-07
6 O 0 3.399395836822805e-06
RFLPs O 0 2.300115374964662e-05
provides O 0 1.195460441749674e-08
additional O 0 3.1742350969921063e-09
data O 0 9.166401859772577e-09
that O 0 2.9921484734352077e-10
the O 0 7.165375404127872e-09
I113F O 0 1.2504036703830934e-06
mutation O 0 8.605587353827104e-09
originated O 0 3.036582540971722e-08
from O 0 7.796090883971374e-09
a O 0 3.11049106471728e-08
common O 0 1.1438028479915374e-07
ancestor O 0 3.6823446407652227e-06
. O 0 1.6142853382916655e-06

The O 0 2.948466317320708e-06
other O 0 9.203774453681035e-08
9 O 0 4.933525588057819e-07
novel O 0 4.480542514784247e-08
mutations O 0 3.7228040650205685e-09
identified O 0 1.807238358964014e-09
in O 0 2.999029247163776e-09
these O 0 8.772785276001116e-10
23 O 0 1.57380185328293e-07
patients O 0 7.330611229150463e-09
were O 0 2.249770814088947e-09
each O 0 1.985210329458198e-10
limited O 0 3.1496949493003967e-09
to O 0 3.4091613976272583e-09
a O 0 7.844810312462869e-08
single O 0 2.4317583324773295e-07
family O 0 3.189749975263112e-07
. O 0 1.668036702540121e-06

These O 0 1.8818647617990791e-07
data O 0 1.1090018858794792e-07
provide O 0 4.920169160982368e-09
further O 0 6.4461596060994e-09
evidence O 0 1.2699035600860498e-08
for O 0 1.1999281568364495e-09
extensive O 0 4.332622083325077e-08
allelic O 0 1.5078397836987278e-06
heterogeneity O 0 7.03363866705331e-07
in O 0 2.655715718447027e-07
MPS B-Disease 1 0.999972939491272
IVA I-Disease 1 1.0
in O 0 2.5030212214005587e-07
British O 0 7.2860048021539114e-06
- O 0 4.5231754484120756e-05
Irish O 0 1.6651469195494428e-05
patients O 0 8.49952712655977e-08
and O 0 2.676953547720018e-09
provide O 0 1.22275467528965e-09
evidence O 0 7.298676329980935e-09
for O 0 6.84828638242152e-10
their O 0 1.5491303795300837e-09
transmission O 0 3.3121491327392505e-08
to O 0 7.699852977438582e-10
Australia O 0 7.399684420761332e-09
by O 0 1.3665866216427958e-09
British O 0 4.514753584317077e-07
- O 0 9.391638400302327e-07
Irish O 0 4.856528335039911e-07
migrants O 0 6.841970989768242e-09
. O 0 1.52951873388929e-08
. O 0 1.2758289358316688e-07

Identification O 0 9.442934242542833e-06
of O 0 6.765010311937658e-06
constitutional O 0 1.0842740266525652e-05
WT1 O 1 0.9999961853027344
mutations O 0 1.2215592732900404e-06
, O 0 3.979608109716537e-08
in O 0 8.183664590433182e-08
patients O 0 1.3789332342639682e-07
with O 0 2.4131974640795306e-08
isolated O 0 0.00012030408106511459
diffuse B-Disease 1 0.9999958276748657
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 1.5191949387372006e-07
and O 0 1.4435800999024195e-08
analysis O 0 1.1883153128167123e-08
of O 0 9.556492841511499e-08
genotype O 0 5.367600806494011e-06
/ O 0 1.0476275747350883e-05
phenotype O 0 7.887194897193694e-08
correlations O 0 2.8587875178232025e-08
by O 0 1.9046491051000203e-09
use O 0 7.541514968067986e-09
of O 0 8.903724335596053e-08
a O 0 7.013357361529415e-08
computerized O 0 3.5379187465878204e-05
mutation O 0 4.2630111352082167e-07
database O 0 6.270977905842301e-07
. O 0 1.499915924796369e-06

Constitutional O 0 2.0896190108032897e-05
mutations O 0 1.625561367291084e-06
of O 0 2.2889448700880166e-06
the O 0 6.850866043350834e-07
WT1 O 1 0.9938793182373047
gene O 0 3.5420563904153823e-07
, O 0 1.5236198080970098e-08
encoding O 0 3.0763995795268784e-08
a O 0 1.4411624249532906e-07
zinc O 0 0.0004348845104686916
- O 0 2.955280797323212e-05
finger O 0 6.322884473775048e-06
transcription O 0 6.735513125022408e-07
factor O 0 3.9678070606896654e-08
involved O 0 2.8025633369566094e-08
in O 0 9.706355541538869e-08
renal O 1 0.9999970197677612
and O 0 4.785820237884764e-07
gonadal O 1 0.9966932535171509
development O 0 3.8643304378638277e-07
, O 0 8.819312391494805e-09
are O 0 3.5837841028119044e-10
found O 0 1.6319877671477911e-09
in O 0 1.4539138781799466e-09
most O 0 2.6729178870255055e-09
patients O 0 1.7741442093210935e-08
with O 0 1.8676468371836563e-08
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00044587842421606183
DDS B-Disease 1 1.0
) O 0 1.0669424455045373e-06
, O 0 4.8620432124835133e-08
or O 0 2.2109676933723676e-07
diffuse B-Disease 1 0.9277144074440002
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 0.00013683487486559898
DMS B-Disease 1 1.0
) O 0 9.391945354764175e-08
associated O 0 3.386919544823286e-08
with O 0 2.9778670196378698e-08
pseudohermaphroditism B-Disease 1 1.0
and O 0 3.8265352486632764e-06
/ O 0 0.001331875566393137
or O 0 7.318987627513707e-06
Wilms B-Disease 1 1.0
tumor I-Disease 1 0.9999735355377197
( O 0 6.718936674587894e-06
WT B-Disease 1 1.0
) O 0 1.5985704067134066e-06
. O 0 9.74161139311036e-07

Most O 0 1.5305276974686421e-06
mutations O 0 1.0471334235262475e-06
in O 0 4.181424628768582e-06
DDS B-Disease 1 1.0
patients O 0 1.3533446690416895e-05
lie O 0 2.0488880636548856e-06
in O 0 6.06419661153268e-08
exon O 0 1.058244833984645e-06
8 O 0 3.483914383650699e-07
or O 0 1.885759104425233e-08
exon O 0 4.843979581892199e-07
9 O 0 4.1178876131198194e-07
, O 0 2.0782120913054314e-08
encoding O 0 5.216738259150588e-07
zinc O 0 0.0001690094795776531
finger O 0 0.00010202667908743024
2 O 0 4.072120191267459e-06
or O 0 9.39823223689018e-07
zinc O 0 0.0002692095295060426
finger O 0 1.2809260624635499e-05
3 O 0 3.6181467066853656e-07
, O 0 8.835240095095287e-09
respectively O 0 2.3447356056749413e-08
, O 0 1.7833511334330865e-09
with O 0 1.03174657706262e-09
a O 0 2.4822847777272727e-08
hot O 0 1.148822957475204e-05
spot O 0 5.64018819204648e-06
( O 0 4.5253923275367924e-08
R394W O 0 3.4849119856517063e-06
) O 0 9.251062138559973e-09
in O 0 6.414322939463091e-08
exon O 0 8.330167474923655e-06
9 O 0 7.479749456251739e-06
. O 0 1.1160356052641873e-06

We O 0 3.420438474677212e-07
analyzed O 0 1.6870730235041265e-07
a O 0 1.4211344101511258e-08
series O 0 2.1565641716847495e-08
of O 0 5.851168083381708e-08
24 O 0 2.0724908722513646e-07
patients O 0 4.093704220053951e-08
, O 0 5.562164506756062e-09
10 O 0 2.5014005089474267e-08
with O 0 5.315823337070924e-09
isolated B-Disease 0 7.6769483712269e-06
DMS I-Disease 1 0.9999998807907104
( O 0 1.7597858459339477e-06
IDMS B-Disease 1 0.999998927116394
) O 0 1.0151706675287642e-07
, O 0 1.3600915949041337e-08
10 O 0 1.082066258817349e-08
with O 0 7.626643316882564e-09
DDS B-Disease 1 1.0
, O 0 1.5089129590251105e-07
and O 0 3.5598208825149413e-08
4 O 0 4.927967438561609e-07
with O 0 1.4316583474283107e-07
urogenital B-Disease 1 0.9999998807907104
abnormalities I-Disease 1 0.9999996423721313
and O 0 4.839074972551316e-05
/ O 1 0.6112115979194641
or O 0 9.846744069363922e-05
WT B-Disease 1 1.0
. O 0 1.7101507182815112e-05

We O 0 2.3740867618471384e-06
report O 0 1.614288407836284e-06
WT1 O 0 0.0030288181733340025
heterozygous O 0 3.090721065746038e-07
mutations O 0 3.8996667228730075e-08
in O 0 3.619426536261017e-08
16 O 0 4.029592162169138e-07
patients O 0 2.7159595461512254e-08
, O 0 8.042062127344707e-09
4 O 0 8.533037032520951e-08
of O 0 9.01713619327893e-08
whom O 0 6.227205062714347e-08
presented O 0 8.822856329970818e-07
with O 0 1.335411297986866e-06
IDMS B-Disease 1 1.0
. O 0 2.6133382561965846e-05

One O 0 5.053053428127896e-06
male O 0 9.42933070291474e-07
and O 0 9.259079547518922e-08
two O 0 1.28045741121241e-07
female O 0 5.660108854499413e-06
IDMS B-Disease 1 1.0
patients O 0 2.2397427528630942e-05
with O 0 3.72480599253322e-06
WT1 O 1 1.0
mutations O 0 0.00010686208406696096
underwent O 1 0.9976844787597656
normal O 0 0.00022161047672852874
puberty O 0 0.006397852674126625
. O 0 3.7822755984961987e-06

Two O 0 9.708204515845864e-07
mutations O 0 9.90613216345082e-07
associated O 0 4.489088212267234e-07
with O 0 2.478415410678281e-07
IDMS B-Disease 1 0.9999995231628418
are O 0 1.6876025021872465e-09
different O 0 6.107907513097643e-10
from O 0 3.1006683887113695e-09
those O 0 9.677546541908555e-10
described O 0 3.554745831024775e-08
in O 0 1.4104698493611068e-06
DDS B-Disease 1 1.0
patients O 0 8.472939225612208e-05
. O 0 3.471693162282463e-06

No O 0 2.6925510610453784e-05
WT1 O 1 0.9695930480957031
mutations O 0 6.873372058180394e-07
were O 0 1.2038056240726291e-07
detected O 0 2.8879773594781e-07
in O 0 1.4275185478140884e-08
the O 0 1.0410516892989108e-08
six O 0 2.7096984211993913e-08
other O 0 1.092864678753358e-07
IDMS B-Disease 1 1.0
patients O 0 8.296053238154855e-06
, O 0 4.7216218490575557e-08
suggesting O 0 7.385869338349949e-08
genetic O 0 1.2857103115493373e-07
heterogeneity O 0 1.1618753887887578e-06
of O 0 2.2029121282685082e-06
this O 0 7.585951493638277e-07
disease O 1 0.974578320980072
. O 0 1.4726904282724718e-06

We O 0 7.720020676060813e-07
analyzed O 0 2.9809696115989937e-06
genotype O 0 1.240742585650878e-05
/ O 0 1.0211465450993273e-05
phenotype O 0 3.0874895173838013e-07
correlations O 0 3.516084348120785e-07
, O 0 1.2745624999865868e-08
on O 0 8.925144179272593e-09
the O 0 1.384210190913393e-09
basis O 0 2.27991425738594e-09
of O 0 9.974318260219661e-09
the O 0 3.577734997151083e-09
constitution O 0 1.891608425452773e-09
of O 0 3.3418977807286865e-08
a O 0 7.93682914945748e-08
WT1 O 0 0.001970460172742605
mutation O 0 1.7824371312258336e-08
database O 0 1.9143962859402563e-08
of O 0 9.031042935703226e-08
84 O 0 4.981815436622128e-06
germ O 1 0.9999531507492065
- O 0 3.6627036024583504e-05
line O 0 7.14846351002052e-07
mutations O 0 1.7036674293535725e-08
, O 0 1.9923656058296046e-09
to O 0 6.702520760626385e-10
compare O 0 1.686872863615463e-08
the O 0 2.908894014552743e-09
distribution O 0 4.072674641975027e-09
and O 0 7.553459524523021e-10
type O 0 1.275272598633137e-08
of O 0 5.739682151784109e-08
mutations O 0 1.548475303536634e-08
, O 0 2.6287239052180666e-09
according O 0 8.414704488757252e-10
to O 0 8.894278646920384e-10
the O 0 1.0515026183099963e-08
different O 0 1.7348355640933733e-08
symptoms O 0 9.553808922646567e-05
. O 0 1.6975440075839288e-06

This O 0 3.187426784734271e-07
demonstrated O 0 7.56905535581609e-07
( O 0 5.247624912385618e-08
1 O 0 1.6312858974742994e-07
) O 0 3.585290508922867e-09
the O 0 5.122229751464147e-09
association O 0 2.0380936049946285e-08
between O 0 1.505316871153184e-09
mutations O 0 3.0492917080238158e-09
in O 0 4.530917863121431e-09
exons O 0 1.3573463775173877e-07
8 O 0 1.0887535495385237e-07
and O 0 6.264693208635208e-09
9 O 0 2.2969871338318626e-07
and O 0 3.0228523684172615e-08
DMS B-Disease 1 0.9952606558799744
; O 0 2.3458403219933643e-08
( O 0 1.2798830439919584e-08
2 O 0 1.8640031385075417e-07
) O 0 2.3440411833774988e-09
among O 0 3.3186353665115575e-09
patients O 0 1.6261035185038963e-08
with O 0 2.422804179502691e-08
DMS B-Disease 1 1.0
, O 0 3.820536420562348e-08
a O 0 4.292421973417504e-09
higher O 0 1.0251326010290995e-08
frequency O 0 5.179683792988499e-09
of O 0 1.188795906159612e-08
exon O 0 2.9346821861508943e-07
8 O 0 1.177196367052602e-07
mutations O 0 2.0681088841456585e-08
among O 0 9.932438871373961e-09
46 O 0 4.357576131042151e-07
, O 0 1.4101401291100046e-07
XY O 0 0.00040788541082292795
patients O 0 7.952223768370459e-08
with O 0 1.082842526756167e-08
female O 0 5.5371440765839e-08
phenotype O 0 5.685041770675525e-08
than O 0 4.016758925473596e-09
among O 0 1.4893474009625152e-08
46 O 0 3.1204956485453295e-07
, O 0 1.066002184302306e-07
XY O 0 0.013364074751734734
patients O 0 6.909156979872932e-08
with O 0 4.184990132216626e-09
sexual O 0 1.4377107504515152e-08
ambiguity O 0 6.04659504688243e-08
or O 0 5.6162910766488494e-08
male O 0 3.095186684731743e-08
phenotype O 0 2.1800422800311026e-08
; O 0 3.4126028669589914e-09
and O 0 1.2362205481508681e-08
( O 0 1.3613270510859365e-08
3 O 0 1.4674412796011893e-07
) O 0 1.0891679780300478e-09
statistically O 0 1.4307098838983734e-09
significant O 0 1.000678429008417e-09
evidence O 0 2.74693534585424e-09
that O 0 1.6701466598600945e-10
mutations O 0 1.8165969839500917e-09
in O 0 8.468583168053101e-09
exons O 0 1.2885963940334477e-07
8 O 0 1.285905426584577e-07
and O 0 1.851618236514696e-08
9 O 0 1.9183151778179308e-07
preferentially O 0 6.918229189523117e-08
affect O 0 2.1187080534446068e-08
amino O 0 3.696083084037127e-08
acids O 0 7.811197910712053e-09
with O 0 5.611798248317257e-10
different O 0 5.603327801750879e-10
functions O 0 9.480564777675227e-09
. O 0 3.824188965495523e-08
. O 0 1.3341366411623312e-07

The O 0 1.0519545867282432e-05
185delAG O 0 0.0001232506474480033
BRCA1 O 0 1.851699926191941e-05
mutation O 0 9.96791342799952e-08
originated O 0 1.2110449176816473e-07
before O 0 3.0835252573524485e-08
the O 0 2.0496355723764736e-09
dispersion O 0 2.5896694566540646e-08
of O 0 1.3618256744507562e-08
Jews O 0 3.22132827079713e-08
in O 0 5.490541798991444e-09
the O 0 2.651120656338435e-09
diaspora O 0 1.679058891923546e-09
and O 0 2.3246597979920125e-09
is O 0 6.44966136054137e-10
not O 0 2.969486601056559e-10
limited O 0 2.8993503153884603e-09
to O 0 3.28017399908731e-08
Ashkenazim O 0 6.869799108244479e-05
. O 0 2.0705306269519497e-06

The O 0 4.327990609453991e-06
185delAG O 0 2.6206756956526078e-05
mutation O 0 2.868447666060092e-07
in O 0 8.225526215710488e-08
BRCA1 O 0 1.4468846529780421e-06
is O 0 1.1204956962274082e-08
detected O 0 1.4282926485975622e-07
in O 0 8.023400610568387e-09
Ashkenazi O 0 3.5990606761515664e-07
Jews O 0 6.336124869221749e-08
both O 0 2.862660108959858e-09
in O 0 1.963877416244486e-08
familial B-Disease 0 0.00011628556967480108
breast I-Disease 1 0.9999847412109375
and I-Disease 1 0.9999644756317139
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.317082904961353e-07
in O 0 1.9897006708902154e-08
the O 0 3.481718025000191e-08
general O 0 6.714886779946028e-08
population O 0 5.4436277707736735e-09
. O 0 1.8908164634012792e-07

All O 0 1.940605216077529e-06
tested O 0 5.428303211374441e-06
Ashkenazi O 0 1.135233287641313e-05
mutation O 0 1.2763986489972012e-07
carriers O 0 2.2822909784281364e-08
share O 0 6.4756244810837416e-09
the O 0 6.481419845272285e-09
same O 0 5.9104006133736675e-09
allelic O 0 1.2846995787185733e-06
pattern O 0 3.043076901576569e-07
at O 0 5.620073011414206e-07
the O 0 2.0135391309850093e-07
BRCA1 O 0 6.465416845458094e-06
locus O 0 4.863898084295215e-06
. O 0 1.5308108913814067e-06

Our O 0 2.9662658107554307e-06
previous O 0 5.535823675018037e-07
study O 0 7.369967391923637e-08
showed O 0 3.6749380427636424e-08
that O 0 2.9865040995780134e-10
this O 0 8.560627762221884e-10
Ashkenazi O 0 1.1076019745814847e-06
mutation O 0 2.0860953853230058e-08
also O 0 2.5377004941873338e-09
occurs O 0 2.368715223965978e-09
in O 0 1.010248107391476e-09
Iraqi O 0 1.3093852224699276e-08
Jews O 0 2.4868816339562727e-08
with O 0 2.108503593944988e-09
a O 0 1.025290963241332e-08
similar O 0 6.765151994159169e-08
allelic O 0 3.645812103059143e-05
pattern O 0 1.804989187803585e-05
. O 0 1.975498889805749e-06

We O 0 5.633262958326668e-07
extended O 0 2.786839274904196e-07
our O 0 2.5764508748693515e-08
analysis O 0 5.171747030630058e-09
to O 0 2.262646514594735e-09
other O 0 5.152508197880934e-09
non O 0 5.474377644532069e-07
- O 0 3.905286973804323e-07
Ashkenazi O 0 2.504719134321931e-07
subsets O 0 6.986933698271969e-08
354 O 0 2.0470938011385442e-07
of O 0 4.085389093688718e-08
Moroccan O 0 9.779294174450115e-08
origin O 0 4.57789584018542e-09
, O 0 4.7655639434651675e-09
200 O 0 4.718614832199819e-08
Yemenites O 0 5.3031594688945916e-06
and O 0 4.0757150543413445e-08
150 O 0 1.0691848473243226e-07
Iranian O 0 2.860140853044868e-07
Jews O 0 1.6529279491805937e-06
. O 0 1.4597297877116944e-06

Heteroduplex O 0 0.0006934154080227017
analysis O 0 5.306673642735404e-07
complemented O 0 1.1484617061796598e-06
by O 0 3.2515432568658298e-09
direct O 0 5.406552983089341e-09
DNA O 0 1.0231853764253174e-07
sequencing O 0 4.4826794720620455e-08
of O 0 6.836116739350473e-08
abnormally O 0 7.77588013534114e-07
migrating O 0 6.188498247183816e-08
bands O 0 7.167564035626128e-07
were O 0 5.246644363410269e-08
employed O 0 7.139933586586267e-07
. O 0 7.03797979895171e-07

Four O 0 1.7486355545770493e-06
of O 0 7.219110784717486e-07
Moroccan O 0 5.85321629387181e-07
origin O 0 1.0790962789997138e-08
( O 0 5.179031870028439e-09
1 O 0 2.0396219824192485e-08
. O 0 1.0686068696585949e-09
1 O 0 7.586224093358851e-09
% O 0 2.9232818943292216e-10
) O 0 1.2663563253578758e-10
and O 0 2.572078106055642e-10
none O 0 2.799265486075342e-09
of O 0 9.835521730394703e-09
the O 0 1.4407743442745868e-08
Yemenites O 0 2.9281729894137243e-06
or O 0 1.1543828115634369e-08
Iranians O 0 1.8750855090843288e-08
was O 0 9.899156339088222e-08
a O 0 6.961855980591736e-09
carrier O 0 3.053070329883667e-08
of O 0 6.218623127551837e-08
the O 0 1.78259611516296e-07
185delAG O 0 2.9580975024146028e-05
mutation O 0 1.1157993640154018e-06
. O 0 1.0574013913355884e-06

BRCA1 O 0 0.0004370720125734806
allelic O 0 0.00016388358199037611
patterns O 0 4.911470568913501e-06
were O 0 1.2618131961517065e-07
determined O 0 1.6122800872153675e-08
for O 0 3.2587827991648055e-09
four O 0 5.964555072068833e-09
of O 0 6.809761199377817e-09
these O 0 2.5258875546718684e-10
individuals O 0 6.093092697057045e-11
and O 0 1.5136432107709652e-09
for O 0 2.418287570193911e-09
12 O 0 2.2632432816749315e-08
additional O 0 9.592519667478427e-09
non O 0 1.2923785561724799e-06
- O 0 3.5828597901854664e-06
Ashkenazi O 0 4.949915364704793e-06
185delAG O 0 3.6328349324321607e-06
mutation O 0 4.618108206955185e-08
carriers O 0 2.8592019418738346e-08
who O 0 3.23770130705725e-08
had O 0 3.128697699139593e-06
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.5370023649884388e-05

Six O 0 1.1955414265685249e-05
non O 0 8.438371878582984e-05
- O 0 2.2465927031589672e-05
Ashkenazi O 0 3.1838826544117182e-06
individuals O 0 3.1906481900989547e-09
shared O 0 2.833906620480775e-08
the O 0 3.625168076837326e-08
common O 0 7.357031961419125e-08
Ashkenazi O 0 5.235496246314142e-06
haplotype O 0 5.149553885530622e-07
, O 0 1.6139662051273262e-08
four O 0 1.441736419138806e-08
had O 0 2.220357409044027e-08
a O 0 1.5181718993062532e-08
closely O 0 8.708919807531856e-09
related O 0 1.2420244388522406e-07
pattern O 0 8.629915555502521e-07
, O 0 1.2313163821886519e-08
and O 0 6.69667077346503e-09
the O 0 1.7025369558609782e-08
rest O 0 1.050314395456553e-07
( O 0 4.955364563130615e-09
n O 0 2.149640287996135e-08
= O 0 2.7117355472228155e-08
6 O 0 2.576827569100715e-07
) O 0 5.585617302017454e-09
displayed O 0 1.0000477601579405e-07
a O 0 2.4339433579712022e-08
distinct O 0 1.3434801360290294e-07
BRCA1 O 0 2.0777322788489982e-05
allelic O 0 9.071938984561712e-05
pattern O 0 3.291401662863791e-05
. O 0 6.5147642089868896e-06

We O 0 1.2331776133578387e-06
conclude O 0 1.1214812047910527e-06
that O 0 9.777854081960413e-09
the O 0 8.92657823214904e-08
185delAG O 0 4.0653307223692536e-05
BRCA1 O 0 6.131005193310557e-06
mutation O 0 4.217212179469243e-08
occurs O 0 8.509288385027958e-09
in O 0 1.8776755705829373e-09
some O 0 6.427458010271891e-10
non O 0 4.1012350493474514e-07
- O 0 5.183279654374928e-07
Ashkenazi O 0 2.94877111173264e-07
populations O 0 1.4936480940974661e-09
at O 0 1.7100385107937655e-08
rates O 0 3.644349266807012e-09
comparable O 0 1.740300525909788e-08
with O 0 1.0172243047890106e-09
that O 0 1.7053960466029139e-09
of O 0 5.205557158660667e-07
Ashkenazim O 0 0.00019625111599452794
. O 0 2.750985004240647e-06

The O 0 4.646789420803543e-06
majority O 0 1.4746353826922132e-07
of O 0 1.1713684244796241e-07
Jewish O 0 1.3360698858377873e-06
185delAG O 0 3.2857944461284205e-05
mutation O 0 9.529026812060692e-08
carriers O 0 2.2642149488660834e-08
have O 0 1.7845760424961554e-09
a O 0 9.365628272917093e-09
common O 0 9.028043201908531e-09
allelic O 0 2.134207306880853e-06
pattern O 0 6.590160523956001e-07
, O 0 1.3186885361449185e-08
supporting O 0 5.704046568411059e-09
the O 0 1.092222490228778e-08
founder O 0 1.4978746776250773e-06
effect O 0 2.885658645368494e-08
notion O 0 3.225158451414245e-08
, O 0 3.714385021780231e-09
but O 0 3.9784808780751746e-10
dating O 0 8.855587374512197e-09
the O 0 6.000313024223658e-10
mutations O 0 3.532923398275045e-10
origin O 0 2.0881751883194966e-10
to O 0 5.832587746112949e-10
an O 0 5.342308817546382e-10
earlier O 0 9.617086682567333e-09
date O 0 3.009695248579192e-08
than O 0 3.0542859352777896e-09
currently O 0 7.681666858161407e-09
estimated O 0 3.887924648893204e-08
. O 0 3.144930929011025e-07

However O 0 1.8948936713059084e-06
, O 0 1.72458491931593e-08
the O 0 4.890538196633543e-09
different O 0 1.0848659748319278e-09
allelic O 0 1.40436816309375e-06
pattern O 0 4.560711772683135e-07
at O 0 5.00012788506865e-07
the O 0 9.843068937698263e-08
BRCA1 O 0 1.2084058198524872e-06
locus O 0 1.21465490110495e-07
even O 0 4.372109785322209e-09
in O 0 6.960869658456659e-10
some O 0 8.513646732044577e-11
Jewish O 0 8.511658045051718e-09
mutation O 0 5.950805626042666e-09
carriers O 0 1.317863862482227e-08
, O 0 5.7609672587943805e-09
might O 0 4.356210947520367e-09
suggest O 0 2.774987573062049e-09
that O 0 3.775511014936228e-10
the O 0 4.602594305680441e-09
mutation O 0 4.834502131956242e-09
arose O 0 3.008082316569016e-08
independently O 0 3.4631401746310075e-08
. O 0 6.922756767835381e-08
. O 0 5.882141067559132e-07

Crystal O 0 0.03746345266699791
structure O 0 1.495410378993256e-05
of O 0 1.2536844224086963e-05
the O 0 2.396387753833551e-05
hemochromatosis B-Disease 1 1.0
protein O 0 1.5684761820011772e-05
HFE O 1 0.9999603033065796
and O 0 2.1260802895994857e-07
characterization O 0 5.585182520917442e-07
of O 0 2.5989851337726577e-07
its O 0 3.0167239373213306e-08
interaction O 0 5.225232868610874e-08
with O 0 3.436242579368809e-08
transferrin O 0 1.2388837603793945e-05
receptor O 0 8.36533388337557e-07
. O 0 5.26508983966778e-07

HFE O 1 0.99970942735672
is O 0 1.6511964986420935e-06
an O 0 1.5899480843017955e-07
MHC O 0 0.0032745806965976954
- O 0 1.80886472662678e-05
related O 0 1.3383513532971847e-06
protein O 0 7.307942695433667e-08
that O 0 2.1656394455504824e-09
is O 0 1.5617390713984491e-09
mutated O 0 1.546836969623655e-08
in O 0 2.7942261837665683e-08
the O 0 9.418060926691396e-07
iron B-Disease 1 1.0
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.013108482584357262

HFE O 1 0.5148059129714966
binds O 0 5.03496221426758e-06
to O 0 2.2701050284013036e-07
transferrin O 0 5.843199687660672e-06
receptor O 0 2.3283513428395963e-07
( O 0 9.859133598411063e-08
TfR O 0 1.802077349566389e-05
) O 0 1.7028032317512043e-08
and O 0 6.177458100609101e-09
reduces O 0 1.6868600738462192e-08
its O 0 5.445341511034485e-09
affinity O 0 9.260170408253998e-09
for O 0 1.9552993890670223e-08
iron O 0 0.0005061303381808102
- O 0 3.344526930959546e-06
loaded O 0 1.809076138670207e-06
transferrin O 0 6.9674374572059605e-06
, O 0 2.1460336085965537e-07
implicating O 0 0.0009174012811854482
HFE O 1 0.9999982118606567
in O 0 0.0001083252063835971
iron O 1 0.9999998807907104
metabolism O 1 0.9899699091911316
. O 0 1.2207638974359725e-05

The O 0 4.921495201415382e-05
2 O 0 8.090966730378568e-05
. O 0 4.736608843813883e-06

6 O 0 0.0001398950262228027
A O 0 0.00011183582682861015
crystal O 0 0.00044281556620262563
structure O 0 4.006599283457035e-06
of O 0 1.2866839824710041e-05
HFE O 1 0.9999990463256836
reveals O 0 1.3000949365959968e-06
the O 0 2.3270965598953808e-08
locations O 0 4.574651057964729e-08
of O 0 3.3848903058242286e-06
hemochromatosis B-Disease 1 1.0
mutations O 0 6.13430529483594e-07
and O 0 1.6028324978378805e-07
a O 0 1.4190372894518077e-06
patch O 1 0.9999926090240479
of O 0 0.00022168020950630307
histidines O 1 0.9374148845672607
that O 0 5.590178986381034e-09
could O 0 5.2034887509933014e-09
be O 0 1.62146940319019e-09
involved O 0 5.625476084958336e-09
in O 0 1.0979878339867355e-07
pH O 0 6.623872650379781e-06
- O 0 6.302163001237204e-06
dependent O 0 2.0164333136563073e-07
interactions O 0 1.000341285362083e-06
. O 0 2.576525275799213e-06

We O 0 5.968438472336857e-07
also O 0 7.608586827245745e-08
demonstrate O 0 1.1572623748179467e-07
that O 0 1.2329826937218513e-08
soluble O 0 6.36498680250952e-06
TfR O 0 0.0005188180948607624
and O 0 6.742955065419665e-07
HFE O 1 0.9050528407096863
bind O 0 2.2404886124149925e-07
tightly O 0 6.09548465035914e-07
at O 0 4.697073165971233e-07
the O 0 2.517573882698798e-08
basic O 0 5.974280981035918e-08
pH O 0 2.2899922669239459e-07
of O 0 7.442859839557059e-08
the O 0 2.689072964301431e-08
cell O 0 2.4712994672881905e-07
surface O 0 1.6419321013927402e-07
, O 0 2.0047312698778796e-09
but O 0 4.797261476952031e-10
not O 0 4.992389279756537e-10
at O 0 2.6228756055957092e-08
the O 0 1.0782260417840916e-08
acidic O 0 7.203478844530764e-07
pH O 0 2.518713245081017e-06
of O 0 9.113928740589472e-07
intracellular O 0 7.846612788853236e-06
vesicles O 0 9.211862197844312e-05
. O 0 2.923022520917584e-06

TfR O 0 0.08178194612264633
HFE O 0 0.2179928869009018
stoichiometry O 0 5.2330957259982824e-05
( O 0 1.2044387176501914e-06
2 O 0 1.7432159893360222e-06
1 O 0 5.966276148683392e-07
) O 0 5.043172990326639e-09
differs O 0 7.83111353541699e-09
from O 0 1.403934835053633e-08
TfR O 0 2.7652438348013675e-06
transferrin O 0 3.9693821918262984e-07
stoichiometry O 0 2.123377242924107e-07
( O 0 8.48934789132727e-09
2 O 0 7.854722383626722e-08
2 O 0 6.868857127528827e-08
) O 0 2.1549759754435627e-09
, O 0 1.1919125686432608e-09
implying O 0 6.0273634971963475e-09
a O 0 6.749048542253888e-10
different O 0 1.5855425306021687e-10
mode O 0 1.3684704924799007e-08
of O 0 3.880099797015646e-09
binding O 0 9.07347885714671e-09
for O 0 1.7182481215627377e-08
HFE O 1 0.9818599820137024
and O 0 1.3159829848063964e-07
transferrin O 0 2.7993505682388786e-06
to O 0 5.143134274021577e-08
TfR O 0 9.239222708856687e-05
, O 0 6.398816054797862e-08
consistent O 0 1.4837452511073934e-07
with O 0 5.578633111014142e-09
our O 0 2.8088352976851638e-08
demonstration O 0 6.237475531634118e-07
that O 0 1.1373922248480994e-08
HFE O 0 0.3810969889163971
, O 0 9.376159226803793e-08
transferrin O 0 4.540584995993413e-06
, O 0 5.239624201180959e-08
and O 0 5.0496247183673404e-08
TfR O 0 5.3746989578939974e-05
form O 0 1.5550081400306226e-07
a O 0 1.1042212122447381e-07
ternary O 0 2.4606286388006993e-05
complex O 0 0.00013287128240335733
. O 0 8.873926162777934e-06

Identification O 0 5.080809387436602e-06
of O 0 1.2645082279050257e-06
three O 0 6.176187383744036e-08
novel O 0 6.832401311385183e-08
mutations O 0 2.0353898122493774e-08
and O 0 7.526082868025696e-09
a O 0 1.6238224986864225e-08
high O 0 1.3576739377185731e-07
frequency O 0 1.3873508564188342e-08
of O 0 5.289435556221633e-09
the O 0 8.655828054315862e-09
Arg778Leu O 0 9.199539817927871e-06
mutation O 0 9.681059509603074e-09
in O 0 1.1615676420717591e-08
Korean O 0 5.063840035290923e-06
patients O 0 1.9499370296216512e-07
with O 0 1.0797102589776841e-07
Wilson B-Disease 1 0.9994231462478638
disease I-Disease 1 0.9999692440032959
. O 0 3.2853820357559016e-06

Four O 0 2.9885411549912533e-06
mutations O 0 5.982086577205337e-07
- O 0 6.603211204492254e-06
- O 0 3.1041431611811277e-06
R778L O 0 1.5219403394439723e-05
, O 0 4.520138574548582e-08
A874V O 0 2.99166094919201e-06
, O 0 1.082999467882928e-08
L1083F O 0 7.606118401781714e-07
, O 0 6.2442699899634135e-09
and O 0 6.141578356988475e-09
2304delC O 0 1.2483162663556868e-06
- O 0 5.576034141085984e-07
- O 0 1.62349479637669e-07
in O 0 5.265599067882931e-09
the O 0 2.7361178212004234e-08
copper O 0 1.6244997596004396e-06
- O 0 1.6632729682442005e-07
transporting O 0 2.2657404485926236e-07
enzyme O 0 1.7491222692456176e-08
, O 0 1.7713512434625045e-08
P O 0 3.4387583127681864e-06
- O 0 4.2490000851103105e-07
type O 0 1.1293521140487428e-07
ATPase O 0 3.785743842854572e-07
( O 0 8.169176624051033e-08
ATP7B O 1 0.9996048808097839
) O 0 1.4225012279212024e-08
, O 0 1.63942537323436e-09
were O 0 2.108382801679909e-09
identified O 0 8.665375972327638e-09
in O 0 1.198730092966116e-08
Korean O 0 7.575665676995413e-06
Patients O 0 3.304671736259479e-07
with O 0 1.5221621652017348e-07
Wilson B-Disease 1 0.9999366998672485
disease I-Disease 1 0.9999587535858154
. O 0 2.5020692646648968e-06

Arg778Leu O 1 0.8832970857620239
, O 0 1.678988269304682e-06
the O 0 1.1177318981481221e-07
most O 0 8.35384472708256e-09
frequently O 0 5.2139998985012426e-09
reported O 0 6.189251777755089e-09
mutation O 0 3.1647922060784595e-09
of O 0 1.0812946982241556e-08
this O 0 4.168124179138033e-10
enzyme O 0 7.3414834211860125e-09
, O 0 5.941913183704628e-09
was O 0 3.239511059405231e-08
found O 0 1.7568552168611973e-09
in O 0 1.0775059733347803e-09
six O 0 2.3775825752636592e-09
of O 0 1.7429446330652354e-08
eight O 0 4.450459556437636e-08
unrelated O 0 2.3213341648897767e-07
patients O 0 4.280471443962597e-08
studied O 0 3.649742552624957e-07
, O 0 4.816040011235145e-09
an O 0 1.1757231854758743e-09
allele O 0 6.767782334549111e-09
frequency O 0 2.7085306442131696e-08
of O 0 1.663615591951384e-07
37 O 0 1.9613376025517937e-06
. O 0 6.6193808834214e-07

5 O 0 3.9851415749581065e-06
% O 0 4.4761009121430106e-08
, O 0 4.562119126916286e-09
which O 0 1.7772593396969683e-09
is O 0 5.666621061273247e-10
considerably O 0 1.777089808641108e-09
higher O 0 2.192371617582012e-09
than O 0 8.489987185500425e-11
those O 0 1.0849252746192306e-10
in O 0 8.474880242026472e-10
other O 0 1.2913976554784767e-09
Asian O 0 2.704184254298525e-08
populations O 0 9.9027026578824e-09
. O 0 9.246549126373793e-08

The O 0 4.065210305270739e-06
novel O 0 5.362334150049719e-07
single O 0 8.594928146976599e-08
nucleotide O 0 7.320456774095874e-08
deletion O 0 1.1976585767570214e-07
, O 0 2.5510475509804564e-08
2304delC O 0 2.589645418993314e-06
, O 0 3.3731360815636435e-08
was O 0 2.1696041585528292e-07
found O 0 1.598043652961678e-08
in O 0 1.5039057998933458e-08
one O 0 7.738744756125016e-08
patient O 0 4.517498382483609e-06
. O 0 2.22652079173713e-06

Since O 0 2.9052528134343447e-06
a O 0 8.86343229922204e-08
mutation O 0 2.8194952150784047e-08
at O 0 1.8219526509710704e-07
cDNA O 0 2.7874213515133306e-07
nucleotide O 0 5.077086484561733e-07
2302 O 0 4.166426515439525e-05
( O 0 3.8279257097428854e-08
2302insC O 0 1.524956246612419e-06
) O 0 6.07169425848042e-09
had O 0 5.8021663029705906e-09
been O 0 3.5849345714211722e-09
previously O 0 2.435824342228443e-08
described O 0 2.660574516255565e-08
, O 0 1.9881365442842025e-09
this O 0 1.8918745736673515e-10
region O 0 5.969722494114649e-09
of O 0 1.753555167738341e-08
the O 0 8.342971824504275e-08
ATP7B O 1 0.9999998807907104
gene O 0 1.7018315645600524e-07
may O 0 7.91851384462916e-09
be O 0 3.0114104543343956e-09
susceptible O 0 4.601973273565818e-07
to O 0 3.8251592116012034e-08
gene O 0 2.6993200208380586e-06
rearrangements O 0 0.005965475924313068
causing O 1 0.9966212511062622
Wilson B-Disease 1 0.999969482421875
disease I-Disease 1 0.9998388290405273
. O 0 1.8390867353446083e-06

Disruption O 0 0.00021525376359932125
of O 0 8.622432687843684e-06
splicing O 0 4.709291715698782e-06
regulated O 0 3.3586150038900087e-07
by O 0 2.7815493908178723e-08
a O 0 1.6117473933263682e-07
CUG O 1 0.999531626701355
- O 0 3.2458185614814283e-06
binding O 0 2.526861635487876e-07
protein O 0 5.023016456107143e-07
in O 0 5.96970721744583e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0005381809896789491

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9997817873954773
DM B-Disease 1 1.0
) O 0 1.5641220670659095e-05
is O 0 3.567753381616967e-08
caused O 0 1.222972656478305e-07
by O 0 7.586773875800645e-09
a O 0 7.659330236720052e-08
CTG O 0 0.00024088688951451331
expansion O 0 2.0551276236346894e-07
in O 0 1.0102061409611451e-08
the O 0 1.4476222887083168e-08
3 O 0 2.2649193454071792e-07
untranslated O 0 3.778835525736213e-05
region O 0 1.0295340047150603e-07
of O 0 1.8668033874291723e-07
the O 0 2.3976249394763727e-06
DM B-Disease 1 1.0
gene O 0 1.897361289593391e-05
. O 0 2.3515979137300747e-06

One O 0 4.841564305024804e-07
model O 0 2.0753547858021193e-07
of O 0 6.6674192567006685e-06
DM B-Disease 1 1.0
pathogenesis O 1 0.9995983242988586
suggests O 0 2.5829314154179883e-07
that O 0 1.7238211968972905e-09
RNAs O 0 2.240305008172072e-07
from O 0 6.884515180161088e-09
the O 0 1.8764689801997747e-09
expanded O 0 1.1033239211144519e-08
allele O 0 1.942718874659022e-09
create O 0 2.214392891275452e-09
a O 0 1.048858599972391e-08
gain O 0 6.354181181222884e-08
- O 0 1.864963365960648e-07
of O 0 1.201622836788374e-07
- O 0 3.3798121990002983e-07
function O 0 4.67095651046634e-09
mutation O 0 8.876450130479441e-10
by O 0 4.0909683973744393e-10
the O 0 1.798696303012548e-09
inappropriate O 0 7.455359885000234e-09
binding O 0 5.13261610990412e-09
of O 0 1.9732642186909288e-08
proteins O 0 2.8397815210468025e-09
to O 0 1.675451244409487e-08
the O 0 6.233931344468147e-07
CUG O 1 0.9998854398727417
repeats O 0 1.462251202610787e-05
. O 0 1.665947820583824e-06

Data O 0 3.136716713925125e-06
presented O 0 1.8317699641556828e-06
here O 0 3.7229902716262586e-08
indicate O 0 1.4633291911536617e-08
that O 0 6.56884602268093e-10
the O 0 2.2915502828624312e-09
conserved O 0 5.745344822116749e-08
heterogeneous O 0 3.6130953162683e-07
nuclear O 0 3.292824112577364e-05
ribonucleoprotein O 0 0.0002873544581234455
, O 0 1.4151531502193393e-07
CUG O 0 0.025769565254449844
- O 0 4.470213923468691e-07
binding O 0 2.9617797991932093e-08
protein O 0 5.4230905988106315e-08
( O 0 2.2282312883703526e-08
CUG O 1 0.9993764758110046
- O 0 1.5276844351319596e-05
BP O 0 0.00018740480300039053
) O 0 2.8699382426111697e-08
, O 0 8.830320474828568e-09
may O 0 1.2093583912076156e-08
mediate O 0 1.1758196194477932e-07
the O 0 8.218123781489339e-08
trans O 0 5.995971150696278e-07
- O 0 1.1083902791142464e-06
dominant O 0 1.2936693849496805e-07
effect O 0 2.5651775814594657e-08
of O 0 5.4865562759687236e-08
the O 0 4.907285244826198e-08
RNA O 0 2.373384859311045e-06
. O 0 3.98699711467998e-07

CUG O 1 0.999983549118042
- O 0 0.004715472459793091
BP O 0 0.011680640280246735
was O 0 2.5986555556301028e-06
found O 0 1.3744293703155108e-08
to O 0 1.4663795733227403e-09
bind O 0 5.240800682315694e-09
to O 0 4.263569941542755e-09
the O 0 2.446309643744371e-08
human O 0 3.4684822480812727e-07
cardiac O 1 0.9999996423721313
troponin O 1 0.9999994039535522
T O 1 0.9999477863311768
( O 0 1.3794422670798667e-07
cTNT O 0 8.337376129929908e-06
) O 0 8.594235545444917e-09
pre O 0 5.046682417741977e-06
- O 0 9.164078278445231e-07
messenger O 0 2.3125531356527063e-07
RNA O 0 2.569338164448709e-07
and O 0 5.546358483599079e-09
regulate O 0 2.0251741617016705e-08
its O 0 2.089376494041062e-08
alternative O 0 4.3396354953983973e-07
splicing O 0 8.139916644722689e-06
. O 0 6.702475161546317e-07

Splicing O 0 6.857782136648893e-05
of O 0 2.2756137695978396e-05
cTNT O 0 0.0014348960248753428
was O 0 4.473268290894339e-06
disrupted O 0 1.4513190762954764e-05
in O 0 1.6848426866999944e-06
DM B-Disease 1 1.0
striated O 1 0.9649967551231384
muscle O 0 1.623845128051471e-05
and O 0 6.00781930870653e-08
in O 0 2.880472926847233e-08
normal O 0 1.186486926485486e-07
cells O 0 1.9575496779111745e-08
expressing O 0 9.154137003974938e-09
transcripts O 0 3.40228467621273e-07
that O 0 1.1053333359711814e-08
contain O 0 1.6357817003154196e-06
CUG O 1 0.9999430179595947
repeats O 0 1.039341077557765e-05
. O 0 1.3394788993537077e-06

Altered O 0 1.2995621545996983e-05
expression O 0 2.4327164283022285e-07
of O 0 1.527723441085982e-07
genes O 0 1.1917449249665424e-08
regulated O 0 2.1337443456559413e-07
posttranscriptionally O 0 2.1065219698357396e-05
by O 0 3.190790494045359e-07
CUG O 1 0.9999998807907104
- O 0 0.00047230321797542274
BP O 0 0.00017644205945543945
therefore O 0 3.911473811513133e-08
may O 0 1.9885890267801187e-08
contribute O 0 3.428785433357007e-08
to O 0 3.5522793950804044e-07
DM B-Disease 1 1.0
pathogenesis O 1 0.999774158000946
. O 0 7.924649025881081e-07
. O 0 5.09658775627031e-07

Identification O 0 5.858381882717367e-06
of O 0 1.5275311397999758e-06
a O 0 1.1602450200598469e-07
novel O 0 2.950433497517224e-07
nonsense O 0 3.4244110338477185e-06
mutation O 0 5.843461536869654e-08
and O 0 9.003606749047322e-09
a O 0 7.657297018681675e-09
missense O 0 8.505981696771414e-08
substitution O 0 9.560667990626825e-08
in O 0 3.873165965728731e-08
the O 0 4.822136645543651e-08
vasopressin O 0 2.292547378601739e-06
- O 0 5.1551833166740835e-06
neurophysin O 0 0.0002858864900190383
II O 1 1.0
gene O 0 1.395843725049417e-07
in O 0 2.3080577449263728e-08
two O 0 1.0383923054746447e-08
Spanish O 0 1.005469698611705e-06
kindreds O 0 3.1375453545479104e-05
with O 0 4.6192448621695803e-07
familial B-Disease 1 0.9817516207695007
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999995231628418
. O 0 0.00010538363858358935

Familial B-Disease 1 0.9999829530715942
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 1 0.8059118390083313
FNDI B-Disease 1 1.0
) O 0 8.336846235579287e-07
is O 0 1.7653745132406584e-08
an O 0 1.4016980465214601e-08
autosomal B-Disease 1 0.9999464750289917
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
caused O 1 0.9930769205093384
by O 0 8.885908755473793e-06
deficiency O 1 0.9999946355819702
in O 0 6.885765060360427e-07
the O 0 1.1729104016922065e-06
antidiuretic O 0 7.222589192679152e-05
hormone O 0 5.155537110113073e-06
arginine O 0 7.519365226471564e-06
vasopressin O 0 3.8083178424130892e-06
( O 0 4.795107884092431e-07
AVP O 1 0.7762765884399414
) O 0 2.3955369243822133e-08
encoded O 0 1.0758061108617767e-08
by O 0 7.1146870617155855e-09
the O 0 9.977824078077902e-08
AVP O 1 0.9951091408729553
- O 0 2.0695686544058844e-05
neurophysin O 0 0.002487818244844675
II O 1 1.0
( O 0 3.416566187297576e-06
AVP O 1 0.9999687671661377
- O 0 4.840833571506664e-05
NPII O 1 0.9922612309455872
) O 0 8.59114237528047e-08
gene O 0 5.5735309700821745e-08
on O 0 2.3201279475415504e-07
chromosome O 0 1.737675574986497e-06
20p13 O 0 5.7655553973745555e-05
. O 0 2.2536946744367015e-06

In O 0 9.686360726846033e-07
this O 0 1.1265838928409266e-08
study O 0 3.137758497473442e-08
, O 0 3.605712839416242e-09
we O 0 4.868348502107267e-10
analyzed O 0 8.169298126858848e-09
two O 0 7.736169482797095e-10
families O 0 7.844294658276851e-10
with O 0 9.40266087212649e-09
FNDI B-Disease 1 1.0
using O 0 1.5560637223188678e-08
direct O 0 9.080334706368376e-09
automated O 0 4.4952830080546846e-07
fluorescent O 0 1.2107301472497056e-06
, O 0 1.0706089348389014e-08
solid O 0 1.306187868976849e-07
phase O 0 4.587946307310631e-07
, O 0 5.9191322954177394e-09
single O 0 8.939591289447435e-09
- O 0 4.668687481057532e-08
stranded O 0 2.239727692199267e-08
DNA O 0 3.5692508504325815e-08
sequencing O 0 1.499889457079462e-08
of O 0 3.8635889154647884e-08
PCR O 0 9.898597454593983e-06
- O 0 7.4188246799167246e-06
amplified O 0 0.00010568019206402823
AVP O 1 0.999707043170929
- O 0 0.0001752307143760845
NPII O 1 0.9989145994186401
DNA O 0 7.63351417845115e-05
. O 0 1.4895044841978233e-06

In O 0 7.962345307532814e-07
one O 0 3.125114034219223e-08
of O 0 6.35215755551144e-08
the O 0 2.4718151081515316e-08
families O 0 2.556291844868497e-09
, O 0 5.439269035178995e-09
affected O 0 3.87277276914233e-09
individuals O 0 5.331904917582619e-10
presented O 0 5.62864528319551e-08
a O 0 2.003551102802703e-08
novel O 0 4.1926064398012386e-08
nonsense O 0 3.788824756156828e-07
mutation O 0 5.206496567211616e-09
in O 0 7.630877263409275e-09
exon O 0 2.7360428589418007e-07
3 O 0 4.3251578318859174e-08
of O 0 2.0499415498420603e-08
the O 0 1.2549292272012735e-08
gene O 0 7.766467469139116e-09
, O 0 1.802336502265689e-09
consisting O 0 9.943243561849613e-09
in O 0 8.541549689766725e-09
a O 0 3.999544873067862e-08
G O 0 2.1821862901560962e-05
to O 0 1.867348089490406e-07
T O 0 0.002463745418936014
transition O 0 6.187985377437144e-07
at O 0 5.004187073609501e-07
nucleotide O 0 3.0849554377709865e-07
2101 O 0 3.9314192690653726e-05
, O 0 1.8237463095260864e-08
which O 0 3.882350441131166e-09
produces O 0 2.2173059832653053e-08
a O 0 5.348877785138484e-09
stop O 0 4.795309038740925e-08
signal O 0 7.496343812363193e-08
in O 0 7.2486212587818954e-09
codon O 0 2.754728996023914e-07
82 O 0 1.040456140799506e-06
( O 0 1.376178317968879e-07
Glu O 1 0.9954922199249268
) O 0 3.289942753781361e-07
of O 0 6.191761713125743e-06
NPII O 1 0.999997615814209
. O 0 1.0556588676990941e-05

The O 0 2.4540342565160245e-05
premature O 0 2.6539848477113992e-05
termination O 0 2.9481177534762537e-06
eliminates O 0 1.950548494278337e-06
part O 0 1.4627173072767619e-07
of O 0 6.849834477407057e-08
the O 0 8.013891772407078e-08
C O 0 3.945594289689325e-05
- O 0 2.359412718533349e-07
terminal O 0 3.556569794227471e-08
domain O 0 4.494457250814321e-09
of O 0 4.0958909153232526e-08
NPII O 1 0.6032752990722656
, O 0 1.637404345444793e-08
including O 0 7.91777399200555e-09
a O 0 1.5597215963225608e-08
cysteine O 0 1.9248170701757772e-07
residue O 0 1.6789608707767911e-06
in O 0 2.2767345342344925e-08
position O 0 2.5321513774656523e-08
85 O 0 1.235542015365354e-07
, O 0 3.4722991149038762e-09
which O 0 9.177908433244397e-10
could O 0 1.349496292490926e-09
be O 0 6.869414481691649e-10
involved O 0 1.7387137285496124e-09
in O 0 5.922700552218885e-09
the O 0 8.54189163845831e-09
correct O 0 8.3662854422073e-08
folding O 0 1.0001523378377897e-06
of O 0 3.268810644385667e-07
the O 0 1.5472626273549395e-06
prohormone O 0 0.021139414981007576
. O 0 2.819724159053294e-06

In O 0 1.8033503010883578e-06
the O 0 3.302431821339269e-07
second O 0 9.656126849222346e-07
family O 0 3.999529951670411e-08
, O 0 1.0394920479939174e-08
a O 0 1.0362277258479935e-08
G279A O 0 6.63928915400902e-07
substitution O 0 1.1718790915438149e-07
at O 0 1.7910923588715377e-07
position O 0 4.927957775180403e-08
- O 0 7.70622250456654e-08
1 O 0 2.293147360887815e-08
of O 0 9.346515561503566e-09
the O 0 6.707447486320461e-09
signal O 0 7.236123167331243e-08
peptide O 0 1.1146745748646936e-07
was O 0 4.2475008399378567e-08
observed O 0 4.597023206542872e-09
in O 0 2.417079425498514e-09
all O 0 1.880855027280859e-09
affected O 0 2.0470970696351287e-08
individuals O 0 1.1298590507635708e-08
. O 0 4.822109076485503e-07

This O 0 6.204364808581886e-07
missense O 0 1.0973385542456526e-05
mutation O 0 4.849951551477716e-07
, O 0 1.2676220251250925e-07
which O 0 8.099159742869233e-08
replaces O 0 0.00011120564886368811
Ala O 0 0.0015828408068045974
with O 0 1.9900141978723696e-07
Thr O 1 0.9999964237213135
, O 0 1.388937391766376e-07
is O 0 4.195548353180811e-09
frequent O 0 1.8326346662433934e-08
among O 0 1.4910889944985684e-07
FNDI B-Disease 1 1.0
patients O 0 3.2885420750972116e-06
and O 0 4.5835683692985185e-08
is O 0 1.3680529598047997e-08
thought O 0 1.4330237441129157e-08
to O 0 2.8852937816736812e-09
reduce O 0 1.4411068782749226e-08
the O 0 6.8947652032136375e-09
efficiency O 0 5.644987055575257e-08
of O 0 4.5738921983229375e-08
cleavage O 0 2.0137581202561705e-07
by O 0 1.5627678706664483e-08
signal O 0 1.5260168311215239e-06
peptidases O 0 2.481985757185612e-05
. O 0 2.562945837780717e-07
. O 0 6.136768888609367e-07

Genetic O 0 1.171378607978113e-05
heterogeneity O 0 1.399943903379608e-05
of O 0 2.0894674889859743e-05
Saethre B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 3.803225752108119e-07
due O 0 2.0793595467694104e-06
to O 0 1.2659114645430236e-07
TWIST O 0 0.00028167880373075604
and O 0 9.473858995079354e-07
FGFR O 1 0.9999961853027344
mutations O 0 5.925567165832035e-06
. O 0 1.7391610072081676e-06

Thirty O 0 0.00020849845896009356
- O 0 1.5985879144864157e-05
two O 0 6.407524466567338e-08
unrelated O 0 1.1809097486548126e-06
patients O 0 6.991079715135129e-08
with O 0 5.013738313408567e-09
features O 0 3.364455949395051e-07
of O 0 3.091243343078531e-05
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 2.0524460353499308e-07
a O 0 1.1010139644440642e-07
common O 0 1.6932543758230167e-06
autosomal B-Disease 0 0.3581969141960144
dominant I-Disease 0 0.07935153692960739
condition I-Disease 0 0.019067110493779182
of O 1 0.9916159510612488
craniosynostosis B-Disease 1 1.0
and O 0 0.029522720724344254
limb B-Disease 1 1.0
anomalies I-Disease 1 0.999736487865448
, O 0 2.150389093458216e-07
were O 0 4.366844663650227e-08
screened O 0 9.266057787726822e-08
for O 0 2.299834767072184e-09
mutations O 0 1.9996724276438727e-08
in O 0 6.613569780711259e-08
TWIST O 0 4.8823407269082963e-05
, O 0 2.8620183911698405e-07
FGFR2 O 1 0.9999889135360718
, O 0 5.782039806945249e-07
and O 0 7.6389619607653e-07
FGFR3 O 1 0.9999101161956787
. O 0 6.387472694768803e-06

Nine O 0 2.341796971450094e-05
novel O 0 1.754373442963697e-06
and O 0 1.0331969235721772e-07
three O 0 1.489244283447988e-07
recurrent O 0 0.00024387075973208994
TWIST O 0 0.0001070273865479976
mutations O 0 1.7278946984333743e-07
were O 0 2.775126617393653e-08
found O 0 1.2479664412978764e-08
in O 0 1.036658670017232e-08
12 O 0 7.752129249638529e-08
families O 0 1.2121456727243185e-08
. O 0 4.396899271341681e-07

Seven O 0 3.1063227652339265e-06
families O 0 8.645697491260762e-09
were O 0 2.059068116011531e-08
found O 0 3.976714957332206e-09
to O 0 1.0591388877045915e-09
have O 0 8.115249583440232e-10
the O 0 5.0294008957507685e-08
FGFR3 O 1 0.9999544620513916
P250R O 0 2.111644971591886e-05
mutation O 0 1.002681599970856e-07
, O 0 8.836251730315325e-09
and O 0 5.580591100340371e-09
one O 0 1.1811807087980242e-09
individual O 0 1.2180316755205922e-09
was O 0 1.887015486090604e-07
found O 0 2.64144972561553e-09
to O 0 8.273856044738181e-10
have O 0 1.0171815612025625e-09
an O 0 5.269909397753736e-09
FGFR2 O 1 0.9993985891342163
VV269 O 0 7.779287989251316e-05
- O 0 1.100997906178236e-05
270 O 0 1.8150967662222683e-06
deletion O 0 3.905710400431417e-06
. O 0 2.0854884041909827e-06

To O 0 3.4485276501072804e-07
date O 0 3.820911842922214e-06
, O 0 4.041460499593086e-08
our O 0 1.0555958773750262e-08
detection O 0 1.641488864834173e-07
rate O 0 4.288837729404804e-09
for O 0 1.366492807797215e-09
TWIST O 0 1.4989677765697706e-06
or O 0 9.211553475552137e-08
FGFR O 1 0.7370713353157043
mutations O 0 4.633009353938178e-08
is O 0 5.945496095449698e-09
68 O 0 1.4816413340668078e-07
% O 0 2.6005773090531648e-09
in O 0 6.690874965187277e-09
our O 0 1.262317539385549e-07
Saethre B-Disease 1 0.9999978542327881
- I-Disease 1 0.9999992847442627
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 5.370867256715428e-06
, O 0 4.136007092370164e-08
including O 0 1.4056556096875283e-07
our O 0 2.7593063123276806e-07
five O 0 1.680370900203343e-07
patients O 0 1.3861492220712535e-07
elsewhere O 0 1.2786902914285747e-07
reported O 0 1.1369784402859295e-07
with O 0 4.0554446911755804e-08
TWIST O 0 0.0011329903500154614
mutations O 0 4.156944214628311e-06
. O 0 2.1342193576856516e-06

More O 0 1.5808899433977786e-07
than O 0 2.7351523712582093e-08
35 O 0 7.324381101625477e-08
different O 0 1.3639565032974588e-09
TWIST O 0 1.6200750678763143e-06
mutations O 0 1.3192571479692106e-08
are O 0 4.740376979839311e-10
now O 0 4.788268892497172e-09
known O 0 5.747391451649264e-09
in O 0 3.4348512922832697e-09
the O 0 1.388417736336578e-08
literature O 0 4.665607775677927e-07
. O 0 2.9319127747839957e-07

The O 0 3.0037508622626774e-06
most O 0 5.5817970689986396e-08
common O 0 1.865660159694471e-08
phenotypic O 0 5.314132778266867e-08
features O 0 5.0940464291215903e-08
, O 0 5.908078914984571e-09
present O 0 3.3405322952262395e-09
in O 0 3.453942909459329e-09
more O 0 3.2204344746489255e-10
than O 0 4.4820422373526014e-10
a O 0 2.521282294054572e-09
third O 0 4.921307450445056e-08
of O 0 2.855844627447368e-08
our O 0 1.875550204033516e-08
patients O 0 1.3343143479005448e-08
with O 0 2.1298371954969753e-09
TWIST O 0 2.7884130759048276e-05
mutations O 0 3.728185049567401e-08
, O 0 1.1880365136107685e-08
are O 0 3.249732927201876e-09
coronal B-Disease 0 0.006248171906918287
synostosis I-Disease 0 0.0002718501491472125
, O 0 1.7139595342996472e-07
brachycephaly B-Disease 0 0.0003227459092158824
, O 0 4.2825294599424524e-07
low B-Disease 0 0.00022678158711642027
frontal I-Disease 1 0.9999992847442627
hairline I-Disease 1 0.9999996423721313
, O 0 2.765694944173447e-06
facial B-Disease 1 0.9999779462814331
asymmetry I-Disease 0 0.00273175654001534
, O 0 1.0153174116567243e-05
ptosis B-Disease 1 0.999983549118042
, O 0 3.892565473506693e-06
hypertelorism B-Disease 0 0.3677274286746979
, O 0 6.500599738501478e-07
broad B-Disease 0 6.581859452126082e-06
great I-Disease 0 0.008551854640245438
toes I-Disease 0 0.002647393848747015
, O 0 5.542696612792497e-07
and O 0 8.940156703829416e-07
clinodactyly B-Disease 0 0.026625238358974457
. O 0 4.84053407490137e-06

Significant O 0 1.5829440599191003e-05
intra O 0 0.0004613737983163446
- O 0 4.1196875827154145e-05
and O 0 2.2062160098812456e-07
interfamilial O 0 3.0400358809856698e-05
phenotypic O 0 1.3388619208853925e-06
variability O 0 1.1669536661429447e-06
is O 0 7.492252152019319e-09
present O 0 9.817902046904692e-09
for O 0 5.211175935215806e-09
either O 0 9.137637846379221e-08
TWIST O 0 0.00010456870222697034
mutations O 0 2.8759777137565834e-07
or O 0 7.483999411306286e-07
FGFR O 1 0.9999926090240479
mutations O 0 5.087432782602264e-06
. O 0 3.0509156658808934e-06

The O 0 2.001906523219077e-06
overlap O 0 2.7056319140683627e-07
in O 0 2.516229713478424e-08
clinical O 0 6.702103974021156e-07
features O 0 4.431096911616805e-08
and O 0 3.742189669253548e-09
the O 0 7.71373276364784e-09
presence O 0 7.606523411141097e-09
, O 0 1.3153168554325134e-09
in O 0 6.236126059988578e-10
the O 0 8.204208978845884e-10
same O 0 2.1755167112225138e-10
genes O 0 2.355230455108881e-10
, O 0 2.7685681525113637e-10
of O 0 2.815635058439625e-09
mutations O 0 1.5161801814045361e-09
for O 0 1.1886207573752472e-09
more O 0 4.871135161899076e-10
than O 0 9.809455470133344e-10
one O 0 1.1059575477645467e-08
craniosynostotic B-Disease 0 1.679234264884144e-05
condition I-Disease 0 5.729683607569314e-07
- O 0 4.472315993098164e-07
such O 0 1.2206069044395917e-08
as O 0 6.465223378882001e-08
Saethre B-Disease 0 0.0002699399774428457
- I-Disease 0 5.692979357263539e-06
Chotzen I-Disease 0 0.0001455248420825228
, I-Disease 0 7.161224147012035e-08
Crouzon I-Disease 0 3.686071795527823e-05
, I-Disease 0 4.062792058334708e-08
and I-Disease 0 1.6513997991296492e-07
Pfeiffer I-Disease 1 0.9974157810211182
syndromes I-Disease 1 0.998819887638092
- O 0 2.9103555789333768e-05
support O 0 5.019080262513853e-08
the O 0 5.4414719841133774e-08
hypothesis O 0 4.178412638111695e-08
that O 0 1.7853999390027298e-09
TWIST O 0 1.4206974583430565e-06
and O 0 1.8998715489715323e-08
FGFRs O 0 1.399554093950428e-05
are O 0 1.0562096752764205e-09
components O 0 1.1214818584903696e-07
of O 0 5.1057092775863566e-08
the O 0 1.3286104660892306e-08
same O 0 2.3535791093820535e-09
molecular O 0 5.7880210846406044e-08
pathway O 0 1.0150811746711952e-08
involved O 0 2.0263710709400584e-09
in O 0 2.2556574386101147e-09
the O 0 4.2786569842689914e-09
modulation O 0 4.28004689467798e-08
of O 0 1.0139066262127017e-06
craniofacial O 1 1.0
and O 0 2.1738303985330276e-05
limb O 1 0.9999966621398926
development O 0 4.1512890902595245e-07
in O 0 1.4902374800840335e-07
humans O 0 5.150201687342815e-08
. O 0 1.7543179353651794e-08
. O 0 1.8751467223410145e-07

Mutation O 0 3.2215025385085028e-06
analysis O 0 3.882589965087391e-07
of O 0 5.513576525117969e-06
UBE3A O 1 1.0
in O 1 0.998513400554657
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9804425835609436
. O 0 3.993160498794168e-05

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.012938912026584148
AS B-Disease 1 1.0
) O 0 5.164716867511743e-07
is O 0 1.2779120872608019e-08
caused O 0 6.744897973476327e-08
by O 0 8.615605118222902e-09
chromosome O 0 1.24724479633187e-07
15q11 O 0 5.650546427204972e-06
- O 0 1.6018957467167638e-06
q13 O 0 2.2910110146767693e-06
deletions O 0 1.0433798536269023e-07
of O 0 9.078313212285138e-08
maternal O 0 1.1458335080760662e-07
origin O 0 6.796668117203808e-09
, O 0 6.055803414284355e-09
by O 0 7.3094450492305896e-09
paternal O 0 1.654800257711031e-06
uniparental B-Disease 1 0.9811828136444092
disomy I-Disease 1 0.689166247844696
( O 0 2.7751882498705527e-06
UPD B-Disease 1 1.0
) O 0 1.1614528006020919e-07
15 O 0 8.100781911934973e-08
, O 0 3.042500029692974e-09
by O 0 5.697576632712753e-09
imprinting O 0 0.00021676818141713738
defects O 1 0.6374967694282532
, O 0 4.1374903503310634e-08
and O 0 8.572838439135921e-09
by O 0 5.282932313832589e-09
mutations O 0 2.168910562261317e-08
in O 0 3.165977346952786e-08
the O 0 2.7785435463556496e-07
UBE3A O 1 0.9998382329940796
gene O 0 3.356979732416221e-06
. O 0 1.146258000517264e-06

UBE3A O 1 0.6053503155708313
encodes O 0 1.1478068699943833e-05
a O 0 1.152471895693452e-06
ubiquitin O 0 1.415324913978111e-05
- O 0 4.157333023613319e-06
protein O 0 8.209225654809416e-08
ligase O 0 7.71035956859123e-07
and O 0 1.296864979849488e-07
shows O 0 1.0623988373481552e-06
brain O 0 0.00021598153398372233
- O 0 4.299522061046446e-06
specific O 0 1.7696990539661783e-07
imprinting O 0 6.895855767652392e-05
. O 0 2.6032271307485644e-06

Here O 0 3.5224281873524887e-06
we O 0 1.0148995954750717e-07
describe O 0 6.078649334995134e-07
UBE3A O 0 0.46512770652770996
coding O 0 9.425174539501313e-06
- O 0 6.435544491978362e-06
region O 0 1.1857652282287745e-07
mutations O 0 3.574407969608728e-08
detected O 0 1.1457395743263987e-07
by O 0 6.0686722314073904e-09
SSCP O 0 0.0007710724021308124
analysis O 0 9.379017562594072e-09
in O 0 1.0981969111867329e-08
13 O 0 2.488227437424939e-07
AS B-Disease 0 0.02201858162879944
individuals O 0 4.408552634060925e-09
or O 0 6.786605410979973e-08
families O 0 8.484366276206856e-08
. O 0 1.159831754193874e-06

Two O 0 9.111686267715413e-07
identical O 0 5.746172519138781e-06
de O 0 2.6643669116310775e-05
novo O 0 3.086992001044564e-05
5 O 0 2.216825350842555e-06
- O 0 1.7330912669422105e-06
bp O 0 1.1773214509958052e-06
duplications O 0 1.8058200339510222e-06
in O 0 7.463188467227155e-08
exon O 0 2.2319227355183102e-06
16 O 0 3.523791747284122e-07
were O 0 6.481236880517827e-08
found O 0 1.7388778417171125e-07
. O 0 5.62684647320566e-07

Among O 0 1.641696940168913e-06
the O 0 1.0554050788869063e-07
other O 0 1.3031142387376349e-08
11 O 0 5.260422142328025e-08
unique O 0 3.717432806027432e-09
mutations O 0 6.130389973435513e-09
, O 0 6.510027628081616e-09
8 O 0 4.841684031475779e-08
were O 0 2.6991124890685114e-09
small O 0 1.7578205557811089e-09
deletions O 0 2.262682130549365e-08
or O 0 1.2306213825752366e-08
insertions O 0 5.382919994190161e-07
predicted O 0 2.2486679540634213e-07
to O 0 1.5724914703696413e-08
cause O 0 9.558312967783422e-07
frameshifts O 0 0.00042966159526258707
, O 0 8.880624591256492e-08
1 O 0 1.6335945929313311e-07
was O 0 9.20340497145844e-08
a O 0 5.030587946208698e-09
mutation O 0 1.466466170718661e-09
to O 0 1.1465199900584366e-09
a O 0 7.97238808303291e-09
stop O 0 7.075310293203074e-08
codon O 0 2.1266764349547884e-07
, O 0 7.749080488395066e-09
1 O 0 7.753859421200104e-08
was O 0 5.768689703700147e-08
a O 0 6.664471641215641e-09
missense O 0 1.0140868766939093e-07
mutation O 0 1.362074986133166e-08
, O 0 5.7082258919649576e-09
and O 0 8.276369811710538e-09
1 O 0 2.1201134359216667e-07
was O 0 2.8061424472980434e-07
predicted O 0 3.0534778261426254e-08
to O 0 2.1723831622466605e-09
cause O 0 2.089814898909026e-08
insertion O 0 8.431340603465287e-08
of O 0 8.171779342092123e-08
an O 0 7.675633462156384e-09
isoleucine O 0 6.593230864382349e-06
in O 0 5.713893003189696e-08
the O 0 3.0929793837231045e-08
hect O 0 2.003694362429087e-06
domain O 0 1.2223355660978541e-08
of O 0 2.0230006114729804e-08
the O 0 4.614295789906464e-08
UBE3A O 0 0.0029906597919762135
protein O 0 5.4699111018408075e-08
, O 0 3.442341300896601e-09
which O 0 6.433860666454905e-10
functions O 0 2.7341808817027413e-09
in O 0 9.906027997885758e-09
E2 O 0 1.4404590729100164e-05
binding O 0 6.421483789154081e-08
and O 0 8.372127524580719e-08
ubiquitin O 0 2.428357220196631e-06
transfer O 0 3.577444431357435e-06
. O 0 3.122741873085033e-06

Eight O 0 5.534986485145055e-06
of O 0 1.120882416216773e-06
the O 0 5.3128456301010374e-08
cases O 0 4.970680755889134e-09
were O 0 6.878687397460226e-09
familial O 0 2.512324499548413e-07
, O 0 2.5935051439773815e-08
and O 0 6.487938186694464e-09
five O 0 2.1840168784592606e-08
were O 0 3.103592760567153e-08
sporadic O 0 2.197364437961369e-06
. O 0 6.317420115919958e-07

In O 0 1.4050968957235455e-06
two O 0 8.3809155171366e-08
familial O 0 9.421879667570465e-07
cases O 0 4.2819742418487294e-08
and O 0 2.517823460834734e-08
one O 0 1.687947914774668e-08
sporadic O 0 3.1441152259503724e-07
case O 0 3.919748792213795e-08
, O 0 1.9916901905503437e-08
mosaicism O 0 1.4609715435653925e-05
for O 0 6.412403052991067e-08
UBE3A O 1 0.9986279010772705
mutations O 0 1.0138103334611515e-07
was O 0 1.8686201030959637e-07
detected O 0 1.0759891466705085e-07
in O 0 2.39678787927744e-09
the O 0 7.076548680373662e-09
mother O 0 1.0086504964590404e-08
of O 0 3.2666317650864585e-08
three O 0 2.0092073782507214e-08
AS B-Disease 1 0.9999935626983643
sons O 0 1.0124331311089918e-05
, O 0 1.5578425660578432e-08
in O 0 3.0690954222478695e-09
the O 0 6.601455382337917e-09
maternal O 0 7.974688998046986e-08
grandfather O 0 5.550800779019482e-07
of O 0 1.5396645380860718e-07
two O 0 1.4630669120663242e-08
AS B-Disease 1 0.8962920308113098
first O 0 1.5232311056934122e-07
cousins O 0 3.894463986853225e-07
, O 0 5.53809220704693e-09
and O 0 4.183442037231089e-09
in O 0 6.889691039901891e-09
the O 0 2.3379028490921883e-08
mother O 0 4.406419407132489e-08
of O 0 1.3557034606037632e-07
an O 0 3.2576096486991446e-08
AS B-Disease 1 0.9999998807907104
daughter O 0 0.00021805858705192804
. O 0 2.0591426164173754e-06

The O 0 1.3314056559465826e-06
frequencies O 0 1.903116384482928e-07
with O 0 3.2523621573687933e-09
which O 0 1.8615786689935021e-09
we O 0 6.131275487319954e-10
detected O 0 1.9557321095931002e-08
mutations O 0 1.9655814753605227e-09
were O 0 4.206910819704035e-09
5 O 0 1.7992871192973325e-08
( O 0 1.7152610443105232e-09
14 O 0 9.499063757800741e-09
% O 0 2.398743981224527e-10
) O 0 1.0640222036784053e-10
of O 0 2.9528379741350363e-09
35 O 0 1.399379279121149e-08
in O 0 1.8052401795642936e-09
sporadic O 0 3.6455745089369884e-08
cases O 0 2.4669908338381674e-09
and O 0 4.233926098606844e-09
8 O 0 1.0533155858638565e-07
( O 0 3.578431106987523e-09
80 O 0 2.317798575290908e-08
% O 0 8.845976728899529e-10
) O 0 1.9351144298074274e-10
of O 0 5.063172103803026e-09
10 O 0 1.8113942346076328e-08
in O 0 1.5046001777818674e-08
familial O 0 7.973948754624871e-07
cases O 0 4.4802177967540047e-08
. O 0 9.25752488001308e-08
. O 0 4.947066258864652e-07

The O 0 0.00013951842265669256
hemochromatosis B-Disease 1 1.0
845 O 0 0.00048505939776077867
G O 0 0.0018812131602317095
- O 0 6.679048965452239e-05
- O 0 1.078762306860881e-05
> O 0 5.73312775031809e-07
A O 0 3.995725421646057e-07
and O 0 7.426308457070263e-09
187 O 0 5.7430220579135494e-08
C O 0 3.1371473596664146e-06
- O 0 1.087315922632115e-06
- O 0 1.2215732567710802e-06
> O 0 5.357733243727125e-07
G O 0 1.8136408471036702e-05
mutations O 0 5.38917674930417e-08
: O 0 1.4147517823914768e-08
prevalence O 0 1.2918570746478508e-07
in O 0 7.659152423400428e-09
non O 0 1.4748366083949804e-06
- O 0 3.3260118925682036e-06
Caucasian O 0 1.4826705410087015e-06
populations O 0 6.584230760608989e-08
. O 0 3.331836069264682e-07

Hemochromatosis B-Disease 1 0.9999996423721313
, O 0 5.755035090260208e-06
the O 0 3.756838486879133e-05
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 1.0
iron I-Disease 1 1.0
metabolism I-Disease 1 0.9999996423721313
, O 0 7.192694511104492e-07
leads O 0 1.6065481531768455e-06
, O 0 4.4630400708456364e-08
if O 0 1.862129828111847e-08
untreated O 1 0.9054819941520691
, O 0 2.4266981313303404e-08
to O 0 9.938620593175074e-08
progressive O 1 0.9935994148254395
iron B-Disease 1 1.0
overload I-Disease 1 0.9999932050704956
and O 0 1.2247518498043064e-05
premature B-Disease 0 0.003687963355332613
death I-Disease 0 0.00021074718097224832
. O 0 4.295653525332455e-06

The O 0 7.892257417552173e-05
hemochromatosis B-Disease 1 1.0
gene O 0 9.51147831074195e-06
, O 0 3.4789903224918817e-07
HFE O 1 0.9999961853027344
, O 0 1.9099145731615863e-07
recently O 0 1.3400087084391998e-07
has O 0 1.1752210316018363e-09
been O 0 5.704696159902767e-10
identified O 0 3.5156628719335004e-09
, O 0 2.3742789956315846e-09
and O 0 1.6195933483231784e-09
characterization O 0 5.953555870519267e-08
of O 0 6.427782750506594e-08
this O 0 1.823908690745668e-09
gene O 0 1.3655685471292145e-08
has O 0 8.019969133243876e-10
shown O 0 1.1016243472994347e-09
that O 0 1.0497020613842167e-10
it O 0 2.3513030411592695e-10
contains O 0 2.3739303856018523e-09
two O 0 2.796942677463221e-10
mutations O 0 8.58492610333883e-10
that O 0 1.8111298571987788e-10
result O 0 5.571359373846008e-09
in O 0 9.602973527478298e-09
amino O 0 1.512509761880665e-08
acid O 0 5.032145011796274e-08
substitutions O 0 4.1420943830416945e-07
- O 0 5.115198291605338e-07
cDNA O 0 3.132792301130394e-07
nucleotides O 0 7.687768288633379e-08
845 O 0 9.006562322610989e-07
G O 0 8.58184830576647e-06
- O 0 2.1892401491641067e-06
- O 0 9.569166650180705e-07
> O 0 2.373033538560776e-07
A O 0 4.1562248043192085e-07
( O 0 9.35254362843807e-09
C282Y O 0 6.399164362846932e-07
) O 0 1.0619101153963584e-09
and O 0 1.2218827061261095e-09
187 O 0 2.1442390973902548e-08
C O 0 1.6066323951235972e-06
- O 0 5.093851882520539e-07
- O 0 1.1592223927436862e-06
> O 0 1.0986221923303674e-06
G O 0 0.00011132479266962036
( O 0 3.8549549685740203e-07
H63D O 1 0.9998323917388916
) O 0 3.228882690109458e-07
. O 0 3.430051833674952e-07

Although O 0 0.0003608493134379387
hemochromatosis B-Disease 1 1.0
is O 0 2.828178367053624e-07
common O 0 6.743894687133434e-08
in O 0 5.404545078135925e-08
Caucasians O 0 2.4578253032814246e-06
, O 0 3.4483758071246484e-08
affecting O 0 5.668151459303772e-08
> O 0 1.757718308681433e-07
= O 0 4.703142053585907e-08
1 O 0 7.951632596814306e-08
/ O 0 4.854129898035353e-08
300 O 0 2.148352162834044e-09
individuals O 0 2.224508251214008e-11
of O 0 2.447811286998558e-09
northern O 0 9.666206501890429e-09
European O 0 5.6333568920763355e-09
origin O 0 5.251006296447258e-09
, O 0 1.5639508577081074e-09
it O 0 3.466718856426354e-10
has O 0 1.840079200121636e-10
not O 0 9.540344209080232e-11
been O 0 4.2900871743967173e-10
recognized O 0 2.716061375807044e-09
in O 0 3.4741605148269628e-09
other O 0 4.8831929611026226e-09
populations O 0 6.324147960867776e-08
. O 0 5.101368287796504e-07

The O 0 4.549045570456656e-06
present O 0 9.796954714147432e-08
study O 0 1.707427976782583e-08
used O 0 1.1120453002888553e-08
PCR O 0 1.452996571060794e-06
and O 0 9.874430162426506e-09
restriction O 0 2.7512047751088176e-08
- O 0 1.488987351194737e-07
enzyme O 0 1.449312936330216e-08
digestion O 0 9.738251094404404e-08
to O 0 2.290034162300003e-09
analyze O 0 6.790076412244161e-08
the O 0 4.3984482722692064e-09
frequency O 0 4.435491973708849e-09
of O 0 1.517494396807706e-08
the O 0 1.2827228168532656e-08
845 O 0 4.5966706352373876e-07
G O 0 2.7293369839753723e-06
- O 0 8.662303798701032e-07
- O 0 4.37969447375508e-07
> O 0 8.405120155430268e-08
A O 0 7.063255225148168e-08
and O 0 2.6951614273684754e-09
187 O 0 1.599080512448836e-08
C O 0 6.341323341985117e-07
- O 0 2.1692937934858492e-07
- O 0 3.15676999207426e-07
> O 0 1.288461106696559e-07
G O 0 2.997689762196387e-06
mutations O 0 9.83929204778633e-09
in O 0 2.2941886612670714e-08
HLA O 0 1.6519856217200868e-05
- O 0 5.142996997165028e-07
typed O 0 7.541316904280393e-08
samples O 0 1.464367915815501e-08
from O 0 7.155268377800894e-09
non O 0 5.047925242251949e-07
- O 0 4.98134227200353e-07
Caucasian O 0 1.3552327970955957e-07
populations O 0 1.3888858951816019e-09
, O 0 1.3723645553298525e-09
comprising O 0 8.655200112173134e-09
Australian O 0 2.2228346097108442e-07
Aboriginal O 0 1.6013031256534305e-07
, O 0 2.023362588587929e-09
Chinese O 0 1.506256808170292e-08
, O 0 8.647742077982912e-09
and O 0 7.630371356981414e-08
Pacific O 0 2.5405408905498916e-06
Islanders O 0 4.372830971988151e-06
. O 0 9.922064236889128e-07

Results O 0 4.983317467122106e-06
showed O 0 1.0047077694252948e-06
that O 0 8.835559839326379e-09
the O 0 6.518727246884737e-08
845 O 0 2.9489779080904555e-06
G O 0 0.00010052824654849246
- O 0 2.451206455589272e-05
- O 0 4.6925611059123185e-06
> O 0 3.766585336961725e-07
A O 0 1.9804024020686484e-07
mutation O 0 1.1953372514028615e-08
was O 0 2.2986782255429716e-08
present O 0 3.171076068397838e-09
in O 0 8.257869388295092e-10
these O 0 1.8584769834184556e-10
populations O 0 3.190099018279824e-10
( O 0 3.6733574515501743e-10
allele O 0 3.576784701753155e-10
frequency O 0 9.955687385598821e-10
0 O 0 1.154681683601666e-09
. O 0 1.6467203989289914e-10
32 O 0 2.858617120793383e-09
% O 0 2.482055116992399e-10
) O 0 1.9729574918248005e-10
, O 0 3.7495606619586397e-10
and O 0 1.154866757779871e-09
, O 0 1.056370879659596e-09
furthermore O 0 1.05868300792622e-08
, O 0 1.6975264527374634e-09
it O 0 7.774377253078057e-10
was O 0 2.86707670937858e-08
always O 0 2.6635433858501756e-09
seen O 0 2.874626314763873e-09
in O 0 5.175129214052276e-10
conjunction O 0 1.8833794968031725e-08
with O 0 7.925464728941733e-09
HLA O 0 0.0013407468795776367
haplotypes O 0 1.717115338806252e-07
common O 0 9.66836388727188e-09
in O 0 1.3835615320090255e-08
Caucasians O 0 3.9207961322063056e-07
, O 0 8.311742405453515e-09
suggesting O 0 1.6957473647494226e-08
that O 0 1.0869805056046289e-09
845 O 0 8.31807994927658e-07
G O 0 6.14998716628179e-05
- O 0 3.616976027842611e-05
- O 0 7.387414825643646e-06
> O 0 4.1525285610077844e-07
A O 0 4.4076386984670535e-07
may O 0 3.0785816118594767e-09
have O 0 8.219052521907244e-11
been O 0 4.037981615745423e-10
introduced O 0 8.424982378407719e-10
into O 0 3.5245703577935217e-10
these O 0 7.766547821530523e-11
populations O 0 2.310548558037695e-10
by O 0 1.9339492229875077e-09
Caucasian O 0 8.132136031235859e-07
admixture O 0 2.133417638106039e-06
. O 0 1.3816121509080403e-06

187 O 0 1.78333320945967e-05
C O 0 0.00010368233051849529
- O 0 7.527659818151733e-06
- O 0 2.9651257591467584e-06
> O 0 1.3077599305688636e-06
G O 0 1.2276213965378702e-05
was O 0 3.871486455864215e-07
present O 0 8.941979601218009e-09
at O 0 1.6211176401270677e-08
an O 0 2.289425871104811e-10
allele O 0 1.5823953258831125e-09
frequency O 0 3.2103657510162975e-09
of O 0 5.0940368367946576e-08
2 O 0 1.402291104568576e-06
. O 0 5.062537979938497e-07

68 O 0 4.9519268941367045e-05
% O 0 6.574053657004697e-08
in O 0 1.3771058959832772e-08
the O 0 5.5605520188350965e-09
two O 0 4.965353128660865e-10
populations O 0 7.508757504659513e-10
analyzed O 0 3.829809713806753e-08
( O 0 8.748994417828726e-09
Australian O 0 7.735821441201551e-07
Aboriginal O 0 3.7657702023352613e-07
and O 0 1.791561565767097e-08
Chinese O 0 2.3465658216537122e-07
) O 0 1.1700566204808638e-07
. O 0 4.857982958128559e-07

In O 0 1.951501189978444e-06
the O 0 4.5027613282400125e-07
Australian O 0 1.8150033156416612e-06
Aboriginal O 0 4.148720620378299e-07
samples O 0 9.209323081904586e-08
, O 0 3.898616096620344e-09
187 O 0 3.2625031565203244e-08
C O 0 1.6525560795344063e-06
- O 0 8.742031809561013e-07
- O 0 8.238179134423262e-07
> O 0 4.365641359527217e-07
G O 0 2.6689469450502656e-05
was O 0 2.948065400687483e-07
found O 0 1.8471163487632225e-09
to O 0 2.5416860283122844e-10
be O 0 6.508285577133677e-10
associated O 0 9.200874728776398e-09
with O 0 1.438928798336292e-08
HLA O 0 0.0026895261835306883
haplotypes O 0 2.4090016381705937e-07
common O 0 1.9817054663917588e-08
in O 0 2.475750271457855e-08
Caucasians O 0 6.217437658051495e-07
, O 0 7.99306487664353e-09
suggesting O 0 7.62837437662256e-09
that O 0 4.234909367628603e-10
it O 0 1.8115937638896185e-09
was O 0 2.7063359553380906e-08
introduced O 0 6.789840245602363e-09
by O 0 3.014548166646591e-09
recent O 0 4.2447553028068796e-08
admixture O 0 7.4060130828002e-07
. O 0 4.01673133865188e-07

In O 0 2.5253059448004933e-06
the O 0 2.280342386029588e-07
Chinese O 0 3.567998518860804e-08
samples O 0 3.2518489234689696e-08
analyzed O 0 2.9593063999300284e-08
, O 0 2.5518152035886033e-09
187 O 0 2.8677714425384693e-08
C O 0 2.0948648398189107e-06
- O 0 4.5407264792629576e-07
- O 0 3.744230241409241e-07
> O 0 3.237528858335281e-07
G O 0 9.952553227776662e-06
was O 0 2.43593177629009e-07
present O 0 1.3794771547281925e-08
in O 0 8.442713195222495e-09
association O 0 3.8091712895038654e-08
with O 0 1.956671491498696e-09
a O 0 9.611109241802751e-09
wide O 0 2.7975005423286348e-08
variety O 0 3.16729398264215e-08
of O 0 4.641536008875846e-07
HLA O 0 0.2672802209854126
haplotypes O 0 5.458081773213053e-07
, O 0 2.2897076235040004e-08
showing O 0 1.745063649138956e-08
this O 0 6.101968930138923e-10
mutation O 0 8.494008829629252e-10
to O 0 2.798863640851579e-10
be O 0 8.932020123531004e-10
widespread O 0 4.6905377359962586e-08
and O 0 1.5575988498994775e-08
likely O 0 1.1444145187056165e-08
to O 0 5.0040891430569445e-09
predate O 0 9.292620575251931e-07
the O 0 1.8303813575926142e-08
more O 0 4.4872261462103324e-10
genetically O 0 4.9226031251237146e-08
restricted O 0 3.4393895731454904e-08
845 O 0 1.5326456832553959e-06
G O 0 9.326645522378385e-05
- O 0 6.293485785135999e-05
- O 0 2.529995981603861e-05
> O 0 2.9096229354763636e-06
A O 0 4.4323073780105915e-06
mutation O 0 4.1851524201774737e-07
. O 0 7.286799359462748e-07

Genotype O 0 0.00045804583351127803
- O 0 0.00019156404596287757
phenotype O 0 8.337121471413411e-06
correlations O 0 1.2482002603064757e-05
in O 0 8.001022251846734e-06
attenuated B-Disease 1 0.9988691210746765
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999995231628418
coli I-Disease 1 0.9999960660934448
. O 0 6.034039688529447e-05

Germ O 1 0.9999995231628418
- O 0 0.00042234701686538756
line O 0 3.86099964089226e-06
mutations O 0 1.1072180683413535e-07
of O 0 1.4469327425103984e-07
the O 0 1.3688509170606267e-07
tumor B-Disease 0 0.012656372971832752
suppressor O 0 4.943263775203377e-05
APC O 0 1.697857260296587e-05
are O 0 1.2928524029121036e-08
implicated O 0 1.116180328608607e-06
in O 0 1.1450398460510769e-06
attenuated B-Disease 1 0.9935089945793152
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999998807907104
coli I-Disease 1 0.9999998807907104
( O 0 0.001557404757477343
AAPC B-Disease 1 1.0
) O 0 4.2595445393089904e-07
, O 0 1.1993978255020465e-08
a O 0 2.1756598300726182e-08
variant O 0 3.877264134644065e-06
of O 0 7.483201625291258e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.0009353492641821504
FAP B-Disease 1 0.9999972581863403
) O 0 4.9131335799756926e-06
. O 0 2.4894691250665346e-06

AAPC B-Disease 1 1.0
is O 0 1.6242224774032366e-06
recognized O 0 1.3969902568078396e-07
by O 0 7.671374646633922e-09
the O 0 1.0582872356224016e-08
occurrence O 0 5.703886074570619e-08
of O 0 9.504685039019023e-08
< O 0 8.627380907455517e-07
100 O 0 2.3506446211740695e-07
colonic B-Disease 0 0.001385728013701737
adenomas I-Disease 0 8.440601959591731e-05
and O 0 4.550076582177098e-08
a O 0 1.8500967868817497e-08
later O 0 1.9590031286043086e-07
onset O 0 0.01188970822840929
of O 1 0.9948225021362305
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.6951402415088523e-07
age O 0 1.645556295670758e-07
> O 0 1.7516572370368522e-07
40 O 0 8.131029005653545e-08
years O 0 7.195357198952479e-08
) O 0 4.160717281820325e-08
. O 0 1.0560292906802715e-07

The O 0 1.7954669147002278e-06
aim O 0 5.34564719600894e-07
of O 0 5.5930616582600123e-08
this O 0 8.152793995463981e-10
study O 0 7.59307106079632e-09
was O 0 1.9899813352708406e-08
to O 0 1.6889195597613593e-09
assess O 0 1.6415812353898218e-07
genotype O 0 1.5281503920050454e-06
- O 0 2.933897803814034e-06
phenotype O 0 3.57800303163458e-07
correlations O 0 1.1397330581530696e-06
in O 0 1.1413351330702426e-06
AAPC B-Disease 1 1.0
families O 0 7.202222036539752e-07
. O 0 1.795235675672302e-06

By O 0 5.39493498763477e-07
protein O 0 7.569661875095335e-07
- O 0 1.8454009023116669e-06
truncation O 0 5.560344106925186e-06
test O 0 2.035812713074847e-06
( O 0 5.486744214522332e-08
PTT O 0 6.019223656039685e-05
) O 0 7.294862935935953e-09
assay O 0 6.003111252539384e-08
, O 0 3.0130995476440603e-09
the O 0 5.8756910448209965e-09
entire O 0 4.780487472544337e-08
coding O 0 4.839311529281076e-08
region O 0 9.489212970947847e-09
of O 0 2.1955571583021083e-08
the O 0 4.7754387111353935e-08
APC B-Disease 0 4.955980330123566e-06
gene O 0 7.93473944327161e-08
was O 0 2.118534894179902e-07
screened O 0 1.465706986891746e-07
in O 0 6.4202323457607235e-09
affected O 0 4.837896749876336e-09
individuals O 0 4.422733290709857e-10
from O 0 6.435290345052636e-08
11 O 0 6.008873242535628e-06
AAPC B-Disease 1 1.0
kindreds O 0 0.00017930558533407748
, O 0 7.975434357376798e-08
and O 0 1.549787320698215e-08
their O 0 1.0387370075193303e-08
phenotypic O 0 1.528787407778509e-07
differences O 0 8.637064041749909e-08
were O 0 1.9834075715152721e-07
examined O 0 2.4139666493283585e-05
. O 0 4.725820417661453e-06

Five O 0 4.384330622997368e-06
novel O 0 5.278002845443552e-06
germ O 1 0.9997149109840393
- O 0 0.0001693287049420178
line O 0 8.549687663617078e-06
APC B-Disease 0 8.020656423468608e-06
mutations O 0 4.028607847317289e-08
were O 0 1.137097171977075e-08
identified O 0 2.945037813617546e-08
in O 0 3.8263852530917575e-08
seven O 0 7.74233171796368e-07
kindreds O 0 0.00019668722234200686
. O 0 2.735346015469986e-06

Mutations O 0 2.6876427909883205e-06
were O 0 4.530315038664412e-07
located O 0 3.8435021565419447e-07
in O 0 9.630670483318227e-09
three O 0 1.3100990292613801e-09
different O 0 2.690465628063521e-10
regions O 0 4.702771949638418e-09
of O 0 4.8439193989224805e-08
the O 0 1.5908929640318092e-07
APC B-Disease 0 1.4523215213557705e-05
gene O 0 5.182295836902995e-08
( O 0 1.3276935106887322e-08
1 O 0 1.773145328343162e-07
) O 0 6.195369550709984e-09
at O 0 3.744225907098553e-08
the O 0 4.79496797822776e-09
5 O 0 2.526352638199114e-08
end O 0 2.2424888612704308e-08
spanning O 0 1.378133873686238e-07
exons O 0 6.741065305959637e-08
4 O 0 6.435904253976332e-08
and O 0 5.574378292294568e-09
5 O 0 4.381779561413168e-08
, O 0 3.4907794432825767e-09
( O 0 2.6358029092676816e-09
2 O 0 3.293979489171761e-08
) O 0 1.2338688959445676e-09
within O 0 4.219205429478734e-09
exon O 0 1.2434537666194956e-07
9 O 0 9.670174705433965e-08
, O 0 2.9344449092860714e-09
and O 0 2.719446445809126e-09
( O 0 2.779548369247209e-09
3 O 0 5.373339817538181e-08
) O 0 1.6332332153368156e-09
at O 0 1.7439489852222323e-08
the O 0 5.1205306661472605e-09
3 O 0 5.950138870502997e-08
distal O 0 1.7400623164576245e-07
end O 0 3.8492533604994605e-08
of O 0 5.72518423780366e-08
the O 0 1.9718069665941584e-07
gene O 0 1.0347207535232883e-06
. O 0 4.962063258062699e-07

Variability O 0 3.5265802580397576e-05
in O 0 2.8461008128033427e-07
the O 0 3.107964730020285e-08
number O 0 1.9160985686994536e-08
of O 0 4.818307934328914e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 1.021885054797167e-05
most O 0 4.0961545266782196e-09
apparent O 0 2.361053041965988e-08
in O 0 4.1240313386481375e-09
individuals O 0 1.0203327766022952e-10
with O 0 7.516566813414727e-10
mutations O 0 4.581267365466601e-09
in O 0 1.8693254943968896e-08
region O 0 4.178204804361485e-08
1 O 0 4.229553667300934e-07
, O 0 1.3768774564937303e-08
and O 0 2.8779414407154036e-08
upper O 0 0.0016511187423020601
- O 1 0.845772385597229
gastrointestinal O 1 0.8741694688796997
manifestations O 0 0.012047522701323032
were O 0 3.3140517530227953e-07
more O 0 6.906163196873649e-09
severe O 0 1.2624993360077497e-05
in O 0 1.5434928002378e-07
them O 0 3.7295083643584803e-07
. O 0 2.4191206193791004e-06

In O 0 1.1178368595210486e-06
individuals O 0 4.215859217282514e-09
with O 0 6.6715557522911695e-09
mutations O 0 1.0111198101014907e-08
in O 0 2.127418419206606e-08
either O 0 2.607104576668462e-08
region O 0 4.6280547394417226e-08
2 O 0 1.0950326867487092e-07
or O 0 1.0845788267488388e-08
region O 0 1.1533440869015976e-08
3 O 0 8.379828386750887e-08
, O 0 1.925557269188971e-09
the O 0 8.683521124375204e-10
average O 0 8.665106965288771e-10
number O 0 1.1018828072195674e-09
of O 0 4.8553520315408605e-08
adenomas B-Disease 0 2.7385816792957485e-05
tended O 0 1.0420612994721523e-07
to O 0 9.682240786901275e-09
be O 0 3.075212751113554e-09
lower O 0 5.814554882022094e-08
than O 0 7.214933650523392e-10
those O 0 4.998344516060627e-10
in O 0 2.2967354684766406e-09
individuals O 0 7.026508541674303e-11
with O 0 7.137830881909224e-10
mutations O 0 6.8201861935790475e-09
in O 0 1.6654212231514975e-08
region O 0 2.217949024441168e-08
1 O 0 6.479037040207913e-08
, O 0 1.0400210692651513e-09
although O 0 1.0574311426481131e-09
age O 0 7.081436326217272e-09
at O 0 9.933352629332148e-08
diagnosis O 0 2.982741079904372e-06
was O 0 2.690274243377644e-07
similar O 0 8.538768270227592e-08
. O 0 9.97500592347933e-07

In O 0 5.652982963511022e-06
all O 0 4.333033302827971e-06
AAPC B-Disease 1 1.0
kindreds O 0 0.00030296703334897757
, O 0 1.4446644058807578e-07
a O 0 3.7512169370756965e-08
predominance O 0 2.6109198643098352e-06
of O 0 6.341683729260694e-06
right O 0 0.0004382123879622668
- O 1 0.9999996423721313
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 0.06499306857585907
rectal B-Disease 1 1.0
polyp I-Disease 1 0.9981595873832703
sparing O 0 3.8295336707960814e-05
was O 0 7.912122782727238e-06
observed O 0 2.27586542678182e-06
. O 0 7.6993086395305e-07

No O 0 8.399299258599058e-05
desmoid B-Disease 1 0.9999895095825195
tumors I-Disease 1 1.0
were O 0 5.343460998119554e-07
found O 0 6.578770239684673e-08
in O 0 2.068992799308944e-08
these O 0 4.05792839330843e-08
kindreds O 0 0.00010960155486827716
. O 0 3.226289436497609e-06

Our O 0 1.6916048934945138e-06
data O 0 2.1598228272523556e-07
suggest O 0 2.8952953812222404e-08
that O 0 1.414945383082511e-09
, O 0 3.6119836011039297e-09
in O 0 3.30521956470875e-08
AAPC B-Disease 1 1.0
families O 0 5.01932673202532e-09
, O 0 4.54466242416629e-09
the O 0 2.1090504898069184e-09
location O 0 2.023270795348253e-08
of O 0 6.818159192789608e-08
the O 0 1.323376892514716e-07
APC B-Disease 0 0.0006710558081977069
mutation O 0 2.908253122768656e-07
may O 0 7.804098345332022e-08
partially O 0 1.1552041314644157e-06
predict O 0 1.002513343451028e-07
specific O 0 1.553107509266738e-08
phenotypic O 0 7.447410439453961e-07
expression O 0 7.976040592438949e-07
. O 0 9.436582217858813e-07

This O 0 1.1938908528463799e-07
should O 0 1.0696985519587088e-08
help O 0 5.268763647592323e-09
in O 0 6.937518559624323e-09
the O 0 5.4091522372345935e-09
design O 0 7.743070540300323e-08
of O 0 3.994345476598937e-08
tailored O 0 1.5026333244350099e-07
clinical O 0 6.604623195016757e-05
- O 0 3.218088750145398e-05
management O 0 2.908385340560926e-06
protocols O 0 1.887466623884393e-06
in O 0 5.404501290939834e-09
this O 0 2.444040525517721e-10
subset O 0 1.159604146039328e-08
of O 0 1.2254699299774074e-07
FAP B-Disease 1 0.798221230506897
patients O 0 1.0676407100618235e-06
. O 0 1.0781441517337953e-07
. O 0 9.488343835073465e-07

Wilms B-Disease 1 0.999991774559021
' I-Disease 0 0.0024819248355925083
tumor I-Disease 0 0.0005800699000246823
1 O 0 3.5961243156634737e-06
and O 0 1.995074683236453e-07
Dax O 1 0.9545753002166748
- O 0 5.606279955827631e-06
1 O 0 2.702228414364072e-07
modulate O 0 9.516494969830092e-08
the O 0 2.7652092171592813e-08
orphan O 0 3.691320671350695e-07
nuclear O 0 2.4457740437355824e-06
receptor O 0 1.059877448028601e-07
SF O 0 0.34791484475135803
- O 0 9.524999313725857e-07
1 O 0 5.5326577097503105e-08
in O 0 2.483675709541444e-09
sex O 0 3.2197724486593415e-09
- O 0 2.7650035150372787e-08
specific O 0 3.744653032100587e-09
gene O 0 1.4548251670021273e-07
expression O 0 1.4881483423323516e-07
. O 0 9.100847933041223e-07

Products O 0 2.1258067135931924e-05
of O 0 6.9566153797495645e-06
steroidogenic O 0 0.00020147064060438424
factor O 0 1.122332946579263e-06
1 O 0 5.419589683697268e-07
( O 0 4.987035850945176e-08
SF O 1 0.9954894185066223
- O 0 2.781231387416483e-06
1 O 0 2.0978787063086202e-07
) O 0 4.519093543819963e-09
and O 0 1.8023921910526042e-08
Wilms B-Disease 1 0.9999867677688599
tumor I-Disease 0 0.00038988678716123104
1 O 0 9.227307486980862e-07
( O 0 6.95885802315388e-08
WT1 O 1 0.7286834716796875
) O 0 9.923160071423354e-09
genes O 0 1.9750368007720454e-09
are O 0 1.1034195779302536e-10
essential O 0 5.012801285175783e-09
for O 0 3.3562561618794007e-09
mammalian O 0 1.4508115100397845e-06
gonadogenesis O 0 6.425824267353164e-06
prior O 0 1.2817793049180182e-07
to O 0 1.2723910813861039e-08
sexual O 0 1.0658762050752557e-07
differentiation O 0 2.598858827695949e-06
. O 0 1.1935668453588733e-06

In O 0 1.1676650046865689e-06
males O 0 7.094580212196888e-08
, O 0 6.469996804980838e-08
SF O 1 0.9998414516448975
- O 0 4.359199010650627e-06
1 O 0 1.6541281411264208e-07
participates O 0 3.126145387000179e-08
in O 0 2.017912947849254e-09
sexual O 0 1.0051777188380129e-09
development O 0 1.5565616573454122e-09
by O 0 9.015167501402743e-10
regulating O 0 3.723963359902882e-08
expression O 0 6.408853892025945e-09
of O 0 3.1222722185475504e-08
the O 0 7.620060671342799e-08
polypeptide O 0 4.263314167474164e-06
hormone O 0 1.6909241367102368e-06
Mullerian O 0 0.000788481964264065
inhibiting O 0 5.064327979198424e-06
substance O 0 1.0833509804797359e-05
( O 0 8.432319305029523e-07
MIS O 1 0.9999790191650391
) O 0 8.635711310489569e-07
. O 0 1.5772230881339055e-06

Here O 0 5.519868409464834e-06
, O 0 1.5457111146588431e-07
we O 0 7.533995649566805e-09
show O 0 3.610993459801648e-08
that O 0 1.1619155415587556e-08
WT1 O 0 0.007331424858421087
- O 0 3.891191954608075e-05
KTS O 1 0.8666372895240784
isoforms O 0 4.4758576223102864e-07
associate O 0 7.81868266130914e-07
and O 0 3.9197111334488e-08
synergize O 0 1.6314617823809385e-05
with O 0 2.3588593478507391e-07
SF O 1 0.9999980926513672
- O 0 1.4359713532030582e-05
1 O 0 2.0016227608721238e-07
to O 0 1.647029712614767e-08
promote O 0 7.160745667533774e-07
MIS O 1 0.9985454082489014
expression O 0 1.2130878985772142e-06
. O 0 3.7743919278909743e-07

In O 0 4.970891041011782e-06
contrast O 0 2.7434709863882745e-06
, O 0 9.131197771239385e-07
WT1 O 1 0.9990083575248718
missense O 0 1.74550532392459e-05
mutations O 0 3.772412640046241e-07
, O 0 6.72596200956832e-08
associated O 0 9.055121807932665e-08
with O 0 3.498579914662514e-08
male B-Disease 0 5.398872531259258e-07
pseudohermaphroditism I-Disease 1 0.9999978542327881
in O 0 9.549020205668057e-07
Denys B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999996423721313
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.7014971263051848e-06
fail O 0 1.5254188383551082e-06
to O 0 8.251232941347553e-08
synergize O 0 5.773792145191692e-05
with O 0 8.206616826100799e-07
SF O 1 1.0
- O 0 0.0006981850601732731
1 O 0 6.1231285144458525e-06
. O 0 6.426796517189359e-07

Additionally O 0 4.683449333242606e-06
, O 0 5.103762035219006e-08
the O 0 2.7062480256745403e-08
X O 0 7.024045316939009e-06
- O 0 1.989277279790258e-06
linked O 0 4.296712745599507e-07
, O 0 2.9398787848577967e-09
candidate O 0 2.912652785624914e-09
dosage O 0 4.081495603713847e-07
- O 0 3.5356103467165667e-07
sensitive O 0 2.4236666718024935e-07
sex O 0 2.0462772809537455e-08
- O 0 1.1620422668556785e-07
reversal O 0 6.39594901485907e-08
gene O 0 1.4084998944952076e-08
, O 0 7.933813606086915e-09
Dax O 0 0.08428885787725449
- O 0 2.1004561858717352e-06
1 O 0 3.444563674293022e-07
, O 0 1.6848213491016395e-08
antagonizes O 0 1.6058420442277566e-06
synergy O 0 1.112154450311209e-06
between O 0 7.8758752408703e-08
SF O 1 0.9985765218734741
- O 0 2.5967133296944667e-06
1 O 0 2.464988995143358e-07
and O 0 2.7057525997520315e-08
WT1 O 1 0.5113189220428467
, O 0 1.4657427271913548e-08
most O 0 1.5112084916779622e-09
likely O 0 8.364905434987691e-10
through O 0 1.2554816075649455e-09
a O 0 1.1476205541427476e-09
direct O 0 1.3748796545698383e-09
interaction O 0 4.756682603357376e-09
with O 0 2.9856810357387076e-08
SF O 1 0.9999992847442627
- O 0 0.00015002224245108664
1 O 0 3.5296072837809334e-06
. O 0 3.365001646216115e-07

We O 0 2.5031289396793e-07
propose O 0 4.5972183215781115e-07
that O 0 4.204257919582233e-08
WT1 O 0 0.002703481586650014
and O 0 1.0445182851981372e-06
Dax O 1 0.9997497200965881
- O 0 1.3508264601114206e-05
1 O 0 2.326932957430472e-07
functionally O 0 5.727390472998195e-08
oppose O 0 1.744680067083948e-09
each O 0 7.026240700369613e-11
other O 0 3.633886802578701e-10
in O 0 4.653252005937247e-09
testis O 0 5.979947559353604e-07
development O 0 2.7792475876253775e-08
by O 0 2.991375680494457e-08
modulating O 0 1.3927794498158619e-05
SF O 1 0.9999599456787109
- O 0 3.413616286707111e-05
1 O 0 2.374865744059207e-06
- O 0 2.4730186396482168e-06
mediated O 0 2.0772865809703944e-06
transactivation O 0 2.4128805307555012e-05
. O 0 1.6304475991546497e-07
. O 0 4.1658756799733965e-07

A O 0 0.00014458858640864491
mouse O 0 5.968990080873482e-06
model O 0 3.1009423651084944e-07
for O 0 4.466468226382858e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 0.9999997615814209
- O 1 0.9999505281448364
centre O 1 0.8133977055549622
mutations O 0 2.0063476767973043e-05
. O 0 7.3937435445259325e-06

Imprinting O 0 0.00017026028945110738
in O 0 1.628023483135621e-06
the O 0 9.351206244900823e-07
15q11 O 0 8.11336503829807e-05
- O 0 1.0440141522849444e-05
q13 O 0 1.0962109627143946e-05
region O 0 6.8270090025635e-08
involves O 0 1.173492503170337e-08
an O 0 2.34473418458947e-09
imprinting O 0 2.7887742817256367e-06
centre O 0 7.123282557586208e-06
( O 0 5.279016690451499e-08
IC O 1 0.9998617172241211
) O 0 1.972094132440816e-08
, O 0 2.5587358898349066e-09
mapping O 0 1.0888029144950906e-08
in O 0 1.2998218057447275e-09
part O 0 3.7324094925850204e-09
to O 0 2.110076557926277e-09
the O 0 2.522899933410372e-08
promoter O 0 2.2678148525301367e-05
and O 0 4.265084641019712e-08
first O 0 2.82771452475572e-07
exon O 0 6.165093509480357e-06
of O 0 3.8255539038800634e-06
SNRPN O 1 0.9999954700469971
. O 0 9.93867615761701e-06

Deletion O 0 2.349895476072561e-05
of O 0 3.689804088935489e-06
this O 0 8.861200484489018e-08
IC O 1 0.9990986585617065
abolishes O 0 2.0845296603511088e-05
local O 0 1.5271845654751814e-07
paternally O 0 2.1866319457330974e-06
derived O 0 1.2043417996210337e-07
gene O 0 1.6462822216567474e-08
expression O 0 4.9134363244718315e-09
and O 0 5.834993821451917e-09
results O 0 8.898937409185237e-08
in O 0 1.2115272056689719e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999998807907104
PWS B-Disease 1 1.0
) O 0 5.5913711548782885e-05
. O 0 5.962191153230378e-06

We O 0 8.795577173259517e-07
have O 0 7.265563706226885e-09
created O 0 4.7907928291124335e-08
two O 0 3.0428541908378293e-09
deletion O 0 8.229025638684107e-08
mutations O 0 3.070888965339691e-08
in O 0 6.653284856383834e-08
mice O 0 3.602216338549624e-07
to O 0 1.661968873634123e-08
understand O 0 9.22470292152866e-07
PWS B-Disease 1 1.0
and O 0 2.521777560104965e-07
the O 0 1.0722461496470714e-07
mechanism O 0 1.0829420915570154e-07
of O 0 1.8247730793063965e-07
this O 0 7.605365226481808e-08
IC O 1 0.999515175819397
. O 0 4.498474481806625e-06

Mice O 0 0.0010120464721694589
harbouring O 0 0.00037125303060747683
an O 0 2.0591276950199244e-07
intragenic O 0 0.00021032340009696782
deletion O 0 2.3512438929174095e-06
in O 0 2.715851223911159e-07
Snrpn O 0 0.0009056091075763106
are O 0 1.5122502361464285e-08
phenotypically O 0 5.035821686760755e-06
normal O 0 2.4998033154588484e-07
, O 0 6.649171879757887e-09
suggesting O 0 6.080711045797216e-09
that O 0 4.258488284225592e-10
mutations O 0 9.307005832681625e-09
of O 0 1.5023925925561343e-07
SNRPN O 1 0.9999920129776001
are O 0 1.5804920705519976e-09
not O 0 7.781824629127243e-10
sufficient O 0 3.019026095785193e-08
to O 0 8.789291428001889e-08
induce O 0 0.0011025117710232735
PWS B-Disease 1 1.0
. O 0 7.045393431326374e-05

Mice O 0 9.550731192575768e-05
with O 0 1.6040526418237278e-07
a O 0 4.24068460347371e-08
larger O 0 2.972079116148052e-08
deletion O 0 1.0145163287234027e-07
involving O 0 1.8798861844970816e-07
both O 0 3.876987264561649e-08
Snrpn O 0 0.0004681586869992316
and O 0 8.562481212948114e-08
the O 0 2.6510571160542895e-07
putative O 0 3.141104389214888e-05
PWS O 1 1.0
- O 0 0.048196107149124146
IC O 1 0.9999736547470093
lack O 0 1.053444748322363e-06
expression O 0 7.705870075369603e-08
of O 0 1.3096878603846562e-07
the O 0 6.567298527215826e-08
imprinted O 0 1.459866325603798e-06
genes O 0 6.699023913370183e-08
Zfp127 O 0 3.7250170862535015e-05
( O 0 1.0632243174768519e-07
mouse O 0 9.373437706017285e-07
homologue O 0 1.2986970432393719e-06
of O 0 4.734332890166115e-07
ZNF127 O 1 0.9997745156288147
) O 0 1.5387220742013596e-07
, O 0 7.560674220030705e-08
Ndn O 0 0.00046303082490339875
and O 0 1.5349890247762232e-07
Ipw O 0 0.00015135954890865833
, O 0 6.830473608943066e-08
and O 0 1.4624614408376146e-08
manifest O 0 4.0735781681178196e-07
several O 0 2.822373623700969e-08
phenotypes O 0 9.567258985043736e-07
common O 0 1.9352958702256728e-07
to O 0 3.943636784242699e-06
PWS B-Disease 1 1.0
infants O 1 0.9543440937995911
. O 0 6.031970315234503e-06

These O 0 1.2967585405476711e-07
data O 0 4.156814625844163e-08
demonstrate O 0 3.0647566262587134e-08
that O 0 7.918434241638295e-10
both O 0 1.2115024539127717e-09
the O 0 5.710893979937737e-09
position O 0 3.2778661562815614e-08
of O 0 4.1124241789702864e-08
the O 0 7.967360460270356e-08
IC O 1 0.6987747550010681
and O 0 1.847466180038282e-08
its O 0 8.199378953577252e-09
role O 0 8.140025542502372e-09
in O 0 1.4934172787306466e-09
the O 0 9.507197251679145e-10
coordinate O 0 2.370631690951086e-09
expression O 0 4.286188293178839e-09
of O 0 1.6550663062275817e-08
genes O 0 3.2722238252347324e-09
is O 0 6.923489559440554e-10
conserved O 0 1.0906861191983808e-08
between O 0 3.5237723849945723e-09
mouse O 0 6.327996260324653e-08
and O 0 1.5950890608351642e-09
human O 0 4.2838994573912714e-09
, O 0 1.3028773615531009e-09
and O 0 1.480024325317686e-09
indicate O 0 3.4168561313663304e-09
that O 0 2.8383612127313995e-10
the O 0 7.923937950238269e-09
mouse O 0 9.090111774412435e-08
is O 0 3.6837347061613457e-10
a O 0 2.3871601917413443e-10
suitable O 0 3.7150651444051164e-09
model O 0 3.389102110062936e-09
system O 0 7.822961833880981e-09
in O 0 1.8056602879568118e-09
which O 0 2.54362086948845e-10
to O 0 4.424572652705905e-10
investigate O 0 1.0118838211781167e-08
the O 0 4.607029424619213e-09
molecular O 0 7.283021119519617e-08
mechanisms O 0 2.8104912175308527e-08
of O 0 1.1491208340430603e-07
imprinting O 0 9.279974051423778e-07
in O 0 4.045407120401023e-09
this O 0 4.367973205354758e-10
region O 0 6.933682072940428e-09
of O 0 3.106903889715795e-08
the O 0 4.311583978733324e-08
genome O 0 1.166040917155442e-07
. O 0 7.370698540398735e-08
. O 0 1.0381368156231474e-06

Mutations O 0 3.7490110571525292e-06
of O 0 3.291045686637517e-06
the O 0 3.0614151569352543e-07
ATM O 0 0.0004381198959890753
gene O 0 2.666709804088896e-07
detected O 0 1.5475400516606896e-07
in O 0 1.5601113290131252e-08
Japanese O 0 0.020013386383652687
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 5.148166746948846e-05
: O 0 4.722900825981924e-08
possible O 0 2.3594278530936208e-08
preponderance O 0 1.3969858628115617e-05
of O 0 3.8859604956087423e-07
the O 0 9.992374572220797e-08
two O 0 1.9514359905770107e-08
founder O 0 3.655214823083952e-05
mutations O 0 5.580561150964058e-07
4612del165 O 0 3.549479151843116e-05
and O 0 1.1595220712479204e-06
7883del5 O 0 0.0003041251911781728
. O 0 3.914541139238281e-06

The O 0 6.717283667967422e-06
ATM O 0 0.002969939261674881
( O 0 4.481906671571778e-06
A O 1 0.9999997615814209
- O 1 0.9999849796295166
T O 1 1.0
, O 0 5.452089268942473e-08
mutated O 0 3.487872746177345e-08
) O 0 1.918979641857277e-09
gene O 0 5.889694065785989e-09
on O 0 1.6290526261286686e-08
human O 0 1.0365247504751096e-07
chromosome O 0 1.0832080761247198e-06
11q22 O 0 3.076820576097816e-05
. O 0 1.0673119277271326e-06

3 O 0 1.3991362720844336e-05
has O 0 5.3026205648620817e-08
recently O 0 4.9138041191554294e-08
been O 0 2.2146127154343276e-09
identified O 0 3.771525314277824e-09
as O 0 1.7829804299651641e-09
the O 0 3.896698075323002e-09
gene O 0 6.123097584520565e-09
responsible O 0 7.198099449823303e-09
for O 0 2.357235961980564e-09
the O 0 7.312390692959525e-08
human O 0 1.8095903442372219e-06
recessive B-Disease 1 0.9999730587005615
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.013472553342580795
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.8498056988391909e-06
. O 0 6.911133141329628e-07

In O 0 1.3767220252702828e-06
order O 0 1.4126881353604404e-07
to O 0 6.78884282123704e-09
define O 0 1.6048554485337263e-08
the O 0 6.030364652076514e-09
types O 0 2.7088303156119764e-08
of O 0 3.3852325032057706e-06
disease O 1 0.9999971389770508
- O 0 2.4969660444185138e-05
causing O 0 8.274997753687785e-07
ATM O 0 1.6896774468477815e-05
mutations O 0 1.851106290473581e-08
in O 0 2.01665173449328e-08
Japanese O 0 6.760411906725494e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 2.3786118674706813e-07
as O 0 3.5625091765467687e-09
well O 0 1.2437217922212085e-09
as O 0 5.671346170466052e-10
to O 0 6.212074188383099e-10
look O 0 3.155570027502108e-09
for O 0 1.1731852156415812e-09
possible O 0 5.928148194556115e-09
mutational O 0 5.268955192150315e-06
hotspots O 0 5.3852845667279325e-06
, O 0 2.1661694660224384e-08
reverse O 0 1.7038500743637996e-07
- O 0 2.891140979954798e-07
transcribed O 0 1.4553747007539641e-07
RNA O 0 5.0326057987604145e-08
derived O 0 5.716484619000539e-09
from O 0 3.2865850041474687e-09
ten O 0 1.884148481678949e-08
patients O 0 3.914471857768831e-09
belonging O 0 4.884947202299372e-08
to O 0 6.828529297564501e-09
eight O 0 5.601666330790067e-08
unrelated O 0 4.948458354192553e-07
Japanese O 0 0.00021569753880612552
A B-Disease 1 1.0
- I-Disease 1 0.9999940395355225
T I-Disease 1 1.0
families O 0 7.419455716473067e-09
was O 0 7.89548764146275e-08
analyzed O 0 7.868243834252553e-09
for O 0 2.3683586203304685e-09
mutations O 0 5.913219247588586e-09
by O 0 3.765530554034058e-09
the O 0 2.8311243127632224e-08
restriction O 0 4.487179339207614e-08
endonuclease O 0 1.5632500662832172e-06
fingerprinting O 0 1.9856836388498778e-06
method O 0 3.926408851384622e-07
. O 0 3.3772246865737543e-07

As O 0 1.925861397467088e-06
has O 0 6.205755909149957e-08
been O 0 9.412565837862985e-09
reported O 0 4.969031408563751e-09
by O 0 1.7028674026420276e-09
others O 0 1.1587285797531877e-08
, O 0 6.787276074504689e-09
mutations O 0 5.424205529180881e-09
that O 0 1.2195683352089759e-09
lead O 0 2.1912020642389507e-08
to O 0 1.8959728009804167e-08
exon O 0 3.2139075756276725e-06
skipping O 0 1.4069673852645792e-06
or O 0 3.8538594537840254e-08
premature O 0 3.6162219885227387e-07
protein O 0 5.429404126289228e-08
truncation O 0 1.5411291087730206e-06
were O 0 4.8252005058202485e-08
also O 0 1.0304450626108519e-08
predominant O 0 2.256928581800821e-07
in O 0 2.898030260212181e-08
our O 0 1.558731952400194e-07
mutants O 0 7.155500952649163e-06
. O 0 9.582079201209126e-07

Six O 0 1.2501782293838914e-06
different O 0 9.584564253373173e-09
mutations O 0 1.5955645693566112e-08
were O 0 1.849112507557038e-08
identified O 0 1.5158512667312607e-08
on O 0 3.442553264676462e-08
12 O 0 6.348245307208344e-08
of O 0 2.3409549854136458e-08
the O 0 5.087220245059143e-08
16 O 0 3.3263623322454805e-07
alleles O 0 5.4450847386533496e-08
examined O 0 3.4891420455096522e-06
. O 0 3.40318433700304e-06

Four O 0 1.5520643046329496e-06
were O 0 1.0582169807094033e-07
deletions O 0 5.305580543790711e-07
involving O 0 1.007074274639308e-06
a O 0 3.471699017154606e-07
loss O 0 1.4517370800604112e-05
of O 0 2.2703786726196995e-06
a O 0 6.34058565651685e-08
single O 0 9.199158057526802e-08
exon O 0 9.471283988204959e-07
exon O 0 1.98967586584331e-06
7 O 0 8.522088705831266e-07
, O 0 5.39023581325182e-08
exon O 0 1.6341710988854175e-06
16 O 0 3.1401057754010253e-07
, O 0 4.967650468756801e-08
exon O 0 3.4885431432485348e-06
33 O 0 1.15832403935201e-06
or O 0 2.6072345349348325e-07
exon O 0 2.1248986740829423e-05
35 O 0 9.612826943339314e-06
. O 0 2.9192256079113577e-06

The O 0 1.9712326775334077e-06
others O 0 1.8428667658554332e-07
were O 0 4.0572011528183793e-08
minute O 0 1.0154843010923287e-07
deletions O 0 1.440391486084991e-07
, O 0 2.6001670150321843e-08
4649delA O 0 1.2750545010931091e-06
in O 0 5.7168037415067374e-08
exon O 0 1.4524907783197705e-06
33 O 0 5.356558290259272e-07
and O 0 7.201370522125217e-08
7883del5 O 0 6.552286777150584e-06
in O 0 4.872473482464557e-07
exon O 0 1.8139468011213467e-05
55 O 0 1.032644559018081e-05
. O 0 2.295700141985435e-06

The O 0 5.272202088235645e-06
mutations O 0 5.646165845973883e-07
4612del165 O 0 1.1576609722396825e-05
and O 0 6.503167071514326e-08
7883del5 O 0 4.216241904941853e-06
were O 0 2.5956827798268023e-08
found O 0 5.804867253544899e-09
in O 0 6.430842525162461e-10
more O 0 5.833274835387314e-11
than O 0 3.3932268106440233e-10
two O 0 3.954030713959611e-10
unrelated O 0 8.199284806664764e-09
families O 0 2.64850641418235e-10
; O 0 8.604991164062881e-10
44 O 0 1.5955645693566112e-08
% O 0 1.980514197086336e-09
( O 0 1.2568496243758887e-09
7 O 0 3.486323052470652e-08
of O 0 3.734504971930619e-08
16 O 0 7.255055578525571e-08
) O 0 1.1485096207408674e-09
of O 0 7.138120761140954e-09
the O 0 6.683884556935027e-09
mutant O 0 4.758463489906717e-08
alleles O 0 1.2174348196225537e-09
had O 0 3.312766505558784e-09
one O 0 2.1415362816412653e-09
of O 0 2.126274445402032e-08
the O 0 3.617204313854927e-08
two O 0 2.4350716998355892e-08
mutations O 0 5.958065116828948e-07
. O 0 1.4842903510725591e-06

The O 0 8.015624189283699e-06
4612del165 O 0 5.061439151177183e-05
mutations O 0 1.2139138050315523e-07
in O 0 1.4225580713400632e-08
three O 0 9.538164702505014e-10
different O 0 1.0358632007712032e-10
families O 0 1.314393316409479e-10
were O 0 2.2685839873304303e-09
all O 0 1.6757123466604185e-09
ascribed O 0 5.430812777262872e-08
to O 0 6.016325659885524e-09
the O 0 3.653677183024229e-08
same O 0 4.8365063065602953e-08
T O 0 8.421915845246986e-05
- O 0 1.6998882301777485e-06
- O 0 4.1296073050034465e-07
> O 0 6.350474279770424e-08
A O 0 2.5533013925382875e-08
substitution O 0 3.068564424779652e-08
at O 0 8.58074358234262e-08
the O 0 4.933447428356885e-09
splice O 0 1.0052684729089378e-06
donor O 0 2.6919929396740372e-08
site O 0 3.6324669849818747e-07
in O 0 1.185549294291377e-07
intron O 0 5.4163137974683195e-05
33 O 0 6.732643669238314e-06
. O 0 2.1784560431115096e-06

Microsatellite O 0 0.0005527056637220085
genotyping O 0 0.00011170889047207311
around O 0 6.271833399296156e-07
the O 0 1.8230146281439374e-07
ATM O 0 8.491680637234822e-05
locus O 0 1.4328974202726386e-06
also O 0 1.2917357850028566e-08
indicated O 0 1.21314256418259e-08
that O 0 4.1705736086861123e-10
a O 0 3.858785291299682e-09
common O 0 1.7369114146958964e-08
haplotype O 0 2.958968821076269e-07
was O 0 1.217949119336481e-07
shared O 0 6.255499673812892e-09
by O 0 8.624709280091736e-10
the O 0 9.07593733501244e-09
mutant O 0 1.1561030532902805e-07
alleles O 0 2.465810000629176e-09
in O 0 3.9654373118480635e-09
both O 0 2.5279915050191448e-08
mutations O 0 6.828193477304012e-07
. O 0 1.3771054909739178e-06

This O 0 2.405998600352177e-07
suggests O 0 9.663094857614851e-08
that O 0 9.618402740940724e-10
these O 0 7.329363227448482e-10
two O 0 3.1613531792373806e-09
founder O 0 3.228610239602858e-06
mutations O 0 5.043166240170649e-08
may O 0 1.4006129589461125e-08
be O 0 1.9535388862124137e-09
predominant O 0 8.338263768337129e-08
among O 0 2.8885425162883394e-09
Japanese O 0 8.360046308553137e-07
ATM O 0 9.537770529277623e-05
mutant O 0 3.2435968932986725e-06
alleles O 0 1.8560157855063153e-07
. O 0 5.915883889429097e-07

W474C O 0 0.0010931878350675106
amino O 0 6.734217095072381e-06
acid O 0 7.720034886915528e-07
substitution O 0 2.761583743904339e-07
affects O 0 5.480406173319352e-08
early O 0 1.5951933107771765e-08
processing O 0 2.7692415471847198e-08
of O 0 1.2496933265992993e-08
the O 0 4.812468201720321e-09
alpha O 0 2.801515819328415e-08
- O 0 1.585287101590893e-08
subunit O 0 2.2120121290214456e-09
of O 0 8.312234456298029e-09
beta O 0 1.5646610052044707e-07
- O 0 3.354520856646559e-07
hexosaminidase O 0 3.898941031366121e-06
A O 0 5.46045555438468e-07
and O 0 1.1163337809705354e-08
is O 0 2.7340556485455636e-09
associated O 0 2.373981367043143e-08
with O 0 5.967732619183153e-08
subacute O 1 0.9995330572128296
G B-Disease 1 0.9999334812164307
( I-Disease 0 1.3145373486622702e-05
M2 I-Disease 1 0.9999852180480957
) I-Disease 0 3.0439989586739102e-06
gangliosidosis I-Disease 0 0.0008715080330148339
. O 0 3.958747129217954e-06

Mutations O 0 4.145131697441684e-06
in O 0 5.241768121777568e-07
the O 0 6.845640996289148e-07
HEXA O 1 0.9987189769744873
gene O 0 1.8454733208272955e-07
, O 0 5.826686244603252e-09
encoding O 0 2.657971176489582e-09
the O 0 8.283238983608499e-09
alpha O 0 5.988199092143986e-08
- O 0 2.5876843778860348e-08
subunit O 0 3.646129176360091e-09
of O 0 9.895264163617412e-09
beta O 0 1.1306700287150306e-07
- O 0 2.7732119178836e-07
hexosaminidase O 0 4.103537776245503e-06
A O 0 1.5291168438125169e-06
( O 0 1.5220569693497055e-08
Hex O 0 2.4517944439139683e-06
A O 0 5.557861300076183e-07
) O 0 6.648994244073947e-09
, O 0 9.776804921202142e-10
that O 0 3.061668418791186e-10
abolish O 0 2.153529123916087e-07
Hex O 0 3.879901214531856e-06
A O 0 3.671586057407694e-07
enzyme O 0 4.900989836187364e-08
activity O 0 1.3493018968802062e-07
cause O 0 0.0015891591319814324
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.3628268789034337e-06
TSD B-Disease 1 1.0
) O 0 8.439014465011496e-08
, O 0 7.905762267057526e-09
the O 0 7.03575935290246e-08
fatal O 0 0.00037639072979800403
infantile B-Disease 0 7.133339386200532e-05
form I-Disease 0 3.9959158470992406e-07
of I-Disease 0 3.058506626985036e-05
G I-Disease 1 0.9790950417518616
( I-Disease 0 1.1570940614546998e-06
M2 I-Disease 1 0.9999028444290161
) I-Disease 0 1.651785623835167e-07
gangliosidosis I-Disease 0 3.427228148211725e-05
, I-Disease 0 7.181495220720535e-08
Type I-Disease 0 2.2257013370108325e-06
1 I-Disease 0 4.076137884112541e-06
. O 0 8.49971968364116e-07

Less O 0 1.3940419194113929e-05
severe O 1 0.9901455044746399
, O 0 4.2242309064022265e-06
subacute O 1 0.9999942779541016
( O 0 3.248983603043598e-06
juvenile O 1 0.9999347925186157
- O 0 0.018666820600628853
onset O 1 0.9999747276306152
) O 0 4.488548555059424e-08
and O 0 1.919738963351847e-07
chronic O 1 0.9999997615814209
( O 0 2.3675562488278956e-07
adult O 0 7.558048196187883e-07
- O 0 4.24579366153921e-06
onset O 0 0.025919996201992035
) O 0 5.88246384936042e-09
variants O 0 1.9042577292793794e-08
are O 0 6.929726237281386e-10
characterized O 0 8.505717907780763e-09
by O 0 1.4356602573428745e-09
a O 0 1.0595515576028447e-08
broad O 0 4.083425864109813e-08
spectrum O 0 1.0491950774849101e-07
of O 0 1.437491903288901e-07
clinical O 0 4.539156179816928e-06
manifestations O 0 7.5396651482151356e-06
and O 0 1.3489205308303553e-08
are O 0 7.522203415710749e-10
associated O 0 1.553540052157132e-08
with O 0 8.003775420206694e-09
residual O 0 5.513981250260258e-06
levels O 0 3.043744527531089e-07
of O 0 2.6259297669639636e-07
Hex O 0 1.025532401399687e-05
A O 0 1.240467099705711e-06
enzyme O 0 2.4245221652563487e-07
activity O 0 7.587607910863881e-07
. O 0 4.35922231645236e-07

We O 0 8.660486514600052e-07
identified O 0 3.885801334035932e-07
a O 0 1.8037204085885605e-07
1422 O 0 0.0001609704049769789
G O 0 0.0001655341766308993
- O 0 1.8454293240210973e-05
- O 0 4.221524704917101e-06
> O 0 6.602314215342631e-07
C O 0 1.3546009540732484e-05
( O 0 1.4551130966822257e-08
amino O 0 1.4695048733415206e-08
acid O 0 2.872090298922103e-08
W474C O 0 3.426530383876525e-07
) O 0 6.80620004800403e-10
substitution O 0 1.1771824404149811e-08
in O 0 3.24373861104732e-09
the O 0 2.8329540935345676e-09
first O 0 1.5133350572682502e-08
position O 0 1.8975791604702863e-08
of O 0 5.027444061056485e-08
exon O 0 7.622981001986773e-07
13 O 0 2.3375602609121415e-07
of O 0 2.1730704702349612e-07
HEXA O 1 0.9997733235359192
of O 0 1.497617517998151e-06
a O 0 6.668797425390949e-08
non O 0 1.4196328947946313e-06
- O 0 9.096752364712302e-07
Jewish O 0 1.2717064237222075e-06
proband O 0 0.012140750885009766
who O 0 5.37640509890025e-08
manifested O 0 7.22318077350792e-07
a O 0 1.5767628269713896e-07
subacute O 0 0.0012414325028657913
variant O 0 8.611174962425139e-06
of O 0 4.806467404705472e-05
G B-Disease 1 0.9998700618743896
( I-Disease 0 4.791529136127792e-06
M2 I-Disease 1 0.9999935626983643
) I-Disease 0 2.802205472107744e-06
gangliosidosis I-Disease 0 0.000654914416372776
. O 0 3.366045802977169e-06

On O 0 6.595532795472536e-06
the O 0 7.997672355486429e-07
second O 0 3.560640379873803e-06
maternally O 0 1.946130214491859e-05
inherited O 0 8.948772301664576e-05
allele O 0 2.0780225895578042e-07
, O 0 3.0458867428251324e-08
we O 0 3.2786708903387307e-09
identified O 0 1.2989898046100734e-08
the O 0 2.4728903369464206e-08
common O 0 8.631281502857746e-07
infantile O 1 0.9999998807907104
disease O 1 0.9999997615814209
- O 0 0.0001315325207542628
causing O 0 1.0416164514026605e-05
4 O 0 3.5069563182332786e-06
- O 0 1.4344205965244328e-06
bp O 0 7.802087225172727e-07
insertion O 0 2.827995047027798e-07
, O 0 4.20522034971782e-08
+ O 0 8.593220854891115e-07
TATC O 1 0.9721353054046631
1278 O 0 0.0007125294650904834
, O 0 6.417308640038755e-08
in O 0 8.575376853059424e-08
exon O 0 8.167638043232728e-06
11 O 0 3.849793301924365e-06
. O 0 2.0256552488717716e-06

Pulse O 0 0.0006869968492537737
- O 0 1.5209697266982403e-05
chase O 0 2.044307166215731e-06
analysis O 0 1.4504966117101503e-08
using O 0 5.0626535852416055e-08
proband O 0 3.1193998438538983e-05
fibroblasts O 0 2.560139364504721e-06
revealed O 0 4.110483757813199e-07
that O 0 2.247506181163317e-09
the O 0 1.877748090350906e-08
W474C O 0 1.199023699882673e-06
- O 0 1.291640359113444e-07
containing O 0 3.631368628020937e-08
alpha O 0 6.160998111681693e-08
- O 0 2.9195344808385926e-08
subunit O 0 7.802696266878684e-09
precursor O 0 2.2720934111930546e-07
was O 0 4.178204804361485e-08
normally O 0 1.6990293616458985e-09
synthesized O 0 7.170888238761108e-08
, O 0 1.4488091837350225e-09
but O 0 4.3531520055317685e-10
not O 0 3.272128679121522e-10
phosphorylated O 0 1.0225181767964386e-07
or O 0 2.620915218187747e-08
secreted O 0 9.610085527356205e-08
, O 0 2.4170898171860244e-08
and O 0 1.566133711605744e-08
the O 0 5.26256975774686e-08
mature O 0 1.7732857315877482e-07
lysosomal O 0 4.524362338997889e-06
alpha O 0 4.4854508018943307e-07
- O 0 2.5617217147555493e-07
subunit O 0 5.1589420735354e-08
was O 0 1.0973450770279669e-07
not O 0 6.754113268669926e-09
detected O 0 9.62085778155597e-07
. O 0 5.529180953089963e-07

When O 0 1.7972897694562562e-06
the O 0 2.0688494828391413e-07
W474C O 0 6.063565706426743e-06
- O 0 4.359554850452696e-07
containing O 0 7.991300776666321e-08
alpha O 0 1.3367755968829442e-07
- O 0 7.423039960485767e-08
subunit O 0 2.3222812117751346e-08
was O 0 1.3958010924852715e-07
transiently O 0 3.949094775634876e-07
co O 0 2.362459099458647e-07
- O 0 1.96212567971088e-07
expressed O 0 3.992142616482397e-09
with O 0 1.3681984434299466e-09
the O 0 6.906531790917825e-09
beta O 0 3.3582619352046095e-08
- O 0 3.9012956420947376e-08
subunit O 0 4.157097777124363e-09
to O 0 1.1666071442206771e-09
produce O 0 2.4007192678254796e-08
Hex O 0 4.722045559901744e-06
A O 0 2.010226808124571e-06
( O 0 2.62321062649562e-08
alphabeta O 0 3.7421739307319513e-06
) O 0 3.2508862268798566e-09
in O 0 1.4469154763219194e-08
COS O 0 0.0010426809312775731
- O 0 3.91343246519682e-06
7 O 0 5.346356033442135e-07
cells O 0 2.343720595376908e-08
, O 0 3.727386843621616e-09
the O 0 6.735639157540163e-09
mature O 0 1.570632868208577e-08
alpha O 0 3.442172413770095e-08
- O 0 3.583664920370211e-08
subunit O 0 7.490165820911443e-09
was O 0 3.0136529716173754e-08
present O 0 3.708268803137571e-09
, O 0 1.2426975004586893e-09
but O 0 2.4319132818639844e-10
its O 0 9.35107657973333e-10
level O 0 1.3246100216690593e-08
was O 0 2.6971376243523082e-08
much O 0 2.131401721783277e-09
lower O 0 5.516543222228165e-09
than O 0 1.3142729959891852e-10
that O 0 3.80985555603619e-11
from O 0 1.4970505946010348e-09
normal O 0 9.672734613275225e-09
alpha O 0 2.803755627667215e-08
- O 0 3.691235761493772e-08
subunit O 0 1.3183667491034612e-08
transfections O 0 6.4907936803138e-07
, O 0 2.2028756596625954e-09
although O 0 5.833143967848287e-10
higher O 0 1.336585730982165e-09
than O 0 1.2311696107047965e-10
in O 0 1.3030662104895896e-09
those O 0 8.381242921906562e-10
cells O 0 2.5191686958692117e-08
transfected O 0 2.8216911118761345e-07
with O 0 2.0511843334958257e-09
an O 0 3.038805873600836e-09
alpha O 0 1.6698736260423175e-07
- O 0 1.6958743742634397e-07
subunit O 0 7.321462192066974e-08
associated O 0 1.8066090490265196e-07
with O 0 2.3775073998422158e-07
infantile O 1 0.9941121935844421
TSD B-Disease 1 0.9999947547912598
. O 0 1.3673802641278598e-05

Furthermore O 0 7.02516399542219e-06
, O 0 1.26767403685335e-07
the O 0 4.0073029339282584e-08
precursor O 0 7.04250453509303e-07
level O 0 6.260491147713765e-08
of O 0 1.4309753382235613e-08
the O 0 6.2868257266757155e-09
W474C O 0 3.3808791499723156e-07
alpha O 0 3.752011323854276e-08
- O 0 1.2968806473168115e-08
subunit O 0 2.4694339906261575e-09
was O 0 1.1658335630215788e-08
found O 0 6.581311606801421e-10
to O 0 5.042930517618061e-10
accumulate O 0 1.809346628078856e-08
in O 0 4.569233436058084e-09
comparison O 0 3.970538120512401e-09
to O 0 1.2369792967703575e-09
the O 0 5.290010651748389e-09
normal O 0 1.3772004869849752e-08
alpha O 0 6.254893492041447e-08
- O 0 5.118950952009982e-08
subunit O 0 1.928042614451897e-08
precursor O 0 1.1285258096904727e-06
levels O 0 4.1945182260860747e-07
. O 0 1.9730427425201924e-07

We O 0 5.471924282574037e-07
conclude O 0 6.084663937144796e-07
that O 0 1.0769640290675397e-08
the O 0 4.014509613625705e-08
1422 O 0 0.00012637561303563416
G O 0 0.0002766796969808638
- O 0 1.334957869403297e-05
- O 0 2.158046982003725e-06
> O 0 5.334351840247109e-07
C O 0 7.343205197685165e-06
mutation O 0 1.0482345658147096e-08
is O 0 7.122041845164517e-10
the O 0 1.8351590247434046e-09
cause O 0 4.221429605877347e-08
of O 0 4.89601518438576e-07
Hex B-Disease 0 0.11019200086593628
A I-Disease 1 0.8752445578575134
enzyme I-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
in O 0 1.766767809385783e-06
the O 0 2.3102570594346616e-06
proband O 0 0.001488171867094934
. O 0 2.612675643831608e-06

The O 0 2.5924698547896696e-06
resulting O 0 1.3342923921300098e-06
W474C O 0 1.0588863005978055e-05
substitution O 0 1.1991596693405882e-06
clearly O 0 1.2262241000371432e-07
interferes O 0 7.070588736723948e-08
with O 0 2.7944324632045436e-09
alpha O 0 4.382556539894722e-08
- O 0 2.6329454172469013e-08
subunit O 0 2.276255850475195e-09
processing O 0 2.178791191909113e-08
, O 0 1.127129167777241e-09
but O 0 2.211648225669549e-10
because O 0 3.374490409324693e-10
the O 0 9.821026214495987e-10
base O 0 7.68971553100073e-09
substitution O 0 3.1590463578368144e-08
falls O 0 1.58575642217329e-06
at O 0 7.299821191963929e-08
the O 0 3.2840410391088426e-09
first O 0 1.2467483934130996e-08
position O 0 2.3009064875623153e-08
of O 0 8.748331481456262e-08
exon O 0 1.4469922007265268e-06
13 O 0 3.6401067404767673e-07
, O 0 1.154726358976177e-08
aberrant O 0 3.17995159093698e-07
splicing O 0 1.373579834762495e-06
may O 0 3.2895531631993435e-08
also O 0 6.507122396470777e-09
contribute O 0 8.286336949936413e-09
to O 0 5.629514632232713e-08
Hex B-Disease 0 0.33225175738334656
A I-Disease 1 0.980404794216156
deficiency I-Disease 1 0.759658932685852
in O 0 1.4315135388187628e-07
this O 0 2.915744801157416e-08
proband O 0 7.39304450689815e-05
. O 0 1.5528208052728587e-07
. O 0 3.355202125021606e-07

Two O 0 1.6805677205411484e-06
frequent O 0 3.2363420814363053e-06
missense O 0 5.7242319599026814e-05
mutations O 0 1.439720199414296e-05
in O 0 0.0001362557231914252
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0006052248645573854

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 7.3357787186978385e-06
an O 0 1.3014535397815052e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9999568462371826
by O 0 2.5333358735224465e-06
early O 1 0.9999675750732422
childhood O 1 1.0
deafness B-Disease 1 1.0
and O 1 0.9999916553497314
goiter B-Disease 1 1.0
. O 0 0.002226980170235038

A O 0 2.767437217698898e-05
century O 0 9.806162779568695e-06
after O 0 9.435774472876801e-08
its O 0 1.965701601491787e-09
recognition O 0 6.513840578037389e-09
as O 0 1.5813794718155805e-08
a O 0 2.1907993641434587e-07
syndrome O 0 0.0005517237586900592
by O 0 4.284155252776145e-08
Vaughan O 0 0.2791370153427124
Pendred O 1 0.9391039609909058
, O 0 1.001103129283365e-07
the O 0 2.24005063387267e-07
disease O 0 0.014376583509147167
gene O 0 1.427967077916037e-07
( O 0 1.1584715053913897e-07
PDS O 1 0.9997294545173645
) O 0 1.0024597685287517e-07
was O 0 3.670945432077133e-07
mapped O 0 7.936252899298779e-08
to O 0 2.6284045162583425e-08
chromosome O 0 8.958915032053483e-07
7q22 O 0 0.00012095834972569719
- O 0 8.882932888809592e-05
q31 O 0 0.0004414853756316006
. O 0 3.668681301860488e-06

1 O 0 5.319195224728901e-06
and O 0 1.2539486249352194e-07
, O 0 3.362780987004044e-08
recently O 0 5.117252754871515e-08
, O 0 3.334198694915358e-09
found O 0 2.5324879970867187e-09
to O 0 1.253266157519306e-09
encode O 0 3.220529620762136e-08
a O 0 1.2902219737043197e-07
putative O 0 1.0912147445196752e-05
sulfate O 0 8.706785592949018e-05
transporter O 0 0.0009032634552568197
. O 0 1.4116235433903057e-05

We O 0 8.44688770484936e-07
performed O 0 1.5466740705960547e-06
mutation O 0 1.1230825158747848e-08
analysis O 0 3.282750959954228e-09
of O 0 2.6833498978362513e-08
the O 0 8.081244118329778e-08
PDS B-Disease 0 0.26230108737945557
gene O 0 4.754535254392067e-08
in O 0 1.4758811950343897e-08
patients O 0 1.6130892177557143e-08
from O 0 2.7223855170177558e-08
14 O 0 4.057480396113533e-07
Pendred B-Disease 0 5.0346552598057315e-06
families O 0 5.973888050903042e-10
originating O 0 2.952670286049397e-08
from O 0 6.322022461091592e-09
seven O 0 8.731174006015863e-09
countries O 0 3.5985861512877193e-10
and O 0 4.489085547731975e-09
identified O 0 1.957672957075829e-08
all O 0 2.801980691913286e-08
mutations O 0 1.1194039188922034e-06
. O 0 1.4468652125287917e-06

The O 0 1.8888208614953328e-06
mutations O 0 1.6065941110809945e-07
include O 0 6.383968553791419e-08
three O 0 3.6815187343108846e-08
single O 0 5.679915204837016e-08
base O 0 1.5231977101848315e-07
deletions O 0 3.4574352980598633e-07
, O 0 4.734815917117885e-08
one O 0 1.9595406186567743e-08
splice O 0 5.618252998829121e-06
site O 0 9.798802693694597e-07
mutation O 0 6.242914452059267e-08
and O 0 3.822810867859516e-08
10 O 0 4.2570999880808813e-07
missense O 0 2.5133163944701664e-05
mutations O 0 3.297325747553259e-06
. O 0 2.469926357662189e-06

One O 0 1.7297969634455512e-06
missense O 0 1.0736377589637414e-05
mutation O 0 7.71792258547066e-07
( O 0 1.0638044756206e-07
L236P O 0 2.3883570975158364e-05
) O 0 8.347095103999891e-08
was O 0 2.8168889798507735e-07
found O 0 7.719944683515223e-09
in O 0 2.076848026888456e-09
a O 0 3.0606892575946176e-09
homozygous O 0 3.0469792022813635e-08
state O 0 4.334479442036354e-09
in O 0 8.554397190607688e-09
two O 0 2.792642117555033e-09
consanguineous O 0 7.985341312632954e-07
families O 0 8.522326733206853e-10
and O 0 4.672444653408547e-09
in O 0 1.5829789035137765e-08
a O 0 6.409318409339448e-09
heterozygous O 0 4.862782621017914e-09
state O 0 3.4541010052180354e-09
in O 0 7.0444974298311536e-09
five O 0 9.163938052836329e-09
additional O 0 1.9667336204065577e-08
non O 0 7.838183591957204e-06
- O 0 2.1352097974158823e-05
consanguineous O 0 5.32563281012699e-05
families O 0 1.2456246167857898e-07
. O 0 1.8264356640429469e-06

Another O 0 1.2803935533156618e-05
missense O 0 3.259040749981068e-05
mutation O 0 5.00495104915899e-07
( O 0 1.1086064688470287e-07
T416P O 0 1.63176518981345e-05
) O 0 2.5456813546043122e-08
was O 0 7.564452886299478e-08
found O 0 1.942496385964887e-09
in O 0 1.2264124160665801e-09
a O 0 1.5065491076882154e-09
homozygous O 0 6.411519315463465e-09
state O 0 1.0665299754464286e-09
in O 0 2.4747008886549793e-09
one O 0 3.798989123282581e-09
family O 0 6.794659501707656e-09
and O 0 4.1925565241740514e-09
in O 0 7.022121994992858e-09
a O 0 4.930550190351823e-09
heterozygous O 0 2.716475933084439e-09
state O 0 3.5755656213609655e-09
in O 0 1.0537029915269613e-08
four O 0 6.817977293849253e-08
families O 0 3.0109067239436627e-08
. O 0 1.3779567780147772e-06

Pendred B-Disease 1 0.9935261011123657
patients O 0 4.900003204966197e-06
in O 0 1.1700510071932513e-07
three O 0 3.655970814975262e-08
non O 0 4.558165073831333e-06
- O 0 3.212197952962015e-06
consanguineous O 0 5.906959358981112e-06
families O 0 2.3133452931034526e-09
were O 0 4.827831023845874e-09
shown O 0 1.161458484943978e-09
to O 0 1.7279887520871284e-09
be O 0 2.2615160855110616e-09
compound O 0 2.6126357965949865e-07
heterozygotes O 0 3.24198083490046e-07
for O 0 4.62510740817379e-08
L236P O 0 2.659239362401422e-05
and O 0 5.612200197901984e-07
T416P O 0 0.00018397215171717107
. O 0 4.811360668099951e-06

In O 0 8.796768611318839e-07
total O 0 1.5789508722718892e-07
, O 0 2.9484327868090077e-08
one O 0 7.055147133172568e-09
or O 0 3.228812994748864e-09
both O 0 6.59331089725157e-10
of O 0 1.147262196354859e-08
these O 0 4.303059852883706e-10
mutations O 0 1.8680164082240935e-09
were O 0 1.6528951540806247e-09
found O 0 1.1290764989624336e-09
in O 0 2.523885322958108e-09
nine O 0 1.3523004049886822e-08
of O 0 1.0769640290675397e-08
the O 0 1.736891519499295e-08
14 O 0 1.0939199768245089e-07
families O 0 2.5921635948833455e-09
analyzed O 0 4.31763282904285e-07
. O 0 7.81586493303621e-07

The O 0 7.748299140075687e-07
identification O 0 3.0795175121056673e-07
of O 0 2.093194382268848e-07
two O 0 1.3088458317156437e-08
frequent O 0 3.2160892260435503e-07
PDS B-Disease 1 0.9877542853355408
mutations O 0 7.03617502040288e-08
will O 0 6.342966152317331e-09
facilitate O 0 2.4332887704758832e-08
the O 0 6.88575241269973e-08
molecular O 0 1.1401394658605568e-05
diagnosis O 0 0.024562254548072815
of O 0 0.4785122871398926
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 8.168343629222363e-05

Insertional O 0 0.0017009758157655597
mutation O 0 8.670370448271569e-07
by O 0 9.098298647813863e-08
transposable O 0 4.2179621232207865e-05
element O 0 1.3347543017516728e-06
, O 0 1.6351188492080837e-07
L1 O 0 0.00025339325657114387
, O 0 2.3085419798007933e-08
in O 0 1.3188546255094025e-08
the O 0 1.9105850412870495e-07
DMD B-Disease 1 1.0
gene O 0 1.906176976262941e-07
results O 0 5.274990755310682e-08
in O 0 1.3334827997368848e-07
X B-Disease 1 0.99998939037323
- I-Disease 1 0.9999980926513672
linked I-Disease 1 0.9999347925186157
dilated I-Disease 1 0.9997112154960632
cardiomyopathy I-Disease 1 1.0
. O 0 6.105430657044053e-05

X B-Disease 1 0.9999198913574219
- I-Disease 1 0.9996374845504761
linked I-Disease 1 0.9649919271469116
dilated I-Disease 1 0.9912055134773254
cardiomyopathy I-Disease 1 1.0
( O 0 0.00011991694918833673
XLDCM B-Disease 1 1.0
) O 0 3.13906667770425e-07
is O 0 9.230756603528789e-09
a O 0 1.5490249083427443e-08
clinical O 0 3.4578974918986205e-06
phenotype O 0 1.8504873366964603e-07
of O 0 1.729414407236618e-06
dystrophinopathy B-Disease 1 0.9324758648872375
which O 0 7.773524401955001e-08
is O 0 2.2624351281308464e-09
characterized O 0 8.09308708937806e-09
by O 0 3.939203629954591e-09
preferential O 0 1.0892828186115366e-06
myocardial B-Disease 1 0.9999868869781494
involvement I-Disease 0 9.704040166980121e-07
without O 0 3.7394372043308977e-08
any O 0 1.0838219210995703e-08
overt O 0 7.612098329445871e-07
clinical O 0 2.1661528080585413e-05
signs O 0 7.397444278467447e-05
of O 1 0.9784577488899231
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 0.0053236642852425575

To O 0 2.7448791684037133e-07
date O 0 1.6757760477048578e-06
, O 0 1.10727462754312e-08
several O 0 2.7435109739570862e-09
mutations O 0 9.771664366553523e-09
in O 0 1.9551205099332947e-08
the O 0 1.6925149566304754e-06
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
gene O 0 0.22715692222118378
, O 0 5.194939149077982e-05
DMD O 1 1.0
, O 0 2.041595905666327e-07
have O 0 1.04985087290288e-09
been O 0 1.6731063201547158e-09
identified O 0 4.009533594029335e-09
in O 0 4.925023500135239e-09
patients O 0 1.499329016496631e-08
with O 0 2.9022730885230885e-08
XLDCM B-Disease 1 1.0
, O 0 6.735628943488337e-08
but O 0 2.661364906231256e-09
a O 0 2.789565245464587e-09
pathogenic O 0 2.0607378914405672e-08
correlation O 0 4.07154043813307e-09
of O 0 8.645961280251413e-09
these O 0 2.200628790305359e-09
cardiospecific O 0 8.305996743729338e-06
mutations O 0 1.0521008420028011e-07
in O 0 2.529188236621849e-07
DMD O 1 1.0
with O 0 6.815884034949704e-08
the O 0 1.4945884458938963e-06
XLDCM B-Disease 1 1.0
phenotype O 0 1.0285854159519658e-06
has O 0 1.0060950295098792e-08
remained O 0 6.451857359479618e-08
to O 0 5.735969033082711e-09
be O 0 1.4874509624007715e-08
elucidated O 0 3.989296601503156e-05
. O 0 2.2917779460840393e-06

We O 0 5.767671495959803e-07
report O 0 3.397841652486022e-08
here O 0 4.258360331022004e-09
the O 0 9.227020258961716e-10
identification O 0 7.935765822253416e-09
of O 0 1.3123555575589307e-08
a O 0 4.402670228387251e-09
unique O 0 1.0921850090994667e-08
de O 0 1.7182667306769872e-06
novo O 0 3.7738557239208603e-06
L1 O 0 6.601220775337424e-06
insertion O 0 1.5704628708590462e-07
in O 0 1.1076337180782048e-08
the O 0 5.6616247690044474e-08
muscle O 0 7.571409241791116e-07
exon O 0 2.067328296107007e-06
1 O 0 5.673645091519575e-07
in O 0 1.8767067899716494e-07
DMD O 1 1.0
in O 0 1.5462389058029657e-07
three O 0 1.0139302020206742e-07
XLDCM B-Disease 1 0.9999998807907104
patients O 0 1.528396609273841e-07
from O 0 3.9423021291895566e-08
two O 0 9.466903705401819e-09
unrelated O 0 5.29832391293894e-07
Japanese O 0 1.00854376796633e-05
families O 0 1.097047928055872e-07
. O 0 7.453485295627615e-07

The O 0 2.879863586713327e-06
insertion O 0 2.546508085288224e-06
was O 0 2.044898110398208e-06
a O 0 5.093376032050401e-08
5 O 0 1.7243144156964263e-07
- O 0 1.2872661159235577e-07
truncated O 0 4.187132063293575e-08
form O 0 8.545460339348665e-09
of O 0 2.594247305864883e-08
human O 0 2.7952761882943378e-08
L1 O 0 1.4466154425463174e-05
inversely O 0 1.986277169407913e-07
integrated O 0 9.674848797658342e-07
in O 0 1.731856613673699e-08
the O 0 1.864898813153104e-08
5 O 0 9.920609755909027e-08
- O 0 3.1843975989431783e-07
untranslated O 0 2.0683768525486812e-05
region O 0 2.1673265848676238e-08
in O 0 6.00840133202496e-09
the O 0 1.6549716264080416e-08
muscle O 0 2.627076867156575e-07
exon O 0 6.942961476852361e-07
1 O 0 1.089434888967844e-07
, O 0 2.360043271920631e-09
which O 0 6.800101037818251e-10
affected O 0 2.260101883422294e-09
the O 0 3.882276278233121e-09
transcription O 0 4.41446168508719e-08
or O 0 5.24253040978806e-09
the O 0 8.116878724706567e-09
stability O 0 1.4994489205832906e-08
of O 0 3.317004271252699e-08
the O 0 3.04090654879019e-08
muscle O 0 4.938929620834642e-08
form O 0 1.5965326838340843e-08
of O 0 2.99135905379444e-07
dystrophin O 0 3.203399728590739e-06
transcripts O 0 3.053752095638629e-07
but O 0 6.888741244104324e-10
not O 0 8.358681108378008e-11
that O 0 5.508168574031025e-11
of O 0 5.028736538292833e-09
the O 0 1.3154961209238536e-07
brain O 0 0.0019089144188910723
or O 0 3.1953155144037737e-07
Purkinje O 1 0.9995362758636475
cell O 0 4.415515832079109e-06
form O 0 1.1495253460225285e-07
, O 0 3.040929641429102e-08
probably O 0 3.039549412164888e-08
due O 0 2.7922283152292948e-08
to O 0 2.586942882132348e-09
its O 0 3.3302582913563583e-09
unique O 0 2.9475035745463174e-09
site O 0 1.3794475250961113e-07
of O 0 8.489303837677653e-08
integration O 0 8.658950605422433e-07
. O 0 1.3999994052937836e-06

We O 0 2.3603782040027e-07
speculate O 0 2.704566668398911e-07
that O 0 2.0426964564279615e-09
this O 0 3.537643233908483e-10
insertion O 0 1.6209012798640288e-08
of O 0 2.265463372452814e-08
an O 0 4.5685104588244485e-09
L1 O 0 1.4989411283750087e-05
sequence O 0 2.842134527725193e-08
in O 0 6.608916436334766e-08
DMD O 1 1.0
is O 0 1.193123289056075e-08
responsible O 0 8.312582622238551e-09
for O 0 8.288276731605038e-10
some O 0 4.88436457946051e-10
of O 0 1.0626502344734945e-08
the O 0 2.1166026709096286e-09
population O 0 7.950028829695199e-11
of O 0 5.160602611908871e-09
Japanese O 0 4.101187869309797e-07
patients O 0 3.859464570155069e-08
with O 0 2.986017122452722e-08
XLDCM B-Disease 1 0.9999998807907104
. O 0 8.046604875744379e-07
. O 0 5.798833058179298e-07

Severe O 1 0.9738634824752808
early O 0 0.01503180991858244
- O 1 0.9988859295845032
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 0.001575235160999
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 0.342823326587677
red O 1 0.9999998807907104
hair O 1 0.999998927116394
pigmentation O 1 0.9991629123687744
caused O 0 1.1769649063353427e-05
by O 0 3.745958849776798e-07
POMC O 1 0.9999985694885254
mutations O 0 9.853388291958254e-07
in O 0 4.10214227031247e-07
humans O 0 1.962834630830912e-06
. O 0 1.2437127452358254e-06

Sequential O 0 2.2241387341637164e-05
cleavage O 0 7.081545845721848e-06
of O 0 3.289551841589855e-06
the O 0 4.503745003603399e-07
precursor O 0 2.267314812343102e-06
protein O 0 8.606854606796333e-08
pre O 0 2.121644683938939e-05
- O 0 2.802307108140667e-06
pro O 0 6.829555331933079e-06
- O 0 7.959863069118e-06
opiomelanocortin O 0 8.623888425063342e-05
( O 0 3.819116329850658e-07
POMC O 1 0.9857397675514221
) O 0 3.3709234514844866e-08
generates O 0 4.084407478899266e-08
the O 0 2.293313450252299e-08
melanocortin O 0 1.4414896213565953e-05
peptides O 0 3.604498033382697e-07
adrenocorticotrophin O 0 2.543827213230543e-05
( O 0 1.8052674022328574e-07
ACTH O 0 9.826662426348776e-05
) O 0 3.7191224322441485e-08
, O 0 2.7999185192584264e-08
melanocyte O 0 1.7194917745655403e-05
- O 0 5.016633622290101e-06
stimulating O 0 1.9544886527000926e-06
hormones O 0 7.793646545906086e-07
( O 0 8.386735572685211e-08
MSH O 0 0.06190585717558861
) O 0 1.1970620938939192e-08
alpha O 0 4.077861248674708e-08
, O 0 9.39372912789338e-10
beta O 0 7.49325312909832e-09
and O 0 1.3819203559251036e-09
gamma O 0 1.8153649250507442e-08
as O 0 2.083438088718026e-09
well O 0 1.2734635568278918e-09
as O 0 1.7633680071682534e-09
the O 0 4.164518507820958e-09
opioid O 0 2.4565406420151703e-07
- O 0 4.178508277163928e-07
receptor O 0 3.4231590007038903e-08
ligand O 0 8.425454893767892e-07
beta O 0 4.439270924194716e-06
- O 0 1.5467107004951686e-05
endorphin O 0 0.00021692553127650172
. O 0 2.2654733129456872e-06

While O 0 3.8728967410861515e-06
a O 0 7.239394506086683e-08
few O 0 1.0385111437472005e-08
cases O 0 6.255021833823093e-09
of O 0 4.849845254284446e-07
isolated O 1 0.9777429103851318
ACTH B-Disease 1 1.0
deficiency I-Disease 1 0.9999914169311523
have O 0 8.377011972982018e-09
been O 0 8.292217579253247e-09
reported O 0 9.785357946157092e-08
( O 0 7.766025333921789e-08
OMIM O 1 0.9999732971191406
201400 O 0 0.00019268719188403338
) O 0 3.972858308998184e-08
, O 0 7.5434858359813e-09
an O 0 1.3831551015641708e-08
inherited O 1 0.9999966621398926
POMC O 1 1.0
defect O 1 0.997563362121582
has O 0 2.742062932270528e-08
not O 0 2.7504005739587e-09
been O 0 8.535034901058225e-09
described O 0 3.7114123330184157e-08
so O 0 9.137739453990434e-09
far O 0 1.1495077956169553e-07
. O 0 4.4262992560106795e-07

Recent O 0 1.3461340131470934e-06
studies O 0 1.493925765316817e-07
in O 0 3.265634873628187e-08
animal O 0 9.395242983600838e-08
models O 0 3.868381881488858e-08
elucidated O 0 7.131426968953747e-07
a O 0 1.4230846723251034e-08
central O 0 5.0137888507606476e-08
role O 0 1.6868792585000847e-08
of O 0 6.668199148407439e-08
alpha O 0 8.082228646344447e-07
- O 0 1.94126232599956e-06
MSH O 0 0.22530034184455872
in O 0 1.2254028902702885e-08
the O 0 3.328511910538623e-09
regulation O 0 4.246139795327508e-08
of O 0 2.1433477215282437e-08
food O 0 9.786399246536348e-09
intake O 0 4.961227428879056e-09
by O 0 4.827312438671072e-10
activation O 0 1.3072091853416623e-08
of O 0 5.4180969044637095e-08
the O 0 1.596795158320674e-07
brain O 0 5.264465016807662e-06
melanocortin O 0 4.452806751942262e-05
- O 0 1.962658643606119e-06
4 O 0 2.0345946438737883e-07
- O 0 1.5028196287403262e-07
receptor O 0 1.074042899062988e-08
( O 0 1.9137319284823207e-08
MC4 O 0 0.0003884958568960428
- O 0 1.6011015304684406e-06
R O 0 2.815905418174225e-06
; O 0 4.448233781317867e-09
refs O 0 8.441990644314501e-07
3 O 0 1.0784361847981927e-07
- O 0 5.7884296467136664e-08
5 O 0 1.6501239485933183e-08
) O 0 7.020108938604608e-10
and O 0 4.3815576167283155e-10
the O 0 1.6045607065251488e-09
linkage O 0 4.707504075440738e-08
of O 0 4.752776305849693e-08
human O 0 5.110956067255756e-07
obesity B-Disease 1 0.9993717074394226
to O 0 1.4368500167449838e-08
chromosome O 0 3.674082904581155e-08
2 O 0 3.901742218204163e-08
in O 0 4.831238964442264e-09
close O 0 5.448084205994519e-09
proximity O 0 1.2439620888926584e-08
to O 0 1.5817013254704193e-09
the O 0 4.69924188450932e-08
POMC O 1 0.8891246318817139
locus O 0 2.5302114181613433e-07
, O 0 9.985702043024958e-09
led O 0 4.017282506652009e-08
to O 0 1.6716867889954301e-09
the O 0 8.250395033826408e-09
proposal O 0 6.559184306809129e-09
of O 0 1.7106094318819487e-08
an O 0 2.1665815808091793e-09
association O 0 1.6338859154529928e-07
of O 0 2.401425945208757e-06
POMC O 1 1.0
with O 0 4.0049386029750167e-07
human O 0 0.00015073345275595784
obesity B-Disease 1 1.0
. O 0 4.102442289877217e-06

The O 0 1.183916083391523e-06
dual O 0 8.93837466264813e-07
role O 0 3.298623312275595e-07
of O 0 1.1269319202256156e-06
alpha O 0 8.338703082699794e-06
- O 0 1.9655579308164306e-05
MSH O 1 0.8386145234107971
in O 0 1.0772356517918524e-07
regulating O 0 3.8418892245317693e-07
food O 0 1.1681724032541752e-07
intake O 0 2.4348216243197385e-07
and O 0 5.5980457602800016e-08
influencing O 0 8.555804924981203e-06
hair O 0 0.001182553474791348
pigmentation O 0 0.00014835219189990312
predicts O 0 6.901595952513162e-07
that O 0 1.5184954405000894e-09
the O 0 1.267551397177158e-08
phenotype O 0 9.245648868727585e-08
associated O 0 1.936922089385007e-08
with O 0 6.223153992124253e-09
a O 0 2.9716153449044214e-07
defect O 0 0.00017138628754764795
in O 0 2.138290028597112e-06
POMC O 1 0.9999971389770508
function O 0 4.1906396575086546e-08
would O 0 6.926426099340688e-09
include O 0 5.129418809701747e-07
obesity B-Disease 1 1.0
, O 0 7.75406618913621e-08
alteration O 0 7.269222805916797e-06
in O 0 1.212452957588539e-06
pigmentation O 1 0.9992511868476868
and O 0 0.0013751527294516563
ACTH B-Disease 1 1.0
deficiency I-Disease 1 0.9999992847442627
. O 0 2.004752604989335e-05

The O 0 1.529952783130284e-06
observation O 0 9.985560609493405e-06
of O 0 9.756040526553988e-07
these O 0 4.904356387669395e-08
symptoms O 0 1.6640673493384384e-05
in O 0 8.586866329096665e-08
two O 0 3.591753028331368e-08
probands O 0 0.0001879127521533519
prompted O 0 3.3859578252304345e-07
us O 0 8.934136985772057e-09
to O 0 8.713035848373352e-10
search O 0 4.925756247331492e-09
for O 0 1.4082922605851422e-09
mutations O 0 2.75875571276174e-08
within O 0 4.3456982012912704e-08
their O 0 1.7923876782788284e-07
POMC O 1 0.9981305003166199
genes O 0 1.2488162610679865e-06
. O 0 2.182544221795979e-06

Patient O 0 9.18024088605307e-05
1 O 0 5.078958565718494e-06
was O 0 1.5165878721745685e-06
found O 0 1.2069802046710265e-08
to O 0 1.187143494618681e-09
be O 0 1.0019542973083162e-09
a O 0 3.51493878447684e-09
compound O 0 1.2503852531153825e-07
heterozygote O 0 1.0189592103415634e-07
for O 0 1.9781281057618116e-09
two O 0 1.588182585443576e-09
mutations O 0 5.6064632936170256e-09
in O 0 1.966729890057195e-08
exon O 0 6.767978106836381e-07
3 O 0 3.141028344089136e-07
( O 0 2.6167993993908567e-08
G7013T O 0 7.2431275839335285e-06
, O 0 2.866546289226335e-08
C7133delta O 0 6.791161285946146e-05
) O 0 9.952312751693171e-09
which O 0 2.0342827422581422e-09
interfere O 0 6.150135511973076e-09
with O 0 4.704420186740776e-10
appropriate O 0 5.858077578579923e-09
synthesis O 0 1.600629673248477e-07
of O 0 4.4642240482062334e-07
ACTH O 0 0.00015325637650676072
and O 0 3.59833649099528e-07
alpha O 0 9.707273420644924e-06
- O 0 5.74152909393888e-05
MSH O 1 0.9927875399589539
. O 0 2.8718329758703476e-06

Patient O 0 6.424077582778409e-05
2 O 0 3.026486865564948e-06
was O 0 6.249073862818477e-07
homozygous O 0 9.333069073136357e-08
for O 0 5.018905291365172e-09
a O 0 7.2796431105359716e-09
mutation O 0 6.8421277532593194e-09
in O 0 2.074833638232576e-08
exon O 0 1.2213890840939712e-06
2 O 0 5.288303555062157e-07
( O 0 4.3613010092258264e-08
C3804A O 0 1.1553557669685688e-05
) O 0 3.508122148332404e-08
which O 0 2.873986382212479e-08
abolishes O 0 8.626463386463001e-05
POMC O 1 0.9994789958000183
translation O 0 2.2913758584763855e-05
. O 0 1.8433289596941904e-06

These O 0 4.2504387920416775e-07
findings O 0 1.7094099291625753e-07
represent O 0 1.5470112302296002e-08
the O 0 1.0789975135594432e-08
first O 0 6.35979269247855e-09
examples O 0 4.666744768400122e-09
of O 0 3.05289553637067e-08
a O 0 1.2159912898823677e-07
genetic B-Disease 1 0.9999997615814209
defect I-Disease 1 0.9999994039535522
within O 0 1.7040061095485726e-07
the O 0 2.2624389828251878e-07
POMC O 1 0.9999988079071045
gene O 0 1.0274742123783653e-07
and O 0 3.3325264769956675e-09
define O 0 1.3925604669395852e-08
a O 0 2.3907258395183817e-08
new O 0 5.620137244477519e-07
monogenic B-Disease 1 1.0
endocrine I-Disease 1 1.0
disorder I-Disease 1 0.9999998807907104
resulting O 0 1.9029906752621173e-06
in O 0 9.629259523080691e-08
early O 0 6.610236141568748e-06
- O 0 0.00030916431569494307
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 0.0003038663708139211
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 0.0050798445008695126
red O 1 0.9999979734420776
hair O 1 0.9999743700027466
pigmentation O 1 0.7729792594909668
. O 0 4.6621204319308163e-07
. O 0 8.176111805369146e-07

A O 0 7.107537385309115e-05
European O 0 3.831907179119298e-06
multicenter O 0 0.00012493407120928168
study O 0 1.2959404784851358e-06
of O 0 0.00037468684604391456
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.4594736512663076e-06
classification O 0 7.367587841144996e-06
of O 0 1.3092774224787718e-06
105 O 0 1.4772803069718066e-06
mutations O 0 1.725835474530868e-08
and O 0 6.358494619718158e-09
a O 0 1.3591839653770421e-08
general O 0 5.346381470872075e-08
system O 0 4.260312280734979e-08
for O 0 5.691580984290567e-09
genotype O 0 1.2986657793589984e-07
- O 0 1.8908524168637086e-07
based O 0 3.815140914298354e-08
prediction O 0 2.836653948179446e-06
of O 0 3.2337532047677087e-06
metabolic O 1 0.9974411725997925
phenotype O 0 1.8060825823340565e-05
. O 0 3.719811502378434e-06

Phenylketonuria B-Disease 1 0.9998840093612671
( O 0 7.586213905597106e-05
PKU B-Disease 1 1.0
) O 0 1.2933144262206042e-06
and O 0 6.956674383218342e-07
mild B-Disease 1 0.9992320537567139
hyperphenylalaninemia I-Disease 1 1.0
( O 1 0.8564092516899109
MHP B-Disease 1 1.0
) O 0 3.2649413128638116e-07
are O 0 1.0490266433293982e-08
allelic B-Disease 1 0.9999921321868896
disorders I-Disease 1 1.0
caused O 0 0.00043886227649636567
by O 0 5.208704934034358e-08
mutations O 0 2.139173638227021e-08
in O 0 1.0268585981521028e-08
the O 0 1.930029469576766e-08
gene O 0 5.536130842642706e-08
encoding O 0 2.2079461814428214e-07
phenylalanine O 0 6.990003021201119e-05
hydroxylase O 0 0.006372692063450813
( O 0 1.396156039845664e-05
PAH O 1 1.0
) O 0 3.6516332784231054e-06
. O 0 2.0272709662094712e-06

Previous O 0 6.082863819756312e-06
studies O 0 2.062667476820934e-07
have O 0 3.4758576017424048e-09
suggested O 0 1.3691232148005383e-08
that O 0 5.483997700395093e-10
the O 0 4.152810539892471e-09
highly O 0 6.636656735281576e-08
variable O 0 1.3177776736483793e-07
metabolic O 0 0.00034068385139107704
phenotypes O 0 3.111624755547382e-05
of O 1 0.9976643323898315
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
correlate O 0 9.074959234567359e-05
with O 0 1.8644755982677452e-05
PAH O 1 1.0
genotypes O 0 0.007240979000926018
. O 0 4.02668520109728e-05

We O 0 5.186914222576888e-07
identified O 0 2.1277476491832203e-07
both O 0 1.5811803422138837e-08
causative O 0 1.1509857813507551e-06
mutations O 0 9.724553251544421e-08
in O 0 1.1074229178120731e-07
686 O 0 5.5378703109454364e-05
patients O 0 2.460348014210467e-07
from O 0 1.1677234823537219e-07
seven O 0 1.9649607452265627e-07
European O 0 8.692566666468338e-07
centers O 0 7.512527190556284e-06
. O 0 2.758835307759e-06

On O 0 1.0577664397715125e-06
the O 0 3.854388452850799e-08
basis O 0 1.4386873914418175e-08
of O 0 2.4517701646686874e-08
the O 0 9.50789047493572e-09
phenotypic O 0 4.126394159698066e-08
characteristics O 0 2.0146373458374e-08
of O 0 8.176986909802508e-08
297 O 0 1.7723317569107166e-06
functionally O 0 6.499089067801833e-06
hemizygous O 0 5.162276647752151e-05
patients O 0 1.2418077233178337e-07
, O 0 9.072077311600424e-09
105 O 0 7.743278018779165e-08
of O 0 3.1565225100393945e-08
the O 0 5.3095812191372715e-09
mutations O 0 4.243530860037481e-09
were O 0 2.28355712117434e-09
assigned O 0 4.0858800787191285e-08
to O 0 2.9779960719622522e-09
one O 0 6.347443903820249e-09
of O 0 3.5030538469982275e-08
four O 0 1.6087936316466767e-08
arbitrary O 0 6.449347722536913e-08
phenotype O 0 7.42992369850981e-07
categories O 0 7.33336207758839e-07
. O 0 8.665724635648075e-07

We O 0 4.783137228514533e-07
proposed O 0 3.4489127642700623e-07
and O 0 3.9780221783303205e-08
tested O 0 2.3331125476033776e-07
a O 0 4.887116045182438e-09
simple O 0 3.605602927336804e-09
model O 0 4.050325408400113e-09
for O 0 7.336972140947751e-10
correlation O 0 4.058282598862206e-09
between O 0 2.0119559351883254e-09
genotype O 0 9.070956252799078e-08
and O 0 1.5391176333423573e-08
phenotypic O 0 1.7058530374924885e-06
outcome O 0 2.38609413827362e-06
. O 0 3.4302618132642237e-06

The O 0 4.197841917630285e-06
observed O 0 1.2773876960636699e-06
phenotype O 0 5.672633847098041e-07
matched O 0 2.227305628821341e-07
the O 0 5.663137159217513e-08
predicted O 0 9.122696553731657e-08
phenotype O 0 3.532616688062262e-08
in O 0 6.30390095679445e-09
79 O 0 1.3434085133212648e-07
% O 0 1.5745044157355892e-09
of O 0 4.356925487059016e-09
the O 0 3.952901561632416e-09
cases O 0 2.130869258820667e-09
, O 0 1.597128873598308e-09
and O 0 1.0816860740447964e-09
in O 0 1.6429564375641803e-09
only O 0 7.305301918947293e-10
5 O 0 1.0636965974697432e-08
of O 0 2.4124105379996763e-08
184 O 0 2.2954891676363331e-07
patients O 0 1.1501876429065305e-07
was O 0 2.3668791016007162e-07
the O 0 1.7074345493028886e-08
observed O 0 1.4417667060229178e-08
phenotype O 0 3.84045817369838e-09
more O 0 1.0440234093911371e-10
than O 0 3.260217373846075e-10
one O 0 7.6332318243999e-10
category O 0 4.648834206477659e-09
away O 0 1.637975977075712e-08
from O 0 5.948172621117465e-09
that O 0 1.1449750036973683e-09
expected O 0 1.0922479276587183e-07
. O 0 8.40188818074239e-07

Among O 0 3.642180217866553e-06
the O 0 3.198974525275844e-07
seven O 0 1.1983989622876834e-07
contributing O 0 4.7950344139735535e-08
centers O 0 1.3030437173711107e-07
, O 0 3.1442990433561135e-09
the O 0 2.450539327014667e-09
proportion O 0 2.4099395812271496e-09
of O 0 1.634249890969386e-08
patients O 0 2.159769696419289e-09
for O 0 2.6662425600676443e-09
whom O 0 4.4688301947815035e-09
the O 0 7.507759747227283e-09
observed O 0 2.216993166825887e-08
phenotype O 0 1.049939424291324e-08
did O 0 2.120700282048915e-09
not O 0 8.458957423407298e-10
match O 0 1.3499004580808105e-07
the O 0 9.143946044787299e-09
predicted O 0 4.918135942943991e-08
phenotype O 0 3.352905153519714e-08
was O 0 7.986622563294077e-08
4 O 0 4.364812866697321e-08
% O 0 2.937087684173889e-09
- O 0 4.049871549227646e-08
23 O 0 4.433159617178717e-08
% O 0 1.8810344393216383e-09
( O 0 5.20221821176392e-09
P O 0 2.166363401556737e-06
< O 0 3.602216338549624e-07
. O 0 5.456570306705544e-09
0001 O 0 1.2940460010213428e-06
) O 0 4.475603443410137e-09
, O 0 2.0065944461578056e-09
suggesting O 0 3.821300165185448e-09
that O 0 1.917368902537575e-10
differences O 0 9.4018137719587e-10
in O 0 4.442330669984784e-10
methods O 0 1.2348294609054733e-09
used O 0 1.7833647891762894e-09
for O 0 2.016008693317417e-09
mutation O 0 3.9948712782234e-08
detection O 0 1.4752669130757567e-06
or O 0 5.720391982322326e-08
phenotype O 0 3.730130515577912e-07
classification O 0 1.4445228089243756e-06
may O 0 7.481514074925144e-09
account O 0 1.6214446452167408e-09
for O 0 1.937493721015926e-09
a O 0 3.8707712590735355e-09
considerable O 0 3.423666461443986e-09
proportion O 0 4.503897255148104e-09
of O 0 5.3764154017699184e-08
genotype O 0 3.6248302421881817e-06
- O 0 3.492016548989341e-05
phenotype O 0 3.5280088468425674e-06
inconsistencies O 0 1.3863921594747808e-05
. O 0 4.28692010245868e-06

Our O 0 1.3578568314187578e-06
data O 0 1.6864457563769975e-07
indicate O 0 1.806198390852387e-08
that O 0 1.8910240040526105e-09
the O 0 9.334208783684517e-08
PAH O 1 1.0
- O 0 3.594761437852867e-05
mutation O 0 4.758835459028887e-08
genotype O 0 6.339170965929952e-08
is O 0 7.97369281713145e-10
the O 0 2.7651971823416943e-09
main O 0 5.998739283086252e-08
determinant O 0 2.191524259842481e-07
of O 0 2.813506227994367e-07
metabolic O 0 0.18238553404808044
phenotype O 0 2.8875010116280464e-07
in O 0 2.6402675601389092e-08
most O 0 4.458173918919783e-08
patients O 0 1.4626032225351082e-06
with O 0 0.0019752278458327055
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.0002545528986956924

In O 0 1.3442020190268522e-06
the O 0 6.42313793264293e-08
present O 0 2.896880779701405e-08
study O 0 3.1177851411712254e-08
, O 0 2.9880782292934782e-09
the O 0 3.8330818519227705e-09
classification O 0 1.3564624623541022e-07
of O 0 2.14921030305959e-07
105 O 0 3.6739678762387484e-05
PAH O 1 1.0
mutations O 0 4.257672685525904e-07
may O 0 1.9677056428690776e-08
allow O 0 3.3251361664099477e-09
the O 0 9.368505082818501e-09
prediction O 0 2.1785754711345362e-07
of O 0 3.175060214744008e-08
the O 0 1.1413953338035299e-08
biochemical O 0 9.68216795627086e-07
phenotype O 0 1.1697431290258464e-07
in O 0 3.0444116561056944e-08
> O 0 1.273623837505511e-07
10 O 0 2.5900250832933125e-08
, O 0 1.0462446464742925e-09
000 O 0 2.7897316456915178e-08
genotypes O 0 7.568522875089911e-08
, O 0 2.532178910996663e-09
which O 0 6.508086847212269e-10
may O 0 1.2732741527798908e-09
be O 0 1.711952524185989e-10
useful O 0 1.3626407779909755e-09
for O 0 5.640999334310948e-10
the O 0 1.7135745267182756e-08
management O 0 5.57686860247486e-07
of O 0 2.840530441972078e-06
hyperphenylalaninemia B-Disease 1 0.9999998807907104
in O 0 2.31756371249503e-06
newborns O 0 1.8016959074884653e-05
. O 0 2.8154518076917157e-06

Somatic O 0 0.0002520744747016579
instability O 0 8.836489541863557e-06
of O 0 3.881340944644762e-06
the O 0 1.6545524204047979e-06
CTG O 1 0.8631061315536499
repeat O 0 2.8115262011851883e-06
in O 0 1.607285327054342e-07
mice O 0 1.9443180576672603e-07
transgenic O 0 7.620661790497252e-07
for O 0 1.2208303701299883e-08
the O 0 5.275637704471592e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 7.747283962089568e-05
is O 0 4.9241617006146043e-08
age O 0 2.9959323910588864e-08
dependent O 0 3.803005910185675e-09
but O 0 4.615224036275123e-10
not O 0 1.3280365696033414e-10
correlated O 0 2.4849267088455917e-09
to O 0 9.231597153380733e-10
the O 0 1.4060411501759518e-08
relative O 0 6.349613812517418e-08
intertissue O 0 5.932386102358578e-06
transcription O 0 7.016955692051852e-07
levels O 0 2.1066639988021052e-07
and O 0 1.0970290276191008e-07
proliferative O 0 0.0023688876535743475
capacities O 0 3.157066021231003e-05
. O 0 3.0991736821306404e-06

A O 0 0.00017794828454498202
( O 0 2.1961659513181075e-06
CTG O 0 0.30244967341423035
) O 0 1.7875653668397717e-07
nexpansion O 0 4.9348145694239065e-06
in O 0 2.9120322153630696e-08
the O 0 4.771104755718625e-08
3 O 0 5.265617346594809e-07
- O 0 1.4521236835207674e-06
untranslated O 0 0.0004832146514672786
region O 0 1.8177266269958636e-07
( O 0 5.373165379296552e-08
UTR O 0 0.02542102336883545
) O 0 1.2258376536067317e-08
of O 0 7.914712085721476e-08
the O 0 2.2684515954551898e-07
DM O 1 1.0
protein O 0 5.220610432843387e-07
kinase O 0 7.751861517135694e-07
gene O 0 3.300139894690801e-07
( O 0 7.502923438096332e-08
DMPK O 1 0.9999821186065674
) O 0 4.899914785028159e-08
is O 0 5.947946135620441e-09
responsible O 0 6.562465415527186e-08
for O 0 2.019027220967473e-07
causing O 1 0.9999814033508301
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999756813049316
DM B-Disease 1 1.0
) O 0 2.0752309865201823e-05
. O 0 3.990343884652248e-06

Major O 0 0.0006617876351810992
instability O 0 4.676689059124328e-05
, O 0 3.076224004416872e-07
with O 0 1.1730673321608265e-08
very O 0 2.1369011005134553e-09
large O 0 6.060286494857792e-09
expansions O 0 2.0945083178958157e-07
between O 0 1.6231627597562692e-08
generations O 0 2.1983645126510964e-08
and O 0 1.08847286739433e-08
high O 0 1.769920174865547e-07
levels O 0 2.2548753975115687e-08
of O 0 1.1176632064291425e-08
somatic O 0 1.3038471706749988e-06
mosaicism O 0 0.00026837404584512115
, O 0 1.845715758008737e-08
is O 0 1.3926100272954045e-09
observed O 0 1.5990559987244524e-08
in O 0 3.587864227938553e-08
patients O 0 4.148317032104387e-07
. O 0 8.692492770023819e-07

There O 0 2.3171637621999253e-06
is O 0 4.776723372401648e-08
a O 0 4.9776758714870084e-08
good O 0 2.375779750707352e-08
correlation O 0 8.63524896033141e-09
between O 0 2.4992863334460935e-09
repeat O 0 3.705442352952559e-08
size O 0 1.4617782539971813e-08
( O 0 4.242656892472496e-09
at O 0 2.818511291025061e-08
least O 0 9.025903913162381e-10
in O 0 3.4525398096008075e-09
leucocytes O 0 5.712787242373452e-06
) O 0 1.2378910341226401e-08
, O 0 5.821032544872651e-09
clinical O 0 6.971132506805588e-07
severity O 0 8.561523259231762e-07
and O 0 3.691292249641265e-08
age O 0 4.748010553612403e-07
of O 0 1.7633927882343414e-06
onset O 0 0.08803579211235046
. O 0 2.117572421411751e-06

The O 0 3.655340333352797e-05
trinucleotide O 1 0.9928171634674072
repeat O 0 2.7109423172078095e-05
instability O 0 2.1803350591653725e-06
mechanisms O 0 2.074759066772458e-07
involved O 0 6.140772512708281e-08
in O 0 4.718957029581361e-07
DM B-Disease 1 1.0
and O 0 2.2674349509088643e-07
other O 0 4.3656786630208444e-08
human O 0 6.948638201720314e-06
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 2.1581483267141266e-08
unknown O 0 1.0572068731562467e-06
. O 0 5.791217745354516e-07

We O 0 4.1944741724364576e-07
studied O 0 3.3734690987330396e-06
somatic O 0 6.6444404183130246e-06
instability O 0 4.3216985545768694e-07
by O 0 4.728841318524246e-08
measuring O 0 7.398709840344964e-06
the O 0 7.694845294281549e-07
CTG O 0 0.3789403438568115
repeat O 0 5.826200322189834e-07
length O 0 1.8022307202159027e-08
at O 0 3.020172556489342e-08
several O 0 1.5601611114135494e-09
ages O 0 7.339607588363606e-09
in O 0 2.1469921396288782e-09
various O 0 7.79598607891785e-09
tissues O 0 4.6751304694225837e-07
of O 0 3.710354974373331e-07
transgenic O 0 1.9245549992774613e-05
mice O 0 1.7279556630001025e-07
carrying O 0 1.0550427731459422e-07
a O 0 5.6408861581758174e-08
( O 0 1.092687540449333e-07
CTG O 1 0.5745730400085449
) O 0 6.458591883529152e-08
55expansion O 0 8.608300049672835e-06
surrounded O 0 5.384757741921931e-07
by O 0 3.666142722735799e-09
45 O 0 2.4383854935194904e-08
kb O 0 1.2265742270756164e-06
of O 0 1.4711348228502175e-07
the O 0 1.0418764873065811e-07
human O 0 1.132309762397199e-06
DM B-Disease 1 1.0
region O 0 6.030424515302002e-07
, O 0 6.286933640353709e-09
using O 0 2.1801616068017893e-09
small O 0 2.2942323596453207e-08
- O 0 7.051449983919156e-07
pool O 0 2.123056447089766e-06
PCR O 0 3.8125239370856434e-05
. O 0 7.089533369253331e-07

These O 0 8.899019690034038e-07
mice O 0 8.023532132028777e-07
have O 0 7.095859455574782e-10
been O 0 3.9548928576493836e-09
shown O 0 2.5305759709937092e-09
to O 0 1.0832345020972411e-09
reproduce O 0 1.203442412389677e-08
the O 0 3.4973108853364465e-09
intergenerational O 0 1.1750898920581676e-07
and O 0 1.273794580924914e-08
somatic O 0 1.234348360412696e-06
instability O 0 2.2368166696651315e-07
of O 0 1.4875736553676688e-07
the O 0 8.557240960271884e-08
55 O 0 6.469793447649863e-07
CTG O 0 0.0004980356898158789
repeat O 0 3.7392629792520893e-07
suggesting O 0 2.258641984553833e-08
that O 0 3.059106024050351e-10
surrounding O 0 2.1684678941369384e-08
sequences O 0 2.8142768115912986e-09
and O 0 1.097270829752972e-09
the O 0 2.29903207582538e-09
chromatin O 0 9.6105623015319e-08
environment O 0 1.1242570430169962e-08
are O 0 2.806021248691337e-10
involved O 0 7.509478372469403e-09
in O 0 2.651460739855338e-08
instability O 0 1.051072445079626e-06
mechanisms O 0 6.042472250555875e-06
. O 0 1.6934999393924954e-06

As O 0 7.656101388420211e-07
observed O 0 2.9421138947327563e-07
in O 0 5.686058290876872e-09
some O 0 1.3923764363710234e-09
of O 0 2.7371511279739025e-08
the O 0 2.64870614330448e-08
tissues O 0 5.259170848148642e-06
of O 0 1.7598678823560476e-05
DM B-Disease 1 1.0
patients O 0 2.964748455269728e-05
, O 0 1.392656034937545e-08
there O 0 2.668221421586736e-09
is O 0 8.543810658956374e-10
a O 0 2.0152128854533657e-09
tendency O 0 5.205255781959295e-09
for O 0 2.854073422042802e-09
repeat O 0 6.972449995146235e-08
length O 0 1.3345612615012215e-08
and O 0 6.028076260378157e-09
somatic O 0 4.768903636431787e-06
mosaicism O 0 3.9417467633029446e-05
to O 0 7.265120061106245e-09
increase O 0 4.215843230070959e-09
with O 0 1.5118544194336891e-09
the O 0 1.318080045109582e-08
age O 0 3.079299659702883e-08
of O 0 2.6584441314980722e-08
the O 0 1.3128179432442266e-07
mouse O 0 3.932249910576502e-06
. O 0 3.78296164171843e-07

Furthermore O 0 6.613180630665738e-06
, O 0 1.1957892809277837e-07
we O 0 3.47252426813327e-09
observed O 0 6.621329262657127e-09
no O 0 1.427330031944507e-09
correlation O 0 9.091872810174095e-10
between O 0 4.820209786871033e-10
the O 0 6.448899192434965e-10
somatic O 0 2.3937175797072996e-07
mutation O 0 1.7619770531496215e-08
rate O 0 1.706633412368319e-08
and O 0 2.7467583763041148e-08
tissue O 0 0.0016670298064127564
proliferation O 0 0.0015109276864677668
capacity O 0 3.156161028528004e-06
. O 0 9.854619520410779e-07

The O 0 3.1679091989644803e-06
somatic O 0 1.3842863154422957e-05
mutation O 0 9.521995991690346e-08
rates O 0 3.181139973662539e-08
in O 0 3.495443712253632e-09
different O 0 7.767114729162472e-10
tissues O 0 2.54846327152336e-07
were O 0 1.241996638867704e-08
also O 0 2.487757999602991e-09
not O 0 2.1979977560260267e-10
correlated O 0 6.4636056507083595e-09
to O 0 1.5750810655745795e-09
the O 0 9.077044893501807e-09
relative O 0 5.404287506394212e-08
inter O 0 6.25900793238543e-06
- O 0 3.1328570457844762e-06
tissue O 0 1.907003934320528e-06
difference O 0 1.2607904054107166e-08
in O 0 2.8453224221181017e-09
transcriptional O 0 2.0793697430576685e-08
levels O 0 9.213799501139874e-09
of O 0 9.222819841170349e-09
the O 0 2.4079225280360106e-09
three O 0 1.1260956611636175e-09
genes O 0 2.570250456912504e-09
( O 0 3.2595799837054074e-08
DMAHP O 1 0.9999706745147705
, O 0 2.828494132245396e-07
DMPK O 1 0.9918667674064636
and O 0 1.1592506865554242e-07
59 O 0 1.2860099332101527e-06
) O 0 1.3576863189257438e-08
surrounding O 0 1.8781857136218605e-07
the O 0 1.281170654010566e-07
repeat O 0 1.5693146906414768e-06
. O 0 1.7693008658170584e-07
. O 0 4.648083233860234e-07

A O 0 0.00010234395449515432
novel O 0 3.8554294405912515e-06
missense O 0 1.0178487173106987e-05
mutation O 0 2.1037730846273917e-07
in O 0 3.903454270925977e-08
patients O 0 4.654932084235952e-08
from O 0 1.3488489969404327e-07
a O 0 6.003546673127858e-07
retinoblastoma B-Disease 0 0.049874063581228256
pedigree O 0 1.79770722752437e-05
showing O 0 9.773286819836358e-07
only O 0 1.9008719931434825e-08
mild O 0 7.227280320876162e-07
expression O 0 3.9035583654367656e-08
of O 0 6.432755981222726e-07
the O 0 3.003983010785305e-06
tumor B-Disease 1 0.9598410725593567
phenotype O 0 4.42614054918522e-06
. O 0 1.1350623481121147e-06

We O 0 5.589402576333669e-07
have O 0 3.2303282271328726e-09
used O 0 1.739696564584392e-08
single O 0 3.059604836153085e-08
strand O 0 5.1342052387326476e-08
conformation O 0 3.2704907226843716e-08
polymorphism O 0 1.3982908164678065e-08
analysis O 0 1.274007788154563e-09
to O 0 8.057841616171402e-10
study O 0 3.3036047231149723e-09
the O 0 8.06210476156366e-09
27 O 0 1.7258263085295766e-07
exons O 0 1.0912567205423329e-07
of O 0 3.8305913108160894e-08
the O 0 3.7936040087060974e-08
RB1 O 0 0.2532236576080322
gene O 0 1.9452114585760683e-08
in O 0 2.756928907388101e-09
individuals O 0 2.2034207791676863e-10
from O 0 2.132675547272811e-08
a O 0 2.9889687169770696e-08
family O 0 4.982434376188394e-08
showing O 0 4.654701513118198e-07
mild O 0 1.008877688946086e-06
expression O 0 5.167805738892639e-08
of O 0 4.875239483226324e-07
the O 0 1.3339755469132797e-06
retinoblastoma B-Disease 0 0.0023336175363510847
phenotype O 0 1.8906710465671495e-05
. O 0 7.012312380538788e-06

In O 0 3.170453965140041e-06
this O 0 3.9140704899409684e-08
family O 0 2.227934103871121e-08
affected O 0 1.3970963941289938e-08
individuals O 0 9.34654686979286e-10
developed O 0 2.85549674572394e-07
unilateral B-Disease 0 6.34437965345569e-05
tumors I-Disease 1 1.0
and O 0 5.628139660984743e-07
, O 0 5.1046967541878985e-08
as O 0 7.071529140034727e-09
a O 0 4.7971728811546654e-09
result O 0 3.822276717357909e-09
of O 0 2.476543592422331e-08
linkage O 0 1.0490430213394575e-07
analysis O 0 9.851272686489665e-09
, O 0 7.113574174155701e-09
unaffected O 0 1.6808677116841864e-07
mutation O 0 7.28157356633119e-09
carriers O 0 3.853107610751749e-09
were O 0 7.565041038049003e-09
also O 0 3.910636259263356e-09
identified O 0 1.0897045932267702e-08
within O 0 3.263026115973844e-08
the O 0 3.117167182153935e-07
pedigree O 0 2.023036176979076e-05
. O 0 2.0346988094388507e-06

A O 0 5.9990983572788537e-05
single O 0 1.2926349199915421e-06
band O 0 3.2499876851943554e-06
shift O 0 3.860863273530413e-08
using O 0 2.290520129122342e-08
SSCP O 0 0.122613824903965
was O 0 3.973245270572079e-07
identified O 0 2.736895332589029e-08
in O 0 2.099980100922494e-08
exon O 0 8.581067731938674e-07
21 O 0 1.7414268427273782e-07
which O 0 2.3826260964199264e-09
resulted O 0 3.663474501536257e-08
in O 0 7.2769776870984515e-09
a O 0 1.4196172237745941e-08
missense O 0 6.591065471184265e-07
mutation O 0 3.052371511103047e-08
converting O 0 7.955816840876651e-07
a O 0 1.4653812741016736e-07
cys O 0 0.000706168997567147
- O 0 1.2695018995145801e-05
- O 0 3.5505354389897548e-06
> O 0 1.142428573075449e-06
arg O 0 2.8781154469470493e-05
at O 0 4.4041050273335713e-07
nucleotide O 0 5.715287798579993e-08
position O 0 4.532890685027269e-08
28 O 0 1.1593966320333493e-07
in O 0 1.3692851297264497e-08
the O 0 1.1241031216968622e-07
exon O 0 1.4915590327291284e-05
. O 0 1.103928070733673e-06

The O 0 5.07323147758143e-06
mutation O 0 7.903961432020878e-07
destroyed O 0 2.2995627659838647e-05
an O 0 8.895542435993775e-08
NdeI O 0 3.997923340648413e-05
restriction O 0 4.089849596766726e-07
enzyme O 0 5.605406840913929e-07
site O 0 5.110598976898473e-06
. O 0 6.857376888547151e-07

Analysis O 0 1.3266375162857003e-06
of O 0 1.1962254120589932e-06
all O 0 2.7024775306472293e-08
family O 0 3.2445012010384744e-08
members O 0 2.970547363645437e-09
demonstrated O 0 1.5165685596230105e-08
that O 0 6.654268802641639e-10
the O 0 1.225265044979551e-08
missense O 0 2.3638253878743853e-06
mutation O 0 1.4284370308814687e-07
co O 0 1.5251540617100545e-06
- O 0 6.8902713792340364e-06
segregated O 0 4.29517422162462e-06
with O 0 1.288411510813603e-08
patients O 0 1.3888076466628263e-07
with O 0 1.3699218470719643e-07
tumors B-Disease 1 1.0
or O 0 2.2817459921498084e-06
who O 0 1.3914936403125466e-07
, O 0 2.1937948346817393e-08
as O 0 9.346230456230842e-09
a O 0 6.4540208732921656e-09
result O 0 5.843113104475606e-09
of O 0 5.2762285207563764e-08
linkage O 0 2.1691509743959614e-07
analysis O 0 1.1530998378361801e-08
had O 0 2.0288858593175974e-08
been O 0 4.84810369627553e-09
predicted O 0 1.7185366019134563e-08
to O 0 3.0400928441309816e-09
carry O 0 3.426536210326958e-08
the O 0 1.0188561816448782e-07
predisposing O 0 8.005669769772794e-06
mutation O 0 5.882522486899688e-07
. O 0 1.2017882227155496e-06

These O 0 1.8301759041605692e-07
observations O 0 1.0785303174998262e-06
point O 0 1.0032535868731429e-07
to O 0 1.9008745688608997e-09
another O 0 8.114138694281792e-09
region O 0 1.4240050916214386e-08
of O 0 6.039828548409787e-08
the O 0 1.1364211616182729e-07
RB1 O 1 0.9989550113677979
gene O 0 5.2284327978213696e-08
where O 0 1.3648107533015263e-08
mutations O 0 8.708222587472392e-09
only O 0 9.781170318134969e-10
modify O 0 1.4624921718109363e-08
the O 0 8.448335364619197e-09
function O 0 9.629930186605407e-10
of O 0 8.39901037608115e-09
the O 0 2.4836298351260666e-08
gene O 0 2.1268503402893657e-08
and O 0 1.956641515477031e-09
raise O 0 5.1919788468524075e-09
important O 0 2.476405303042384e-09
questions O 0 9.457045146987753e-10
for O 0 6.396004281761236e-10
genetic O 0 3.464910847128522e-08
counseling O 0 1.9785025173746362e-08
in O 0 3.2512208480994786e-09
families O 0 2.1059624877306504e-10
with O 0 8.043944399460656e-10
these O 0 4.378151174933009e-09
distinctive O 0 9.168378483082051e-07
phenotypes O 0 1.1132536883451394e-06
. O 0 1.3566126710884419e-07
. O 0 1.1088618521171156e-06

Maternal B-Disease 0 0.001857364783063531
disomy I-Disease 1 0.8986061811447144
and O 0 0.00016140553634613752
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 0.4748667776584625
with O 0 1.7650432937443838e-06
gamete O 0 0.0012974846176803112
complementation O 1 0.9996625185012817
in O 0 9.132268701250723e-07
a O 0 7.288788594905782e-08
case O 0 6.941201036170241e-08
of O 0 4.887109525952837e-07
familial O 0 3.648291567515116e-06
translocation O 0 2.879201701944112e-06
( O 0 5.986988327322251e-08
3 O 0 1.8321877348626003e-07
; O 0 2.325333925412565e-09
15 O 0 2.3355140044145628e-08
) O 0 2.7346451769716396e-09
( O 0 3.745431520485454e-09
p25 O 0 1.2585542208398692e-06
; O 0 6.503858784867589e-09
q11 O 0 1.0375588317401707e-06
. O 0 2.089974415753204e-08
2 O 0 3.66633400972205e-07
) O 0 4.791724705910383e-08
. O 0 2.913894547873497e-07

Maternal B-Disease 0 0.001264612190425396
uniparental I-Disease 1 0.9998753070831299
disomy I-Disease 1 0.9995937943458557
( I-Disease 0 4.664298103307374e-05
UPD I-Disease 1 1.0
) I-Disease 0 1.757862406748245e-07
for I-Disease 0 1.4445963536502404e-08
chromosome I-Disease 0 3.412005966652032e-08
15 I-Disease 0 3.239671642063513e-08
is O 0 8.582257127187631e-10
responsible O 0 3.821380101243221e-09
for O 0 1.1518793696652097e-09
an O 0 4.5149728400417644e-10
estimated O 0 1.3243669494400478e-09
30 O 0 8.6051272774057e-09
% O 0 2.3058202569536945e-10
of O 0 1.1226150009591152e-09
cases O 0 2.2529742516042006e-09
of O 0 9.32550392462872e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999996423721313
PWS B-Disease 1 1.0
) O 0 8.086470188573003e-05
. O 0 5.6703793234191835e-06

We O 0 5.307179549163266e-07
report O 0 1.547976893334635e-07
on O 0 4.856991608903627e-08
an O 0 1.3927589082030067e-09
unusual O 0 7.864732864959478e-09
case O 0 6.044885925149401e-09
of O 0 8.488526503924732e-08
maternal B-Disease 0 1.4625446738136816e-06
disomy I-Disease 0 9.442443115403876e-05
15 I-Disease 0 2.1812552120081818e-07
in O 0 1.0427372387766809e-07
PWS B-Disease 1 1.0
that O 0 8.887974800586562e-09
is O 0 2.952522448751438e-09
most O 0 1.616090816725091e-09
consistent O 0 2.619570871331689e-08
with O 0 2.276750565854968e-09
adjacent O 0 6.451980425481452e-07
- O 0 3.0583044008380966e-07
1 O 0 1.2630810886093968e-07
segregation O 0 4.241324234044441e-07
of O 0 9.846051085560248e-09
a O 0 4.0762802022698e-09
paternal O 0 9.78925953631915e-08
t O 0 4.4911351437804115e-07
( O 0 8.021961761528473e-09
3 O 0 2.309784186138586e-08
; O 0 8.299841369741046e-10
15 O 0 1.494116119715727e-08
) O 0 1.2904127766333318e-09
( O 0 3.0315812082903904e-09
p25 O 0 1.8470067288944847e-06
; O 0 5.202079655930447e-09
q11 O 0 6.026244818713167e-07
. O 0 4.025856092937374e-09
2 O 0 1.6292299065412408e-08
) O 0 7.179845606941626e-10
with O 0 2.6070223757557187e-10
simultaneous O 0 5.7706262879264614e-08
maternal O 0 1.3975435422253213e-06
meiotic O 0 0.00031349927303381264
nondisjunction O 0 0.00014048842422198504
for O 0 8.57660154451878e-07
chromosome O 0 2.4919252155086724e-06
15 O 0 2.5662723146524513e-06
. O 0 1.8001974240178242e-06

The O 0 1.0296581422153395e-05
patient O 0 1.153281846200116e-05
( O 0 3.382488387160265e-07
J O 1 0.7530153393745422
. O 0 4.454799196196291e-08
B O 0 1.934225110744592e-06
. O 0 1.9801817963127633e-09
) O 0 7.49659390120172e-10
, O 0 5.865946062222349e-10
a O 0 2.2168988866866357e-09
17 O 0 4.632055095044052e-08
- O 0 9.537863832065341e-08
year O 0 3.43131709712452e-08
- O 0 4.028301248126809e-07
old O 0 1.7434089158996358e-06
white O 0 8.912797966331709e-08
male O 0 1.8060848816503494e-08
with O 0 9.505189524361413e-09
PWS B-Disease 1 1.0
, O 0 3.759426192573301e-07
was O 0 4.281680219264672e-07
found O 0 3.891988953341752e-09
to O 0 1.225766932400063e-09
have O 0 7.700147186540107e-10
47 O 0 1.9820644681090016e-08
chromosomes O 0 6.357403492529556e-09
with O 0 3.6604272946050287e-09
a O 0 7.179687600000761e-08
supernumerary O 0 8.653726399643347e-05
, O 0 3.663139125364978e-08
paternal O 0 2.9746490781690227e-07
der O 0 0.02139889821410179
( O 0 3.7732110769184146e-08
15 O 0 8.286039587801497e-08
) O 0 2.7716711148428885e-09
consisting O 0 1.8620092134824517e-08
of O 0 1.2738097154851857e-07
the O 0 1.1031518454274192e-07
short O 0 7.0314786171366e-07
arm O 0 4.45150799350813e-05
and O 0 6.080307457523304e-08
the O 0 2.931320182142372e-07
proximal O 0 7.686067692702636e-05
long O 0 1.50522203057335e-06
arm O 0 0.00012104189954698086
of O 0 3.750090854737209e-06
chromosome O 0 5.515977363756974e-07
15 O 0 3.4470414789211645e-07
, O 0 6.011705266928402e-08
and O 0 1.5306750356103294e-07
distal O 0 0.0006863457383587956
chromosome O 0 0.0002998726849909872
arm O 1 0.9963674545288086
3p O 1 0.9999209642410278
. O 0 7.571846072096378e-05

The O 0 1.1753911167033948e-05
t O 0 1.4386358998308424e-05
( O 0 4.27998152474629e-08
3 O 0 5.852943019135637e-08
; O 0 1.5820361687346463e-09
15 O 0 6.4307115188455555e-09
) O 0 3.9495687276236424e-10
was O 0 1.1053164605812071e-08
present O 0 1.1615337580650476e-09
in O 0 1.3086703942732925e-09
the O 0 2.4524657860069965e-09
balanced O 0 2.500588180964769e-09
state O 0 6.780596084610124e-10
in O 0 2.2406065891544813e-09
the O 0 8.129831918779473e-09
patients O 0 3.183458829880692e-08
father O 0 4.1472486600468983e-07
and O 0 4.706453538005917e-08
a O 0 5.762294108535571e-07
sister O 0 2.5701916456455365e-05
. O 0 2.3159220745583298e-06

Fluorescent O 0 0.0002147433115169406
in O 0 5.70657903153915e-07
situ O 0 4.778810307470849e-06
hybridization O 0 6.79331435549102e-08
analysis O 0 6.622314696613785e-09
demonstrated O 0 2.228754247823872e-08
that O 0 8.869950884893285e-10
the O 0 8.951128904755024e-08
PWS B-Disease 1 1.0
critical O 0 7.443214258273656e-07
region O 0 7.709589056048571e-08
resided O 0 4.831646833736158e-07
on O 0 3.190759301219259e-08
the O 0 7.041112581873676e-09
derivative O 0 9.19301967883257e-08
chromosome O 0 4.7454296492333015e-08
3 O 0 2.919039054916084e-08
and O 0 2.470588178482558e-09
that O 0 3.1626182228627897e-10
there O 0 1.0616386658668375e-09
was O 0 2.700298118440969e-08
no O 0 3.2454836595974257e-09
deletion O 0 1.555680917419977e-08
of O 0 6.418961362442133e-08
the O 0 5.173047270545794e-07
PWS B-Disease 1 1.0
region O 0 1.0346892622692394e-06
on O 0 1.484212361901882e-07
the O 0 3.022586980705455e-08
normal O 0 4.535433362207186e-08
pair O 0 5.994827034783157e-08
of O 0 5.7931565322633105e-08
15s O 0 8.255896318587475e-06
present O 0 4.6321969193741097e-07
in O 0 1.4294906804934726e-06
J O 1 0.9990389347076416
. O 0 4.504764092416735e-06

B O 0 0.04355194792151451
. O 0 5.762015643995255e-05

Methylation O 0 3.886215381498914e-06
analysis O 0 3.388167328921554e-07
at O 0 4.327889655542094e-07
exon O 0 5.693754587809963e-07
alpha O 0 1.2245902780705364e-07
of O 0 4.0432801995393675e-08
the O 0 1.491030054978637e-08
small O 0 1.3509726670690725e-08
nuclear O 0 3.7459374198078876e-06
ribonucleoprotein O 0 4.7806399379624054e-05
- O 0 1.1868824003613554e-06
associated O 0 1.0193538457770046e-07
polypeptide O 0 7.849777148294379e-07
N O 0 9.700846703708521e-07
( O 0 1.8869393159093306e-08
SNRPN O 1 0.932658314704895
) O 0 2.8302443055849835e-08
gene O 0 5.1423981517473294e-08
showed O 0 3.433746087466716e-08
a O 0 9.794784538996737e-09
pattern O 0 8.671182882835637e-08
characteristic O 0 7.791753375840926e-08
of O 0 5.06647879205957e-08
only O 0 1.4784161672665164e-09
the O 0 8.279432250901664e-09
maternal O 0 2.262054863422236e-07
chromosome O 0 7.427543380345014e-08
15 O 0 1.3819203559251036e-07
in O 0 4.0827026737133565e-07
J O 1 0.9921635389328003
. O 0 2.2759804778615944e-06

B O 0 0.023672759532928467
. O 0 2.8454127459554e-05

Maternal B-Disease 0 0.0003619731869548559
disomy I-Disease 0 0.23877832293510437
was O 0 6.701262464048341e-06
confirmed O 0 8.183009470030811e-08
by O 0 3.3456526438158107e-09
polymerase O 0 2.697783827443345e-07
chain O 0 2.3684258110279188e-07
reaction O 0 8.15466361103745e-09
analysis O 0 8.853628052918339e-09
of O 0 3.302654860704024e-08
microsatellite O 0 9.40332483878592e-07
repeats O 0 1.6447545192477264e-07
at O 0 8.343115354136899e-08
the O 0 1.4856052388267926e-08
gamma O 0 1.543635562484269e-06
- O 0 1.0850640137505252e-06
aminobutyric O 0 1.0983823813148774e-05
acid O 0 4.4136913857073523e-07
receptor O 0 9.121669819478484e-08
beta3 O 0 1.1853060641442426e-05
subunit O 0 6.366664706547454e-07
( O 0 2.485691936726653e-07
GABRB3 O 1 0.8375250101089478
) O 0 5.400051463766431e-07
locus O 0 3.6796625408896944e-06
. O 0 4.809800770999573e-07

A O 0 0.0001433540164725855
niece O 0 0.00010355378617532551
( O 0 9.153212090495799e-07
B O 0 2.3706888896413147e-05
. O 0 1.083177103566868e-08
B O 0 1.1182836487932946e-06
. O 0 1.0501250979899623e-09
) O 0 1.472696548043828e-10
with O 0 1.9742824042268126e-10
45 O 0 5.2216830859208585e-09
chromosomes O 0 2.36555486310408e-09
and O 0 1.6577825778796296e-09
the O 0 2.916271668595982e-09
derivative O 0 2.5064963438126142e-08
3 O 0 4.921927043710639e-08
but O 0 1.569173790905154e-09
without O 0 2.683845146123076e-09
the O 0 8.751414704022409e-09
der O 0 3.5448287235340104e-05
( O 0 1.040962338549889e-08
15 O 0 3.295550499160527e-08
) O 0 2.9972451187632032e-09
demonstrated O 0 7.583504491037729e-09
a O 0 5.556905158243808e-09
phenotype O 0 3.7272677388955344e-08
consistent O 0 1.78894588032108e-08
with O 0 1.7201360336116522e-09
that O 0 1.3535847998014106e-09
reported O 0 1.3805354193152652e-08
for O 0 1.1875199490418709e-08
haploinsufficiency O 0 5.827414497616701e-05
of O 0 5.0584344535309356e-06
distal O 0 4.30084255640395e-05
3 O 0 1.1852450370497536e-05
p O 0 1.2218412848596927e-05
. O 0 1.8888713384512812e-06

Uniparental B-Disease 1 1.0
disomy I-Disease 1 0.9999998807907104
associated O 0 6.547376870003063e-06
with O 0 1.1535843214005581e-07
unbalanced O 0 3.853242105833488e-06
segregation O 0 3.030171683349181e-05
of O 0 6.235560476852697e-07
non O 0 2.2949488993617706e-05
- O 0 1.4834165995125659e-05
Robertsonian O 0 0.00030432792846113443
translocations O 0 1.3313192539499141e-06
has O 0 1.2075881627993112e-08
been O 0 5.236384215123735e-09
reported O 0 6.345385994421804e-09
previously O 0 1.1529085242045767e-08
but O 0 4.687062959973787e-10
has O 0 1.0585142484753618e-10
not O 0 1.3435577650433572e-10
, O 0 1.9504442505535735e-10
to O 0 2.405410315375889e-10
our O 0 2.823729250422957e-09
knowledge O 0 2.9353307340329593e-08
, O 0 2.915175878470677e-09
been O 0 5.501409883201802e-10
observed O 0 3.2691855889055432e-09
in O 0 2.809332100284223e-09
a O 0 7.859034312218682e-09
case O 0 6.432063059946813e-08
of O 0 6.252917501115007e-06
PWS B-Disease 1 1.0
. O 0 2.6915753551293164e-05

Furthermore O 0 4.036427344544791e-05
, O 0 8.403675337831373e-07
our O 0 1.548690278241338e-07
findings O 0 5.395358115833915e-08
are O 0 2.2287405254672876e-09
best O 0 1.4194305286707731e-08
interpreted O 0 1.635185320481014e-08
as O 0 1.9415676177914065e-08
true O 0 6.469861091318307e-08
gamete O 0 4.6932054829085246e-06
complementation O 0 0.0003781132400035858
resulting O 0 6.411693789232231e-07
in O 0 3.620759798650397e-07
maternal B-Disease 0 0.00015889204223640263
UPD I-Disease 1 1.0
15 I-Disease 0 0.0001681973080849275
and O 0 9.18078440008685e-05
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.9850515127182007
- I-Disease 1 0.9998382329940796
Jampel I-Disease 1 1.0
syndrome I-Disease 1 0.9999982118606567
type I-Disease 0 0.00010100455256178975
2 I-Disease 0 2.6489229639992118e-05
and O 0 7.359782330240705e-07
Stuve B-Disease 1 0.9999998807907104
- I-Disease 1 0.999998927116394
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
: O 0 5.040338919570786e-07
a O 0 1.0390208160515613e-07
case O 0 5.741883057908126e-08
for O 0 6.793391804649218e-08
" O 0 4.847320838052838e-07
lumping O 0 9.196206519845873e-06
" O 0 1.6644518154862453e-06
. O 0 4.690627122272417e-07

Recent O 0 9.353319683214067e-07
studies O 0 8.142793461729525e-08
demonstrated O 0 4.0994159178353584e-08
the O 0 6.6324270520112805e-09
existence O 0 4.670023301400761e-08
of O 0 2.7175552475000586e-08
a O 0 8.572364151859801e-09
genetically O 0 1.0270156991509793e-07
distinct O 0 6.531021057298858e-09
, O 0 4.956441923553712e-09
usually O 0 1.3347514205008792e-09
lethal O 0 2.8443635002872725e-08
form O 0 4.600961389655822e-09
of O 0 2.7559789117503897e-08
the O 0 8.508107640636808e-08
Schwartz B-Disease 0 8.135251846397296e-05
- I-Disease 1 0.5197896957397461
Jampel I-Disease 1 1.0
syndrome I-Disease 1 0.9999996423721313
( O 0 4.381388407637132e-06
SJS B-Disease 1 1.0
) O 0 7.376661415037233e-08
of O 0 1.563411046845431e-06
myotonia B-Disease 1 0.9999996423721313
and O 0 3.66623280569911e-05
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 7.897609179963183e-07
which O 0 9.966753822254759e-08
we O 0 3.97106241223355e-08
called O 0 1.0976774547089008e-06
SJS B-Disease 1 0.999985933303833
type I-Disease 0 2.525473610148765e-05
2 I-Disease 0 1.9680170225910842e-05
. O 0 2.475198925822042e-06

This O 0 5.474395493365591e-06
disorder O 1 0.9999703168869019
is O 0 1.8681194546843471e-07
reminiscent O 0 0.00024829330504871905
of O 0 2.878007535400684e-06
another O 0 2.6103418804268586e-07
rare O 0 1.5522685998803354e-06
condition O 0 1.9952847651438788e-05
, O 0 8.602111023492398e-08
the O 0 4.588121100823628e-07
Stuve B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999972581863403
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 2.858718107745517e-05
SWS B-Disease 1 1.0
) O 0 1.8412575286674837e-07
, O 0 1.0648515846867213e-08
which O 0 4.295960476241589e-09
comprises O 0 1.0180830400940977e-07
campomelia B-Disease 0 2.778697853500489e-05
at O 0 8.223194072343176e-07
birth O 0 1.193052412418183e-06
with O 0 1.9074789747719478e-07
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 4.419041215442121e-05
contractures B-Disease 1 1.0
, O 0 8.843334171615425e-07
and O 0 1.4159280681269593e-07
early B-Disease 0 7.564779480162542e-06
death I-Disease 0 3.952383849537e-05
. O 0 1.7616697505218326e-06

To O 0 2.7680832204168837e-07
test O 0 4.5318017782847164e-07
for O 0 4.839354694752274e-09
possible O 0 3.803994275131117e-08
nosologic O 0 0.00017370573186781257
identity O 0 2.4119870545291633e-08
between O 0 6.890952697347075e-09
these O 0 3.275485127574029e-08
disorders O 1 0.9999985694885254
, O 0 4.78625352684503e-08
we O 0 1.6736139141215745e-09
reviewed O 0 6.314141209884383e-09
the O 0 3.265901105109492e-09
literature O 0 5.026703497890139e-09
and O 0 4.979426870832526e-10
obtained O 0 3.155786743036515e-09
a O 0 2.21521245791223e-09
follow O 0 5.4332138788026896e-09
- O 0 4.9917563416101984e-08
up O 0 1.446981734432029e-08
of O 0 7.396664614134352e-09
the O 0 2.167879653569571e-09
only O 0 2.8612667790639534e-10
two O 0 3.483169030982225e-10
surviving O 0 3.53103104089314e-07
patients O 0 2.3890301292794902e-08
, O 0 7.3036194869757765e-09
one O 0 6.6408829546560355e-09
with O 0 1.5573879963426407e-08
SJS B-Disease 1 0.9998492002487183
type I-Disease 0 1.4618697150581283e-06
2 I-Disease 0 2.492338353476953e-07
at O 0 1.6391548740557482e-07
age O 0 6.944362862526532e-09
10 O 0 3.6218141818977756e-09
years O 0 1.6290456761325345e-09
and O 0 7.882449692964144e-10
another O 0 8.258125738791477e-09
with O 0 8.939387008410904e-09
SWS B-Disease 1 0.9999961853027344
at O 0 7.097271009115502e-06
age O 0 2.1159523555525084e-07
7 O 0 5.852931508343318e-07
years O 0 2.1289248763878277e-07
. O 0 3.9750949554218096e-07

Patients O 0 6.467387720476836e-05
reported O 0 8.67430685502768e-07
as O 0 8.424539998941327e-08
having O 0 1.6727648244341253e-07
either O 0 1.3253664974399726e-06
neonatal O 1 1.0
SJS B-Disease 1 1.0
or O 0 0.00016281013085972518
SWS B-Disease 1 1.0
presented O 0 1.5390331782327848e-06
a O 0 7.975236115953521e-08
combination O 0 2.2650662856449344e-07
of O 0 7.465835665243503e-07
a O 0 5.51877633370168e-07
severe O 1 0.9841973185539246
, O 0 5.177672619538498e-07
prenatal O 1 0.9999411106109619
- O 1 0.999992847442627
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 0.7800526022911072
with O 1 0.9990279674530029
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 0.9999998807907104
respiratory O 1 1.0
and O 0 0.025758428499102592
feeding O 0 0.08749433606863022
difficulties O 0 7.221108535304666e-05
, O 0 1.10027293942494e-07
tendency O 0 1.0617854684369377e-07
to O 0 3.33913874328573e-08
hyperthermia B-Disease 1 0.9976553916931152
, O 0 8.496382974954031e-08
and O 0 9.338034345773849e-09
frequent O 0 3.1370340991543344e-08
death O 0 5.561838065659686e-07
in O 0 8.791269578978245e-08
infancy O 0 1.0983510037476663e-05
) O 0 3.0231162018168334e-09
with O 0 1.0698673058584518e-09
a O 0 1.9279765339774713e-08
distinct O 0 2.9375746635196265e-07
campomelic B-Disease 1 0.9999181032180786
- I-Disease 1 0.9999797344207764
metaphyseal I-Disease 1 1.0
skeletal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.00011791021097451448

The O 0 1.382718210152234e-06
similarity O 0 3.2285717566082894e-07
of O 0 2.650743624599272e-07
the O 0 1.2100440471840557e-07
clinical O 0 2.6107623853022233e-05
and O 0 7.407228252986897e-08
radiographic O 0 0.0003842886071652174
findings O 0 3.0385763238882646e-07
is O 0 5.231053368248695e-09
so O 0 4.779634465990057e-10
extensive O 0 2.2175132841084633e-08
that O 0 1.0714316101001486e-09
these O 0 3.770836798366872e-08
disorders O 1 0.9999997615814209
appear O 0 5.6322964070432135e-08
to O 0 4.1081413826304924e-09
be O 0 3.0376354764882763e-09
a O 0 1.8356676179109854e-08
single O 0 5.100453037698571e-08
entity O 0 8.307670782414789e-07
. O 0 6.423566674129688e-07

The O 0 4.135650669923052e-06
follow O 0 3.8506783539560274e-07
- O 0 1.1703684776875889e-06
up O 0 5.880626829934954e-08
observation O 0 4.992822937310848e-07
of O 0 2.296736667517507e-08
an O 0 1.4381926760620445e-09
identical O 0 1.4096877443137146e-08
and O 0 1.543455918628922e-09
unique O 0 1.9902992587361723e-09
pattern O 0 6.329505453095408e-08
of O 0 7.701401614212955e-07
progressive O 1 0.9999815225601196
bone B-Disease 1 1.0
dysplasia I-Disease 1 1.0
in O 0 7.892007829468639e-07
the O 0 1.5704118538906187e-07
two O 0 2.2418046086158938e-08
patients O 0 1.2939753446516988e-07
( O 0 1.1926545084861573e-08
one O 0 2.871833082451758e-08
with O 0 5.903823208086578e-08
SJS B-Disease 1 0.9999961853027344
type I-Disease 0 6.080224920879118e-06
2 I-Disease 0 1.4551653748640092e-06
, O 0 6.522804518738212e-09
one O 0 2.8073607882816987e-09
with O 0 7.732146478645063e-09
SWS B-Disease 1 0.9999997615814209
) O 0 3.1676442802108795e-08
surviving O 0 1.8999622852788889e-06
beyond O 0 1.122388539442909e-06
infancy O 0 1.4267667438616627e-06
adds O 0 5.779193124055837e-09
to O 0 1.6245031986272807e-09
the O 0 4.630568817276526e-09
evidence O 0 9.695510172491595e-09
in O 0 2.1963852958606367e-09
favor O 0 6.617667747121914e-09
of O 0 5.4069481336682657e-08
identity O 0 1.3988407943088532e-07
. O 0 4.1076270917983493e-07

The O 0 2.971262574646971e-06
hypothesis O 0 9.016119406624057e-07
that O 0 8.059386402692326e-08
SWS B-Disease 1 0.9999630451202393
and O 0 1.5969917512848042e-06
SJS B-Disease 1 0.9999946355819702
type I-Disease 0 2.285564050907851e-06
2 I-Disease 0 1.876173598702735e-07
are O 0 1.3064127557527172e-10
the O 0 1.9704988751811925e-09
same O 0 2.0816157686454062e-08
disorder O 0 0.00012025774049106985
should O 0 1.2113244851619243e-09
be O 0 1.5255440244388296e-09
testable O 0 9.412497803396036e-08
by O 0 2.219699979377765e-09
molecular O 0 1.6388767676289717e-07
methods O 0 7.306855565047954e-08
. O 0 4.788819651935228e-08
. O 0 2.183167850944301e-07

A O 0 8.509100007358938e-05
mouse O 0 1.8814442910297657e-06
model O 0 6.060716373212927e-08
of O 0 8.831872264636331e-07
severe O 1 0.9999980926513672
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 1 0.6272759437561035
defects O 1 0.9999996423721313
in O 0 1.5045023246784694e-05
hemostasis O 1 0.9999984502792358
and O 0 8.686615183250979e-05
thrombosis B-Disease 1 0.9999979734420776
. O 0 4.260832065483555e-05

von B-Disease 1 0.9997929930686951
Willebrand I-Disease 1 0.9999927282333374
factor I-Disease 0 0.0001162285843747668
( I-Disease 0 2.107894397340715e-05
vWf I-Disease 1 0.9998992681503296
) I-Disease 0 0.007288325112313032
deficiency I-Disease 1 1.0
causes O 1 0.9996278285980225
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 0.00010651902266545221
humans O 0 6.6425459408492316e-06
. O 0 1.917991085065296e-06

We O 0 2.1430147967294033e-07
generated O 0 8.75028405289413e-08
a O 0 3.4835714757264213e-08
mouse O 0 8.258238892722147e-08
model O 0 5.30461097270063e-09
for O 0 3.17401704919007e-09
this O 0 9.948783130653283e-09
disease O 0 5.821462423227786e-07
by O 0 1.5010963583250714e-09
using O 0 1.0212528600561654e-08
gene O 0 7.370782384441554e-08
targeting O 0 2.2461667015249986e-07
. O 0 3.529627008447278e-07

vWf B-Disease 0 0.47034338116645813
- I-Disease 1 0.9379479885101318
deficient I-Disease 1 0.8773646354675293
mice O 0 1.1100797564722598e-05
appeared O 0 2.967160810385394e-07
normal O 0 8.025271114320276e-08
at O 0 1.2197368448596535e-07
birth O 0 5.497638611018374e-08
; O 0 9.329911287991877e-10
they O 0 3.0578051202212464e-10
were O 0 3.7169363142908196e-09
viable O 0 2.023736698220091e-07
and O 0 6.106899519409126e-08
fertile O 0 3.2394420941272983e-06
. O 0 9.128942792813177e-07

Neither O 0 0.00015550461830571294
vWf O 0 0.001065217424184084
nor O 0 2.7119171136291698e-05
vWf O 0 0.0004531435843091458
propolypeptide O 0 0.0007592145702801645
( O 0 2.25291682909301e-06
von B-Disease 1 0.7130231261253357
Willebrand I-Disease 1 0.9999265670776367
antigen O 0 8.183671161532402e-05
II O 1 1.0
) O 0 3.6411755388598976e-08
were O 0 7.018586600793242e-09
detectable O 0 1.1675352595830191e-07
in O 0 1.4148588967088926e-09
plasma O 0 2.962215717161598e-07
, O 0 1.3759296813020683e-08
platelets O 0 8.037202405830612e-07
, O 0 1.718910347392466e-08
or O 0 2.749132832491341e-08
endothelial O 0 5.799723226118658e-07
cells O 0 2.5965640304548288e-08
of O 0 3.239165025092916e-08
the O 0 1.0120000837332555e-07
homozygous O 0 4.622947471943917e-06
mutant O 0 1.9206603610655293e-05
mice O 0 1.0683907930797432e-05
. O 0 1.7528748230688507e-06

The O 0 9.68745462159859e-06
mutant O 0 5.3281677537597716e-05
mice O 0 1.0829387974808924e-05
exhibited O 0 1.9344102838658728e-05
defects O 1 0.6751970052719116
in O 0 8.187769253709121e-07
hemostasis O 0 0.18846170604228973
with O 0 8.69085354793242e-08
a O 0 2.338871354368166e-07
highly O 0 4.209840699331835e-05
prolonged O 1 0.9999902248382568
bleeding O 1 0.9999158382415771
time O 0 2.748255667484045e-07
and O 0 6.899767157619863e-08
spontaneous O 0 4.741146312881028e-06
bleeding O 0 5.67402494198177e-05
events O 0 4.4235139995407735e-08
in O 0 9.366717179659645e-09
approximately O 0 1.17732170679119e-08
10 O 0 1.3102321005931117e-08
% O 0 3.284504446199321e-09
of O 0 4.143729270822405e-08
neonates O 0 6.829444828326814e-06
. O 0 2.219596581198857e-06

As O 0 7.440914373546548e-07
in O 0 6.88562167283635e-08
the O 0 4.336764192203191e-08
human O 0 5.050116556049034e-07
disease O 0 0.002011394826695323
, O 0 4.031695866046903e-09
the O 0 6.83513601273944e-09
factor O 0 2.5744316900500053e-08
VIII O 1 0.9999849796295166
level O 0 1.8542429813805938e-07
in O 0 2.2534341059810004e-09
these O 0 1.0420225793339455e-09
mice O 0 6.60478320924085e-08
was O 0 4.055096525235058e-08
reduced O 0 1.2913589308993778e-08
strongly O 0 1.7878467595267011e-09
as O 0 8.781608218377812e-10
a O 0 1.481425204730158e-09
result O 0 2.470418536404395e-09
of O 0 1.5490071447743503e-08
the O 0 9.968918135427884e-09
lack O 0 2.868367587893772e-08
of O 0 7.322020678657282e-08
protection O 0 7.381052000710042e-07
provided O 0 1.0636989600243396e-07
by O 0 1.6760272103510943e-07
vWf O 0 0.00010527105041546747
. O 0 2.6349207473685965e-06

Defective O 1 0.9997413754463196
thrombosis B-Disease 1 0.9936292767524719
in O 0 5.575897375820205e-06
mutant O 0 3.485974593786523e-05
mice O 0 4.439897111296887e-06
was O 0 4.1737129663488304e-07
also O 0 6.1513087956655e-09
evident O 0 4.562625832704725e-08
in O 0 3.4674150217739452e-09
an O 0 5.717768480906216e-10
in O 0 3.1274081102594664e-09
vivo O 0 1.206863231573152e-07
model O 0 7.02670632790614e-08
of O 0 1.207925561175216e-05
vascular B-Disease 1 1.0
injury I-Disease 1 1.0
. O 0 5.877139847143553e-05

In O 0 4.7008913384161133e-07
this O 0 4.717523705011217e-09
model O 0 2.3008757565889937e-08
, O 0 9.799362210571871e-09
the O 0 6.297882038097669e-08
exteriorized O 0 8.457891817670316e-05
mesentery O 0 0.00016752950614318252
was O 0 7.000739515206078e-06
superfused O 0 4.812613406102173e-05
with O 0 1.3251310804207606e-07
ferric O 0 0.011064319871366024
chloride O 0 7.680244380026124e-06
and O 0 2.5655600666141254e-07
the O 0 1.2205875066229055e-07
accumulation O 0 4.6682966967637185e-06
of O 0 2.061653958662646e-06
fluorescently O 0 0.00012237418559379876
labeled O 0 5.582324774877634e-06
platelets O 0 6.961977760511218e-06
was O 0 4.916016678180313e-07
observed O 0 3.3609598659722906e-08
by O 0 2.8511367489159056e-08
intravital O 0 3.7005018384661525e-05
microscopy O 0 1.9267803509137593e-05
. O 0 2.2790015918872086e-06

We O 0 1.4145095974527067e-06
conclude O 0 1.3880571714253165e-06
that O 0 4.336703884888493e-09
these O 0 4.72779237981058e-09
mice O 0 2.3282203187591222e-07
very O 0 3.826916117333212e-09
closely O 0 6.610959246700077e-08
mimic O 0 5.3213130740914494e-05
severe O 0 0.005508934613317251
human O 0 1.8851727872970514e-05
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 6.644533527833119e-07
will O 0 1.0746289191843061e-08
be O 0 3.1471310002473274e-09
very O 0 5.524669610679211e-10
useful O 0 8.258184691634085e-10
for O 0 1.5126995212000338e-09
investigating O 0 1.826771622859269e-08
the O 0 1.4173120455041044e-08
role O 0 1.9642781623474548e-08
of O 0 4.9452641093239436e-08
vWf O 0 2.0683478396676946e-06
in O 0 3.68951162954545e-08
normal O 0 8.080781555008798e-08
physiology O 0 2.2148960852064192e-06
and O 0 1.8990599315316103e-08
in O 0 1.6727089757750946e-07
disease O 0 2.9135686418158002e-05
models O 0 6.009847908217125e-08
. O 0 7.139620805673985e-08
. O 0 2.6029539412775193e-07

Oral O 1 0.9030197262763977
contraceptives O 0 0.0731612890958786
and O 0 5.168170673641725e-07
the O 0 4.1395554717382765e-07
risk O 0 1.2712699799521943e-06
of O 0 0.020897557958960533
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00011235627607675269

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 1.0
Clinical O 1 0.9999850988388062
Study O 0 5.20552639500238e-05
Group O 0 1.5017341866041534e-05
. O 0 1.5675121858294006e-06

BACKGROUND O 0 0.0001555940689286217
Women O 0 1.2198893273307476e-07
with O 0 1.8214274533079333e-08
mutations O 0 2.7893856113792026e-08
in O 0 1.4833316797080442e-08
either O 0 1.868968979579222e-08
the O 0 6.3368133851327e-08
BRCA1 O 0 1.0928850997515838e-06
or O 0 5.3164139757200246e-08
the O 0 2.6226635441162216e-07
BRCA2 O 0 5.254743882687762e-06
gene O 0 6.13082491440764e-08
have O 0 1.9577801602110867e-09
a O 0 1.9873755974231244e-08
high O 0 1.0713523579397588e-06
lifetime O 0 1.2359515721982461e-06
risk O 0 1.3748039009442437e-06
of O 1 0.9318075776100159
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.9442677512415685e-05

Oral O 1 0.9420728087425232
contraceptives O 1 0.947860062122345
protect O 0 0.00017314050637651235
against O 1 0.9999996423721313
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 9.365881226131023e-08
general O 0 1.9092043146429205e-07
, O 0 6.087963910772487e-09
but O 0 5.371161848621853e-10
it O 0 2.2035762103911338e-10
is O 0 1.1320387682811628e-10
not O 0 5.488934307074089e-11
known O 0 1.6698927796099383e-09
whether O 0 8.955219898965083e-10
they O 0 1.27487553847061e-09
also O 0 3.563609851653382e-09
protect O 0 1.4543867621341633e-07
against O 0 9.317369631389738e-07
hereditary B-Disease 1 0.9555528163909912
forms I-Disease 0 1.1065631042583846e-05
of I-Disease 1 0.9999905824661255
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.7406015103915706e-05

METHODS O 0 5.05992938997224e-05
We O 0 1.4483408961041278e-07
enrolled O 0 6.926546802787925e-07
207 O 0 4.542445992683497e-07
women O 0 1.0984607889952258e-08
with O 0 1.369963626984827e-07
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.812835132066539e-07
161 O 0 6.240932748369232e-07
of O 0 2.6208633130409e-07
their O 0 3.631243927770811e-08
sisters O 0 9.405692367181473e-07
as O 0 1.0482006373990771e-08
controls O 0 6.09765820058783e-08
in O 0 7.885115671513176e-09
a O 0 1.0846243903017694e-08
case O 0 5.319294515970796e-08
- O 0 2.65443918578967e-06
control O 0 4.032056324376754e-07
study O 0 2.046510161335391e-07
. O 0 2.0315079041210993e-07

All O 0 1.36557594032638e-06
the O 0 4.0256088595924666e-07
patients O 0 1.1997873627933586e-07
carried O 0 1.0082527523991303e-07
a O 0 1.8034102211572645e-08
pathogenic O 0 2.3588749797909259e-07
mutation O 0 2.3587032771388294e-08
in O 0 1.5185774415726883e-08
either O 0 4.747222348555624e-08
BRCA1 O 0 1.3817729040965787e-06
( O 0 2.5954005167250216e-08
179 O 0 3.5951842392023536e-07
women O 0 2.139259436262364e-08
) O 0 9.203191098094976e-09
or O 0 1.4034213791092043e-07
BRCA2 O 0 8.828605132293887e-06
( O 0 1.5719523105417466e-07
28 O 0 3.4593983855302213e-06
women O 0 1.0548335183102608e-07
) O 0 1.5886764970218792e-07
. O 0 8.273893854493508e-07

The O 0 3.502948629829916e-06
control O 0 1.5703850522186258e-06
women O 0 8.160187192629564e-09
were O 0 9.793980737526908e-09
enrolled O 0 3.979524620945085e-08
regardless O 0 1.1093971075126774e-08
of O 0 2.117172925863997e-08
whether O 0 3.0300493225610126e-09
or O 0 6.684548026214543e-09
not O 0 1.1022506241076258e-09
they O 0 1.1196427118775887e-09
had O 0 9.709055781570441e-09
either O 0 3.6437324268945304e-08
mutation O 0 1.5391975694001303e-07
. O 0 4.7666389946243726e-07

Lifetime O 0 2.655737080203835e-05
histories O 0 2.9482355330401333e-06
of O 0 3.7556415009021293e-06
oral O 0 0.0003993223363067955
- O 0 8.702464583620895e-06
contraceptive O 0 1.6096425952127902e-06
use O 0 1.1300099522770779e-08
were O 0 8.988164879042415e-09
obtained O 0 7.515009059488875e-09
by O 0 2.1869253075124107e-09
interview O 0 2.1903913349774484e-08
or O 0 2.2277373279422363e-09
by O 0 1.2184988573693545e-09
written O 0 1.1764456075979979e-09
questionnaire O 0 3.3844123059623143e-09
and O 0 1.867360932550355e-09
were O 0 5.530956137533849e-09
compared O 0 9.02890473497564e-09
between O 0 4.316823343231135e-09
patients O 0 9.979723714081956e-09
and O 0 9.283407820248613e-09
control O 0 3.30776487089679e-07
women O 0 5.635603539388967e-09
, O 0 2.560825551611856e-09
after O 0 1.3732686099388047e-08
adjustment O 0 2.3271807592095684e-08
for O 0 2.614203742368204e-09
year O 0 1.0092393587513016e-08
of O 0 6.324967927184844e-08
birth O 0 1.3040809108133544e-06
and O 0 9.12441890932314e-08
parity O 0 1.1157025255670305e-05
. O 0 1.386592543894949e-06

RESULTS O 0 0.0001787732617231086
The O 0 8.732807827982469e-07
adjusted O 0 1.1636774388534832e-06
odds O 0 2.935129828074423e-07
ratio O 0 5.171799344338979e-08
for O 0 5.554851441047504e-07
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 1.4069485132495174e-07
with O 0 1.8121880662747003e-09
any O 0 1.8040148264120148e-09
past O 0 7.080545039173103e-09
use O 0 3.6152711935244497e-09
of O 0 3.001085246978619e-08
oral O 0 1.1435543456173036e-05
contraceptives O 0 7.478643965441734e-05
was O 0 3.4913389299617847e-06
0 O 0 6.117031148278329e-07
. O 0 2.522025113194104e-07

5 O 0 1.034052729664836e-05
( O 0 1.7366240001592814e-07
95 O 0 1.070144321602129e-06
percent O 0 7.691171077794934e-08
confidence O 0 8.66769340746032e-08
interval O 0 1.4605149090129999e-07
, O 0 5.425653704094202e-09
0 O 0 4.822437560392245e-09
. O 0 3.356568079038169e-10
3 O 0 4.208451809262215e-09
to O 0 7.185215200600226e-10
0 O 0 6.1292206865459775e-09
. O 0 3.753505506409738e-09
8 O 0 1.1295266233446455e-07
) O 0 2.1845627529160083e-08
. O 0 1.4103257228725852e-07

The O 0 4.65440052721533e-06
risk O 0 6.834219448137446e-07
decreased O 0 1.3790712216632528e-07
with O 0 1.6603015629002016e-09
increasing O 0 3.4867868592414197e-09
duration O 0 2.512340380178557e-08
of O 0 3.759021982574495e-09
use O 0 7.396312007301731e-09
( O 0 4.9991664141657566e-09
P O 0 6.283471520873718e-07
for O 0 2.8038611432634752e-09
trend O 0 1.754511913532042e-08
, O 0 7.875867735762654e-10
< O 0 1.1717255610221855e-08
0 O 0 3.719730745643801e-09
. O 0 2.8061386547761913e-10
001 O 0 6.504035354737425e-08
) O 0 2.3298965534657157e-10
; O 0 3.0540847628657275e-11
use O 0 2.984180680343229e-10
for O 0 5.659546165048823e-10
six O 0 3.1391333976671376e-09
or O 0 1.109565883616881e-09
more O 0 7.267607349259464e-11
years O 0 3.123908687285848e-09
was O 0 2.764048900871785e-08
associated O 0 2.5296447159206537e-09
with O 0 9.92342097383414e-10
a O 0 8.043013366432206e-09
60 O 0 4.8442892364164436e-08
percent O 0 1.9683286112126552e-08
reduction O 0 1.0046955623010945e-07
in O 0 1.0615161727400846e-07
risk O 0 1.3625968904307229e-06
. O 0 1.1451456884969957e-06

Oral O 0 0.29760801792144775
- O 0 0.0001198380850837566
contraceptive O 0 4.1525636333972216e-05
use O 0 1.8831232750926574e-07
protected O 0 4.4133979827165604e-05
against O 1 0.9997106194496155
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 8.485010027925455e-09
for O 0 1.3463802295277105e-09
carriers O 0 6.020113296756335e-09
of O 0 1.7327355550378343e-08
the O 0 3.9449648880918176e-08
BRCA1 O 0 6.857540029159281e-07
mutation O 0 1.3847732738270224e-08
( O 0 1.0468759192860944e-08
odds O 0 1.26924533105921e-07
ratio O 0 2.3819413996761796e-08
, O 0 2.0737487282929123e-09
0 O 0 5.605703901068182e-09
. O 0 4.439653644716657e-10
5 O 0 3.848017904317658e-09
; O 0 2.2481741468460825e-10
95 O 0 1.8903760334865183e-08
percent O 0 6.1442966270419674e-09
confidence O 0 1.6160146998345226e-08
interval O 0 1.6007771108661473e-08
, O 0 1.1006036082505943e-09
0 O 0 2.380237118515538e-09
. O 0 2.0610109452423586e-10
3 O 0 2.53691179175064e-09
to O 0 4.170207512643742e-10
0 O 0 2.4692599076558963e-09
. O 0 3.203769749493546e-10
9 O 0 1.735209487208067e-08
) O 0 2.0875341733006536e-10
and O 0 1.0998874033774086e-10
for O 0 1.92834234691297e-10
carriers O 0 1.863966314630261e-09
of O 0 1.8354295860945058e-08
the O 0 6.263919516413807e-08
BRCA2 O 0 1.1901273637704435e-06
mutation O 0 2.8362427073602703e-08
( O 0 9.041812631949142e-09
odds O 0 8.617252689191446e-08
ratio O 0 1.2604656873804743e-08
, O 0 2.115876140962314e-09
0 O 0 5.552222237525939e-09
. O 0 6.549130127098124e-10
4 O 0 4.203093428856164e-09
; O 0 4.886684945581976e-10
95 O 0 3.180660712587269e-08
percent O 0 9.243424692328972e-09
confidence O 0 3.8410316705039804e-08
interval O 0 6.45402380428095e-08
, O 0 4.0566727754765e-09
0 O 0 1.1841612135299329e-08
. O 0 7.363862297715684e-10
2 O 0 7.58673035505808e-09
to O 0 1.7634553817202914e-09
1 O 0 3.601968501243391e-08
. O 0 8.662301986817056e-09
1 O 0 2.477543432632956e-07
) O 0 4.511413465024816e-08
. O 0 2.3658138559312647e-07

CONCLUSIONS O 0 0.00013774825492873788
Oral O 0 0.1334608644247055
- O 0 9.166402014670894e-05
contraceptive O 0 2.322569525858853e-05
use O 0 1.3491050765424006e-07
may O 0 2.6579673573223772e-08
reduce O 0 2.627988315850871e-08
the O 0 1.2739622690105534e-08
risk O 0 4.533029240860742e-08
of O 0 6.641481741098687e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 3.669635617598033e-08
women O 0 7.386538602993653e-10
with O 0 5.70095470830978e-10
pathogenic O 0 9.345645679559311e-08
mutations O 0 9.567724390535659e-09
in O 0 1.9301729992093897e-08
the O 0 3.0109126214483695e-07
BRCA1 O 0 2.488353493390605e-05
or O 0 8.387898560613394e-06
BRCA2 O 0 0.0007417662418447435
gene O 0 7.055929017951712e-05

A O 0 5.509967741090804e-05
Japanese O 0 4.790863022208214e-05
family O 0 6.044410838512704e-07
with O 0 8.837727705213183e-07
adrenoleukodystrophy B-Disease 1 1.0
with O 0 2.5821901772360434e-07
a O 0 1.8237867038806144e-07
codon O 0 1.0420518492537667e-06
291 O 0 6.879851071062149e-07
deletion O 0 4.985571990800963e-07
: O 0 2.2095717255865566e-08
a O 0 2.5259671687649643e-08
clinical O 0 6.028646112099523e-06
, O 0 4.244674300935003e-08
biochemical O 0 7.679789996473119e-05
, O 0 1.6519354062438651e-07
pathological O 0 0.10930432379245758
, O 0 8.965071884858844e-08
and O 0 3.621422450805767e-08
genetic O 0 1.6101279243230238e-06
report O 0 3.868718465582788e-07
. O 0 1.221335651280242e-06

We O 0 8.767012218413583e-07
report O 0 1.3149417554814136e-07
a O 0 3.9154596009893794e-08
Japanese O 0 9.86902705335524e-07
family O 0 5.631651944781879e-08
with O 0 1.1678236688794641e-07
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.49781641364097595
ALD B-Disease 1 1.0
) O 0 1.2358390222289017e-07
with O 0 2.929864129086468e-09
a O 0 1.0568328434601426e-08
three O 0 6.866077484346533e-09
base O 0 9.094274133758518e-08
pair O 0 1.5818052645499847e-07
deletion O 0 2.029656798185897e-07
( O 0 3.218079669409235e-08
delGAG O 0 1.475273438700242e-05
291 O 0 7.475795769096294e-07
) O 0 3.885965771388555e-09
in O 0 2.1433598007547516e-08
the O 0 1.625090135348728e-06
ALD B-Disease 1 1.0
gene O 0 3.6906472814735025e-05
. O 0 3.851702786050737e-06

A O 0 9.006493201013654e-06
variety O 0 2.9253439493004407e-07
of O 0 4.30327816047793e-07
phenotypes O 0 4.79101231576351e-07
were O 0 2.3530866144483298e-08
observed O 0 4.123860364302345e-08
within O 0 2.2160250523484137e-08
this O 0 7.069857144159641e-09
family O 0 1.4572648865396332e-07
. O 0 6.260872851271415e-07

While O 0 3.1966096685209777e-06
the O 0 5.533939315682801e-07
proband O 0 0.00030461038113571703
( O 0 1.5636122441264888e-07
patient O 0 6.694240823890141e-07
1 O 0 9.80577624432044e-07
) O 0 1.5079326232125823e-08
was O 0 9.098611997160333e-08
classified O 0 3.8454299300383354e-08
as O 0 4.873506931346583e-09
having O 0 6.732941759679534e-09
a O 0 4.527237695839403e-09
rare O 0 2.134209786675001e-08
intermediate O 0 3.4530231118878874e-07
type O 0 2.3541016958006367e-07
of O 0 3.617829236191028e-07
adult O 0 7.0333896928787e-07
cerebral O 0 6.549050795001676e-06
and O 0 2.1413273998405202e-07
cerebello O 1 0.9999786615371704
- O 1 0.9972988963127136
brain O 0 0.23668621480464935
stem O 0 6.151094567030668e-07
forms O 0 9.061687933353824e-08
, O 0 1.3111620233985377e-08
his O 0 1.313092070631683e-07
younger O 0 2.627222102091764e-07
brother O 0 3.0331730158650316e-06
( O 0 3.5286504385112494e-08
patient O 0 3.177829626110906e-07
2 O 0 4.7522595991722483e-07
) O 0 8.217869940096989e-09
and O 0 2.4561744638162963e-08
nephew O 0 0.0002612057432997972
( O 0 2.2166595670114475e-07
patient O 0 1.7191616734635318e-06
3 O 0 1.3601483033198747e-06
) O 0 1.729928555960214e-08
had O 0 2.4500078410483184e-08
a O 0 2.599096546873625e-07
childhood O 1 0.9999798536300659
ALD B-Disease 1 1.0
type O 1 0.923319935798645
. O 0 1.294140201935079e-05

Another O 0 1.3849939932697453e-05
nephew O 0 0.0004392186237964779
( O 0 4.0882704865907726e-07
patient O 0 1.973442749658716e-06
4 O 0 6.887656809340115e-07
) O 0 3.8516230205232205e-09
of O 0 4.1217450785779874e-08
patient O 0 5.237056370788196e-07
1 O 0 6.402112830983242e-07
was O 0 3.261807250964921e-07
classified O 0 6.407561414789598e-08
as O 0 3.934405246042161e-09
having O 0 4.929835650813175e-09
an O 0 3.5134910536527286e-09
adolescent O 0 7.039394859020831e-06
form O 0 6.521389082081441e-07
. O 0 8.365581720681803e-07

The O 0 3.200071432729601e-06
tau O 0 2.4684334221092286e-06
level O 0 9.347374430035416e-08
in O 0 5.946210634988347e-09
the O 0 2.0392640465161094e-08
cerebrospinal O 0 1.6924633428061497e-06
fluid O 0 1.1879139947268413e-06
( O 0 5.407483172348293e-07
CSF O 1 1.0
) O 0 4.1912471715477295e-08
in O 0 2.087448613963261e-08
patient O 0 1.7805623997446673e-07
1 O 0 2.8962602982574026e-07
was O 0 1.8527209988405957e-07
as O 0 5.9008931074799875e-09
high O 0 1.0547571349661666e-07
as O 0 1.8430236226052443e-09
that O 0 1.1837693325578158e-10
of O 0 8.32532354166915e-09
patients O 0 6.001187813353681e-08
with O 0 1.9685994345763902e-07
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
( O 0 2.65275161837053e-07
AD B-Disease 0 6.858213600935414e-05
) O 0 2.2016990897100186e-07
. O 0 3.7099798078088497e-07

His O 0 0.00019916774181183428
brain O 0 0.000215026069781743
magnetic O 0 1.1679206181725021e-05
resonance O 0 3.311882210255135e-06
image O 0 2.784126763799577e-06
( O 0 1.244544023393246e-07
MRI O 1 0.977532148361206
) O 0 1.1618140405289523e-07
showed O 0 5.844497650286939e-07
abnormalities B-Disease 0 0.00019527305266819894
in I-Disease 0 5.1002395196064754e-08
the I-Disease 0 9.290744884538071e-08
bilateral I-Disease 0 2.817076619976433e-06
cerebellar I-Disease 1 0.9998335838317871
hemispheres I-Disease 0 1.3576389392255805e-05
and O 0 2.706011173359002e-06
brain O 1 0.8762260675430298
stem O 0 3.12881411446142e-06
, O 0 1.4672979276042497e-08
but O 0 6.077321978992245e-10
not O 0 1.8518954425505996e-10
in O 0 3.6029630390288503e-09
the O 0 9.33787660528651e-08
cerebral O 0 0.0005174726829864085
white O 0 4.2169352809651173e-07
matter O 0 2.7107736499942803e-08
, O 0 2.9522073674570493e-09
where O 0 2.324003656184459e-09
marked O 0 3.929448322281814e-09
reductions O 0 5.4698901408301026e-08
of O 0 5.7248453089187024e-08
the O 0 8.143631902157722e-08
cerebral O 0 1.7967611711355858e-05
blood O 0 2.875511597721925e-07
flow O 0 1.7430975773891078e-08
and O 0 1.966009932630186e-08
oxygen O 0 4.739139285447891e-07
metabolism O 0 5.478921707435802e-07
were O 0 3.0563036546027433e-08
clearly O 0 1.0936004102291008e-08
demonstrated O 0 3.177869745130124e-09
by O 0 6.23708917846244e-10
positron O 0 1.655392196653338e-07
emission O 0 7.14994996542373e-07
tomography O 0 2.7458111162559362e-06
( O 0 4.3405668748164317e-07
PET O 0 0.0027008766774088144
) O 0 4.1483286850052536e-07
. O 0 6.379646606546885e-07

In O 0 4.433934918779414e-06
patients O 0 9.896491519612027e-07
2 O 0 7.732945164207194e-07
and O 0 1.6565476101959575e-08
3 O 0 1.404185780984335e-07
, O 0 5.51084333721974e-09
the O 0 4.937043218689041e-09
autopsy O 0 1.1283062804068322e-06
findings O 0 5.3198526472897356e-08
showed O 0 1.3912307395003154e-07
massive O 0 6.1367263697320595e-06
demyelination B-Disease 1 1.0
of I-Disease 0 6.637960905209184e-05
the I-Disease 0 1.368212451779982e-05
cerebral I-Disease 1 0.6236168146133423
white I-Disease 0 7.811914883859572e-07
matter I-Disease 0 2.094879292258156e-08
with O 0 9.886109708645563e-10
sparing O 0 4.5183373487134304e-08
of O 0 2.3397235793254367e-07
the O 0 3.0619872859460884e-07
U O 1 0.924379289150238
- O 0 0.0001912714506033808
fibers O 0 0.00107709935400635
, O 0 3.294400485742699e-08
compatible O 0 1.3692151412669773e-07
with O 0 1.8513877098058629e-09
the O 0 5.369218847306456e-09
findings O 0 2.0878028195170373e-08
of O 0 6.323978709588118e-07
childhood O 1 0.9999814033508301
ALD B-Disease 1 1.0
. O 0 2.3692831746302545e-05

Oleic O 0 0.004821359179913998
and O 0 1.5513953258050606e-05
erucic O 0 0.0025718710385262966
acids O 0 4.400626039569033e-06
( O 0 5.624496566269954e-07
Lorenzos O 0 0.00030021078418940306
Oil O 0 1.762597435117641e-06
) O 0 1.2753552880440111e-08
were O 0 4.458851954325382e-09
administered O 0 1.3868852732912273e-08
to O 0 3.495896905292284e-09
patients O 0 2.4271471943393408e-08
1 O 0 1.2448728625713557e-07
and O 0 1.6479914322076183e-08
4 O 0 1.2347928191047686e-07
, O 0 2.492626327565972e-09
but O 0 2.522430875284698e-10
sufficient O 0 3.4834368722869158e-09
effectiveness O 0 5.71866856091674e-08
was O 0 1.6089508392269636e-07
not O 0 2.889313899245849e-09
obtained O 0 1.0325290134005627e-07
. O 0 3.1483099860452057e-07

The O 0 2.9044995244476013e-06
findings O 0 4.139602651775931e-07
in O 0 2.452532399388474e-08
this O 0 1.4430011630039985e-09
family O 0 3.3176608127405416e-09
suggest O 0 3.4782847713188403e-09
that O 0 4.048091584163416e-10
delGAG291 O 0 3.595935140765505e-07
is O 0 1.3994799763494825e-09
part O 0 1.1625649776192404e-08
of O 0 2.8247166383721378e-08
the O 0 2.3777380064871068e-08
cause O 0 8.12848597320226e-08
of O 0 5.263925686449511e-07
Japanese O 1 0.6537914276123047
ALD B-Disease 1 1.0
with O 0 1.7730269519233843e-07
phenotypic O 0 2.2674878437101142e-06
variations O 0 7.009691671555629e-06
. O 0 4.484634700929746e-06

Moreover O 0 3.7621873616444645e-06
, O 0 4.837253442246947e-08
although O 0 3.0635511905074964e-09
the O 0 1.1969198965289252e-09
scale O 0 2.0779861387154597e-08
of O 0 8.653978866846046e-09
the O 0 2.33266361782114e-09
study O 0 2.3872250842771336e-09
is O 0 1.2806142257737463e-10
limited O 0 1.3475003335372548e-09
, O 0 1.2362881829375283e-09
there O 0 7.397450985102694e-10
is O 0 2.2192712945123816e-10
a O 0 9.057256056266283e-10
possibility O 0 6.545374908739632e-09
that O 0 1.5458305746562928e-09
PET O 0 0.00011871492461068556
can O 0 5.988402662637782e-09
detect O 0 7.18101546226535e-07
an O 0 2.718561020742527e-08
insidious B-Disease 0 8.165485633071512e-05
lesion I-Disease 0 0.0021543928887695074
which O 0 2.6938471009430032e-08
is O 0 5.165624816783065e-09
undetectable O 0 5.591418243966473e-07
by O 0 5.986240947386534e-10
computed O 0 1.730879084504977e-08
tomogram O 0 4.367129804450087e-06
( O 0 3.3252518960580346e-08
CT O 0 0.40841761231422424
) O 0 1.2935035265115857e-08
or O 0 7.664632484249978e-09
MRI O 0 3.3038173569366336e-05
analysis O 0 1.4356720257069355e-08
, O 0 3.2344342759671463e-09
and O 0 1.5651893114920767e-09
that O 0 3.82364556683612e-10
the O 0 2.99944691306564e-09
higher O 0 1.7109291761130407e-08
level O 0 1.688643358477293e-08
of O 0 2.3747647404093186e-08
tau O 0 5.379872192179391e-08
reflects O 0 2.2023631807144284e-09
the O 0 9.955003488215652e-10
process O 0 2.391207898355674e-09
of O 0 4.609299608659967e-08
neuronal B-Disease 0 7.376565190497786e-05
degeneration I-Disease 1 0.9999997615814209
in O 0 4.270697172614746e-05
ALD B-Disease 1 1.0
. O 0 2.2633508706348948e-05

Lorenzos O 0 0.02021578885614872
Oil O 0 7.38655535315047e-06
should O 0 1.6330035990108627e-08
be O 0 1.2541652161246475e-09
given O 0 4.283317311948309e-10
in O 0 2.0446571102894495e-09
the O 0 3.0828710695374184e-09
early O 0 1.040557791043284e-07
stage O 0 1.2405498637235723e-06
. O 0 2.9346141516839452e-08
. O 0 2.5211232923538773e-07

Nonsense O 0 9.223605593433604e-05
mutation O 0 3.6801819192078256e-07
in O 0 1.3533768594697904e-07
exon O 0 1.8108124777427292e-06
4 O 0 4.787778493664518e-07
of O 0 1.0919937665221369e-07
human O 0 2.0597752836692962e-08
complement O 0 2.98550503430306e-07
C9 O 1 0.9999994039535522
gene O 0 1.8908885124346853e-07
is O 0 1.914782554734984e-09
the O 0 9.672643130897995e-09
major O 0 2.769379818801099e-07
cause O 0 2.828396929999144e-07
of O 0 1.0410258255433291e-06
Japanese O 0 0.00011875353811774403
complement B-Disease 0 0.0020866512786597013
C9 I-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
. O 0 2.6775891456054524e-05

Deficiency B-Disease 1 0.9999971389770508
of I-Disease 0 0.000664508726913482
the I-Disease 0 2.014642086578533e-05
ninth I-Disease 1 0.9925293326377869
component I-Disease 0 2.89887657345389e-06
of I-Disease 0 4.787970055986079e-07
human I-Disease 0 6.221186055199723e-08
complement I-Disease 0 4.6989012503217964e-07
( O 0 1.7326304657672154e-07
C9 O 1 1.0
) O 0 3.7596048940713445e-08
is O 0 1.5988234070007934e-09
the O 0 1.989874043317741e-09
most O 0 1.5724936908156906e-09
common O 0 5.858058216290374e-08
complement B-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
in O 0 3.973847526594909e-07
Japan O 0 5.456433882500278e-06
but O 0 3.3125897580532637e-09
is O 0 1.0421318252795686e-09
rare O 0 6.734046209544431e-09
in O 0 2.558325995494215e-09
other O 0 1.8483462538299023e-09
countries O 0 4.300436451387668e-09
. O 0 4.081059614691185e-07

We O 0 3.7240596384435776e-07
studied O 0 6.158543328638189e-07
the O 0 1.1772901764572907e-08
molecular O 0 7.493598985774952e-08
basis O 0 2.0280888080037585e-08
of O 0 1.5309832406273927e-06
C9 B-Disease 1 1.0
deficiency I-Disease 1 0.9999815225601196
in O 0 2.1308343889359094e-07
four O 0 5.0863278033830284e-08
Japanese O 0 5.393480387283489e-05
C9 B-Disease 1 1.0
- I-Disease 1 0.9999992847442627
deficient I-Disease 1 0.9987123012542725
patients O 0 1.2031689493596787e-06
who O 0 7.032740256818215e-08
had O 0 1.1361659062458784e-06
suffered O 1 0.9999938011169434
from O 1 0.9983928799629211
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 4.541966518445406e-06

Direct O 0 1.4965937680244679e-06
sequencing O 0 2.4885364382498665e-06
of O 0 1.0952702496069833e-06
amplified O 0 1.1417758287279867e-05
C9 O 0 0.0203699953854084
cDNA O 0 2.6761183562484803e-06
and O 0 6.268903263162429e-08
DNA O 0 2.231888856840669e-06
revealed O 0 3.9500551451965293e-07
a O 0 5.435476069237666e-08
nonsense O 0 1.1383480114091071e-06
substitution O 0 3.196312263753498e-07
( O 0 6.638973104600154e-08
CGA O 0 1.3186680916987825e-05
- O 0 2.765457566056284e-06
- O 0 1.5738138472443097e-06
> O 0 8.085513059086225e-07
TGA O 0 1.14818994916277e-05
) O 0 6.116747996998129e-09
at O 0 2.427688983175358e-08
codon O 0 2.961039946569599e-08
95 O 0 1.3975575363645021e-08
in O 0 3.528890957227304e-09
exon O 0 3.0163906217239855e-07
4 O 0 7.987323868974272e-08
in O 0 1.718825082264175e-08
the O 0 2.704205037673546e-08
four O 0 2.82412486285466e-07
C9 B-Disease 1 1.0
- I-Disease 1 0.9572852253913879
deficient I-Disease 0 0.00027305964613333344
individuals O 0 1.3903050444241671e-07
. O 0 1.7094146187446313e-06

An O 0 5.514083909474721e-07
allele O 0 2.923123929576832e-07
- O 0 4.914197688776767e-07
specific O 0 1.7893656334422303e-08
polymerase O 0 6.756085895176511e-07
chain O 0 3.6465485209191684e-07
reaction O 0 2.198054360746937e-08
system O 0 5.13057329953881e-08
designed O 0 1.0051843446490238e-07
to O 0 8.925008287974379e-09
detect O 0 3.2683334438843303e-07
exclusively O 0 3.2522397219736376e-08
only O 0 8.122326144999192e-10
one O 0 5.289463311797249e-10
of O 0 2.4986144264715904e-09
the O 0 1.902644930495967e-09
normal O 0 4.7594594931865686e-09
and O 0 1.369817370644455e-09
mutant O 0 1.7505740856904595e-08
alleles O 0 6.461580159822233e-10
indicated O 0 2.0630848140967828e-09
that O 0 9.487121505058482e-11
all O 0 7.499053600312777e-10
the O 0 3.070524057235957e-09
four O 0 1.887471068329205e-09
patients O 0 2.692962075556693e-09
were O 0 5.691678683916734e-09
homozygous O 0 9.500494613234878e-09
for O 0 9.98809701613368e-10
the O 0 1.0162241714795073e-08
mutation O 0 3.6874341358128504e-09
in O 0 7.381894207014739e-09
exon O 0 1.8079033736739802e-07
4 O 0 8.316074939784812e-08
and O 0 1.6799238666820315e-09
that O 0 2.2203212879379208e-10
the O 0 1.2998020437748892e-09
parents O 0 1.5313688095375255e-09
of O 0 3.1483573081914074e-08
patient O 0 2.597359696210333e-07
2 O 0 5.197381369725917e-07
were O 0 1.3805517085074825e-07
heterozygous O 0 4.119281982184475e-07
. O 0 4.856524356000591e-07

The O 0 4.360516868473496e-06
common O 0 5.956077302471385e-07
mutation O 0 1.0071456557625424e-07
at O 0 1.67576345688758e-07
codon O 0 1.6662671953326935e-07
95 O 0 1.147826296232779e-07
in O 0 1.2857062081650383e-08
exon O 0 5.990569889036124e-07
4 O 0 1.1475132311034031e-07
might O 0 3.34633565302056e-09
be O 0 8.378510107931447e-10
responsible O 0 1.0874415146133742e-08
for O 0 2.856131997575062e-09
most O 0 4.0916589227890654e-08
Japanese O 0 0.04249880835413933
C9 B-Disease 1 1.0
deficiency I-Disease 1 0.9999996423721313
. O 0 1.4234966556614381e-06
. O 0 1.8910756125478656e-06

BRCA1 O 0 3.4808323107426986e-05
required O 0 2.5676112613837176e-07
for O 0 6.002928643056293e-08
transcription O 0 1.5752610124764033e-05
- O 0 2.952908653242048e-05
coupled O 0 6.358403879858088e-06
repair O 0 0.002738298149779439
of O 0 3.3237540719710523e-06
oxidative O 0 6.856709660496563e-05
DNA O 0 0.005752687342464924
damage O 0 0.0006206928519532084
. O 0 3.713785417858162e-06

The O 0 5.0510534492786974e-05
breast B-Disease 1 0.999882698059082
and I-Disease 1 0.8611149191856384
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 0 0.0002904852444771677
gene O 0 1.5288237591448706e-06
BRCA1 O 0 3.0263133794505848e-06
encodes O 0 2.678820010260097e-07
a O 0 4.0864304651222483e-07
zinc O 0 0.007459336891770363
finger O 0 4.495143730309792e-05
protein O 0 4.2445046233297035e-07
of O 0 9.64471496445185e-07
unknown O 0 1.7733883623805013e-06
function O 0 2.4382512719967053e-07
. O 0 6.23538767285936e-07

Association O 0 3.003902929776814e-05
of O 0 5.427444193628617e-06
the O 0 7.020597081464075e-07
BRCA1 O 0 1.1119487908217707e-06
protein O 0 2.63726764870853e-08
with O 0 5.690050652873424e-09
the O 0 4.239867834598954e-08
DNA O 0 2.843731635948643e-06
repair O 0 3.0427740057348274e-05
protein O 0 1.5080887294516288e-07
Rad51 O 0 8.305489245685749e-06
and O 0 8.076186830408005e-09
changes O 0 1.592711629250232e-09
in O 0 1.6426994209339796e-09
the O 0 6.583069089849403e-10
phosphorylation O 0 1.1287820456118425e-08
and O 0 4.655675400755399e-09
cellular O 0 3.2828407370288915e-07
localization O 0 5.497061579262663e-07
of O 0 6.793624862666547e-08
the O 0 1.334879407011158e-08
protein O 0 8.593580069771178e-09
after O 0 2.7123460810685174e-08
exposure O 0 6.99525415370772e-08
to O 0 4.0393319800102745e-09
DNA O 0 6.12518442721921e-06
- O 0 1.8024924202109105e-06
damaging O 0 1.2390175925247604e-06
agents O 0 1.4069962084306553e-08
are O 0 7.408973434763766e-10
consistent O 0 2.0018857682657654e-08
with O 0 1.2855216890983456e-09
a O 0 5.709815731336221e-09
role O 0 9.898057484747369e-09
for O 0 1.7432437715569904e-08
BRCA1 O 0 2.108405851686257e-06
in O 0 2.6719973789113283e-07
DNA O 0 0.00021885844762437046
repair O 1 0.576500415802002
. O 0 5.541757673199754e-06

Here O 0 3.607800181271159e-06
, O 0 8.366732373588093e-08
it O 0 5.8702469551974445e-09
is O 0 6.482528402962373e-10
shown O 0 8.163748566047957e-10
that O 0 5.256314827839503e-10
mouse O 0 1.4718310126227152e-07
embryonic O 0 8.282751196020399e-07
stem O 0 1.1672898381220875e-06
cells O 0 3.2860640430953936e-07
deficient B-Disease 0 1.947290456882911e-06
in I-Disease 0 3.6503756462025194e-08
BRCA1 I-Disease 0 4.893526579508034e-07
are O 0 1.2305081398267248e-09
defective O 0 2.7265014068689197e-06
in O 0 3.797947911721167e-08
the O 0 1.7042719235860204e-08
ability O 0 1.8154401315584323e-09
to O 0 1.1534754262854108e-09
carry O 0 4.650235307934736e-09
out O 0 9.456527116924462e-09
transcription O 0 3.7245959561005293e-07
- O 0 1.1572661833270104e-06
coupled O 0 5.575815862357558e-07
repair O 0 2.5099223421420902e-05
of O 0 3.1987607940209273e-07
oxidative O 0 1.458761289541144e-06
DNA O 0 1.887207145045977e-05
damage O 0 1.0270905477227643e-05
, O 0 2.2542176125739388e-08
and O 0 7.952023040047607e-09
are O 0 9.300914483034717e-10
hypersensitive O 0 5.609080062640714e-07
to O 0 1.1296952706629781e-08
ionizing O 0 7.341253513004631e-05
radiation O 0 0.0001342523464700207
and O 0 9.26600449702164e-08
hydrogen O 0 1.4017053899806342e-06
peroxide O 0 2.9167376851546578e-05
. O 0 1.8428138446324738e-06

These O 0 2.886955883241171e-07
results O 0 2.8636617344091064e-07
suggest O 0 3.9576864452328664e-08
that O 0 5.712102790766949e-09
BRCA1 O 0 8.340313684129796e-07
participates O 0 3.2559827900513483e-07
, O 0 1.2652325409590048e-08
directly O 0 5.457454932411565e-09
or O 0 3.759474065390123e-09
indirectly O 0 1.4546524873537692e-08
, O 0 5.2594462118804586e-09
in O 0 8.087779335141931e-09
transcription O 0 7.937597956697573e-07
- O 0 1.3393281506068888e-06
coupled O 0 7.698390618315898e-07
repair O 0 3.4415043046465144e-05
of O 0 8.09708012639021e-07
oxidative O 0 1.5702511518611573e-05
DNA O 0 0.0003809852642007172
damage O 0 9.936369315255433e-05
. O 0 4.5999593112355797e-07
. O 0 1.1470377785371966e-06

Truncation O 0 0.00022811679809819907
mutations O 0 2.0413751826708904e-06
in O 0 2.739345745794708e-07
the O 0 2.3808927096524712e-07
transactivation O 0 1.8416352759231813e-05
region O 0 2.1034239239270391e-07
of O 0 9.868367669696454e-07
PAX6 O 1 0.9975645542144775
result O 0 3.052383590329555e-07
in O 0 1.1953696343880438e-07
dominant O 0 1.2982809494133107e-06
- O 0 1.971309757209383e-06
negative O 0 3.7563259525086323e-07
mutants O 0 9.301005775341764e-06
. O 0 1.058129669218033e-06

PAX6 O 1 0.9993901252746582
is O 0 2.0049596969329286e-06
a O 0 1.9945571239077253e-07
transcription O 0 1.2658886134886416e-06
factor O 0 1.0501921821060023e-07
with O 0 3.910360479864039e-09
two O 0 3.4494003209317725e-09
DNA O 0 6.046520866220817e-07
- O 0 2.0616938911643956e-07
binding O 0 5.235148492488406e-08
domains O 0 7.646368516134316e-08
( O 0 6.774099858830596e-08
paired O 0 3.805823496350058e-07
box O 0 2.507592171241413e-06
and O 0 1.1100896557536544e-07
homeobox O 0 3.187042466379353e-06
) O 0 2.2576255531703282e-08
and O 0 1.9885243673911646e-08
a O 0 4.417224275243825e-08
proline O 0 6.533928626595298e-06
- O 0 3.4945767311000964e-06
serine O 0 1.1651882232399657e-05
- O 0 1.126553524954943e-05
threonine O 0 2.3029031581245363e-05
( O 0 4.6698542632839235e-07
PST O 1 0.999991774559021
) O 0 3.953484792873496e-07
- O 0 3.189158178429352e-06
rich O 0 5.03504452353809e-07
transactivation O 0 4.508077836362645e-05
domain O 0 1.467144898015249e-06
. O 0 7.405843689411995e-07

PAX6 O 1 0.9999973773956299
regulates O 0 0.0018512398237362504
eye O 0 0.018872283399105072
development O 0 2.9099149401190516e-07
in O 0 4.044413870474273e-08
animals O 0 3.10134424807984e-08
ranging O 0 1.8864001560814359e-07
from O 0 6.884478409574513e-08
jellyfish O 0 5.382016965427283e-08
to O 0 2.317271263763132e-09
Drosophila O 0 2.0204352324526553e-07
to O 0 3.558734817943332e-08
humans O 0 3.773823209485272e-07
. O 0 5.048859179623832e-07

Heterozygous O 0 7.1072072387323715e-06
mutations O 0 4.2734518501674756e-07
in O 0 4.520811458519347e-08
the O 0 4.844510925750001e-08
human O 0 2.226749273859241e-07
PAX6 O 1 0.9998277425765991
gene O 0 5.6617544430537237e-08
result O 0 7.9116446727312e-09
in O 0 2.905589324697644e-09
various O 0 3.6170371142674185e-09
phenotypes O 0 1.3132198262155725e-07
, O 0 1.131780802410276e-08
including O 0 4.1906599790308974e-07
aniridia B-Disease 1 1.0
, O 0 4.258486569597153e-06
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 1.8441729707774357e-06
autosomal B-Disease 0 0.08686383068561554
dominant I-Disease 0 0.06510526686906815
keratitis I-Disease 1 0.9999877214431763
, O 0 1.3012087265451555e-06
and O 0 4.216539309709333e-06
familial B-Disease 1 0.9999926090240479
foveal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.0007852367125451565

It O 0 5.966276148683392e-07
is O 0 3.948849425228218e-08
believed O 0 3.701148187928993e-08
that O 0 5.780733669524807e-10
the O 0 6.472413716096526e-09
mutated O 0 9.329492201004541e-08
allele O 0 2.1597296395725607e-08
of O 0 2.721132261740422e-07
PAX6 O 1 0.550086498260498
produces O 0 2.1354441059884266e-07
an O 0 8.024287900809668e-09
inactive O 0 9.294259939451877e-07
protein O 0 8.530514605809003e-08
and O 0 1.2741620025735756e-07
aniridia B-Disease 1 1.0
is O 0 3.364121425875055e-08
caused O 0 1.92665368103917e-07
due O 0 1.3231409923264437e-07
to O 0 4.1769382619349926e-08
genetic O 0 3.7586908092634985e-06
haploinsufficiency O 0 0.0010679445695132017
. O 0 1.7756628949427977e-06

However O 0 2.4716089228604687e-06
, O 0 5.305433603552956e-08
several O 0 6.093853865962728e-09
truncation O 0 9.705187267172732e-07
mutations O 0 3.640015933115137e-08
have O 0 1.5686472121245743e-09
been O 0 2.574479518457906e-09
found O 0 2.894852357826494e-09
to O 0 7.869755958012092e-10
occur O 0 9.37924515831412e-10
in O 0 5.2337880696029515e-09
the O 0 1.2757640277527571e-08
C O 0 2.8945203666808084e-05
- O 0 5.901954409637256e-07
terminal O 0 9.674381118429665e-08
half O 0 4.804937780988894e-09
of O 0 2.238587271108372e-08
PAX6 O 0 0.2653914988040924
in O 0 4.238970419123689e-08
patients O 0 3.801572034944911e-08
with O 0 1.5913704132231032e-08
Aniridia B-Disease 1 1.0
resulting O 0 4.4570859358827875e-07
in O 0 3.849201846151118e-08
mutant O 0 5.7200647773925084e-08
proteins O 0 1.373867797305195e-09
that O 0 2.93286506192203e-10
retain O 0 2.7653040746145052e-08
the O 0 2.610996041596536e-08
DNA O 0 1.4308668596640928e-06
- O 0 2.2271825628195074e-07
binding O 0 2.5313932283665963e-08
domains O 0 7.017368464090623e-09
but O 0 1.248918302110269e-09
have O 0 8.394377970510902e-10
lost O 0 5.2396938343690636e-08
most O 0 1.1796003063224703e-09
of O 0 1.9718795485346163e-08
the O 0 5.0092484826791406e-08
transactivation O 0 9.457399755774532e-06
domain O 0 6.934312750672689e-07
. O 0 5.052091296420258e-07

It O 0 7.20379489393963e-07
is O 0 3.3316258196691706e-08
not O 0 1.4101818601730542e-09
clear O 0 4.275842346856962e-09
whether O 0 1.0194539656893653e-09
such O 0 5.017708915033836e-09
mutants O 0 3.9438509702449664e-06
really O 0 8.791739247726582e-08
behave O 0 1.0509412007309038e-08
as O 0 1.3846597646249847e-08
loss O 0 1.3455551197694149e-06
- O 0 4.841554641643597e-07
of O 0 3.446278924457147e-07
- O 0 1.081313143913576e-06
function O 0 1.2241694768988509e-08
mutants O 0 2.434937869111309e-07
as O 0 1.3139584531529636e-08
predicted O 0 1.1449083814341066e-07
by O 0 7.794190537424583e-08
haploinsufficiency O 0 0.00024251986178569496
. O 0 3.882388682541205e-06

Contrary O 0 2.3400186819344526e-06
to O 0 1.9220870228764397e-08
this O 0 2.639838125872984e-09
theory O 0 2.213465144507154e-08
, O 0 3.2052263065907027e-09
our O 0 2.7755593379197308e-09
data O 0 9.263208866627792e-09
showed O 0 3.8760314957642095e-09
that O 0 3.1460594546173226e-11
these O 0 1.4538438508626683e-10
mutants O 0 3.00841520584072e-08
are O 0 4.663449626463034e-10
dominant O 0 3.450468000210094e-08
- O 0 4.3077861278106866e-08
negative O 0 1.658649217972652e-09
in O 0 1.1253483700457423e-09
transient O 0 9.081963625590106e-09
transfection O 0 5.728443284169771e-07
assays O 0 4.0434958492596706e-08
when O 0 4.288461585844061e-09
they O 0 8.430673381631948e-10
are O 0 8.486138458607684e-10
coexpressed O 0 1.2984060049348045e-06
with O 0 1.0564741970142677e-08
wild O 0 3.655441560113104e-06
- O 0 3.429509888519533e-05
type O 0 4.886691385763697e-05
PAX6 O 1 0.9999884366989136
. O 0 7.077400823618518e-06

We O 0 4.499601971019729e-07
found O 0 3.658119140936833e-08
that O 0 1.468657973013876e-09
the O 0 1.4775824119794834e-08
dominant O 0 6.601798077099374e-07
- O 0 3.583768091175443e-07
negative O 0 9.963176950122943e-09
effects O 0 1.2121969916734088e-07
result O 0 6.767614468827787e-09
from O 0 4.869883607483416e-09
the O 0 3.745174392832951e-09
enhanced O 0 5.244843137575117e-08
DNA O 0 2.0352466378881218e-07
binding O 0 1.3190206260560444e-08
ability O 0 5.370714095676021e-09
of O 0 3.805953951996344e-08
these O 0 6.255931594978392e-08
mutants O 0 1.0500652933842503e-05
. O 0 1.0399977554698125e-06

Kinetic O 0 2.3557244276162237e-05
studies O 0 1.21856191981351e-06
of O 0 3.7991802059877955e-07
binding O 0 1.6699547700227413e-07
and O 0 4.647382567668501e-08
dissociation O 0 8.574654657422798e-07
revealed O 0 1.7561231402396515e-07
that O 0 6.103901273313284e-10
various O 0 4.05685085524965e-09
truncation O 0 1.1565997510842863e-06
mutants O 0 4.514426450441533e-07
have O 0 1.5452469304122474e-09
3 O 0 5.064788055619829e-08
- O 0 1.6382672640702367e-07
5 O 0 6.121138795833758e-08
- O 0 9.230830499973308e-08
fold O 0 1.353699108364026e-08
higher O 0 5.646707101902848e-09
affinity O 0 1.738183152966144e-09
to O 0 4.851505863712191e-10
various O 0 3.945775706171162e-09
DNA O 0 4.702021385583066e-07
- O 0 5.8952039694304403e-08
binding O 0 2.7524631462938487e-09
sites O 0 9.629201436212043e-09
when O 0 3.572361739756502e-09
compared O 0 2.447974489783178e-09
with O 0 4.6498074834921965e-10
the O 0 2.4506059403961444e-08
wild O 0 2.2079682366893394e-06
- O 0 9.112015504797455e-06
type O 0 2.0855299226241186e-05
PAX6 O 1 0.9999257326126099
. O 0 7.206892860267544e-06

These O 0 1.503757118825888e-07
results O 0 8.731094425229458e-08
provide O 0 6.842988842237219e-09
a O 0 4.633069039527982e-09
new O 0 1.7715709788035383e-08
insight O 0 5.3972311064853784e-08
into O 0 4.231713646163371e-09
the O 0 5.087179122398311e-09
role O 0 5.438770767085543e-09
of O 0 4.4903984530719754e-08
mutant O 0 2.1206969904596917e-06
PAX6 O 1 0.970161497592926
in O 0 1.1430279300839175e-06
causing O 0 8.873671322362497e-05
aniridia B-Disease 1 0.9999998807907104
. O 0 7.138102091630572e-07
. O 0 4.321851463373605e-07

Reversal O 0 0.000129142397781834
of O 0 0.003902347758412361
severe O 1 1.0
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 0 0.05504334345459938
excellent O 0 0.00071593007305637
neuropsychologic O 0 0.40718841552734375
outcome O 0 1.5758113249830785e-06
in O 0 4.3857932041646563e-07
very B-Disease 0 1.0600614075428894e-07
- I-Disease 0 1.0177459444093984e-05
long I-Disease 0 7.247116968756018e-07
- I-Disease 0 1.2516249626060016e-05
chain I-Disease 0 1.9051207118536695e-06
acyl I-Disease 0 2.938010538855451e-06
- I-Disease 0 5.151737423148006e-05
coenzyme I-Disease 0 8.276140761154238e-06
A I-Disease 1 0.700818657875061
dehydrogenase I-Disease 1 0.9997791647911072
deficiency I-Disease 1 0.9999998807907104
. O 0 4.313653698773123e-05

Very B-Disease 0 1.0118423233507201e-05
- I-Disease 0 4.400550824357197e-05
long I-Disease 0 1.931493443407817e-06
- I-Disease 0 4.5877459342591465e-06
chain I-Disease 0 4.930078034703911e-07
acyl I-Disease 0 6.053484185031266e-07
- I-Disease 0 1.1577154737096862e-06
coenzyme I-Disease 0 2.494228681371169e-07
A I-Disease 0 1.4801515817453037e-06
dehydrogenase I-Disease 0 2.533814267735579e-06
( I-Disease 0 1.2571520073834108e-06
VLCAD I-Disease 1 1.0
) I-Disease 0 4.073992749908939e-05
deficiency I-Disease 1 0.9999251365661621
is O 0 3.516268165526526e-08
a O 0 2.0581106241479574e-07
disorder O 1 0.9990894794464111
of O 1 0.895492672920227
fatty O 0 0.0018998375162482262
acid O 0 1.8022363974523614e-06
beta O 0 1.9469713663511357e-07
oxidation O 0 5.188031693137418e-08
that O 0 1.1668986887869437e-09
reportedly O 0 5.3372421149333604e-08
has O 0 2.302138923937491e-09
high O 0 1.0151706675287642e-07
rates O 0 2.177802294056619e-08
of O 0 7.583579275660668e-08
morbidity O 0 4.0447659557685256e-05
and O 0 6.19775960331026e-07
mortality O 0 2.7344820409780368e-05
. O 0 1.2406906080286717e-06

We O 0 3.10138318582176e-07
describe O 0 1.6875510766567459e-07
the O 0 3.0231866787744366e-08
outcome O 0 4.0125041067540224e-08
of O 0 7.922702138785098e-08
a O 0 2.4451059843499934e-08
5 O 0 1.2070761101767857e-07
- O 0 2.0592906935235078e-07
year O 0 4.960019239774738e-08
- O 0 4.0932835077001073e-07
old O 0 3.0273151878645876e-06
girl O 0 1.1309153933325433e-06
with O 0 2.5905148959282087e-07
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 1.7378380334776011e-06
was O 0 2.5309402644779766e-06
first O 0 1.0647483605907837e-07
seen O 0 5.465686925276714e-08
at O 0 1.1600746319118116e-07
5 O 0 3.208139176535951e-08
months O 0 3.4600091680658807e-09
of O 0 2.349256789102583e-08
age O 0 1.2860721199103864e-07
with O 0 7.216206654447888e-08
severe O 1 1.0
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 1 0.999992847442627
hepatomegaly B-Disease 1 1.0
, O 1 0.9999992847442627
encephalopathy B-Disease 1 1.0
, O 0 0.0007282699807547033
and O 0 0.0015167652163654566
hypotonia B-Disease 1 0.9999984502792358
. O 0 0.00010372229007771239

Biochemical O 0 0.0019305326277390122
studies O 0 6.150098488433287e-05
indicated O 1 0.9944286346435547
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 1 0.7814056873321533
by O 0 4.130311879180226e-07
a O 0 3.3514157848912873e-07
stable O 0 1.1024802688552882e-06
yet O 0 3.710999010309024e-07
inactive O 0 7.943543096189387e-06
enzyme O 0 2.370842366872239e-06
. O 0 1.9066692402702756e-06

Molecular O 0 4.683254155679606e-05
genetic O 0 1.1570002698135795e-06
analysis O 0 7.471734164710142e-08
of O 0 6.263620662139147e-07
her O 0 4.916162197332596e-07
VLCAD O 1 0.9999998807907104
gene O 0 1.2861963796240161e-06
revealed O 0 6.451353442571417e-07
a O 0 1.3888553951346694e-07
T1372C O 0 1.9570514268707484e-05
( O 0 2.473093729804532e-07
F458L O 0 2.357695484533906e-05
) O 0 7.358617892805341e-08
missense O 0 2.2385331703844713e-06
mutation O 0 1.6934370705712354e-07
and O 0 9.632657338443096e-08
a O 0 9.777687637324561e-07
1668 O 1 0.995368480682373
ACAG O 1 0.9999980926513672
1669 O 0 0.01091726403683424
splice O 0 0.0014685301575809717
site O 0 4.886486567556858e-05
mutation O 0 3.302426875961828e-06
. O 0 2.6663358312362107e-06

After O 0 4.593134690367151e-06
initial O 0 4.571066654079914e-07
treatment O 0 1.9037041738556582e-06
with O 0 3.370653445244898e-08
intravenous O 0 3.908828512066975e-05
glucose O 0 0.00035781407495960593
and O 0 3.28964489426653e-07
carnitine O 0 0.00012388492177706212
, O 0 2.3971685081392025e-08
the O 0 2.9241322252460122e-08
patient O 0 9.339996864810018e-08
has O 0 2.668837373320798e-09
thrived O 0 1.51668061221244e-07
on O 0 3.160800332580038e-08
a O 0 1.8823524072786313e-08
low O 0 6.742569667039788e-07
- O 0 1.8721426613410586e-06
fat O 0 1.8769247844829806e-06
diet O 0 1.7661920992395608e-07
supplemented O 0 5.836333016873141e-08
with O 0 3.6332652442183644e-09
medium O 0 1.3114480452713906e-06
- O 0 1.9041580117118428e-06
chain O 0 6.020466685185966e-07
triglyceride O 0 8.268923465948319e-07
oil O 0 1.8258977263485576e-07
and O 0 1.8437170012930437e-08
carnitine O 0 4.269718374416698e-06
and O 0 5.3487781315197935e-08
avoidance O 0 3.010481668752618e-05
of O 0 3.800140120802098e-06
fasting O 0 1.5014849850558676e-05
. O 0 9.846587545325747e-07

Her O 0 0.00021676591131836176
ventricular O 1 0.9999997615814209
hypertrophy O 1 0.9999629259109497
resolved O 0 6.444044629461132e-06
significantly O 0 1.406583578500431e-07
over O 0 2.0785648757737363e-08
1 O 0 3.722628250102389e-08
year O 0 8.32224422708805e-09
, O 0 2.4744224447204033e-09
and O 0 4.447513024530281e-09
cognitively O 0 1.6870551462488947e-06
, O 0 2.0975940984158115e-08
she O 0 2.33684072092899e-09
is O 0 2.2109312991513974e-10
in O 0 9.457333804974155e-10
the O 0 2.687328359840535e-09
superior O 0 1.2660683523790794e-07
range O 0 4.694896915680147e-08
for O 0 1.52125014807325e-08
age O 0 4.351961422344175e-07
. O 0 3.364433496244601e-07

Clinical O 0 0.0001475340104661882
recognition O 0 6.997909622441512e-06
of O 1 0.9999353885650635
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 3.3359947337885387e-07
important O 0 8.015955188511725e-08
because O 0 3.658500835612699e-09
it O 0 1.2713230468364145e-09
is O 0 5.122676727253861e-10
one O 0 4.317414203924841e-10
of O 0 9.649204102402109e-09
the O 0 2.1331150179548786e-08
few O 0 2.129102938397409e-08
directly O 0 2.4781769525361597e-07
treatable O 1 0.9999972581863403
causes O 0 2.89887657345389e-06
of O 0 0.01665952242910862
cardiomyopathy B-Disease 1 1.0
in O 0 1.0169298548134975e-05
children O 0 7.073474534990964e-07
. O 0 3.103128562997881e-07
. O 0 6.965417469473323e-07

Cloning O 0 3.074655614909716e-05
of O 0 1.7600980299903313e-06
a O 0 1.0977072406603838e-07
novel O 0 8.223769043524953e-08
member O 0 3.417379446091218e-08
of O 0 6.460317081291578e-08
the O 0 3.7516819872962515e-08
low O 0 2.2882151995418099e-07
- O 0 1.6071933828243345e-07
density O 0 1.9311857002435318e-08
lipoprotein O 0 1.1719751455530059e-05
receptor O 0 3.217672315258824e-07
family O 0 3.9123546002883813e-07
. O 0 6.830159691162407e-07

A O 0 3.092699989792891e-05
gene O 0 2.9461318717949325e-07
encoding O 0 9.346376828034408e-08
a O 0 1.1339485439521013e-07
novel O 0 2.7365726396055834e-07
transmembrane O 0 5.006607466384594e-07
protein O 0 1.9920270233342308e-07
was O 0 2.617865675347275e-07
identified O 0 8.564421172252423e-09
by O 0 6.153535458963688e-10
DNA O 0 8.773815096674298e-08
sequence O 0 2.980985236433753e-09
analysis O 0 1.1125708132553314e-09
within O 0 6.755530357338557e-09
the O 0 2.2128530119402967e-08
insulin B-Disease 0 7.20922980690375e-06
- I-Disease 0 0.00011774604354286566
dependent I-Disease 0 0.00016580731607973576
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 3.8961603422649205e-05
IDDM B-Disease 1 1.0
) O 0 2.0580557702487567e-07
locus O 0 9.398805786986486e-07
IDDM4 O 0 0.007396650034934282
on O 0 2.7339115149516147e-06
chromosome O 0 6.8031113187316805e-06
11q13 O 0 0.0001295121037401259
. O 0 5.459598924062448e-06

Based O 0 5.369080099626444e-06
on O 0 3.8809386637694843e-07
its O 0 3.841156370754106e-08
chromosomal O 0 9.505987463853671e-07
position O 0 2.4779831164778443e-07
, O 0 1.1153590051549145e-08
this O 0 7.441831595400572e-10
gene O 0 8.55575166269773e-09
is O 0 6.258288887117658e-10
a O 0 3.3798321918965257e-09
candidate O 0 4.488015736825446e-09
for O 0 3.4205989152269467e-09
conferring O 0 2.6712764338299166e-06
susceptibility O 0 6.04429078521207e-05
to O 0 1.2201167010061909e-05
diabetes B-Disease 1 0.9999998807907104
. O 0 2.2051268388167955e-05

The O 0 1.1227011782466434e-05
gene O 0 1.1264214663242456e-06
, O 0 9.228875796907232e-08
termed O 0 2.8058582302037394e-06
low O 0 3.6741432722919853e-06
- O 0 8.27600047159649e-07
density O 0 5.7332595559955735e-08
lipoprotein O 0 3.3236208309972426e-06
receptor O 0 1.6931327451175093e-08
related O 0 6.350450121317408e-08
protein O 0 4.245986318096584e-08
5 O 0 1.2721027076167957e-07
( O 0 2.4746171334300016e-08
LRP5 O 1 0.9602136611938477
) O 0 7.70943842098859e-09
, O 0 1.7446067923643227e-09
encodes O 0 2.0272408196575498e-09
a O 0 6.153726417323924e-09
protein O 0 1.9502675030480532e-08
of O 0 2.3096505685771263e-07
1615 O 0 5.996845175104681e-06
amino O 0 2.74228799668208e-08
acids O 0 6.341260405662297e-09
that O 0 3.0580327159412946e-10
contains O 0 4.593998959023793e-09
conserved O 0 1.2187968856380849e-08
modules O 0 6.011533315586348e-08
which O 0 1.4384395896627211e-09
are O 0 1.9919615956709436e-10
characteristic O 0 9.209828455425395e-09
of O 0 1.9483826108057656e-08
the O 0 1.8281413716181305e-08
low O 0 2.243069161522726e-07
- O 0 1.2121553538690932e-07
density O 0 3.166369566542926e-08
lipoprotein O 0 3.336664303787984e-05
( O 0 3.8511336697411025e-07
LDL O 1 0.9998806715011597
) O 0 1.4745705811947118e-07
receptor O 0 3.123886642697471e-07
family O 0 4.1514238091622246e-07
. O 0 7.086072741913085e-07

These O 0 4.0971809767142986e-07
modules O 0 3.5402770208747825e-06
include O 0 3.31273071196847e-07
a O 0 1.114192187401386e-07
putative O 0 1.5471240430997568e-06
signal O 0 6.290888450166676e-07
peptide O 0 8.85447661858052e-08
for O 0 7.06559744045876e-09
protein O 0 2.0632194619452093e-08
export O 0 2.164672849858107e-07
, O 0 1.2865746690238211e-08
four O 0 1.9783101379289292e-08
epidermal O 0 6.869911430840148e-07
growth O 0 6.673950991853417e-08
factor O 0 8.05231863409972e-08
( O 0 3.295167161354584e-08
EGF O 0 3.290384847787209e-05
) O 0 2.674750021469663e-08
repeats O 0 3.310361762487446e-08
with O 0 2.0964650015997677e-09
associated O 0 3.069284204570977e-08
spacer O 0 1.7527110003356938e-06
domains O 0 1.9589771227401798e-07
, O 0 2.500718210285413e-08
three O 0 4.371961637161803e-08
LDL O 0 0.13816381990909576
- O 0 4.242835075274343e-06
receptor O 0 7.187305328670845e-08
( O 0 4.9330736828778754e-08
LDLR O 1 0.9993851184844971
) O 0 2.6873038905250723e-08
repeats O 0 1.4802856185269775e-07
, O 0 5.1493640462751955e-09
a O 0 1.047726883030009e-08
single O 0 4.193342206804118e-08
transmembrane O 0 1.3234917162208149e-07
spanning O 0 6.08646359978593e-07
domain O 0 9.994547411906751e-08
, O 0 1.5655901464128874e-08
and O 0 2.130033216474203e-08
a O 0 3.4038741603126255e-08
cytoplasmic O 0 9.723956964080571e-07
domain O 0 1.2686248282989254e-06
. O 0 1.0663819693945698e-06

The O 0 1.7058513321899227e-06
encoded O 0 1.5254479990289838e-07
protein O 0 6.553259623842678e-08
has O 0 1.963880169597587e-09
a O 0 1.2531227167045245e-09
unique O 0 4.520352092640678e-09
organization O 0 2.5568736461423214e-08
of O 0 4.0944428292277735e-07
EGF O 0 0.0014625478070229292
and O 0 1.7774644334167533e-07
LDLR O 1 0.9998754262924194
repeats O 0 1.4160630712467537e-07
; O 0 2.9016518077185083e-09
therefore O 0 7.9971211874863e-09
, O 0 1.3637698970114798e-08
LRP5 O 1 0.9747586250305176
likely O 0 2.4916484875348033e-08
represents O 0 9.542209689072934e-09
a O 0 3.759057953800493e-09
new O 0 9.025219682712304e-09
category O 0 3.951139504465573e-08
of O 0 1.0087047286333473e-07
the O 0 5.539473022508901e-07
LDLR O 1 0.9999711513519287
family O 0 5.0754092626448255e-06
. O 0 3.5399800708546536e-06

Both O 0 2.016157395701157e-06
human O 0 7.244483981594385e-07
and O 0 6.896530067024287e-07
mouse O 0 0.00010535518958931789
LRP5 O 1 0.9999995231628418
cDNAs O 0 8.928025636123493e-05
have O 0 7.927142497976547e-09
been O 0 9.552917568100838e-09
isolated O 0 4.4562778356294075e-08
and O 0 1.5645654771745399e-09
the O 0 3.848876772849508e-09
encoded O 0 4.575268164330737e-09
mature O 0 7.876321816979726e-09
proteins O 0 5.866953034505684e-10
are O 0 1.8398475798431235e-10
95 O 0 1.5434419964321933e-08
% O 0 1.2192892251405851e-09
identical O 0 1.2489618228528343e-08
, O 0 4.8031054689090524e-09
indicating O 0 1.5651513862735555e-08
a O 0 5.867985652940888e-09
high O 0 1.1363973584366249e-07
degree O 0 5.022489091288662e-08
of O 0 1.4999496755763175e-08
evolutionary O 0 6.951071185312685e-08
conservation O 0 2.6259147034579655e-07
. O 0 2.8920281280875315e-08
. O 0 1.4782990831463394e-07

The O 0 1.878145667433273e-05
APC B-Disease 0 8.828918362269178e-05
variants O 0 2.6774764592119027e-06
I1307K O 0 2.2644822820439003e-05
and O 0 1.3749595950685034e-07
E1317Q O 0 3.3257326776947593e-06
are O 0 4.088739125052143e-09
associated O 0 2.0083342633370194e-07
with O 0 0.00024461315479129553
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 8.968977454060223e-07
but O 0 3.942195014872141e-09
not O 0 1.852913933397815e-09
always O 0 4.888691673698986e-09
with O 0 6.890817361160373e-10
a O 0 1.2105191515843217e-08
family O 0 5.775515177219859e-08
history O 0 2.72375700660632e-06
. O 0 1.2401784488247358e-06

Classical O 0 0.4164736866950989
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 8.971688657766208e-05
FAP B-Disease 1 0.9999936819076538
) O 0 2.834001975315914e-07
is O 0 3.0568870101888024e-08
a O 0 4.545453435866875e-08
high O 0 0.3240930140018463
- O 1 0.9829030632972717
penetrance O 1 0.999976396560669
autosomal B-Disease 1 0.9999001026153564
dominant I-Disease 1 0.9999995231628418
disease I-Disease 1 0.9999995231628418
that O 0 3.582421115311263e-08
predisposes O 0 3.527746457621106e-06
to O 0 1.3680268473592605e-08
hundreds O 0 3.4846610930117095e-08
or O 0 8.356649594531973e-09
thousands O 0 2.951077071600139e-08
of O 0 0.0005487349117174745
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9935094714164734
carcinoma I-Disease 1 1.0
and O 0 5.203402793085843e-07
that O 0 3.6345890741529274e-09
results O 0 2.54417180656219e-08
from O 0 2.0801987687946166e-08
truncating O 0 1.0728399502113461e-06
mutations O 0 2.997218473410612e-08
in O 0 4.026226818609757e-08
the O 0 2.9354686148508335e-07
APC B-Disease 0 0.00037226258427836
gene O 0 8.347949005838018e-06
. O 0 3.6262927096686326e-06

A O 0 5.742788562201895e-05
variant O 0 2.3643107851967216e-05
of O 0 1.1474631719465833e-05
FAP B-Disease 1 0.9970267415046692
is O 0 1.5858186088735238e-06
attenuated B-Disease 0 0.21674934029579163
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999972581863403
coli I-Disease 1 0.9996284246444702
, O 0 1.5870924130467756e-07
which O 0 2.0959225466299358e-08
results O 0 4.5613898436158706e-08
from O 0 1.8097613008194458e-07
germ O 1 0.9999386072158813
- O 0 1.0153309631277807e-05
line O 0 4.1128481598207145e-07
mutations O 0 7.874579210920274e-09
in O 0 2.3884820787856142e-09
the O 0 5.469167341232151e-09
5 O 0 2.252300923544226e-08
and O 0 1.6417096571075263e-09
3 O 0 2.220713213318959e-08
regions O 0 5.364243715888506e-09
of O 0 4.0236550091776735e-08
the O 0 2.9711787874475704e-07
APC B-Disease 0 0.00013766119081992656
gene O 0 2.036506202784949e-06
. O 0 7.311838885470934e-07

Attenuated B-Disease 1 0.9999963045120239
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 0 0.00033104559406638145
have O 0 9.611221685190685e-08
" O 0 7.806448252267728e-07
multiple O 0 3.8702050915162545e-06
" O 1 0.9999829530715942
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 1.8012484304108511e-07
typically O 0 5.723314266958823e-09
fewer O 0 1.8859236394774825e-09
than O 0 2.688803624195657e-10
100 O 0 1.2010392680394943e-08
) O 0 1.0003425865434679e-09
without O 0 1.5848117262962091e-09
the O 0 9.04279584545975e-09
florid O 0 3.919068149116356e-06
phenotype O 0 1.7656161332979536e-07
of O 0 2.3614815347627882e-07
classical O 0 1.7187656339956447e-05
FAP B-Disease 0 0.005002236925065517
. O 0 4.541745511232875e-06

Another O 0 8.41690598463174e-06
group O 0 1.4411103848033235e-06
of O 0 1.260625253962644e-06
patients O 0 8.100609534267278e-07
with O 0 5.232243438513251e-08
multiple O 0 4.033116510981927e-06
adenomas B-Disease 1 0.9864978790283203
has O 0 2.6545070141992255e-08
no O 0 7.560799986094935e-09
mutations O 0 4.0824117419901995e-09
in O 0 6.019344578334085e-09
the O 0 6.055863366327685e-08
APC B-Disease 0 1.3501838111551479e-05
gene O 0 1.1669364141653205e-07
, O 0 1.0180322362884908e-08
and O 0 2.61134336376756e-09
their O 0 3.940841875049728e-09
phenotype O 0 4.12777936276143e-08
probably O 0 1.1313145975577754e-08
results O 0 7.785897260248476e-09
from O 0 8.014652053134341e-09
variation O 0 4.1681122553427485e-08
at O 0 1.1008061306938544e-07
a O 0 9.265046507778152e-09
locus O 0 5.3287891432773904e-08
, O 0 3.473537901754753e-09
or O 0 4.209045556535784e-09
loci O 0 1.9570007836478e-08
, O 0 3.5010547794200875e-09
elsewhere O 0 8.760332903534618e-09
in O 0 7.694278103542729e-09
the O 0 4.197791625415448e-08
genome O 0 4.969356268702541e-07
. O 0 3.3495274465167313e-07

Recently O 0 1.698581218079198e-05
, O 0 9.558206670590152e-08
however O 0 2.3050223063592057e-08
, O 0 8.014621855068071e-09
a O 0 6.016887876825194e-09
missense O 0 4.1852720755741757e-07
variant O 0 8.477974802190147e-07
of O 0 3.353229885760811e-06
APC B-Disease 0 0.001936078886501491
( O 0 3.714500849127944e-07
I1307K O 0 6.743940321030095e-05
) O 0 4.6304212020231716e-08
was O 0 1.8468271889560128e-07
described O 0 2.2465217242029212e-08
that O 0 4.258610131202545e-10
confers O 0 1.1624895712714078e-08
an O 0 8.840106979768336e-10
increased O 0 5.142650749689892e-09
risk O 0 9.915748222510956e-08
of O 0 0.12373123317956924
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.1152870627029188e-07
including O 0 4.377218232320956e-08
multiple O 0 1.1276630402790033e-06
adenomas B-Disease 0 0.07809611409902573
, O 0 2.5352690613544837e-07
in O 0 5.017524813411001e-07
Ashkenazim O 0 0.0004052497388329357
. O 0 8.05770014267182e-06

We O 0 3.2859762200132536e-07
have O 0 5.943885827974782e-09
studied O 0 6.695268695011691e-08
a O 0 2.548561139903427e-09
set O 0 9.659387067983971e-09
of O 0 2.623676031987543e-08
164 O 0 2.45733502879375e-07
patients O 0 2.805638565916979e-08
with O 0 1.846458630438974e-08
multiple O 1 0.9981350898742676
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.00017196314001921564
/ I-Disease 1 0.9997323155403137
or I-Disease 0 0.05000076815485954
carcinoma I-Disease 1 1.0
and O 0 7.943020250422705e-07
analyzed O 0 1.032866407513211e-06
codons O 0 1.034037268254906e-06
1263 O 0 8.562096627429128e-05
- O 0 7.455969807779184e-06
1377 O 0 0.0001258135016541928
( O 0 2.597337527276977e-07
exon O 0 2.4053315428318456e-06
15G O 0 1.2525814781838562e-05
) O 0 1.6157127191718246e-08
of O 0 5.033824734823611e-08
the O 0 5.862417395974262e-08
APC B-Disease 0 6.40187090539257e-06
gene O 0 6.707142574668978e-08
for O 0 5.7117027552067157e-08
germ O 1 0.999981164932251
- O 0 0.0003249335859436542
line O 0 1.2612982573045883e-05
variants O 0 2.3716449959465535e-06
. O 0 4.864584752795054e-07

Three O 0 2.7461776426207507e-06
patients O 0 6.450073328778672e-07
with O 0 2.3357053180461662e-08
the O 0 1.83933764219546e-07
I1307K O 0 7.334540441661375e-06
allele O 0 3.2324255272442315e-08
were O 0 1.317914133380782e-08
detected O 0 9.220377705787541e-08
, O 0 1.5376497852770399e-09
each O 0 2.403901244729667e-10
of O 0 3.0770920034228766e-08
Ashkenazi O 0 1.172051179310074e-05
descent O 0 4.516335593507392e-06
. O 0 2.3041006897983607e-06

Four O 0 5.270603651297279e-06
patients O 0 1.6380469105570228e-06
had O 0 4.441636178853514e-07
a O 0 4.135672497795895e-07
germ O 1 0.9999983310699463
- O 0 0.0006286737625487149
line O 0 4.586381237459136e-06
E1317Q O 0 8.57908253237838e-06
missense O 0 1.1694960448949132e-06
variant O 0 8.283383294838131e-07
of O 0 7.127646881599503e-07
APC O 0 1.568371408211533e-05
that O 0 1.003687710721124e-08
was O 0 1.1338133987237597e-07
not O 0 2.7808622071745503e-10
present O 0 1.2913458080632267e-09
in O 0 2.5607769238433775e-09
controls O 0 1.2116394998429314e-08
; O 0 9.935636757774091e-10
one O 0 8.209561919159114e-10
of O 0 3.3308744651350253e-09
these O 0 2.2449174463812227e-10
individuals O 0 2.873298265981816e-10
had O 0 3.961158512311158e-09
an O 0 6.400360796909865e-10
unusually O 0 1.0930894411842473e-08
large O 0 2.5371489353887e-09
number O 0 1.6106533884396868e-09
of O 0 6.197723934064925e-08
metaplastic B-Disease 0 0.0001729816140141338
polyps I-Disease 0 1.3401649994193576e-06
of I-Disease 0 2.0908362330374075e-07
the I-Disease 0 7.252039608829364e-07
colorectum I-Disease 0 0.0011415008921176195
. O 0 3.841746547550429e-06

There O 0 5.806375611427939e-07
is O 0 6.36645580698314e-09
increasing O 0 2.0222090668653436e-09
evidence O 0 9.334650385994792e-09
that O 0 2.2406140831598975e-10
there O 0 3.602170783878478e-10
exist O 0 2.4178954394216134e-09
germ O 0 0.0002226750075351447
- O 0 5.374010356717918e-07
line O 0 5.2267477457235145e-08
variants O 0 1.508605862454715e-08
of O 0 1.419931372481642e-08
the O 0 1.5488327065327212e-08
APC B-Disease 0 6.262566785153467e-06
gene O 0 3.7776541006451225e-08
that O 0 8.740083656810782e-10
predispose O 0 1.959189432909625e-08
to O 0 3.231677814241607e-09
the O 0 7.4242545444747066e-09
development O 0 1.8751926234017446e-08
of O 0 2.426684773126908e-07
multiple O 1 0.8454406261444092
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9919241070747375
carcinoma I-Disease 1 1.0
, O 0 6.978409601288149e-07
but O 0 1.330558152545791e-08
without O 0 8.700817843987352e-09
the O 0 3.045962770897859e-08
florid O 0 4.290380275051575e-06
phenotype O 0 7.731456719284324e-08
of O 0 6.722267897885104e-08
classical O 0 2.951307578769047e-06
FAP B-Disease 0 0.001394421560689807
, O 0 4.55762432238771e-08
and O 0 8.64632365704665e-09
possibly O 0 3.871969411761711e-08
with O 0 3.05074587814147e-09
importance O 0 1.1882987394074007e-07
for O 0 7.382180774584413e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 4.1200519262929447e-07
in O 0 2.4296806344636934e-08
the O 0 1.106157920816031e-08
general O 0 1.4205707721259841e-08
population O 0 4.197611147560565e-10
. O 0 1.4818611226985468e-08
. O 0 1.0542824213644053e-07

Genomic O 0 2.859762571461033e-05
structure O 0 4.928338512399932e-06
of O 0 1.1967809996349388e-06
the O 0 8.404973641518154e-07
human O 0 0.3810778260231018
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9978514909744263
CLD B-Disease 1 1.0
) O 0 4.049396011396311e-06
gene O 0 2.396237505308818e-06
. O 0 1.6478064708280726e-06

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999974966049194
CLD B-Disease 1 1.0
) O 0 3.6881788219034206e-06
is O 0 2.3534637350053345e-08
caused O 0 9.413143686742842e-08
by O 0 5.063037100683232e-09
mutations O 0 9.241115428437752e-09
in O 0 6.242043326665225e-09
a O 0 1.8219070696545714e-08
gene O 0 2.648994090748147e-08
which O 0 5.340762943006894e-09
encodes O 0 2.65153161649323e-08
an O 0 3.8225554277460105e-08
intestinal O 0 0.10520298779010773
anion O 0 4.0026796341408044e-05
transporter O 0 0.003101953538134694
. O 0 1.0926642971753608e-05

We O 0 9.910422704706434e-07
report O 0 1.7216081005244632e-07
here O 0 1.2845467800559618e-08
the O 0 2.8929645345954214e-09
complete O 0 1.548688111085994e-08
genomic O 0 1.6527478052807965e-08
organization O 0 1.2151735617749182e-08
of O 0 4.056574098854071e-08
the O 0 4.6601112302369074e-08
human O 0 2.1707651853830612e-07
CLD B-Disease 1 0.9999955892562866
gene O 0 2.0413506263139425e-07
which O 0 1.034706986757783e-08
spans O 0 1.0227542190932581e-07
approximately O 0 5.7422663957140685e-08
39kb O 0 7.552877832495142e-06
, O 0 3.527069125652815e-08
and O 0 4.475827353189743e-08
comprises O 0 8.706870744390471e-07
21 O 0 7.523497060901718e-06
exons O 0 1.8564187485026196e-05
. O 0 1.7580965732122422e-06

All O 0 1.07862333607045e-05
exon O 0 0.0003510771202854812
/ O 0 6.327823211904615e-05
intron O 0 1.891522333608009e-05
boundaries O 0 1.32622986370734e-07
conform O 0 1.432797347433734e-07
to O 0 2.0018054769366245e-08
the O 0 9.327176258011605e-07
GT O 1 0.9999551773071289
/ O 1 0.9536478519439697
AG O 1 1.0
rule O 0 1.029084887704812e-05
. O 0 2.5443086997256614e-06

An O 0 1.2219140899105696e-07
analysis O 0 1.30901355532842e-07
of O 0 1.6586064077728224e-07
the O 0 9.507314757684071e-08
putative O 0 4.836423158849357e-06
promoter O 0 0.00010614295752020553
region O 0 1.7118995288001315e-07
sequence O 0 2.2362870666370327e-08
shows O 0 2.2553830802962693e-08
a O 0 3.574169582520881e-08
putative O 0 7.336492217291379e-06
TATA O 1 1.0
box O 0 8.90111259650439e-05
and O 0 1.3694319989099313e-07
predicts O 0 4.478376638417103e-07
multiple O 0 4.676958553773147e-08
transcription O 0 9.009105497170822e-07
factor O 0 1.505730438111641e-07
binding O 0 1.4194593234151398e-07
sites O 0 1.2480614941523527e-06
. O 0 1.0076968237626716e-06

The O 0 2.666529326234013e-06
genomic O 0 1.6493237353643053e-06
structure O 0 1.761807652655989e-06
was O 0 2.1616629908294271e-07
determined O 0 9.221605701270619e-09
using O 0 2.531628462421054e-09
DNA O 0 1.3158449974071118e-07
from O 0 3.4224914013947227e-09
several O 0 6.36031116663105e-10
sources O 0 3.447413909896113e-09
including O 0 2.814888766522472e-09
multiple O 0 1.972748542300451e-08
large O 0 3.3921892850230506e-07
- O 0 1.6894260625122115e-05
insert O 0 6.9688794610556215e-06
libaries O 0 2.7867596145370044e-05
and O 0 1.612077227264308e-08
genomic O 0 1.4328315955935977e-07
DNA O 0 7.879042982494866e-07
from O 0 2.3435691787199175e-07
Finnish O 1 0.9997017979621887
CLD B-Disease 1 1.0
patients O 0 1.2655792488658335e-05
and O 0 1.3757219221588457e-06
controls O 0 2.916612538683694e-05
. O 0 4.021877884952119e-06

Exon O 0 0.0003079035668633878
- O 0 5.146336661709938e-06
specific O 0 7.242253019512646e-08
primers O 0 1.199274038299336e-06
developed O 0 1.4968821915317676e-07
in O 0 6.8321903690105046e-09
this O 0 4.508003137448924e-10
study O 0 1.1732054217006294e-09
will O 0 3.238858903298336e-10
facilitate O 0 3.0101872106058636e-09
mutation O 0 6.5048637587494795e-09
screening O 0 2.2503213514823983e-08
studies O 0 2.7889055509433547e-09
of O 0 1.829505258399422e-08
patients O 0 4.790016205902248e-08
with O 0 1.5630748251282967e-08
the O 0 1.533402974018827e-05
disease O 1 0.9999233484268188
. O 0 2.1386613298091106e-06

Genomic O 0 5.45122293260647e-06
sequencing O 0 3.766053396248026e-06
of O 0 2.507498948034481e-06
a O 0 1.4916350892235641e-06
BAC O 1 0.9998300075531006
clone O 0 0.0010270400671288371
H O 1 1.0
_ O 0 7.465052362931601e-07
RG364P16 O 0 8.273655112134293e-06
revealed O 0 2.880262286453217e-07
the O 0 7.495969178705764e-09
presence O 0 3.931487135844236e-09
of O 0 1.74669860797394e-08
another O 0 1.036676522403468e-08
, O 0 1.7257786311120071e-09
highly O 0 1.0122912286192332e-08
homologous O 0 1.2771883994844302e-08
gene O 0 1.2870950527599234e-08
3 O 0 4.3012345685156106e-08
of O 0 6.19022202386077e-08
the O 0 1.6513888567715185e-07
CLD B-Disease 1 0.9999996423721313
gene O 0 2.4255464836642204e-07
, O 0 1.3900870676764043e-08
with O 0 5.800038782588501e-10
a O 0 9.39985977943536e-10
similar O 0 2.121145259437185e-09
genomic O 0 9.767344977262837e-08
structure O 0 3.798209320393653e-07
, O 0 1.627307355533958e-08
recently O 0 2.8584112854446175e-08
identified O 0 4.485260163278326e-09
as O 0 5.0421635755526495e-09
the O 0 4.224148142384365e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 7.356368769251276e-06
( O 0 6.446728093578713e-07
PDS B-Disease 1 0.9999547004699707
) O 0 2.4554631750106637e-07
. O 0 1.204919755082301e-07
. O 0 5.986606765873148e-07

The O 0 1.1587655535549857e-05
APCI1307K O 1 0.9999872446060181
allele O 0 3.5443918022792786e-06
and O 0 7.511285389227851e-07
cancer B-Disease 1 0.7929224967956543
risk O 0 9.767531139459606e-08
in O 0 1.3891355621353796e-08
a O 0 7.694219483767029e-09
community O 0 3.372832013681659e-09
- O 0 5.911237721534235e-08
based O 0 6.3774665548521625e-09
study O 0 5.851701345704896e-09
of O 0 8.553389818644064e-08
Ashkenazi O 0 9.10497965378454e-06
Jews O 0 3.130945515295025e-06
. O 0 1.4097328175921575e-06

Mutations O 0 1.1136966350022703e-05
in O 0 1.7679121810942888e-06
APC O 0 9.866510663414374e-05
are O 0 3.292415584610353e-08
classically O 0 3.431597360759042e-05
associated O 0 1.2879971791335265e-06
with O 0 1.8058390196529217e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.00012176355812698603
FAP B-Disease 1 0.9999990463256836
) O 0 6.919567567820195e-07
, O 0 3.702327333598987e-08
a O 0 8.596977352226531e-08
highly O 0 9.064935147762299e-05
penetrant O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.983117938041687
by O 0 1.2186526419100119e-06
multiple O 0 0.10920797288417816
intestinal O 1 1.0
polyps B-Disease 0 0.12613022327423096
and O 0 2.437400326016359e-07
, O 0 4.796205388402086e-08
without O 0 4.30345856727854e-08
surgical O 1 0.9402567744255066
intervention O 0 2.3139925815485185e-06
, O 0 2.3933720783020362e-08
the O 0 2.367939622160975e-08
development O 0 2.853460614460346e-07
of O 1 0.8688529133796692
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 7.089009886840358e-05
CRC B-Disease 1 1.0
) O 0 8.131631830110564e-07
. O 0 7.350242867687484e-07

APC B-Disease 0 0.0019046455854550004
is O 0 1.8228092812933028e-06
a O 0 1.4067541087570135e-06
tumour O 1 1.0
- O 0 2.326491267012898e-05
suppressor O 0 6.459088126575807e-06
gene O 0 7.955166836381977e-08
, O 0 1.3558102196498112e-08
and O 0 1.7838349464227576e-08
somatic O 0 7.392494444502518e-05
loss O 0 0.00186322967056185
occurs O 0 7.965975896695454e-07
in O 0 2.7850323931488674e-06
tumours B-Disease 1 1.0
. O 0 1.0659096915333066e-05

The O 0 1.4171549992170185e-05
germline O 0 0.000325879460433498
T O 0 0.17214874923229218
- O 0 6.346021109493449e-06
to O 0 8.990997457658523e-08
- O 0 2.298276285728207e-06
A O 0 2.3086845430952962e-06
transversion O 0 9.60392935667187e-06
responsible O 0 1.1955133061292145e-07
for O 0 1.3968299406030837e-08
the O 0 1.2599699061865977e-07
APC O 0 1.2585670447151642e-05
I1307K O 0 5.486709596880246e-06
allele O 0 3.535036796620261e-08
converts O 0 5.1749864837802306e-08
the O 0 1.3506969764875976e-08
wild O 0 2.8959703968212125e-07
- O 0 2.574935820121027e-07
type O 0 6.971399102440046e-08
sequence O 0 6.996212498222576e-09
to O 0 2.612977612059808e-09
a O 0 6.842443411869681e-08
homopolymer O 0 0.1872212290763855
tract O 0 0.21369794011116028
( O 0 8.524283430233481e-07
A8 O 1 0.9999572038650513
) O 0 6.201626234769719e-08
that O 0 2.7930577850554528e-09
is O 0 8.426336961520065e-09
genetically O 0 1.5092497278601513e-06
unstable O 0 1.1204656402696855e-05
and O 0 2.886399670387618e-07
prone O 0 1.920184149639681e-05
to O 0 1.3190739878155e-07
somatic O 0 8.766687096795067e-05
mutation O 0 2.531741756683914e-06
. O 0 1.7719801235216437e-06

The O 0 1.8726799680734985e-05
I1307K O 0 0.00012579874601215124
allele O 0 1.3677616834684159e-06
was O 0 4.971977887180401e-07
found O 0 5.350788612190627e-08
in O 0 8.504505188966505e-08
6 O 0 4.385276042739861e-06
. O 0 8.881036706043233e-07

1 O 0 9.486494491284247e-06
% O 0 6.739664115684718e-08
of O 0 9.841022574619274e-08
unselected O 0 0.00017949510947801173
Ashkenazi O 0 3.0942269404476974e-06
Jews O 0 1.7159744913897157e-07
and O 0 1.1947127731559704e-08
higher O 0 2.3394283843458652e-08
proportions O 0 3.029333939252865e-08
of O 0 3.327466302494031e-08
Ashkenazim O 0 2.941211960205692e-06
with O 0 6.987384004730757e-09
family O 0 1.7116702721864385e-08
or O 0 1.1889818019028553e-08
personal O 0 7.165815674170517e-08
histories O 0 6.279164495026635e-07
of O 0 7.44184035283979e-06
CRC B-Disease 1 0.999996542930603
( O 0 4.0652847133060277e-07
ref O 0 5.0617771194083616e-05
. O 0 8.388943939507953e-08
2 O 0 7.315696279874828e-07
) O 0 1.1187514559196643e-07
. O 0 2.2821349432433635e-07

To O 0 2.5270594505855115e-07
evaluate O 0 4.920500487060053e-07
the O 0 6.234775185021135e-08
role O 0 4.526480168465241e-08
of O 0 8.783190708072652e-08
I1307K O 0 1.0122805178980343e-05
in O 0 1.3026175338382018e-07
cancer B-Disease 0 0.00011995001113973558
, O 0 1.627239143431325e-08
we O 0 6.254998297094971e-09
genotyped O 0 5.048564162279945e-06
5 O 0 1.857407454508575e-07
, O 0 3.1637316766364165e-08
081 O 0 7.716627442277968e-05
Ashkenazi O 0 2.9599384561151965e-06
volunteers O 0 4.858418947151222e-07
in O 0 4.330300384935981e-08
a O 0 3.378899293693394e-08
community O 0 3.339680176850379e-08
survey O 0 9.467482300351548e-07
. O 0 1.8654344557944569e-06

Risk O 0 6.208044396771584e-06
of O 0 9.181555469695013e-06
developing O 0 0.04544393718242645
colorectal B-Disease 1 1.0
, I-Disease 0 1.8137703591492027e-05
breast I-Disease 1 0.6824398040771484
and I-Disease 0 1.147601906836826e-07
other I-Disease 0 1.4835599415619072e-07
cancers I-Disease 0 0.009985889308154583
were O 0 7.463344786629023e-08
compared O 0 7.131318824349364e-08
between O 0 3.059307474018169e-08
genotyped O 0 2.6865825930144638e-05
I1307K O 0 5.904469617235009e-06
carriers O 0 2.747827387850066e-08
and O 0 7.599692430915184e-09
non O 0 5.740863571190857e-07
- O 0 5.793189643554797e-07
carriers O 0 1.4930334302221127e-08
and O 0 2.1778425729479522e-09
their O 0 2.4429884781795863e-09
first O 0 5.3730115467942596e-08
- O 0 4.3798490878543817e-07
degree O 0 6.140345476524089e-07
relatives O 0 6.049266403351794e-07
. O 0 1.8691438299356378e-06

Sperm O 0 1.6926360331126489e-06
DNA O 0 2.5266258489864413e-06
analysis O 0 4.72855248290216e-08
in O 0 3.673893900213443e-08
a O 0 3.251210500820889e-07
Friedreich B-Disease 1 0.9999992847442627
ataxia I-Disease 1 0.9999998807907104
premutation O 1 0.999991774559021
carrier O 0 4.937742050969973e-05
suggests O 0 3.541806563589489e-07
both O 0 2.7878220620891625e-08
meiotic O 0 2.7332855097483844e-05
and O 0 5.850532147633203e-08
mitotic O 0 1.1269405604252825e-06
expansion O 0 6.640865990448219e-07
in O 0 8.88584352765065e-08
the O 0 3.9584347177878954e-07
FRDA B-Disease 1 0.9998960494995117
gene O 0 2.1729781565227313e-06
. O 0 7.742900152152288e-07

Friedreich B-Disease 1 0.9999998807907104
ataxia I-Disease 1 1.0
is O 0 2.816055712173693e-05
usually O 0 1.2449397672753548e-06
caused O 0 1.1630460221567773e-06
by O 0 1.0079696188824983e-08
an O 0 1.5064800518160837e-09
expansion O 0 6.187294587789438e-08
of O 0 3.0676869755552616e-07
a O 0 2.2596573501232342e-07
GAA O 0 0.006668851710855961
trinucleotide O 0 0.0001616881781956181
repeat O 0 6.352194077408058e-07
in O 0 8.719760558051348e-08
intron O 0 3.060754579564673e-06
1 O 0 2.913033085860661e-07
of O 0 4.0864887296265806e-07
the O 0 7.264637815751485e-07
FRDA B-Disease 1 0.9999871253967285
gene O 0 5.736820639867801e-06
. O 0 1.400763380843273e-06

Occasionally O 0 1.2845224773627706e-05
, O 0 1.7076600045129453e-07
a O 0 2.8229013793179547e-08
fully O 0 2.2959307344194713e-08
expanded O 0 3.6240273004750634e-08
allele O 0 5.000253988640679e-09
has O 0 5.87725701439723e-10
been O 0 1.019457962492254e-09
found O 0 1.0860997656791938e-09
to O 0 5.608588593553065e-10
arise O 0 6.783614114880265e-09
from O 0 1.9135930173774796e-08
a O 0 2.8215717762236636e-08
premutation O 0 5.8004920902021695e-06
of O 0 1.7457418266531022e-07
100 O 0 8.681956842337968e-08
or O 0 2.4101522555497468e-08
less O 0 7.71968302615278e-08
triplet O 0 3.917429785360582e-05
repeats O 0 1.1773679034376983e-05
. O 0 1.8825697907232097e-06

We O 0 4.7074817643988354e-07
have O 0 1.2918467184874771e-08
examined O 0 3.726187856045726e-07
the O 0 2.3867073650762904e-08
sperm O 0 3.355028965756901e-08
DNA O 0 6.188239467519452e-07
of O 0 2.486571588633524e-07
a O 0 2.7395259394324967e-07
premutation O 0 0.0005712617421522737
carrier O 0 9.063715879165102e-06
. O 0 2.3617772058059927e-06

This O 0 1.0726363370849867e-06
mans O 0 3.584946534829214e-05
leucocyte O 0 0.000114028065581806
DNA O 0 9.643330486142077e-06
showed O 0 2.079953702605053e-07
one O 0 4.826854915762624e-09
normal O 0 1.4488265698275882e-08
allele O 0 5.285169635271814e-09
and O 0 4.575294365594118e-09
one O 0 5.857608620374322e-09
allele O 0 7.872897889171782e-09
of O 0 1.9672027562478434e-08
approximately O 0 5.069156117087914e-08
100 O 0 3.744883656509046e-07
repeats O 0 1.1650898841253365e-06
. O 0 5.910498543926224e-07

His O 0 4.319183062762022e-06
sperm O 0 2.1322125576261897e-07
showed O 0 2.1857093202015676e-07
an O 0 1.8356106634698222e-09
expanded O 0 1.1759526685750643e-08
allele O 0 7.817742009308404e-09
in O 0 3.747389065722473e-09
a O 0 1.9820001639914153e-08
tight O 0 3.442645777340658e-07
range O 0 1.850079627274681e-07
centering O 0 2.5397557124051673e-07
on O 0 2.1781136894105657e-08
a O 0 3.046995322719681e-09
size O 0 4.976429490710643e-09
of O 0 5.891067544894213e-08
approximately O 0 5.006984338251641e-08
320 O 0 1.163111505775305e-06
trinucleotide O 0 0.0003512066905386746
repeats O 0 1.3228991520009004e-05
. O 0 2.064111185973161e-06

His O 0 6.14271339145489e-05
affected O 0 1.9978302589152008e-05
son O 0 0.00020191274234093726
has O 0 3.172905138626447e-08
repeat O 0 1.6493316934429458e-07
sizes O 0 1.5229782945880288e-07
of O 0 1.4924875131328008e-06
1040 O 0 1.1570032256713603e-05
and O 0 5.389057946558751e-07
540 O 0 2.8611320885829628e-05
. O 0 3.003023266501259e-06

These O 0 1.8857022610063723e-07
data O 0 1.2988824948934052e-07
suggest O 0 2.3379474356488572e-08
that O 0 5.428870686330356e-10
expansion O 0 2.2978190017397537e-08
occurs O 0 1.2594005838195699e-09
in O 0 4.788001661815144e-10
two O 0 4.61077176439062e-10
stages O 0 1.1887600948057298e-07
, O 0 1.4079618582130138e-09
the O 0 2.717906344429366e-09
first O 0 6.687634002133791e-09
during O 0 1.736729160484174e-08
meiosis O 0 9.686012703014057e-08
followed O 0 2.5434923500711193e-08
by O 0 3.811894799810034e-09
a O 0 1.7574727451119543e-08
second O 0 2.97983660857426e-07
mitotic O 0 6.329219104372896e-06
expansion O 0 9.611241694074124e-06
. O 0 5.5055165830708575e-06

We O 0 4.019133825750032e-07
also O 0 4.858928193129941e-08
show O 0 1.2046618813599252e-08
that O 0 2.5712784679221556e-10
in O 0 1.2833070162088234e-09
all O 0 9.39831656943113e-10
informative O 0 1.1843351188645102e-08
carrier O 0 4.880011417185415e-08
father O 0 3.7804795738338726e-08
to O 0 2.214688654689212e-09
affected O 0 1.909021740686967e-08
child O 0 1.4666228764781408e-07
transmissions O 0 4.262783477315679e-07
, O 0 1.806838456630544e-09
with O 0 5.10408770804105e-10
the O 0 3.2786211523472275e-09
notable O 0 6.239079475278686e-09
exception O 0 1.4051671826109668e-08
of O 0 4.296438049777862e-08
the O 0 9.299485270730656e-08
premutation O 0 1.6712734577595256e-05
carrier O 0 4.195294422970619e-07
, O 0 8.691098507540573e-09
the O 0 5.803505676027498e-09
expansion O 0 3.3178331193539634e-08
size O 0 2.2596632121008042e-08
decreases O 0 1.036350738559122e-07
. O 0 4.360552452453703e-08
. O 0 2.0232310760093242e-07

The O 0 1.5860010535106994e-05
R496H O 0 7.361822645179927e-05
mutation O 0 3.0436979159276234e-07
of O 0 9.080431482288986e-07
arylsulfatase O 1 0.6737508773803711
A O 0 0.0001801397738745436
does O 0 1.2331430809808808e-07
not O 0 1.1188111415094681e-07
cause O 0 0.0009561581537127495
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 2.081051752611529e-05

Deficiency B-Disease 1 0.9999992847442627
of I-Disease 0 0.17387479543685913
arylsulfatase I-Disease 1 0.9999779462814331
A I-Disease 0 0.2700863182544708
( O 0 5.264430001261644e-06
ARSA O 1 0.9999912977218628
) O 0 2.3387464409552194e-07
enzyme O 0 2.789551274418045e-07
activity O 0 1.0290309546689969e-06
causes O 0 3.2543543056817725e-05
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 0.0001104967959690839
MLD B-Disease 1 1.0
) O 0 2.959385255962843e-06
. O 0 1.55387408540264e-06

A O 0 1.8825658116838895e-05
number O 0 1.3869954784695437e-07
of O 0 1.6744053255024482e-06
ARSA O 1 0.9999865293502808
gene O 0 1.406986257279641e-06
mutations O 0 1.1529771626328511e-07
responsible O 0 9.520404091745149e-07
for O 0 9.747457170306006e-07
MLD B-Disease 1 1.0
have O 0 9.062793537850666e-08
been O 0 7.734421103577915e-08
identified O 0 3.904106620211678e-07
. O 0 7.151491558943235e-07

Recently O 0 1.124826303566806e-05
, O 0 1.0786440185484025e-07
the O 0 4.7618410548011525e-08
R496H O 0 2.047739599220222e-06
mutation O 0 4.0788101784983155e-08
of O 0 3.8479103636746004e-07
ARSA O 1 0.9999885559082031
was O 0 4.239261670591077e-07
proposed O 0 9.866316652562546e-09
to O 0 3.4434051165987967e-09
be O 0 1.271885818887597e-09
a O 0 1.1920905151896477e-08
cause O 0 1.7273676178319874e-07
of O 0 3.8704893086105585e-06
MLD B-Disease 1 1.0
( O 0 4.518596199432068e-07
Draghia O 0 0.00010889274562941864
et O 0 3.6438270853977883e-06
al O 0 3.7709341995650902e-06
. O 0 1.7055532097742798e-08
, O 0 1.8466911555492516e-08
1997 O 0 7.603740073136578e-07
) O 0 8.128750295099962e-08
. O 0 4.1212547330360394e-07

We O 0 3.208078567240591e-07
have O 0 6.851268885554873e-09
investigated O 0 2.4560227984693483e-07
the O 0 3.471956588896319e-08
R496H O 0 1.8331976434637909e-06
mutation O 0 7.00105839968046e-09
and O 0 1.3447608582239923e-09
found O 0 1.301593166580517e-09
this O 0 2.385348585320912e-10
mutation O 0 1.5796060015560442e-09
at O 0 3.2770035574003487e-08
a O 0 1.3763069572902964e-09
relatively O 0 1.932334292575888e-09
high O 0 1.6623143750393865e-08
frequency O 0 2.526447495654338e-09
in O 0 4.927417363020936e-10
an O 0 2.2004222055560518e-10
African O 0 3.4655569525199326e-09
American O 0 4.331983660676997e-09
population O 0 2.35505503987099e-10
( O 0 8.321113242892864e-10
f O 0 4.650424045848922e-08
= O 0 1.4068700870950579e-08
0 O 0 1.436197827331398e-08
. O 0 2.5484736543290865e-09
09 O 0 2.7904667376787984e-07
, O 0 3.1578579751112557e-09
n O 0 2.036069268740448e-08
= O 0 5.0217419556020104e-08
61 O 0 2.0833145697451982e-07
subjects O 0 4.3642845071190095e-07
) O 0 1.1078073924863929e-07
. O 0 5.411362167251355e-07

The O 0 4.8213554691756144e-05
ARSA O 0 0.22090211510658264
enzyme O 0 5.39770383056748e-07
activity O 0 1.3674092258497694e-07
in O 0 1.0415461382251578e-08
subjects O 0 6.09713524113431e-08
with O 0 3.081530808302091e-09
and O 0 6.5911893720738135e-09
without O 0 5.640582223520596e-09
the O 0 9.138000578445826e-09
R496H O 0 1.3016829143452924e-06
mutation O 0 9.242031140388463e-09
was O 0 1.5384426177433852e-08
determined O 0 5.003993663876827e-09
and O 0 4.397433528424699e-09
found O 0 5.876699571416566e-09
to O 0 3.8540188818103616e-09
be O 0 1.2209934396878452e-08
normal O 0 5.095741926197661e-07
. O 0 5.993918534841214e-07

It O 0 1.0343932217438123e-06
is O 0 4.462078706524153e-08
therefore O 0 2.9504185761197732e-08
concluded O 0 8.240883886401207e-08
that O 0 1.991985687510578e-09
the O 0 2.134392929065143e-08
R496H O 0 1.908495733005111e-06
mutation O 0 2.1861758625618677e-08
of O 0 3.419065421894629e-07
ARSA O 1 0.999614953994751
does O 0 1.5216274462659385e-08
not O 0 1.0928512539365443e-09
negatively O 0 6.721291079259117e-09
influence O 0 1.027681495457955e-08
the O 0 1.0092817248619212e-08
activity O 0 2.9846734861394e-08
of O 0 2.0939330624969443e-07
ARSA O 1 0.9882302284240723
and O 0 3.94110664103664e-08
is O 0 6.881088587817885e-09
not O 0 2.1942623273929485e-09
a O 0 7.481816766130578e-08
cause O 0 7.724196620984003e-06
of O 0 0.000276372826192528
MLD B-Disease 1 1.0

Down O 0 0.00037986840470694005
- O 0 1.496982713433681e-05
regulation O 0 1.145530291069008e-06
of O 0 1.8331086266698549e-06
transmembrane O 0 1.1394719876989257e-05
carbonic O 0 0.0015880768187344074
anhydrases O 0 0.07024835795164108
in O 0 2.6538633392192423e-05
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9647964239120483
lines O 0 6.197150810294261e-07
by O 0 2.97488647049704e-08
wild O 0 1.6403479321525083e-06
- O 0 4.20084552388289e-06
type O 0 2.771963863779092e-06
von B-Disease 1 0.9999200105667114
Hippel I-Disease 1 0.9999984502792358
- I-Disease 1 0.9972668886184692
Lindau I-Disease 1 0.9998533725738525
transgenes O 0 0.0023912121541798115
. O 0 1.033878288581036e-05

To O 0 8.971252896117221e-07
discover O 0 5.622903813673474e-07
genes O 0 3.773110179849937e-08
involved O 0 3.45710162719115e-08
in O 0 9.861579286507549e-08
von B-Disease 1 0.6727282404899597
Hippel I-Disease 1 0.9999687671661377
- I-Disease 1 0.984252393245697
Lindau I-Disease 1 0.9999710321426392
( O 0 6.875568033137824e-06
VHL B-Disease 1 0.9999998807907104
) O 0 6.38838400845998e-07
- O 0 4.701174475485459e-06
mediated O 0 8.922337656258605e-06
carcinogenesis O 1 0.9515153765678406
, O 0 1.2920135361582652e-07
we O 0 1.532158400152639e-08
used O 0 2.758256641754997e-06
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.999622106552124
lines O 0 6.262823262659367e-06
stably O 0 1.4165888387651648e-05
transfected O 0 1.5136575939322938e-06
with O 0 1.5994404023444986e-08
wild O 0 3.4978575058630668e-06
- O 0 1.3706402569368947e-05
type O 0 6.0039168602088466e-05
VHL O 1 1.0
- O 0 0.0003460504813119769
expressing O 0 9.354353096568957e-06
transgenes O 0 0.00046990433475002646
. O 0 6.057837254047627e-06

Large O 0 9.99749045149656e-06
- O 0 6.941928859305335e-06
scale O 0 1.7339988289677422e-06
RNA O 0 5.292637865750294e-07
differential O 0 8.524627048700495e-08
display O 0 3.4998222986359906e-07
technology O 0 1.5139160325361445e-07
applied O 0 1.3727814440755992e-08
to O 0 1.2181083919315938e-09
these O 0 2.3341812926958028e-09
cell O 0 2.516813708552945e-07
lines O 0 1.8297845016945757e-08
identified O 0 3.4389353587016558e-09
several O 0 1.6018179005428124e-09
differentially O 0 7.325890294396231e-08
expressed O 0 4.2281960155321485e-09
genes O 0 3.444482699066498e-09
, O 0 1.880937627873891e-09
including O 0 6.082984338462438e-09
an O 0 6.723419598841929e-09
alpha O 0 2.2214983346202644e-06
carbonic O 0 5.9464644436957315e-05
anhydrase O 0 0.00014389566786121577
gene O 0 1.0265295031786081e-06
, O 0 2.2517625097862037e-07
termed O 0 3.648834899649955e-05
CA12 O 1 0.9999843835830688
. O 0 6.975427822908387e-06

The O 0 1.6071411437224015e-06
deduced O 0 7.764202223370376e-07
protein O 0 1.4109177470800205e-07
sequence O 0 5.0359762582274925e-08
was O 0 1.9666630635128968e-07
classified O 0 7.69780470477599e-08
as O 0 3.411060767177787e-09
a O 0 8.84174777837643e-09
one O 0 1.2275737759637195e-08
- O 0 8.077489610514021e-07
pass O 0 7.715015613030118e-07
transmembrane O 0 3.0882276860211277e-06
CA O 0 0.00017827995179686695
possessing O 0 3.430618562560994e-06
an O 0 4.057355695863407e-08
apparently O 0 4.352272640062438e-07
intact O 0 4.898719225820969e-07
catalytic O 0 1.9893141711690987e-07
domain O 0 4.269072917395533e-08
in O 0 2.27484626691421e-08
the O 0 1.1925492060527176e-07
extracellular O 0 8.38232517708093e-06
CA O 0 0.002681461162865162
module O 0 0.00018410237680654973
. O 0 2.5300039396825014e-06

Reintroduced O 0 0.00015277983038686216
wild O 0 4.685702151618898e-05
- O 0 4.184440695098601e-05
type O 0 4.14419591834303e-05
VHL B-Disease 1 0.999967098236084
strongly O 0 3.3918982467184833e-07
inhibited O 0 3.014449703186983e-07
the O 0 4.107446116563551e-08
overexpression O 0 2.3822599359846208e-07
of O 0 8.673333695696783e-08
the O 0 7.829414272464419e-08
CA12 O 1 0.9945914149284363
gene O 0 1.4917667101599363e-08
in O 0 5.075819320410346e-09
the O 0 6.247108075285723e-08
parental O 0 4.378081575850956e-05
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999903440475464
lines O 0 0.0001316106936428696
. O 0 5.615269401459955e-06

Similar O 0 1.2761980769937509e-06
results O 0 2.166155610439091e-07
were O 0 2.4041789004058955e-08
obtained O 0 4.130425423909401e-08
with O 0 2.6893088644897034e-08
CA9 O 1 0.9981369972229004
, O 0 1.3740053361743776e-07
encoding O 0 1.5346304849117587e-07
another O 0 4.579465837650787e-07
transmembrane O 0 1.3860589206160512e-05
CA O 0 0.00010661912529030815
with O 0 4.452548196809403e-08
an O 0 5.0127468398386554e-08
intact O 0 6.238515197765082e-06
catalytic O 0 5.138259439263493e-06
domain O 0 1.3471923239194439e-06
. O 0 6.097246227909636e-07

Although O 0 1.45708440868475e-06
both O 0 2.9051143712877092e-08
domains O 0 5.988793105871082e-08
of O 0 2.87734110315796e-07
the O 0 5.480249001266202e-07
VHL B-Disease 1 0.9999481439590454
protein O 0 8.520043337512107e-08
contribute O 0 1.2101797786101542e-08
to O 0 4.983059298524495e-09
regulation O 0 2.2266176813445782e-07
of O 0 7.342662229348207e-07
CA12 O 1 0.9999691247940063
expression O 0 1.3103225171562372e-07
, O 0 7.47041983828467e-09
the O 0 1.7230791016231706e-08
elongin O 0 4.689456091000466e-06
binding O 0 8.65182130382891e-08
domain O 0 1.4137623338683625e-07
alone O 0 3.842724538571929e-08
could O 0 8.53057535721291e-09
effectively O 0 2.349013072944217e-07
regulate O 0 1.7470755437898333e-06
CA9 O 1 0.9857674837112427
expression O 0 2.51654751082242e-06
. O 0 1.1628475249381154e-06

We O 0 4.296874067222234e-06
mapped O 0 3.1447641958948225e-05
CA12 O 1 0.999043881893158
and O 0 3.6006679238198558e-06
CA9 O 1 0.9937466382980347
loci O 0 3.611424972405075e-06
to O 0 2.5557383764862607e-07
chromosome O 0 1.207069658448745e-06
bands O 0 1.7899030353873968e-05
15q22 O 0 3.780223414651118e-05
and O 0 9.306695005761867e-07
17q21 O 0 0.0003109583631157875
. O 0 7.158600055845454e-06

2 O 0 2.6435172912897542e-05
respectively O 0 2.1254286366456654e-06
, O 0 5.495521193665809e-08
regions O 0 1.2548481720386917e-07
prone O 0 3.7243867154757027e-06
to O 0 2.2767952856384e-08
amplification O 0 3.558460775821004e-06
in O 0 5.30787289676482e-08
some O 0 2.299787560389177e-08
human O 0 2.214530695709982e-06
cancers B-Disease 1 0.9857235550880432
. O 0 2.4911460059229285e-06

Additional O 0 7.321258976844547e-07
experiments O 0 2.075025577141787e-06
are O 0 2.227202200444367e-09
needed O 0 1.1892063334073555e-08
to O 0 2.456220116187069e-09
define O 0 8.518397542900402e-09
the O 0 9.363466446643542e-09
role O 0 1.887047318405166e-08
of O 0 2.8289579745433e-07
CA O 0 0.00011591182556003332
IX O 1 0.9999728202819824
and O 0 4.568138081140205e-07
CA O 0 0.0002737932081799954
XII O 1 0.9999902248382568
enzymes O 0 3.5745856052926683e-08
in O 0 1.546786876360784e-08
the O 0 5.208473652373868e-09
regulation O 0 6.32231405006678e-08
of O 0 8.23569834551563e-08
pH O 0 3.293502857104613e-07
in O 0 2.0694269409204935e-08
the O 0 2.5184574425907158e-08
extracellular O 0 3.017331664523226e-07
microenvironment O 0 8.35779076169274e-07
and O 0 5.473498543295818e-09
its O 0 4.49022463655524e-09
potential O 0 9.736948136662704e-09
impact O 0 8.908379101058017e-08
on O 0 3.232029712307849e-06
cancer B-Disease 1 0.9873353838920593
cell O 0 2.360784674237948e-05
growth O 0 7.738890985820035e-07
. O 0 3.1590468552167295e-07

A O 0 7.832711708033457e-05
gene O 0 5.644787393066508e-07
encoding O 0 1.38106528879689e-07
a O 0 6.946618213987676e-08
transmembrane O 0 7.666885721846484e-07
protein O 0 4.035472329633194e-07
is O 0 1.7859559164890015e-08
mutated O 0 1.7855037981462374e-07
in O 0 3.993736541474391e-08
patients O 0 3.2205335287471826e-07
with O 0 1.146102567872731e-05
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 0.9999969005584717
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 2.0436600607354194e-06
. O 0 1.382656137138838e-06

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.03513823449611664
WFS B-Disease 1 1.0
; O 0 2.0229897927492857e-05
OMIM O 1 1.0
222300 O 1 0.7628000974655151
) O 0 1.3381021801706083e-07
is O 0 3.863690256622476e-09
an O 0 1.2677254801474191e-08
autosomal B-Disease 1 0.9999978542327881
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 1.0
defined O 0 7.529748927481705e-06
by O 0 3.504223968775477e-07
young O 0 4.019523657916579e-06
- O 0 1.7124597434303723e-05
onset O 1 0.9906472563743591
non O 1 0.8377134799957275
- O 1 0.9983008503913879
immune O 0 0.1394747644662857
insulin B-Disease 1 0.7420588731765747
- I-Disease 1 0.8633074164390564
dependent I-Disease 0 0.0923960730433464
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9856458306312561
progressive O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
. O 0 0.0001356813736492768

Linkage O 0 4.248104596626945e-05
to O 0 3.2168009056476876e-07
markers O 0 2.809446414175909e-06
on O 0 1.138929974331404e-06
chromosome O 0 1.9958711163781118e-06
4p O 0 0.005792579613626003
was O 0 1.0408133448436274e-06
confirmed O 0 8.724335742726907e-08
in O 0 6.4118621523334696e-09
five O 0 1.0034312047935146e-08
families O 0 8.632712322764746e-09
. O 0 2.1727285570705135e-07

On O 0 4.422908205015119e-06
the O 0 8.056343858697801e-08
basis O 0 4.098563977095182e-08
of O 0 1.4423243044348055e-07
meiotic O 0 0.46596550941467285
recombinants O 1 0.9344611167907715
and O 0 3.010154387084185e-06
disease O 1 0.9999240636825562
- O 0 5.532458999368828e-06
associated O 0 1.4750868615465151e-07
haplotypes O 0 3.4429544371050724e-07
, O 0 1.6421207504890845e-08
the O 0 1.1539727040599246e-07
WFS B-Disease 1 0.9999628067016602
gene O 0 2.448562668178056e-07
was O 0 1.2391612358442217e-07
localized O 0 1.6462013263662811e-07
to O 0 2.3816598471171346e-08
a O 0 5.929049962105637e-07
BAC O 1 0.9999948740005493
/ O 0 5.202906686463393e-05
P1 O 0 0.016695495694875717
contig O 0 3.43756219081115e-05
of O 0 3.6574672890310467e-07
less O 0 1.804166949170849e-08
than O 0 5.850094186854449e-09
250 O 0 3.0312014587252634e-07
kb O 0 2.771752951957751e-05
. O 0 2.556065282988129e-06

Mutations O 0 2.958358209070866e-06
in O 0 2.92309607630159e-07
a O 0 8.455899802584099e-08
novel O 0 4.0364690789829183e-07
gene O 0 1.8440833571276016e-07
( O 0 1.2540778016045806e-07
WFS1 O 1 0.9996860027313232
) O 0 2.9875440787918706e-08
encoding O 0 2.6183370138710416e-08
a O 0 1.6062823959828165e-08
putative O 0 2.3265424431428983e-07
transmembrane O 0 2.6951892095894436e-07
protein O 0 6.763371374063354e-08
were O 0 2.8097302262608537e-08
found O 0 6.302626420762181e-09
in O 0 2.5315318730179115e-09
all O 0 9.73278346805273e-10
affected O 0 2.654612085706276e-09
individuals O 0 3.011161875399182e-10
in O 0 1.0008813333683975e-08
six O 0 1.4211811105724337e-07
WFS B-Disease 1 0.999975323677063
families O 0 7.848339755867073e-09
, O 0 7.965928361386432e-09
and O 0 1.6078693931831367e-09
these O 0 2.744938165655242e-10
mutations O 0 4.1404724093752066e-09
were O 0 3.2518723269703287e-09
associated O 0 9.93211735078603e-09
with O 0 6.193266344212134e-09
the O 0 3.7372949464042904e-06
disease O 1 0.9998899698257446
phenotype O 0 5.394315394369187e-06
. O 0 9.839236554398667e-07

WFS1 O 1 0.9999942779541016
appears O 0 2.2120377707324224e-06
to O 0 9.782480603348631e-09
function O 0 5.1788937582841754e-09
in O 0 1.0687869256287286e-08
survival O 0 1.041622113007179e-07
of O 0 6.60677414998645e-08
islet O 0 1.2571628076329944e-06
beta O 0 8.534613584743056e-07
- O 0 1.4413454891837318e-06
cells O 0 1.47881948464601e-07
and O 0 7.224938514127643e-08
neurons O 0 7.31209752302675e-07
. O 0 8.708259713330335e-08
. O 0 3.800321906055615e-07

Stable O 0 1.239278481079964e-05
interaction O 0 1.2360983703274542e-07
between O 0 3.4479878507909234e-08
the O 0 1.5859827229292023e-08
products O 0 8.796452277692879e-08
of O 0 6.169264565869526e-08
the O 0 4.624481064752217e-08
BRCA1 O 0 8.451335133941029e-07
and O 0 6.269656438462334e-08
BRCA2 O 0 1.2776479707099497e-05
tumor B-Disease 0 1.4541605196427554e-05
suppressor O 0 3.910537088813726e-06
genes O 0 2.5306931661361887e-08
in O 0 3.070853793474271e-08
mitotic O 0 2.027624759648461e-06
and O 0 6.754798391739314e-07
meiotic O 0 0.08021004498004913
cells O 0 2.2487573005491868e-05
. O 0 5.078604772279505e-06

BRCA1 O 0 0.0004342260945122689
and O 0 2.9959949188196333e-06
BRCA2 O 0 6.526729066536063e-06
account O 0 2.1109954673192988e-08
for O 0 5.684496429125829e-09
most O 0 2.3945672111835847e-09
cases O 0 2.3337227705866326e-09
of O 0 2.776375929158803e-08
familial O 0 6.479901912825881e-07
, O 0 1.701021190569918e-08
early O 0 5.910853815294104e-07
onset O 1 0.9825156927108765
breast B-Disease 0 0.0003711939207278192
and I-Disease 0 5.325121037458302e-07
/ I-Disease 1 0.9974802136421204
or I-Disease 1 0.9979618787765503
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.225583000698862e-08
encode O 0 1.300901519840636e-08
products O 0 5.961828009048986e-08
that O 0 2.012270572393504e-09
each O 0 7.249834066413996e-10
interact O 0 8.275438112548272e-09
with O 0 3.238788437442963e-08
hRAD51 O 0 0.00010183919221162796
. O 0 5.028268333262531e-06

Results O 0 4.958939825883135e-06
presented O 0 1.706111788735143e-06
here O 0 1.3790568686999904e-07
show O 0 5.380682566169526e-08
that O 0 4.165948475076675e-09
BRCA1 O 0 6.098635481066594e-07
and O 0 8.625984548871202e-08
BRCA2 O 0 2.6802638330991613e-06
coexist O 0 1.9421979402522993e-07
in O 0 1.12977289745686e-08
a O 0 8.330200529371723e-09
biochemical O 0 8.766334644860763e-07
complex O 0 1.2310590591368964e-06
and O 0 1.5011809750831162e-07
colocalize O 0 3.33002426486928e-05
in O 0 8.907122150958457e-08
subnuclear O 0 1.493749823566759e-05
foci O 0 2.5757021830941085e-06
in O 0 4.876066483916475e-08
somatic O 0 2.1934490632702364e-06
cells O 0 1.457041207686416e-07
and O 0 2.795521503173859e-08
on O 0 4.4235139995407735e-08
the O 0 4.600865022297285e-09
axial O 0 1.9738928713763926e-08
elements O 0 3.913085677709205e-08
of O 0 2.744345124483516e-07
developing O 0 1.2346132507445873e-06
synaptonemal O 0 0.0003628857375588268
complexes O 0 2.7738047720049508e-05
. O 0 4.0668578549230006e-06

Like O 0 4.8353755119023845e-05
BRCA1 O 0 0.00010324005415895954
and O 0 4.1959051486628596e-06
RAD51 O 1 0.9999850988388062
, O 0 2.1369139631133294e-06
BRCA2 O 0 1.1909996828762814e-05
relocates O 0 6.061235581000801e-06
to O 0 2.983424565172754e-07
PCNA O 0 0.003592871828004718
+ O 0 2.964637815239257e-07
replication O 0 6.494526871847484e-08
sites O 0 1.7304895294500966e-08
following O 0 2.0609581596886528e-08
exposure O 0 3.8292660065053497e-07
of O 0 1.9625373681719793e-07
S O 0 2.0444907931960188e-05
phase O 0 4.6757463678659406e-06
cells O 0 5.265692237799158e-08
to O 0 1.6279283698850122e-08
hydroxyurea O 0 4.759739113069372e-06
or O 0 2.0929807931224786e-07
UV O 1 0.7675222158432007
irradiation O 0 1.5604078726028092e-05
. O 0 1.2216034974699141e-06

Thus O 0 4.798383088200353e-06
, O 0 7.612969739057007e-07
BRCA1 O 0 5.551622507482534e-06
and O 0 9.425882296909549e-08
BRCA2 O 0 1.9016173382624402e-06
participate O 0 9.086472374519872e-08
, O 0 3.100989331983328e-08
together O 0 1.6501710220495625e-08
, O 0 4.299829825527013e-09
in O 0 3.819186744635772e-09
a O 0 4.376063955646714e-09
pathway O 0 3.3886383477010895e-08
( O 0 6.365727056589776e-09
s O 0 1.3677599497441406e-07
) O 0 3.1229969721380257e-09
associated O 0 3.692177674707864e-09
with O 0 1.52644619166864e-09
the O 0 6.1424452191261025e-09
activation O 0 6.538376595699447e-08
of O 0 1.184082591976221e-07
double O 0 5.934180649092013e-07
- O 0 4.327164788264781e-06
strand O 0 4.078954702890769e-07
break O 0 2.65618410821844e-07
repair O 0 2.05601318157278e-05
and O 0 2.602489814762521e-07
/ O 0 3.971589194406988e-06
or O 0 1.1404839739270756e-07
homologous O 0 3.8022903936507646e-07
recombination O 0 9.184402642858913e-07
. O 0 8.6853333414183e-07

Dysfunction O 0 0.4760650396347046
of O 0 1.7707923689158633e-05
this O 0 7.729303774794971e-08
pathway O 0 3.574851916710031e-07
may O 0 1.1349325923504239e-08
be O 0 1.0530675220721264e-09
a O 0 3.061144671079319e-09
general O 0 7.557152237325226e-09
phenomenon O 0 3.2750225642530495e-08
in O 0 2.3792112724407843e-09
the O 0 1.7557163500825368e-09
majority O 0 1.3947945576298082e-10
of O 0 7.809436430861183e-10
cases O 0 2.315455382984055e-09
of O 0 4.868381324740767e-07
hereditary B-Disease 1 1.0
breast I-Disease 1 0.9999741315841675
and I-Disease 0 0.00018472905503585935
/ I-Disease 1 0.9999998807907104
or I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.9744707060453948e-06
. O 0 1.1230813470319845e-06

A O 0 7.827872468624264e-05
novel O 0 5.181844244361855e-06
Arg362Ser O 0 0.00010906609531957656
mutation O 0 1.0387730497996017e-07
in O 0 3.703909001728789e-08
the O 0 7.710765004276254e-08
sterol O 0 1.4938210370019078e-05
27 O 0 5.6491508075851016e-06
- O 0 2.8382396521919873e-06
hydroxylase O 0 3.8884136301930994e-05
gene O 0 3.189427388861077e-07
( O 0 6.268400909448246e-08
CYP27 O 1 0.9999903440475464
) O 0 1.4649209845174482e-08
: O 0 3.0575850740177657e-09
its O 0 5.0047761490645826e-09
effects O 0 1.406201306508592e-07
on O 0 6.773053229380821e-08
pre O 0 4.689702109317295e-06
- O 0 2.813994512962381e-07
mRNA O 0 7.844795391065418e-08
splicing O 0 5.181436222301272e-07
and O 0 2.6419247234343857e-08
enzyme O 0 2.4962204747680516e-07
activity O 0 3.3625795481384557e-07
. O 0 5.397317863753415e-07

A O 0 4.277320113033056e-05
novel O 0 1.2684239436566713e-06
C O 0 1.3184291674406268e-05
to O 0 1.109845726432468e-08
A O 0 1.989209863495489e-07
mutation O 0 6.4506000541086905e-09
in O 0 9.181607474317843e-09
the O 0 1.4723721797338385e-08
sterol O 0 1.828802624004311e-06
27 O 0 9.458800036554749e-07
- O 0 8.534906328350189e-07
hydroxylase O 0 1.3497279724106193e-05
gene O 0 2.5489470090178656e-07
( O 0 7.101728272118635e-08
CYP27 O 1 0.9999028444290161
) O 0 2.5887061383400578e-08
was O 0 4.7233871924845516e-08
identified O 0 1.1344147843317387e-09
by O 0 5.401942781979585e-10
sequencing O 0 8.407380391872721e-08
amplified O 0 2.2169733711052686e-06
CYP27 O 1 0.8498201370239258
gene O 0 1.0364654201566736e-07
products O 0 1.1930940502224985e-07
from O 0 8.819720420660815e-08
a O 0 7.890640318919395e-08
patient O 0 8.065343308771844e-07
with O 0 3.377076609467622e-07
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 3.232190647395328e-05
CTX B-Disease 1 1.0
) O 0 6.903254870849196e-06
. O 0 3.1651218250772217e-06

The O 0 2.5118383746303152e-06
mutation O 0 3.7210102732387895e-07
changed O 0 2.2580395864224556e-07
the O 0 1.2600575871601905e-07
adrenodoxin O 0 2.1263460439513437e-05
cofactor O 0 1.3149258393241325e-06
binding O 0 3.924888858364284e-07
residue O 0 9.956395842891652e-06
362Arg O 0 7.785432899254374e-06
to O 0 8.070337997878596e-08
362Ser O 0 2.419862721581012e-05
( O 0 4.1756482005439466e-07
CGT O 1 0.768002986907959
362Arg O 0 3.5404904338065535e-05
to O 0 3.491131792543456e-07
AGT O 1 0.9999896287918091
362Ser O 0 7.05817001289688e-05
) O 0 4.015972621118635e-08
, O 0 8.363090664431638e-09
and O 0 6.084632353520192e-09
was O 0 1.1931373933293798e-07
responsible O 0 1.5936416275508236e-07
for O 0 1.0059726207600761e-07
deficiency O 1 0.8379555344581604
in O 0 2.593753265500709e-07
the O 0 1.2366101032057486e-07
sterol O 0 5.9942494772258215e-06
27 O 0 1.7304653283645166e-06
- O 0 4.842090106649266e-07
hydroxylase O 0 2.7030089313484496e-06
activity O 0 7.61956613359871e-08
, O 0 4.395312114269245e-09
as O 0 4.300272582469233e-09
confirmed O 0 3.5269798193127144e-09
by O 0 3.8804826019145366e-10
expression O 0 2.8971667287436276e-09
of O 0 2.40092532521885e-08
mutant O 0 9.692684699302845e-08
cDNA O 0 1.2538302485154418e-07
into O 0 1.1011756839707232e-07
COS O 0 0.0005760042113251984
- O 0 1.4966115486458875e-05
1 O 0 2.283846924910904e-06
cells O 0 1.097704739549954e-06
. O 0 3.381369140242896e-07

Quantitative O 0 4.615537818608573e-06
analysis O 0 3.876418475101673e-07
showed O 0 9.712541526596397e-08
that O 0 8.468352685753189e-10
the O 0 3.874774723300334e-09
expression O 0 9.149179192036172e-09
of O 0 1.8524630718275148e-07
CYP27 O 0 0.4148539900779724
gene O 0 3.334219300654695e-08
mRNA O 0 3.035216167290855e-08
in O 0 9.898265318497579e-09
the O 0 1.7527325368860147e-08
patient O 0 2.2301793478618492e-07
represented O 0 1.3121983499786438e-07
52 O 0 2.121208581229439e-06
. O 0 1.8901974954133038e-06

5 O 0 5.575812338065589e-06
% O 0 7.643845378879632e-08
of O 0 1.4212812970981759e-07
the O 0 1.0483749690592958e-07
normal O 0 3.8081944353507424e-07
level O 0 9.690444358056993e-07
. O 0 2.1671515071375325e-07

As O 0 1.1413123957026983e-06
the O 0 2.564630676715751e-07
mutation O 0 5.1657462307730384e-08
occurred O 0 4.0454639815834526e-07
at O 0 1.327668570638707e-07
the O 0 2.5326391650537516e-08
penultimate O 0 1.3623864560941001e-06
nucleotide O 0 3.714868412885153e-08
of O 0 5.7076515957987795e-08
exon O 0 7.093619274201046e-07
6 O 0 2.8962713827240805e-07
( O 0 8.404779983095523e-09
- O 0 1.6887601361759152e-07
2 O 0 4.63000588979412e-08
position O 0 8.931240635945414e-09
of O 0 1.6104607425404538e-08
exon O 0 2.83298874137472e-07
6 O 0 2.7193630103283795e-07
- O 0 4.1660982219582365e-07
intron O 0 1.5541111224592896e-06
6 O 0 1.8289684078354185e-07
splice O 0 1.0121890454684035e-06
site O 0 2.9086248787280056e-07
) O 0 1.5242874740195589e-09
of O 0 4.3127088567018745e-09
the O 0 5.6368607559420525e-09
gene O 0 2.4357870387348157e-08
, O 0 5.375756284564659e-09
we O 0 4.27289731375069e-10
hypothesized O 0 5.273649961168303e-09
that O 0 1.1565722685125124e-10
the O 0 3.310530516387189e-09
mutation O 0 8.23362178437037e-09
may O 0 6.84908663117767e-09
partially O 0 1.7263695895053388e-07
affect O 0 1.1912540287539741e-08
the O 0 1.2377399549734491e-08
normal O 0 3.250055335968227e-09
splicing O 0 2.2035658631125443e-08
efficiency O 0 2.8388786432742563e-08
in O 0 7.330065887600767e-09
exon O 0 5.212392011344491e-07
6 O 0 2.175264199877347e-07
and O 0 7.534469936842925e-09
cause O 0 1.7858162948414247e-08
alternative O 0 2.363905338143013e-08
splicing O 0 3.060883955186e-07
elsewhere O 0 6.783939454635401e-08
, O 0 3.324755804001711e-09
which O 0 1.2187452158585188e-09
resulted O 0 1.7078058078823233e-08
in O 0 1.038047781065643e-08
decreased O 0 1.0631310232156466e-07
transcript O 0 3.475581422662799e-07
in O 0 2.5048093377222358e-08
the O 0 1.2271762273030618e-07
patient O 0 5.8748587434820365e-06
. O 0 1.1209422154934146e-06

Transfection O 0 0.00038654840318486094
of O 0 2.260141263832338e-05
constructed O 0 0.00016566034173592925
minigenes O 0 0.0076650395058095455
, O 0 1.4138028348043008e-07
with O 0 8.778765270278654e-09
or O 0 3.0018583174751257e-08
without O 0 8.337448065276476e-09
the O 0 7.684422875797736e-09
mutation O 0 6.768349880559299e-09
, O 0 2.7354327691853086e-09
into O 0 2.8474085311813724e-08
COS O 0 0.011888689361512661
- O 0 4.716051080322359e-06
1 O 0 2.73266579142728e-07
cells O 0 2.0674423950595155e-08
confirmed O 0 3.341685816948825e-09
that O 0 1.578292080361976e-10
the O 0 4.660215768836906e-09
mutant O 0 3.159625237003638e-07
minigene O 0 6.094954187574331e-06
was O 0 1.7932475770976453e-07
responsible O 0 1.2640168911559613e-08
for O 0 2.0084285345944863e-09
a O 0 4.7674002523478975e-09
mRNA O 0 2.436372525949082e-08
species O 0 5.419859561150986e-10
alternatively O 0 1.7456628143008857e-08
spliced O 0 4.0375471144216135e-07
at O 0 2.2280876521563187e-07
an O 0 1.1195108839956447e-08
activated O 0 1.9002369299414568e-05
cryptic O 0 2.692091129574692e-06
5 O 0 3.445056222517451e-07
splice O 0 3.960922640544595e-06
site O 0 1.1830480843855185e-06
88 O 0 1.042429516928678e-06
bp O 0 7.623758619956789e-07
upstream O 0 1.2597283216564392e-07
from O 0 2.5152557370233808e-08
the O 0 1.4618674271105192e-08
3 O 0 7.855366845888057e-08
end O 0 9.148241275624969e-08
of O 0 1.6415829406923876e-07
exon O 0 1.159523890237324e-05
6 O 0 1.0363155524828471e-05
. O 0 1.8505661500967108e-06

Our O 0 2.0324625893408665e-06
data O 0 1.659628594552487e-07
suggest O 0 1.1097399443826816e-08
that O 0 2.5817559201612994e-10
the O 0 3.1391573784844695e-09
C O 0 1.8743614873528713e-06
to O 0 3.622657063218071e-09
A O 0 1.909610460870681e-07
mutation O 0 6.258494611444121e-09
at O 0 4.763966643395179e-08
the O 0 6.675858088556197e-09
penultimate O 0 2.604533335670567e-07
nucleotide O 0 1.431870799706303e-08
of O 0 1.6934814439650836e-08
exon O 0 2.990951202264114e-07
6 O 0 1.611200275419833e-07
of O 0 2.4597751391297606e-08
the O 0 6.299202937043447e-08
CYP27 O 1 0.9999804496765137
gene O 0 4.396589048383248e-08
not O 0 1.0782871262549065e-09
only O 0 1.736619070769052e-09
causes O 0 8.188661126951047e-08
the O 0 4.05845554496409e-07
deficiency B-Disease 0 0.028034664690494537
in I-Disease 0 2.5994280505869938e-08
the I-Disease 0 4.525660202148174e-08
sterol I-Disease 0 3.0927608349884395e-06
27 I-Disease 0 3.174571702402318e-06
- I-Disease 0 6.831795076323033e-07
hydroxylase I-Disease 0 4.19973230236792e-06
activity I-Disease 0 7.444492666763836e-08
, O 0 7.977469351772015e-09
but O 0 7.034692273144572e-10
also O 0 2.1685744311383814e-09
partially O 0 1.0142319695205515e-07
leads O 0 8.016716179781724e-09
to O 0 5.908571409918295e-10
alternative O 0 2.489197292732115e-08
pre O 0 1.4652935078629525e-06
- O 0 2.0427060576366785e-07
mRNA O 0 3.168756279592344e-08
splicing O 0 1.629179280371318e-07
of O 0 8.774333082328667e-08
the O 0 1.1419064094297937e-07
gene O 0 7.62319871228101e-07
. O 0 4.829389581573196e-07

To O 0 4.941294378113525e-07
our O 0 2.8963347631361103e-07
knowledge O 0 8.768558927840786e-07
, O 0 1.5144292930813208e-08
this O 0 5.902939248514372e-10
is O 0 3.9163522425056385e-10
the O 0 8.119181993393454e-10
first O 0 4.799790342957522e-09
report O 0 8.897384495831773e-10
regarding O 0 4.849149082275517e-09
effects O 0 9.66154658499363e-08
on O 0 2.3526020243025414e-08
pre O 0 1.0867116770896246e-06
- O 0 5.24524317313535e-08
mRNA O 0 8.81890915849226e-09
splicing O 0 2.1913692194175383e-08
of O 0 8.448513000303137e-09
a O 0 4.084358629086182e-09
mutation O 0 5.557891036289675e-09
at O 0 5.598782593096985e-08
the O 0 2.0155365376695045e-08
- O 0 1.8420462311041774e-07
2 O 0 4.539483811072387e-08
position O 0 3.9484952196744416e-08
of O 0 3.522040614711841e-08
a O 0 4.259572961018421e-08
5 O 0 5.628644430544227e-07
splice O 0 4.359786908025853e-05
site O 0 6.996788215474226e-06
. O 0 8.737289931559644e-07

ATM O 0 0.0026606505271047354
germline O 0 7.333585381275043e-05
mutations O 0 4.305404388560419e-07
in O 0 1.7720736877890886e-07
classical O 1 0.9667269587516785
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 7.071442087180912e-05
in O 0 2.148443769556252e-07
the O 0 3.6232711408956675e-07
Dutch O 0 4.048362097819336e-05
population O 0 2.2570441515767925e-08
. O 0 4.0766329334473994e-07

Germline O 0 0.000356918724719435
mutations O 0 8.180518307199236e-07
in O 0 1.3766705819762137e-07
the O 0 2.9549070745815698e-08
ATM O 0 0.00020295308786444366
gene O 0 3.5582122137611805e-08
are O 0 2.835385259913892e-10
responsible O 0 9.133417577800174e-09
for O 0 3.488809463547682e-09
the O 0 4.844676823267946e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9785833358764648
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.1407337246491807e-06
. O 0 1.6392594943681615e-06

In O 0 2.1914336230111076e-06
our O 0 1.6166535488082445e-07
study O 0 7.217500552769707e-08
, O 0 6.091204429736763e-09
we O 0 7.933733670029142e-10
have O 0 1.0563501462446112e-10
determined O 0 2.0848691661967678e-09
the O 0 5.1355146801768115e-09
ATM O 0 4.0270128920383286e-06
mutation O 0 1.1252094367364407e-08
spectrum O 0 4.879192516682451e-08
in O 0 1.531933335741087e-08
19 O 0 6.583815803651305e-08
classical O 0 9.902363444780349e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 4.3672906713254633e-07
, O 0 3.2562352814125006e-09
including O 0 9.785535715067795e-10
some O 0 1.2508152846812948e-10
immigrant O 0 7.892078102145206e-10
populations O 0 2.1021900886708522e-10
, O 0 5.618160381359871e-10
as O 0 6.480687098076032e-10
well O 0 2.3643955682217666e-09
as O 0 3.3633178464498314e-09
12 O 0 1.5835706079769807e-08
of O 0 1.8203717644382778e-08
Dutch O 0 8.374441335945448e-07
ethnic O 0 5.3336166594419865e-09
origin O 0 5.0415120966817994e-08
. O 0 2.1387437243447494e-07

Both O 0 1.0191861292696558e-06
the O 0 2.998819752519921e-07
protein O 0 9.252864430209229e-08
truncation O 0 4.0310706026502885e-06
test O 0 1.7655449937592493e-06
( O 0 5.998235508286598e-08
PTT O 0 8.29005366540514e-05
) O 0 3.5910254769788708e-09
and O 0 8.64890881135949e-10
the O 0 1.3818044486413328e-09
restriction O 0 4.445799284269469e-09
endonuclease O 0 1.6813439174256928e-07
fingerprinting O 0 9.369961730953946e-07
( O 0 3.482428567735951e-08
REF O 0 0.00011596687545534223
) O 0 8.728255895817938e-10
method O 0 5.863171614883811e-10
were O 0 2.7960411763672255e-10
used O 0 1.22499088650585e-09
and O 0 1.0303994324445398e-09
compared O 0 3.782663071660863e-09
for O 0 6.001434904590042e-10
their O 0 5.364548250064161e-10
detection O 0 1.4584925622784795e-07
efficiency O 0 7.228494069977387e-08
, O 0 4.834778799533979e-09
identifying O 0 2.3584965092027232e-08
76 O 0 1.1917772013703143e-07
% O 0 9.42675382198388e-10
and O 0 9.249503940544912e-10
60 O 0 4.925427621316203e-09
% O 0 3.8100173016530903e-10
of O 0 2.6907185368685305e-09
the O 0 1.4321931196548121e-08
mutations O 0 3.4327310771686825e-08
, O 0 5.4248705083637105e-08
respectively O 0 1.2009484180453e-06
. O 0 7.883710395617527e-07

Most O 0 1.24230439269013e-06
patients O 0 1.5876965164807189e-07
were O 0 3.135921389230134e-08
found O 0 7.600794660334032e-09
to O 0 7.472458207757882e-09
be O 0 2.653732344981563e-08
compound O 0 6.733715963491704e-06
heterozygote O 0 4.0164832171285525e-05
. O 0 1.9877982140315e-06

Seventeen O 0 2.1213027139310725e-05
mutations O 0 2.1182420084642217e-07
were O 0 3.598562514639525e-08
distinct O 0 9.976259818245126e-09
, O 0 4.451153223783422e-09
of O 0 2.696684830993945e-08
which O 0 3.7098109029187754e-09
10 O 0 8.151864960836974e-09
were O 0 2.330688975149542e-09
not O 0 1.1857403947601597e-09
reported O 0 5.4287827566668057e-08
previously O 0 1.0615611927278223e-06
. O 0 5.473249871101871e-07

Mutations O 0 5.136339041200699e-06
are O 0 2.652811481596018e-08
small O 0 9.537027523265351e-08
deletions O 0 1.465367631681147e-06
or O 0 3.263807855091727e-07
point O 0 6.901977371853718e-07
mutations O 0 1.0868323130353019e-07
frequently O 0 5.3614847672633914e-08
affecting O 0 2.938305954103271e-07
splice O 0 3.879986979882233e-05
sites O 0 4.879332209384302e-06
. O 0 2.8271422252146294e-06

Moreover O 0 3.339985050843097e-05
, O 0 1.1040017398045165e-06
a O 0 7.727445563432411e-07
16 O 0 7.824442036508117e-06
. O 0 1.466084768253495e-06

7 O 0 3.398237095098011e-05
- O 0 4.626149348041508e-06
kb O 0 4.551432084554108e-06
genomic O 0 3.060527546949743e-07
deletion O 0 7.667018309120976e-08
of O 0 6.302123978230156e-08
the O 0 2.844281965508344e-08
3 O 0 5.8637816380269214e-08
end O 0 1.1110572906147809e-08
of O 0 5.414602544107083e-09
the O 0 3.764195177780039e-09
gene O 0 5.804867253544899e-09
, O 0 4.432571809598329e-10
most O 0 3.846071516822036e-10
likely O 0 1.5849719314786626e-09
a O 0 1.1187312187743714e-09
result O 0 2.4548618693387425e-09
of O 0 1.397954729753792e-08
recombination O 0 5.110188272539062e-09
between O 0 1.6130299318461994e-09
two O 0 2.0205010997642603e-09
LINE O 0 2.0801689970539883e-06
elements O 0 6.953325737413252e-08
, O 0 1.618436051842309e-08
was O 0 2.8790017836399784e-07
identified O 0 1.626547856403704e-07
. O 0 3.1223916607814317e-07

The O 0 3.0001006052771118e-06
most O 0 4.780788387392931e-08
frequently O 0 1.8186122829888518e-08
found O 0 1.0155769558650718e-08
mutation O 0 9.535805034488476e-09
, O 0 2.2445074687738042e-09
identified O 0 6.606670321929187e-09
in O 0 2.968225221167131e-09
three O 0 5.591021423612119e-09
unrelated O 0 7.842566418503338e-08
Turkish O 0 7.963180905790068e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999978542327881
T I-Disease 1 1.0
individuals O 0 7.892187348090829e-09
, O 0 1.5483809789884617e-08
was O 0 2.41011605339736e-07
previously O 0 5.202082320465706e-08
described O 0 5.182776874335104e-09
to O 0 1.0074138190319104e-09
be O 0 1.5747085857498178e-09
a O 0 1.2253000392092872e-08
Turkish O 0 5.698638574358483e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999991655349731
T I-Disease 1 1.0
founder O 1 0.8897837400436401
mutation O 0 2.239212108179345e-06
. O 0 5.162776801626023e-07

The O 0 2.1809671579831047e-06
presence O 0 1.581336306344383e-07
of O 0 3.601783475914999e-07
a O 0 2.3459706710582395e-07
founder O 0 0.00632768077775836
mutation O 0 1.88265460110415e-07
among O 0 8.043749666342137e-09
relatively O 0 2.957764255739903e-09
small O 0 5.743038267169709e-10
ethnic O 0 4.101818537605162e-11
population O 0 1.5599809638500162e-11
groups O 0 3.588351490946273e-11
in O 0 1.189219389630125e-09
Western O 0 4.4728491133128045e-08
Europe O 0 1.7481859515555698e-07
could O 0 2.4099808815236656e-09
indicate O 0 2.6711646228250174e-09
a O 0 4.207344250772849e-09
high O 0 7.780466404483377e-08
carrier O 0 1.2667973336988325e-08
frequency O 0 1.134250915413304e-08
in O 0 2.3409625349302132e-09
such O 0 6.107538030875048e-09
communities O 0 1.1533521160345117e-07
. O 0 5.252912842479418e-07

In O 0 2.9204368274804438e-06
patients O 0 4.712067607215431e-07
of O 0 5.657873316522455e-07
Dutch O 0 1.0506792932574172e-05
ethnic O 0 2.8704183474559386e-09
origin O 0 5.6139213278072475e-09
, O 0 2.627230211160736e-09
however O 0 1.893442291844849e-09
, O 0 1.4074410525921621e-09
no O 0 7.569020965547679e-10
significant O 0 7.643595090200961e-09
founder O 0 4.999931206839392e-06
effect O 0 1.2706514951332792e-07
could O 0 1.4598779962682329e-08
be O 0 9.624995911394763e-09
identified O 0 1.4850478180505888e-07
. O 0 6.460471126956691e-07

The O 0 1.0165439334741677e-06
observed O 0 3.3934577459149295e-07
genetic O 0 1.801812032908856e-07
heterogeneity O 0 2.1454728482694918e-07
including O 0 1.9926591932062365e-08
the O 0 3.551499361265087e-08
relative O 0 5.7302091960309554e-08
high O 0 2.6890378990174213e-07
percentage O 0 2.191034909060363e-08
of O 0 4.150389543156052e-08
splice O 0 3.296201248303987e-05
- O 0 1.7070394733309513e-06
site O 0 7.015570417934214e-07
mutations O 0 4.6492885985571775e-08
had O 0 1.544260719299473e-08
no O 0 8.424279940300039e-09
reflection O 0 1.391270672002065e-07
on O 0 1.56172703213997e-07
the O 0 1.5222566673855908e-07
phenotype O 0 1.535204091851483e-06
. O 0 9.672863825471723e-07

All O 0 4.6806453610770404e-06
patients O 0 1.340829726359516e-06
manifested O 0 1.7364828863719595e-06
classical O 0 5.1173061365261674e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999973773956299
T I-Disease 1 1.0
and O 0 4.5986563890210164e-08
increased O 0 3.258604053257841e-08
cellular O 0 2.3629893348697806e-06
radioresistant O 0 6.167307583382353e-05
DNA O 0 1.538092692499049e-05
synthesis O 0 1.0127942005055957e-05
. O 0 2.17592719309323e-06

Determination O 0 7.869200089771766e-06
of O 0 2.0703510017483495e-06
the O 0 5.9266813678959807e-08
genomic O 0 2.3763492151829269e-07
structure O 0 1.5259411156876013e-07
of O 0 1.8930789735804865e-07
the O 0 1.7392144968653156e-07
COL4A4 O 1 0.9999858140945435
gene O 0 4.388980912040097e-08
and O 0 3.349247323924942e-09
of O 0 8.00671031697675e-08
novel O 0 1.1386824780856841e-06
mutations O 0 6.795556600991404e-06
causing O 0 0.1671777367591858
autosomal B-Disease 1 0.9999995231628418
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0016248223837465048

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 1.9019666069652885e-05
a O 0 4.604363130056299e-05
progressive O 1 0.9999940395355225
hematuric B-Disease 1 1.0
glomerulonephritis I-Disease 1 1.0
characterized O 0 0.002690104069188237
by O 0 3.940824626624817e-06
glomerular B-Disease 1 0.9999984502792358
basement I-Disease 1 1.0
membrane I-Disease 0 0.0001720884465612471
abnormalities I-Disease 1 0.9344700574874878
and O 0 6.725731083179198e-08
associated O 0 8.554336261568096e-08
with O 0 5.330819785598351e-09
mutations O 0 1.5870417868768527e-08
in O 0 1.2885123190642389e-08
either O 0 1.9858410027495665e-08
the O 0 1.5424656396589853e-07
COL4A3 O 1 0.9999796152114868
or O 0 8.568379428197659e-08
the O 0 1.3192098435865773e-07
COL4A4 O 1 0.999788224697113
gene O 0 9.904596254273201e-08
, O 0 4.493223126900148e-09
which O 0 7.023631676261743e-10
encode O 0 6.9806969094088345e-09
the O 0 4.503882067297127e-08
alpha3 O 0 2.6276176868123002e-05
and O 0 1.6256235824130272e-07
alpha4 O 0 0.00022245896980166435
type O 0 0.0003616572357714176
IV O 1 1.0
collagen O 1 1.0
chains O 0 0.0033646465744823217
, O 0 9.073696674022358e-07
respectively O 0 1.9171643543813843e-06
. O 0 5.374958504944516e-07

To O 0 2.6615444426170143e-07
date O 0 1.899275730465888e-06
, O 0 1.891854850555319e-08
mutation O 0 6.688284592826221e-09
screening O 0 2.672057597408184e-08
in O 0 7.681140168358525e-09
the O 0 4.528014851956641e-09
two O 0 9.813611034914516e-10
genes O 0 3.313379348668377e-09
has O 0 2.2575510350009154e-09
been O 0 6.856183620840284e-09
hampered O 0 7.367591479123803e-07
by O 0 3.10678371917561e-09
the O 0 1.0640049730170631e-08
lack O 0 1.0286777651913326e-08
of O 0 2.159840839510707e-08
genomic O 0 6.694158116715698e-08
structure O 0 8.465114831324172e-08
information O 0 5.631641286640843e-08
. O 0 3.59592490895011e-07

We O 0 1.5388776546387817e-06
report O 0 2.111789427772237e-07
here O 0 2.2214164729916774e-08
the O 0 1.0719532816949595e-08
complete O 0 3.454076491493652e-08
characterization O 0 8.465776346611165e-08
of O 0 6.061699053816483e-08
the O 0 3.2075519129648455e-08
48 O 0 1.1042317282772274e-07
exons O 0 2.6859419222091674e-07
of O 0 6.79423450833383e-08
the O 0 1.8344046281981718e-07
COL4A4 O 1 0.9999916553497314
gene O 0 9.96426336996592e-08
, O 0 3.6489744559276005e-09
a O 0 2.623344652619153e-09
comprehensive O 0 5.1509484677580986e-08
gene O 0 2.2705851421278567e-08
screen O 0 6.483858072670046e-08
, O 0 4.093046346298479e-09
and O 0 2.951795918804123e-09
the O 0 3.4410807536744414e-09
subsequent O 0 1.745842581613033e-08
detection O 0 1.2432558094133128e-07
of O 0 1.4534099257446087e-08
10 O 0 1.358105983229052e-08
novel O 0 1.1021081824935663e-08
mutations O 0 4.633113448448967e-09
in O 0 9.316862836783457e-09
eight O 0 2.629468269788049e-07
patients O 0 3.886960257659666e-05
diagnosed O 1 0.9999582767486572
with O 0 1.3856149962521158e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.005343109369277954

Furthermore O 0 1.900229835882783e-05
, O 0 2.6985171075466496e-07
we O 0 5.3281463685550534e-09
identified O 0 1.5823477639287375e-08
a O 0 1.0712196463202872e-08
glycine O 0 2.182120937277432e-07
to O 0 6.53089626823089e-09
alanine O 0 7.760798581557538e-08
substitution O 0 1.0995512411682284e-07
in O 0 3.998309239250375e-08
the O 0 1.2797835324818152e-07
collagenous O 0 0.00015044212341308594
domain O 0 3.00622993165689e-08
that O 0 1.3061542958325845e-09
is O 0 1.7803942764516023e-09
apparently O 0 2.0969540770465755e-08
silent O 0 1.6957383763838152e-07
in O 0 2.2721176051732073e-09
the O 0 3.884431887257733e-09
heterozygous O 0 1.0103795133886706e-08
carriers O 0 1.0546078677009518e-08
, O 0 1.4453598318198146e-08
in O 0 1.0528717098168272e-07
11 O 0 1.9557378436729778e-06
. O 0 9.506314313512121e-07

5 O 0 3.8472021515190136e-06
% O 0 3.724872499333287e-08
of O 0 2.2982046488095875e-08
all O 0 1.2915651881328927e-09
control O 0 6.696338594736062e-09
individuals O 0 9.78829378661672e-11
, O 0 8.599511658324843e-10
and O 0 8.639461923642955e-10
in O 0 5.2272333128655646e-09
one O 0 1.9263506345623682e-09
control O 0 9.127705702383082e-09
individual O 0 1.5639002315381845e-09
homozygous O 0 4.8713069134009856e-08
for O 0 5.120842860861785e-09
this O 0 1.3431082024339958e-08
glycine O 0 2.4670262064319104e-06
substitution O 0 3.4838953979487997e-06
. O 0 2.4041435153776547e-06

There O 0 6.36040169865737e-07
has O 0 4.266411224307376e-08
been O 0 1.2454006714790467e-08
no O 0 2.394740628020031e-09
previous O 0 1.1331719562690523e-08
finding O 0 7.590189810002812e-09
of O 0 1.1188064696909805e-08
a O 0 3.6178788853646893e-09
glycine O 0 6.428469134789339e-08
substitution O 0 7.746852759282774e-08
that O 0 2.806959331635994e-09
is O 0 1.883558198301216e-09
not O 0 4.2324382887315437e-10
associated O 0 4.240545248279659e-09
with O 0 6.028050281159381e-10
any O 0 8.887652391820211e-09
obvious O 0 6.584155443078998e-08
phenotype O 0 4.0243840260245634e-08
in O 0 1.1052553539059318e-08
homozygous O 0 1.895449059929888e-07
individuals O 0 8.192110101390426e-09
. O 0 5.827500331179181e-07

Founder O 1 0.878614068031311
BRCA1 O 0 0.00023047023569233716
and O 0 1.2712796433334006e-06
BRCA2 O 0 2.116941504937131e-05
mutations O 0 9.331324690720066e-08
in O 0 4.29983195715522e-08
French O 0 9.1787269411725e-06
Canadian O 0 0.23428429663181305
breast B-Disease 1 0.9999998807907104
and I-Disease 1 0.9999912977218628
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 6.386555924109416e-07
. O 0 1.5991345208021812e-06

We O 0 3.775083143864322e-07
have O 0 3.1740956529802133e-09
identified O 0 1.752411549205135e-08
four O 0 3.618955357609366e-09
mutations O 0 2.8438413846032518e-09
in O 0 3.8064311702612486e-09
each O 0 9.230575748198078e-10
of O 0 4.5975689033639355e-08
the O 0 1.424890115231392e-06
breast B-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999831914901733
- O 0 3.325824945932254e-05
susceptibility O 0 4.450519384135987e-07
genes O 0 1.5282997978260937e-08
, O 0 1.3996809933303211e-08
BRCA1 O 0 7.594188673465396e-07
and O 0 7.029012039083682e-08
BRCA2 O 0 2.8343799840513384e-06
, O 0 2.3230388279671388e-08
in O 0 1.3570494949988188e-08
French O 0 4.6467362153634895e-06
Canadian O 0 0.05841019004583359
breast B-Disease 1 0.9999994039535522
cancer I-Disease 1 0.9999725818634033
and O 0 5.936305387876928e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.438742192050313e-08
from O 0 5.970545089439838e-07
Quebec O 0 2.3536991648143157e-05
. O 0 1.8905292336057755e-06

To O 0 1.8082896531268489e-06
identify O 0 3.899733201251365e-06
founder O 0 0.0014357842737808824
effects O 0 0.0002234798448625952
, O 0 6.655442064129602e-08
we O 0 2.5609134812754064e-09
examined O 0 8.165313403196706e-08
independently O 0 1.6129199309489195e-08
ascertained O 0 1.8616493946410628e-07
French O 0 1.3027757859163103e-06
Canadian O 0 3.8361969927791506e-05
cancer B-Disease 0 0.00010587598808342591
families O 0 6.60417276421299e-10
for O 0 1.0440398545696894e-09
the O 0 4.342556092495897e-09
distribution O 0 8.845661092493629e-09
of O 0 1.5421795396264315e-08
these O 0 1.747091027404224e-09
eight O 0 8.90713849344138e-08
mutations O 0 4.6561976319026144e-07
. O 0 9.378489949085633e-07

Mutations O 0 2.3141383280744776e-06
were O 0 1.6752682086007553e-07
found O 0 2.751377792264975e-08
in O 0 1.682438544037268e-08
41 O 0 8.446116339655418e-08
of O 0 5.184045548389804e-08
97 O 0 1.449022192900884e-06
families O 0 1.4074633014615756e-08
. O 0 5.93341042076645e-07

Six O 0 6.358573500619968e-06
of O 0 1.4812558220000938e-06
eight O 0 1.8653422273473552e-07
mutations O 0 3.757912736546132e-08
were O 0 1.2929954884555173e-08
observed O 0 5.689120285978788e-08
at O 0 1.660904729305912e-07
least O 0 2.482100214251659e-08
twice O 0 3.312613898742711e-07
. O 0 5.921602337366494e-07

The O 0 1.8105594790540636e-05
BRCA1 O 0 0.00012206396786496043
C4446T O 0 0.00011143503797939047
mutation O 0 8.522275152245129e-07
was O 0 5.009506480746495e-07
the O 0 1.2651408809460918e-08
most O 0 1.6341182851320468e-09
common O 0 3.474240006795526e-09
mutation O 0 4.305426681838753e-09
found O 0 4.262187491832492e-09
, O 0 2.2927306719822127e-09
followed O 0 1.1358941343075912e-08
by O 0 4.072689741008162e-09
the O 0 1.656500785429671e-07
BRCA2 O 0 1.9486042219796218e-05
8765delAG O 0 4.418451135279611e-05
mutation O 0 1.718160206110042e-06
. O 0 1.3537077165892697e-06

Together O 0 1.947793862200342e-06
, O 0 6.264767904440305e-08
these O 0 2.115553288106753e-09
mutations O 0 1.3166327583746806e-08
were O 0 3.97104571447926e-09
found O 0 4.143047682703127e-09
in O 0 4.259164576581043e-09
28 O 0 3.147528815361511e-08
of O 0 3.505045143015195e-08
41 O 0 3.607702936392343e-08
families O 0 3.9852096622716715e-10
identified O 0 3.824325744972157e-09
to O 0 7.341287577844469e-09
have O 0 4.795397856582895e-09
a O 0 1.1414088163519409e-07
mutation O 0 7.367029297711269e-07
. O 0 8.875119306139823e-07

The O 0 5.764889465353917e-06
odds O 0 6.747844963683747e-06
of O 0 2.5412046511519293e-07
detection O 0 8.639862585368974e-07
of O 0 1.0985324649936956e-07
any O 0 4.540052778168047e-09
of O 0 4.46395951314571e-08
the O 0 2.0325190419612227e-08
four O 0 2.8108557259542977e-08
BRCA1 O 0 1.1656711649266072e-06
mutations O 0 8.83966038145445e-08
was O 0 1.5864145552768605e-06
18 O 0 3.0276069082901813e-06
. O 0 7.388608764813398e-07

7x O 0 0.3706955313682556
greater O 0 1.8202314322479651e-06
if O 0 3.121343183920544e-08
one O 0 8.920736149775621e-09
or O 0 3.8888203768294716e-09
more O 0 1.8321154315881216e-10
cases O 0 1.9786261518106585e-09
of O 0 5.718892680306453e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 1.2738581744997646e-07
also O 0 2.6696060917430486e-09
present O 0 3.7639940053679766e-09
in O 0 5.379428014151699e-09
the O 0 9.499972719595462e-08
family O 0 2.1151231521798763e-07
. O 0 6.524020363940508e-07

The O 0 4.175531103101093e-06
odds O 0 1.9804940620815614e-06
of O 0 2.0527534161374206e-07
detection O 0 1.6315003676936612e-06
of O 0 7.980911931326773e-08
any O 0 4.262723951597991e-09
of O 0 3.269274628792118e-08
the O 0 2.0301788694609968e-08
four O 0 4.333208636353447e-08
BRCA2 O 0 2.0421227873157477e-06
mutations O 0 1.0916376425029739e-07
was O 0 2.599285153337405e-06
5 O 0 4.371080194687238e-06
. O 0 7.082073807396227e-07

3x O 0 0.0002772152074612677
greater O 0 3.7080519632581854e-07
if O 0 9.550658930379541e-09
there O 0 2.3858459652359443e-09
were O 0 5.652213364015779e-09
at O 0 3.114670832360389e-08
least O 0 3.296339312619523e-10
five O 0 7.252268785506999e-10
cases O 0 1.787601178193654e-09
of O 0 6.317907832453784e-07
breast B-Disease 1 0.9999982118606567
cancer I-Disease 1 0.993728518486023
in O 0 1.0972948416565487e-07
the O 0 2.7452506401459686e-07
family O 0 7.77443460719951e-07
. O 0 1.0668711638572859e-06

Interestingly O 0 2.655362186487764e-05
, O 0 2.4496532091689005e-07
the O 0 1.7529265150528772e-08
presence O 0 2.2544799804791182e-08
of O 0 2.3327410758611222e-07
a O 0 1.7104778180510039e-06
breast B-Disease 1 0.9999958276748657
cancer I-Disease 1 0.7881994247436523
case O 0 3.20212976134826e-08
< O 0 1.4304245610219368e-07
36 O 0 2.7522595758000534e-08
years O 0 2.178083491344296e-09
of O 0 1.2337189936317827e-08
age O 0 1.9458978428588125e-08
was O 0 2.4200330628332267e-08
strongly O 0 6.329837765051138e-10
predictive O 0 4.844268097770055e-09
of O 0 8.064272805086148e-09
the O 0 4.0004430879037045e-09
presence O 0 2.7178805872551948e-09
of O 0 5.2226991620329954e-09
any O 0 1.92701210544044e-09
of O 0 4.340827075566267e-08
the O 0 2.6674086939237895e-08
eight O 0 9.38444344456002e-08
mutations O 0 2.504984593088011e-07
screened O 0 5.297401912685018e-06
. O 0 1.5711175365140662e-06

Carriers O 0 1.8364734160059015e-06
of O 0 6.693812792946119e-07
the O 0 4.0100097464801365e-08
same O 0 6.410663111466874e-09
mutation O 0 4.534419062451889e-09
, O 0 5.866326313608283e-10
from O 0 5.054640039858782e-10
different O 0 8.710871607364723e-11
families O 0 1.3602095838560757e-10
, O 0 8.273319251905775e-10
shared O 0 1.502362456662354e-09
similar O 0 2.524771280931759e-09
haplotypes O 0 1.0919771398221201e-07
, O 0 5.907154765338873e-09
indicating O 0 8.740804524620671e-09
that O 0 2.195249121372811e-10
the O 0 2.5451265539544465e-09
mutant O 0 1.3338511628546712e-08
alleles O 0 2.818610622679074e-10
were O 0 9.949840951151145e-10
likely O 0 8.671075524269156e-10
to O 0 8.824069808177626e-10
be O 0 1.0335112765602616e-09
identical O 0 5.178221851309672e-09
by O 0 7.132469059811797e-10
descent O 0 5.546855863514111e-09
for O 0 8.49310122230662e-10
a O 0 4.1679348861123344e-09
mutation O 0 4.638665895839722e-09
in O 0 5.120803781011318e-09
the O 0 4.027317146437781e-08
founder O 0 6.138247499620775e-06
population O 0 9.29786825309975e-09
. O 0 2.2782684538924514e-07

The O 0 5.733674584007531e-07
identification O 0 2.4169659695871815e-07
of O 0 5.107638116896851e-07
common O 0 4.743231158954586e-07
BRCA1 O 0 2.186365054512862e-05
and O 0 6.49099774818751e-07
BRCA2 O 0 1.8983098925673403e-05
mutations O 0 6.990505596604635e-08
will O 0 1.2815343453098649e-08
facilitate O 0 7.913097022083093e-08
carrier O 0 4.6713509505025286e-07
detection O 0 2.3463785510102753e-06
in O 0 3.1307280323744635e-08
French O 0 1.457146936445497e-06
Canadian O 0 0.0002345400134800002
breast B-Disease 1 0.9999947547912598
cancer I-Disease 1 0.9999836683273315
and O 0 0.00048812993918545544
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 9.888680096992175e-07
. O 0 1.8072672673952184e-06

Are O 0 1.5013112033557263e-06
Dp71 O 0 0.0022209149319678545
and O 0 4.434218681126367e-06
Dp140 O 1 0.8219377398490906
brain O 1 0.6036763191223145
dystrophin O 0 4.9406673497287557e-05
isoforms O 0 2.415640949493536e-07
related O 0 2.5130719905064325e-07
to O 0 2.05232481675921e-07
cognitive B-Disease 0 0.006432388909161091
impairment I-Disease 1 0.9999963045120239
in O 1 0.9917324781417847
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 1 0.9999464750289917

Molecular O 0 5.0853293942054734e-05
study O 0 5.690280886483379e-07
and O 0 6.376447458933399e-08
neuropsychological O 0 1.795779462554492e-05
analysis O 0 4.117792684610322e-08
were O 0 3.486216826331656e-08
performed O 0 1.2361620349565783e-07
concurrently O 0 2.572193658068045e-08
on O 0 6.509819172606512e-08
49 O 0 3.166520912145643e-07
patients O 0 1.1330534732678643e-07
with O 0 1.4642989754065638e-06
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999997615814209
DMD B-Disease 1 1.0
) O 0 1.967854217355125e-07
in O 0 1.1852752557217627e-08
order O 0 5.983150863642095e-09
to O 0 1.589943510182934e-09
find O 0 1.7983805555843446e-09
a O 0 1.592571963193734e-09
molecular O 0 2.6398495833745983e-08
explanation O 0 3.3180846958913435e-09
for O 0 1.6556465087802508e-09
the O 0 6.496050275472953e-08
cognitive B-Disease 0 4.358701698947698e-05
impairment I-Disease 0 0.00044282214366830885
observed O 0 1.546584087463998e-07
in O 0 1.4212109533673356e-07
most O 0 1.056746100402961e-06
DMD B-Disease 1 1.0
patients O 0 5.3599018428940326e-05
. O 0 3.3923004139069235e-06

Complete O 0 4.43921135229175e-06
analysis O 0 1.1567768609666018e-07
of O 0 2.9045389737802907e-07
the O 0 7.408443281065047e-08
dystrophin O 0 1.1942695891775656e-05
gene O 0 1.6135913938342128e-07
was O 0 3.4447410257598676e-07
performed O 0 1.6543820891001815e-07
to O 0 1.3562569955993808e-09
define O 0 4.836604894364882e-09
the O 0 6.841370581156525e-09
localization O 0 2.71101754378833e-07
of O 0 1.2156023743159494e-08
deletions O 0 3.058461572891247e-08
and O 0 6.9761711962712525e-09
duplications O 0 3.913548880518647e-07
in O 0 7.729388684651894e-09
relation O 0 1.8850975891382404e-08
to O 0 7.839093818517995e-09
the O 0 9.793330946195056e-08
different O 0 1.864021044184483e-07
DMD B-Disease 1 1.0
promoters O 0 0.010746095329523087
. O 0 1.184729717351729e-05

Qualitative O 0 7.725655450485647e-06
analysis O 0 8.758179319556803e-07
of O 0 9.987493285734672e-07
the O 0 3.716414198606799e-07
Dp71 O 0 0.0011900811223313212
transcript O 0 3.2917173484747764e-06
and O 0 1.2438411189918952e-08
testing O 0 6.446838796136944e-08
for O 0 8.357537994996278e-10
the O 0 1.808341809628189e-09
specific O 0 1.102473445868668e-09
first O 0 2.954106648189736e-08
exon O 0 1.8904557919086074e-07
of O 0 7.392549861151565e-08
Dp140 O 0 2.1057171579741407e-06
were O 0 3.131623671492889e-08
also O 0 5.920340218068532e-09
carried O 0 7.770322696387666e-08
out O 0 2.3511805125053797e-07
. O 0 6.328853032755433e-07

Neuropsychological O 0 0.002250354504212737
analysis O 0 2.2888098101248033e-06
assessed O 0 3.569721911844681e-06
verbal O 0 4.121295660297619e-06
and O 0 3.609079612942878e-07
visuospatial O 0 0.00011172732047270983
intelligence O 0 2.134993110303185e-06
, O 0 1.014415715872019e-07
verbal O 0 2.0222482817189302e-06
memory O 1 0.9251580834388733
, O 0 1.983732857979703e-07
and O 0 2.3827486472782766e-07
reading O 0 1.9435150534263812e-05
skills O 0 6.542002665810287e-06
. O 0 2.0392560600157594e-06

Comparison O 0 5.451388915389543e-06
of O 0 3.1198098895401927e-06
molecular O 0 3.9508718145953026e-06
and O 0 9.024275726687847e-08
psychometric O 0 1.6871719708433375e-05
findings O 0 1.3579148117059958e-07
demonstrated O 0 6.932878449106283e-08
that O 0 7.998643414275364e-10
deletions O 0 4.4936712129128864e-08
and O 0 1.277997352389093e-08
duplications O 0 3.5537874509827816e-07
that O 0 2.457489989282635e-09
were O 0 4.733838210313479e-09
localized O 0 9.963484615127527e-08
in O 0 3.267560089170729e-08
the O 0 5.5707143786776214e-08
distal O 0 3.767738689930411e-07
part O 0 3.942783521893034e-08
of O 0 4.683528942450721e-08
the O 0 4.800671860039074e-08
gene O 0 4.079572590853786e-08
seemed O 0 2.3857243292013663e-08
to O 0 1.399426574621998e-09
be O 0 1.0409577644310275e-09
preferentially O 0 8.828455122511514e-08
associated O 0 7.176894456506488e-08
with O 0 2.320360295016144e-07
cognitive B-Disease 1 0.7944076657295227
impairment I-Disease 1 0.9999806880950928
. O 0 3.3997188438661397e-05

Two O 0 2.0681111436715582e-06
altered O 0 5.786519523098832e-06
Dp71 O 0 0.00020990890334360301
transcripts O 0 5.5308501032413915e-06
and O 0 6.48747047193865e-08
two O 0 1.083040856997286e-08
deleted O 0 1.0497395663833231e-07
Dp140 O 0 6.647854888797156e-07
DNA O 0 1.079337579312778e-07
sequences O 0 2.1642025949120125e-09
were O 0 1.1692914414496158e-09
found O 0 1.0471830069747057e-09
in O 0 1.6764508670163991e-09
four O 0 9.683607693489193e-09
patients O 0 1.0643626779938131e-07
with O 0 6.877286296003149e-07
severe O 1 1.0
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 1.0
. O 0 0.00021925568580627441

These O 0 3.282646900970576e-07
findings O 0 1.4863512376450672e-07
suggest O 0 2.3404192361908827e-08
that O 0 2.16569637223607e-10
some O 0 2.2122471909913344e-10
sequences O 0 9.233639408634531e-10
located O 0 9.30977517299425e-09
in O 0 9.035101555809888e-10
the O 0 5.671068059598383e-09
distal O 0 9.69181570553701e-08
part O 0 1.7569766086467098e-08
of O 0 5.6638281620280395e-08
the O 0 1.924313686174628e-08
gene O 0 6.10374151222004e-09
and O 0 2.3177000318952423e-09
, O 0 1.7084305081738194e-09
in O 0 1.3550675026507975e-09
particular O 0 2.0056798444301194e-09
, O 0 2.5571746942176787e-09
some O 0 6.501738258890555e-09
DMD B-Disease 1 0.9999997615814209
isoforms O 0 1.72333560755078e-08
expressed O 0 2.5881765619573116e-09
in O 0 1.4024040595472798e-08
the O 0 2.1317671894394152e-07
brain O 0 0.40161311626434326
may O 0 3.002826076681231e-08
be O 0 8.342630475333124e-10
related O 0 2.08490984476839e-08
to O 0 2.4699191580879187e-09
the O 0 1.1309860781238967e-07
cognitive B-Disease 0 9.184285590890795e-05
impairment I-Disease 0 0.2526923716068268
associated O 0 3.2344412375096e-06
with O 0 3.0627165870100725e-06
DMD B-Disease 1 1.0
. O 0 2.563569296398782e-06
. O 0 1.859755457189749e-06

I1307K O 0 0.0028043200727552176
APC O 0 0.0007449412951245904
and O 0 1.1798481409641681e-06
hMLH1 O 0 2.651910654094536e-05
mutations O 0 2.682127728803607e-07
in O 0 5.901706501276749e-08
a O 0 3.8341365637961644e-08
non O 0 2.0975276129320264e-06
- O 0 6.492855391115882e-07
Jewish O 0 2.9362388431763975e-07
family O 0 5.117369639151548e-08
with O 0 6.956920373113462e-08
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0001031526699080132

We O 0 5.094381663184322e-07
describe O 0 3.0108296300568327e-07
a O 0 9.885552998412095e-08
French O 0 7.720617759332526e-06
Canadian O 0 9.243549720849842e-05
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.026944195851683617
HNPCC B-Disease 1 1.0
) O 0 2.5220351744792424e-06
kindred O 0 3.5533848858904094e-05
which O 0 5.3567720925684625e-08
carries O 0 1.8074345575769257e-07
a O 0 4.30368807258219e-08
novel O 0 2.46036933049254e-07
truncating O 0 4.5452811718860175e-06
mutation O 0 3.7845671840841533e-07
in O 0 4.360927050583996e-07
hMLH1 O 0 0.00010986733104800805
. O 0 4.286904186301399e-06

Interestingly O 0 1.7291889889747836e-05
, O 0 1.655884886986314e-07
the O 0 8.34782767356046e-08
I1307K O 0 1.5436282410519198e-05
APC O 0 4.997823907615384e-06
polymorphism O 0 3.533520498422149e-07
, O 0 1.6940436609047538e-08
associated O 0 2.4902611528432317e-08
with O 0 2.1289598972629165e-09
an O 0 1.507535096756385e-09
increased O 0 7.247515032560159e-09
risk O 0 1.459946759041486e-07
of O 0 0.2533150315284729
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 8.103903326173167e-08
is O 0 1.5976527878436286e-09
also O 0 7.767914089740202e-10
present O 0 1.6566762406355906e-09
in O 0 4.994686886305999e-09
this O 0 3.5663161312982083e-09
family O 0 9.237646736437455e-08
. O 0 6.448966018979263e-07

The O 0 6.600308552151546e-06
I1307K O 0 5.445710485219024e-05
polymorphism O 0 1.1933209407288814e-06
has O 0 1.1870580962636268e-08
previously O 0 3.385117608445398e-08
only O 0 6.326675294765494e-10
been O 0 5.497696187184431e-10
identified O 0 1.3561043399334949e-09
in O 0 5.733625241255424e-10
individuals O 0 1.1627834112237778e-10
of O 0 2.750344307855812e-08
self O 0 1.9503738712955965e-06
- O 0 1.1214876394660678e-05
reported O 0 2.378641426048489e-07
Ashkenazi O 0 1.1650021178866155e-06
Jewish O 0 6.587439997929323e-07
origins O 0 4.515629370871466e-06
. O 0 1.038424898069934e-06

In O 0 6.281782134465175e-07
addition O 0 9.056521577122112e-08
, O 0 1.8327323658695605e-08
in O 0 7.3639783160217576e-09
this O 0 4.675152487365608e-10
family O 0 1.947021877057864e-09
, O 0 1.8254854294852407e-09
there O 0 4.4611467298061314e-10
appears O 0 1.294509832661106e-09
to O 0 3.09544306853482e-10
be O 0 9.570603198838512e-10
no O 0 2.761296968856186e-09
relationship O 0 7.961625803076799e-10
between O 0 1.5031077493787848e-09
the O 0 5.062959829160718e-09
I1307K O 0 4.078009681052208e-07
polymorphism O 0 2.3939747961776447e-08
and O 0 2.01687400114281e-09
the O 0 3.356371180984752e-09
presence O 0 4.492229255248503e-09
or O 0 8.34478264266636e-09
absence O 0 1.8494198172902543e-07
of O 0 4.608205472322879e-06
cancer B-Disease 0 0.32835763692855835
. O 0 1.366393718171821e-07
. O 0 8.112158980111417e-07

Identification O 0 4.193077074887697e-06
of O 0 1.4179659046931192e-06
a O 0 1.493707912914033e-07
novel O 0 1.1097002072801843e-07
mutation O 0 2.248879660271541e-08
of O 0 6.519821482697807e-08
the O 0 1.5165792888183205e-07
CPO O 1 0.7435662150382996
gene O 0 6.450208900332655e-08
in O 0 1.154942186332164e-08
a O 0 5.278483428128311e-08
Japanese O 0 6.416210089810193e-05
hereditary B-Disease 1 0.9999984502792358
coproporphyria I-Disease 1 0.9998180270195007
family O 0 1.762733700161334e-05
. O 0 9.955095265468117e-06

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999972581863403
( O 0 0.0007364842458628118
HCP B-Disease 1 1.0
) O 0 5.111282916914206e-07
is O 0 8.313136845572444e-09
an O 0 5.971088956613357e-09
autosomal B-Disease 1 0.9986617565155029
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
characterized O 0 3.907472546416102e-06
by O 0 1.0125735627752874e-07
a O 0 6.559282155649271e-06
deficiency B-Disease 1 0.9999816417694092
of I-Disease 0 0.11071500182151794
coproporphyrinogen I-Disease 1 0.999846339225769
oxidase I-Disease 0 8.869129487720784e-06
( O 0 5.395439757194254e-07
CPO O 1 0.999991774559021
) O 0 6.380912509484915e-08
caused O 0 1.0064907485229924e-07
by O 0 3.1679929790584538e-09
a O 0 3.964605532758014e-09
mutation O 0 9.693327918114392e-09
in O 0 1.5788236495950514e-08
the O 0 3.767505063478893e-07
CPO O 1 0.9904548525810242
gene O 0 2.5077022201003274e-06
. O 0 1.2020656185995904e-06

Only O 0 7.519835776292894e-07
11 O 0 7.634672556378064e-07
mutations O 0 3.491087596785292e-08
of O 0 7.17508754632945e-08
the O 0 5.3161503643650576e-08
gene O 0 1.312085196047974e-08
have O 0 2.4619598026909273e-10
been O 0 3.81931064552532e-09
reported O 0 2.5288835914238916e-08
in O 0 2.360488622343837e-07
HCP B-Disease 1 1.0
patients O 0 2.7853622668772005e-05
. O 0 3.268133013989427e-06

We O 0 7.630239338141109e-07
report O 0 2.1106458802933048e-07
another O 0 4.064155945115999e-08
mutation O 0 1.2786605552150831e-08
in O 0 1.4478072074552983e-08
a O 0 5.299011363035788e-08
Japanese O 0 9.429022611584514e-06
family O 0 9.343896181235323e-07
. O 0 1.139474420597253e-06

Polymerase O 0 8.196097041945904e-05
chain O 0 1.5288620488718152e-05
reaction O 0 5.046331921221281e-07
- O 0 2.125339278791216e-06
single O 0 1.0276544770704277e-07
strand O 0 5.478336717601451e-08
conformational O 0 4.805313924549637e-09
polymorphism O 0 9.418456237142436e-09
and O 0 1.0082825685486796e-09
direct O 0 7.506437693649559e-10
sequence O 0 7.789546785375023e-10
analyses O 0 1.249652825663361e-08
demonstrated O 0 8.775316473474959e-09
a O 0 9.753862606487473e-09
C O 0 1.2084381069144001e-06
to O 0 8.783522353894568e-09
T O 0 2.593233830339159e-06
substitution O 0 3.047566465852469e-08
in O 0 4.776884665602665e-09
exon O 0 1.5478205739327677e-07
1 O 0 2.995006553874191e-08
of O 0 1.866649768089701e-08
the O 0 5.3471460148557526e-08
CPO O 0 0.00013702236174140126
gene O 0 2.531074549949608e-08
at O 0 1.722195364095569e-08
nucleotide O 0 1.2545630312388312e-08
position O 0 2.9169630266778768e-08
85 O 0 8.399254625146568e-08
, O 0 1.6793856305596933e-09
which O 0 1.696720319799283e-09
lies O 0 4.186660973459766e-08
in O 0 2.8021984732617966e-09
the O 0 1.1063457705517976e-08
putative O 0 2.721124587878876e-07
presequence O 0 2.9872587674617535e-06
for O 0 8.809662332964763e-09
targeting O 0 6.16668813790966e-08
to O 0 5.12636688654311e-08
mitochondria O 0 4.317976163292769e-06
. O 0 1.5461076827705256e-06

This O 0 9.963655855926845e-08
mutation O 0 3.302302076235719e-08
changes O 0 6.481951420056475e-09
the O 0 2.3615752908767718e-08
codon O 0 1.5516322093844792e-07
for O 0 4.834963096556066e-09
glutamine O 0 1.1760495510770852e-07
to O 0 4.7344883569166996e-09
a O 0 1.408655680990023e-08
termination O 0 4.905516561848344e-07
codon O 0 1.4521265256917104e-06
at O 0 5.681290531356353e-07
amino O 0 1.1294221025082152e-07
acid O 0 5.400607960837078e-07
position O 0 1.393410002492601e-06
29 O 0 6.583064532605931e-06
. O 0 1.0839490869329893e-06

MaeI O 0 0.00028293795185163617
restriction O 0 6.470632456512249e-07
analysis O 0 3.3621336115174927e-07
showed O 0 1.1514125475287074e-07
two O 0 1.8862977846367812e-09
other O 0 1.0784476645042673e-09
carriers O 0 8.025129893951544e-09
in O 0 1.614773026403782e-08
the O 0 5.7502781203311315e-08
family O 0 4.2989464077436423e-07
. O 0 1.1202433825019398e-06

The O 0 2.017912811425049e-05
C O 1 0.9895229935646057
- O 0 0.15300263464450836
T O 1 0.6585080027580261
mutation O 0 5.8622941168096077e-08
is O 0 1.5907232198131283e-09
located O 0 2.4658534769628204e-08
within O 0 7.171582439013946e-09
a O 0 7.398640367028975e-09
recently O 0 2.443208479974146e-08
proposed O 0 9.54719769907797e-09
putative O 0 1.9956988239755447e-07
alternative O 0 7.783079070122767e-08
translation O 0 6.384650674817749e-08
initiation O 0 3.399112813440297e-07
codon O 0 8.475234380966867e-07
( O 0 3.309105522930622e-08
TIC O 0 3.573259891709313e-05
- O 0 1.1640125876510865e-06
1 O 0 9.125515987307153e-08
) O 0 1.9607138135313562e-09
, O 0 7.325352546772024e-10
supporting O 0 1.827892837091838e-09
that O 0 1.6714860606725779e-09
TIC O 0 3.980943438364193e-05
- O 0 8.392102017751313e-07
1 O 0 9.517782473267289e-08
is O 0 1.386545989134902e-09
the O 0 4.993239599571098e-09
real O 0 1.9905590420421504e-07
TIC O 0 2.2416466890717857e-05
rather O 0 1.9051986654972097e-08
than O 0 9.86737003216831e-09
TIC O 0 5.9458576288307086e-05
- O 0 4.124940915062325e-06
2 O 0 7.516022151321522e-07
. O 0 7.950828262437426e-08
. O 0 1.951857058202222e-07

Human B-Disease 0 1.0617693078529555e-05
complement I-Disease 0 2.1235291569610126e-05
factor I-Disease 0 0.000885738932993263
H I-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 0.0014584019081667066
with O 1 0.8509525656700134
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9991908669471741

This O 0 3.2944043937277456e-07
study O 0 1.8707277149587753e-07
reports O 0 3.288079142294009e-08
on O 0 3.7265568408884064e-08
six O 0 5.084463072790868e-09
cases O 0 7.288159409313266e-09
of O 0 2.2658623493043706e-06
deficiency B-Disease 1 0.9979057312011719
in I-Disease 0 1.7440211763641855e-07
the I-Disease 0 6.363617188753778e-08
human I-Disease 0 1.50007828381149e-08
complement I-Disease 0 2.549004740615146e-08
regulatory I-Disease 0 9.465968986432927e-08
protein I-Disease 0 5.8998836038881564e-08
Factor I-Disease 0 3.9536544704787957e-07
H I-Disease 1 0.9999563694000244
( O 0 7.608050367480246e-08
FH O 0 0.0003586793318390846
) O 0 2.9309765725571424e-09
in O 0 1.2975007734894461e-09
the O 0 7.384510225527663e-10
context O 0 1.1760619145206874e-09
of O 0 2.5308379392185998e-08
an O 0 3.3179003366967663e-07
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.00011460800305940211

Five O 0 1.632091766623489e-06
of O 0 7.907693770903279e-07
the O 0 5.6742955223398894e-08
cases O 0 4.389480778854704e-09
were O 0 3.171342299879143e-09
observed O 0 4.760658089963954e-09
in O 0 2.353130135190895e-09
children O 0 6.294397003614449e-09
presenting O 0 4.4976459889767284e-07
with O 0 9.57050815486582e-07
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 1.0
HUS B-Disease 1 1.0
) O 0 0.00023397381301037967
. O 0 1.029551185638411e-05

Two O 0 3.6026389693688543e-07
of O 0 4.488818490244739e-07
the O 0 5.915252643262647e-08
children O 0 3.1019123269970805e-08
exhibited O 0 1.2450905160221737e-06
a O 0 5.073819124845613e-07
homozygous O 1 0.6440169215202332
deficiency O 1 0.9999966621398926
characterized O 0 1.5874526297920966e-06
by O 0 2.6852340795358032e-08
the O 0 7.075310293203074e-08
absence O 0 2.0643598475089675e-07
of O 0 3.005025916991144e-08
the O 0 1.0895674584787685e-08
150 O 0 2.356293293814815e-08
- O 0 1.1175038139299431e-07
kD O 0 5.749043907599116e-07
form O 0 2.8134503615717676e-09
of O 0 2.0429117952858178e-08
Factor O 0 6.710533995146761e-08
H O 1 0.9999922513961792
and O 0 8.481450208819297e-09
the O 0 5.496000987648131e-09
presence O 0 2.1732449173583746e-09
, O 0 6.266817065281316e-10
upon O 0 6.162006460641578e-09
immunoblotting O 0 9.819017350309878e-07
, O 0 2.3841035812210976e-09
of O 0 9.991417471155728e-09
the O 0 1.511203606696654e-08
42 O 0 1.6848848360950797e-07
- O 0 3.5264508824184304e-07
kD O 0 4.9008212954504415e-06
Factor O 0 5.216569434196572e-07
H O 1 0.7374925017356873
- O 0 1.0216043619948323e-06
like O 0 4.786125629152593e-08
protein O 0 2.15527702351892e-08
1 O 0 1.1024744850374191e-07
( O 0 1.0751722179236367e-08
FHL O 0 0.00027675199089571834
- O 0 2.7484466613714176e-07
1 O 0 4.1735379596730127e-08
) O 0 7.221542253077473e-10
and O 0 8.006916241143358e-10
other O 0 3.671216219913731e-09
FH O 0 0.00013452375424094498
- O 0 8.401591458095936e-07
related O 0 2.6519217044551624e-07
protein O 0 2.5417958227080817e-07
( O 0 1.7202508217906143e-07
FHR O 1 0.9999681711196899
) O 0 1.979220485281985e-07
bands O 0 1.749072725942824e-05
. O 0 9.063568882083928e-07

Southern O 0 6.563966599060223e-05
blot O 0 5.8669596910476685e-05
and O 0 6.949613151618905e-08
PCR O 0 1.18345667488029e-06
analysis O 0 1.6580049333470015e-08
of O 0 6.335967839277146e-08
DNA O 0 3.797941303673724e-07
of O 0 5.544785608435632e-08
one O 0 1.4557071104093211e-08
patient O 0 1.5727320601399697e-07
with O 0 3.275110316280916e-08
homozygous O 0 0.14939112961292267
deficiency O 1 0.9999516010284424
ruled O 0 7.961487426655367e-06
out O 0 6.161021559591973e-08
the O 0 1.547725325679039e-08
presence O 0 4.912264373047037e-09
of O 0 1.0171509856604644e-08
a O 0 2.1647474923724985e-09
large O 0 3.807919757292666e-09
deletion O 0 2.364802753618278e-08
of O 0 3.562171002613468e-08
the O 0 6.036799504727242e-08
FH O 0 0.23339560627937317
gene O 0 4.920631724303348e-08
as O 0 1.125664539358695e-08
the O 0 6.4007203093297e-08
underlying O 0 1.464281649532495e-05
defect O 0 9.392889296577778e-06
for O 0 1.2359674883555272e-07
the O 0 7.958446076372638e-05
deficiency O 1 0.999998927116394
. O 0 1.2923495887662284e-05

The O 0 2.9856325909349835e-06
other O 0 6.349493020252339e-08
four O 0 6.656711803998405e-08
children O 0 1.03953770036469e-08
presented O 0 1.8377525634605263e-07
with O 0 6.92854200678994e-08
heterozygous O 0 1.237178821611451e-05
deficiency O 1 0.9995914101600647
and O 0 5.227984161138011e-07
exhibited O 0 1.4822881894360762e-05
a O 0 1.4286386829098774e-07
normal O 0 3.750734549612389e-07
immunoblotting O 0 1.3904358638683334e-05
pattern O 0 1.2185545017473487e-07
of O 0 2.1047116049999204e-08
proteins O 0 7.693251369289555e-09
of O 0 1.451838329558086e-07
the O 0 4.285667216663569e-07
FH O 1 0.9138474464416504
family O 0 7.687957577218185e-07
. O 0 1.5549992440355709e-06

Factor B-Disease 1 0.976547360420227
H I-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 8.856063971052208e-08
the O 0 7.90974752362672e-08
only O 0 6.380133754646522e-08
complement B-Disease 1 0.9999980926513672
deficiency I-Disease 1 1.0
associated O 0 7.242652645800263e-05
with O 0 2.7884078008355573e-05
HUS B-Disease 1 1.0
. O 0 7.03263285686262e-05

These O 0 1.0897425539724281e-07
observations O 0 6.519971407215053e-07
suggest O 0 1.0003053318996535e-07
a O 0 1.7541873731374835e-08
role O 0 2.3087183720349458e-08
for O 0 2.229085893645788e-08
FH O 0 0.0026167400646954775
and O 0 1.4373219414665073e-07
/ O 0 3.2051323159976164e-06
or O 0 8.463758405241606e-08
FH O 0 0.0002953108341898769
receptors O 0 2.8963340170662377e-08
in O 0 1.8446211669242984e-08
the O 0 2.885972527622016e-08
pathogenesis O 0 2.486232915543951e-05
of O 0 6.724519607814727e-06
idiopathic O 1 0.9999988079071045
HUS B-Disease 1 1.0
. O 0 1.0097525773744565e-05
. O 0 5.375397449824959e-06

Further O 0 9.600876182958018e-07
evidence O 0 4.898429324384779e-07
for O 0 1.1041954905977036e-08
a O 0 1.7291963416710132e-08
major O 0 1.7028625620696403e-07
ancient O 0 7.298467153304955e-06
mutation O 0 2.2772569536755327e-06
underlying O 1 0.6614644527435303
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 6.82376921758987e-05
linkage O 0 4.4379656173987314e-05
disequilibrium O 0 4.7706387704238296e-05
studies O 0 1.2346914957106492e-07
in O 0 3.1941937095325557e-08
the O 0 2.507113272542938e-08
Japanese O 0 4.243751732246892e-07
population O 0 6.452224088349112e-09
. O 0 3.026865442734561e-07

The O 0 0.003961683250963688
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9996036887168884
DM B-Disease 1 1.0
) O 0 1.5200022289718618e-06
mutation O 0 7.11569398959e-08
is O 0 3.2483138401318e-09
an O 0 3.7095562177569263e-09
unstable O 0 2.771049139482784e-06
( O 0 1.5463170655038994e-07
CTG O 1 0.8462258577346802
) O 0 1.3657846409387275e-08
n O 0 1.8363714104907558e-08
repeat O 0 4.99912147233772e-08
, O 0 1.7900304571938364e-09
present O 0 3.6649263623900197e-09
at O 0 4.5287688266171244e-08
a O 0 2.751864514038971e-09
copy O 0 1.9454265753893196e-08
number O 0 2.3359538747769193e-09
of O 0 1.129118043508015e-08
5 O 0 5.8676526748513425e-08
- O 0 1.929205666328926e-07
37 O 0 7.833745740981612e-08
repeats O 0 1.6219093623703884e-08
on O 0 8.771602111323773e-09
normal O 0 6.974228750067368e-09
chromosomes O 0 2.3132395998715083e-09
but O 0 1.0019829410623515e-09
amplified O 0 4.9772101107237177e-08
to O 0 6.2601306360932085e-09
50 O 0 8.907937143476374e-08
- O 0 2.1184560239362327e-07
3000 O 0 3.4937264103973575e-07
copies O 0 3.0689162144881266e-07
on O 0 7.353524438258319e-07
DM B-Disease 1 1.0
chromosomes O 0 2.3433642581949243e-06
. O 0 1.2950324617122533e-06

Previous O 0 7.711802027188241e-06
findings O 0 4.730640910111106e-07
in O 0 6.217366887995013e-08
Caucasian O 0 1.9921732530292502e-07
populations O 0 2.499586981841162e-09
of O 0 7.248416977745364e-08
a O 0 8.307623602377134e-07
DM B-Disease 1 1.0
founder O 1 0.9999992847442627
chromosome O 0 1.0309738627256593e-06
raise O 0 6.750354941686965e-08
a O 0 1.4335021170097662e-08
question O 0 6.954423259486475e-09
about O 0 1.0347184220549366e-09
the O 0 1.6675819614064835e-09
molecular O 0 4.5821611394103456e-08
events O 0 6.4088054863020716e-09
involved O 0 5.9698592735912825e-09
in O 0 4.127257646757698e-09
the O 0 1.787619119397732e-08
expansion O 0 5.866287438038853e-07
mutation O 0 4.918323384117684e-07
. O 0 5.251785637483408e-07

To O 0 5.546365855479962e-07
investigate O 0 7.621737836416287e-07
whether O 0 5.238534939167039e-08
a O 0 7.463501816573626e-08
founder O 0 2.3187607439467683e-05
chromosome O 0 4.8468216107266926e-08
for O 0 6.490648907231389e-09
the O 0 2.4960894506875775e-07
DM B-Disease 1 1.0
mutation O 0 1.0767446667614422e-07
exists O 0 7.655062361777709e-09
in O 0 3.1126969890493683e-09
the O 0 2.3595030373968484e-09
Japanese O 0 2.3448247787882792e-08
population O 0 2.4982033108855717e-10
, O 0 7.905637255944953e-10
we O 0 7.292438319872474e-10
genotyped O 0 2.440089019728475e-07
families O 0 1.928548293284038e-10
using O 0 1.878979638547662e-09
polymorphic O 0 1.0106536763032636e-07
markers O 0 4.113734917154943e-07
near O 0 6.14704276813427e-07
the O 0 6.656915019220833e-08
( O 0 1.2195903309475398e-07
CTG O 0 0.15754251182079315
) O 0 4.73878181139753e-08
n O 0 4.161304545391431e-08
repeat O 0 1.0138818851146425e-07
region O 0 4.3216861200789936e-08
and O 0 3.432397477354243e-08
constructed O 0 1.1684129276545718e-05
haplotypes O 0 1.1229142728552688e-05
. O 0 1.287183067688602e-06

Six O 0 2.010938260355033e-06
different O 0 1.4618507293562288e-08
haplotypes O 0 4.355723319804383e-07
were O 0 6.925067452812073e-08
found O 0 3.76026427773013e-08
and O 0 1.4903582723491127e-07
DM B-Disease 1 1.0
alleles O 0 1.4307329365692567e-07
were O 0 1.7697227860935527e-07
always O 0 1.7658888395999384e-07
haplotype O 0 2.8538245260278927e-06
A O 0 1.2670925571001135e-05
. O 0 2.36451523960568e-06

To O 0 4.532363391263061e-07
find O 0 2.0755381413550822e-08
an O 0 9.54227807881125e-10
origin O 0 1.3708889579078232e-09
of O 0 1.566429652655188e-08
the O 0 3.059278341766003e-08
( O 0 3.5481210858279155e-08
CTG O 0 0.033709634095430374
) O 0 5.480759401876867e-09
n O 0 1.1060503624094054e-08
repeat O 0 1.8363785159181134e-08
mutation O 0 2.7936863933319955e-09
and O 0 1.289841788931767e-09
to O 0 9.017093738350468e-10
investigate O 0 1.4289515348764326e-08
the O 0 4.006406761902781e-09
mechanism O 0 1.0285227780570949e-08
of O 0 1.5495686511712847e-08
the O 0 4.054290680954864e-09
expansion O 0 1.78396444283635e-08
mutation O 0 1.6566004124030087e-09
in O 0 6.736561308784417e-10
the O 0 1.0893217439189584e-09
Japanese O 0 2.4260133457687516e-08
population O 0 8.15356671068912e-11
we O 0 5.677707609619276e-11
have O 0 5.276763748174318e-11
studied O 0 3.1949493717320365e-08
90 O 0 4.311575807491863e-08
Japanese O 0 4.171582986600697e-06
DM B-Disease 1 1.0
families O 0 2.483800187746965e-08
comprising O 0 8.943381146764295e-08
190 O 0 1.498744808259289e-07
affected O 0 3.2505962366258245e-08
and O 0 2.8163080756371528e-08
130 O 0 4.049864514854562e-07
unaffected O 0 2.353231366214459e-06
members O 0 1.2466965415569575e-07
. O 0 9.642590157454833e-07

The O 0 4.291108780307695e-06
results O 0 3.46626990221921e-07
suggest O 0 4.28801385510269e-08
that O 0 9.81327352711503e-10
a O 0 4.755122073873963e-09
few O 0 4.340916515133131e-09
common O 0 7.681638436451976e-09
ancestral O 0 1.5036638956189563e-07
mutations O 0 4.814258325325227e-09
in O 0 6.908376537495542e-09
both O 0 5.739000386029147e-09
Caucasian O 0 2.4866571379789093e-07
and O 0 5.678742365233802e-09
Japanese O 0 1.5269370123860426e-07
populations O 0 1.5010735987530666e-09
have O 0 9.351321106354504e-11
originated O 0 2.754784400593735e-09
by O 0 2.194897458229761e-10
expansion O 0 9.146806867477153e-09
of O 0 1.0482226642238857e-08
an O 0 1.8196902873413023e-09
ancestral O 0 1.1051019299657128e-07
n O 0 3.0847900234221015e-08
= O 0 1.579233099846533e-08
5 O 0 3.1114762322204115e-08
repeat O 0 3.9433928122889483e-08
to O 0 6.217435455369014e-09
n O 0 3.572540663299151e-08
= O 0 5.8710110550919126e-08
19 O 0 3.3966566093113215e-07
- O 0 4.148827201788663e-07
37 O 0 2.3056692555201153e-07
copies O 0 3.4845655250137497e-07
. O 0 3.838747204554238e-07

These O 0 2.722985925629473e-07
data O 0 1.9444162546733423e-07
support O 0 2.0714567838808762e-08
multistep O 0 3.502393326471065e-07
models O 0 1.931980335712069e-07
of O 0 4.581737584885559e-07
triplet O 0 8.991133654490113e-06
repeat O 0 3.859811101847299e-07
expansion O 0 1.4521997115934937e-07
that O 0 5.333247732330904e-10
have O 0 9.535468248333956e-11
been O 0 2.4355895078542744e-10
proposed O 0 7.076382813053783e-10
for O 0 1.7938380780790908e-09
both O 0 5.5903630169495955e-08
DM B-Disease 1 1.0
and O 0 1.505847194493981e-05
Friedreichs B-Disease 1 0.9999970197677612
ataxia I-Disease 1 0.9999101161956787
. O 0 7.698149602219928e-06
. O 0 5.761070042353822e-06

The O 0 9.135796972259413e-07
molecular O 0 8.248870813076792e-07
basis O 0 2.6217409754281107e-07
of O 0 0.016379907727241516
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 9.050528859688711e-08
the O 0 3.170636375671165e-08
western O 0 1.068320543140544e-07
Cape O 0 1.475002591178054e-06
, O 0 1.7419012010577717e-08
South O 0 4.2553017465252196e-07
Africa O 0 3.50185217712351e-07
. O 0 4.058207707657857e-07

Deficiency B-Disease 1 0.9999867677688599
of I-Disease 0 9.071826934814453e-05
the I-Disease 0 6.258977919060271e-06
sixth I-Disease 0 0.018509401008486748
component I-Disease 0 1.302845362260996e-06
of I-Disease 0 3.4239172919114935e-07
human I-Disease 0 2.5088592536803844e-08
complement I-Disease 0 1.678676255778555e-07
( O 0 1.3316680735897535e-07
C6 O 1 0.9997232556343079
) O 0 9.389792943181874e-09
has O 0 5.543193681845082e-10
been O 0 5.176540862628087e-10
reported O 0 1.261978188615842e-09
in O 0 7.389892031639533e-10
a O 0 4.15071810255796e-10
number O 0 2.8008773078624927e-10
of O 0 4.5279628935190885e-09
families O 0 1.7739969215835316e-10
from O 0 8.171978649329503e-09
the O 0 1.0294668228993942e-08
western O 0 1.1342687145088348e-07
Cape O 0 3.3148651255032746e-06
, O 0 3.5199924752760126e-08
South O 0 4.5297144879441475e-07
Africa O 0 4.829187219002051e-07
. O 0 3.179924306095927e-07

Meningococcal B-Disease 1 1.0
disease I-Disease 1 0.9999980926513672
is O 0 1.7128351714745804e-07
endemic O 0 4.259621846358641e-07
in O 0 2.6275221998162124e-08
the O 0 5.447432727123669e-08
Cape O 0 2.043015001618187e-06
and O 0 4.562840771882293e-09
almost O 0 2.2911963437621807e-09
all O 0 1.17205578575863e-09
pedigrees O 0 5.352064391672684e-08
of O 0 9.72648237507201e-08
total O 0 9.60910529101966e-06
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 2.4246259272331372e-05
C6Q0 O 1 1.0
) O 0 3.860708730485385e-08
have O 0 8.877906187976237e-10
been O 0 1.249051750917829e-09
ascertained O 0 6.672398455975781e-08
because O 0 1.270960048316283e-08
of O 0 1.4470128917309921e-06
recurrent O 1 0.9999997615814209
disease O 1 0.9999957084655762
. O 0 4.845147941523464e-06

We O 0 3.028713422281726e-07
have O 0 4.380957818739262e-09
sequenced O 0 1.830390630175316e-07
the O 0 1.4204649900761979e-08
expressed O 0 8.104023230259827e-09
exons O 0 2.505610154912574e-07
of O 0 1.314653417239242e-07
the O 0 2.3545598537566548e-07
C6 O 1 0.9992358684539795
gene O 0 2.5379147672310864e-08
from O 0 3.898326106366312e-09
selected O 0 9.064052619578433e-09
cases O 0 1.1596896776211452e-09
and O 0 1.3676766386083727e-09
have O 0 3.8652361866731155e-10
found O 0 5.380413004019147e-09
three O 0 8.391148220709965e-09
molecular O 0 0.0001880498748505488
defects O 1 0.9990119934082031
leading O 0 9.720502021082211e-06
to O 0 6.148003706130112e-08
total O 0 9.129673799179727e-07
deficiency O 1 0.9992663264274597
879delG O 0 0.002052426803857088
, O 0 3.247825830499096e-08
which O 0 3.2494231749780056e-09
is O 0 7.657993683629627e-10
the O 0 1.647739167331963e-09
common O 0 1.9828622299655763e-08
defect O 0 6.674574706266867e-07
in O 0 1.3432875256569332e-08
the O 0 4.693293931268272e-08
Cape O 0 1.1469907121863798e-06
and O 0 6.4888787676409265e-09
hitherto O 0 9.849660642657909e-08
unreported O 0 1.5722147850283363e-07
, O 0 4.726972147039987e-09
and O 0 4.483275972688716e-09
1195delC O 0 4.858293891629728e-07
and O 0 3.325175867985308e-08
1936delG O 0 2.9739815090579214e-06
, O 0 1.2936071769331647e-08
which O 0 1.7871921720313821e-09
have O 0 2.472010651732859e-10
been O 0 1.1594442073104005e-09
previously O 0 9.10034358980738e-09
reported O 0 5.575899297838305e-09
in O 0 5.591074714317301e-09
African O 0 1.0566437680381568e-07
- O 0 1.6581888075961615e-06
Americans O 0 4.930571506633896e-08
. O 0 3.3459005521763174e-07

We O 0 4.96360655688477e-07
also O 0 2.69127937713165e-08
show O 0 1.7555228382093446e-08
that O 0 4.814522114315878e-10
the O 0 7.11970971067899e-09
879delG O 0 1.3031659591433709e-06
and O 0 4.90385119178427e-08
1195delC O 0 0.0002852205652743578
defects O 0 0.00040478643495589495
are O 0 3.376082302608552e-09
associated O 0 9.174171822223798e-08
with O 0 1.0952164331001768e-07
characteristic O 0 0.08542285114526749
C6 O 1 1.0
/ O 1 0.9999533891677856
C7 O 1 0.9999984502792358
region O 0 5.442893211693445e-07
DNA O 0 3.1887509521766333e-06
marker O 0 1.6333015082636848e-06
haplotypes O 0 3.0262506811595813e-07
, O 0 1.2615409161753632e-08
although O 0 2.7862046003690466e-09
small O 0 2.0713608606115486e-09
variations O 0 4.7077108433768444e-08
were O 0 3.8486586362296293e-08
observed O 0 3.4965560757882486e-07
. O 0 6.035827482264722e-07

The O 0 2.2134025130071677e-05
1936delG O 0 0.0009771622717380524
defect O 0 0.000441847019828856
was O 0 3.260020548623288e-06
observed O 0 1.447455844072465e-07
only O 0 8.4325106897154e-09
once O 0 2.0255335186902812e-08
in O 0 5.1071578077710456e-09
the O 0 1.338448640808565e-08
Cape O 0 9.809442644836963e-07
, O 0 2.636094675878553e-09
but O 0 3.357611966237073e-10
its O 0 8.677230045606166e-10
associated O 0 3.880183285787098e-08
haplotype O 0 3.126685612642177e-07
could O 0 1.6419987147742177e-08
be O 0 2.7713552341879222e-08
deduced O 0 2.6013931346824393e-06
. O 0 1.0843554036910064e-06

The O 0 1.2564089502120623e-06
data O 0 2.1825806584274687e-07
from O 0 2.5889976384974034e-08
the O 0 1.75758660958536e-08
haplotypes O 0 5.318797491327132e-08
indicate O 0 3.626321021243939e-09
that O 0 2.791469277951819e-10
these O 0 2.669187093573555e-10
three O 0 5.6025184491659274e-09
molecular O 0 9.43458144320175e-06
defects O 0 3.518236189847812e-05
account O 0 1.059693044425103e-08
for O 0 1.4775373813336046e-08
the O 0 2.5401044467798783e-07
defects O 0 0.0002296152524650097
in O 0 2.9597467587905157e-08
all O 0 2.9586220140487285e-09
the O 0 1.0444028752942813e-08
38 O 0 8.659993255832887e-08
unrelated O 0 2.983111357934831e-07
C6Q0 O 1 0.9818477630615234
individuals O 0 7.695682979758089e-10
we O 0 1.2791355752383993e-09
have O 0 3.619630151163733e-10
studied O 0 6.045141276445065e-08
from O 0 2.1819975160042304e-08
the O 0 1.0366018443619396e-07
Cape O 0 1.3300019418238662e-05
. O 0 7.302842277567834e-07

We O 0 3.7355061976995785e-07
have O 0 5.57265611433877e-09
also O 0 2.752358119195719e-09
observed O 0 8.269347873124389e-09
the O 0 1.8733409490323538e-08
879delG O 0 6.958194262551842e-06
defect O 0 1.646573423386144e-06
in O 0 5.584853113305144e-08
two O 0 4.4196344362035234e-08
Dutch O 1 0.9989266991615295
C6 B-Disease 1 1.0
- I-Disease 1 0.9999971389770508
deficient I-Disease 1 0.9999998807907104
kindreds O 0 0.00010064699017675593
, O 0 3.8695478821182405e-08
but O 0 2.75503664326493e-09
the O 0 1.3394293674195978e-08
879delG O 0 5.815048098156694e-06
defect O 0 2.4963067062344635e-06
in O 0 4.523649010934605e-08
the O 0 1.6409443048814865e-07
Cape O 0 7.144455139496131e-06
probably O 0 5.520177381868052e-08
did O 0 3.368582301987999e-09
not O 0 4.658933239198859e-10
come O 0 2.065057014277727e-09
from O 0 1.0700719421663507e-08
The O 0 3.1961072011199576e-08
Netherlands O 0 2.679141744010849e-06
. O 0 3.952647276150856e-08
. O 0 2.442147035708331e-07

Complement B-Disease 1 0.9999979734420776
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 3.240121714043198e-06
seven O 0 4.519156391324941e-07
further O 0 5.248455892115089e-08
molecular O 0 0.0006984812789596617
defects O 1 0.83610999584198
and O 0 8.974446785714463e-08
their O 0 6.970189048161046e-08
associated O 0 7.771662353661668e-07
marker O 0 3.749558163690381e-05
haplotypes O 0 1.5218213775369804e-05
. O 0 1.999269898078637e-06

Seven O 0 5.5905775298015215e-06
further O 0 1.6095171417873644e-07
molecular O 0 2.2180602172738872e-06
bases O 0 5.181760570849292e-06
of O 1 0.7563162446022034
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 7.468484568562417e-07
described O 0 5.336155027180212e-06
. O 0 1.865843614723417e-06

All O 0 2.767346813925542e-07
these O 0 1.2871097077038485e-08
new O 0 1.2019977191357611e-07
molecular O 0 3.67513821402099e-05
defects O 0 0.00019106094259768724
involve O 0 2.0530255540052167e-07
single O 0 2.92987522243493e-07
- O 0 4.3870477384189144e-07
nucleotide O 0 7.879872043758951e-08
events O 0 4.2290693613722397e-08
, O 0 7.613969899011863e-09
deletions O 0 4.566125610949712e-08
and O 0 5.9854681211390925e-09
substitutions O 0 2.0702310621345532e-07
, O 0 5.562101446088263e-09
some O 0 3.1381083842596524e-10
of O 0 1.2488189149451046e-08
which O 0 2.435534884881463e-09
alter O 0 3.857690700215244e-08
splice O 0 1.2392988537612837e-06
sites O 0 8.459965528118119e-08
, O 0 2.6028116550946834e-08
and O 0 2.2308084268729544e-08
others O 0 5.0168690535201677e-08
codons O 0 3.9633446249354165e-06
. O 0 1.709541720629204e-06

They O 0 1.631617294606258e-07
are O 0 2.8947420016578462e-09
distributed O 0 4.099875106078343e-09
along O 0 1.4209554421995563e-08
the O 0 5.117594170656048e-08
C7 O 1 0.9993847608566284
gene O 0 1.1551442469226458e-07
, O 0 4.772067185854212e-09
but O 0 5.741143671578186e-10
predominantly O 0 2.2281241296440157e-09
towards O 0 5.161203020520588e-09
the O 0 2.0638140085793566e-08
3 O 0 4.319123547702475e-07
end O 0 5.890763645766128e-07
. O 0 5.766846129517944e-07

All O 0 5.709610491066996e-07
were O 0 1.4482276355920476e-07
found O 0 6.167711319449154e-08
in O 0 1.8566646886597482e-08
compound O 0 1.1440508842497366e-06
heterozygous O 0 2.0695183877705858e-07
individuals O 0 2.171033663955768e-08
. O 0 8.316422395182599e-07

The O 0 0.0009448527125641704
C6 O 1 1.0
/ O 1 0.999901294708252
C7 O 1 0.9999983310699463
marker O 0 0.00012061973393429071
haplotypes O 0 8.79073195392266e-06
associated O 0 4.7570750894010416e-07
with O 0 5.9544191799432156e-08
most O 0 2.0225859316269634e-06
C7 B-Disease 1 1.0
defects I-Disease 1 0.999956488609314
are O 0 2.9366354681314988e-08
tabulated O 0 4.054605142300716e-06
. O 0 1.7324867940260447e-07
. O 0 7.942694537632633e-07

A O 0 0.00010695842502173036
genome O 0 2.521258238630253e-06
- O 0 3.003183792316122e-06
wide O 0 7.112708999557071e-08
search O 0 1.266724769521943e-08
for O 0 4.241782924907511e-09
chromosomal O 0 2.5332728910143487e-06
loci O 0 1.125637595578155e-06
linked O 0 5.285764927975833e-06
to O 0 2.505454972379084e-07
mental O 1 0.999998927116394
health O 0 0.00020085510914213955
wellness O 0 0.0017444262048229575
in O 0 5.2825221530383715e-08
relatives O 0 5.175015971303765e-08
at O 0 9.975623243008158e-07
high O 0 1.1255924619035795e-06
risk O 0 7.907242860483166e-08
for O 0 6.509477543659159e-07
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
among O 0 3.5095590646960773e-06
the O 0 1.9045247654503328e-06
Old O 0 4.372602779767476e-05
Order O 0 1.5089992757566506e-06
Amish O 0 0.00012722137034870684
. O 0 2.4018427211558446e-06

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 0.9999896287918091
BPAD B-Disease 1 1.0
; O 1 0.9842915534973145
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 2.5564759198459797e-05
is O 0 6.08307999527824e-08
characterized O 0 5.1629680086762164e-08
by O 0 7.2273609319495336e-09
episodes O 0 3.704874131926772e-07
of O 0 7.055270430100791e-07
mania B-Disease 0 0.1174011155962944
and O 0 3.868607620916009e-07
/ O 0 0.0007914426387287676
or O 0 1.4132098158370354e-06
hypomania B-Disease 1 0.9961605072021484
interspersed O 0 4.86932822241215e-06
with O 0 1.6102395861139485e-08
periods O 0 1.8394637208984932e-06
of O 0 4.769006045535207e-05
depression B-Disease 1 0.9999573230743408
. O 0 7.598313004564261e-06

Compelling O 0 1.0509598723729141e-05
evidence O 0 1.8546138562669512e-06
supports O 0 1.415921246916696e-07
a O 0 1.552251482905831e-08
significant O 0 2.8154703457516916e-08
genetic O 0 1.3538958398839895e-07
component O 0 1.5816075915608963e-07
in O 0 1.8202745977191626e-08
the O 0 4.342119197531247e-08
susceptibility O 0 8.728661669010762e-07
to O 0 3.149402800772805e-07
develop O 0 0.00021156054572202265
BPAD B-Disease 1 1.0
. O 0 3.1405146728502586e-05

To O 0 1.4045862428702094e-07
date O 0 8.816715535431285e-07
, O 0 1.4608751541800302e-08
however O 0 3.2757456747134484e-09
, O 0 1.3605008231110105e-09
linkage O 0 5.113759371511151e-08
studies O 0 6.880052083602095e-09
have O 0 1.846259534143968e-10
attempted O 0 2.185108627372756e-08
only O 0 8.202925561029417e-10
to O 0 1.380334513356729e-09
identify O 0 2.9382208666106635e-08
chromosomal O 0 2.1827318050782196e-06
loci O 0 4.6740962034164113e-07
that O 0 8.662136785630992e-09
cause O 0 1.484748821667381e-07
or O 0 2.3997532849762138e-08
increase O 0 5.862034413439687e-09
the O 0 3.157371608608628e-08
risk O 0 4.832319788761197e-08
of O 0 3.816942637513421e-07
developing O 0 9.8163227448822e-06
BPAD B-Disease 1 1.0
. O 0 4.162855475442484e-06

To O 0 2.491028965323494e-07
determine O 0 1.5240912887293234e-07
whether O 0 2.780652685885343e-08
there O 0 7.593738082789514e-09
could O 0 5.399401370453916e-09
be O 0 2.3942838822677004e-09
protective O 0 1.0436858701723395e-06
alleles O 0 1.5248747819995856e-09
that O 0 3.010501570255286e-10
prevent O 0 3.07068965810231e-08
or O 0 1.3477838400888231e-08
reduce O 0 2.750548944163711e-08
the O 0 1.3468792303683585e-08
risk O 0 5.7106430695341714e-09
of O 0 4.378562934448382e-08
developing O 0 2.192453621319146e-06
BPAD B-Disease 1 1.0
, O 0 8.340741430856724e-09
similar O 0 1.0534130234773897e-09
to O 0 1.542472927162919e-09
what O 0 1.91451232645079e-09
is O 0 4.710059009482848e-10
observed O 0 2.733722137548966e-09
in O 0 1.3815725230514886e-09
other O 0 1.856253994958479e-08
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 7.354309445872786e-07
we O 0 1.1705774127790392e-08
used O 0 2.4084573624350014e-07
mental O 1 0.997858464717865
health O 0 5.528694237000309e-05
wellness O 1 0.6137994527816772
( O 0 9.33846493467172e-08
absence O 0 8.13321378245746e-07
of O 0 5.09758422140294e-07
any O 0 2.836140993167646e-07
psychiatric B-Disease 1 1.0
disorder I-Disease 1 1.0
) O 0 9.645012255532492e-08
as O 0 2.0675017253779515e-08
the O 0 3.074792331858589e-08
phenotype O 0 4.906096506829272e-08
in O 0 1.0720739851421968e-08
our O 0 1.8497122056260196e-08
genome O 0 4.8188358192646774e-08
- O 0 4.6964194666543335e-07
wide O 0 2.2878616334764956e-07
linkage O 0 3.369034686784289e-07
scan O 0 4.5717291641267366e-07
of O 0 7.004199886750939e-08
several O 0 1.608833599675563e-08
large O 0 6.450147083114643e-08
multigeneration O 0 9.490032971370965e-05
Old O 0 3.380673661013134e-06
Order O 0 1.3513391650121775e-07
Amish O 0 5.098910150991287e-06
pedigrees O 0 9.101481737161521e-07
exhibiting O 0 3.4342710364398954e-07
an O 0 1.5069780090470886e-08
extremely O 0 4.0878686036194267e-07
high O 0 1.2756328942487016e-05
incidence O 0 1.2870190403191373e-05
of O 0 1.6882375348359346e-05
BPAD B-Disease 1 1.0
. O 0 1.2119362509110942e-05

We O 0 3.9334400980806095e-07
have O 0 1.2696129481071239e-08
found O 0 1.991469922302258e-08
strong O 0 9.760264596536672e-09
evidence O 0 1.6848535011604326e-08
for O 0 2.8388282835578593e-09
a O 0 1.1320377524270953e-08
locus O 0 9.284969593181813e-08
on O 0 1.393890869394454e-07
chromosome O 0 5.567261496253195e-07
4p O 0 0.0002647500659804791
at O 0 3.513403726174147e-06
D4S2949 O 0 7.0371261244872585e-06
( O 0 2.3858426345668704e-08
maximum O 0 1.2622176370769012e-07
GENEHUNTER O 0 0.32324254512786865
- O 0 4.665070264309179e-06
PLUS O 0 4.244733190716943e-06
nonparametric O 0 4.2187475628452376e-06
linkage O 0 1.2650583585127606e-06
score O 0 3.6731026398229005e-07
= O 0 4.392372687789248e-08
4 O 0 8.913376348118618e-08
. O 0 4.516138130128411e-09
05 O 0 3.375696223884006e-06
, O 0 1.0567502428671105e-08
P O 0 1.0081063237521448e-06
= O 0 3.646297841441992e-08
5 O 0 2.210056493368029e-08
. O 0 1.4018095573220535e-09
22 O 0 7.385259959136192e-09
x O 0 1.0188208499073426e-08
10 O 0 1.5000210851212614e-08
( O 0 2.4782480512186567e-09
- O 0 4.89216382959512e-08
4 O 0 6.788612694208496e-08
) O 0 2.003187171695231e-09
; O 0 3.5256413344342263e-09
SIBPAL O 0 0.0002062223938992247
Pempirical O 0 5.072995008958969e-06
value O 0 1.5429622024498713e-08
< O 0 7.41825658678863e-08
3 O 0 3.054648800571158e-08
x O 0 2.1222835044909516e-08
10 O 0 1.773562274820506e-08
( O 0 1.541490712853033e-09
- O 0 4.9622144615568686e-08
5 O 0 2.668716447828956e-08
) O 0 1.5278734943890981e-09
) O 0 4.5649364843747264e-10
and O 0 6.90134005498777e-10
suggestive O 0 5.1485912422322144e-08
evidence O 0 1.2985266195641998e-08
for O 0 1.8539355606250751e-09
a O 0 1.245165570651352e-08
locus O 0 1.8904702869804169e-07
on O 0 1.4859062957839342e-07
chromosome O 0 1.0484154699952342e-06
4q O 0 0.0001331014500465244
at O 0 2.1468351860676194e-06
D4S397 O 0 7.99661302153254e-06
( O 0 2.540578591947451e-08
maximum O 0 1.0208364642494416e-07
GENEHUNTER O 0 0.09719152003526688
- O 0 3.450074700594996e-06
PLUS O 0 3.3655899187579053e-06
nonparametric O 0 2.217506107626832e-06
linkage O 0 6.555515597028716e-07
score O 0 1.0019054030863117e-07
= O 0 2.665582954364254e-08
3 O 0 3.038998741544674e-08
. O 0 1.447820308086989e-09
29 O 0 6.575520927754042e-08
, O 0 5.647180945089758e-09
P O 0 4.731669491775392e-07
= O 0 2.112949282206955e-08
2 O 0 2.1993123766606004e-08
. O 0 6.115018491570368e-10
57 O 0 9.324471861305028e-09
x O 0 1.6522655243988993e-08
10 O 0 1.1908838359886431e-08
( O 0 3.3684923739230044e-09
- O 0 6.142307285017523e-08
3 O 0 4.5518298463775864e-08
) O 0 2.2685060496741016e-09
; O 0 2.841255009045085e-09
SIBPAL O 0 0.00025188946165144444
Pempirical O 0 3.4228767162858276e-06
value O 0 8.008234075873588e-09
< O 0 7.02997766666158e-08
1 O 0 1.3689143152362249e-08
x O 0 2.3131525139774567e-08
10 O 0 2.0214811158325574e-08
( O 0 6.184602163727959e-09
- O 0 1.3475310822741449e-07
3 O 0 1.0553285534342649e-07
) O 0 2.187392711405778e-09
) O 0 4.0218323116292254e-10
that O 0 5.182109602541729e-11
are O 0 1.3404964638308314e-10
linked O 0 8.351108249371464e-08
to O 0 6.77377727242856e-08
mental O 1 0.9999992847442627
health O 1 0.6803945302963257
wellness O 1 0.9985740184783936
. O 0 7.061651558615267e-06

These O 0 2.734261386194703e-07
findings O 0 2.483223227045528e-07
are O 0 3.09646064344804e-09
consistent O 0 2.633814233377052e-08
with O 0 1.3725948155851597e-09
the O 0 3.772071988095149e-09
hypothesis O 0 1.3321376002295438e-08
that O 0 7.884400077262654e-11
certain O 0 6.805161434364493e-10
alleles O 0 1.4088591404615158e-09
could O 0 4.126029740092463e-09
prevent O 0 3.781994450946513e-08
or O 0 9.680173107540213e-09
modify O 0 7.401579438237604e-08
the O 0 5.180734419241162e-08
clinical O 0 8.094941676972667e-07
manifestations O 0 2.2522535800817423e-05
of O 0 0.0001883879886008799
BPAD B-Disease 1 1.0
and O 0 2.0268288380975719e-07
perhaps O 0 2.070666660358711e-08
other O 0 1.3038053303660035e-08
related O 0 0.00020255638810340315
affective B-Disease 1 1.0
disorders I-Disease 1 1.0
. O 0 0.00023694185074418783

Segregation O 1 0.5316564440727234
distortion O 1 0.7962842583656311
in O 0 0.0010690470226109028
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0018314664484933019

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999885559082031
DM B-Disease 1 1.0
) O 0 7.577963515359443e-06
is O 0 1.595044274438351e-08
an O 0 1.0860734533935101e-08
autosomal B-Disease 1 0.9095249772071838
dominant I-Disease 1 0.9999979734420776
disease I-Disease 1 0.9999990463256836
which O 0 3.050730157383441e-08
, O 0 5.547458936661087e-09
in O 0 3.5546694476806806e-09
the O 0 7.363865517362456e-09
typical O 0 1.0715796605609285e-07
pedigree O 0 6.694993999190046e-07
, O 0 1.381241165887559e-08
shows O 0 1.7293412923891083e-08
a O 0 8.884110336282447e-09
three O 0 2.206114402270032e-08
generation O 0 2.430136419206974e-06
anticipation O 0 2.224652052973397e-05
cascade O 0 0.005439394153654575
. O 0 5.9997287280566525e-06

This O 0 1.6396255375639157e-07
results O 0 2.0687410540176643e-07
in O 0 2.431310974770895e-07
infertility B-Disease 1 0.992334246635437
and O 1 0.9898942112922668
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9972792267799377
CDM B-Disease 1 0.9999998807907104
) O 0 9.309120940770299e-08
with O 0 9.748208462667662e-09
the O 0 3.479155452623672e-08
disappearance O 0 3.182754824138101e-07
of O 0 2.550153567426605e-06
DM B-Disease 1 1.0
in O 0 1.6751961311456398e-06
that O 0 6.693480969488519e-08
pedigree O 0 9.708644029160496e-06
. O 0 1.4610919834012748e-06

The O 0 7.701731874476536e-07
concept O 0 3.261732501869119e-07
of O 0 5.796803748125967e-07
segregation O 0 4.706436811829917e-05
distortion O 0 5.286705709295347e-05
, O 0 8.34584934494842e-09
where O 0 1.6338812525162894e-09
there O 0 3.968703699008813e-10
is O 0 3.9217862290996663e-10
preferential O 0 4.970955647110031e-09
transmission O 0 9.457234284582228e-08
of O 0 1.6752050413515462e-08
the O 0 9.73912062107729e-09
larger O 0 5.514049661314857e-09
allele O 0 8.38778824174824e-09
at O 0 5.835843097656834e-08
the O 0 1.222826853108927e-07
DM B-Disease 1 1.0
locus O 0 1.5745405335110263e-06
, O 0 1.0968487451634701e-08
has O 0 1.473978716859392e-09
been O 0 2.0224673047408714e-09
put O 0 1.2239290470006381e-08
forward O 0 6.815166653240112e-09
to O 0 4.3077923450596245e-09
explain O 0 2.9152110059271763e-08
partially O 0 5.298182941260166e-07
the O 0 4.6585469704041316e-08
maintenance O 0 4.3233030737610534e-05
of O 0 8.453773261862807e-06
DM B-Disease 1 1.0
in O 0 3.414851903471572e-07
the O 0 7.32491187704909e-08
population O 0 7.74134001346738e-09
. O 0 1.378906944182745e-07

In O 0 1.0548058071435662e-06
a O 0 9.105434628509101e-08
survey O 0 1.0909299419381568e-07
of O 0 8.481217719236156e-07
DM B-Disease 1 1.0
in O 0 2.9095596687511716e-07
Northern O 0 7.911827424322837e-07
Ireland O 0 8.449900406048982e-07
, O 0 3.307470919367006e-08
59 O 0 3.547489200173004e-07
pedigrees O 0 9.715893156680977e-07
were O 0 3.312746628125751e-07
ascertained O 0 1.6789268556749448e-05
. O 0 2.7134019546792842e-06

Sibships O 0 0.0019007762894034386
where O 0 3.149715155359445e-07
the O 0 1.5999225055907118e-08
status O 0 2.083828398724563e-08
of O 0 1.3380045515987149e-08
all O 0 9.838311276766376e-10
the O 0 2.117822139879877e-09
members O 0 4.787298890640557e-10
had O 0 1.7600045865151515e-09
been O 0 6.788697382020814e-10
identified O 0 1.102767988037101e-09
were O 0 1.6522457846335215e-09
examined O 0 2.28040253347217e-08
to O 0 1.0092080504620071e-09
determine O 0 4.971685729771025e-09
the O 0 2.3165345197639908e-08
transmission O 0 2.9096568709974235e-07
of O 0 1.3129142928391957e-07
the O 0 3.235247731936397e-07
DM B-Disease 1 1.0
expansion O 0 1.5886597566350247e-06
from O 0 4.202141568043771e-08
affected O 0 1.0460216692820268e-08
parents O 0 1.5485100979262256e-09
to O 0 4.458409641472372e-09
their O 0 1.520403181132224e-08
offspring O 0 1.9287360828457167e-06
. O 0 1.1779167152781156e-06

Where O 0 3.4979409520019544e-06
the O 0 4.253565180079022e-07
transmitting O 0 3.25694345519878e-05
parent O 0 1.8118628304364393e-06
was O 0 2.2353353870130377e-06
male O 0 2.915959953497804e-07
, O 0 7.119088252238726e-08
58 O 0 2.566176817708765e-06
. O 0 6.253378046494618e-07

3 O 0 3.1656863939133473e-06
% O 0 2.689109024345271e-08
of O 0 2.5172138151674517e-08
the O 0 5.19262233211748e-09
offspring O 0 8.764979853026489e-09
were O 0 5.178558026841529e-09
affected O 0 7.569587623379448e-09
, O 0 2.907723839484788e-09
and O 0 2.0385473309403324e-09
in O 0 3.078710841819543e-09
the O 0 3.854092600619197e-09
case O 0 2.5582918006250566e-09
of O 0 8.557710096113169e-09
a O 0 9.484615759447479e-09
female O 0 1.771912216952387e-08
transmitting O 0 4.217673904349795e-06
parent O 0 5.18414481120999e-07
, O 0 1.6720518658530636e-07
68 O 0 1.3404869605437852e-05
. O 0 9.635227797843982e-07

7 O 0 2.323181070096325e-05
% O 0 2.3245308966579614e-07
were O 0 1.6520803569619602e-07
affected O 0 5.37410755896417e-07
. O 0 5.128259772391175e-07

Studies O 0 3.8307084651023615e-06
on O 0 9.281044413000927e-07
meiotic O 0 6.503889744635671e-05
drive O 0 1.663080979596998e-06
in O 0 3.581598377877526e-07
DM B-Disease 1 1.0
have O 0 1.2514870917357257e-08
shown O 0 4.694025612650421e-09
increased O 0 1.7058451318163748e-09
transmission O 0 4.220672522592395e-08
of O 0 1.2672805915769914e-08
the O 0 2.3754340716664046e-09
larger O 0 1.649550274152034e-09
allele O 0 2.529634723913432e-09
at O 0 2.063101511851073e-08
the O 0 4.531680630748269e-08
DM B-Disease 1 1.0
locus O 0 2.6158966193179367e-07
in O 0 2.1682197370864742e-08
non O 0 1.182248888653703e-05
- O 0 0.0019430704414844513
DM O 1 1.0
heterozygotes O 0 1.8256525436299853e-05
for O 0 7.342115964092955e-07
CTGn O 0 0.01081638690084219
. O 0 7.325635579036316e-06

This O 0 2.1154399121314782e-07
study O 0 6.034623822870344e-08
provides O 0 7.580047700628256e-09
further O 0 2.63789523557989e-09
evidence O 0 1.0027079611063527e-08
that O 0 5.838308725358843e-10
the O 0 7.364318577174345e-08
DM B-Disease 1 1.0
expansion O 0 2.683202183106914e-06
tends O 0 3.489662958600093e-08
to O 0 5.063848451669628e-09
be O 0 1.2943722538238944e-08
transmitted O 0 3.834038579952903e-07
preferentially O 0 1.3452638540911721e-06
. O 0 9.510567338111287e-07

Diagnosis O 1 0.9999676942825317
of O 1 0.9998388290405273
hemochromatosis B-Disease 1 1.0
. O 0 0.000908812100533396

If O 0 4.378511221148074e-05
untreated O 1 1.0
, O 0 0.11587793380022049
hemochromatosis B-Disease 1 1.0
can O 0 5.186639555176953e-06
cause O 1 0.9919261336326599
serious O 1 0.9999964237213135
illness O 1 0.9999982118606567
and O 0 1.4104185197538754e-07
early B-Disease 0 1.0797858749356237e-06
death I-Disease 0 2.52767426900391e-06
, O 0 7.83916842550525e-09
but O 0 1.5211680803872696e-09
the O 0 5.969770455749313e-08
disease O 0 0.06968139111995697
is O 0 6.318960465989676e-09
still O 0 7.959458869777336e-09
substantially O 0 5.222522503345317e-08
under O 0 3.6487579109234503e-06
- O 1 0.9899274706840515
diagnosed O 1 0.5743768215179443
. O 0 5.717206477129366e-07

The O 0 5.902814791625133e-06
cornerstone O 0 0.0015890061622485518
of O 0 1.5482443131986656e-06
screening O 0 7.45726083550835e-07
and O 0 1.0205751799219343e-08
case O 0 5.28900212515282e-09
detection O 0 3.554817737949634e-07
is O 0 4.4870376858519023e-10
the O 0 7.859660144937664e-10
measurement O 0 5.2687465057488225e-08
of O 0 4.810846121472423e-08
serum O 0 5.916172085562721e-07
transferrin O 0 6.808230637034285e-07
saturation O 0 2.071123503810668e-07
and O 0 1.1516206654960115e-08
the O 0 5.175025918902065e-08
serum O 0 5.058357146481285e-06
ferritin O 0 4.7456647735089064e-05
level O 0 3.224969987059012e-06
. O 0 6.454897629737388e-07

Once O 0 7.3735204750846606e-06
the O 0 4.6225056848925306e-07
diagnosis O 0 0.00012238622002769262
is O 0 1.848206210297576e-08
suspected O 0 1.3590837397714495e-06
, O 0 2.2633383167658394e-08
physicians O 0 1.9745242241242522e-07
must O 0 4.7596047103581895e-09
use O 0 1.2364968426936684e-07
serum O 0 4.0150207496481016e-05
ferritin O 0 0.0008644426125101745
levels O 0 3.1937788662617095e-06
and O 0 6.085459176574659e-07
hepatic O 1 0.9895704984664917
iron O 1 0.9973995685577393
stores O 0 4.358026671980042e-06
on O 0 2.0274178496038076e-06
liver O 1 0.5030988454818726
biopsy O 0 6.322021363303065e-05
specimens O 0 3.7607637182190956e-07
to O 0 1.0878460798835476e-08
assess O 0 2.5090466237998044e-07
patients O 0 4.583629475973794e-08
for O 0 1.0373510050953882e-08
the O 0 1.2909789859349985e-07
presence O 0 1.3410532062607672e-07
of O 0 1.4786342035222333e-05
iron B-Disease 1 1.0
overload I-Disease 1 0.9987398982048035
. O 0 3.963839844800532e-06

Liver O 1 0.9999995231628418
biopsy O 1 0.9999140501022339
is O 0 1.19280855415127e-07
also O 0 6.435827870632238e-09
used O 0 3.6146849957674476e-09
to O 0 7.051161876603373e-10
establish O 0 9.806224277042475e-09
the O 0 7.181643280063099e-09
presence O 0 1.1979163438979867e-08
or O 0 8.889381675203367e-09
absence O 0 2.273985870715478e-07
of O 0 6.421192665584385e-06
cirrhosis B-Disease 1 1.0
, O 0 4.858983970734698e-08
which O 0 9.280256563215517e-09
can O 0 4.9240278521267555e-09
affect O 0 1.5968622335549298e-07
prognosis O 0 9.225418034475297e-05
and O 0 5.392373623180902e-07
management O 0 0.00013024761574342847
. O 0 5.626151050819317e-06

A O 0 3.477308200672269e-05
DNA O 0 1.7210948499268852e-05
- O 0 1.0480046057637082e-06
based O 0 4.863202462956906e-08
test O 0 6.37701873529295e-08
for O 0 2.4380446550509305e-09
the O 0 2.9224317188436544e-08
HFE O 1 0.6006845831871033
gene O 0 3.520106162113734e-08
is O 0 2.4760357653086373e-10
commercially O 0 1.2023984474751614e-08
available O 0 9.912261011990608e-10
, O 0 4.898433880740072e-10
but O 0 1.438137109399662e-10
its O 0 4.337388503916628e-10
place O 0 3.716475793780205e-09
in O 0 5.669096858618161e-10
the O 0 5.170701644630071e-09
diagnosis O 0 5.8330992942501325e-06
of O 0 1.9986420738860033e-05
hemochromatosis B-Disease 1 1.0
is O 0 1.259318764823547e-07
still O 0 5.0644306526237415e-08
being O 0 4.435925404777663e-08
evaluated O 0 1.2498004480221425e-06
. O 0 1.6655188801451004e-06

Currently O 0 4.499349870457081e-06
, O 0 2.903867724057818e-08
the O 0 8.130002449036056e-09
most O 0 8.584696842284245e-10
useful O 0 4.4637533669344975e-09
role O 0 5.3473270256176875e-09
for O 0 8.852272248560666e-10
this O 0 3.2075608835668845e-10
test O 0 2.176531488373712e-08
is O 0 4.919932239388913e-10
in O 0 7.707199323192526e-10
the O 0 2.0130690447928146e-09
detection O 0 7.347579185079667e-07
of O 0 1.685260599515459e-06
hemochromatosis B-Disease 1 1.0
in O 0 3.7045943201974296e-08
the O 0 2.8572230803547427e-08
family O 0 8.531389816823776e-09
members O 0 3.4113731839369166e-09
of O 0 6.214948200522485e-08
patients O 0 3.728198905150748e-08
with O 0 2.923617570260717e-09
a O 0 5.7268550790468e-08
proven O 0 3.1008823953015963e-06
case O 0 3.2656100046324354e-08
of O 0 4.015448098471097e-07
the O 0 8.431020432908554e-06
disease O 1 0.9986151456832886
. O 0 8.859237823344301e-07

It O 0 9.000423233374022e-07
is O 0 5.5584344238468475e-08
crucial O 0 7.157414074754342e-07
to O 0 8.468358601021464e-07
diagnose O 1 1.0
hemochromatosis B-Disease 1 1.0
before O 1 1.0
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 0 0.3215526044368744
because O 0 4.139265001867898e-06
phlebotomy O 1 1.0
therapy O 1 0.9992417097091675
can O 0 2.7836622962240654e-07
avert O 1 0.9998952150344849
serious O 1 1.0
chronic O 1 1.0
disease O 1 1.0
and O 0 1.5545069800282363e-06
can O 0 1.239185554169353e-08
even O 0 1.448367914491655e-08
lead O 0 2.9707756254993e-08
to O 0 3.308990192962824e-09
normal O 0 8.201744350344597e-08
life O 0 1.3469195891957497e-07
expectancy O 0 2.2565971846688626e-07
. O 0 2.254492770248362e-08
. O 0 2.1523732129935524e-07

Prevalence O 0 7.038652256596833e-05
of O 0 1.4798353049627622e-06
the O 0 4.49519291123579e-07
I1307K O 0 6.0339651099639013e-05
APC B-Disease 0 4.7810226533329114e-05
gene O 0 1.2571720731102687e-07
variant O 0 2.5898330591189733e-07
in O 0 4.301289990849e-09
Israeli O 0 5.616794851448503e-08
Jews O 0 4.709757916998569e-08
of O 0 2.135402787928342e-08
differing O 0 1.3286326483452626e-09
ethnic O 0 4.148834331640927e-10
origin O 0 2.899549267354473e-09
and O 0 9.55240775368793e-09
risk O 0 2.6017801246780436e-07
for O 0 6.729151209583506e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.4621329430374317e-05

BACKGROUND O 0 0.001955218380317092
& O 0 0.0008445080020464957
AIMS O 0 6.611389835597947e-06
Israeli O 0 2.3337312882176775e-07
Jews O 0 1.3674248577899561e-07
of O 0 8.046576738252043e-08
European O 0 6.926283191432958e-08
birth O 0 1.4324656376629719e-06
, O 0 2.8891335546177288e-08
i O 0 1.4356035471507766e-08
. O 0 6.787014283915482e-10
e O 0 1.6407329939127635e-09
. O 0 6.663286589159156e-10
, O 0 9.341057927159113e-10
Ashkenazim O 0 6.297827894741204e-07
, O 0 5.223914634200355e-09
have O 0 6.911641814433267e-10
the O 0 3.9935688533887514e-08
highest O 1 0.9999212026596069
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 2.8663485863944516e-05
of O 0 1.5607102454850974e-07
any O 0 3.562318662275743e-09
Israeli O 0 3.0757664148950425e-07
ethnic O 0 3.418076843786366e-08
group O 0 4.3679861505552253e-07
. O 0 4.4912593466506223e-07

The O 0 2.192018655478023e-05
I1307K O 0 0.0005839605000801384
APC B-Disease 0 0.00017653629765845835
gene O 0 2.460592668285244e-06
variant O 0 9.854442396317609e-06
was O 0 2.592076498331153e-06
found O 0 1.1077947448256964e-07
in O 0 4.804757125498327e-08
6 O 0 5.809078629681608e-06
. O 0 1.2602297374542104e-06

1 O 0 5.300262728269445e-06
% O 0 3.095588141377448e-08
of O 0 4.581671930736775e-08
American O 0 1.532824889238782e-08
Jews O 0 6.320168211004784e-08
, O 0 8.488959757357861e-09
28 O 0 5.7218322524477117e-08
% O 0 5.653245649384075e-10
of O 0 6.394007101562238e-09
their O 0 7.919543776324645e-08
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 3.4649184499357943e-07
, O 0 1.8005815505262035e-08
but O 0 1.4624327304701978e-09
not O 0 7.761961073882162e-10
in O 0 1.4309861740002816e-08
non O 0 1.4752304196008481e-06
- O 0 2.5471758817730006e-06
Jews O 0 2.460522409819532e-06
. O 0 1.3363235211727442e-06

We O 0 1.242472649209958e-06
assessed O 0 3.807700522884261e-06
the O 0 3.325493480588193e-07
I1307K O 0 2.5964336600736715e-05
prevalence O 0 2.3171251939402282e-07
in O 0 1.9897830050297216e-09
Israeli O 0 2.2059797544216053e-08
Jews O 0 3.721548935686769e-08
of O 0 1.1038164160481756e-08
differing O 0 1.5603337510938786e-09
ethnic O 0 1.8196823214911007e-10
origin O 0 1.3663050690837508e-09
and O 0 7.577301452954543e-09
risk O 0 3.5621988558887097e-07
for O 0 8.424052793998271e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.5414863810292445e-05

METHODS O 0 3.574504080461338e-05
DNA O 0 5.064004199084593e-06
samples O 0 4.225707357363717e-07
from O 0 3.772131762502795e-08
500 O 0 3.639085832674027e-08
unrelated O 0 3.4047832997430305e-08
Jews O 0 6.98157904821528e-08
of O 0 6.780576455867049e-08
European O 0 1.1199811211781707e-07
or O 0 3.121903091596323e-08
non O 0 8.337721055795555e-07
- O 0 1.5425244725975062e-07
European O 0 7.163106552354748e-09
origin O 0 1.5113238438502208e-09
, O 0 9.64275881365495e-10
with O 0 3.8311209760166776e-10
or O 0 2.562946299633495e-09
without O 0 2.9649658284114366e-09
a O 0 2.6120405838270244e-09
personal O 0 2.4756086958177548e-08
and O 0 6.453383605276031e-08
/ O 0 1.1655455409709248e-06
or O 0 1.3856584324400956e-08
family O 0 4.057214564312517e-09
history O 0 5.034084438193531e-08
of O 0 1.6714157879960112e-07
neoplasia B-Disease 0 0.284282386302948
, O 0 1.91863307463791e-08
were O 0 3.699812234359001e-09
examined O 0 8.439916143743176e-08
for O 0 2.895349293652316e-09
the O 0 4.375398532374675e-08
I1307K O 0 4.138436452194583e-06
variant O 0 3.1961687341208744e-07
by O 0 5.0288710973234174e-09
the O 0 2.2013814771071338e-08
allele O 0 1.6808060721018592e-08
- O 0 6.713670330782406e-08
specific O 0 9.827363811609757e-09
oligonucleotide O 0 6.001187557558296e-06
( O 0 3.481811745587038e-07
ASO O 1 0.9960969090461731
) O 0 5.7294116118100646e-08
method O 0 3.629385219028336e-07
. O 0 4.2855609194702993e-07

RESULTS O 0 2.3581947971251793e-05
In O 0 1.2362256995857024e-07
persons O 0 1.3072591009688495e-08
at O 0 1.5968683442224574e-07
average O 0 2.2309999181402418e-08
risk O 0 7.7838208767389e-08
for O 0 1.1699008837240399e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.8655040889825614e-07
I1307K O 0 1.1968818398599979e-05
was O 0 2.1905840696945234e-07
found O 0 8.803732853834845e-09
in O 0 1.2895744028185163e-08
5 O 0 5.160275691196148e-07
. O 0 4.827745669899741e-07

0 O 0 2.3988256998563884e-06
% O 0 5.799336832978952e-08
of O 0 4.3492228485320084e-08
120 O 0 1.731981456032372e-07
European O 0 4.827147108699137e-07
and O 0 2.918149277775228e-07
1 O 0 6.7668111114471685e-06
. O 0 7.558899142168229e-07

6 O 0 1.369736037304392e-05
% O 0 4.634821237914366e-08
of O 0 3.878636434251348e-08
188 O 0 2.0537049749691505e-07
non O 0 9.945501915353816e-07
- O 0 8.040628927119542e-07
European O 0 1.6180446493763156e-07
Jews O 0 3.4277135796401126e-07
( O 0 4.307843681772283e-08
P O 0 3.309085059299832e-06
= O 0 6.692357601423282e-08
0 O 0 2.6073632142242786e-08
. O 0 2.7596227525350514e-09
08 O 0 7.492611757697887e-07
) O 0 2.2475331817872757e-08
. O 0 1.1919773612589779e-07

It O 0 6.718461236232542e-07
occurred O 0 1.086815245798789e-06
in O 0 1.434885490425586e-07
15 O 0 1.0837536592589458e-06
. O 0 5.938924800830137e-07

4 O 0 9.524658707960043e-06
% O 0 8.184508004660529e-08
of O 0 5.009430026348127e-08
52 O 0 1.4777324963688443e-07
Ashkenazi O 0 1.4625362609876902e-06
Israelis O 0 1.2456638387448038e-07
with O 0 4.777415796297646e-08
familial O 0 0.3551732003688812
cancer B-Disease 1 0.9999809265136719
( O 0 4.980154812983528e-07
P O 0 5.695330037269741e-05
= O 0 4.6350422167051875e-08
0 O 0 7.583749628281566e-09
. O 0 6.274711306097913e-10
02 O 0 1.9819667329556978e-07
) O 0 4.992893876121229e-10
and O 0 1.3294082501502658e-09
was O 0 2.3989843001004374e-08
not O 0 4.3365860902255804e-10
detected O 0 1.8934287027150276e-08
in O 0 3.8598746421314445e-09
51 O 0 3.1150033663607246e-08
non O 0 1.5195573155324382e-07
- O 0 3.083476087795134e-07
European O 0 8.27673645176219e-08
Jews O 0 2.546213977439038e-07
at O 0 1.1484113429105491e-06
increased O 0 4.6445026669061917e-07
cancer B-Disease 0 0.12062490731477737
risk O 0 1.2926818726555211e-06
. O 0 5.456088274513604e-07

Colorectal B-Disease 1 0.9999998807907104
neoplasia I-Disease 1 0.9999892711639404
occurred O 0 0.00019314279779791832
personally O 0 5.238422545517096e-06
or O 0 6.952132025617175e-08
in O 0 9.861330418914349e-09
the O 0 8.102477799809549e-09
families O 0 4.184597113265909e-10
of O 0 3.0400364892102516e-08
13 O 0 5.78720396049448e-08
of O 0 3.6614906662180147e-08
20 O 0 1.1778645614413108e-07
Ashkenazi O 0 1.2050821851516957e-06
I1307K O 0 2.0371198843349703e-06
carriers O 0 2.6165746902506726e-08
, O 0 9.027492531288317e-09
8 O 0 5.032231698010037e-08
of O 0 2.412322963607494e-08
whom O 0 5.481198162016199e-09
also O 0 2.690538902783146e-09
had O 0 6.933933871522413e-09
a O 0 3.6623200028174097e-09
personal O 0 6.951787412390331e-08
or O 0 4.816465093426814e-08
family O 0 2.4903560102984557e-08
history O 0 6.393454441422364e-07
of O 0 4.1014482121681795e-06
noncolonic O 1 0.9789384603500366
neoplasia B-Disease 1 0.9998195767402649
. O 0 2.194930311816279e-05

CONCLUSIONS O 0 8.220934250857681e-05
The O 0 1.1462338079581968e-05
I1307K O 0 0.0007660540286451578
APC O 0 0.0007191789336502552
variant O 0 4.8734378651715815e-05
may O 0 9.104930853709448e-08
represent O 0 1.37035636171845e-08
a O 0 1.6675636871354982e-08
susceptibility O 0 3.7134381614123413e-07
gene O 0 6.366239801991469e-08
for O 0 1.7609767155590816e-07
colorectal B-Disease 1 1.0
, I-Disease 0 9.603434136806754e-08
or I-Disease 0 2.0664765898459336e-08
other I-Disease 0 9.465856543044993e-09
, I-Disease 0 5.6790376845583523e-08
cancers I-Disease 0 3.06468500639312e-05
in O 0 2.750575234244934e-08
Ashkenazi O 0 1.732446662572329e-06
Jews O 0 4.1934504224627744e-07
, O 0 4.191959135368961e-08
and O 0 3.085172650685308e-08
partially O 0 1.6385608887503622e-06
explains O 0 2.5897879396552526e-08
the O 0 7.561636650166292e-09
higher O 0 6.419108444788435e-08
incidence O 0 1.2962927939952351e-06
of O 0 0.00038481486262753606
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 8.149194741235988e-08
European O 0 4.339312624779268e-07
Israelis O 0 3.5388251262702397e-07
. O 0 6.937295324860315e-07

Systematic O 0 4.7809621719352435e-06
analysis O 0 3.415141804907762e-07
of O 0 2.181162699343986e-06
coproporphyrinogen O 0 0.0019874025601893663
oxidase O 0 8.902393892640248e-05
gene O 0 1.9338644051458687e-05
defects O 0 0.19824160635471344
in O 0 3.1890367608866654e-06
hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999886751174927
and O 0 3.591254653656506e-06
mutation O 0 1.2172877177363262e-06
update O 0 1.2933532161696348e-05
. O 0 3.7776185308757704e-06

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999992847442627
( O 0 0.0007032897556200624
HC B-Disease 1 1.0
) O 0 5.730832526751328e-06
is O 0 4.16858121354835e-08
an O 0 1.3796527298381989e-07
acute O 1 1.0
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 0 0.0008012520265765488
autosomal O 1 0.9999986886978149
dominant O 1 0.9977632761001587
inheritance O 0 0.0012690501753240824
caused O 0 0.0012673699529841542
by O 0 2.9050045213807607e-07
deficient B-Disease 0 1.1685199751809705e-05
activity I-Disease 0 1.4250436208840256e-07
of I-Disease 0 4.070083434726257e-07
coproporphyrinogen I-Disease 0 0.002063256921246648
III I-Disease 1 1.0
oxidase I-Disease 0 5.6224034779006615e-05
( O 0 2.5908359475579346e-06
CPO O 0 0.3360428512096405
) O 0 1.2729149148071883e-06
. O 0 7.996085855666024e-07

Clinical O 0 0.00388111243955791
manifestations O 0 0.020960235968232155
of O 0 0.00019709272601176053
the O 0 0.006941908039152622
disease O 1 0.9999996423721313
are O 0 2.107144680962847e-09
characterized O 0 1.1726404380851818e-07
by O 0 1.5288158294879395e-08
acute O 0 0.00038614662480540574
attacks O 0 1.4309212303942331e-07
of O 0 0.23053696751594543
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 8.018949984034407e-07
precipitated O 0 1.787899122973613e-06
by O 0 2.8460837242505477e-08
drugs O 0 9.395652114108088e-07
, O 0 3.302169915286868e-08
fasting O 0 1.7378562233716366e-06
, O 0 5.5675805299415515e-08
cyclical O 0 0.00015889130008872598
hormonal O 0 8.353745215572417e-05
changes O 0 1.5030231281798478e-07
, O 0 2.662377198703325e-07
or O 0 0.0003271994355600327
infectious B-Disease 1 1.0
diseases I-Disease 1 1.0
. O 0 6.462057626777096e-06

Skin O 1 1.0
photosensitivity O 1 0.9999994039535522
may O 0 2.3474784029531293e-05
also O 0 1.8206638685569487e-07
be O 0 2.3162474604987437e-08
present O 0 1.9944963014495443e-07
. O 0 8.960128070611972e-07

The O 0 5.96695235799416e-06
seven O 0 1.6637487760817748e-06
exons O 0 2.63020569946093e-06
, O 0 3.118189439987873e-08
the O 0 1.0046821330433886e-07
exon O 0 6.451946319430135e-06
/ O 0 2.2949579943087883e-06
intron O 0 1.1671874062813004e-06
boundaries O 0 1.793527637516945e-08
and O 0 4.239404827188764e-09
part O 0 4.1922866955701465e-08
of O 0 1.504164544030573e-07
3 O 0 1.9130081341245386e-07
noncoding O 0 2.383810056016955e-07
sequence O 0 3.839462081600686e-09
of O 0 1.4822681748682953e-08
the O 0 4.837770006815845e-08
CPO O 0 0.0004560673551168293
gene O 0 1.993765508245815e-08
were O 0 3.8897622900435636e-09
systematically O 0 1.1413320955000472e-08
analyzed O 0 9.771812692349613e-09
by O 0 1.7744750113735108e-09
an O 0 2.19871587603393e-09
exon O 0 3.1736831829221046e-07
- O 0 4.550063579245034e-07
by O 0 2.6496357108385382e-08
- O 0 1.822541662477306e-06
exon O 0 2.982607156809536e-06
denaturing O 0 1.3090117136016488e-05
gradient O 0 1.2122333146180608e-06
gel O 0 3.796423470703303e-06
electrophoresis O 0 3.8325028981489595e-06
( O 0 2.3365704748812277e-07
DGGE O 1 0.999231219291687
) O 0 3.60430476575857e-08
strategy O 0 1.80748749301074e-08
followed O 0 5.60757484890928e-09
by O 0 3.335539067172988e-10
direct O 0 5.03098840365368e-10
sequencing O 0 1.5277111131695165e-08
in O 0 4.0415355506695505e-09
seven O 0 3.3230453055921316e-08
unrelated O 0 4.988625050827977e-07
heterozygous O 0 1.0962944543280173e-06
HC B-Disease 1 1.0
patients O 0 3.0928441674404894e-07
from O 0 1.0018232643460578e-07
France O 0 2.905632527472335e-06
, O 0 4.079860360661769e-08
Holland O 0 1.4625622497987933e-05
, O 0 2.7136291436136162e-08
and O 0 3.546659499420457e-08
Czech O 0 4.1936284105759114e-05
Republic O 0 1.6888268874026835e-05
. O 0 3.5702053082786733e-06

Seven O 0 5.767837137682363e-06
novel O 0 9.985941460399772e-07
mutations O 0 9.028494218910055e-08
and O 0 2.6082188853138177e-08
two O 0 6.1512150928422216e-09
new O 0 4.750972593114966e-08
polymorphisms O 0 8.223468626056274e-07
were O 0 2.6609203018779226e-07
detected O 0 1.2154063369962387e-05
. O 0 1.1307095064694295e-06

Among O 0 8.679486995788466e-07
these O 0 2.397145770771658e-08
mutations O 0 1.864955834207649e-08
two O 0 1.4436233319869984e-09
are O 0 3.794266012491221e-10
missense O 0 1.648633514150788e-07
( O 0 3.684138860649e-08
G197W O 0 8.001418791536707e-06
, O 0 2.873586169016562e-08
W427R O 0 3.560667664714856e-06
) O 0 1.1167831104330617e-08
, O 0 1.1655861831272318e-09
two O 0 3.6889094556791235e-10
are O 0 4.4047010483438953e-10
nonsense O 0 5.238325115897169e-07
( O 0 2.062684423265182e-08
Q306X O 0 6.526168817799771e-06
, O 0 2.6244068251912722e-08
Q385X O 0 3.6214751162333414e-06
) O 0 6.651607264984705e-09
, O 0 1.7287338227589544e-09
two O 0 3.5924485608518353e-10
are O 0 1.0381259740732673e-10
small O 0 2.4674049470263526e-09
deletions O 0 7.146623914877637e-08
( O 0 7.626690745610176e-08
662de14bp O 0 9.059490366780665e-06
; O 0 8.274574270217272e-08
1168del3bp O 0 1.5429395716637373e-05
removing O 0 1.4621150512539316e-06
a O 0 6.485799985966878e-08
glycine O 0 5.944704639659903e-07
at O 0 2.9163743420212995e-07
position O 0 4.925871621708211e-08
390 O 0 2.3986785890883766e-07
) O 0 5.521259005547563e-09
, O 0 2.7674977864933226e-09
and O 0 3.6518776891369953e-09
one O 0 3.50269147020299e-09
is O 0 8.776048776582002e-10
a O 0 4.156265553945104e-09
splicing O 0 5.570043981606432e-07
mutation O 0 5.866835905976586e-08
( O 0 4.233386974306086e-08
IVS1 O 0 0.16013570129871368
- O 0 1.9479386992315995e-06
15c O 0 3.9226388253155164e-06
- O 0 1.1221445674891584e-06
- O 0 7.845765708225372e-07
> O 0 2.424094418529421e-07
g O 0 3.455731132362416e-07
) O 0 5.558792093296461e-09
which O 0 1.280360928390678e-09
creates O 0 1.1096446428382478e-08
a O 0 4.4501349272252355e-09
new O 0 1.4685242355483297e-08
acceptor O 0 2.898291029396205e-07
splice O 0 6.763919373042881e-05
site O 0 1.1339683624100871e-05
. O 0 1.4672386896563694e-06

The O 0 6.291426416282775e-06
pathological O 0 3.058142101508565e-05
significance O 0 6.515253403449606e-07
of O 0 5.174384796191589e-07
the O 0 6.582146028222269e-08
point O 0 4.585299606674198e-08
mutations O 0 1.1574607050590657e-08
G197W O 0 1.0671978998288978e-06
, O 0 2.488959971458371e-08
W427R O 0 2.597273123683408e-06
, O 0 1.7737855628752186e-08
and O 0 4.586530710781744e-09
the O 0 5.901726662926876e-09
in O 0 1.4480833421259831e-08
- O 0 3.849132497180108e-07
frame O 0 2.233795868278321e-07
deletion O 0 9.044282478498644e-08
390delGly O 0 7.533100188084063e-07
were O 0 1.4404940351653295e-08
assessed O 0 6.064126978344575e-08
by O 0 2.5708581929961838e-09
their O 0 2.6873796521442728e-09
respective O 0 9.122866906352556e-09
expression O 0 6.265649332704015e-09
in O 0 4.2350083440112485e-09
a O 0 2.498938389550176e-09
prokaryotic O 0 5.258887370018783e-08
system O 0 1.773088698087122e-08
using O 0 6.270323815726897e-09
site O 0 3.742802050510363e-07
- O 0 1.2619532299140701e-06
directed O 0 3.412771150124172e-07
mutagenesis O 0 4.876538514508866e-05
. O 0 1.1630239669102593e-06

These O 0 3.217122923615534e-07
mutations O 0 3.886257218255196e-07
resulted O 0 3.099026741892885e-07
in O 0 2.9310450955222223e-08
the O 0 4.2062392680009e-08
absence O 0 1.7613662350868253e-07
or O 0 2.5726352603783198e-08
a O 0 1.3916682917169965e-08
dramatic O 0 9.3316273819255e-08
decrease O 0 2.1392841631495685e-07
of O 0 2.1160383312235354e-06
CPO O 1 0.6872135400772095
activity O 0 4.045879450131906e-06
. O 0 1.0949611350952182e-06

The O 0 1.7713668967189733e-06
two O 0 4.2242003672754436e-08
polymorphisms O 0 2.651102590789378e-07
were O 0 3.033827056242444e-08
localized O 0 2.366883649074225e-07
in O 0 3.846794527362363e-08
noncoding O 0 6.146960345176922e-07
part O 0 2.7931392310165393e-08
of O 0 5.0536137052858976e-08
the O 0 1.6323930651651608e-08
gene O 0 1.1713344960639915e-08
1 O 0 3.164667106148045e-08
) O 0 1.967209284359228e-09
a O 0 1.8252599431889394e-08
C O 0 1.2433365554898046e-05
/ O 0 1.1724206387953018e-06
G O 0 2.5125859792751726e-06
polymorphism O 0 4.103616646489172e-08
in O 0 1.0746822098894881e-08
the O 0 4.188346380828989e-08
promotor O 0 6.20340506429784e-05
region O 0 2.511447689812485e-07
, O 0 3.012273808167265e-08
142 O 0 5.664227842316905e-07
bp O 0 5.543753331949119e-07
upstream O 0 4.535649722470225e-08
from O 0 1.216527767411435e-08
the O 0 6.604603974835754e-09
transcriptional O 0 4.4904755469588054e-08
initiation O 0 1.808327567687229e-07
site O 0 3.695688803873054e-07
( O 0 1.1814291767109353e-08
- O 0 3.183234582593286e-07
142C O 0 4.2212950575049035e-06
/ O 0 1.2235552730999188e-06
G O 0 5.385854819905944e-06
) O 0 9.673804868270963e-09
, O 0 3.355091315881964e-09
and O 0 3.1548959000815557e-09
2 O 0 5.655149237782098e-08
) O 0 1.8800230261462048e-09
a O 0 5.8656355328423615e-09
6 O 0 1.2086115930287633e-07
bp O 0 1.9012531993212178e-07
deletion O 0 4.0857319305587225e-08
polymorphism O 0 1.9573965559516182e-08
in O 0 4.428112099219561e-09
the O 0 1.3545151666960464e-08
3 O 0 1.4012573501531733e-07
noncoding O 0 6.243391226234962e-07
part O 0 5.054500462620126e-08
of O 0 6.863317736360841e-08
the O 0 1.0807774941667958e-07
CPO O 0 0.004316695965826511
gene O 0 1.4041991391877673e-07
, O 0 2.3191031317537636e-08
574 O 0 9.349743095299345e-07
bp O 0 8.022491329029435e-07
downstream O 0 2.407740851140261e-07
of O 0 1.1020770784853084e-07
the O 0 1.8323060402281044e-08
last O 0 1.9193027611663638e-08
base O 0 2.0658342592128065e-08
of O 0 1.2482615829867427e-08
the O 0 1.2456644604696976e-08
normal O 0 2.1241909564650996e-08
termination O 0 2.52204927164712e-07
codon O 0 1.0055254051621887e-06
( O 0 6.024492194001141e-08
+ O 0 7.05825186742004e-07
574 O 0 1.741707274049986e-05
delATTCTT O 0 9.895135008264333e-05
) O 0 6.525569347104465e-07
. O 0 1.0285158396072802e-06

Five O 0 1.4234534319257364e-05
intragenic O 0 0.002040912862867117
dimorphisms O 0 0.00025275503867305815
are O 0 1.8989766203958425e-08
now O 0 3.4618459210378205e-08
well O 0 6.62671162388051e-09
characterized O 0 4.2862719595859744e-08
and O 0 5.7809566023081516e-09
the O 0 8.58021564908995e-09
high O 0 1.2622382428162382e-07
degree O 0 4.330647129791032e-08
of O 0 1.318796716276438e-08
allelic O 0 5.600666668215126e-07
heterogeneity O 0 4.491323579713935e-07
in O 0 4.325199256527412e-07
HC B-Disease 1 1.0
is O 0 1.3650196706294082e-07
demonstrated O 0 3.4335560172849e-08
with O 0 1.5635273076242129e-09
seven O 0 1.1215284700938355e-08
new O 0 3.53315399159726e-09
different O 0 2.822909406230423e-10
mutations O 0 3.813581894718254e-09
making O 0 6.570553434670501e-09
a O 0 1.8389854083977752e-09
total O 0 3.474352805454828e-09
of O 0 6.737825941627307e-08
nineteen O 0 1.4812903827987611e-05
CPO O 1 0.9999988079071045
gene B-Disease 0 3.754700082936324e-05
defects I-Disease 0 0.2757563591003418
reported O 0 8.427760462836886e-07
so O 0 1.5566545386036523e-08
far O 0 3.877770993199192e-08
. O 0 4.3331841226290635e-08
. O 0 3.434500399634999e-07

Coincidence O 0 4.051815267303027e-05
of O 0 1.3476098956743954e-06
two O 0 2.989299474620566e-08
novel O 0 6.19497029674676e-07
arylsulfatase O 0 3.557182208169252e-05
A O 0 1.0799857363963383e-06
alleles O 0 1.423429374369789e-08
and O 0 2.0956425927920463e-08
mutation O 0 4.122570729236941e-08
459 O 0 1.559172005727305e-06
+ O 0 1.5500260133194388e-06
1G O 0 0.04658859968185425
> O 0 1.446699684493069e-06
A O 0 5.9972524013574e-07
within O 0 3.4344012078690866e-08
a O 0 1.8401021151248642e-08
family O 0 2.5754534505040283e-08
with O 0 1.2319534903326712e-07
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
: O 0 8.53784030141469e-08
molecular O 0 2.681250634850585e-07
basis O 0 2.4759769345905625e-08
of O 0 1.3839526502579247e-07
phenotypic O 0 1.8253978169013862e-06
heterogeneity O 0 1.6156041965587065e-05
. O 0 2.7354503799870145e-06

In O 0 2.2566305233340245e-06
a O 0 1.8788342970310623e-07
family O 0 4.666577524403692e-08
with O 0 8.013918417759669e-09
three O 0 5.433444627556128e-08
siblings O 0 3.0069585932324117e-07
, O 0 1.2821064210299937e-08
one O 0 5.1182942328864556e-09
developed O 0 6.148027154040392e-08
classical O 0 3.4820684504666133e-06
late O 0 8.573690865887329e-05
infantile O 1 0.9999294281005859
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 1.1093907232861966e-05
MLD B-Disease 1 1.0
) O 0 4.1149746721202973e-07
, O 0 3.4149749694734055e-08
fatal O 0 2.5404597181477584e-05
at O 0 5.388050681176537e-07
age O 0 3.960389705071066e-08
5 O 0 1.4036804607542308e-08
years O 0 9.213799501139874e-09
, O 0 2.895172546146796e-09
with O 0 4.5134944670621735e-09
deficient O 0 0.00011330609413562343
arylsulfatase O 0 0.01892530918121338
A O 0 0.00014460568490903825
( O 0 3.3935128840312245e-07
ARSA O 1 0.9999005794525146
) O 0 1.5955221144281495e-08
activity O 0 1.9555978170160415e-08
and O 0 4.370525275021464e-09
increased O 0 2.4986730906562116e-08
galactosylsulfatide O 0 4.5092128857504576e-05
( O 0 5.731017722609977e-07
GS O 1 1.0
) O 0 5.114481496093504e-07
excretion O 0 8.77112051966833e-06
. O 0 1.1602211316130706e-06

The O 0 1.8984371763508534e-06
two O 0 3.686507810130024e-08
other O 0 1.748662015188529e-08
siblings O 0 3.2860984333638044e-07
, O 0 2.5282856697117495e-08
apparently O 0 1.7697480814149458e-07
healthy O 0 1.123322874718724e-07
at O 0 3.0205390544324473e-07
12 O 0 2.3112346525522298e-07
( O 0 7.917456912309717e-09
1 O 0 1.553353996541773e-07
/ O 0 2.328349211211389e-07
2 O 0 3.97694464027154e-08
) O 0 7.574754712358356e-10
and O 0 7.204785101855293e-10
15 O 0 2.534169540879816e-09
years O 0 1.4720851204685914e-09
, O 0 4.027482236601543e-10
respectively O 0 3.9765253312396e-09
, O 0 8.796997574833654e-10
and O 0 4.3019932061127975e-10
their O 0 1.2228759116439392e-09
father O 0 2.7243754630035255e-07
, O 0 1.2651794278895068e-08
apparently O 0 7.847145155892576e-08
healthy O 0 8.871139378641146e-09
as O 0 4.085433769063229e-09
well O 0 7.754507258539434e-09
, O 0 7.295363868564664e-09
presented O 0 3.397592820419959e-07
ARSA O 1 0.9996389150619507
and O 0 5.04894615005469e-07
GS O 1 0.9999994039535522
values O 0 4.6593289226848356e-08
within O 0 2.698640244602757e-08
the O 0 5.308416373139835e-09
range O 0 1.4470789722054178e-07
of O 0 2.219325551777729e-06
MLD B-Disease 1 1.0
patients O 0 3.236687552998774e-05
. O 0 2.1890793959755683e-06

Mutation O 0 1.9287508621346205e-06
screening O 0 1.6357801086996915e-06
and O 0 1.3687733613210185e-08
sequence O 0 3.805589177119373e-09
analysis O 0 2.005710486585599e-09
disclosed O 0 5.929056001718891e-08
the O 0 6.147015785273879e-09
involvement O 0 3.103060208786701e-08
of O 0 3.515463475878278e-08
three O 0 3.881506227543241e-09
different O 0 4.364244521326555e-09
ARSA O 1 0.9259825944900513
mutations O 0 5.928626478635124e-08
being O 0 1.5889561666426744e-08
the O 0 6.162300003609289e-09
molecular O 0 9.635983388989189e-08
basis O 0 3.946379933950084e-08
of O 0 2.0487811980274273e-07
intrafamilial O 0 6.0000656958436593e-05
phenotypic O 0 2.990702341776341e-06
heterogeneity O 0 1.6352671082131565e-05
. O 0 3.624377313826699e-06

The O 0 3.8103739825601224e-06
late O 0 7.038752664811909e-05
infantile O 1 0.9671237468719482
patient O 0 7.930272840894759e-05
inherited O 0 0.01838812790811062
from O 0 4.190622803434962e-06
his O 0 6.476043381553609e-06
mother O 0 8.954968393481977e-07
the O 0 7.674201896179511e-08
frequent O 0 2.4660511854790457e-08
0 O 0 8.842813770115754e-08
- O 0 3.8355122455868695e-07
type O 0 1.7867557744466467e-07
mutation O 0 2.6206802061778944e-08
459 O 0 6.93306276389194e-07
+ O 0 4.3531193227863696e-07
1G O 0 0.0006469415966421366
> O 0 6.939168315511779e-07
A O 0 9.908466154229245e-07
, O 0 4.6094905670202024e-09
and O 0 3.3890503736699884e-09
from O 0 9.018818580841526e-09
his O 0 4.2711253200877763e-08
father O 0 1.9743151824513916e-07
a O 0 2.283850086826078e-08
novel O 0 3.4376451907291994e-08
, O 0 6.626673876297673e-09
single O 0 3.815002358464881e-08
basepair O 0 6.153855792945251e-06
microdeletion O 0 8.698018064023927e-06
of O 0 4.925669827571255e-07
guanine O 0 5.529956297323224e-07
at O 0 2.896439923461003e-07
nucleotide O 0 3.1947362089113085e-08
7 O 0 1.324808920344367e-07
in O 0 2.335478299642091e-08
exon O 0 1.4904975387253216e-06
1 O 0 4.831771320823464e-07
( O 0 1.4640851020431e-07
7delG O 0 2.471435072948225e-05
) O 0 4.606021661857085e-07
. O 0 8.909804591894499e-07

The O 0 2.1782877865916817e-06
two O 0 2.0974165693132818e-07
clinically O 0 0.00010816110443556681
unaffected O 0 6.277959073486272e-06
siblings O 0 4.26335276415557e-07
carried O 0 1.1627783891299259e-07
the O 0 4.817549381641584e-08
maternal O 0 3.053553996323899e-07
mutation O 0 2.4340129911593067e-08
459 O 0 1.164373429674015e-06
+ O 0 3.832031438832928e-07
1G O 0 0.0015718229115009308
> O 0 1.1399743016227148e-06
A O 0 8.66658467657544e-07
and O 0 1.3292239309237175e-08
, O 0 2.8310742639092723e-09
on O 0 2.6463768953988165e-09
their O 0 7.805281976303036e-10
paternal O 0 1.4594436770209995e-08
allele O 0 7.828633741269186e-09
, O 0 2.441055357849109e-09
a O 0 9.967662251142428e-09
novel O 0 1.5381845130946203e-08
cytosine O 0 1.5381645823708823e-07
to O 0 5.222858590059332e-09
thymidine O 0 1.0382436812506057e-06
transition O 0 1.95665435853698e-07
at O 0 2.964764860280411e-07
nucleotide O 0 9.373101761411817e-08
2435 O 0 1.5829529729671776e-05
in O 0 2.0266194056262066e-08
exon O 0 3.689561083319859e-07
8 O 0 1.1119735887632487e-07
, O 0 2.786778363628173e-09
resulting O 0 6.213048742154115e-09
in O 0 1.2574251639918543e-09
substitution O 0 2.587630021366749e-08
of O 0 3.9359761672130844e-08
alanine O 0 3.991566472905106e-07
464 O 0 1.3587973626272287e-06
by O 0 1.252303007959199e-07
valine O 0 7.778478902764618e-05
( O 0 6.283675588747428e-07
A464V O 0 0.00017314909200649709
) O 0 6.145085080788704e-07
. O 0 8.921239782466728e-07

The O 0 8.754891496209893e-06
fathers O 0 6.307863259280566e-06
genotype O 0 1.4894802689013886e-06
thus O 0 1.6318367102030606e-07
was O 0 3.011532726304722e-06
7delG O 0 0.000155036905198358
/ O 0 8.57310151332058e-05
A464V O 0 0.00013990848674438894
. O 0 3.0394971872738097e-06

Mutation O 0 2.1124929844518192e-05
A464V O 0 0.0001466503890696913
was O 0 3.3325684398732847e-06
not O 0 1.1558898727059841e-08
found O 0 7.789818567971452e-09
in O 0 1.01570085675462e-08
18 O 0 4.5921441937935015e-07
unrelated O 0 4.586097929859534e-05
MLD B-Disease 1 1.0
patients O 0 6.3842389863566495e-06
and O 0 4.2403533484502987e-07
50 O 0 1.6968932641248102e-06
controls O 0 8.310266821354162e-06
. O 0 2.3166996925283456e-06

A464V O 0 0.001096791704185307
, O 0 1.1602288623180357e-06
although O 0 1.8882359142935456e-07
clearly O 0 1.286742019601661e-07
modifying O 0 4.7501616791123524e-06
ARSA O 1 0.9971789121627808
and O 0 1.7520827668704442e-06
GS O 1 1.0
levels O 0 2.4560561087128008e-06
, O 0 2.1830008023471237e-08
apparently O 0 6.050713352578896e-08
bears O 0 2.575213500222162e-07
little O 0 9.109270671103786e-09
significance O 0 1.2423140738349048e-08
for O 0 4.688468724367567e-09
clinical O 0 1.1047948191844625e-06
manifestation O 0 1.991197859751992e-05
of O 0 0.00017151331121567637
MLD B-Disease 1 1.0
, O 0 1.099353767131106e-06
mimicking O 0 6.287539690674748e-06
the O 0 3.351080124502914e-07
frequent O 0 5.716602117900038e-06
ARSA O 1 0.9999529123306274
pseudodeficiency O 0 0.007287828717380762
allele O 0 2.2040314433979802e-05
. O 0 4.943368367094081e-06

Our O 0 3.361317567396327e-06
results O 0 3.3087684414567775e-07
demonstrate O 0 7.013330360905456e-08
that O 0 1.67665559214214e-09
in O 0 5.845955719507856e-09
certain O 0 9.133348299883437e-09
genetic O 0 2.553107094627194e-07
conditions O 0 1.3029861293034628e-05
MLD B-Disease 1 1.0
- O 0 0.0006725921994075179
like O 0 2.5313604510301957e-06
ARSA O 1 0.9999426603317261
and O 0 7.09638641183119e-07
GS O 1 0.9999990463256836
values O 0 1.784532699389274e-08
need O 0 4.729884928167394e-09
not O 0 6.127534590838479e-10
be O 0 6.179222133972928e-10
paralleled O 0 1.8315231997689807e-08
by O 0 5.434975580698165e-09
clinical O 1 0.7838160395622253
disease O 1 0.9943256974220276
, O 0 1.7997402679270635e-08
a O 0 1.3174290991457838e-08
finding O 0 1.279668193632233e-08
with O 0 3.713733098820171e-09
serious O 0 2.6906177481578197e-06
diagnostic O 0 0.06951189786195755
and O 0 1.7668099872025778e-06
prognostic O 1 0.7221821546554565
implications O 0 2.805770236591343e-05
. O 0 4.649617494578706e-06

Moreover O 0 7.95650794316316e-06
, O 0 2.610294700389204e-07
further O 0 2.203860702820748e-07
ARSA O 1 0.6032601594924927
alleles O 0 1.7676934760402219e-07
functionally O 0 2.5247493340430083e-07
similar O 0 1.0210502665586318e-08
to O 0 2.0468080563773583e-08
A464V O 0 6.277479769778438e-06
might O 0 2.1423829821287654e-08
exist O 0 1.1037658786960947e-08
which O 0 4.35175939728083e-09
, O 0 6.0090088460640345e-09
together O 0 2.6922433171705507e-09
with O 0 1.1256168219730966e-09
0 O 0 2.5572052919642374e-08
- O 0 5.396356428377658e-08
type O 0 6.31209644552655e-08
mutations O 0 3.062378439722124e-08
, O 0 1.746961864057539e-08
may O 0 5.38161692986705e-08
cause O 0 9.180208166981174e-07
pathological O 1 0.8018974661827087
ARSA O 1 0.9999994039535522
and O 0 2.0907095859001856e-06
GS O 1 1.0
levels O 0 2.163627641493804e-06
, O 0 6.686588172044594e-09
but O 0 2.493547590631806e-10
not O 0 1.933527921105238e-10
clinical O 0 1.527973978454611e-07
outbreak O 0 3.1131386890592694e-07
of O 0 3.2882897471608885e-07
the O 0 8.373144737561233e-06
disease O 1 0.9790312647819519
. O 0 1.0033281938603977e-07
. O 0 3.7243614769977285e-07

Human O 1 0.9979731440544128
MLH1 O 1 1.0
deficiency O 1 1.0
predisposes O 1 0.8624070882797241
to O 0 1.149568288383307e-05
hematological B-Disease 1 1.0
malignancy I-Disease 1 1.0
and O 0 1.3693938853975851e-05
neurofibromatosis B-Disease 1 1.0
type I-Disease 0 0.1761428415775299
1 I-Disease 0 0.000215498948819004
. O 0 4.4695889300783165e-06

Heterozygous O 0 0.00011166724289068952
germ O 1 0.9998101592063904
- O 0 7.850636029615998e-05
line O 0 2.2562151116289897e-06
mutations O 0 3.699595652051357e-08
in O 0 1.998658127888575e-08
the O 0 6.994934409476627e-08
DNA O 0 3.633892265497707e-05
mismatch O 0 0.3638984262943268
repair O 1 0.8450814485549927
genes O 0 2.6403057518109563e-07
lead O 0 8.134842914842011e-07
to O 0 9.704270951260696e-07
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 6.945643690414727e-05

The O 0 0.00019564911781344563
disease O 1 0.9996830224990845
susceptibility O 0 4.632330274034757e-06
of O 0 8.200726142604253e-07
individuals O 0 9.860107397230422e-09
who O 0 4.998387126420312e-08
constitutionally O 0 8.238092163992405e-07
lack O 0 1.1275441380576012e-07
both O 0 1.2757251255379742e-08
wild O 0 7.314957315429638e-07
- O 0 8.2543641610755e-07
type O 0 1.8053070505175128e-07
alleles O 0 1.6560830928824544e-08
is O 0 1.2776025570815364e-08
unknown O 0 4.3055931087110366e-07
. O 0 7.286931804628693e-07

We O 0 2.7228742283114116e-07
have O 0 5.302354999514591e-09
identified O 0 2.0741332207308005e-08
three O 0 1.0151702589666911e-08
offspring O 0 8.21497465608445e-08
in O 0 2.4162970291286e-08
a O 0 3.840299598323327e-07
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 4.879974312643753e-06
who O 0 4.458884177438449e-07
developed O 0 2.059453254332766e-05
hematological B-Disease 1 1.0
malignancy I-Disease 1 0.9999997615814209
at O 0 2.1238047338556498e-05
a O 0 1.5242360262845978e-08
very O 0 1.3883720839658054e-09
early O 0 2.914971908296593e-08
age O 0 1.693575235606204e-08
, O 0 1.096176927006809e-09
and O 0 1.3230766482408285e-09
at O 0 2.642050667134299e-08
least O 0 2.476593097266999e-10
two O 0 2.176122476660325e-10
of O 0 3.6999321384456607e-09
them O 0 1.891810486043255e-09
displayed O 0 3.345760148931731e-07
signs O 0 1.0541854180701193e-06
of O 0 1.7641514205024578e-06
neurofibromatosis B-Disease 1 0.9999948740005493
type I-Disease 0 0.00031437742291018367
1 I-Disease 0 9.309771121479571e-05
( O 0 3.23212248076743e-06
NF1 B-Disease 1 0.9999289512634277
) O 0 8.468568921671249e-07
. O 0 1.2877036397185293e-06

DNA O 0 2.0043855329276994e-05
sequence O 0 1.230347379532759e-07
analysis O 0 2.3056598408288664e-08
and O 0 4.471524484017664e-09
allele O 0 1.2562773932245364e-08
- O 0 3.597032005586698e-08
specific O 0 1.3371569407283346e-09
amplification O 0 2.3004375293567136e-07
in O 0 7.453184736050389e-09
two O 0 3.3530758170030595e-09
siblings O 0 2.113667250114304e-07
revealed O 0 6.472681661762181e-07
a O 0 1.0540813377701852e-07
homozygous O 0 3.4640468129509827e-06
MLH1 O 1 0.9607279896736145
mutation O 0 4.296671534120833e-07
( O 0 9.268762113379125e-08
C676T O 0 2.1366924556787126e-05
- O 0 4.7821722546359524e-05
- O 0 2.5761377401067875e-05
> O 0 7.740522960375529e-06
Arg226Stop O 0 0.000712659559212625
) O 0 6.228785309758678e-07
. O 0 9.783227596926736e-07

Thus O 0 4.11521205023746e-06
, O 0 1.0659046267846861e-07
a O 0 6.530786578196057e-08
homozygous O 0 3.260542825955781e-06
germ O 1 0.9999960660934448
- O 0 0.04337872937321663
line O 0 0.00012692752352450043
MLH1 O 1 0.9999953508377075
mutation O 0 3.12668845481312e-07
and O 0 6.381508654840218e-08
consequent O 0 0.02388305775821209
mismatch O 1 1.0
repair O 1 1.0
deficiency O 1 1.0
results O 0 8.394997166760731e-06
in O 0 1.5578386580727965e-07
a O 0 1.6742252739732066e-07
mutator O 0 0.10458832234144211
phenotype O 0 1.1383849596313667e-06
characterized O 0 3.4966262774105417e-07
by O 0 2.2563411050668947e-07
leukemia B-Disease 1 1.0
and O 0 2.3369000700768083e-05
/ O 1 0.9999922513961792
or O 1 0.987346887588501
lymphoma B-Disease 1 1.0
associated O 0 0.00010914005542872474
with O 0 1.9451429125183495e-06
neurofibromatosis B-Disease 1 1.0
type I-Disease 0 0.08101257681846619
1 I-Disease 0 8.68827264639549e-05
. O 0 4.362378831501701e-07
. O 0 2.578297539912455e-07

Missense O 0 0.00019393798720557243
mutations O 0 2.054041260635131e-06
in O 0 1.7854493705726782e-07
the O 0 3.931594250161652e-08
most O 0 5.820854465099501e-09
ancient O 0 1.267653431114013e-07
residues O 0 2.2748078265522054e-07
of O 0 1.238186655427853e-07
the O 0 2.3821351646802214e-07
PAX6 O 1 0.9999327659606934
paired O 0 1.357733822260343e-06
domain O 0 1.8460190176483593e-07
underlie O 0 2.3405007141263923e-06
a O 0 5.875783415376645e-08
spectrum O 0 3.171052640027483e-06
of O 0 3.6257544707041234e-05
human O 1 0.9999833106994629
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 0 0.0010258577531203628

Mutations O 0 1.0371480129833799e-05
of O 0 2.1337514226615895e-06
the O 0 4.1266861217081896e-07
human O 0 2.2851411358715268e-06
PAX6 O 1 0.9999983310699463
gene O 0 2.4651522835483775e-05
underlie O 1 0.9954648613929749
aniridia B-Disease 1 1.0
( O 1 0.9556538462638855
congenital B-Disease 1 1.0
absence I-Disease 0 0.04047170281410217
of I-Disease 0 0.0009078143048100173
the I-Disease 0 8.411280759901274e-06
iris I-Disease 0 0.00021600646141450852
) O 0 4.4580549030115435e-08
, O 0 1.261319493295332e-08
a O 0 2.3588384578943078e-08
rare O 0 3.373086201463593e-06
dominant O 0 0.30962374806404114
malformation B-Disease 1 0.9999998807907104
of I-Disease 1 0.9872766137123108
the I-Disease 1 0.8505026698112488
eye I-Disease 1 0.9999970197677612
. O 0 6.345325346046593e-06

The O 0 2.8561471481225453e-06
spectrum O 0 3.4233532915095566e-06
of O 0 2.964936356875114e-06
PAX6 O 1 0.9998641014099121
mutations O 0 5.665999651682796e-07
in O 0 7.748476491542533e-07
aniridia B-Disease 1 1.0
patients O 0 1.684155108705454e-06
is O 0 1.4819685034694885e-08
highly O 0 6.802805785355304e-08
biased O 0 7.503625454319263e-08
, O 0 5.528646429553419e-09
with O 0 2.1447081888226194e-09
92 O 0 2.6851529355553794e-07
% O 0 2.1723334242551573e-09
of O 0 1.1629397889123538e-08
all O 0 5.562992289043223e-09
reported O 0 5.821401671823878e-08
mutations O 0 3.455565789067805e-08
leading O 0 6.0431136716943e-07
to O 0 2.8669127516423032e-08
premature O 0 1.028460815177823e-06
truncation O 0 3.471292529866332e-06
of O 0 3.04218616520302e-07
the O 0 6.514601125218178e-08
protein O 0 3.61881937749331e-08
( O 0 9.921381050048694e-09
nonsense O 0 5.104375304654241e-07
, O 0 7.3804016231804326e-09
splicing O 0 1.6788428069958172e-07
, O 0 4.657318974921054e-09
insertions O 0 7.708750615620374e-08
and O 0 5.959631454999226e-09
deletions O 0 7.476638330672358e-08
) O 0 7.2572814424631815e-09
and O 0 8.927596439889385e-09
just O 0 8.088149705542946e-09
2 O 0 3.4979329655016045e-08
% O 0 1.1017083911823988e-09
leading O 0 6.779047545535377e-09
to O 0 5.533929425816098e-10
substitution O 0 4.2361250507383374e-08
of O 0 4.869384184758019e-08
one O 0 9.757789243280968e-09
amino O 0 1.868316701347794e-08
acid O 0 1.8493064857239006e-08
by O 0 4.0362664321946795e-09
another O 0 4.34572342555839e-08
( O 0 4.2390837506900425e-08
missense O 0 3.831296908174409e-06
) O 0 1.9289149122414528e-07
. O 0 1.037080892274389e-06

The O 0 3.93112532037776e-06
extraordinary O 0 1.085207827600243e-06
conservation O 0 5.1905112741224e-07
of O 0 1.731464465137833e-07
the O 0 1.3305434265475924e-07
PAX6 O 0 0.013603650964796543
protein O 0 1.7807185770379874e-07
at O 0 4.928681391902501e-07
the O 0 2.527461262502584e-08
amino O 0 5.6808794113294425e-08
acid O 0 1.517854002486274e-07
level O 0 1.22325033657944e-07
amongst O 0 2.289883127559733e-07
vertebrates O 0 1.9986387087556068e-06
predicts O 0 3.9462449308302894e-07
that O 0 5.06724928683866e-09
pathological O 0 1.68674741871655e-05
missense O 0 1.6513791933903121e-06
mutations O 0 9.993632943405828e-08
should O 0 6.667917329394868e-09
in O 0 1.9877282042557454e-08
fact O 0 3.730615816266436e-09
be O 0 2.471488347310924e-09
common O 0 5.338929742748633e-09
even O 0 2.5045117091337943e-09
though O 0 6.511153283206284e-10
they O 0 1.3902475004545778e-10
are O 0 1.2197445831141351e-10
hardly O 0 1.0910106595929392e-08
ever O 0 2.451699998573531e-08
seen O 0 4.048056467809147e-08
in O 0 1.7205184121849015e-07
aniridia B-Disease 1 1.0
patients O 0 1.283042183786165e-05
. O 0 2.4727025902393507e-06

This O 0 1.8074672425427707e-07
indicates O 0 1.2034463736654288e-07
that O 0 1.117752224111257e-09
there O 0 2.813654198519089e-09
is O 0 1.7146264408296474e-09
a O 0 1.0828591356926154e-08
heavy O 0 1.3216658771852963e-05
ascertainment O 0 0.00035970148746855557
bias O 0 9.01237342532113e-08
in O 0 5.416120885115561e-09
the O 0 3.446940510798413e-09
selection O 0 9.293755098838119e-09
of O 0 8.711133148153749e-08
patients O 0 3.937177339707887e-08
for O 0 2.3185723563301508e-08
PAX6 O 1 0.9999194145202637
mutation O 0 5.477657794017432e-08
analysis O 0 7.994590767168575e-09
and O 0 5.063413688333185e-09
that O 0 1.270169303069224e-09
the O 0 2.6192960689286338e-08
missing O 0 1.1035333500331035e-06
PAX6 O 1 0.9999003410339355
missense O 0 1.811008587537799e-05
mutations O 0 3.5449693314149044e-07
frequently O 0 1.1079595196861192e-07
may O 0 1.280154435789882e-07
underlie O 0 8.382452506339177e-06
phenotypes O 0 1.5618239785908372e-06
distinct O 0 1.0659981342087121e-07
from O 0 9.091878041544987e-07
textbook O 0 0.0012794474605470896
aniridia B-Disease 1 0.9999997615814209
. O 0 9.492167919233907e-06

Here O 0 4.7324820116045885e-06
we O 0 5.013903958683841e-08
present O 0 1.4134415948774404e-07
four O 0 1.1846496050793576e-07
novel O 0 8.330233640663209e-07
PAX6 O 1 0.990450918674469
missense O 0 1.3639498320117127e-05
mutations O 0 3.458751223206491e-07
, O 0 3.37713359499503e-08
two O 0 4.213817295095623e-09
in O 0 2.773316865045672e-08
association O 0 2.158527507845065e-07
with O 0 3.736122167197209e-08
atypical O 0 8.293784776469693e-05
phenotypes O 0 6.218057387741283e-05
ectopia B-Disease 1 0.8293880820274353
pupillae I-Disease 0 0.014871506951749325
( O 0 1.4416944793538278e-07
displaced B-Disease 0 4.5517431601638236e-08
pupils I-Disease 0 3.774402728140558e-07
) O 0 1.0609271328121395e-07
and O 0 2.353202262384002e-06
congenital B-Disease 1 1.0
nystagmus I-Disease 1 0.9999023675918579
( O 0 8.080995712589356e-07
searching B-Disease 0 3.8163420867931563e-07
gaze I-Disease 0 2.754158458628808e-06
) O 0 9.639602005506731e-09
, O 0 4.895988947595242e-09
and O 0 2.531396647853512e-09
two O 0 2.9335269768893113e-09
in O 0 1.8128147871721012e-08
association O 0 1.717387192456954e-07
with O 0 1.5490483562530244e-08
more O 0 3.688111149813267e-08
recognizable O 0 0.0014920419780537486
aniridia B-Disease 1 0.9999998807907104
phenotypes O 0 0.0001185763394460082
. O 0 7.578570148325525e-06

Strikingly O 0 2.680898251128383e-05
, O 0 1.6378017164697667e-07
all O 0 9.458818617247289e-09
four O 0 8.914120108727275e-09
mutations O 0 5.286278970118019e-09
are O 0 5.88231463538591e-10
located O 0 3.917999435998354e-08
within O 0 1.3796483067096688e-08
the O 0 9.927840238788121e-08
PAX6 O 1 0.9958588480949402
paired O 0 5.191154741623905e-07
domain O 0 3.954275840101218e-08
and O 0 7.645563293579016e-09
affect O 0 2.0027947300604865e-08
amino O 0 2.3487281453071773e-08
acids O 0 1.6095638599722406e-08
which O 0 2.3691084649613003e-09
are O 0 1.568700308540727e-10
highly O 0 1.185582654272821e-08
conserved O 0 1.951767103491875e-08
in O 0 6.072736091766728e-09
all O 0 5.090051935496831e-09
known O 0 8.69139995529622e-08
paired O 0 3.67550626378943e-07
domain O 0 1.3965814105176833e-07
proteins O 0 1.148736288314467e-07
. O 0 1.324295112681284e-06

Our O 0 1.7216899550476228e-06
results O 0 2.0197204264604807e-07
support O 0 1.8412535496281635e-08
the O 0 1.4285699734273294e-08
hypothesis O 0 2.4501947137878233e-08
that O 0 1.410875166696357e-10
the O 0 1.7567177712507487e-09
under O 0 2.7312006878332795e-08
- O 0 5.033344763205605e-08
representation O 0 1.2191404552552854e-09
of O 0 1.3424653388938168e-08
missense O 0 8.249453458120115e-07
mutations O 0 6.474613911677807e-08
is O 0 1.1126732424315833e-08
caused O 0 1.779044822569631e-07
by O 0 3.699214445873622e-08
ascertainment O 0 0.00023063356638886034
bias O 0 2.8428374321265437e-07
and O 0 1.9590810751424215e-08
suggest O 0 1.2205020993860671e-08
that O 0 5.550017112554428e-10
a O 0 3.6191485364156506e-09
substantial O 0 2.0034672587598834e-08
burden O 0 6.750753982487367e-07
of O 0 2.4885052880563308e-06
PAX6 B-Disease 1 1.0
- I-Disease 1 0.9410556554794312
related I-Disease 1 0.9955860376358032
disease I-Disease 1 0.9999978542327881
remains O 0 5.701525083168235e-07
to O 0 4.58497373401201e-09
be O 0 3.6152574267589443e-09
uncovered O 0 1.6971230252238456e-06
. O 0 7.56318385697341e-08
. O 0 4.669261954859394e-07

The O 0 5.674425665347371e-06
chromosomal O 0 6.481721356976777e-06
order O 0 3.996213422396977e-07
of O 0 1.5119580893951934e-06
genes O 0 7.464014117886109e-08
controlling O 0 7.643385515621048e-07
the O 0 1.5222740046283434e-07
major O 0 3.49337051375187e-06
histocompatibility O 1 0.9669004678726196
complex O 0 1.3508947631635237e-05
, O 0 7.686595182576639e-08
properdin O 0 9.058263458427973e-06
factor O 0 2.391282976077491e-07
B O 0 1.0942786502710078e-05
, O 0 2.1024566976279857e-08
and O 0 6.613581859937767e-08
deficiency B-Disease 0 0.0015061406884342432
of I-Disease 0 1.5733907048343099e-06
the I-Disease 0 2.0863943461790768e-07
second I-Disease 0 8.145509582391242e-07
component I-Disease 0 6.655911874986487e-07
of I-Disease 0 5.238150038167078e-07
complement I-Disease 0 5.386018983699614e-06
. O 0 1.853552930697333e-06

The O 0 1.5226979712679167e-06
relationship O 0 8.354198399729285e-08
of O 0 1.32897724824943e-07
the O 0 1.6694604809686098e-08
genes O 0 1.7446966094070149e-09
coding O 0 1.815510408675891e-08
for O 0 5.860245622102411e-09
HLA O 0 8.786029866314493e-06
to O 0 5.872049957389436e-09
those O 0 2.238099261475668e-09
coding O 0 3.513009971811698e-08
for O 0 6.607678404435546e-09
properdin O 0 4.068720045324881e-06
Factor O 0 2.4774064399935014e-07
B O 0 4.8700808292778675e-06
allotypes O 0 1.4807798152105534e-06
and O 0 6.862450607769688e-09
for O 0 3.006699955676595e-08
deficiency B-Disease 0 9.386325837112963e-05
of I-Disease 0 9.471293651586166e-07
the I-Disease 0 1.1771457764098159e-07
second I-Disease 0 1.0969767316737489e-07
component I-Disease 0 5.813867431925246e-08
of I-Disease 0 5.2877940248663435e-08
complement I-Disease 0 1.0709993603086332e-07
( O 0 5.849103956734325e-08
C2 O 0 0.020857561379671097
) O 0 1.1868950267057699e-08
was O 0 1.5286556021010256e-08
studied O 0 2.0561012448183646e-08
in O 0 9.426250890953725e-10
families O 0 2.223406458945476e-10
of O 0 3.347231114503302e-08
patients O 0 1.7382345163241553e-07
with O 0 1.57416661750176e-06
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 1 0.7928087711334229

Patients O 0 8.79640083439881e-06
were O 0 2.580306954769185e-07
selected O 0 3.1053639304445824e-07
because O 0 1.8410990065831356e-08
they O 0 1.7733583490553428e-09
were O 0 7.238563526357211e-09
heterozygous O 0 2.1229920932341884e-08
or O 0 2.8780622329804828e-08
homozygous O 0 2.1615651348838583e-06
for O 0 3.457956700003706e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 9.437707922188565e-05

12 O 0 9.226302609022241e-06
families O 0 2.815942856670972e-08
with O 0 3.0238442860763826e-08
15 O 0 2.846057327587914e-07
matings O 0 2.0816414689761586e-06
informative O 0 1.5715821746198344e-06
for O 0 1.4250452295527793e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 1.0329134056519251e-05
found O 0 1.5792021486049634e-06
. O 0 1.2718664947897196e-06

Of O 0 4.25830548920203e-05
57 O 0 1.5029047972348053e-05
informative O 0 1.990419605135685e-06
meioses O 0 4.998717486159876e-05
, O 0 4.087259597440607e-08
two O 0 1.4463353847915528e-09
crossovers O 0 2.4501385809116982e-08
were O 0 1.0970684805045039e-08
noted O 0 4.950149623539346e-09
between O 0 1.5199132619159172e-08
the O 0 3.8077512272138847e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 1.491467287451087e-07
and O 0 1.2854683539842426e-08
the O 0 6.980992850458279e-08
HLA O 0 8.896658255252987e-05
- O 0 4.636754511011532e-06
B O 0 1.036221601680154e-05
gene O 0 1.1229582597138688e-08
, O 0 1.5500525307743374e-09
with O 0 4.26932073027686e-10
a O 0 3.80162790136751e-09
recombinant O 0 4.1273068518421496e-08
fraction O 0 1.4488044541849376e-08
of O 0 1.3080288852052036e-07
0 O 0 3.2057664611784276e-07
. O 0 1.202594006599611e-07

035 O 0 0.23699837923049927
. O 0 0.0002556115505285561

A O 0 3.049437509616837e-05
lod O 0 0.00011720443580998108
score O 0 2.4859293716872344e-06
of O 0 4.115586875741428e-07
13 O 0 2.7073949127043306e-07
was O 0 3.610903931416942e-08
calculated O 0 3.0782763005277047e-09
for O 0 3.6858520680027596e-09
linkage O 0 1.4471468148258282e-06
between O 0 1.861073906184174e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 7.401183097499597e-07
HLA O 0 0.0017652316018939018
- O 0 5.421236892289016e-06
B O 0 8.125585736706853e-06
at O 0 3.831051742508862e-08
a O 0 8.422958441833828e-10
maximum O 0 7.610262975354942e-10
likelihood O 0 1.0718588239200244e-09
value O 0 1.444824371255038e-09
of O 0 6.444955236162286e-09
the O 0 3.1226992103228213e-09
recombinant O 0 2.7745498343278996e-08
fraction O 0 1.8075528629424298e-08
of O 0 4.1339326628531126e-08
0 O 0 4.936603659189132e-07
. O 0 2.1563960217463318e-07

04 O 0 0.028449101373553276
. O 0 6.447712075896561e-05

18 O 0 1.2567334124469198e-05
families O 0 3.7499578553479296e-08
with O 0 3.1862953164818464e-08
21 O 0 5.367643325371318e-07
informative O 0 2.1330362187654828e-07
matings O 0 9.942448286892613e-07
for O 0 1.3544531718423514e-08
both O 0 4.0880628660033835e-08
properdin O 0 2.704192593228072e-05
Factor O 0 1.1237124226681772e-06
B O 0 1.868470098997932e-05
allotype O 0 8.987482033262495e-06
and O 0 8.501050530185239e-08
HLA O 0 0.0001485013635829091
- O 0 1.5620486010448076e-05
B O 0 2.267326090077404e-05
were O 0 1.114661927203997e-07
found O 0 1.4220934474451496e-07
. O 0 1.478472597682412e-07

Of O 0 5.653393964166753e-05
72 O 0 1.1739864930859767e-05
informative O 0 2.189213091696729e-06
meioses O 0 0.00011266247020103037
, O 0 7.26752062973901e-08
three O 0 1.9195883993461393e-08
recombinants O 0 6.532981387863401e-06
were O 0 4.079346993535182e-08
found O 0 1.2441685015573967e-08
, O 0 3.414224014619549e-09
giving O 0 2.7586333217755055e-09
a O 0 4.943035758486758e-09
recombinant O 0 9.135372636137618e-08
fraction O 0 4.315829471579491e-08
of O 0 2.5016564109137107e-07
0 O 0 6.567235573129437e-07
. O 0 3.737006295523315e-07

042 O 0 0.07368989288806915
. O 0 0.0001820762554416433

A O 0 4.70685881737154e-05
lod O 0 9.645063983043656e-05
score O 0 1.3014595197091694e-06
of O 0 2.8705466093015275e-07
16 O 0 2.703919506075181e-07
between O 0 5.247354906146029e-08
HLA O 0 4.6535507863154635e-05
- O 0 5.026533017371548e-06
B O 0 2.5632955384935485e-06
and O 0 4.902585892807565e-09
Factor O 0 9.117999866248283e-08
B O 0 2.921311534009874e-06
allotypes O 0 2.2565679955732776e-06
was O 0 2.4528505448984106e-08
calculated O 0 4.013558374538206e-09
at O 0 1.293286544523653e-08
a O 0 5.259945257130028e-10
maximum O 0 5.20348597543574e-10
likelihood O 0 6.815579212116063e-10
value O 0 1.342159938744203e-09
of O 0 4.014124588280765e-09
the O 0 2.9690971903306718e-09
recombinant O 0 2.7819314851740273e-08
fraction O 0 1.2877482191697709e-08
of O 0 7.368056031964443e-08
0 O 0 3.2827406926116964e-07
. O 0 1.7480127212365915e-07

04 O 0 0.025038287043571472
. O 0 8.76927879289724e-05

A O 0 1.4401266525965184e-05
crossover O 0 1.940977199410554e-06
was O 0 3.9780300653546874e-07
shown O 0 5.0035353638122615e-09
to O 0 1.3438993251568832e-09
have O 0 1.6525601720385197e-10
occurred O 0 9.781099485905997e-09
between O 0 6.766139315494968e-10
genes O 0 2.9091648534596004e-10
for O 0 2.991840386545874e-10
Factor O 0 2.6391598240138592e-08
B O 0 1.0577160765024018e-06
and O 0 6.050515644062671e-09
HLA O 0 8.374238859687466e-06
- O 0 1.9688072825374547e-06
D O 0 9.727613360155374e-06
, O 0 4.556344634920606e-09
in O 0 1.9583590304961263e-09
which O 0 1.5354985061222237e-09
HLA O 0 2.288211544509977e-05
- O 0 6.74597913530306e-06
D O 0 6.305355782387778e-05
segregared O 0 1.740475454425905e-05
with O 0 1.1008312839067003e-07
HLA O 0 0.0005870478926226497
- O 0 5.1440647439449094e-06
A O 0 2.431560005788924e-06
and O 0 2.878551583762601e-07
B O 0 0.00012458005221560597
. O 0 4.039920042941958e-07

These O 0 1.5016148324775713e-07
studies O 0 2.3800843962362705e-07
suggest O 0 1.2102697510840699e-08
that O 0 7.755804332099103e-10
the O 0 1.3467295056912576e-09
genes O 0 4.080829563157806e-10
for O 0 1.3172901658364822e-09
Factor O 0 3.980690337357373e-07
B O 0 0.0025266080629080534
and O 0 2.9720392831222853e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.8931387568699165e-09
located O 0 2.5421975635708804e-08
outside O 0 1.0224105118084026e-08
those O 0 3.874891241206768e-10
for O 0 4.865194913605819e-09
HLA O 0 0.00010967705020448193
, O 0 1.1644313069325563e-08
that O 0 3.874432996653354e-10
the O 0 2.454431102805188e-09
order O 0 7.951825864438433e-09
of O 0 6.706913069365328e-08
genese O 0 1.635903572605457e-05
is O 0 1.3961800604533892e-08
HLA O 0 7.451618785125902e-06
- O 0 7.38730534521892e-07
A O 0 9.2488915015565e-07
, O 0 1.814284900092389e-08
- O 0 2.3351203992660885e-07
B O 0 1.7229087916348362e-06
, O 0 3.651682733973871e-09
- O 0 1.280640589129689e-07
D O 0 1.5338124512709328e-06
, O 0 7.741826735241375e-09
Factor O 0 9.289433933190594e-08
B O 0 1.3244834008219186e-05
allotype O 0 0.00010211456537945196
, O 0 4.534180789050879e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 2.5793026381393247e-08
that O 0 6.408263919510659e-10
the O 0 3.6259200086874444e-09
genes O 0 3.057835984421331e-09
coding O 0 1.2342654542862874e-07
for O 0 6.548473834300239e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 2.4914470486692153e-07
Factor O 0 5.201180215408385e-07
B O 0 1.0853582352865487e-05
allotypes O 0 6.209141929502948e-07
are O 0 1.5766132843708647e-10
approximately O 0 1.4702331574412142e-09
3 O 0 1.2295561901964902e-08
- O 0 9.149182744749851e-08
- O 0 1.747914240013415e-07
5 O 0 2.6150031473548552e-08
centimorgans O 0 8.855622581904754e-07
from O 0 1.3227543504967798e-08
the O 0 2.6597474445111402e-08
HLA O 0 1.8429054762236774e-05
- O 0 1.1585538004510454e-06
A O 0 3.641530383902136e-07
and O 0 3.705880757820523e-08
HLA O 0 8.78888531588018e-05
- O 0 6.2647886807098985e-06
B O 0 2.1753381588496268e-05
loci O 0 8.884046565071912e-08
, O 0 6.387717021993922e-09
and O 0 1.4774408363393832e-09
that O 0 4.56087223543733e-10
the O 0 4.1129868399991665e-09
apparent O 0 1.0714386178278801e-07
lack O 0 1.0762661872831814e-07
of O 0 4.123731400795805e-07
recombinants O 0 6.441924597311299e-06
between O 0 7.942412949546451e-09
the O 0 9.141905898957248e-09
Factor O 0 5.654113977016095e-08
B O 0 1.812964546843432e-05
gene O 0 2.9198528750384867e-07
and O 0 2.7437351945991395e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 8.658388992444088e-07
suggests O 0 1.7788948980523855e-08
that O 0 3.2666222504751374e-10
these O 0 2.7186100592935247e-10
two O 0 8.743935020483207e-10
genes O 0 3.3892315620676072e-09
lie O 0 2.393694558122661e-07
in O 0 2.4324164016320537e-08
close O 0 5.2227616009759004e-08
proximity O 0 8.252398231434199e-08
to O 0 1.2397671333985727e-08
one O 0 3.844417761911245e-08
another O 0 2.104941074776434e-07
. O 0 6.43546229639469e-07

Distribution O 0 6.2812705436954275e-06
of O 0 7.703884875809308e-06
emerin O 0 0.0006639054627157748
and O 0 3.989842696228152e-07
lamins O 0 0.0001310841616941616
in O 0 1.0297559072114382e-07
the O 0 5.959423674539721e-07
heart O 0 0.0015526933129876852
and O 0 4.912876150342527e-08
implications O 0 3.541827027220279e-07
for O 0 1.9472275880616507e-07
Emery B-Disease 1 0.9997071623802185
- I-Disease 1 0.9999783039093018
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.014593738131225109

Emerin O 0 0.008735109120607376
is O 0 5.842825885338243e-07
a O 0 1.1718333325916319e-07
nuclear O 0 4.1955890992539935e-06
membrane O 0 2.3178455421657418e-07
protein O 0 2.9323201644615438e-08
which O 0 1.1513153985731606e-08
is O 0 2.6809852116116417e-09
missing O 0 2.2493644280530134e-08
or O 0 9.26801568823521e-09
defective O 0 5.340864390745992e-06
in O 0 3.111384501153225e-07
Emery B-Disease 1 0.9959532022476196
- I-Disease 1 0.9993487000465393
Dreifuss I-Disease 1 0.9999998807907104
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999983310699463
EDMD B-Disease 1 1.0
) O 0 2.3884573238319717e-05
. O 0 5.80365758651169e-06

It O 0 6.684065851914056e-07
is O 0 1.5625502669536218e-08
one O 0 4.642277229294223e-09
member O 0 1.3624751993290829e-08
of O 0 4.8436053390332745e-08
a O 0 2.1108062853159026e-08
family O 0 3.2760535617626374e-08
of O 0 8.202603112295037e-07
lamina O 1 0.9991335272789001
- O 0 1.0039433618658222e-05
associated O 0 4.46089600814048e-08
proteins O 0 5.077582354573451e-09
which O 0 1.7286809761429822e-09
includes O 0 5.0422816144646276e-08
LAP1 O 1 0.994840681552887
, O 0 3.262357779476588e-07
LAP2 O 0 0.14914186298847198
and O 0 2.3470964549687778e-07
lamin O 0 4.057391197420657e-05
B O 0 3.967644079239108e-05
receptor O 0 2.2528644194608205e-07
( O 0 1.6781561384959787e-07
LBR O 0 0.25728604197502136
) O 0 4.5712104679296317e-07
. O 0 5.178363267077657e-07

A O 0 5.7186389312846586e-05
panel O 0 3.685699766720063e-06
of O 0 1.6476603832416004e-06
16 O 0 1.6053658100645407e-06
monoclonal O 0 1.4370097005667049e-06
antibodies O 0 2.87286923139618e-07
( O 0 1.119835957297255e-07
mAbs O 0 1.2231666914885864e-05
) O 0 2.6892729820815475e-08
has O 0 1.2493877044050805e-09
been O 0 1.383191450265997e-09
mapped O 0 1.1492639728771792e-08
to O 0 7.364424070566145e-10
six O 0 1.6040588857180182e-09
specific O 0 9.218224517049123e-10
sites O 0 1.0826979313094398e-08
throughout O 0 2.1592146737248186e-08
the O 0 1.6438882255442877e-08
emerin O 0 1.5586947483825497e-06
molecule O 0 5.996334540014914e-09
using O 0 3.810920468083623e-09
phage O 0 1.701378806728826e-07
- O 0 1.6120502266403491e-07
displayed O 0 7.207650298823864e-08
peptide O 0 2.7466326102398853e-08
libraries O 0 6.283146003482898e-09
and O 0 1.7506134319944522e-09
has O 0 5.807710423688661e-10
been O 0 3.64575175604287e-10
used O 0 1.3010496013876605e-09
to O 0 2.6996067603590745e-09
localize O 0 5.351148047338938e-06
emerin O 0 2.642972867761273e-05
in O 0 6.499831073369933e-08
human O 0 8.139346618918353e-08
and O 0 1.2522031056505512e-06
rabbit O 0 0.2359810173511505
heart O 1 0.9798228144645691
. O 0 5.78839080844773e-06

Several O 0 5.5666737353021745e-06
mAbs O 0 4.4323063775664195e-05
against O 0 3.3807080512815446e-07
different O 0 2.7405572922134525e-08
emerin O 0 4.2835654312511906e-05
epitopes O 0 4.771050953422673e-06
did O 0 7.764588616510082e-08
not O 0 3.105960155735943e-09
recognize O 0 2.2118909370760775e-08
intercalated O 0 9.456912266614381e-06
discs O 0 2.4281845981022343e-05
in O 0 5.1419767999050237e-08
the O 0 1.9969496634075767e-07
heart O 0 0.01934596337378025
, O 0 1.4494096589601213e-08
though O 0 1.871083288307318e-09
they O 0 3.2400265803644857e-10
recognized O 0 7.82714071334567e-09
cardiomyocyte O 0 1.454862854188832e-06
nuclei O 0 3.285070704350801e-07
strongly O 0 2.250497388445183e-08
, O 0 6.49014086917532e-09
both O 0 2.3354325140445553e-09
at O 0 1.754974761070116e-07
the O 0 2.9471397766656082e-08
rim O 0 1.0288013072567992e-06
and O 0 1.574595209774543e-08
in O 0 2.692449996288815e-08
intranuclear O 0 6.44820393063128e-05
spots O 0 1.2307468750805128e-06
or O 0 1.4895185529439914e-07
channels O 0 3.0476832080239546e-07
. O 0 4.986750923308136e-07

A O 0 0.00026120725669898093
polyclonal O 0 0.001032646163366735
rabbit O 0 0.000173646752955392
antiserum O 0 6.206813122844324e-05
against O 0 6.689022484351881e-06
emerin O 0 0.0008494981448166072
did O 0 1.1256961585104364e-07
recognize O 0 3.451850361102515e-08
both O 0 1.535516958028893e-08
nuclear O 0 7.575073141197208e-06
membrane O 0 1.7701565013794607e-07
and O 0 1.839175745033117e-08
intercalated O 0 7.145184099499602e-06
discs O 0 5.8888372223009355e-06
but O 0 4.4392414189076135e-09
, O 0 9.089028973896518e-10
after O 0 2.4568855838680292e-09
affinity O 0 1.2712114694224397e-09
purification O 0 5.667264417752449e-07
against O 0 6.893532145113568e-08
a O 0 2.1671901606623578e-08
pure O 0 2.744774292295915e-06
- O 0 2.2377648747351486e-06
emerin O 0 7.785633351886645e-05
band O 0 3.7772040286654374e-06
on O 0 2.5569761419319548e-08
a O 0 5.13744469188282e-09
western O 0 5.001095715329029e-08
blot O 0 3.152373028569855e-05
, O 0 5.723294904669274e-08
it O 0 2.5283098281647653e-08
stained O 0 0.00015806501323822886
only O 0 1.5159553612420495e-08
the O 0 6.513904793337133e-08
nuclear O 0 2.184908044000622e-05
membrane O 0 2.610207729958347e-06
. O 0 9.386614578943409e-07

These O 0 1.8068520546421496e-07
results O 0 8.214676228135431e-08
would O 0 4.381058182900688e-09
not O 0 1.1493641594029214e-09
be O 0 6.878224656503562e-10
expected O 0 8.083584468465688e-09
if O 0 5.708890249422893e-09
immunostaining O 0 5.790389423054876e-06
at O 0 3.847880805096793e-07
intercalated O 0 2.6935961159324506e-06
discs O 0 3.1752317681821296e-06
were O 0 9.050180160841137e-09
due O 0 1.8905238263755564e-08
to O 0 1.9430819175880742e-09
a O 0 3.683638283291657e-09
product O 0 1.4848630769392912e-08
of O 0 2.3741398180732176e-08
the O 0 2.3968393492168616e-08
emerin O 0 1.1107839782198425e-05
gene O 0 1.4847639562276527e-08
and O 0 5.535071956330739e-09
, O 0 3.666723369377678e-09
therefore O 0 3.4914588997736473e-09
, O 0 2.2086901196871622e-09
cast O 0 2.9619420249815676e-09
some O 0 3.780425139598975e-10
doubt O 0 1.377266123370191e-08
upon O 0 2.5404949255403153e-09
the O 0 3.4157481287877545e-09
hypothesis O 0 2.3839730189934016e-08
that O 0 6.180545408795979e-09
cardiac B-Disease 1 0.999998927116394
defects I-Disease 1 0.9995662569999695
in O 0 8.29557848192053e-06
EDMD B-Disease 1 1.0
are O 0 1.5203916348127677e-08
caused O 0 1.85542276653905e-07
by O 0 8.872155454753283e-09
absence O 0 2.358886206366151e-07
of O 0 8.145897822942061e-07
emerin O 0 0.0001618661917746067
from O 0 6.468454785135691e-07
intercalated O 0 0.00023263602633960545
discs O 0 0.000759054790250957
. O 0 2.2653523501503514e-06

Although O 0 8.716137017472647e-06
emerin O 0 0.00013018515892326832
was O 0 1.4463657862506807e-06
abundant O 0 1.2275228300495655e-07
in O 0 1.8231862242146235e-08
the O 0 1.4203810572155362e-08
membranes O 0 1.4626657218741457e-07
of O 0 1.0415624984716487e-07
cardiomyocyte O 0 2.782075898721814e-05
nuclei O 0 2.2604210698773386e-06
, O 0 2.076258809324827e-08
it O 0 3.912471679967666e-09
was O 0 7.675988200617212e-08
absent O 0 3.228691269896444e-08
from O 0 5.5535354093194655e-09
many O 0 7.361222187363126e-10
non O 0 3.6318124330136925e-07
- O 0 3.904716322722379e-06
myocyte O 0 0.0009850795613601804
cells O 0 1.1295029622715447e-07
in O 0 2.9538306023368932e-08
the O 0 3.09017309518822e-07
heart O 0 0.3368586301803589
. O 0 1.5333123428717954e-06

This O 0 9.963826386183428e-08
distribution O 0 7.343138719306808e-08
of O 0 3.1205817663249036e-07
emerin O 0 5.554043673328124e-05
was O 0 1.6742572483963158e-07
similar O 0 1.8135712931410808e-09
to O 0 8.528782124983536e-10
that O 0 3.6893460508835574e-10
of O 0 5.1355563357446954e-08
lamin O 0 4.819507012143731e-06
A O 0 2.3610384687344776e-06
, O 0 6.1572720255753666e-09
a O 0 4.848390577905093e-09
candidate O 0 4.816076870639563e-09
gene O 0 7.604956664408746e-09
for O 0 2.6138946562781484e-09
an O 0 7.805613044808979e-09
autosomal O 0 4.29324518336216e-06
form O 0 3.921471943613142e-06
of O 1 0.7878938913345337
EDMD B-Disease 1 1.0
. O 0 7.985304546309635e-05

In O 0 1.8756452391244238e-06
contrast O 0 1.4133163404039806e-06
, O 0 6.066458695386245e-07
lamin O 0 0.00010255634697386995
B1 O 1 0.9996228218078613
was O 0 7.992572136572562e-06
absent O 0 1.5227908534143353e-06
from O 0 1.8204764273832552e-07
cardiomyocyte O 0 2.1818867026013322e-05
nuclei O 0 4.000879016530234e-06
, O 0 5.23159506826687e-08
showing O 0 2.6512162776271e-07
that O 0 2.3041783592248066e-08
lamin O 0 0.00010523822857066989
B1 O 1 0.9617466330528259
is O 0 3.655663860513414e-08
not O 0 1.6547563319591063e-09
essential O 0 1.3165473156107055e-08
for O 0 4.170686462856565e-09
localization O 0 7.174696747824783e-07
of O 0 1.6120824852805526e-07
emerin O 0 6.1831283346691635e-06
to O 0 3.0435582942800465e-08
the O 0 3.4084845879078784e-07
nuclear O 0 0.0005744542577303946
lamina O 1 0.9799291491508484
. O 0 6.973831659706775e-06

Lamin O 1 0.9836977124214172
B1 O 1 0.9999690055847168
is O 0 1.7337375766146579e-06
also O 0 6.133292629328935e-08
almost O 0 1.4521963187519304e-08
completely O 0 6.089720727686654e-07
absent O 0 7.544625759692281e-07
from O 0 1.2283734349693987e-06
skeletal O 1 0.9349701404571533
muscle O 0 0.00025976530741900206
nuclei O 0 0.002067583380267024
. O 0 1.4527453458867967e-05

In O 0 5.2443312597461045e-05
EDMD B-Disease 1 1.0
, O 0 3.239026398205169e-07
the O 0 3.962754746567043e-08
additional O 0 7.795614820338415e-09
absence O 0 2.6611510861584975e-07
of O 0 6.719383236486465e-07
lamin O 0 0.00013809096708428115
B1 O 1 0.999885082244873
from O 0 1.0456870768393856e-05
heart O 1 0.999452531337738
and O 0 2.2718904801877216e-06
skeletal O 1 0.9999986886978149
muscle O 0 0.0011339070042595267
nuclei O 0 9.613797010388225e-05
which O 0 1.121943995485708e-07
already O 0 8.42968432834823e-08
lack O 0 4.740065833175322e-07
emerin O 0 0.0002413017937215045
may O 0 7.1006152069230666e-09
offer O 0 1.0570239128426806e-09
an O 0 3.331113995752588e-10
alternative O 0 5.29744204058602e-09
explanation O 0 4.688746280123723e-09
of O 0 3.790877300957618e-08
why O 0 8.652394356545301e-09
these O 0 3.0717308696637247e-09
tissues O 0 8.100068953353912e-07
are O 0 3.2380083059280196e-09
particularly O 0 6.443322320137668e-08
affected O 0 1.625674741490002e-07
. O 0 8.71854695105867e-08
. O 0 5.128822522237897e-07

Genetic O 0 1.489495116402395e-05
mapping O 0 3.594132522266591e-06
of O 0 2.1219896098045865e-06
the O 0 1.1736869964806829e-06
copper B-Disease 0 0.015750877559185028
toxicosis I-Disease 1 0.8093628287315369
locus O 0 2.2069114038458792e-06
in O 0 2.8511104233075457e-07
Bedlington O 0 0.0001923906966112554
terriers O 0 1.0737708180386107e-05
to O 0 8.895084846471946e-08
dog O 0 1.124871414504014e-05
chromosome O 0 1.4913406687355746e-07
10 O 0 8.563396391991773e-08
, O 0 5.902435429305797e-09
in O 0 6.588650069971891e-09
a O 0 3.1192957550274514e-08
region O 0 2.3643028157493973e-07
syntenic O 0 3.36767261615023e-05
to O 0 3.5744285753480654e-08
human O 0 1.3602738135887193e-07
chromosome O 0 4.835948175241356e-07
region O 0 4.653023779610521e-07
2p13 O 0 8.307304960908368e-05
- O 0 4.991923924535513e-05
p16 O 0 6.181872595334426e-05
. O 0 2.2363972220773576e-06

Abnormal O 1 0.9999994039535522
hepatic B-Disease 1 1.0
copper I-Disease 1 0.999992847442627
accumulation I-Disease 1 0.8882007002830505
is O 0 1.7611814939755277e-07
recognized O 0 7.087317754894684e-08
as O 0 9.120536326179263e-09
an O 0 2.7714873951367736e-08
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 3.4631048038136214e-05
man O 0 2.8605891202460043e-05
, O 0 7.750769270842284e-08
mouse O 0 1.9131809949612943e-06
, O 0 3.31622658222841e-07
rat O 0 0.012386910617351532
and O 0 1.1406028761484777e-06
dog O 0 0.0008274197462014854
. O 0 5.242760835244553e-06

The O 0 1.0674039003788494e-05
major O 0 2.7680391212925315e-05
cause O 0 3.014015055669006e-05
of O 1 0.6744830012321472
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9995695948600769
accumulation I-Disease 0 0.012372499331831932
in O 0 9.301522823079722e-07
man O 0 8.602174830230069e-07
is O 0 4.3937449234476844e-09
a O 0 2.4900092654434047e-08
dysfunctional O 0 2.7065325411967933e-05
ATP7B O 1 1.0
gene O 0 1.7242369949599379e-06
, O 0 2.2003828803462966e-07
causing O 0 0.0003013489185832441
Wilson B-Disease 1 0.9814181923866272
disease I-Disease 1 0.9997178912162781
( O 0 2.156687060050899e-06
WD B-Disease 1 0.9999871253967285
) O 0 1.5455564152944135e-06
. O 0 1.6919823337957496e-06

Mutations O 0 4.1956814129662234e-06
in O 0 4.4163147094877786e-07
the O 0 5.544356440623233e-07
ATP7B O 1 0.999789297580719
genes O 0 2.244371799520195e-08
have O 0 1.2868537346832909e-09
also O 0 2.5530029201803472e-09
been O 0 2.4712056845288544e-09
demonstrated O 0 1.7220015635643904e-08
in O 0 2.3979414010000255e-08
mouse O 0 2.104709210470901e-06
and O 0 6.016959446242254e-07
rat O 0 0.0039670830592513084
. O 0 2.2276656181929866e-06

The O 0 3.0252225769800134e-05
ATP7B O 1 0.9999809265136719
gene O 0 1.1962322332692565e-06
has O 0 2.2335417071417396e-08
been O 0 3.839755180479187e-09
excluded O 0 4.131749165026122e-08
in O 0 5.479190878787676e-09
the O 0 1.061108800826105e-08
much O 0 1.899875279320895e-08
rarer O 0 2.032524889727938e-06
human O 0 5.799806217510195e-07
copper B-Disease 1 0.9999890327453613
overload I-Disease 1 0.9999998807907104
disease O 1 0.9999614953994751
non B-Disease 0 3.877756171277724e-05
- I-Disease 0 1.3385757483774796e-05
Indian I-Disease 0 1.2356852039374644e-06
childhood I-Disease 1 0.7667275071144104
cirrhosis I-Disease 1 1.0
, O 0 1.0662706273478761e-07
indicating O 0 4.2776230202434817e-07
genetic O 0 1.6139558738359483e-06
heterogeneity O 0 2.6343517674831674e-05
. O 0 2.3631944259250304e-06

By O 0 2.1171099433558993e-06
investigating O 0 5.198023700359045e-06
the O 0 7.327245157284779e-07
common O 0 4.949424692313187e-06
autosomal O 1 0.717817485332489
recessive O 1 0.9197632670402527
copper B-Disease 1 0.9999997615814209
toxicosis I-Disease 1 0.9999998807907104
( O 0 2.034885255852714e-06
CT B-Disease 1 0.9999443292617798
) O 0 4.2538246702861215e-08
in O 0 4.782648943546519e-08
Bedlington O 0 0.0055832997895777225
terriers O 0 4.791676110471599e-05
, O 0 8.842573784306751e-09
we O 0 6.236625105238147e-10
have O 0 1.1479307782114034e-10
identified O 0 1.118778181208313e-09
a O 0 1.136309712990169e-09
new O 0 4.133875464162884e-09
locus O 0 3.713494223234193e-08
involved O 0 8.304120058255648e-09
in O 0 5.468376684802934e-07
progressive O 1 1.0
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 2.6330282707931474e-05

We O 0 8.448160428997653e-07
examined O 0 2.0651862087106565e-06
whether O 0 4.1176669185460923e-08
the O 0 8.407397444898379e-08
WD B-Disease 0 0.19032342731952667
gene O 0 1.2691209576587426e-06
ATP7B O 1 0.9998784065246582
was O 0 1.1259113534833887e-06
also O 0 2.8238906768507377e-09
causative O 0 5.295940042060465e-08
for O 0 8.595613110173872e-09
CT B-Disease 0 0.002066398272290826
by O 0 1.4395053149485193e-08
investigating O 0 1.1863319571148168e-07
the O 0 6.544690478449411e-08
chromosomal O 0 3.2802445275592618e-06
co O 0 3.7230868201731937e-06
- O 0 2.1141381694178563e-06
localization O 0 4.2177703107881825e-06
of O 0 9.121179687099357e-07
ATP7B O 1 0.9997143149375916
and O 0 6.207579161809917e-08
C04107 O 0 1.8353406403548433e-06
, O 0 3.3419600420359075e-09
using O 0 7.802036794402056e-10
fluorescence O 0 3.784598945344442e-08
in O 0 4.908490502941731e-09
situ O 0 7.410222906401032e-07
hybridization O 0 1.0828181729038988e-07
( O 0 3.374719170778917e-08
FISH O 0 3.6713131521537434e-06
) O 0 5.303176919824182e-08
. O 0 1.6488033338646346e-07

C04107 O 0 0.0007678834954276681
is O 0 3.0632492098447983e-07
an O 0 1.1921882148158147e-08
anonymous O 0 3.5138049270244665e-07
microsatellite O 0 1.5062048078107182e-05
marker O 0 8.72610053193057e-06
closely O 0 3.122972316305095e-07
linked O 0 2.1072678464406636e-06
to O 0 8.153887733897136e-07
CT B-Disease 1 0.9999860525131226
. O 0 5.295947175909532e-06

However O 0 4.338693997851806e-06
, O 0 1.318713430009666e-06
BAC O 0 0.39209458231925964
clones O 0 9.232235242961906e-06
containing O 0 3.249994051657268e-06
ATP7B O 1 0.9998940229415894
and O 0 1.9054117217365274e-07
C04107 O 0 5.661614977725549e-06
mapped O 0 1.5074660097980086e-07
to O 0 9.389935939907446e-09
the O 0 8.17825025478669e-08
canine O 0 1.5104827980394475e-05
chromosome O 0 3.489760445063439e-07
regions O 0 2.3482851929657045e-07
CFA22q11 O 0 9.219895582646132e-05
and O 0 1.6360252175218193e-07
CFA10q26 O 0 0.0009086321224458516
, O 0 4.5200266640677e-08
respectively O 0 7.459559725475629e-08
, O 0 5.4449160735714486e-09
demonstrating O 0 3.682670524085552e-08
that O 0 2.855075287300224e-09
WD B-Disease 0 0.00013697207032237202
cannot O 0 3.0565313835495544e-08
be O 0 4.576822032476002e-09
homologous O 0 5.0663146566876094e-08
to O 0 1.5997432001313427e-07
CT B-Disease 1 0.9957970380783081
. O 0 5.489289833349176e-06

The O 0 1.3329071407497395e-05
copper O 0 0.00012711527233477682
transport O 0 4.832421382161556e-06
genes O 0 4.888102012046147e-07
CTR1 O 1 0.9964200258255005
and O 0 1.6061912333498185e-07
CTR2 O 1 0.9971652626991272
were O 0 6.060958668285821e-08
also O 0 2.5668551728585953e-09
excluded O 0 4.1480785029079925e-08
as O 0 3.213208144003943e-09
candidate O 0 1.1719439863000503e-09
genes O 0 7.413793468025176e-10
for O 0 6.569776722642473e-09
CT B-Disease 1 0.9970476031303406
since O 0 4.943490949926854e-08
they O 0 9.83382819619294e-10
both O 0 1.0092889857205023e-09
mapped O 0 6.71643647365272e-08
to O 0 5.7268437103630276e-08
canine O 0 6.284112168941647e-05
chromosome O 0 2.5184683636325644e-06
region O 0 2.197527692260337e-06
CFA11q22 O 0 0.01834537647664547
. O 0 3.217498715457623e-06

2 O 0 0.00011202174937352538
- O 0 9.860999853117391e-05
22 O 0 1.0552864296187181e-05
. O 0 1.8993446246895473e-06

5 O 0 0.00031078170286491513
. O 0 2.1836311134393327e-05

A O 0 3.620606003096327e-05
transcribed O 0 3.6752437608811306e-06
sequence O 0 1.24830961567568e-07
identified O 0 5.0454751487905014e-08
from O 0 1.2485378064752695e-08
the O 0 1.4035225426312081e-08
C04107 O 0 2.427176468700054e-06
- O 0 5.837044909640099e-07
containing O 0 5.760915087194007e-07
BAC O 1 0.9998844861984253
was O 0 2.099041438441418e-07
found O 0 2.350429628705797e-09
to O 0 3.2991320786379674e-10
be O 0 2.444026370174157e-10
homologous O 0 1.3503717033458429e-09
to O 0 9.929309596756752e-10
a O 0 9.954666424505376e-09
gene O 0 7.877208219042586e-09
expressed O 0 1.1461723792294265e-09
from O 0 2.096618167968245e-08
human O 0 2.308454227772927e-08
chromosome O 0 5.354045029548615e-08
2p13 O 0 2.4497005597368116e-06
- O 0 1.4062068203202216e-06
p16 O 0 1.4503701777357492e-06
, O 0 1.4464464292984758e-08
a O 0 6.573035005175143e-09
region O 0 1.2642917823768585e-08
devoid O 0 4.877052788287983e-07
of O 0 2.4591651381911106e-08
any O 0 4.3743448863153844e-09
positional O 0 5.66428843740141e-06
candidate O 0 2.512321941594564e-07
genes O 0 2.7631668331196124e-07
. O 0 1.0302032933395822e-06

Molecular O 0 7.2954608185682446e-06
analysis O 0 1.391934176808718e-07
of O 0 3.28554676798376e-07
the O 0 7.871474849707738e-08
APC B-Disease 0 7.117605946405092e-06
gene O 0 4.1746044843193886e-08
in O 0 1.0348689016836943e-08
205 O 0 3.495191691627042e-08
families O 0 1.1693539470059022e-09
: O 0 3.253547209425278e-09
extended O 0 6.202844815561548e-08
genotype O 0 3.4883194643953175e-07
- O 0 7.468285048162215e-07
phenotype O 0 8.721474387130002e-08
correlations O 0 7.947265601160325e-08
in O 0 2.2742735694691874e-08
FAP B-Disease 0 3.215539618395269e-05
and O 0 2.5455648255956476e-08
evidence O 0 2.0134041989194884e-08
for O 0 1.4843950513210302e-09
the O 0 1.0064367117479378e-08
role O 0 2.191607428869702e-08
of O 0 5.074443834018894e-07
APC B-Disease 0 3.408850898267701e-05
amino O 0 2.9390739086920803e-07
acid O 0 2.3582092012475186e-07
changes O 0 9.078208762502982e-08
in O 0 0.00014272496628109366
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 0 0.4363768398761749
. O 0 7.0745800258009695e-06

BACKGROUND O 0 0.0037756734527647495
/ O 0 8.808258280623704e-05
AIMS O 0 1.2107718248444144e-05
The O 0 9.283748170219042e-08
development O 0 2.4919961560954107e-07
of O 1 0.8179388046264648
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.3103050378049375e-07
a O 0 8.339611667906865e-09
variable O 0 5.243780076824578e-09
range O 0 9.471151685147561e-08
of O 0 2.540499508540961e-07
extracolonic O 0 0.000641904363874346
manifestations O 0 8.69107389007695e-05
in O 0 1.2253722161403857e-06
familial B-Disease 1 0.9999998807907104
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 1.1886531865457073e-05
FAP B-Disease 1 0.9998636245727539
) O 0 1.133518239271325e-07
is O 0 3.7166669741850455e-09
the O 0 5.882845321991681e-09
result O 0 8.143458352094513e-09
of O 0 8.43965892727283e-08
the O 0 6.040427535936033e-08
dominant O 0 5.375040359467675e-07
inheritance O 0 7.079953547872719e-07
of O 0 2.9873393941670656e-05
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9999977350234985
coli I-Disease 1 0.9999895095825195
( O 0 6.37087077848264e-06
APC B-Disease 0 0.19645465910434723
) O 0 1.067953348865558e-06
gene O 0 3.556072670107824e-06
mutations O 0 1.3887139402868343e-06
. O 0 3.124014028799138e-06

In O 0 5.615219151877682e-07
this O 0 3.332456754989721e-09
study O 0 7.3424639701613614e-09
, O 0 3.626768885212073e-10
direct O 0 2.911185181808662e-10
mutation O 0 4.1490874624905416e-10
analysis O 0 7.703613857934499e-10
of O 0 9.413140489300531e-09
the O 0 2.7906949640055245e-08
APC B-Disease 0 6.757356914022239e-06
gene O 0 1.1022768120483306e-07
was O 0 1.707549301954714e-07
performed O 0 1.1350748252425547e-07
to O 0 1.9960171293575968e-09
determine O 0 8.817496066626518e-09
genotype O 0 3.8780530076110153e-07
- O 0 1.1505841257530847e-06
phenotype O 0 1.4414840165954956e-07
correlations O 0 8.509746152185471e-08
for O 0 2.1415619499975946e-08
nine O 0 2.663814768766315e-07
extracolonic O 0 6.734056660206988e-05
manifestations O 0 2.1631451090797782e-05
and O 0 4.3427238693993786e-08
to O 0 8.589942979142506e-09
investigate O 0 6.832375731846696e-08
the O 0 4.610934922766319e-08
incidence O 0 1.4355140365296393e-06
of O 0 3.07947345845605e-07
APC B-Disease 0 1.1143319170514587e-05
mutations O 0 4.901317396388549e-08
in O 0 6.664944152134922e-08
non O 0 0.0016942420043051243
- O 1 0.9999970197677612
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 8.835714652377646e-06

METHODS O 0 5.8306610299041495e-05
The O 0 3.276340294178226e-06
APC B-Disease 0 3.470941010164097e-05
gene O 0 2.694009708648082e-07
was O 0 2.841379398432764e-07
analysed O 0 3.0964889674578444e-07
in O 0 2.5850008356087528e-08
190 O 0 8.924552474809389e-08
unrelated O 0 3.127765069166344e-07
FAP B-Disease 0 5.394102481659502e-05
and O 0 9.277216150849199e-08
15 O 0 6.089273369980219e-07
non O 0 0.0010865952353924513
- O 1 0.9999825954437256
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 1.2488889069572906e-06
using O 0 2.2361106744028802e-07
denaturing O 0 6.801666313549504e-05
gradient O 0 2.6579627956380136e-06
gel O 0 2.9910645480413223e-06
electrophoresis O 0 9.86255372481537e-07
, O 0 2.100524731929454e-08
the O 0 7.69951924439738e-09
protein O 0 1.0008889717028069e-08
truncation O 0 4.6554828259104397e-07
test O 0 2.2712353597853507e-07
, O 0 1.8880506047480594e-09
and O 0 2.7422657478126666e-09
direct O 0 9.776139009431972e-09
sequencing O 0 6.044785436642997e-07
. O 0 5.626030770145007e-07

RESULTS O 0 0.0004523852257989347
Chain O 0 1.9674071154440753e-05
terminating O 0 2.7968767426500563e-06
signals O 0 4.7674754455329094e-07
were O 0 7.228464049546801e-09
only O 0 4.678684661918453e-10
identified O 0 2.3395967385653194e-09
in O 0 1.1190753212986237e-08
patients O 0 2.4448448598946015e-08
belonging O 0 2.4982995228128857e-07
to O 0 2.783911234871539e-08
the O 0 2.4545337851122895e-07
FAP B-Disease 0 0.15238451957702637
group O 0 5.046245519224613e-07
( O 0 6.181868172916438e-08
105 O 0 2.9798779905831907e-06
patients O 0 6.925470188434701e-07
) O 0 1.4446231944020838e-07
. O 0 6.997829586907756e-07

Amino O 0 7.3496930781402625e-06
acid O 0 6.041407800694287e-07
changes O 0 1.8865902617903885e-08
were O 0 7.916566069354758e-09
identified O 0 5.922429657800876e-09
in O 0 5.524482649121865e-09
four O 0 7.611413721519966e-09
patients O 0 1.2508786007003891e-08
, O 0 1.7958783349314444e-09
three O 0 2.0592594296431344e-09
of O 0 9.712337600831233e-08
whom O 0 2.6209502124174833e-08
belonged O 0 2.1456398826558143e-06
to O 0 8.11899969477281e-09
the O 0 7.17971460062472e-08
non O 0 2.472998312441632e-05
- O 0 4.3768752220785245e-05
FAP O 0 0.06505726277828217
group O 0 1.6740269757065107e-06
of O 1 0.9943444728851318
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.0011245463974773884
. O 0 3.297825742265559e-06

Genotype O 0 0.0004911480355076492
- O 0 0.0001426441449439153
phenotype O 0 3.2719656246626982e-06
correlations O 0 7.855176704651967e-07
identified O 0 7.644297994602312e-08
significant O 0 2.740703664017019e-08
differences O 0 1.979068819935037e-08
in O 0 2.0089583330218375e-08
the O 0 1.7014201603160473e-08
nature O 0 1.2134896643090087e-08
of O 0 1.572572294605834e-08
certain O 0 7.792254841376689e-09
extracolonic O 0 2.7717900593415834e-05
manifestations O 0 1.013681321637705e-05
in O 0 1.7999519741351833e-07
FAP B-Disease 0 0.12665562331676483
patients O 0 3.342478578360897e-07
belonging O 0 5.72406975152262e-07
to O 0 4.012978394030142e-08
three O 0 1.739446702231362e-07
mutation O 0 5.893753041164018e-07
subgroups O 0 5.539823632716434e-06
. O 0 3.3787430311349453e-06

CONCLUSIONS O 0 7.104649557732046e-05
Extended O 0 6.8240669861552306e-06
genotype O 0 1.0165673302253708e-05
- O 0 1.032206455420237e-05
phenotype O 0 3.9369149362755707e-07
correlations O 0 2.8228538440089324e-07
made O 0 4.177997681154011e-08
in O 0 1.7331057478031653e-08
this O 0 7.079838937329441e-10
study O 0 8.327420530918062e-09
may O 0 3.0674334183800056e-09
have O 0 1.4121298574920615e-10
the O 0 1.1356574569632016e-09
potential O 0 1.2409683280978356e-09
to O 0 7.081770170280777e-10
determine O 0 3.877821175279905e-09
the O 0 2.8872535473567496e-09
most O 0 4.2976136538364074e-10
appropriate O 0 3.0431908104588956e-09
surveillance O 0 1.5463716351860057e-07
and O 0 8.496783721057e-09
prophylactic O 0 9.427367331227288e-06
treatment O 0 2.853212208719924e-06
regimens O 0 2.1690032099286327e-06
for O 0 6.818833053756634e-09
those O 0 6.57331122866367e-09
patients O 0 1.798367676997259e-08
with O 0 2.7867679275317414e-09
mutations O 0 1.0976025777154064e-07
associated O 0 1.627399655035333e-07
with O 0 9.983135385027708e-08
life O 0 3.02148619084619e-05
threatening O 0 9.79463875410147e-05
conditions O 0 0.0001319581497227773
. O 0 6.382698757079197e-06

This O 0 1.2855326758653973e-07
study O 0 5.46887832797438e-08
also O 0 2.6969613209359977e-09
provided O 0 4.1627870039917525e-09
evidence O 0 2.224066086853327e-08
for O 0 2.7156159543295644e-09
the O 0 1.3620230276956136e-08
pathological O 0 6.698584911646321e-06
nature O 0 1.204614079597377e-07
of O 0 2.4975918222480686e-07
amino O 0 3.513164159585358e-08
acid O 0 3.351287602981756e-08
changes O 0 4.479429271952995e-09
in O 0 3.947034699081087e-08
APC O 0 5.919151135458378e-06
associated O 0 5.555784809985198e-08
with O 0 6.694244714111619e-09
both O 0 1.6293759230734395e-08
FAP B-Disease 0 0.00037020054878666997
and O 0 2.578452438228851e-07
non O 1 0.5939645767211914
- O 1 0.9999980926513672
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 3.265785926487297e-05
. O 0 2.8511212235571293e-07
. O 0 9.575246622262057e-07

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 1 0.744310736656189
cancer B-Disease 1 0.9999998807907104
risk O 0 4.904346496914513e-06
of O 0 1.2045252333336975e-05
the O 0 8.591807272750884e-06
APC O 0 0.013463315553963184
I1307K O 0 0.00036166139761917293
polymorphism O 0 2.2978771085035987e-05
. O 0 3.7578090541501297e-06

Germ O 1 0.9999960660934448
- O 0 0.0005873948684893548
line O 0 3.828316494036699e-06
and O 0 2.8077264957460102e-08
somatic O 0 1.4411584743356798e-06
truncating O 0 1.2061664165230468e-06
mutations O 0 4.793846031247995e-08
of O 0 1.6532072777408757e-07
the O 0 1.696154185992782e-07
APC B-Disease 0 2.578772728156764e-05
gene O 0 1.7440987321037937e-08
are O 0 2.527477949154644e-10
thought O 0 4.178888346473286e-09
to O 0 5.325078156204199e-09
initiate O 0 6.27240733592771e-05
colorectal B-Disease 1 1.0
tumor I-Disease 1 0.9997640252113342
formation O 0 0.00044315107516013086
in O 0 5.917773250985192e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 0.009551542811095715
sporadic O 1 1.0
colorectal O 1 1.0
carcinogenesis O 1 0.9999998807907104
, O 0 9.734935701999348e-06
respectively O 0 1.236409843841102e-05
. O 0 4.253234692441765e-06

Recently O 0 3.1910123652778566e-05
, O 0 2.968505157241452e-07
an O 0 8.597830714052179e-08
isoleucine O 0 0.00017220368317794055
- O 0 8.345973765244707e-05
- O 0 1.7255662896786816e-05
> O 0 1.443839778403344e-06
lysine O 0 1.123956735682441e-06
polymorphism O 0 1.788029209137676e-07
at O 0 2.8663120588134916e-07
codon O 0 8.24746280159161e-07
1307 O 0 1.756154597387649e-05
( O 0 2.022904155296601e-08
I1307K O 0 2.0670699996117037e-06
) O 0 5.754642096178486e-09
of O 0 2.5560641603306067e-08
the O 0 4.3799158078172695e-08
APC B-Disease 0 6.386857876350405e-06
gene O 0 3.68816763796076e-08
has O 0 8.798440309654154e-10
been O 0 1.046198683241073e-09
identified O 0 1.3115640795646755e-09
in O 0 1.239955693677075e-09
6 O 0 4.494211225392064e-08
% O 0 1.9010342189318408e-09
- O 0 4.219119276172023e-08
7 O 0 5.416691806203744e-08
% O 0 9.787533006289095e-10
of O 0 4.8669210883645064e-09
the O 0 9.318622318232883e-09
Ashkenazi O 0 1.1363100611561094e-06
Jewish O 0 2.59434699501071e-07
population O 0 1.8017839664707935e-08
. O 0 2.573084998402919e-07

To O 0 4.214072646391287e-07
assess O 0 5.773262614638952e-07
the O 0 1.862585179424059e-07
risk O 0 4.975663259187968e-08
of O 0 3.422206162895236e-08
this O 0 1.5427848998328386e-09
common O 0 3.292773342877808e-08
APC B-Disease 0 6.586104063899256e-06
allelic O 0 4.4447356231103186e-06
variant O 0 5.8815799093281385e-06
in O 0 3.0111391424725298e-06
colorectal O 1 1.0
carcinogenesis O 1 0.9999961853027344
, O 0 1.5691199450884596e-07
we O 0 4.682686682855319e-09
have O 0 2.92802476709042e-10
analyzed O 0 7.724982431511762e-09
a O 0 2.7458297857663183e-09
large O 0 6.983360556489515e-09
cohort O 0 4.599586702624947e-07
of O 0 1.6318242046509113e-07
unselected O 0 0.00017530773766338825
Ashkenazi O 0 3.474399136393913e-06
Jewish O 0 5.687920747732278e-07
subjects O 0 1.004773821478011e-06
with O 0 1.374202014403636e-07
adenomatous B-Disease 1 0.9913199543952942
polyps I-Disease 0 3.423380258027464e-05
and O 0 9.54527124008564e-08
. O 0 1.16564507379735e-07
or O 0 0.19748590886592865
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 6.384236428402801e-08
for O 0 1.4505851630985944e-08
the O 0 5.256701456346491e-07
APC O 0 0.00026201963191851974
I1307K O 0 0.0001269294589292258
polymorphism O 0 9.380509254697245e-06
. O 0 2.439535819576122e-06

The O 0 2.1647545509040356e-05
APC O 0 0.000180253351572901
I1307K O 0 6.151307024993002e-05
allele O 0 5.626615688925085e-07
was O 0 1.9959425401339104e-07
identified O 0 1.3370810236779107e-08
in O 0 6.631731608308655e-09
48 O 0 5.217643916921588e-08
( O 0 4.515423146500552e-09
10 O 0 1.3825906641784513e-08
. O 0 1.0693491647728592e-09
1 O 0 1.145615691200419e-08
% O 0 1.069655142238446e-09
) O 0 7.48128170524609e-10
of O 0 1.6625712362383638e-08
476 O 0 4.944660304317949e-06
patients O 0 2.300653477504966e-06
. O 0 1.6692268900442286e-06

Compared O 0 2.4391683837166056e-06
with O 0 1.5427207955553968e-08
the O 0 1.434210528117319e-08
frequency O 0 1.2879545430166672e-08
in O 0 9.056115857219993e-10
two O 0 1.3088694017504565e-10
separate O 0 3.460865205529018e-10
population O 0 3.1976084974294494e-11
control O 0 1.372128966004027e-09
groups O 0 3.7567335353649867e-10
, O 0 1.9044019694547387e-09
the O 0 1.7264708773723214e-08
APC O 0 9.172313184535597e-06
I1307K O 0 5.6748694987618364e-06
allele O 0 4.111279139351609e-08
is O 0 2.8913702543320596e-09
associated O 0 5.022678273292058e-09
with O 0 7.192564877023244e-10
an O 0 6.765313864676159e-10
estimated O 0 1.4521346347606823e-09
relative O 0 9.376405429861734e-09
risk O 0 2.903524531916446e-08
of O 0 2.0469845196657843e-07
1 O 0 2.303122982993955e-06
. O 0 4.5185745989329007e-07

5 O 0 0.00012235321628395468
- O 0 0.00014795947936363518
1 O 0 1.5422641808982007e-05
. O 0 1.4111976724962005e-06

7 O 0 6.231990118976682e-05
for O 0 4.65344146505231e-06
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9999955892562866
( O 0 2.1537130123761017e-06
both O 0 3.5071596471425437e-07
P O 0 7.537769852206111e-05
= O 0 9.511084044788731e-07
. O 0 1.4238712253700214e-07
01 O 0 4.7189754695864394e-05
) O 0 1.354500227535027e-07
. O 0 2.1246533776775323e-07

Furthermore O 0 7.187632490968099e-06
, O 0 3.40015702704477e-07
compared O 0 1.649355283461773e-07
with O 0 2.2090912210614988e-08
noncarriers O 0 0.00011308417015243322
, O 0 3.352918440668873e-07
APC O 0 7.816259312676266e-05
I1307K O 0 9.024213795782998e-06
carriers O 0 4.4009095034880374e-08
had O 0 4.533147635044088e-09
increased O 0 8.816616881013317e-10
numbers O 0 8.072702506467522e-10
of O 0 3.737440579243412e-08
adenomas B-Disease 0 0.0023561520501971245
and O 0 9.108080121222883e-06
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9999834299087524
per O 0 3.6421832305677526e-07
patient O 0 4.180025371169904e-06
( O 0 1.3844133661677915e-07
P O 0 3.8726382626919076e-05
= O 0 1.261571469513001e-07
. O 0 7.12927672452679e-09
03 O 0 1.1234080830035964e-06
) O 0 2.3084001377071672e-09
, O 0 5.753278409237339e-10
as O 0 4.925565511015861e-10
well O 0 1.2928467185702175e-09
as O 0 1.5391755647797822e-09
a O 0 6.587418610592977e-09
younger O 0 7.322774564499923e-08
age O 0 1.6114185541482584e-07
at O 0 2.322601858395501e-06
diagnosis O 0 4.269548662705347e-05
. O 0 7.691323276048934e-07

We O 0 6.278787623159587e-07
conclude O 0 1.1756183084798977e-06
that O 0 6.799300233950589e-09
the O 0 1.5547783505098778e-07
APC O 0 6.16404358879663e-05
I1307K O 0 3.557460513547994e-05
variant O 0 1.0443766768730711e-05
leads O 0 1.9318954969094193e-07
to O 0 1.6673283198542777e-08
increased O 0 6.870592983432289e-07
adenoma B-Disease 1 1.0
formation O 0 0.0002468124439474195
and O 0 8.234881931912241e-08
directly O 0 3.226832134828328e-08
contributes O 0 8.827070629990885e-09
to O 0 3.0838416265055457e-09
3 O 0 3.8776306610088795e-08
% O 0 1.0148792917163973e-09
- O 0 1.2787947589742998e-08
4 O 0 1.3994966963082334e-08
% O 0 3.388143932081533e-10
of O 0 1.6586428897014116e-09
all O 0 2.6412181330925932e-09
Ashkenazi O 0 1.8235661627841182e-05
Jewish O 1 0.999832034111023
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 9.729849807627033e-06

The O 0 1.047702880896395e-06
estimated O 0 6.99940514437003e-08
relative O 0 8.231740622477446e-08
risk O 0 1.8089222564299234e-08
for O 0 5.546104908660254e-09
carriers O 0 4.358681238159079e-08
may O 0 9.550111812473006e-09
justify O 0 1.3955303579393785e-08
specific O 0 2.590201386709623e-09
clinical O 0 1.1720076287247139e-07
screening O 0 1.6425937943154167e-08
for O 0 6.366525084899877e-10
the O 0 1.87184712174826e-09
360 O 0 2.2157630397146022e-08
, O 0 7.809808910685945e-10
000 O 0 1.156959594794671e-08
Americans O 0 5.647383116702542e-10
expected O 0 2.0973369707633083e-09
to O 0 2.23080731664993e-09
harbor O 0 3.174467053668195e-07
this O 0 4.752291338228076e-10
allele O 0 4.933183639366234e-09
, O 0 1.1808406474855815e-09
and O 0 9.944299828035241e-10
genetic O 0 1.0561095109551388e-08
testing O 0 3.3864285597928756e-08
in O 0 2.66358912703879e-09
the O 0 2.3202919585685322e-09
setting O 0 1.9807757212220167e-08
of O 0 3.3122436349231066e-08
long O 0 1.7158704679332004e-08
- O 0 7.88133007745273e-08
term O 0 1.653599213113921e-08
- O 0 4.924903862502106e-08
outcome O 0 4.5067327647529964e-09
studies O 0 4.6126920061340115e-09
may O 0 1.5554664223316195e-09
impact O 0 9.371452946993486e-09
significantly O 0 2.131736209776136e-08
on O 0 5.192724711378105e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 5.2076662541367114e-05
in O 0 5.968197047678814e-09
this O 0 6.329861634846168e-10
population O 0 1.4471466247556464e-09
. O 0 7.385320088815206e-08

Localization O 0 5.9731475630542263e-05
of O 0 4.013027137261815e-06
human O 0 4.6032243972149445e-07
BRCA1 O 0 2.3526345103164203e-06
and O 0 1.7374150118598664e-08
its O 0 3.414330151940703e-08
loss O 0 1.3076078175799921e-06
in O 0 3.987890195844557e-08
high O 0 2.751940201051184e-06
- O 0 2.0783070340257837e-06
grade O 0 1.1735107364074793e-05
, O 0 9.722472604778432e-09
non B-Disease 0 2.7495647373143584e-05
- I-Disease 1 0.9452769756317139
inherited I-Disease 1 1.0
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 3.2442156225442886e-05

Although O 0 1.6146626649060636e-06
the O 0 3.8917835354368435e-07
link O 0 2.724593741731951e-07
between O 0 5.2755439128304715e-08
the O 0 3.560820118764241e-07
BRCA1 O 0 0.0002562117879278958
tumour B-Disease 1 1.0
- O 0 6.595710146939382e-05
suppressor O 0 1.0350571756134741e-05
gene O 0 2.5291376459790627e-07
and O 0 1.6140407410603075e-07
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 0.9999979734420776
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 2.5298824368746864e-08
established O 0 6.643520578109019e-08
, O 0 1.8419763492261154e-09
the O 0 3.1313593940041073e-09
role O 0 1.003157557022405e-08
, O 0 2.530416765011978e-09
if O 0 2.6284216469996124e-10
any O 0 3.787939129029638e-10
, O 0 1.0008120998605818e-09
of O 0 2.6297284350107475e-08
BRCA1 O 0 2.7378541744838003e-07
in O 0 4.0514166244065564e-08
non B-Disease 0 0.00016349274665117264
- I-Disease 1 0.7564484477043152
familial I-Disease 1 0.9995579123497009
cancers I-Disease 1 0.9999969005584717
is O 0 9.584129401218888e-08
unclear O 0 4.562438675748126e-07
. O 0 5.829612632624048e-07

BRCA1 O 0 0.0004256272513885051
mutations O 0 1.2353340252957423e-06
are O 0 1.1551955836353045e-08
rare O 0 1.5251511342739832e-07
in O 0 4.276472864717107e-08
sporadic B-Disease 0 4.7964123950805515e-05
cancers I-Disease 1 0.9909412264823914
, O 0 2.5497536526586373e-08
but O 0 5.318459894709804e-09
loss O 0 1.2207044619572116e-06
of O 0 1.428409973414091e-06
BRCA1 O 0 2.2329745661409106e-06
resulting O 0 1.1468054594843125e-07
from O 0 7.132176449431427e-08
reduced O 0 3.5636794848414866e-08
expression O 0 8.889941227607778e-09
or O 0 6.941343499988761e-09
incorrect O 0 3.917693192079241e-08
subcellular O 0 5.825349944643676e-07
localization O 0 8.533270374755375e-07
is O 0 4.126234465218204e-09
postulated O 0 2.575895585721355e-08
to O 0 2.2309178948631825e-09
be O 0 1.0268110806066488e-09
important O 0 5.727791574372532e-09
in O 0 1.0137402917109739e-08
non B-Disease 0 7.2123025347536895e-06
- I-Disease 0 0.00012625829549506307
familial I-Disease 0 0.26620033383369446
breast I-Disease 1 0.9999996423721313
and I-Disease 1 0.9999911785125732
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 6.223450327524915e-05

Epigenetic O 0 0.0007240570266731083
loss O 0 0.07344525307416916
, O 0 3.0321064059535274e-07
however O 0 2.502383367186667e-08
, O 0 4.5235437617918706e-09
has O 0 2.2029501833831233e-10
not O 0 1.0945404305129358e-10
received O 0 2.5517907786820615e-09
general O 0 1.26618857620997e-08
acceptance O 0 3.962082217867646e-08
due O 0 6.749505132574996e-08
to O 0 3.9078029701045125e-09
controversy O 0 6.962694953926984e-08
regarding O 0 1.975452157410018e-08
the O 0 1.2408245986250677e-08
subcellular O 0 1.6758752963141887e-07
localization O 0 3.448994618793222e-07
of O 0 6.432983212789622e-08
BRCA1 O 0 1.3530954845464294e-07
proteins O 0 3.568112472152052e-09
, O 0 3.290034689129584e-09
reports O 0 3.6683391879677174e-09
of O 0 8.56641424462623e-09
which O 0 1.540467864380446e-09
have O 0 1.93265764503181e-10
ranged O 0 3.202013942882331e-08
from O 0 5.654024803902757e-09
exclusively O 0 1.0652112081288578e-08
nuclear O 0 1.1666008958854945e-06
, O 0 3.2647242687033895e-09
to O 0 1.6543648673206235e-09
conditionally O 0 5.897880441807501e-07
nuclear O 0 2.5568601813574787e-06
, O 0 3.320826280628353e-09
to O 0 1.3123048203667054e-09
the O 0 8.260114015001818e-08
ER O 1 0.9990691542625427
/ O 0 6.59554507365101e-06
golgi O 0 2.1920101062278263e-05
, O 0 2.7180529826864586e-08
to O 0 2.358037676231106e-08
cytoplasmic O 0 5.065754180577642e-07
invaginations O 0 1.1962941243837122e-05
into O 0 2.868007413781015e-07
the O 0 5.356185397431545e-07
nucleus O 0 1.2224880265421234e-05
. O 0 2.8184579150547506e-06

In O 0 2.01399166144256e-06
an O 0 2.9699993575604822e-08
attempt O 0 1.5810813636107923e-07
to O 0 1.3249234598333715e-08
resolve O 0 3.770491474597293e-08
this O 0 1.2083201106349861e-09
issue O 0 6.522854700818925e-09
, O 0 4.065146441689649e-09
we O 0 4.3011072481391466e-10
have O 0 3.2214539369412876e-10
comprehensively O 0 7.588121775370382e-07
characterized O 0 1.4900525968641887e-07
19 O 0 1.4214807606549584e-06
anti O 0 3.4613021853147075e-05
- O 0 7.920892676338553e-05
BRCA1 O 0 2.9400673156487755e-05
antibodies O 0 3.528271236064029e-06
. O 0 1.620809030100645e-06

These O 0 1.0973446933348896e-06
reagents O 0 2.3179030904429965e-05
detect O 0 1.4034847481525503e-05
a O 0 3.311303089503781e-07
220 O 0 1.068914230017981e-06
- O 0 3.0701855848747073e-06
kD O 0 8.632734534330666e-06
protein O 0 5.6272817516855866e-08
localized O 0 2.8199102075632254e-07
in O 0 3.924354619044834e-09
discrete O 0 1.9587934829701226e-08
nuclear O 0 1.6027560150178033e-06
foci O 0 1.6489290146637359e-06
in O 0 1.2726386167116743e-08
all O 0 5.4548947581167795e-09
epithelial O 0 9.747317335495609e-07
cell O 0 1.7484805994172348e-06
lines O 0 9.493922448200465e-08
, O 0 5.518437262708176e-09
including O 0 5.364980459887647e-09
those O 0 1.5965014865670923e-09
derived O 0 4.163519662370163e-08
from O 0 1.1269812603131868e-06
breast B-Disease 0 0.00585122499614954
malignancies I-Disease 0 0.016761433333158493
. O 0 6.8882081905030645e-06

Immunohistochemical O 0 0.0014307273086160421
staining O 0 0.0001127587747760117
of O 0 1.3594813935924321e-05
human O 0 1.926395952978055e-06
breast O 0 0.00028834404656663537
specimens O 0 1.3199263548813178e-06
also O 0 5.967003602336263e-08
revealed O 0 1.4429875818677829e-06
BRCA1 O 0 7.786368769302499e-06
nuclear O 0 6.680463411612436e-05
foci O 0 4.792535401065834e-05
in O 0 6.707948614348425e-07
benign O 1 0.999760091304779
breast O 1 0.9868021607398987
, O 0 1.5834096984690404e-06
invasive B-Disease 1 0.9999997615814209
lobular I-Disease 1 1.0
cancers I-Disease 1 0.9999978542327881
and O 0 4.864074526267359e-06
low B-Disease 1 0.9767482280731201
- I-Disease 1 0.9974961876869202
grade I-Disease 1 0.9999988079071045
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 2.3561782654724084e-05

Conversely O 0 5.202479587751441e-05
, O 0 9.73256646830123e-07
BRCA1 O 0 2.340607807127526e-06
expression O 0 1.0096518110458419e-07
was O 0 4.3400908111834724e-07
reduced O 0 6.662707363602749e-08
or O 0 1.4477658183409403e-08
undetectable O 0 8.838495091367804e-07
in O 0 2.051645964229465e-09
the O 0 1.4399164083300775e-09
majority O 0 5.51860335207266e-10
of O 0 1.1042291525598102e-08
high O 0 1.4724278116773348e-06
- O 0 3.998544798378134e-06
grade O 0 0.0001507702691014856
, O 0 1.626656427333728e-07
ductal B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 0 1.491060572789138e-07
suggesting O 0 6.329481294642392e-08
that O 0 1.460852105950039e-09
absence O 0 1.231306328008941e-07
of O 0 2.1578123323706677e-06
BRCA1 O 0 2.2231824914342724e-05
may O 0 3.228482015060763e-08
contribute O 0 3.728325204122029e-09
to O 0 6.666136975752579e-09
the O 0 8.629605474652635e-08
pathogenesis O 0 2.1717809431720525e-05
of O 0 1.314980551114786e-07
a O 0 6.4872942573401815e-09
significant O 0 4.5189385566857254e-09
percentage O 0 1.8585744498977874e-08
of O 0 1.0493911872799799e-07
sporadic B-Disease 0 0.00024236959870904684
breast I-Disease 1 0.9999923706054688
cancers I-Disease 1 0.999108612537384
. O 0 8.079231292867917e-07
. O 0 2.034463932432118e-06

